<SEC-DOCUMENT>0001410578-23-001985.txt : 20230817
<SEC-HEADER>0001410578-23-001985.hdr.sgml : 20230817
<ACCEPTANCE-DATETIME>20230817163051
ACCESSION NUMBER:		0001410578-23-001985
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		71
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230817
DATE AS OF CHANGE:		20230817

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CureVac N.V.
		CENTRAL INDEX KEY:			0001809122
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			P7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39446
		FILM NUMBER:		231182338

	BUSINESS ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076
		BUSINESS PHONE:		49 7071 9883 0

	MAIL ADDRESS:	
		STREET 1:		PAUL-EHRLICH-STRABE 15 TUBINGEN
		CITY:			BADEN-WURTTEMBERG
		STATE:			2M
		ZIP:			72076

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CureVac B.V.
		DATE OF NAME CHANGE:	20200410
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>cvac-20230630x6k.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.3.0.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/17/2023 6:46:30 PM -->
      <!-- iXBRL Library version: 1.0.8528.25195 -->
      <!-- iXBRL Service Job ID: fadbf635-6315-4710-86ac-f1609a868cb6 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:cvac="http://www.curevac.com/20230630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:references><link:schemaRef xlink:href="cvac-20230630.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_jJMos62EfkW5YNIpjhOWeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_c616ZXiH_EKOpj5dNuZ83w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_tuyUV0cxakyr_-Yg3O_syQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_P3-yf9evlk-uil2HqOhCJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_BqGmW8UGOUGYcz2zq4SB2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_daj6pxuUI0CyzoQOjX4GZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_iZr_fiR4-kqzHWO6nRRciw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_T1yTr60wpEmNL4M4Ko8K2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_KiOskkojkkONBK40fmVQSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_2VGMUPX1L0m2mtmN3QdB5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_wLsvd5ls7kqTDYk-S9CpjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_YqWM6UyJ9EOQ0t7oMP82XQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_5Y1Bpfn7ukWQA4eeXs_knA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_3anFBkhjW0Csz9tHCp7JTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_lgsJNQOs-kebpPDEL6dBqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_p5-6N-xf00qjDgzfyTQFUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_4_d4F69gaEGw4TgM7DDcuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_mqqCc3YqhUaOpO3VV41sVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_0FmV3jCD_EecBMzp1kB-ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_c9WMa6qFu0SqkKP148olXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_FGpCXR_Dc0CnL6--y0XVzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_gLKqZqvImUCP4bVr6G8mmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_W2T3qdsYzUe0esN9Oty_VA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_mI2esD2990ujSWl2t4bAJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_CTQr6H0pakGthZr8dk5c2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_vUXz2-MgLkyPVrGTn6EwAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_NmehV27LsECWx1f7ZlhZVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_1JdarqUTqUixoudVPfLIxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_pfPO-Kfo-02aNkaKFsNshw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_Susx1Gdb5kyVZMPzZFwQjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_JrMg0504CkiFtakq5tBxSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_DrPAKCYehUOOTvRPc2PSVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_lYvFatpdQkefXIkc7q5t-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_uu0hAMQGFE6RW7mIBHTXqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_VPTtXuLSnUmuuBX4S-iEMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_9dT7Tb1Duk2jWvysh9Lqaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_t_V-9jzIX06zZ0Zkpmf8dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_vDdXBJ99MUy29plp5BCfpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BepharbelManufacturingS.aMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_fO5tW3MsVE60EMuNs7InYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:VincentStphenneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_YRShJABpk0-UxZwCv3pqAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:BaronJeanStephenneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_bb_-yK9N50-YjTv-FAr2SA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_k77XHGsGdUayZMsUw-y9ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_1dYKs1W9uU6tOrLCufufjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_bao9oCjt3kWO6XoHSsX7IQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ThenChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_VWrFMaoDW0iaJ10vlf3I3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_K24THxuJwkSYpgfVd96a9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_NDbK_W7H-0umensvBwuEXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_xb55tI_uTEK9tu0gMHp17g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_SYdnaM4Hv0amPp2G2fTAcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_JiZFgfyfoUWlbX4a-OgfAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_KwYMhWFPZU6Rg7XLlTdlAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_xUdA4vFkmkehfhynMJzhzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_46FI4ABSf02M9Rryg4sClw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_OUkDYWpJJkyy_omK2KmOjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ThenChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_yrSvY_lt6UyqrvMk85XVag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_eekSXKejL0WDf-eAeVRHbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_xmJZx23S6Ee9MA0czFqYMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_4WXyX6UBnEeF_hShCcUFxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_eOb3THsiDEK9JLgQVfEwTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_UlK7_VcP00Ke20ec2b3Low"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:SupervisoryBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_TvnlUpmmVUa_HJFdi00FrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-31</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_30_2022_To_11_30_2022_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_z47nsJniAkW9xj3JyFsA3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-30</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_7_1_2022_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_Nww_GsAWTEubPvNVau2dgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:FormerFrameEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_q81lEiXrw0OgCYslUicbLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:SupervisoryBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_zK3-o7Q200KTZ8l2pvMR8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-22</xbrli:startDate><xbrli:endDate>2022-06-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_31_2022_To_1_31_2022_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerMember_g2GxNhtCAEyWmUGgwRuryA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_g-FjX7APF0qbbMyAZKIHGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_24_2021_To_6_24_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_41E5ssbhMEW4sOS5GBDjpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:SupervisoryBoardMembersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_31_2022_To_1_31_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_aDZJW6AtK0-IUzIePmSJgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_23_2021_To_12_23_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_YkGL88cFUUiH_hFBBekkPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-23</xbrli:startDate><xbrli:endDate>2021-12-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_OAM4KSbtK0GhMJvgcN7Cyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_OQguCGk5x0movmkxQwGifA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_wa5QFol_rkS8gG7WwJPCXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_slG_08aRiU2zjF60wKoFFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_GHafoSH-TkqVmnjZDhADVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_wLccfvwhOU-7QN08Mnbskw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3RD6LGn_q0aJE9VANwQwiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_earTaqxquUCS_GN9m5R30w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_iDouUQemZEC34ma64ZGubg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_BYtQ55ZkAkixCPBAi-kTXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_uyKdAo0yT0en_uX9rr_yVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_89R1ELqZg0iF1defo-Zzrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ajhe72dYmU6ikfxrecPTtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_q2iBsZHaNEGTSntINrtOmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Q6eV7yFRmkKgW83cIj_dXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_nLufrI8XVUO1H8-sgxRRdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_DUk2M43_BkOYQjRrfn4Oaw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_LeOPOA5JLUa_Tp1X3mtBNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3SmXevtwJUGcfplEE1poRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_oMKzJtdhmE-IN4Rb0YyEGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_f-R_nyf_ukOQR2DltOYQdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_X5PE41bPzEOwyIJ4t92A6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_EL-e9XEpg060VUWMc35I0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_6j-rWZQ0mEyD1-UORlTFiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_kPAAhLB8vEeSoaGBtF4VwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BepharbelManufacturingS.aMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_cSA1WqHadE-LZYGzr1BGfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_CeiTmQbyAU6m7Qb98_JtDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_C0dEV8ymUEuwP4xIHoAt0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember__JCd2jsBx0aS7CNRVo1ClA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_CompanyOwnedGmpIvFacilityMember_epTIr0WyBkir6RkvPsvAWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:CompanyOwnedGmpIvFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_TQ5I85ZFr0KjUsctPczaJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_tDwKd8WW10KShixVy7Uj8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_F3innQ88Ak6o2rkcUJY0ZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:LicensesSoftwareAndPrepaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_xDhMyn6Lpkahl29jhpRNOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:LicensesSoftwareAndPrepaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_kEyr9vg-3UGfXM6bAe71zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ZuAhdHNvcUy-pqQHWJ5p2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_61WhBItdi0aToAp0G6sGBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_xXPjPpafwkWy53dbFgOTyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_JK3MBg80MEGeA_HLbxHAbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_3c8WG3Tl-EmEVVoAZn9cRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember__rwT7Mu1jUex_FmfwPvK4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_IcUfvwha0UqENVJCntKS0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_qyAt21N52UKd6WnZPLKiQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_v1QdYh7Q4UaITnRX6S5L5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_oTatH5MWGk2wkKXabym88g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_6ysCqrsi0EqepTGp5T4G7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3ZJGf8rl2EqLWLcsDr1j5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_1A2s3zl5FUeobT5soQuz-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_kXJFYB4hY0uYWJFAb4CEQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_GIDUORdEfE2sHWHYyWOsSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:AntonyBlancMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_HRw1loMHOkC_Vjug3m60AQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:LargestShareholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_gU3vE82A102SoPkxvd1bwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:LargestShareholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_K4r7ZDLT-E2fEsXEmmY8ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_av40YHBBh0K9mS0uze6WHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_XOHc_alf0UOQ75cQ9xGNTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_H6yYmBXYOEe8_bIhxb-C8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2023_To_8_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_PatentInfringementLawsuitFilledMember_OxwKIZvNZUe6ydx3xJju_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">cvac:PatentInfringementLawsuitFilledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_4_30_2023_MpR9Fyh8qkmIM9QPSU-9Eg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_30_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_AZJ95UjEWEaSLSw3FoAPFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:FormerFrameEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-30</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_Zhw8mSG_RkaWjTgdo48LVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_7_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_PatentInfringementLawsuitFilledMember_Qz-L5Ejndka-M5jETiVyOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">cvac:PatentInfringementLawsuitFilledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_PatentInfringementLawsuitFilledMember_oqeBQyU8LUS4jK_f0UnMNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">cvac:PatentInfringementLawsuitFilledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2023_To_5_31_2023_opUMBeSJAU6Y3pCknLUBYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2022_To_6_30_2022_IMdJRoUvhk2KhVqXkyy6DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_LfUbJgvVEEOMs9Xu0dY_aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_0W76eZNJTky2YBlodKXOPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_1OMKhPZxMEiydfIE4wQ-aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_TeB4gwzvG0OqfuENGvfJvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_6Escb8lmq0qNNDpw732R3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_hOXsDH0Qk0OcmChZ7BhnqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_xghJZOz2zkyZscGxuWn0yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_CraigToomanMember_PoIqBBw0NUOkeFya4T-Bsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:CraigToomanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BarkerBiomedicalGmbhMember_mv3p0pRW2UerXnYaXscbzg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BarkerBiomedicalGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_MgjlzqfYXUmUABPH0VTY7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:PriorVirtualStockOptionsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember_GWqoCAnOUEuJVuboxaAwqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:NewVirtualStockOptionsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_0ynCSSVH80efoVzNnwRQmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanAndRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_y9w5TmE7JUaqCnNvnmrbsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_Qk-XTh-xFkGe4eGf7kiL-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:PriorVirtualStockOptionsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember__LjcvGfb1UeNNJhvKnzSfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:NewVirtualStockOptionsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_FNWBdKYT4kyF3rOWErcVcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanAndRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_eyoLMAfpYEmjeoloCR63rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_RTmSmZOXXk-2ImmT99fn8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:PriorVirtualStockOptionsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember_B5CF27FqDkiLjSzyYwknTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:NewVirtualStockOptionsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_Ef21cT4Rt0mtb7YnbaYYow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanAndRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_fVrZQK9ylkijyiOuCYXjRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_OP3JSfO8UkukL75fSOwjDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:PriorVirtualStockOptionsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember_Fdqd0vf59kCIZsGxx1aGZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:NewVirtualStockOptionsPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_QbDJ8ZCETEeFxx_3bkTRQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanAndRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_DRNBrHJkukm3DAjZM2_dVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_jV-ZSqS8kU2_OpwJggs-Ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_H7lU27CSYkW4Hf-ukTllUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_lxpzPHOK-kuFcVc1SH9Lbw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_2zrm9PnhCkaFBrsWd2DlfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_3_31_2023_f3TFOs23C0GFOdZGdiwIzA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_T6BMdSYhU0uLBiXs_xHhqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_nZ9aTIkD-kKH94WcSt1n3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2021_To_9_30_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_ayQw-BmgEkylsqF_f4Z52Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_3EZn4_xdeES1B53nwQWIjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:FollowOnPublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_DI_gvTm7Okm-0sSSRRNn3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001809122</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_CHF_jBH-rjz8PUGNxxRiXvE2kQ"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_WivF9OzOw0qggSizEvs2xg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ"><xbrli:measure>cvac:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_OIXcQb-ZL02u7t-A0Qaj8g"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_loan_5iHDzlzZyki6zzA0B9i78A"><xbrli:measure>cvac:loan</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag"><xbrli:measure>cvac:Option</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:16.1pt;"><a id="_ebb927ec_6bc0_42bc_a19f_49c1fc0126bc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="dei:DocumentType" id="Narr_U_uVL5GAuE6G2YBU0RwKow"><b style="font-weight:bold;">6-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">PURSUANT TO RULE 13a-16 OR 15d-16 OF THE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:14pt;">For the month of August, 2023</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:14.0pt;margin-bottom:6pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">Commission File Number: 001-39446</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="dei:EntityRegistrantName" id="Narr_ro_e58693EqJh3UloQVcOQ"><b style="font-weight:bold;">CureVac N.V.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<i style="font-style:italic;">Exact Name of Registrant as Specified in Its Charter</i>)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Friedrich-Miescher-Strasse 15, 72076</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">T&#xFC;bingen, Germany</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">+49 7071 9883 0</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">(Address of principal executive office)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&#xA0;20-F or Form 40-F:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr><td style="vertical-align:top;width:28.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Form 20-F</p></td><td style="vertical-align:top;width:15.49%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2612;</span></p></td><td style="vertical-align:top;width:14.83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;</p></td><td style="vertical-align:top;width:27.69%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Form 40-F</p></td><td style="vertical-align:top;width:13.84%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2610;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:28.12%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.49%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:14.83%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:27.69%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.84%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:28.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Yes</p></td><td style="vertical-align:top;width:15.49%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2610;</span></p></td><td style="vertical-align:top;width:14.83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;</p></td><td style="vertical-align:top;width:27.69%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">No</p></td><td style="vertical-align:top;width:13.84%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2612;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:28.12%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:15.49%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:14.83%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:27.69%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:13.84%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:28.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Yes</p></td><td style="vertical-align:top;width:15.49%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2610;</span></p></td><td style="vertical-align:top;width:14.83%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;</p></td><td style="vertical-align:top;width:27.69%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">No</p></td><td style="vertical-align:top;width:13.84%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 1pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#x2612;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_de6d2826_5ce2_4694_9f45_a106a84f9585"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">This Report of Foreign Private Issuer on Form 6-K (this &#x201C;Form 6-K&#x201D;) is being furnished by CureVac N.V. ("CureVac") to the Securities and Exchange Commission (the &#x201C;SEC&#x201D;) for the sole purposes of: (i) furnishing, as Exhibit 99.1 to this Form 6-K, Unaudited Interim Condensed Consolidated Financial Statements announcing CureVac&#x2019;s financial results and business updates as of June 30, 2023 and for the three and six month periods ended June 30, 2023 and 2022; and (ii) furnishing, as Exhibit 99.2 to this Form 6-K, Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations, which discusses and analyzes CureVac's financial condition and results of operations as of June 30, 2023 and for the six month periods ended June 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The information included in this Form 6-K (including Exhibits 99.1 and 99.2) is hereby incorporated by reference into the Company&#x2019;s Registration Statement on Form F-3 (File No. 333-259613).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_6102ec04_d7d2_4c9b_a6f3_f2196116ccb7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CUREVAC N.V.</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:46.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:46.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/Alexander Zehnder</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:46.94%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:46.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:46.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: August 17, 2023</p></td><td style="vertical-align:bottom;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;width:46.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_1b24fcc5_679a_4944_a4d8_2c903cdc3de1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EXHIBIT INDEX</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:13.38%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">EXHIBIT NO.</p></td><td style="vertical-align:bottom;width:2.16%;border-bottom:1px solid transparent;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;width:84.44%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 1.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">DESCRIPTION</p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:13.38%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.1</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"></td><td style="vertical-align:top;width:84.44%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20230630xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2023 and for three and six months ended June 30, 2023 and 2022</span></a></p></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:13.38%;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">99.2</p></td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:top;width:84.44%;margin:0pt;padding:0pt 0.25pt 0.25pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="cvac-20230630xex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>cvac-20230630xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.3.0.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/17/2023 6:46:48 PM -->
      <!-- iXBRL Library version: 1.0.8528.25195 -->
      <!-- iXBRL Service Job ID: fadbf635-6315-4710-86ac-f1609a868cb6 -->

  <html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:cvac="http://www.curevac.com/20230630" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="dei:DocumentPeriodEndDate" id="Tc_NGnz0PbQ-E2JXAd0yiYv-Q_7_1">2023-06-30</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="dei:CurrentFiscalYearEndDate" id="Tc_yad1LJJvlkmgYJqJr4VJug_15_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="dei:DocumentFiscalYearFocus" id="Tc_u3nQaPVOO0iWMoZZoq6CcA_16_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="dei:DocumentFiscalPeriodFocus" id="Tc_H1m5I97MA0uENqiL59C1lQ_17_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="dei:EntityCentralIndexKey" id="Tc_HRMEMyIBP0mYU1xsblbMTg_18_1">0001809122</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="dei:AmendmentFlag" id="Tc_YiIvo9dvAkas9Eh6xcvvJA_19_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q" contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_1dYKs1W9uU6tOrLCufufjQ" decimals="INF" name="ifrs-full:ParValuePerShare" id="Hidden_MiCnzCrlpkmaZN49iUzGgg">0.12</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cvac-20230630.xsd"></link:schemaRef></ix:references><ix:resources></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:75.74pt;"><a id="_1ba707b7_c96d_4b44_ae72_6c0053965dc1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 50pt 0pt;"><b style="font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="cvac-20230630xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:75.74pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:217.47pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 50pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 17pt 0pt;"><b style="font-size:17pt;font-weight:bold;letter-spacing:-0.3pt;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;letter-spacing:-0.2pt;">Unaudited Interim Condensed Consolidated Financial</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 30pt 0pt;"><b style="font-size:17pt;font-weight:bold;letter-spacing:-0.2pt;">Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">As of June 30, 2023 and December 31, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">and for the three and six months ended</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.2pt;">June 30, 2023 and 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:18pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_945bcc17_01dd_4558_b7f4_f15e6a375641"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Interim Condensed Consolidated Statements of Operations and</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Other Comprehensive Income (Loss)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_1ddfc555_2be3_4812_8506_3b38be9cee9f"></a><a id="_da8fe3b7_3ba5_4de4_a879_147f3c3a2419"></a><a id="Tc_MDMJ-k_v0UmKdvoG7ZuQRQ_1_4"></a><a id="Tc_cKl0BnRSk0GgTZ4D1Qe0NA_1_8"></a><a id="Tc_qgrrWPhH00SbSaEwjgw4Dg_2_2"></a><a id="Tc_EMpyOa_CX0CtpQTSfbAX1g_2_4"></a><a id="Tc_ofUd0QbutUGmXoqUtL2XqA_2_6"></a><a id="Tc_HyYo1hcaTUWWpBsg6l9Cdw_2_8"></a><a id="Tc_X0BoMmtuQ0aadZNlcvUW5A_2_10"></a><a id="Tc_X65v4CWAa0S9NFyMhgxi5w_3_0"></a><a id="Tc_GIuo4FEDw0-wAbYpLuQ5ww_3_4"></a><a id="Tc_rXz9g5SEJkqhWMbhZMt3jA_3_8"></a><a id="Tc_pmb1HZN9t0KbSJpVmqp-8A_4_0"></a><a id="Tc_pGeqxWw5zEua4-ZLoTCQbQ_4_2"></a><a id="Tc_r1Tsw7kWUUS76OQiyvqX4g_5_0"></a><a id="Tc_B54k0CZLEUa-UPVzwha6ZQ_5_2"></a><a id="Tc_1B14IKzqPEeeHFtwH6ZUrA_6_0"></a><a id="Tc__jugx8dMlEaRhBmyRr1fXw_6_2"></a><a id="Tc_3KNwGjwD3k2A6Re9_ylmfw_7_0"></a><a id="Tc_ix44CKaOqkmEmpB-vzcfWQ_7_2"></a><a id="Tc_-NdcAqZRl06GnyEhg9y0ew_8_0"></a><a id="Tc_0KjP9vXp00OEbtNvSfKVJw_8_2"></a><a id="Tc_n5JdAzzNJEarx7XJLxLOFg_9_0"></a><a id="Tc_MfbHoBdqYkiWgDxkSM4dZw_9_2"></a><a id="Tc_ofihDj6V4UuePd6mCMPyPQ_10_0"></a><a id="Tc_qTQw5JFpgEmWb1_Riy5UhQ_11_0"></a><a id="Tc_b6y2S6RRUU2Nq02fdDWPBA_12_0"></a><a id="Tc_-hocuibHUUm-vyV2XjI5oA_13_0"></a><a id="Tc_TfnYA8OPW0iGa9RxI4qcpA_14_0"></a><a id="Tc_wGC89-jxI0mWe60OU_cATQ_15_0"></a><a id="Tc_3yTN_o8MXk62AyRe6_9cPQ_15_2"></a><a id="Tc_N_bSCGxOgky4oPjKHW0lig_16_0"></a><a id="Tc_ByUCqu_RT0e27r_C8Y19dQ_17_0"></a><a id="Tc_sBwQ2qKZ3EOwpbEgWqtZ0Q_18_0"></a><a id="Tc_lGB9IwKtEEiVZ9D1RnkY8A_19_0"></a><a id="Tc_xDSBFSv0qka3QpavX59bZg_20_0"></a><a id="Tc_jEOai4YDskKTkKSuXHteXg_20_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:56.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:56.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="11" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR, except per share amounts)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_eko0ETKRnEOj9atVrfCNUQ_4_4">20,146</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_l07HI9wB-ECNXueEHBfwlQ_4_6">7,579</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_Zjovh9ADJUCbh3VVsw1jZA_4_8">44,519</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_BKXj7BjEyUqkhLnPjzJKlQ_4_10">14,708</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CostOfSales" scale="3" id="Tc_Yc-Tw07_A0uEy4l84a02qg_5_4">42,681</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CostOfSales" scale="3" id="Tc_xlTCw70y1UyNPttW8WI36A_5_6">25,854</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CostOfSales" scale="3" id="Tc_n9EZCV_IeUuyPlnou9rkhw_5_8">79,913</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CostOfSales" scale="3" id="Tc_Wru5XMfckk6HvLUl8o9POw_5_10">46,489</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_bhBIGlKN7UCj0eURNr5FaQ_6_4">548</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_FD2xHZCUfkSAB5B5qoAxxQ_6_6">1,408</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_aXvnQkGkqUC1XfBF0szTJg_6_8">819</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_IB5mOdn1a0GglL-U7lZOxg_6_10">2,232</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_Kv6Lu0jj10G_DLtUB6goqg_7_4">11,635</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_M_bdBPRuUE6wEi9YpRlRKg_7_6">30,868</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_g-BcMi3EgUWE9vF-qr9dbQ_7_8">22,422</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_xM8qoVbOfkOTggTdHsIixQ_7_10">55,118</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_kBMfdOA75kG6ULVT8MprPg_8_4">27,112</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_Jayudat5Ek2QeYDmMYyVGA_8_6">22,245</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_LFXA_R-4N0Ssh5JXvdTZ2w_8_8">51,678</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GeneralAndAdministrativeExpense" scale="3" id="Tc_So9rM41AH0-p4RVeAQeJaQ_8_10">45,532</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 3.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_TP6pg2Q_7USkdPa7gOlZcw_9_4">1,771</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_koIwpO28o0ShGXszs3dq5w_9_6">1,442</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_Du1vpBj9uU6gz9XqGIqzHw_9_8">35,207</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_zdbL4y5n2EmWl5dHG50SaQ_9_10">3,448</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="Tc_MZpYgT0u10qw0npfQpxUIA_10_4">238</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="Tc_ey6S4Svbt02zf7j95rKmcg_10_6">447</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="Tc_i0zVno-hSUOLKxyw2JPi8Q_10_8">461</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingExpense" scale="3" id="Tc_TwkW1Yy7DEmkCC5mkG3lwA_10_10">942</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_EVSytpN0o0qy39wqYuqmVg_11_4">60,298</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_o6kHTPDNskm7ohUTKrLp9A_11_6">71,801</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_NDqQPbbFVUGQCwBTVk9iwA_11_8">75,567</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_SZR4ss-SqEeCRDpI4IGsmA_11_10">132,157</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_CZeozgiL_E-oHkjL2P0ACA_12_4">3,322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_Ql1-aAUcK0ik6ma0krObCQ_12_6">6,197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_OgcJQiU02keHgyqyy24O2A_12_8">5,343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_5xs3qZDzF0ioxvJKgPq8VQ_12_10">10,085</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_EmaUk-oZoE-VLb_vq6Tflw_13_4">594</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_pcjJIYPlOEOMIFdSed8D2A_13_6">1,783</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_l_4vgyp3SkuhEFn1BYjsbg_13_8">2,535</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_10EQCEVFBU27j-63fSqw-w_13_10">2,734</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Loss before income tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_kYzS9qjdrEqcM-VKk3nD1A_14_4">57,570</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_C82yC6ABkUCh-AuyUFHZiA_14_6">67,387</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_xOVm6BXj5k-KIB6k644FBA_14_8">72,759</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_39uFCaqSpE2RHp1TcL0voA_14_10">124,806</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax benefit/ (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> 13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="Tc_Nl2V2pP6eUu4R9dTHsU11A_15_4">14</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="Tc_c_rxiJ8mX0uCAF3xDl9_1Q_15_6">26</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" sign="-" scale="3" id="Tc_TB60QvrKn0iuSXsKj95DDQ_15_8">82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncomeTaxExpenseContinuingOperations" scale="3" id="Tc_8NDlfEUEeUyCx6fSx0lnDw_15_10">27</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_g8s15-QQD0iP9GYHDYIibA_16_4">57,584</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_AbTlT6PLG0CEcppMZofwoA_16_6">67,414</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_M0m8AVWY0E2b_LxNyUkqTw_16_8">72,677</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_VhXA4mzlcUGrH23U_RbuPA_16_10">124,833</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Other comprehensive income (loss):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Foreign currency adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="3" id="Tc_KVhRcMdOUkK96pLPJ9apgw_18_4">158</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="3" id="Tc_2n7t-B5P3k6tkUYj7QVABQ_18_6">3</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" sign="-" scale="3" id="Tc_5ERhUZbizEizLAXCKTSBew_18_8">212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" scale="3" id="Tc_vKT9Kr1mh02jj9liDfG8vg_18_10">16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total comprehensive loss for the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_hPcIoEIM3kW6An9Ay50gNw_19_4">57,742</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_nppLadYcA0S6ondstNnZVw_19_6">67,416</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_BNPMlHaPp0muKOg6SaZfOg_19_8">72,889</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_BGFiqrVL8U6yNGbizYR8LA_19_10">124,816</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share (basic and diluted)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_AMNs1elE50-2RUo5KbD5yw_20_4"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_AMNs1elE50-2RUo5KbD5yw_20_4_2">0.31</ix:nonFraction></ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_FujabZ_KI0esQLT8qVI0UA_20_6"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_FujabZ_KI0esQLT8qVI0UA_20_6_2">0.30</ix:nonFraction></ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_U5sCrOmJKEaDglFnQV6gnA_20_8"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_U5sCrOmJKEaDglFnQV6gnA_20_8_2">0.39</ix:nonFraction></ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Tc_L2_sq3N8c0eP22v65xAE3w_20_10"><ix:nonFraction unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:DilutedEarningsLossPerShare" sign="-" scale="0" id="Tc_L2_sq3N8c0eP22v65xAE3w_20_10_2">0.57</ix:nonFraction></ix:nonFraction>)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these interim condensed consolidated financial statements</i>.<br /><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_4aa7dd01_c5cd_4758_98d3_bbe0606ab44b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Interim Condensed Consolidated Statements of Financial Position</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_6e74aabb_0b12_4803_9703_0900f19ee9c2"></a><a id="Tc_g0awcJ8LQU2lE_kUgszNHw_1_4"></a><a id="Tc_QKMC6VLLMkeLkiCng_jFJQ_1_6"></a><a id="Tc_-yHlXiz4NUKS8L67bJOEkA_2_2"></a><a id="Tc_f19MARJCsU6uRh_j_vlNKg_2_4"></a><a id="Tc_dTH6ZqOJa0Shh2NnndDb7A_2_6"></a><a id="Tc_GDiARWYhkEu2D9VVnbdIOw_3_0"></a><a id="Tc_-mhLLGwcf0-4EOK9z3-n7w_3_6"></a><a id="Tc_uV8EbxT-skSYWtzxD_8xrQ_4_0"></a><a id="Tc_q2BYNyvcM0C4qM1CcniDjQ_5_0"></a><a id="Tc_YU7f2ZbX50iddL_R3Kg__A_6_0"></a><a id="Tc_NorKsk9LaU-1H2xuM5i2qw_6_2"></a><a id="Tc_fznvbP9eLEORVcpq9IU4mg_7_0"></a><a id="Tc_oeJ33lYbUU-ZgtoGEpwKmg_7_2"></a><a id="Tc_cinekNEeiUaTM59zYIA8_g_8_0"></a><a id="Tc_ih60gNukMEyoLpWWuwSfzQ_9_0"></a><a id="Tc_FiDsQxTSAkStrFyITgDohg_10_0"></a><a id="Tc_y8kWijNu3kSM7u5Wql_PCQ_11_0"></a><a id="Tc_mvMd7QVVwEOnZxesE_t41Q_12_0"></a><a id="Tc_5Ehnl41MT0e8--i0kBUBow_13_0"></a><a id="Tc_vrqEkzS-5ECdb5yR14tmAQ_13_2"></a><a id="Tc_HqPOmHcuzkuOBqcdlIvHIA_14_0"></a><a id="Tc_WYuIu8PdvkySaCFbikJUCg_14_2"></a><a id="Tc_D6CPMQZluUKhAIdA-EI2AA_15_0"></a><a id="Tc_nOKW6gdlgUOQUgKrh6-cBg_15_2"></a><a id="Tc_BMm11VpBfUyhZXNanyV2xA_16_0"></a><a id="Tc_B_iM1QMEyk6MDcsGU0QBag_16_2"></a><a id="Tc_SQYKw55h0EqWTgU5zDByaA_17_0"></a><a id="Tc_-WyIQYKDBkOw1KRDN8gf8Q_17_2"></a><a id="Tc_cj0H3eAPAUy-r3haim0Pog_18_0"></a><a id="Tc_HRbY3j1Qq06IHpYI-S-E2A_18_2"></a><a id="Tc_JHySxbguGUGQJImhwI4beg_19_0"></a><a id="Tc_5_1karsoHkCRetTGZo1C7g_19_2"></a><a id="Tc_3EzPrxuRS0uqcmV0HTaR0Q_20_0"></a><a id="Tc_MULWrQQN1kG1WdYu-v-c8Q_21_0"></a><a id="Tc_rS_hNlVndkOZDyM4pciQAg_22_0"></a><a id="Tc_Dj9uDh9UJ0yjBS1EfaqZSQ_23_0"></a><a id="Tc_S6J9JJgM8E2QH_b76nMxRA_23_2"></a><a id="Tc_jHsKzqjs30-1Sg9Phl3xIw_24_0"></a><a id="Tc__a-2ajjHT0Ck6Q1iU16o5g_25_0"></a><a id="Tc_61U6Mtq6EESwebnlpCx6MA_26_0"></a><a id="Tc_U9_-Ap0e2kC8SjRc9bUIEA_26_6"></a><a id="Tc_1GnAJv-D20e5RqW0EeIKzQ_27_0"></a><a id="Tc_Ka5Kw1YCKEy2Jovi4aYwww_28_0"></a><a id="Tc_g2eC3-hMeUqxu2kGAa2AsA_29_0"></a><a id="Tc_-kAGXtrTc0mtABYLeNGydw_30_0"></a><a id="Tc_SCPXhuWQuEiU58q9ZYZKQQ_31_0"></a><a id="Tc_tIKJ8dmJe0a2W1YKCBkYhA_32_0"></a><a id="Tc_bytvuV9YMU2z2jKB1FLPMw_32_2"></a><a id="Tc_jOVniQAvA0WStWQozp2ZQg_33_0"></a><a id="Tc_2D0U4bYWzkeQpuKi12GHTg_33_2"></a><a id="Tc_L8ciG06gm0SeDoRpu5bSnA_33_6"></a><a id="Tc_kRl1bIFEqEq8TNj7gyQ3bA_34_0"></a><a id="Tc_UpWk6GzXo0uvp7k0LKFOGA_35_0"></a><a id="Tc_hRMaJqd6JUuaN0LlKqm2ow_36_0"></a><a id="Tc_d3mCCywM_0Gnvl1Eo0o_5w_37_0"></a><a id="Tc_ZXPYR-_6hE6R1n7OxVGdEg_38_0"></a><a id="Tc_Z2SvnCgX7USE63n2PD5sOw_38_2"></a><a id="Tc_3mI50lupdUuRamqDOFrseg_39_0"></a><a id="Tc_ZBMwEm5LxEOtTubymStlCw_39_2"></a><a id="Tc_RHB3RZZNtECFq0YDQpmRYQ_40_0"></a><a id="Tc_Q9yarCMhmUuXWxQr5i1MTA_40_2"></a><a id="Tc_b05oMtV7CUasVKnH0QZhlQ_41_0"></a><a id="Tc_wyjudlTe_Ea8gdkA1BShJg_42_0"></a><a id="Tc_oOuhYOyM9EC54tc1HuxWKA_42_2"></a><a id="Tc_TjMAsosmeUSLGnj-Ee0_DQ_43_0"></a><a id="Tc_4dTIkJ-3f06sSM-yQrbNjw_44_0"></a><a id="Tc_cl_hNDb3ZkaywlXm3UV-uA_45_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Note</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Intangible assets and goodwill</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="3" id="Tc_QeEwpSKzoUek3FAs0zAL_w_6_4">31,778</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsAndGoodwill" scale="3" id="Tc_ko5crp8xb0Of-7GaXZhz9A_6_6">31,700</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_YeJIMUX93kOjiEHwC7ctAA_7_4">197,941</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_9mhdGrkw7Uyc3gJMyaQSGg_7_6">219,539</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_hccnLPE6P0aKtNlNzWR4tQ_8_4">43,761</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_k_rX7ReYrkyF-fDTw-zDyg_8_6">42,031</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentAssets" scale="3" id="Tc_PbkTaZjslE-qxtFDclw0vA_9_4">1,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentAssets" scale="3" id="Tc_rJJaa2R8iEGmihR5c5aMOw_9_6">1,704</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NetDeferredTaxAssets" scale="3" id="Tc_pPhPss6YP0iJ0gxfe16jpg_10_4">1,297</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NetDeferredTaxAssets" scale="3" id="Tc_klmKI1mUskWLt-S7bRMCYw_10_6">1,296</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non-current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="3" id="Tc_vCZAkLfRP0OtfrCIw6vbSw_11_4">276,443</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="3" id="Tc_AfwFGdxdFka7nJUcCs3-Eg_11_6">296,270</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" scale="3" id="Tc_tfsNDD673kKeXJUgQRTKmg_13_4">10,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" scale="3" id="Tc_9fsLxFUExkaxBM541gTwRw_13_6">9,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_aobjQXFid0ioruGmEBEEYQ_14_4">23,989</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_TLT-GlU5x0CukfCyAkL9Iw_14_6">22,194</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_IsdadCeQRUCuWCVCEnSogg_15_4">6,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_XNmggKCat0-Mbb5hpDntNQ_15_6">6,443</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contract assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractAssets" scale="3" id="Tc_afGggTohvE-ZzpyKVOV03w_16_4">2,707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractAssets" scale="3" id="Tc_OYlelHZZg02o-CKGZwrTVA_16_6">119</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" id="Tc_pD3djsliwkad81X182V2-g_17_4">4,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentFinancialAssets" scale="3" id="Tc_hyKIRsQ100yVKUmi5MBKFw_17_6">5,354</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Tc_gwHKaXv2X0KR32O4kHOWCw_18_4">40,287</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Tc_87CZYVWD3E2HGayBUiZWxQ_18_6">21,221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_4UhfhTo0Dku-o-DBpLsJZA_19_4">495,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_bKa-AkwD2kalAWkwnGwZaA_19_6">537,925</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="3" id="Tc_H-HghU-exkWYXiO6hYKmDQ_20_4">584,029</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="3" id="Tc_vVgu_nXxg0OKW1s0UfNokQ_20_6">603,210</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="3" id="Tc_mFxx91197ku4kTRfeZip6Q_21_4">860,472</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="3" id="Tc_nJdjB4BgSUGXxgSLCFEePQ_21_6">899,480</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Issued capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="3" id="Tc_8yX-c9p2KUe7MK1k8smC9A_24_4">23,400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="3" id="Tc_E8coekaJekycRiQdM_nkTg_24_6">26,866</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Capital reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CapitalReserve" scale="3" id="Tc_o40sFcLDVEGCTskjBnqAPQ_25_4">1,817,287</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CapitalReserve" scale="3" id="Tc_-g2NlV9hHki2j8R-Fw3kDw_25_6">2,052,951</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Treasury Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TreasuryShares" scale="3" id="Tc_vi-nOc0VtEu4JDHkizHmMw_26_4">1,481</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" sign="-" scale="3" id="Tc_05yLuvw6JEOeFyIE-d_FyQ_27_4">1,305,814</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" sign="-" scale="3" id="Tc_QoD5CiOH4kW7auZHJYxq1w_27_6">1,430,647</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AccumulatedOtherComprehensiveIncome" sign="-" scale="3" id="Tc_ilpYOkgwtUW_Jc5P4vqdeA_28_4">139</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AccumulatedOtherComprehensiveIncome" sign="-" scale="3" id="Tc_3KlUri77gECiCUjeXQyAmw_28_6">123</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_lfJ6zoLv7UyBFt0EHz1jfg_29_4">533,253</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_SdBnG4grEUm6EwRTkvzXQw_29_6">649,047</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="Tc_cD7llIDoSU6mEpgIZ03GrA_31_4">37,106</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="Tc_2E64VLQtjkS1HTG1KJ4CyA_31_6">35,276</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentContractLiabilities" scale="3" id="Tc_jeiR7DdH6UG_-2WLeGNKZg_32_4">72,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentContractLiabilities" scale="3" id="Tc_bWyzmX8puE-UEsgN-an5DA_32_6">58,862</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentProvisions" scale="3" id="Tc_UaLitzZhYUKNdrLEGjBiUQ_33_4">61,320</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="3" id="Tc_2ATXj5fgYk6-1tO04lx4FQ_34_4">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherNoncurrentLiabilities" scale="3" id="Tc_LgupaQ8AFUqu61n6zM8q8w_34_6">19</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total non-current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="3" id="Tc_db3IqlRXcE2g1BpZvFGoBw_35_4">170,994</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="3" id="Tc_icP50DSzYU-VIWvIs8x0aA_35_6">94,157</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="Tc_RcKTNmyttUaSCuqMgGIRCg_37_4">4,980</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="Tc_jYjaSE5MVkiIhRsZH1Riiw_37_6">5,205</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Trade and other payables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_TG5eo893H0WeQlty0X23IA_38_4">73,463</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_bBlMCtVwZkaW4VP0Sz5gKg_38_6">13,419</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentProvisions" scale="3" id="Tc_d65S9-oNRUOtsEhZJFFpvw_39_4">1,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentProvisions" scale="3" id="Tc_jbZt7alYDUOtVJWcYSL6pQ_39_6">61,608</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_LmcT1AdKFkWmGO0tF7Q-hw_40_4">40,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherCurrentLiabilities" scale="3" id="Tc_MxIKjgIFc0-JgKiXLyqzsg_40_6">35,514</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Income taxes payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxLiabilities" scale="3" id="Tc_qBP34i6B6U-Y6v8rGryQAA_41_4">610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTaxLiabilities" scale="3" id="Tc_QBZ2mjUhh0uKmFlHIHkLDA_41_6">629</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractLiabilities" scale="3" id="Tc_SkNrMf8uhkmBJPdV9qomzg_42_4">34,759</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractLiabilities" scale="3" id="Tc_kMQgW4QwF0yjkpVCgVqbvg_42_6">39,901</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_vsQoaahdH0-kXWcfeggWYg_43_4">156,225</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_YFId4uVt20ecumWWsE0rIQ_43_6">156,276</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_TtvjbOTXm06Shv9Vu2rK_w_44_4">327,219</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_OoC1_StTTEeREkv4LD7Sww_44_6">250,433</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:70.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total equity and liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_n5l9IXdmRkOfcbSzffK9gA_45_4">860,472</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_UW2uireSKEaI5kG_wXi1GQ_45_6">899,480</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these interim condensed consolidated financial statements</i>.<i style="font-style:italic;"><br /></i><span style="font-style:italic;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_69607e31_d64a_43a6_8e07_2f67a25f0289"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Interim Condensed Consolidated Statements of Changes in Shareholders&#x2019; Equity </b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">for the six months ended June 30, 2023 and 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_8affb9f5_7a37_4d0e_97bd_0bd3dcd38810"></a><a id="Tc_rCYT9ssHwECnsu6XExWvHg_1_10"></a><a id="Tc_53d4Ud8lkkWCu7cf74v_Kg_2_2"></a><a id="Tc_mYGmQQwigkyRQVHtGZuddA_2_4"></a><a id="Tc_MyXI6B6keka9gOlKJn3How_2_6"></a><a id="Tc_XmFKsdczUE-1DEmKzKcnCw_2_8"></a><a id="Tc_HQRb9u_rA0eJ_4JnyfzamQ_2_10"></a><a id="Tc_xb-PBB2WaUeOMx_Pd6Q5Xw_2_12"></a><a id="Tc_BKZi726XHEu1H0FBjlanzQ_3_0"></a><a id="Tc_4LP7S9mu206jREpwRKtTzQ_3_2"></a><a id="Tc_P11Mppk-lkq-uGR-nPyh8w_3_4"></a><a id="Tc_4q9XG6OkKUKqhENp0D4zyw_3_6"></a><a id="Tc_qPzcEEGs0EepvXf5MXbWpQ_3_8"></a><a id="Tc_HitGndkyhU25w_uutHE06g_3_10"></a><a id="Tc_3T_6RC7oJ0yb_gHd5jsgiw_3_12"></a><a id="Tc_iQ0Fl_tHo0i5wRw-kqaCUw_4_0"></a><a id="Tc_xo4eKEe_CEagiEUEebNH_g_5_0"></a><a id="Tc_25TM2PGd-kqDnPXlWy3iDQ_5_2"></a><a id="Tc_gNOGdtp0KUGHiGDi5z1nOQ_5_4"></a><a id="Tc_-KL5BgD9_0qA8WKtGzQOUg_5_6"></a><a id="Tc_gWGvDPE9_kO83oL0_uPNTQ_5_10"></a><a id="Tc_62sEXYQOWkeOQ_nlUt63OQ_6_0"></a><a id="Tc_F0imn-2QjkeeH0wjwxY5Ew_6_2"></a><a id="Tc_4Awp_WxmE0WeudBOOhl70A_6_4"></a><a id="Tc_fzvTSxJd4kGN3r3qlQtrSg_6_6"></a><a id="Tc_7hZYjWxXjEm_Cj63GShLHw_6_8"></a><a id="Tc_t7_ak9Zeo0mYnPw1ChVvHA_7_0"></a><a id="Tc_eDHhcczof0GpMDwNsDmItA_7_2"></a><a id="Tc_lFca373VikOVOIsa53rseA_7_4"></a><a id="Tc_DobKGPwqik-DCui1boP6Zg_7_6"></a><a id="Tc_7rHw7p9CP06hXT3fmQmkiQ_8_0"></a><a id="Tc_3zri-8g3GUy1Z-JBRFmRuw_8_2"></a><a id="Tc_Nw5qHQuvW0Ojl0ZwV-7MSw_8_6"></a><a id="Tc_xydXnjjgSk6DzINAO3WbMg_8_8"></a><a id="Tc_uAPRTKNYDkWHai1Y09potw_8_10"></a><a id="Tc_sZ1CvuRra0SBMUU-Xde_Zw_9_0"></a><a id="Tc_UBoxOOkf6Eer28FM6VvNEQ_9_6"></a><a id="Tc_nXV97bfa50W7xr2BR7tK2w_9_8"></a><a id="Tc_wPLdEy2SgEuZPtJdkGt9gQ_9_10"></a><a id="Tc_HTWwVvVeL0mtUNiyMt1QWQ_10_0"></a><a id="Tc_vSvtcWQcoUOlBjaKppWokg_10_4"></a><a id="Tc_6oVGT1sZOkWVPaLVbuEAbQ_10_6"></a><a id="Tc_6oD25C9d0kilNPPgYX8OrA_10_8"></a><a id="Tc_ARDYOtYeIEqu5QK_j0Mzhg_10_10"></a><a id="Tc_dgvxc3pGZEGp-fKYaEcgEA_11_0"></a><a id="Tc_0mfs71SeDEOYnQ7EIcaEEg_11_2"></a><a id="Tc_rLT9rD2prUWDmIsrjDplfg_11_8"></a><a id="Tc_AWXUf29PxEWGiZk6cS2vTw_11_10"></a><a id="Tc__F4uV1k6eUq6SYYfhLi5pw_12_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:47.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:47.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Treasury</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">translation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(in thousands of EUR)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3SmXevtwJUGcfplEE1poRw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_8XIFPA-I2E-Pya_5drTl9Q_4_2">22,454</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_oMKzJtdhmE-IN4Rb0YyEGQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_Sj93zgWH20iMaN97x_QMeQ_4_4">1,728,658</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_nLufrI8XVUO1H8-sgxRRdA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_DD-xRz-FW0Gr8nr4MroDng_4_6">5,817</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_DUk2M43_BkOYQjRrfn4Oaw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_2ZxEaJf25UWXovCedMgB8g_4_8">1,056,785</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_LeOPOA5JLUa_Tp1X3mtBNw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_gb-3fWVSyk6WuKrB2H9HYQ_4_10">34</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2021_CeiTmQbyAU6m7Qb98_JtDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_Rf-NGduwGEaYYa3pi_XohQ_4_12">688,476</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_EL-e9XEpg060VUWMc35I0A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_N5kOuH025EaAl01HcUuLDA_5_8">72,677</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_xAlZ-z13LkSyFgcDGgH_5g_5_12">72,677</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_6j-rWZQ0mEyD1-UORlTFiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_BOU_RwCAcEqCY_DpzNwnQg_6_10">212</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" sign="-" scale="3" id="Tc_KRl_7c1rgk2FsM9JxX4rkg_6_12">212</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_EL-e9XEpg060VUWMc35I0A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_oifdczIGaEqNXz_1uZag5Q_7_8">72,677</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_6j-rWZQ0mEyD1-UORlTFiQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_ehcKjBC0IUqgCgXqLSuS6g_7_10">212</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_Opoor8bx-0u7DVOZzV9Bjw_7_12">72,889</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based payments (net of taxes)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_6ysCqrsi0EqepTGp5T4G7g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_F5krPDHm7U2_tPREUhuNyg_8_4">2,262</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_S1kWaWtdYke2BA2tE43Lzw_8_12">2,262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of share capital (net of transaction costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_OAM4KSbtK0GhMJvgcN7Cyw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_g9A4gYpHJkmgYvHnt-40iA_9_2">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_6ysCqrsi0EqepTGp5T4G7g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_5At97KLcmEq8yZhuvmHJSA_9_4">4,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_j8tuQQ7g9EqB3Wipq7Qt4g_9_12">4,721</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_OAM4KSbtK0GhMJvgcN7Cyw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_3otER7AGBEO7T7L5vEMZHg_10_2">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughExerciseOfOptions" scale="3" id="Tc_DhqbtC4gIEaQfbgdye339A_10_12">1</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Settlement of share-based payment awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_6ysCqrsi0EqepTGp5T4G7g" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" sign="-" scale="3" id="Tc_lxeXTS_yC0OKHK9GJCpSDA_11_4">3,452</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_oTatH5MWGk2wkKXabym88g" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_nvj2yTIyCUKvAaKO2C9_Hg_11_6">4,083</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_qWMaglAvZUuDQS77YuXpCw_11_12">631</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:47.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of June 30, 2022 (unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_q2iBsZHaNEGTSntINrtOmg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_WnE-FD6OtUeMFjL5sC9yBg_12_2">22,496</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Q6eV7yFRmkKgW83cIj_dXw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc__8oRiSOw7EKQsAZONv-wxQ_12_4">1,732,148</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_uyKdAo0yT0en_uX9rr_yVw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_hA7Eo4C2OkOMLIRLAx5eZA_12_6">1,734</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_89R1ELqZg0iF1defo-Zzrw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_b-nhHovJpUy5Iquk8FYE7A_12_8">1,129,462</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ajhe72dYmU6ikfxrecPTtw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_HnA74gErfEShG-MKpIa-xg_12_10">246</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2022_cSA1WqHadE-LZYGzr1BGfQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_-vLaxeUSnUG70Dk_Rte4ww_12_12">623,202</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="_53791026_d2a8_485c_af8f_0dafa30aee62"></a><a id="Tc_xfHj80VjGEi957VArHLHsw_1_10"></a><a id="Tc_wP0kmYqopEiBFIo-0kXX9w_2_2"></a><a id="Tc__ncM1HMTLUK2j7IVtxCLRg_2_4"></a><a id="Tc_ENRr0PHvDkanf9S2ss7GmQ_2_6"></a><a id="Tc_P9Him1t520yXVWr21wBNvQ_2_8"></a><a id="Tc_vx2rkc6g9kKTQl2gnpMMuA_2_10"></a><a id="Tc_5E4hGoRLlU6tOOEkYHVrog_2_12"></a><a id="Tc_oWYvgZFT2UOSRzOqxI51dg_3_0"></a><a id="Tc_6Pfc7jDsFUKiUzcSD98oLA_3_2"></a><a id="Tc_nbOgRHRJXEW_kazSG-Kgyw_3_4"></a><a id="Tc_l6dBd7xhRUqJN9vv3-a1og_3_6"></a><a id="Tc__1tjgtouAkOof6s8C1WKUQ_3_8"></a><a id="Tc_AskNBsrI1ka9nPxX9TrG9A_3_10"></a><a id="Tc_4rbwnlcuwUGxiomSS6Qz1w_3_12"></a><a id="Tc_-Svk3LOAgECYA-4ovF8COQ_4_0"></a><a id="Tc_jti_k0Q9w0WaFLHSpDzWMw_5_0"></a><a id="Tc_nsSFN_WX5ka1zuP0onnHGA_5_2"></a><a id="Tc_PGO8qMAIckyA0saoa6vQpg_5_4"></a><a id="Tc_EySxp6gwHUyVmpBFEnY8YA_5_6"></a><a id="Tc_uP8c0cnW4ke45jRACCBLVQ_5_10"></a><a id="Tc_aIebmg1ZaEaIk4ThUxTx6w_6_0"></a><a id="Tc_HAWd-Xgb90ONT-N9akRUJg_6_2"></a><a id="Tc_z_JGpIOPrEedmDjdCaKKWg_6_4"></a><a id="Tc_jXTSHaUqukCYhxP7wJm62A_6_6"></a><a id="Tc_pjtgF2V8Bkaj33Sb-wMhVQ_6_8"></a><a id="Tc_xy40JnqP70eBoFWwYH_zyQ_7_0"></a><a id="Tc_ksauSZrK80eSo0DssSqohw_7_2"></a><a id="Tc_VPwln-pRikiZ2Z2gGy8cxw_7_4"></a><a id="Tc_KzjC0R7BO0qwpiQZ-x3vow_7_6"></a><a id="Tc_NBzcM1Nzq0SujnDWsfXBmA_8_0"></a><a id="Tc_OcTB91gQvUef8mMNYdDztw_8_2"></a><a id="Tc_9LvZXt_vPUudd1FMFZ0jFQ_8_6"></a><a id="Tc_YnR2U6JiWU2xvSXwoW5S-g_8_8"></a><a id="Tc_YYubbj6DTU-GtNI5DuGP-w_8_10"></a><a id="Tc_1WhpB1w37UCbI9npS71lDw_9_0"></a><a id="Tc_vJjiDhuc10aqWM-XeCaLyA_9_6"></a><a id="Tc_wFpPAu9pxkS9JgegC9HsAQ_9_8"></a><a id="Tc_uId6v3vgTkuNi19wnpojkg_9_10"></a><a id="Tc_Uucxx2P1uUGGKESkCRQPbg_10_0"></a><a id="Tc_9JcBCRvU-EW6XV3tDj1MHw_10_8"></a><a id="Tc_Tux3qWFXo0eIKgfZpm0xrw_10_10"></a><a id="Tc_uUbKAkRD30-gRi8yqsYFiQ_11_0"></a><a id="Tc_bO6jxob9kka597LvZMT10g_11_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Currency&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Issued&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Treasury</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">translation&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(in thousands of EUR)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">reserve</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of January 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_iDouUQemZEC34ma64ZGubg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_CqDwlyCk4E-Q7rW_Q4X4TQ_4_2">23,400</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_BYtQ55ZkAkixCPBAi-kTXg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_kqoUtUpLKE6RX-olLTXiYg_4_4">1,817,287</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_wLccfvwhOU-7QN08Mnbskw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_tA1A3lXjDkePC2s8Y2hZbA_4_6">1,481</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3RD6LGn_q0aJE9VANwQwiA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_vOD-q5wJG0uTH6C7PrpAag_4_8">1,305,814</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_earTaqxquUCS_GN9m5R30w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_7tCFGKXTCkah8ZzFkU3b-g_4_10">139</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_F0ZdkCq5JEuAnLO8GkYzAA_4_12">533,253</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_f-R_nyf_ukOQR2DltOYQdw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_LZ59zywcG0O9w8TSrVGy2Q_5_8">124,833</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_V0JXUOL6uEut4HYOhmI91Q_5_12">124,833</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_X5PE41bPzEOwyIJ4t92A6w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="Tc_tu8q7noOyk60LlHkdiZSoQ_6_10">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherComprehensiveIncome" scale="3" id="Tc_mHhEmLJwIUKJIgYnNVIiaA_6_12">16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_f-R_nyf_ukOQR2DltOYQdw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_EqWXzZod7UG9rIokaTt_fQ_7_8">124,833</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_X5PE41bPzEOwyIJ4t92A6w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" scale="3" id="Tc_8xMo7dGU70ulLLW2voFtGw_7_10">16</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ComprehensiveIncome" sign="-" scale="3" id="Tc_99Gt6uRC40qYV66BOpqNmw_7_12">124,816</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Share-based payments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_v1QdYh7Q4UaITnRX6S5L5w" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_clL36HZh1Uihw5IWTU9kXQ_8_4">4,572</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes" scale="3" id="Tc_8M_ULEoCQEmrkvr7r8k8TA_8_12">4,572</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of share capital (net of transaction costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_qyAt21N52UKd6WnZPLKiQQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_oUU1BNmr-k2XBE4_of4Mgw_9_2">3,453</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_v1QdYh7Q4UaITnRX6S5L5w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_lPWw8NkJy0OpnQtGt2jSYw_9_4">232,387</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_eUVULYXjD0KSHoN0dq0bKQ_9_12">235,840</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Settlement of share-based payment awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_qyAt21N52UKd6WnZPLKiQQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_JnsaIzrDKk6MD8YJK9joBQ_10_2">13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_v1QdYh7Q4UaITnRX6S5L5w" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" sign="-" scale="3" id="Tc_sdpLprrWjECNldZGLB2Zcw_10_4">1,295</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_IcUfvwha0UqENVJCntKS0Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_rvNJFkpeG0W9vfnTiCRYLQ_10_6">1,481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:SettlementOfShareBasedPaymentAwardsAmount" scale="3" id="Tc_-E6U7UQbBkW5HaaTgtYK2w_10_12">199</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of June 30, 2023 (unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_slG_08aRiU2zjF60wKoFFw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_boe3eqq9AEGLHVXi3BV4LQ_11_2">26,866</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_GHafoSH-TkqVmnjZDhADVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_hk3uRzdJDEmv8p2ppyJHgQ_11_4">2,052,951</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#x2014;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_OQguCGk5x0movmkxQwGifA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_CX6fpq6Eq0qUU1juMtdW1g_11_8">1,430,647</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_wa5QFol_rkS8gG7WwJPCXQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_9HhQs0VEgUy3Y_7e-DSUoA_11_10">123</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_oVLh6STzF0u9vGV1axPsqg_11_12">649,047</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these interim condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_8b0f3600_3d89_4b1a_9a33_0245faa24c91"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CureVac N.V.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Interim Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><a id="_c0e2a4b1_ab2f_4c85_b08c_3a239209dafc"></a><a id="Tc_GuloLRcq0kmXEwWBShbZUg_1_2"></a><a id="Tc_oZBodY99WEOnFr_-q3hCCw_2_2"></a><a id="Tc_SShaBZZHM022vgufzzB3MA_2_4"></a><a id="Tc_Qire1iHShEOqJA8y-xSdaQ_3_0"></a><a id="Tc_Zk4neEJgak2PydaGlNS6gQ_3_2"></a><a id="Tc_vbEenVkw3kqHosOYuFhlmw_4_0"></a><a id="Tc_v2VwvS2Rxk-2dIXrrOtyUA_5_0"></a><a id="Tc_0KI8LfcriEOLVYNJDYxVGA_6_0"></a><a id="Tc_ZpBsBLKYMUWQ8ebHp-kMKw_7_0"></a><a id="Tc_wzg77getHk6xHHAINQF6Bg_8_0"></a><a id="Tc_SChwZdjaU0OL8AvyA5oT9g_9_0"></a><a id="Tc_Is5t5yqd80OldgTp9Txirw_10_0"></a><a id="Tc_qJm_UHW-bEiGG6E-t3BZNg_10_2"></a><a id="Tc_JmMFo76Ppk63O_sUy_sZQQ_11_0"></a><a id="Tc_HBTTiu1aY0yyOXU0U1HWoA_12_0"></a><a id="Tc_zGRNraWL50ykX4wW5NZtBg_13_0"></a><a id="Tc_ZTb3VI508E65rTo9XcUcdw_15_0"></a><a id="Tc_6NttY7QCDE-bEemGxDtM0w_16_0"></a><a id="Tc_2nMRyRokjkmgoxqoFekezg_16_2"></a><a id="Tc_U-USmIw2jE-UhlGf-tnB3A_17_0"></a><a id="Tc_DFocODNFAUefbzN8FSir4A_18_0"></a><a id="Tc_Dn4V_czq4UewyRJtAJLtcQ_19_0"></a><a id="Tc_XCBcUv3ihEWLzGilYIDEXw_20_0"></a><a id="Tc_ERUnEc2_OEanCR2WS4u5YA_21_0"></a><a id="Tc_DXTrSRjlvEifdIuD3_bcvw_22_0"></a><a id="Tc_Hfb_bfT6xUKPQMTfY59loA_23_0"></a><a id="Tc_lLylWPNiKU610yeLXAx67g_23_2"></a><a id="Tc_4dAG3p-fIEGf_M9PMz16KQ_24_0"></a><a id="Tc_hdwVmXPJIUySrV1G-laksw_25_0"></a><a id="Tc_j0JPSov3qkqPNqLLPnxeTw_27_0"></a><a id="Tc_6Y9QTHEFQUClaSise3TH-Q_28_0"></a><a id="Tc_qqWcPOndF0Kq3nDIkNjJUw_29_0"></a><a id="Tc_wQW0e1khe0CEF3v1WHdP9A_30_0"></a><a id="Tc_aBTKfhMzz0eZQlfIhKGSHQ_32_0"></a><a id="Tc_sRBRWpVo6ESZEAiAf2hE1A_33_0"></a><a id="Tc_PmgrAqzcUUClbIQYYriPVA_34_0"></a><a id="Tc_vBHsTrkiakO2CcIGAX7qgQ_35_0"></a><a id="Tc_8KVUBvsoF0iVI2ahwzAM_g_36_0"></a><a id="Tc_940NT5z0YUqCI2flDlpSwQ_37_0"></a><a id="Tc_vS67StXYz0eZybImEwBN0w_38_0"></a><a id="Tc_X1mX5yeCKkS7RB1rtRmQaw_39_0"></a><a id="Tc_3C51-ca500qp20mUDu3xcQ_40_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands of EUR)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_eTSPa1xbx0qroY4O-xndkw_5_2">72,759</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossBeforeTax" sign="-" scale="3" id="Tc_m-kADuHy4UmBGPW7xbmX-Q_5_4">124,806</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments to reconcile loss before tax to net cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" id="Tc_ISVNYktCskOr-QhhkwGf_g_7_2">5,343</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceIncome" scale="3" id="Tc_e9fzJMlFQ0KydEfbblXj6g_7_4">10,085</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Finance expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceCosts" scale="3" id="Tc_-5EhBpaUq0yEm_oO8TzurA_8_2">2,536</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForFinanceCosts" scale="3" id="Tc_6P5tvHsNnEiPmhCrTiB07Q_8_4">2,734</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and impairment of property, plant and equipment and right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="Tc_A66Ywyr1MU6yKV0AjopMbQ_9_2">16,651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense" scale="3" id="Tc_MnbQVa5T4UmyCodz8_uV2g_9_4">11,489</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss on disposal of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" scale="3" id="Tc_-kReIjew-kiVfXInNY5LtQ_10_4">694</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Impairment of inventory and prepayments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ImpairmentsOfInventoryAndPrepayments" scale="3" id="Tc__PP6e2k0WUaCzSLOvmKGpg_11_2">25,687</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ImpairmentsOfInventoryAndPrepayments" scale="3" id="Tc_S_bJZq9wI0W3q2DJV4P1PQ_11_4">6,879</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based payment expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_GsE9vwa6VUiJWfaF_0jwJw_12_2">3,597</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_KgH6lUtbfUa84w4SzilqcQ_12_4">4,572</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Non-cash income from release of provisions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdjustmentsForNonCashIncomeFromReleaseOfProvisions" scale="3" id="Tc_6dyUi58M4kWiF7PWnTq9OQ_13_2">47,242</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdjustmentsForNonCashIncomeFromReleaseOfProvisions" scale="3" id="Tc_uOS8a_Hs2E-6-s-PQonr-Q_13_4">1,634</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Working capital changes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" scale="3" id="Tc_Y-o1umhVpEKKBIvz8Cv1wA_16_4">513</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in trade receivables and contract assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="3" id="Tc_ddvV0MdELUy-cNh82MBqxg_17_2">5,164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" scale="3" id="Tc_At5y-O_xXEqK9HMze30arA_17_4">2,440</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" id="Tc_mn7Rv7rFVUSNPl3gQf-iYw_18_2">16,367</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" sign="-" scale="3" id="Tc_6ZDAEbuS10GNNoveoRnDRA_18_4">5,084</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" sign="-" scale="3" id="Tc_eh32LUH-7USRWu4YSF3ATA_19_2">14,051</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets" scale="3" id="Tc_0aU8krbGokiQcq3kxuFImw_19_4">18,751</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">(Decrease) / increase in trade and other payables, other liabilities and contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" sign="-" scale="3" id="Tc_V3r-uxJDMECrEGak0YZ_rg_20_2">129,038</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" sign="-" scale="3" id="Tc_RQ3y_yvYhEeLUDV4S9Vp5w_20_4">76,002</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Decrease / (increase) in deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDeferredTaxExpense" sign="-" scale="3" id="Tc_c6UobIfXBk-a1U0I7FSx-g_21_2">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDeferredTaxExpense" sign="-" scale="3" id="Tc_n3XUp9Y0i0evJ36zPZQPoQ_21_4">25</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income taxes paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities" scale="3" id="Tc_yiwIx1lUAE2RvtQF3FA9Bw_22_2">126</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities" sign="-" scale="3" id="Tc_kwnAQLMOpkG_GX8C-yXHMA_22_4">18</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestReceivedClassifiedAsOperatingActivities" scale="3" id="Tc_p37h0RMTIUaGnmhboTZfiA_23_4">6,838</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="Tc_96yJcXSDe0asdi9OT8wASA_24_2">2,608</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InterestPaidClassifiedAsOperatingActivities" scale="3" id="Tc_j6dNJAsq2U6LtStOUmydfA_24_4">994</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash flow (used in) operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_g2QOwAPGqkmj0GOn2gjudg_25_2">201,175</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_VLnvUBuxAU-g4se3hQWg6w_25_4">163,702</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  <span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchase of property, plant and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_tyDhKXn8GUaZVImTqMs3pg_28_2">43,507</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_kLR9k2f8h0a6vfCsuYMJ0Q_28_4">27,222</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Purchase of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="Tc_i14tOvthkU2xcEI2tI-s1g_29_2">1,208</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" scale="3" id="Tc_3z4lkCMeP0GtIysFCdZoiA_29_4">147</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash flow (used in) investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_MhUQ6pTwA0qU-_93pnfQnw_30_2">44,715</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_9CulnPJCv0Gq4ghc0VbBxg_30_4">27,369</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments on lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_eZwOF-p8SkuaYt_qhY8nrw_33_2">1,943</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_z9vO1mfFTUWyWRGcbQbATg_33_4">2,526</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Proceeds from the issuance of Shares (net of transaction costs)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" id="Tc_IU5Zsg3efEWkNex0SLa2WA_34_2">4,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" id="Tc_g5dXqJ_7IE2-9ZQ4lxhWjQ_34_4">235,840</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payment on / proceeds from treasury shares/exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" scale="3" id="Tc_t0POOmq4kUaSaJkRvTOMnA_35_2">631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" scale="3" id="Tc_D4zSR05SDkGPyM3sFNXX4w_35_4">199</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net cash flow provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="Tc_0FC6H2sCtUuuHR_AQFIjiw_36_2">3,409</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="Tc_qFwuJ-ca2k6fJqrzXXwo5g_36_4">233,513</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" sign="-" scale="3" id="Tc_nNrLHanxvEqJ8QQUxZVBRg_37_2">242,481</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" id="Tc_LutRKJfB402tdpcAfONxiw_37_4">42,442</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Currency translation gains (losses) on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" scale="3" id="Tc_VfDMKEqaTEmg_z2Ncd9syA_38_2">4,583</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_I8j2d-tenky48okImx8DXQ_38_4">314</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents, beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2021_CeiTmQbyAU6m7Qb98_JtDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_wBn0FW3HFkapgZvvKXldFA_39_2">811,464</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_1aqkuqdTpk-uVHvz57K1mg_39_4">495,797</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Cash and cash equivalents, end of period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2022_cSA1WqHadE-LZYGzr1BGfQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_I_1tXOhUfUG2ixW53ekz4Q_40_2">573,566</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_CW2jIkqHqke5jcb4GgZNCQ_40_4">537,925</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">The accompanying notes are an integral part of these interim condensed consolidated financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="cvac:CorporateInformationTextBlock" id="Tb_PJop5EfKeESzFZ5tMsUIaw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">1. Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac N.V. (&#x201C;CureVac&#x201D; or &#x201C;CV&#x201D; or the &#x201C;Company&#x201D;) is the parent company of CureVac Group (&#x201C;Group&#x201D;) and, along with its subsidiaries, is a global biopharmaceutical company developing a new class of transformative medicines based on the messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company is incorporated in the Netherlands and is registered in the commercial register at the Netherlands Chamber of Commerce under 77798031. The Company&#x2019;s registered headquarters is Friedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany. During 2021 until now, Dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac. Together with its related parties, dievini has held shares and voting rights in CureVac between appr. <ix:nonFraction unitRef="Unit_Standard_pure_OIXcQb-ZL02u7t-A0Qaj8g" contextRef="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_gU3vE82A102SoPkxvd1bwQ" decimals="2" format="ixt:numdotdecimal" name="cvac:PercentageOfVotingInterestsHeld" scale="-2" id="Narr_L1vb7FBmwEagYRwP4PI1OQ">37</ix:nonFraction> &#x2013; <ix:nonFraction unitRef="Unit_Standard_pure_OIXcQb-ZL02u7t-A0Qaj8g" contextRef="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_HRw1loMHOkC_Vjug3m60AQ" decimals="2" format="ixt:numdotdecimal" name="cvac:PercentageOfVotingInterestsHeld" scale="-2" id="Narr_YrWYYsKjMEOdb91kWDcCQg">46</ix:nonFraction> % during that period. dievini is thus considered to be the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock" id="Tb_JLGEw9F140eT278v8y1Q5A" continuedAt="Tb_JLGEw9F140eT278v8y1Q5A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of preparation</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="Tb_Y5sMOzQi7E2ZTN8PK4OhNw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements for the three and six months ended June 30, 2023, have been prepared in accordance with IAS 34 Interim Financial Reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#x2019;s annual consolidated financial statements as of December 31, 2022. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on August 16, 2023. The Group&#x2019;s interim condensed consolidated financial statements are presented in Euros (&#x201C;EUR&#x201D;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts. Due to rounding, differences may arise when individual amounts or percentages are added together.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="cvac:DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" id="Tb_4b-gA7jIDkWkmjS0vUZxzQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New standards, interpretations and amendments adopted by the Group</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#x2019;s annual consolidated financial statements for the year ended December 31, 2022. The new and amended standards and interpretations applied for the first time as of January 1, 2023, as disclosed in the notes to the consolidated financial statements as of December 31, 2022, had no impact on the interim condensed consolidated financial statements of the Group as of and for the three and six months ended June 30, 2023. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="cvac:DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" id="Tb_tu4Wz8x0vU-TZbZ8kTimmQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Impact of COVID-19 and the Russia-Ukraine Conflict</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#x2019;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#x2019;s operations, including research and manufacturing, could also be disrupted due to the potential impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to the Group&#x2019;s laboratory and production operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#x2019;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:5.75pt;"><ix:continuation id="Tb_JLGEw9F140eT278v8y1Q5A_cont1"></ix:continuation><a id="_Hlk143038140"></a><a id="Tc_uEjC9CtLc0-aDhjBQqFEDg_1_2"></a><a id="Tc__XawB1wn7k-yxptlaIMNuA_1_6"></a><a id="Tc_7ptOM5B82EyT3qUij2ZiUg_2_2"></a><a id="Tc_eTNSpb2nOU6dL3FXFwEpAQ_2_4"></a><a id="Tc_3puts20q8U626VOhm0CC5w_2_6"></a><a id="Tc_MFVIfUv96EeKmk9934z2WQ_2_8"></a><a id="Tc_cRTWKCCHMU6I51Lsj8dP2w_3_2"></a><a id="Tc_pCiwOIPk5Uaqdg6As41b9w_3_4"></a><a id="Tc_6ZPaBqe8BEe4hp9zYeCWaQ_3_6"></a><a id="Tc_NhgYbDe-CUiJcQ8T1Zk09w_3_8"></a><a id="Tc_gDTvpwtgVUOnfgr_MfOa-Q_4_0"></a><a id="Tc_pka1Cfv8_EKhCo-858pDpw_5_0"></a><a id="Tc_B8qu73Tq00qREhbZ95joWQ_6_0"></a><a id="Tc_97BySOboiE--dHLNLYOJSw_7_0"></a><a id="Tc_Rf5c-iqYr0WiWqvk_jf7Qw_8_0"></a><a id="Tc_plWmF964mkSzpP_vkst0XQ_9_0"></a><a id="Tc_C9iUHW6NGEC4o1646fuN7g_10_0"></a><a id="_e90e3f68_b522_416b_8175_63d388a14daf"></a><a id="Tc_GxPm82Ulzki9TR6OfScRUA_1_4"></a><a id="Tc_mQUltcmTA06453adQRtyIw_1_6"></a><a id="Tc_vtnzulZd1EeoO_tQIuNfIg_2_4"></a><a id="Tc_XlM2gyp00UOqbdsSAIFAZA_2_6"></a><a id="Tc_kelp6WiU_EWKBO0-YgwyCg_3_4"></a><a id="Tc_EUQF9jYQcEmPfSKh3tt5DA_3_6"></a><a id="Tc_zWgtpzuLdUqWs8k7ST_dxw_4_2"></a><a id="Tc_XoIDbN_arU2s0UobA5nj_Q_4_4"></a><a id="Tc_nDkaEe6GyECn00qJ02Udlw_4_6"></a><a id="Tc_kSfHyLRySE2ytUMsS-lbgA_5_0"></a><a id="Tc_nGaRWlOSh0K8RQ17weQL2Q_5_2"></a><a id="Tc_q_Nwp8ZZj0aoxroRBMFhww_5_4"></a><a id="Tc_S-KAqOHv_kaZapy0_SPG6A_5_6"></a><a id="Tc_SFot7VZETkCKvnMDz-NPIg_6_4"></a><a id="Tc_imabxyaTQkCn-vOQnltkWQ_6_6"></a><a id="Tc_ioe3YhWB0UuvOQPmp-zo7A_7_0"></a><a id="Tc_W3j7NevoY0qTwRKng9Sq0A_7_2"></a><a id="Tc_IjLout_iBUSqyWI1dDAfOA_8_0"></a><a id="Tc_PTdZrDH_J0y80zZ19BZ1pQ_8_2"></a><a id="Tc_iZgsmnUNXE-payQXIOrXeA_9_0"></a><a id="Tc_zLE_mRMLOkmOKh1Q8iJrSA_9_2"></a><a id="Tc_yMhNfu6Gfk-zA2djvPgKEw_10_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" id="Tb_3J43JMZkR0GVaM5gZzkDTw" continuedAt="Tb_3J43JMZkR0GVaM5gZzkDTw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Notes to the Consolidated Statements of Operations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.1 Revenue from contract with customers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group recognized the following revenues:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="Tb_Rbyoh_lCeEmmoeEKF5Z6HQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Belgium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_Susx1Gdb5kyVZMPzZFwQjQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_cGFzjFArOk-qXpi2al5qeQ_5_2">19,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_c9WMa6qFu0SqkKP148olXQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_qc6JklcU2U6Aa4oaN0XzwA_5_4">6,283</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_lYvFatpdQkefXIkc7q5t-A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_4LPjKO-ILEa8Yb6FvvJ1tg_5_6">43,041</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_W2T3qdsYzUe0esN9Oty_VA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_t4HTz_xWtUWO-vnHiy-8AA_5_8">12,756</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_pfPO-Kfo-02aNkaKFsNshw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_HRzks8xJukeCPmY2X4dS7A_7_2">406</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_0FmV3jCD_EecBMzp1kB-ig" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_ln4oKxnAZEGHWmEjIj15mQ_7_4">844</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_DrPAKCYehUOOTvRPc2PSVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_-jLL3v-YJUihPnA70wTx5w_7_6">586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_gLKqZqvImUCP4bVr6G8mmA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_z_tx5c0XIECHvgNuR-G1Lw_7_8">1,053</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netherlands</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_1JdarqUTqUixoudVPfLIxA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_DVVqK5T05ka5f_1naukuog_9_2">445</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_mqqCc3YqhUaOpO3VV41sVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_T9ohJmiJykWc50RDozjMKQ_9_4">452</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_JrMg0504CkiFtakq5tBxSg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_gLvJlYnCCE61I7qWIOAAVw_9_6">892</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_FGpCXR_Dc0CnL6--y0XVzA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_tbV4GGyW1kCdWNW2JUIfuw_9_8">899</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_DNgvEXfok0Cfj7ONyAD7HA_10_2">20,146</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_V3_-DOvhbUSISq57PQDrRg_10_4">7,579</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_u2ZySs2bFUG5cSNjER0NXw_10_6">44,519</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Tc_bGJz8hFm6kehx845xSkv5w_10_8">14,708</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of these revenues, all of which were recognized over time as part of collaboration agreements, during the six months ended June 30, 2023 EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_mI2esD2990ujSWl2t4bAJA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_dZ8bB60qO0WFhPb-KPJ8OQ">8,545</ix:nonFraction>k (June 30, 2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_uu0hAMQGFE6RW7mIBHTXqw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_G8R9xr2VVke_e9qYIdW_7w">31,818</ix:nonFraction>k) related to (i) delivery of research services combined with an IP license (recognized from the upfront payments and achievement of certain milestones as further illustrated in the table below), (ii) EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_NmehV27LsECWx1f7ZlhZVA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_VxMIzeO9fkq_-ZnemqKluA">903</ix:nonFraction>k (June 30, 2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_t_V-9jzIX06zZ0Zkpmf8dw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_YoUzku5u0U-gEERfJJMnUw">431</ix:nonFraction>k) related to delivery of products and (iii) EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_CTQr6H0pakGthZr8dk5c2w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_78daE2LRZE-dVZ7ROpXIMw">5,260</ix:nonFraction>k (June 30, 2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_VPTtXuLSnUmuuBX4S-iEMw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_K3CYL4U9w0m3doEPyFl_tw">12,270</ix:nonFraction>k) were recognized from research and development services that are considered distinct from other performance obligations in the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of the total revenues recognized, in the six months ended June 30, 2023, EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_W2T3qdsYzUe0esN9Oty_VA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_tzGNisKdj0mtZ2crkxbjKQ">12,756</ix:nonFraction>k in revenue was recognized under the collaboration agreements with GSK, entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens (&#x201C;GSK I&#x201D;) and in April 2021 for research, development and manufacturing of next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as the CureVac&#x2019;s second-generation COVID-19 vaccine candidate, CV2CoV (&#x201C;GSK II&#x201D;). In the first quarter of 2022, the Company reached a development milestone of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_DI_gvTm7Okm-0sSSRRNn3g" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdditionalDevelopmentMilestonePaymentsReceived" scale="3" id="Narr_JUTEwpaQJkur4rbNeX7Kqg">10,000</ix:nonFraction>k under the GSK I collaboration. Therefore, revenue for the six months ending June 30, 2023, also includes recognition of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_vUXz2-MgLkyPVrGTn6EwAw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_NmTzwEHpukiG_XsYKFA08g">755</ix:nonFraction>k of the milestone amount (June 30, 2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_9dT7Tb1Duk2jWvysh9Lqaw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_qCjMncy8bU27anFVWHw1kg">5,321</ix:nonFraction>k). The remaining EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_hOXsDH0Qk0OcmChZ7BhnqA" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" scale="3" id="Narr_MxO34eCT0UaCZ92y5OuuiQ">2,989</ix:nonFraction>k of the milestone amount is deferred as contract liability and will be recognized into revenue through the latest expected submission to authorities, which represents the period of time during which CureVac is responsible for development as, subsequent to this period, GSK will be responsible for further development and commercialization. In the six months ended June 30, 2022, revenue consisted of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_lYvFatpdQkefXIkc7q5t-A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueFromContractsWithCustomers" scale="3" id="Narr_dGmAcdHOh0uQRjJG0QSAbQ">43,041</ix:nonFraction>k primarily recognized from the upfront payments under both collaboration agreements with GSK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Group has received upfront payments which were initially deferred and are subsequently recognized as revenue as the Group renders services over the performance period. Below is a summary of such payments and the related revenues recognized:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" id="Tb_oAyiSj00g0GppvnCqAFZ1A" continuedAt="Tb_oAyiSj00g0GppvnCqAFZ1A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and milestone&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;liabilities&#xA0;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;liabilities&#xA0;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">GSK  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:25.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ZuAhdHNvcUy-pqQHWJ5p2A" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_Itjl036pnUiR8lpKKwFtzQ">205,000</ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_kEyr9vg-3UGfXM6bAe71zQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_-Zi1l-N5kE2I2VtHEsMivg">10,000</ix:nonFraction>k milestone payment included)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_JK3MBg80MEGeA_HLbxHAbg" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_6wDXBmLfnE-SGrZfboK-Jg_7_4">102,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ZuAhdHNvcUy-pqQHWJ5p2A" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_EFF-EbKvHEuwk2Ix4GunyQ_7_6">95,307</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">CRISPR  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD <ix:nonFraction unitRef="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw" contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_xXPjPpafwkWy53dbFgOTyw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_aOgxYu6JL0iiYd_7QhddWw">3,000</ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_xXPjPpafwkWy53dbFgOTyw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_CY1rLYEViUazQ7Ox6pOy2w">2,524</ix:nonFraction>k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember__rwT7Mu1jUex_FmfwPvK4w" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_MEBe6XjC9Uu_c0Hol-fP9w_8_4">929</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_xXPjPpafwkWy53dbFgOTyw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_HG_GhHCaCkmZCZ-YE-crzA_8_6">775</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Genmab  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;width:25.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD <ix:nonFraction unitRef="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw" contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_61WhBItdi0aToAp0G6sGBw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_HuZfzFmlKUCd_SjY39TUCw">10,000</ix:nonFraction>k (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_61WhBItdi0aToAp0G6sGBw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsReceivedOrReceivable" scale="3" id="Narr_euq-_AV_eU2emt7qKscELw">8,937</ix:nonFraction>k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_3c8WG3Tl-EmEVVoAZn9cRw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_LEkdvNNJuEGeKrDemuOZ6Q_9_4">3,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_61WhBItdi0aToAp0G6sGBw" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_HC--IRRmAEWvrYveUM9rDQ_9_6">2,681</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_aqQDEC4-fk-oap6JzOo0Ag_10_4">107,308</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:UpfrontPaymentsIncludedInContractLiabilities" scale="3" id="Tc_k0gRpiDfEkypDB3rIVRIVg_10_6">98,763</ix:nonFraction></b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* Translated at the currency exchange rate prevailing on the transaction date.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_2af181b7_14d1_43ff_9a12_c690ebe72743"></a><a id="Tc_OqtdRnUeLU6c6cg_onYy2Q_1_2"></a><a id="Tc_PFYF1yt46U-JPon3ityiLA_2_2"></a><a id="Tc_HB6t3lrFQ0OSQlBj14xHEw_3_2"></a><a id="Tc_nqkkgkY92kSzySUJVYMfaA_3_6"></a><a id="Tc_PusIM5qOTEWr_G6CJuytlg_4_2"></a><a id="Tc_l9tJxrMrKEy0m9HIpQ5aSw_4_6"></a><a id="Tc_i9-TTja8zUCC_7bJwOaaGQ_5_0"></a><a id="Tc_ZJh8Sy2O40C_trNE_IxHZQ_5_2"></a><a id="Tc_MDcnTg9Mdkegjli8wWtDRg_5_4"></a><a id="Tc_jia30ToVc0CTaC16Idk4AQ_5_6"></a><a id="Tc_CjbXa5DiuEu1oax4eEdeQQ_5_8"></a><a id="Tc_k-5F_r7mekWmQbYg3yQs7A_6_2"></a><a id="Tc_5sTio0Tme0KMN_DMhdkOzQ_6_4"></a><a id="Tc_1G12js4orEObEzJOfYPaPA_6_6"></a><a id="Tc_q2Pdkwwp90WEbX0gevtuTw_6_8"></a><a id="Tc_jQz1F4mXZk2XcVet5-YcXg_7_0"></a><a id="Tc_h2-VUovDcUarlrNFNgCa_Q_8_0"></a><a id="Tc_y6G36Na7nU6j1Am093yzfg_9_0"></a><a id="Tc_ldKFD627j021UBxz57CyFw_10_0"></a><a id="Tc_dahyHBfTU0uysiB44JwtfA_1_2"></a><a id="Tc_y_BrkANCGUCiAEYFTsUP7Q_1_4"></a><a id="Tc_IkU6ohVA00OYR7jxVtAmwQ_2_2"></a><a id="Tc_3hGr5pEoJ0uHfmUDkgLaVw_2_4"></a><a id="Tc_Bsype3jQdUqcerWXJ5vvGQ_3_2"></a><a id="Tc_e5rE5GH0vES6Nl31OYBWPQ_3_4"></a><a id="Tc_4hADPESOeUux1wYM8fPRcw_4_0"></a><a id="Tc_6BPkkg93WEWERW_s4ea4_g_5_0"></a><a id="Tc_AItdKJHt9EqTbyPD5i1APQ_6_0"></a><a id="_a57e6c2d_85a8_49ce_b083_2cd0093d1b8c"></a><a id="Tc_2vaLDAh1skeEoFe7pMSVSg_1_2"></a><a id="Tc_XaaRp_R1uEeGtx6ooIjFLQ_1_6"></a><a id="Tc_pHjgJCOIO0-ymLD9cOsSZA_2_2"></a><a id="Tc_Xb9EMmy4WUOm5s4e-9x2jw_2_4"></a><a id="Tc_ABzz4fxW-UudtsB1FxUjZA_2_6"></a><a id="Tc_6Gl3AufI1E-jwGaxBmZetw_2_8"></a><a id="Tc_lACQ9TJRHkWzW-1W1mNKnA_3_2"></a><a id="Tc_WKyCRTQLkEmHyXaxZk8srQ_3_4"></a><a id="Tc_Gc8ZrG2-40aIWgle5Oz0_A_3_6"></a><a id="Tc_Q947sRLxiUKHGmprCOwgGg_3_8"></a><a id="Tc_ddUZ5K2GO0eimGOzK5txpA_4_0"></a><a id="Tc_KkZBpJm9kkeJXavbwGN7ZQ_5_0"></a><a id="Tc_-K2cCkXZ-EKcPdlph-705Q_6_0"></a><a id="Tc_4JPHTBmokUuVxxj_mU3_zA_7_0"></a><a id="Tc_xPNeweM8N0yfqJZRe8CoXA_8_0"></a><a id="Tc_mzig40y9aUaYfu0-ZcGTHQ_9_0"></a><a id="Tc_dCtQIzuBu0mSQuoF6i_38w_10_0"></a><a id="_b8cc9470_7330_458c_a4e5_9e6eb4e16312"></a><a id="Tc_Ts_Zklgxs0Oc8XnYkDe2Tw_1_2"></a><a id="Tc_WgvQh34_rEGr6IuFt3uI0g_1_6"></a><a id="Tc_bf_OioHN_0C47JA1Rs48_w_2_2"></a><a id="Tc_aYJoQQClkUyX-ij1HF70PQ_2_4"></a><a id="Tc_bSEBisww_UGnjb_Sd-7VSA_2_6"></a><a id="Tc_GpBCHcA7EU-kjz6_LC0X6g_2_8"></a><a id="Tc__IPMJ4YMpE-iwhRgoMtiRQ_3_2"></a><a id="Tc_Q16yjXPhR02BH0Yg9tg1YQ_3_4"></a><a id="Tc_nsLVvF1os0SdE0l1rPdPEw_3_6"></a><a id="Tc_9M4rQZSsGUeo7UFEStuGXg_3_8"></a><a id="Tc_m5vY_1jkLEajEZq5F1QtQg_4_0"></a><a id="Tc_8zXbC2ytOUqpTA1hB3QYfg_5_0"></a><a id="Tc_jogfNFC8VkG2viQ8_OUTOw_6_0"></a><a id="Tc_0aVRyHi2O0GcHrXFN7Q0_A_7_0"></a><ix:continuation id="Tb_3J43JMZkR0GVaM5gZzkDTw_cont1" continuedAt="Tb_3J43JMZkR0GVaM5gZzkDTw_cont2"><ix:continuation id="Tb_oAyiSj00g0GppvnCqAFZ1A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="7" style="vertical-align:bottom;width:37.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue&#xA0;recognized&#xA0;from</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="7" style="vertical-align:bottom;width:37.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">upfront&#xA0;and&#xA0;milestones&#xA0;payments</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#xA0;three&#xA0;months&#xA0;ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:16.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#xA0;six&#xA0;months&#xA0;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#xA0;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#xA0;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_wLsvd5ls7kqTDYk-S9CpjA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_4CLfy75qJkONfpGN8JflQw_7_2">13,051</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_P3-yf9evlk-uil2HqOhCJA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_DL3t9_mLLU-jfSZvmQpyPA_7_4">3,873</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_lgsJNQOs-kebpPDEL6dBqg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_tfBdHRRxpUOs6NEe-0BmCw_7_6">30,769</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_T1yTr60wpEmNL4M4Ko8K2Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_ikqCkA1NlEiwcxAPrxm50g_7_8">7,496</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_5Y1Bpfn7ukWQA4eeXs_knA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_IOZrwMBPz0ufQBPcSKD7zQ_8_2">77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_daj6pxuUI0CyzoQOjX4GZA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_VuD65cF4DEiKUgsMinTCKA_8_4">77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_4_d4F69gaEGw4TgM7DDcuQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_A4qlDPvb5EWlGwOrLN7W2g_8_6">155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_2VGMUPX1L0m2mtmN3QdB5w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_RJe0qiHA2EqGsQBUtHpgRg_8_8">155</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_YqWM6UyJ9EOQ0t7oMP82XQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_W1oG7OKc20OqYeKRdbxQOQ_9_2">447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_BqGmW8UGOUGYcz2zq4SB2w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_aLvM3qU9eka9DBXAV7RjSw_9_4">447</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_p5-6N-xf00qjDgzfyTQFUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_xUe1bDsgGUS0t0LBAHJCyw_9_6">894</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_KiOskkojkkONBK40fmVQSQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_6arc6felj0e29P7pdfuqCg_9_8">894</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_3anFBkhjW0Csz9tHCp7JTw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_Uf6asT8PvEiy_3f3uMkJXQ_10_2">13,575</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_iZr_fiR4-kqzHWO6nRRciw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_T4q_A5e-NUCu_movkDuW2Q_10_4">4,397</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_uu0hAMQGFE6RW7mIBHTXqw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_-an1svXubUKX2M16It_WMw_10_6">31,818</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_mI2esD2990ujSWl2t4bAJA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" scale="3" id="Tc_Zmxp8qjmuEuboIrgxZpFoQ_10_8">8,545</ix:nonFraction></b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Contract balances:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" id="Tb_GMYPcGmTckehECDC1nW_gA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_qZkcIku-S0-PhLkp128Mfg_4_2">6,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentTradeReceivables" scale="3" id="Tc_PbGnERzIlEiAtin5xwVv9w_4_4">6,443</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractAssets" scale="3" id="Tc_BcKEQwM6HkC3KfJbyc2wKQ_5_2">2,707</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentContractAssets" scale="3" id="Tc_H3ZXT7sw7Uqkud12maObbA_5_4">119</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractLiabilities" scale="3" id="Tc_gwr5KmD8vkiVWbE9OdUOGw_6_2">107,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ContractLiabilities" scale="3" id="Tc_F68GKU-w7kKMQgoCGYlhfw_6_4">98,763</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.2 Cost of sales</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfExpensesByNatureExplanatory" id="Group_PmMgPIYmWkaSsVCtatsaRw" continuedAt="Group_PmMgPIYmWkaSsVCtatsaRw_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The cost of sales consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_1hxDnjQjzUS3T1Bu6aQCDw_4_2">5,933</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_ysZ4CeSVLkGwpa12c3C3Vg_4_4">9,371</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_-5qsCIOJpUugXYpweAL_UQ_4_6">13,869</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_QpJaj8oBbUWWm6RMysI_QA_4_8">17,559</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_rFHrrFafkU6r8C1XqjlCXQ_5_2">14,055</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_HHGGe0_cykmxRNMRMQXeMA_5_4">8,096</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_x9a42piRyUegLap_nw0iKg_5_6">36,883</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_hoDmz7LhA0ufkFOJsmIsag_5_8">12,630</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_sJrAoOE010C2wP3MNDlvqA_6_2">18,552</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_MwuWoUtyr0mFXD1jvV2C3w_6_4">6,386</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_f_pvm_uztUaddSCR1MMPIg_6_6">19,516</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_8S9BGqF4LkmoLHhwhlp4vw_6_8">11,839</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_9dHHuCod10yJV_5EHyBNBw_7_2">919</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_AKSaL00l70Cb0ulrqlCwFA_7_4">534</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_SiqOeRDll0COUQcmxC4OJQ_7_6">1,150</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_T6kvFFxbskiRqOvq6h3uUw_7_8">1,115</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_mwYXXwMIckCsT2j2tvk98g_8_2">3,158</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_Xwwoum1Sb0yTLKpX6QgBdQ_8_4">1,049</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_j9wDb7bxQUubAmY7RQePrA_8_6">8,326</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_02X1H3IOQE6TWvfCwGhhkw_8_8">2,219</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_SyKjMzrXFEa6i7hg-zQI4g_9_2">64</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_5FQLNvqjIUyTtCbMYFDrWw_9_4">418</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_Ky9Sjrfi6EGmT3B9zVi1ag_9_6">169</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_QsMT25HEDkaBM4K-1yWfow_9_8">1,127</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_gukhQocnHkyyNmbqJGGOTA_10_2">42,681</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_yo-H7XiiDU2A2HBuFBBg9w_10_4">25,854</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_zsd3J91SEUSmf8EtgYwNNw_10_6">79,913</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_YriZBFsVWEqsW9zBdH1Iug_10_8">46,489</ix:nonFraction>)</b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the six months ended June 30, 2023, cost of sales decreased in comparison to corresponding period in 2022. This decline was primarily attributable to higher material costs in the prior year, which were driven by write-offs of raw materials originally procured for the manufacturing of products intended to be sold to GSK. However, these raw materials were no longer expected to be sold to them. Personnel expenses increased mainly due to increased workforce in the manufacturing organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.3 Selling and distribution expenses</span></p><ix:continuation id="Group_PmMgPIYmWkaSsVCtatsaRw_2" continuedAt="Group_PmMgPIYmWkaSsVCtatsaRw_3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.75pt;margin:0pt;">Selling and distribution expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_XOHc_alf0UOQ75cQ9xGNTQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_dnHMFSrNGkaLOXjHTwcdrg_4_2">363</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_K4r7ZDLT-E2fEsXEmmY8ZA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_etdlSqOUN0mX7PmY1SnYXw_4_4">1,314</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_H6yYmBXYOEe8_bIhxb-C8g" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_UBpjQrAfE02aH1DVCAidMQ_4_6">560</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_av40YHBBh0K9mS0uze6WHQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_jixU-7RBvUGFrsz9Oy6iYQ_4_8">2,030</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_XOHc_alf0UOQ75cQ9xGNTQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_9c6qufNd6U-R6ehbPg_srQ_5_2">16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_K4r7ZDLT-E2fEsXEmmY8ZA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_SSdT8uXNlU-xNjAMLiweiw_5_4">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_H6yYmBXYOEe8_bIhxb-C8g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_BrjMH-2Zt0OJos-wxA8hHw_5_6">32</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_av40YHBBh0K9mS0uze6WHQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_NQjV7ZkOnk6wqyFL7hOw2g_5_8">6</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_XOHc_alf0UOQ75cQ9xGNTQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_GCwYNBTEbUG1hzXIiYjxDQ_6_2">169</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_K4r7ZDLT-E2fEsXEmmY8ZA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_l-C-oyHTS0-dycoh2QJ2Tg_6_4">88</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_H6yYmBXYOEe8_bIhxb-C8g" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_DukY7dLRPEmrwieZwCKHVw_6_6">227</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_av40YHBBh0K9mS0uze6WHQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_A51m-8E7rUSf8EsOU3H3rw_6_8">196</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_XOHc_alf0UOQ75cQ9xGNTQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_uolUPQ-iI0a-Gsib421Png_7_2">548</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_K4r7ZDLT-E2fEsXEmmY8ZA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_cZ2vACc7Q0y55EZcaIQLrg_7_4">1,408</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_H6yYmBXYOEe8_bIhxb-C8g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_IvXhpz0ppEOhOXT9XHDm5Q_7_6">819</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_av40YHBBh0K9mS0uze6WHQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_hRWigeRPtECSTbKvSd7SMg_7_8">2,232</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_7ed042bf_5bb6_4c25_90ed_255d0d66ff45"></a><a id="Tc_MlNxdLtTt0K392XU0XNooQ_1_2"></a><a id="Tc_NBwFr8we_kaLo14-bM7WEQ_1_6"></a><a id="Tc_J8pQWuuav0Oe20tRR1fj5A_2_2"></a><a id="Tc_06He_cYevEqYNzarJ7Co2Q_2_4"></a><a id="Tc_8dwehb9rFUGL5KUlA609Cw_2_6"></a><a id="Tc_sbDBjYnglU6mguWKoUKeBA_2_8"></a><a id="Tc_OWwVGEsYf0WeoOSyZNEZqQ_3_2"></a><a id="Tc_Mtcm95wBk0y7qj3l9xB1JA_3_4"></a><a id="Tc_YvOt1pgaVEWxUwJLwQdCcg_3_6"></a><a id="Tc_6wTbC6z1_E6QTihdwHU8NA_3_8"></a><a id="Tc_T1eGO_JJ602Kc0EfUvCHwA_4_0"></a><a id="Tc_9nzrIYgJLkiZX_5ykVnw0A_5_0"></a><a id="Tc_SrB4PG70JE-oPXo2Qe8uKA_6_0"></a><a id="Tc_jhZIWZ0jl0q1SttV8sEBRA_7_0"></a><a id="Tc_MasOeg7MGEq7fYVxL72IUg_8_0"></a><a id="Tc_uaYx20QCkk2AIaoluoLzPw_9_0"></a><a id="Tc_5r0h-h8z5Uee53yq12GnJg_10_0"></a><a id="Tc_E1E0ZdGIbEa8kCe_TadCVg_11_0"></a><a id="_4327f95d_500a_46c4_8df7_d7cca2e714e3"></a><a id="Tc_SZGSaiu9YECaqkuIJx7GGA_1_2"></a><a id="Tc_Ikkwvg9zdUaEcStlzeU-FQ_1_6"></a><a id="Tc_rtcrox_o3UqZD0_LpEQs2A_2_2"></a><a id="Tc_wMWnl0VjIkqXQRSrdx8nNg_2_4"></a><a id="Tc_eUsvjAoQ5UGkHKoRMAhl-A_2_6"></a><a id="Tc_0NDuM7FVwkWxhyafRDnBtQ_2_8"></a><a id="Tc_Yaa0o9US70yzXSckkZyq0A_3_2"></a><a id="Tc_FFidQOl6J029t9Z6lqCMgg_3_4"></a><a id="Tc_vC2jzPcBqUyl4nWTch3tSQ_3_6"></a><a id="Tc_fBA3Uv359UKMNRheumcSSw_3_8"></a><a id="Tc_wEUC92KfN0KJANhFcVV2RA_4_0"></a><a id="Tc_X6kv4k0suk-s9Za0lppcmA_5_0"></a><a id="Tc_zTDPdwy50UaeR2Iqzi0eDQ_6_0"></a><a id="Tc_eNd9bIPmA066IPsvyTZ8wg_7_0"></a><a id="Tc_giaESX0h2EWGzdYpdiZkAQ_8_0"></a><a id="Tc_udBfrWm4lUeaJSITC8tOLg_9_0"></a><a id="Tc_boZ2zTK9Uk6axjbE2LvONg_10_0"></a><a id="Tc_RRAMFJ2E4EGUrioa7Um0dw_1_2"></a><a id="Tc_fYKi9GcdhEagfj78UeDKhg_1_6"></a><a id="Tc_YUJfaOIYZEiV8FpJfItljA_2_2"></a><a id="Tc_VMnKHpkXEUeVeWRUyl7hvg_2_4"></a><a id="Tc_IHfFISs1mUi3KmRHnT1NhA_2_6"></a><a id="Tc_fYPuSNGm-UyGKh8bDXnFkg_2_8"></a><a id="Tc_ugopMtbWHkqyfSA9DsUWZA_3_2"></a><a id="Tc_5tXLp90aaU2ZZ2Y4O2REyA_3_4"></a><a id="Tc_dhlwTUHFeE68Mp629IHlJA_3_6"></a><a id="Tc_vxy5-D5IF0-PT8uorQeMNg_3_8"></a><a id="Tc_V_M5pUWKIE-zfdCn7t2W-g_4_0"></a><a id="Tc_6VFJybCEqkeT-F8Nxz1c-g_5_0"></a><a id="Tc_CMbZgx46VUmM4C1DBnEqSQ_5_4"></a><a id="Tc_ibVqZQZHmEql2N9eA88HOQ_5_8"></a><a id="Tc_HnopAnYKb06v9i8srXIRUw_6_0"></a><a id="Tc_V1WBbaRCF0ebgShSbmmzaQ_6_2"></a><a id="Tc_FaFCnEuqWUiq_l5dq0ojtA_7_0"></a><a id="Tc_Aa4q9BgCd0CftiwiyG6Kkw_8_0"></a><a id="Tc_mi1fL4XYmUWOG_GqYQ_tZQ_9_0"></a><ix:continuation id="Tb_3J43JMZkR0GVaM5gZzkDTw_cont2" continuedAt="Tb_3J43JMZkR0GVaM5gZzkDTw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.4 Research and development expenses</span></p><ix:continuation id="Group_PmMgPIYmWkaSsVCtatsaRw_3" continuedAt="Group_PmMgPIYmWkaSsVCtatsaRw_4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">R&amp;D expenses consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_c_wprvfXoEiAEMA6CY6EhQ_4_2">6,131</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_CU0ExqQJgUCHIBQRkZkwog_4_4">5,728</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_9S0O_p5uaEG8swRFsHXQjw_4_6">23,419</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterialsAndConsumablesUsed" scale="3" id="Tc_Er04GKlQr0GeF5pcwMVWJg_4_8">9,217</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_O2I-sZU2S0y2jBnGFwYV7g_5_2">7,795</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_fn6z2CSXAUqLlIN4CbZfxg_5_4">12,533</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_vcDrTMbecUuDZcNucboNcQ_5_6">14,849</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_HG2D6qUoa0-eXZh4boFiDA_5_8">23,570</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_k4ww3oBjZ0CBTIMqawEAOQ_6_2">1,106</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_C0vdNhVgRk6MFyb0pM_k5A_6_4">1,783</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_V0ulmSBbB0Kj8UctZH8xFA_6_6">2,119</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_wXCMCg35WkqfLdcVw67b0g_6_8">3,508</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PatentsAndFeesToRegisterLegalRight" sign="-" scale="3" id="Tc_DpHbR2F7qUG1cB6TNC-BIg_7_2">502</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg" decimals="-3" format="ixt:numdotdecimal" name="cvac:PatentsAndFeesToRegisterLegalRight" scale="3" id="Tc_N4QEjp2_EkWfFYLoNAlGjA_7_4">1,191</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PatentsAndFeesToRegisterLegalRight" scale="3" id="Tc_bfap9Oi1FECFkgm6bZt93w_7_6">1,354</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:PatentsAndFeesToRegisterLegalRight" scale="3" id="Tc_h8zCxT6BFUamXlCU2dEViw_7_8">2,048</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" sign="-" scale="3" id="Tc_M8Cd65HmSkuUOxcGMm7HGQ_8_2">4,252</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_SfWJ8guy2EmNAzNpYVkt2Q_8_4">7,081</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" sign="-" scale="3" id="Tc_faEU_VYbWE65yrKTGH7U3A_8_6">21,053</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_j878Ot8sXUaQkrD7CsfMTg_8_8">11,773</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_EoD5azAHFUSk3ePVE1D8XA_9_2">428</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_kiBQkAGaukaSXIPObG0IIQ_9_4">1,827</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_90fbLjScPEaViKYOwzu2Wg_9_6">464</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_hzBjHSqiZ0uJWF6q0iCNrw_9_8">3,593</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_D2cwkdl7gEmDVs7FnjnKNQ_10_2">929</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_dENTb0XpiEuraaRe6A0DOA_10_4">727</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_Sj8SkwdwgUesKtXhF5duig_10_6">1,270</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_UFwhCIvTbE6lLCuNeai0fw_10_8">1,410</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_fycjJ0V6DU6vEKgpRoR1Ng_11_2">11,635</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_Cjz67lvoXUewt8FIiDinBg_11_4">30,868</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_X8n0MN5FO0iDQ3JOnwgoiw_11_6">22,422</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_RVxVscPj_Ui9Az9CBq2rAg_11_8">55,118</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2023, research and development expenses increased in comparison to the same period of 2022, as the prior year period was largely impacted by the reversal of provision for onerous contracts in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract" scale="3" id="Narr_2quaIxGuqkOFKgunMH89Kw">21,303</ix:nonFraction>k as a result of more participants leaving the clinical trials, prior to completion, than originally estimated and of renegotiations of contracts with CROs. Additionally in 2022, GSK took over the Group&#x2019;s committed capacity at Novartis (see Note 3.6 for additional information) which resulted in a reduction in the estimated contract termination provisions in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_6Escb8lmq0qNNDpw732R3A" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsProvisionForLossOnContracts" scale="3" id="Narr_Ivu_wIKvP0SB70iWmYwopQ">25,059</ix:nonFraction>k. The net effect of these two events resulted in an overall gain within the Third-party services category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses increased mainly due to increased workforce and the acquisition of Frame Pharmaceuticals. Additionally, share-based payment expense was higher compared to prior year period (refer to Note 5 for further details).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.5 General and administrative expenses</span></p><ix:continuation id="Group_PmMgPIYmWkaSsVCtatsaRw_4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">General and administrative expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_lZ0tUFI0yUKQwCXy3B8UTg_4_2">9,190</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_PFoiRunHjkiJn9WGQSGaZg_4_4">6,644</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_BaUWfQrgMESJK-CNbpC_Kg_4_6">18,971</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A" decimals="-3" format="ixt:numdotdecimal" name="cvac:PersonnelExpenses" scale="3" id="Tc_e0J0EB8G1UeLxJd-oVpiBQ_4_8">15,742</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_045kDvveHEuH1k_iCa-2Ww_5_2">1,404</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_EDz-C7Zs6kuHYeXiT1zaMw_5_4">1,614</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_h3vL0X7wXkiv3xc3pgbPxQ_5_6">2,704</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A" decimals="-3" format="ixt:numdotdecimal" name="cvac:MaintenanceAndLeaseExpenses" scale="3" id="Tc_GikxI58PGE2hM3cEuXWTdg_5_8">2,915</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_zkJBu493DU-WqBQnVrurFw_6_2">7,514</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_W3XvKB6A9kOIOfcmnl_7kQ_6_4">5,871</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_huT-R_uYrUOZ0RVomTk_lg_6_6">12,796</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A" decimals="-3" format="ixt:numdotdecimal" name="cvac:ThirdPartyServiceExpenses" scale="3" id="Tc_BfvxGl0iG0yInWmL5qZ6MA_6_8">12,873</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="Tc_LF4_w2RHi066jAPuef1DoA_7_2">2,995</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="Tc_C2GQLtK64U-wbBgVBdMxNQ_7_4">4,446</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="Tc_BYOPNXaUM02In88ZiDXeNA_7_6">5,320</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfessionalFeesExpense" scale="3" id="Tc_PO0fjZjCpkyQKrp8ShVmoA_7_8">6,074</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_zlxuAr2_bEuSan-NgM1wcQ_8_2">3,152</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_zjHHDkEaKEmPW33WXn9REA_8_4">2,965</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_y3zk2uStA0aHpfGgDLDMUw_8_6">6,091</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationAndAmortisationExpense" scale="3" id="Tc_YzCPBNGM7EWA7irKryjeug_8_8">6,071</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_uIVSInRwkEO42aeX6EWBMg_9_2">2,857</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_ZPAInXuLEEO_33VL0ipzsg_9_4">705</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_HsxSZ_aWDEOrngDovP0yUw_9_6">5,796</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherExpense" scale="3" id="Tc_8lB262NM9kOtPSK_YB4cgg_9_8">1,857</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_rZwJJme7TU6Y1zScpSJDaQ_10_2">27,112</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_06thqdMUa0uH9x3OSsQMPQ_10_4">22,245</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_csxuXS_S7EC3-BYcypZCKw_10_6">51,678</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseByNature" scale="3" id="Tc_nzEFCObuIEyd2Y1PoFVU5w_10_8">45,532</ix:nonFraction>)</b></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses decreased due to lower workforce in the corporate service functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Others include mainly expenses for D&amp;O insurance and allocations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.6 Other operating income</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory" id="Tb_grwepVLzF0C6WVVKqe43hg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Compensation for CMO/Material transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Tc_BIhH128ClEaDIklaGaqqFA_4_2">949</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Tc_7rCSmLt4V0uwaStEWFxx-g_4_4">259</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Tc_emdc5Cu3aUqas7EAZkeTjg_4_6">33,961</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Tc_w3CDQkqeZ06NmNb62lSqqQ_4_8">1,803</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Reimbursement Claim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="cvac:CostOfReimbursementClaim" scale="3" id="Tc_oBUgzsBHTk20gfBKtluIFQ_5_2">610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:CostOfReimbursementClaim" scale="3" id="Tc_l5Bag6ya-UO1FBnSEjRO2Q_5_6">610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sale of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="cvac:SaleOfEquipment" scale="3" id="Tc_nPWmR0jeJkSwj8bAXkvVGA_6_4">176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:SaleOfEquipment" scale="3" id="Tc_xzqr4Y7c-UeBrkuS4cqF8A_6_6">310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:SaleOfEquipment" scale="3" id="Tc_19AXtOzJVUa4SNx5jzJ7ow_6_8">484</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Grants and other cost reimbursements from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherOperatingIncomeGovernmentGrants" scale="3" id="Tc_u6muM6K9EkK81ybYDKkuig_7_2">35</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherOperatingIncomeGovernmentGrants" scale="3" id="Tc_A7IWrSqZE0ilEbs-RFAPfQ_7_4">237</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherOperatingIncomeGovernmentGrants" scale="3" id="Tc_dO5Kp8mF80GoCN8xGGcnFg_7_6">104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:OtherOperatingIncomeGovernmentGrants" scale="3" id="Tc_ccoIPkHjXUerjjC1-Rrv7g_7_8">239</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MiscellaneousOtherOperatingIncomeOther" scale="3" id="Tc_ffDETpQzNUubn8RDwXmgJQ_8_2">177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="cvac:MiscellaneousOtherOperatingIncomeOther" scale="3" id="Tc_gsZrfZnUtEmAev5ehM-IGg_8_4">770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:MiscellaneousOtherOperatingIncomeOther" scale="3" id="Tc_smfM8npIsUuUtZmfdle_aA_8_6">222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:MiscellaneousOtherOperatingIncomeOther" scale="3" id="Tc_Y77RoDnZjEuFmuG5eKaZ6Q_8_8">922</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_t_py8xIDvEKd9hgZKxosIg_9_2">1,771</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_tth9UVovvkCBkJTkq1_w8Q_9_4">1,442</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_-zH5Cf_8h0CJp_NliU6Ipg_9_6">35,207</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_RaGXeTv4YUy80dSEiau94A_9_8">3,448</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#x200B;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_3J43JMZkR0GVaM5gZzkDTw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In March 2022, CureVac AG and GlaxoSmithKline Biologicals SA amended and restated the 2020 GSK agreement and the GSK COVID Agreement in connection with GSK entering into a direct agreement with Novartis for use of Novartis as a CMO at the same time as CureVac exits its CMO agreement with Novartis. Additionally, under the restated agreement, CureVac is entitled to further compensation by GSK. The compensations mainly consist of a consideration for set-up activities undertaken by CureVac (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_T6BMdSYhU0uLBiXs_xHhqQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" scale="3" id="Narr_FytWbQVO40e3hLWgbf_K3g">20,500</ix:nonFraction>k) and for reimbursement of prepayments (EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_T6BMdSYhU0uLBiXs_xHhqQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" scale="3" id="Narr_gObbRoQ_JkG8eRpf0Z215w">12,000</ix:nonFraction>k), which were recognized in other operating income in the six months ended June&#xA0;30, 2022. As an additional result of this agreement, certain reserved capacity at Novartis was also taken over from the Group by GSK, which resulted in the reversal of provisions of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3ZJGf8rl2EqLWLcsDr1j5A" decimals="-3" format="ixt:numdotdecimal" name="cvac:ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" scale="3" id="Narr_ta_WLqn9q0OrhmgsObwwiA">25,059</ix:nonFraction>k which had been recognized as of December 31, 2021, and the recognition of a corresponding gain in research and development expenses in the six months ended June 30, 2022 (see Note 3.4).</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><a id="Tc_7egD0yY9ZUatikScS6Gzkg_1_0"></a><a id="Tc_r9SOqkGFh0uKZ3uvHICPXQ_2_0"></a><a id="Tc_aJayntCfPkKBvfdJiBpWug_3_0"></a><a id="Tc_EXD8oohOEkqu9FdmfgHMEg_4_0"></a><a id="Tc_xk2CXaPwfEi20xQypp6mEw_5_0"></a><a id="Tc_iTcnhsoRvU-yfjtEVa5sOg_6_0"></a><a id="Tc_VW8NIrWbd02bioDE__IMkw_7_0"></a><a id="Tc_87kUL4Bfx0mt42sm95foeQ_8_0"></a><a id="Tc_qJLBc8rN4E-btHid5BZE1g_9_0"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" id="Tb_T_qyOs_9eUesd3noTJAMZQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">4. Issued Capital and Reserves</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Company&#x2019;s articles of association, the Company&#x2019;s authorized shares are divided into <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_1dYKs1W9uU6tOrLCufufjQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" id="Narr_oNIyUm2hD0Kmwlf3-ZoqiQ">386,250,000</ix:nonFraction> common shares and <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_k77XHGsGdUayZMsUw-y9ZA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" id="Narr_bF3y6vICaUO329jHkL2KLg">386,250,000</ix:nonFraction> preferred shares, each having a <span style="-sec-ix-hidden:Hidden_MiCnzCrlpkmaZN49iUzGgg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nominal</span></span> value of EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q" contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_k77XHGsGdUayZMsUw-y9ZA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Narr_ow06z8JZvk-k-xkPDTzD7w">0.12</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_k77XHGsGdUayZMsUw-y9ZA" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfSharesIssued" scale="0" id="Narr_uLL7XMpzOkiZnyzaIxckiA">no</ix:nonFraction> preferred shares had been issued and all issued common shares issued and outstanding were fully paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All payments received from shareholders in excess of the nominal value of the shares issued and net of transaction costs are recognized in capital reserves. Capital reserves also consists of recognition of share-based payments and the equity components of convertible loans. The Company may only make distributions, whether a distribution of profits or of freely distributable reserves, to shareholders to the extent shareholders&#x2019; equity exceeds the sum of the paid-in and called-up share capital plus any reserves required by Dutch law or by the Company&#x2019;s articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2021, the Company entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market (ATM) offering program, pursuant to which it may sell, from time to time, ordinary shares for aggregate gross proceeds of up to USD <ix:nonFraction unitRef="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw" contextRef="Duration_9_1_2021_To_9_30_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_ayQw-BmgEkylsqF_f4Z52Q" decimals="-5" format="ixt:numdotdecimal" name="cvac:AggregateGrossProceedsReceivableFromIssuingShares" scale="6" id="Narr_eNPhoIu6QU6D3USDcpfnAA">600.0</ix:nonFraction> million. In the first quarter of 2023, <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_1OMKhPZxMEiydfIE4wQ-aQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_VvIQoHMn-0GPFddKkfuSzw">1,748,218</ix:nonFraction> shares were issued under the ATM program, raising USD <ix:nonFraction unitRef="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw" contextRef="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_1OMKhPZxMEiydfIE4wQ-aQ" decimals="-5" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="Narr_xV2rBEIbQUaXSEMa88FVUA">17.5</ix:nonFraction> million in net proceeds; related offering expenses were recorded against the proceeds in equity. Following these issuances, the remaining value authorized for sale under the at-the-market program amounts to $<ix:nonFraction unitRef="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw" contextRef="As_Of_6_30_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_1A2s3zl5FUeobT5soQuz-w" decimals="-5" format="ixt:numdotdecimal" name="cvac:RemainingAuthorizedForSaleValue" scale="6" id="Narr_f2iPbFv76E-6R528wBOP6A">497.5</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2023, the Group completed a follow-on public offering whereby it sold <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_3EZn4_xdeES1B53nwQWIjg" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_zEfH4RLDqUmb_OW9I_2qIw">27,027,028</ix:nonFraction> common shares at a price of USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_WivF9OzOw0qggSizEvs2xg" contextRef="As_Of_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_TeB4gwzvG0OqfuENGvfJvA" decimals="2" format="ixt:numdotdecimal" name="cvac:IfrsSharesIssuedPricePerShare" scale="0" id="Narr_PqTPh1ffh0G2kRCf1-4pGA">9.25</ix:nonFraction> per share. The aggregate proceeds, net of underwriting discounts, received by the Group from these transactions were EUR&#xA0;<ix:nonFraction unitRef="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw" contextRef="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_3EZn4_xdeES1B53nwQWIjg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="3" id="Narr_I0K9BFqdtkGHD66GkS9TXQ">219,832</ix:nonFraction>k. Additional offering costs for legal, accounting, printing and registration fees of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_3EZn4_xdeES1B53nwQWIjg" decimals="-3" format="ixt:numdotdecimal" name="cvac:AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve" scale="3" id="Narr_qjlc7BNzo0ycR7DMZdx5_A">14,580</ix:nonFraction>k were recognized as reduction to capital reserve against the proceeds from the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The number of shares issued and outstanding developed as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory" id="Tb_TexrmAA1ZEiwHmcm3dFeHQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2022</b></p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="INF" format="ixt:numdotdecimal" name="cvac:CommonSharesIssuedAndOutstanding" scale="0" id="Tc_tCos-eR-3E2vjXdm5B9opg_1_2">194,997,091</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At-the-market offering program issuances</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_1OMKhPZxMEiydfIE4wQ-aQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_dc1QVCNchUO3ox3yN7wnbg_2_2">1,748,218</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances as part of the public offering</p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_0W76eZNJTky2YBlodKXOPw" decimals="INF" format="ixt:numdotdecimal" name="cvac:IfrsStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_bIxVPyc1b0WlD_yq9nfaRA_3_2">27,027,028</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between Jan to Mar 2023</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_1_1_2023_To_3_31_2023_f3TFOs23C0GFOdZGdiwIzA" decimals="INF" format="ixt:numdotdecimal" name="cvac:StockIssuedDuringPeriodForExercises" scale="0" id="Tc_WbP0o1tSnkyfdSqco5MA1A_4_2">112,089</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_1_1_2023_To_3_31_2023_f3TFOs23C0GFOdZGdiwIzA" decimals="INF" format="ixt:numdotdecimal" name="cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares" sign="-" scale="0" id="Tc_VFoJq71VqEG66X0pKMAaWA_5_2">32,913</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at March 31, 2023</b></p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="As_Of_3_31_2023_nZ9aTIkD-kKH94WcSt1n3g" decimals="INF" format="ixt:numdotdecimal" name="cvac:CommonSharesIssuedAndOutstanding" scale="0" id="Tc_3v004IoZzkiyKq0gDuBZpg_6_2">223,851,513</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between Apr to Jun 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="INF" format="ixt:numdotdecimal" name="cvac:StockIssuedDuringPeriodForExercises" scale="0" id="Tc_zkycjLlP-k-T-Za-NHCpOw_7_2">41,524</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="INF" format="ixt:numdotdecimal" name="cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares" sign="-" scale="0" id="Tc_RGnN2D6IK0injVdiZ0GQow_8_2">9,953</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="INF" format="ixt:numdotdecimal" name="cvac:CommonSharesIssuedAndOutstanding" scale="0" id="Tc_eyRrJv9Lik6QKjpX7g4dng_9_2">223,883,084</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="Tb_0cH4bsk0q0uQ58Y9ul3UWg" continuedAt="Tb_0cH4bsk0q0uQ58Y9ul3UWg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">5. Share-based payments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2023 and 2022, the Group recognized share-based payment expenses of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Narr_Vmtq59SX6k-m1uHOeew4lg">4,572</ix:nonFraction>k and EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Narr__EsyWNbQg0OUwrj5a2jUbw">3,597</ix:nonFraction>k, respectively, as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" id="Tb_OgTCqx_WiUSXNC4JmxEH-A" continuedAt="Tb_OgTCqx_WiUSXNC4JmxEH-A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#x200B;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_03bf7b14_b737_4a4d_8eba_4fe934d6b53f"></a><a id="Tc_KfWMMqx6ZkGxUjqS7aM86A_1_2"></a><a id="Tc_mHg3I0fcT0ObbPDNCmmlng_1_6"></a><a id="Tc_A0OXV-3vQUSjQHIAej723g_2_2"></a><a id="Tc_TV57VbEMcEqG5MzCLd0dcg_2_4"></a><a id="Tc_httS3380NUe2qYiNV79dsQ_2_6"></a><a id="Tc_u97e5hWfgE247ntjZdqIIg_2_8"></a><a id="Tc_cyh6Q30r-0KkslWixHEUZg_3_2"></a><a id="Tc_jjkX1RYEy0Cnkm3TjYYXwQ_3_4"></a><a id="Tc_A7SYfHjaYka3CtOaLhoy_w_3_6"></a><a id="Tc_7LznfnvlP0u8bFf8Bq-Cpw_3_8"></a><a id="Tc_DrA9bEyM6E-CpQeBKbu2Tg_4_0"></a><a id="Tc_WzPugauutUSyGrRu7EYKNg_4_2"></a><a id="Tc_TolMo_MhHUWFQESjqu39rQ_4_6"></a><a id="Tc_4C6wTizAB0qAdp6l3r33gw_5_0"></a><a id="Tc_2ohpcbbeb0G_wWfDdz1A1Q_6_0"></a><a id="Tc_jhLrGHRXlU2dsRibTbkedQ_7_0"></a><a id="Tc_XNP3ocbeYk6_fcl-BLj1QQ_8_0"></a><a id="Tc_2o8zYkXuxk-C9xJJOkZgRQ_9_0"></a><a id="_3abf0353_fdeb_45f9_88e5_72c70aa14878"></a><a id="Tc_e37OqX3PVkW0WTpJt_H3ow_1_2"></a><a id="Tc_C78gA-HCxUyhlaRBxftILw_1_6"></a><a id="Tc_dloFProGiEWZBdoxpx2DWw_2_0"></a><a id="Tc_6PmFo8aN9EuRu3699G-I1w_2_2"></a><a id="Tc_JQpyzmTYH0aJPZr_KP8RPg_2_4"></a><a id="Tc_q87iXkhVW0SCDF7ZdGjN3w_2_6"></a><a id="Tc_gjeFe5odEUye1vW4jpKhLg_2_8"></a><a id="Tc_ceuI-G5tW0iPUrTEjiHncA_3_2"></a><a id="Tc_wjPam-TY3ESzlUEZw_-WlQ_3_4"></a><a id="Tc_q4B8S2b4vEaJzTR4gur7Ig_3_6"></a><a id="Tc_tdNgEkl98kGJj8EwGOU-aA_3_8"></a><a id="Tc_syCm4-a8-kKq_UIebRKQlw_4_0"></a><a id="Tc_AVRe_b9bxkCPGrIqgByo7w_5_0"></a><a id="Tc_hoDg_Ot81ki1TYbfao8jaA_6_0"></a><a id="Tc_NODqxngKmkGDfUZBij6PvQ_7_0"></a><a id="Tc_dtq7eIRPeE--axC7BPkwNA_8_0"></a><a id="Tc_QYhpSEh25kiYCeL_EhrirQ_9_0"></a><ix:continuation id="Tb_0cH4bsk0q0uQ58Y9ul3UWg_cont1" continuedAt="Tb_0cH4bsk0q0uQ58Y9ul3UWg_cont2"><ix:continuation id="Tb_OgTCqx_WiUSXNC4JmxEH-A_cont1"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#xA0;&#xA0;&#xA0;&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" scale="3" id="Tc_CuQvHw1-AkSVgFUqNl9tjw_4_4">147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#x2014;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" scale="3" id="Tc_b1bJkchgXEug492pvdwMhA_4_8">147</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="cvac:Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses" sign="-" scale="3" id="Tc_AoZLGRuPzEWevSGReANcGA_5_2">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="cvac:Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses" scale="3" id="Tc_z5diGzCkIEO-hFLsQfd_Dw_5_4">112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses" scale="3" id="Tc_UOOkfIaAGU2qMmw_7p3iOg_5_6">61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses" scale="3" id="Tc_7OXTQSvHH0WzTIbjus1utA_5_8">153</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" sign="-" scale="3" id="Tc_7TCTq6g9NUepxKaSRmSkEw_6_2">100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" scale="3" id="Tc_SsQvhHCMi0mNiYOm0QcKeg_6_4">609</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" scale="3" id="Tc_Dw5bfIvMC0ynoT0z6cbhFQ_6_6">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" scale="3" id="Tc_1TsgC9gUvUyFGI4htGHvrQ_6_8">761</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Tc_afyjBQi-U0K2mKx4ly2QUg_7_2">1,380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Tc_0LmJZjgqWU-qhDOyxikyJw_7_4">1,891</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Tc_UyEB-R8xEUWMRGZdUzzXPg_7_6">3,359</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" scale="3" id="Tc__ZDiesp9z0yCxZ5ja2KO4g_7_8">3,221</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses" scale="3" id="Tc__oVgsaQNuEeYciaA9wJobA_8_2">50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses" scale="3" id="Tc_tIXmlL1ZDk6md0mXhdhLTQ_8_4">235</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses" scale="3" id="Tc_TinGoYsYuUKbP-WMN8BfAg_8_6">87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses" scale="3" id="Tc_gp_wbi7Z0U2IMfu7CeQX0g_8_8">291</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#xA0;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="cvac:BenefitExpenseRecognizedForShareBasedPayment" scale="3" id="Tc_AfyHMsH3S0yfWDL0qCq7rg_9_2">1,324</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="cvac:BenefitExpenseRecognizedForShareBasedPayment" scale="3" id="Tc_iCsUyj0IMUG6bQMUZkiLXg_9_4">2,994</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:BenefitExpenseRecognizedForShareBasedPayment" scale="3" id="Tc_WudmAYsIHkudRGzmr36llA_9_6">3,597</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:BenefitExpenseRecognizedForShareBasedPayment" scale="3" id="Tc_0nmIDYIDVU-lmRNQi0a0nA_9_8">4,572</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expense recognized for the equity-settled programs was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock" id="Tb_2pw78Y87BEK8gesQ5lNIeA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#x200B;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;&#xA0;&#xA0;&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#xA0;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LTIP Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_lxpzPHOK-kuFcVc1SH9Lbw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_iqn3uEGRxEa33JVLjVPIaA_4_2">1,254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_jV-ZSqS8kU2_OpwJggs-Ig" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_k-PXCvJkCEi8w1-IjGXg3A_4_4">1,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_2zrm9PnhCkaFBrsWd2DlfQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_LAVvgOr97kS5LpmUMCYUbw_4_6">3,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_H7lU27CSYkW4Hf-ukTllUA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_4_1d3qWMf0yNLDan-trMBw_4_8">2,337</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU Supervisory Board</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_fVrZQK9ylkijyiOuCYXjRw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_nYpO-Wkc5EyPyQZW3iYvCg_5_2">50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_y9w5TmE7JUaqCnNvnmrbsw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_4iMI24StE0qEtZWThxfOdw_5_4">235</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_DRNBrHJkukm3DAjZM2_dVQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_9Vc7lnwsf0mCp4wUNu5gtA_5_6">87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_eyoLMAfpYEmjeoloCR63rw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_mweSpSiR0UmsOGyDr9WzAA_5_8">291</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">New VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember_B5CF27FqDkiLjSzyYwknTA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" sign="-" scale="3" id="Tc_HNtKai0E2ECq-W_ZbqLbQg_6_2">185</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember_GWqoCAnOUEuJVuboxaAwqA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" sign="-" scale="3" id="Tc_3ggOXMt1Ak-spK-NIMGm9w_6_4">12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember_Fdqd0vf59kCIZsGxx1aGZg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" sign="-" scale="3" id="Tc_TlfGs0BSIkWWFYQei13OYA_6_6">82</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember__LjcvGfb1UeNNJhvKnzSfg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_OV7IHuex7UqDB2AbrMpRGQ_6_8">45</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prior VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_RTmSmZOXXk-2ImmT99fn8A" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" sign="-" scale="3" id="Tc_8Pwu7gYp1kmhd-qKSErjdA_7_2">75</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_MgjlzqfYXUmUABPH0VTY7Q" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_Yn_V4FcCbkqDdkzMLWwF1w_7_4">30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_OP3JSfO8UkukL75fSOwjDA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_AIom0MmjpkKU-viwXdJI8Q_7_6">17</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_Qk-XTh-xFkGe4eGf7kiL-g" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" sign="-" scale="3" id="Tc_GSCpinU0Y0mcXT3L-_AfAg_7_8">21</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LTIP RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_Ef21cT4Rt0mtb7YnbaYYow" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_jlllR_8V8kWOYzSlDo-JQQ_8_2">281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_0ynCSSVH80efoVzNnwRQmg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_QF8Jy0OO9EaaA65vvaaCig_8_4">1,379</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_QbDJ8ZCETEeFxx_3bkTRQA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_usHoWHvBIky0IDcgPFJEQA_8_6">497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_FNWBdKYT4kyF3rOWErcVcA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_YCFdeuXlrUmcuAEFqHAHfQ_8_8">1,920</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#xA0;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_e8b1R3nYLUayF36B9rVIdw_9_2">1,324</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_8uxCS-THjEWaoPp5NnHSJA_9_4">2,994</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_z2PH9rXAGkeJtos25rjOdw_9_6">3,597</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#x200B;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedForEmployeeServices" scale="3" id="Tc_UW6-hkGygUGGibSXdzncMA_9_8">4,572</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 16, 2020, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_KwYMhWFPZU6Rg7XLlTdlAA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_HuUy0i-y0kiX7mLSk7Rzbg">266,155</ix:nonFraction> options to the former Chief Scientific Officer (CSO). Furthermore, on December 1, 2020, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_JiZFgfyfoUWlbX4a-OgfAw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_Si9JqVE2d0qXDOaBnI4ZHA">266,156</ix:nonFraction> options (in 3 tranches) to the Group&#x2019;s Chief Business Officer (CBO) and Chief Commercial Officer (CCO). All grants were made under the terms of a new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_xmJZx23S6Ee9MA0czFqYMg" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_SSzzpAoq3UCVl3JEJtZToQ">no</ix:nonFraction>ne of the options granted to the CBO/CCO under the LTIP were exercised. The CSO exercised <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_eOb3THsiDEK9JLgQVfEwTA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_Iyug2e7at0-jutmOGxne3A">6,303</ix:nonFraction> options during the six months ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 1, 2021, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_xb55tI_uTEK9tu0gMHp17g" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_JYc28nabekG8joHpKXt8Hw">20,000</ix:nonFraction> options to the Chief Operations Officer (COO). This grant was made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_46FI4ABSf02M9Rryg4sClw" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_IpxltZjfvE6MIFZiKeWvsQ">none</ix:nonFraction> of the options granted to the COO were exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 1, 2021, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_SYdnaM4Hv0amPp2G2fTAcA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_wYT_PvlQaUeOftRn5yhDOA">2,000</ix:nonFraction> options to a key employee and on January 1, 2022, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_NDbK_W7H-0umensvBwuEXw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_dV1HbwVe-EOjjFzUb4Yynw">9,500</ix:nonFraction> options to a key employee. All grants were made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_yrSvY_lt6UyqrvMk85XVag" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_uop4p1lwikqSHqZU3rJPdQ">no</ix:nonFraction>ne of the options were exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 1, 2022, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_K24THxuJwkSYpgfVd96a9w" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_DxMfAeBAhEWE8FxH7LVPfw">130,000</ix:nonFraction> options to the Executive Board. All grants were made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June&#xA0;30, 2023, <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_eekSXKejL0WDf-eAeVRHbQ" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_hrMXSm6KakGqC8rzpC7qgw">no</ix:nonFraction>ne of the options were exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2022, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_VWrFMaoDW0iaJ10vlf3I3A" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_TIh3dqjSVUiWeyOv6R0d1Q">700</ix:nonFraction> options to a key employee. All grants were made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_yrSvY_lt6UyqrvMk85XVag" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_OEbKtEYiW0utjwbAqU2Nfg">no</ix:nonFraction>ne of the options were exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2023, CureVac granted <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_bao9oCjt3kWO6XoHSsX7IQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_B4rgN2WITkekZoUhaWbt8Q">144,379</ix:nonFraction> options to the newly appointed CEO. All grants were made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_OUkDYWpJJkyy_omK2KmOjA" decimals="INF" format="ixt-sec:numwordsen" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_Romphp_xzUWqH1wzPylP9g">no</ix:nonFraction>ne of the options were exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expenses recognized for employee services received under the LTIP Stock Options during the three and six months ended June 30, 2023, is in the amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_jV-ZSqS8kU2_OpwJggs-Ig" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_PpzkybfrZEavT9Y8IYpJIg">1,362</ix:nonFraction>k and EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_H7lU27CSYkW4Hf-ukTllUA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_nR1UtdXIvEmSQ5mY2y3UfQ">2,337</ix:nonFraction>k, respectively (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_lxpzPHOK-kuFcVc1SH9Lbw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_7SvGfO05WUelq_gUZF6SHQ">1,254</ix:nonFraction>k and EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_2zrm9PnhCkaFBrsWd2DlfQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="3" id="Narr_XtaGSay9sUuJlFO1jeUAOQ">3,078</ix:nonFraction>k, respectively) and is included in general and administrative expenses and selling and distribution expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2021, as part of the LTIP program, the Group awarded RSUs (restricted stock units) to senior executives as well as Supervisory Board members. On June 24, 2021, the Group awarded <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_6_24_2021_To_6_24_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_41E5ssbhMEW4sOS5GBDjpg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_QhuWAVaGc0CxzijNmqk4Pg">10,956</ix:nonFraction> RSUs to Supervisory Board members and on December 23, 2021, the Group awarded <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_12_23_2021_To_12_23_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_YkGL88cFUUiH_hFBBekkPw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr_9fSMtNV2xkCfdbjBDZdM4w">63,095</ix:nonFraction> RSUs to the Executive Board and various key employees. Up to June 30, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_H7lU27CSYkW4Hf-ukTllUA" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" scale="0" id="Narr_GrMY2khe_UadRL66zDmDhQ">47,424</ix:nonFraction> RSUs were settled. The related RSU expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 1, 2022, CureVac awarded <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_1_1_2022_To_1_1_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_g-FjX7APF0qbbMyAZKIHGA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_AynjbcZRXEqJdTC2r-nyNA">36,000</ix:nonFraction> RSUs to the Chief Executive Officer (CEO). The related RSU expense is included in general and administrative expenses. For the three and six months ended June 30, 2023, all RSUs were settled.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_0cH4bsk0q0uQ58Y9ul3UWg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 31, 2022, CureVac awarded <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_1_31_2022_To_1_31_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_aDZJW6AtK0-IUzIePmSJgg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" scale="0" id="Narr__SgXujy150O1yX_BFwXZSg">5,000</ix:nonFraction> RSUs to the Chief Operations Officer (COO) and <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_1_31_2022_To_1_31_2022_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerMember_g2GxNhtCAEyWmUGgwRuryA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_h2Ak7uuHn0-8LpNMf08_cQ">30,000</ix:nonFraction> RSUs to the Chief Business Officer (CBO). The related RSU expense is included in general and administrative expenses. Up to June 30, 2023, none of these RSUs were settled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022, the Group awarded <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_q81lEiXrw0OgCYslUicbLw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_ZbIrjpvemEa3cF3R2BrUbw">36,902</ix:nonFraction> RSUs to Supervisory Board members and <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_zK3-o7Q200KTZ8l2pvMR8w" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_RVmtd5_zfE2gU6E49OeJQQ">188,986</ix:nonFraction> RSUs to the Executive Board and various key employees. On November 30, 2022, the Group awarded further <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_11_30_2022_To_11_30_2022_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_z47nsJniAkW9xj3JyFsA3w" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_PKra9VeA3UaEFS7P7u-RGg">7,633</ix:nonFraction> RSU awards to key employees who joined the Group during fiscal 2022. The related RSU expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified. Up to June 30, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" scale="0" id="Narr_20f4qvGR2U686o1qgQTPxw">73,056</ix:nonFraction> RSUs were settled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Effective July 1, 2022, CureVac N.V. acquired all shares of Frame Pharmaceuticals B.V., Amsterdam, Netherlands (formerly Frame Pharmaceuticals), now CureVac Netherlands B.V. On July 1, 2022, CureVac awarded <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_7_1_2022_To_7_1_2022_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_Nww_GsAWTEubPvNVau2dgw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_ugZnicXcGECJ5jtS8rhLaA">89,655</ix:nonFraction> RSUs to the former Frame employees. The related RSU expense is recorded in the functional cost category to which the award recipients&#x2019; costs are classified. Up to June 30, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_6_30_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_AZJ95UjEWEaSLSw3FoAPFg" decimals="INF" format="ixt:numdotdecimal" name="cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" scale="0" id="Narr_Ee1yYQDkPkas5RecDzFQeg">29,881</ix:nonFraction> RSUs were settled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 31, 2023, the Group awarded <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_UlK7_VcP00Ke20ec2b3Low" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_Sy8rGl7X7EG0XTCVJgFoOQ">92,701</ix:nonFraction> RSUs to the Supervisory Board members and <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_TvnlUpmmVUa_HJFdi00FrQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_KHTHQYR5TUe6VJga73_4xA">646,914</ix:nonFraction> RSUs to the Executive Board and various key employees. The related RSU expense is recorded in the functional cost category to which the award recipient's costs are classified. Up to June 30, 2023, <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_Zhw8mSG_RkaWjTgdo48LVQ" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" scale="0" id="Narr_yaOX-l5KLkmowkCIN6Mv-A">no</ix:nonFraction> RSUs were settled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expenses recognized for employee services received under the LTIP RSUs during the three and six months ended June 30, 2023, is in an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_jV-ZSqS8kU2_OpwJggs-Ig" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu" scale="3" id="Narr_xwwmLcXNGEGI_GEcQgPI9Q">1,379</ix:nonFraction>k and EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_H7lU27CSYkW4Hf-ukTllUA" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu" scale="3" id="Narr_cF4z7mfPsEC4muP1QUNa4A">1,920</ix:nonFraction>k, respectively (2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_lxpzPHOK-kuFcVc1SH9Lbw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu" scale="3" id="Narr_asnewevp_EK_uTP4fRbPDA">281</ix:nonFraction>k and EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_2zrm9PnhCkaFBrsWd2DlfQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu" scale="3" id="Narr_KMwYPhw4HE2vxM9_brDkGA">497</ix:nonFraction>k, respectively) and is included in research and development expenses, general and administrative expenses and selling and distribution expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the former CEO has left the Group as of March 31, 2023, all remaining unvested awards are subject to accelerated vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a Supervisory Board member has left the Group as of June 19, 2023, all remaining unvested awards are subject to accelerated vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the CSO has left the Group as of July 14, 2023, all remaining unvested awards are subject to accelerated vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exercise of options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the New VSOP plan, <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_xUdA4vFkmkehfhynMJzhzA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_eOq_I7_8TkCNtiZLxwr0IA">11,643</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_4WXyX6UBnEeF_hShCcUFxg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" scale="0" id="Narr_oVhosA2EBEKIljxPLBXi7Q">48,159</ix:nonFraction> options were exercised within the three and six months ended June 30, 2023, respectively, at a weighted average share price of USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_WivF9OzOw0qggSizEvs2xg" contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_xUdA4vFkmkehfhynMJzhzA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="Narr_KM5MFHMexE-GSGKhGpUS9g">7.90</ix:nonFraction> and USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_WivF9OzOw0qggSizEvs2xg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_4WXyX6UBnEeF_hShCcUFxg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" scale="0" id="Narr_7v0HVwNJLUSlG4BHBwt4Ow">9.81</ix:nonFraction>, respectively.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="cvac:DisclosureOfFixedAssetsExplanatory" id="Tb_xt9he-TzwkuhkUvIBkWNMg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6. Fixed Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6.1 Intangible assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2023, the Group acquired intangible assets of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_F3innQ88Ak6o2rkcUJY0ZQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="Narr_HXIrIP8hz0Sxaian-Kk4Lg">2,567</ix:nonFraction>k (six months ended June 30, 2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_xDhMyn6Lpkahl29jhpRNOg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" scale="3" id="Narr_7_jd-z8UWU2BH1Ayb5e4mA">1,207</ix:nonFraction>k). Acquired intangibles mainly related to licenses, software and prepayments made to acquire those.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6.2 Property, plant and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2023, the increase in property, plant and equipment was attributable to the purchase of technical equipment and machines and other equipment of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember__JCd2jsBx0aS7CNRVo1ClA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr_T6NL6xRkjkKrQ4mMw6JUgw">5,940</ix:nonFraction>k (June 30, 2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_tDwKd8WW10KShixVy7Uj8g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr_uvtxITfJj0WKBdYJ3jIlig">3,034</ix:nonFraction>k) as well as additional amounts recognized as construction in progress of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_C0dEV8ymUEuwP4xIHoAt0Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr___Jp9PhUO0GG80syXgS3sg">22,421</ix:nonFraction>k (June 30, 2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_TQ5I85ZFr0KjUsctPczaJA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr_1eTHyy7dAEeC5b9TD252jg">39,386</ix:nonFraction>k) primarily related to the Company-owned GMP IV facility EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_CompanyOwnedGmpIvFacilityMember_epTIr0WyBkir6RkvPsvAWQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" scale="3" id="Narr_RaTe4ulNQEWKaMtrea5Uyw">20,666</ix:nonFraction>k.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" id="Tb_g503DTzXq0uL7dkJ3qGjWw" continuedAt="Tb_g503DTzXq0uL7dkJ3qGjWw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">7. Assets held for sale</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2022, Management decided to dispose of certain equipment which had been procured for CMO activities (CMO Equipment) but that was no longer planned to be used by the Company. An external service-provider was appointed on June 14, 2022 to organize the sale of the CMO Equipment. As of December 31, 2022, the CMO-Equipment identified for sale had a gross book value of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="cvac:GrossBookValueOfCmoEquipmentHeldForSale" scale="3" id="Narr_pvTZKfbUVE2NR6jjG0f2uA">29,531</ix:nonFraction>k and was written down by EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2022_To_12_31_2022_LfUbJgvVEEOMs9Xu0dY_aQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ImpairmentOfAssetsHeldForSale" scale="3" id="Narr_sOT0RZLiRkCksIgaGpF70w">19,064</ix:nonFraction>k (with the corresponding expense recognized in cost of sales) to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:InventoriesAtFairValueLessCostsToSell" scale="3" id="Narr_LCE0-X0y-UKs1c5ay7wgBw">10,467</ix:nonFraction>k, the fair value less anticipated costs to sell. Criteria for the determination of the fair value were defined based on certain sales scenarios considering different sales campaigns. All sales activities are scheduled for 2023 and as of June 30, 2023 Assets held for sale with a net book value of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:AssetsHeldForSaleNetBookValueSold" scale="3" id="Narr_EUrVSe-3pkmWx5ca6A37iQ">513</ix:nonFraction>k were sold through an external service provider.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_g503DTzXq0uL7dkJ3qGjWw_cont1"></ix:continuation><a id="_Hlk135550786"></a><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfInventoriesExplanatory" id="Tb_tyiwvFyIVUGufokOQjWyBw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">8. Inventories</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The inventories include only raw materials and supplies amounting to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterials" scale="3" id="Narr_fSDvkcoy-0mDghxhEem9fg">22,194</ix:nonFraction>k (December 31, 2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RawMaterials" scale="3" id="Narr_9IhOBTOmzEyUHsaGyscmPw">23,989</ix:nonFraction>k), which are recoverable under the Company&#x2019;s agreements with its collaboration partners. During the six months ended June 30, 2023, the decrease in inventory of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:IncreaseDecreaseInInventory" scale="3" id="Narr_nXCG0Qs83E-QW2KS_m7yCA">1,795</ix:nonFraction>k is due primarily to further write-offs and the usage of raw material for R&amp;D purposes, partially compensated by purchases of raw material.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" id="Tb_-djELHnenE2CaM2sBW7k2w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">9. Prepaid expenses and other assets (current)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other current assets as of June 30, 2023 amounted to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Narr_iURLnW2AgkCF5k7EODyOdg">21,221</ix:nonFraction>k (December 31, 2022: <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets" scale="3" id="Narr_2Izf3qi_k0uqMq33zQi-vQ">40,287</ix:nonFraction>k) and include receivables for the GSK compensation of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Narr_s-gVgC9NkEm65CN_LBIfrg">1,491</ix:nonFraction>k (December 31, 2022; EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer" scale="3" id="Narr_Jnjl26xkr0WworXt_VMjmA">5,595</ix:nonFraction>k). In addition, other assets include tax claims against the tax authorities of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="Narr_w5zzTAg4i0ix95btN3CxrA">7,852</ix:nonFraction>k (December 31, 2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax" scale="3" id="Narr_Ea1-xo4500ivfs-JxCf4Ow">24,840</ix:nonFraction>k). These net amounts of VAT refund claims and VAT payables do not bear interest and are reported to the tax authorities on a monthly basis.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="Tb_-s4R9y95Okaaxm6KsKPprQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">10. Financial assets and financial liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fair values of cash and cash equivalents, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. Cash and cash equivalents compromise cash at banks and term deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Cash and cash equivalents compromise cash at banks and term deposits. There were <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" scale="0" id="Narr_qOQ_jsTN-kKYL7Gnj9lE3g"><ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" scale="0" id="Narr_EgaNkQUYakmkKTr9nv5upg">no</ix:nonFraction></ix:nonFraction> transfers between Level 1 and Level 2 fair value measurements and <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets" scale="0" id="Narr_TxNE8jYJZEWIdzbn7hbNfw"><ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="0" format="ixt-sec:numwordsen" name="ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets" scale="0" id="Narr_V_0mNo1Rlk6Qipus6t2OAg">no</ix:nonFraction></ix:nonFraction> transfers into or out of Level 3 fair value measurements during the six months ended June 30, 2023 and 2022.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory" id="Tb__yHZ3-VWM0qBoqfKmwbGFw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">11. Trade and other payables</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Trade and other payables are all due within one year amounting to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Narr_KwyMmJJSZE6aeZPa6iR01Q">13,419</ix:nonFraction>k (December 31, 2022: EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Narr_8pkaedMSC0SEGGWPHW-1Qg">73,463</ix:nonFraction>k). During the six months ended June 30, 2023, the decrease of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ChangeInTradeAndOtherPayables" scale="3" id="Narr_a67YJqD2MEqORSigJ6w2eQ">60,043</ix:nonFraction>k in trade and other payables was primarily due payments to raw material suppliers for invoices received before December 31, 2022.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="cvac:OtherLiabilitiesAndProvisionsTextBlock" id="Tb_8SVY98r-DU6WsjDWKr47tA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">12. Other liabilities and provisions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2023, the decrease of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ChangeInOtherLiabilities" scale="3" id="Narr_PLPLenAEikiKjZ9GeNsPxg">4,977</ix:nonFraction>k in other liabilities was primarily due to lower accruals for outstanding invoices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of June 30, 2023 the contract terminations provisions of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ" decimals="-3" format="ixt:numdotdecimal" name="cvac:ProvisionsForDecreaseInContractTerminations" scale="3" id="Narr_mBbuCUSWCUCsGKFnjlcrhg">61,320</ix:nonFraction>k which are reflecting amounts which the Company expects to pay out to settle its obligations under certain CMO contracts which it has terminated, were reclassed from Provisions (non-current) into Provisions (current) due to an expected maturity within one year. In addition, during the six months ended June 30, 2023, the decrease of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ChangesInOtherProvisions" scale="3" id="Narr_DJAq7kOzQUGW2UYnv_FpoQ">1,932</ix:nonFraction>k in Provisions (current) was primarily due to a consumption of the CRO provision for onerous losses.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfIncomeTaxExplanatory" id="Tb_2tk4o2I6uEira7KKY29dBw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">13. Income tax</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The increase in expense was primarily attributable to the income tax expense of CureVac Swiss AG and CureVac Belgium S.A.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfFinancialRiskManagementExplanatory" id="Tb_2ePzb00zQ0C2WY-le9x_0w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">14. Disclosure of financial instruments and risk management</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group requires significant liquid funds available for the financing of its COVID-19 and influenza research and development activities, during the six months ended June 30, 2023, it has maintained funds as cash and cash equivalents and not in less liquid financial instruments. The Group has distributed the cash amongst several banks and amongst the legal entities in the Group in order to reduce negative interest penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Refer to note 16 to the consolidated financial statements as of December&#xA0;31, 2022 for additional information on the Group&#x2019;s risk management activities. As of June 30, 2023, the Group held cash and cash equivalents of USD <ix:nonFraction unitRef="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw" contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_c616ZXiH_EKOpj5dNuZ83w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Narr_lFvU2xnZu0maFNbXh-nhzw">73,600</ix:nonFraction>k and CHF <ix:nonFraction unitRef="Unit_Standard_CHF_jBH-rjz8PUGNxxRiXvE2kQ" contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_tuyUV0cxakyr_-Yg3O_syQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic" scale="3" id="Narr_g1I8j5ijCUSluU_RF99TCA">132</ix:nonFraction>k, which are exposed to foreign currency exchange risk. The Group intends to settle expenses arising in US dollars using these US dollar funds. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:EarningsPerShareExplanatory" id="Tb_ovt343xpCE2Dk0PVuxXsUg" continuedAt="Tb_ovt343xpCE2Dk0PVuxXsUg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">15. Earnings per share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;">Earnings per share is calculated pursuant to <i style="font-style:italic;">IAS 33 Earnings per Share</i> by dividing the consolidated net loss in CureVac N.V. by the average weighted number of shares outstanding in the fiscal period.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ovt343xpCE2Dk0PVuxXsUg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt;">The weighted number of shares outstanding for the three and six months ended June 30, 2023 was <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Narr_qA-Bn9t85kGTv_SZNPnuYQ">223,883,084</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Narr_iCOZYifSzkCYJOdD4gPZSw">217,698,351</ix:nonFraction>, respectively (2022: <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Narr_K4cjYwsOSU6tosN43x7NRA">187,089,253</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="0" id="Narr_aOMmm-eCLUONy-Xd7RjSiA">187,041,805</ix:nonFraction>, respectively). This has led to a basic loss per share for the three and six months ended June 30, 2023 of EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q" contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Narr_nv2ObAlDoEOgf5StwQpa6w">0.30</ix:nonFraction> and EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Narr_QnxAv3YnEE-GXNjZ4AYHNg">0.57</ix:nonFraction>, respectively (2022: EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q" contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Narr_WwBqHdBYMkCmDVHDojfW-w">0.31</ix:nonFraction> and EUR <ix:nonFraction unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q" contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" sign="-" scale="0" id="Narr_riVFeonjGUK7c_4UjWvgAg">0.39</ix:nonFraction>, respectively). Since the conversion of options to ordinary shares would decrease loss per share, they are considered antidilutive. Therefore, the diluted earnings per share equals basic earnings per share for the three and six months ended June 30, 2023 and 2022. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#x200B;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#x200B;</span></p><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfRelatedPartyExplanatory" id="Tb_oiLIkikIjkS5xdAvoJLgow" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">16. Related party disclosures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dietmar Hopp</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">During fiscal 2019, Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), the largest shareholder of the Group, granted <ix:nonFraction unitRef="Unit_Standard_loan_5iHDzlzZyki6zzA0B9i78A" contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_kXJFYB4hY0uYWJFAb4CEQg" decimals="INF" format="ixt-sec:numwordsen" name="cvac:RelatedPartyTransactionNumberOfLoansReceived" scale="0" id="Narr_8O1L33vVQ0awQwIMXBlHTQ">two</ix:nonFraction> convertible loans to the Group, which were repaid in 2020. Additionally, in August 2020, DH-LT Investments GmbH, a company beneficially owned by Dietmar Hopp, managing director of dievini, the Group<span style="font-family:'Arial','Helvetica','sans-serif';">&#x2019;</span>s largest shareholder, purchased EUR <ix:nonFraction unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q" contextRef="As_Of_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_bb_-yK9N50-YjTv-FAr2SA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesIssued" scale="0" id="Narr_uJLZ-8AAsUKw62deg_-cJA">100,000</ix:nonFraction>k of the Group<span style="font-family:'Arial','Helvetica','sans-serif';">&#x2019;</span>s common shares at a price of USD <ix:nonFraction unitRef="Unit_Divide_USD_shares_WivF9OzOw0qggSizEvs2xg" contextRef="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_jJMos62EfkW5YNIpjhOWeQ" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageSharePrice2019" scale="0" id="Narr_2J4Pnk0XHEGhF8sC6wpJUQ">16.00</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Antony Blanc</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.2pt;margin:0pt 0pt 8pt 0pt;">In 2020, a consulting agreement between CureVac AG and Clarentis SRL was made. Clarentis SRL is a wholly owned consulting company of Antony Blanc, PhD, the CBO of CureVac. After the transition of Antony Blanc to the Management Board in February 2021, the contract was no longer active, and no new orders were placed. In Q3 2021, a milestone payment, which related to the submission of the EMA dossier for CVnCoV and which amounted to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_xghJZOz2zkyZscGxuWn0yg" decimals="-3" format="ixt:numdotdecimal" name="cvac:IfrsContractualObligation" scale="3" id="Narr_ax2K5X3HhkaxLqf3DeeXuw">100</ix:nonFraction>k was made to fulfill a contractual obligation from the consulting agreement in place before Antony Blanc joined the Management Board. In addition to his Management Board position at CureVac N.V., Antony also took over the role as Management Director at CureVac Belgium SA. He executes this function by using Clarentis SRL. As it relates to these services, CureVac paid in 2023 until June 2023 an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_GIDUORdEfE2sHWHYyWOsSA" decimals="-3" format="ixt:numdotdecimal" name="cvac:RelatedPartyTransactionConsultingFees" scale="3" id="Narr_QcIrFzE8o0eRKVLprOr_Ew">42</ix:nonFraction>k. The amounts invoiced for this function/services will be offset/deducted from his base compensation for his function on the Board of Management of CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">BePharBel Manufacturing S.A.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In December 2020, CureVac Real Estate GmbH and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group&#x2019;s first concentrated COVID-19 vaccine candidate, CVnCoV, to the amount specified by each dose level. Pursuant to the terms of the agreement, it was intended that BePharBel Manufacturing would manufacture and deliver to CureVac Real Estate GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021 due to COVID-19 virus drift, WHO COVID vaccine efficiency recommendation and market expectations, CureVac Real Estate GmbH terminated the commercial and supply agreement with BePahrBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_kPAAhLB8vEeSoaGBtF4VwQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions" scale="3" id="Narr_QSLJcbqo60-a8jG5IWMfCQ">3,900</ix:nonFraction>k, which had been already recognized in provisions, based on an estimate, as of December 31, 2021. In total an amount of EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_vDdXBJ99MUy29plp5BCfpQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" scale="3" id="Narr_EJlika1Q40Cm5T3C9OEepQ">4,016</ix:nonFraction>k was paid. Baron Jean St&#xE9;phenne, Chairman of our Supervisory Board, holds directly and indirectly <ix:nonFraction unitRef="Unit_Standard_pure_OIXcQb-ZL02u7t-A0Qaj8g" contextRef="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_YRShJABpk0-UxZwCv3pqAA" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Narr_6E-mODaPNEyJ3yvS8K0i3A">15.61</ix:nonFraction>% of BePharBel Manufacturing&#x2019;s equity and is a director of BePharBel Manufacturing, and Baron Jean St&#xE9;phenne&#x2019;s son, Vincent St&#xE9;phenne, holds <ix:nonFraction unitRef="Unit_Standard_pure_OIXcQb-ZL02u7t-A0Qaj8g" contextRef="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_fO5tW3MsVE60EMuNs7InYQ" decimals="4" format="ixt:numdotdecimal" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" scale="-2" id="Narr_hhMd9XwgqUeFsYzaoJyYBg">1.43</ix:nonFraction>% of BePharBel Manufacturing&#x2019;s equity and is a managing director of BePharBel Manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Franz-Werner Haas</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In Q1 2023, a consulting agreement between CureVac SE and Franz-Werner Haas was entered into. For the six-month period ended June 30, 2023 no costs have been paid under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alexander Zehnder</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In Q1 2023, a first addendum to the future service agreement was entered into to ensure a smooth transition from CEO Franz-Werner Haas to the new CEO Alexander Zehnder. Total compensation amounted to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpensesToHandleFutureServiceAgreement" scale="3" id="Narr_vKff8sE4L020jqqa5z3fDA">51</ix:nonFraction>k during the month of March.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Barker BioMedical GmbH</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In Q1 2023, a consulting agreement between CureVac SE and Barker BioMedical GmbH was entered into. Barker BioMedical GmBH is a wholly-owned consulting company of Debra Barker, Supervisory Board member of CureVac N.V.. For the six-month period ended June 30, 2023 total costs incurred under this agreement amount to EUR <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BarkerBiomedicalGmbhMember_mv3p0pRW2UerXnYaXscbzg" decimals="-3" format="ixt:numdotdecimal" name="cvac:ExpenseRecognizedFromRelatedPartyTransaction" scale="3" id="Narr_C4n0v7M_r0yx7DhPg3rVBg">14</ix:nonFraction>k.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Craig Tooman</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In Q1 2023, a consulting agreement was entered into between CureVac SE and Craig Tooman. For the six-month period ended June&#xA0;30, 2023, <ix:nonFraction unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_CraigToomanMember_PoIqBBw0NUOkeFya4T-Bsw" decimals="-3" format="ixt-sec:numwordsen" name="cvac:ExpenseRecognizedFromRelatedPartyTransaction" scale="3" id="Narr_ezmebbNh302SJGzH0Tw9IA">no</ix:nonFraction> costs have been incurred under this agreement.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#x200B;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="Tb_kTTTlFsHnEGRTZS6sbFk3g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">17. Subsequent events</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of July 14, 2023, Dr. Igor Splawski, CureVac&#x2019;s Chief Scientific Officer (CSO), stepped down from his role as CSO. During the search for a successor, CureVac&#x2019;s Chief Development Officer, Dr. Myriam Mendila, will head the advancement of CureVac&#x2019;s mRNA technology platform and its integration with the clinical development of novel mRNA vaccines and therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">CureVac filed a patent infringement lawsuit in Germany against BioNTech regarding <ix:nonFraction unitRef="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ" contextRef="Duration_6_1_2022_To_6_30_2022_IMdJRoUvhk2KhVqXkyy6DA" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfIntellectualPropertyRightsInfringementCaseFilled" scale="0" id="Narr_i4CiEsvYqkCXjDDrgEwuOA">four</ix:nonFraction> of its intellectual property rights in June 2022. The patent litigation was strengthened by the addition of a fifth intellectual property right as announced in May 2023. In July 2023, CureVac announced that it has extended these <ix:nonFraction unitRef="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ" contextRef="Duration_5_1_2023_To_5_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_PatentInfringementLawsuitFilledMember_oqeBQyU8LUS4jK_f0UnMNg" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfIntellectualPropertyRightsInfringementCaseFilled" scale="0" id="Narr_8xPqKVWHP0K1d9EpmmSSpg">five</ix:nonFraction> intellectual property rights by <ix:nonFraction unitRef="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ" contextRef="Duration_7_1_2023_To_7_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_PatentInfringementLawsuitFilledMember_Qz-L5Ejndka-M5jETiVyOw" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfIntellectualPropertyRightsInfringementCaseFilled" scale="0" id="Narr_x0FkDTwS6Eel3W9og3brkw">three</ix:nonFraction> more recent intellectual property rights. In total, the patent litigation in Germany now covers <ix:nonFraction unitRef="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ" contextRef="Duration_7_1_2023_To_7_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_PatentInfringementLawsuitFilledMember_Qz-L5Ejndka-M5jETiVyOw" decimals="INF" format="ixt-sec:numwordsen" name="cvac:TotalNumberOfIntellectualPropertyRightsInfringementCase" scale="0" id="Narr_Bs3ya8PWSUqG4GxMzy4Wqw">eight</ix:nonFraction> intellectual property rights. A first public hearing on this lawsuit took place on August 15, 2023, before the Regional Court D&#xFC;sseldorf. A nullity action covering <ix:nonFraction unitRef="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ" contextRef="Duration_8_1_2023_To_8_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_PatentInfringementLawsuitFilledMember_OxwKIZvNZUe6ydx3xJju_Q" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfPatentOnWhichNullityActionIsFilled" scale="0" id="Narr_x-JmZ1zdPkqi3KHLROS7Sw">one</ix:nonFraction> of the patents at issue was filed by Pfizer/BioNTech in September 2022. A preliminary opinion issued in April 2023 by the German Federal Patent Court supports the validity of the CureVac patent. In the U.S., Pfizer/BioNTech filed a case in late July 2022, asking for confirmation that Comirnaty&#xAE; does not infringe three CureVac patents. In May 2023, CureVac filed a counterclaim in the U.S. that alleges infringement of <ix:nonFraction unitRef="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ" contextRef="Duration_5_1_2023_To_5_31_2023_opUMBeSJAU6Y3pCknLUBYw" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfIntellectualPropertyRightsInfringementCaseFilled" scale="0" id="Narr_UFGO8arDWEKlGyoB6Xm--w">nine</ix:nonFraction> U.S. patents, expanding the scope of the case beyond the <ix:nonFraction unitRef="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ" contextRef="Duration_4_1_2023_To_4_30_2023_MpR9Fyh8qkmIM9QPSU-9Eg" decimals="INF" format="ixt-sec:numwordsen" name="cvac:NumberOfPatentOnWhichNullityActionIsFilled" scale="0" id="Narr_oCqsCvY9gUuiGBDOlyyU1A">three</ix:nonFraction> patents originally named by Pfizer/BioNTech. These nine patents have been extended by a tenth patent as announced in July 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#x200B;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#x200B;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>cvac-20230630xex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 8/17/2023 06:46:15 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:right;margin:0pt 0pt 12pt 0pt;">Exhibit 99.2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">The following discussion and analysis of our financial condition and results of operations provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read in conjunction with our unaudited interim condensed consolidated financial statements and the notes to the financial statements, which are included in this Report of Foreign Private Issuer on Form&#160;6-K. In addition, this information should also be read in conjunction with the information contained in our Annual Report on Form&#160;20-F for the&#160;year ended December&#160;31, 2022, filed with the Securities and Exchange Commission on April&#160;25, 2023, or the Annual Report, including the consolidated annual financial statements as of and for the&#160;year ended December&#160;31, 2022 and their accompanying notes included therein.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Forward-Looking Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This Report of Foreign Private Issuer on Form&#160;6-K contains historical information and forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 with respect to the business, financial condition and results of operations of CureVac N.V. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate&#8221; and &#8220;potential,&#8221; and similar expressions are intended to identify forward-looking statements. Such statements reflect the current views, assumptions and expectations of CureVac N.V. with respect to future events and are subject to risks and uncertainties. Many factors could cause the actual results, performance or achievements of CureVac N.V. to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, or financial information, including, among others, our ability to obtain funding for our operations necessary to complete further development and commercialization of our product candidates, the initiation, timing, progress, results, and cost of our research and development programs and our current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs, the timing of and our ability to obtain and maintain regulatory approval for our product candidates, the ability and willingness of our third-party collaborators to continue research and development activities relating to our product candidates and cost associated with the cancellation of manufacture and supply agreements in the event of termination of our research and development programs, the exercise by the Bill&#160;&amp; Melinda Gates Foundation of withdrawal rights, our and our collaborators&#8217; ability to obtain, maintain, defend and enforce our intellectual property protection for our proprietary and collaborative product candidates, and the scope of such protection, the rate and degree of market acceptance of our products, our ability to commercialize our product candidates, if approved, our ability and the potential to successfully manufacture our drug substances and delivery vehicles for preclinical use, for clinical trials and on a larger scale for commercial use, if approved, general economic, political, demographic and business conditions in the United States and Europe, the impact of unstable market and economic conditions such as rising inflation and interest rates and the conflict involving Russia and Ukraine on our business, our ability to implement our growth strategy, our ability to compete and conduct our business in the future, our ability to enroll patients for our clinical trials, the availability of qualified personnel and the ability to retain such personnel, regulatory developments and changes in the United States, Europe and countries outside of Europe including tax matters, our ability to overcome the challenges posed by pandemics (such as COVID-19), to the conduct of our business and other various other factors, whether referenced or not referenced in this Report of Foreign Private Issuer on Form&#160;6-K, that may affect our financial condition, liquidity and results of operations. Various other risks and uncertainties may affect CureVac and its results of operations, as described in reports filed by CureVac with the Securities and Exchange Commission from time to time, including its Annual Report. CureVac does not assume any obligation to update these forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Unless otherwise indicated or the context otherwise requires, all references in this Report of Foreign Private Issuer on Form&#160;6-K to &#8220;CureVac&#8221; or the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;ours,&#8221; &#8220;ourselves,&#8221; &#8220;us&#8221; or similar terms refer to CureVac N.V. together with its subsidiaries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We are a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. Our vision is to revolutionize medicine and open new avenues for developing therapies by enabling the body to make its own drugs. Messenger ribonucleic acid, or mRNA, plays a central role in cellular biology in the production of proteins in every living cell. We are pioneers in successfully harnessing mRNAs designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Our technology platform is based on a targeted approach to optimize mRNA constructs that encode functional proteins that either induce a desired immune response or replace defective or missing proteins using the cell&#8217;s intrinsic translation machinery. Our current product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology and molecular therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In prophylactic vaccines, we are advancing our second-generation mRNA backbone against coronavirus (SARS-CoV-2) and a range of infectious diseases, including influenza, in collaboration with GlaxoSmithKline Biologicals SA (&#8220;GSK&#8221;).</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">COVID-19 Program (second-generation mRNA backbone)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The collaboration on COVID-19 vaccine candidates with GSK, initiated in April 2021, aims to research, develop and manufacture mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CV2CoV was introduced as the first representative of our joint COVID-19 vaccine program based on our second-generation backbone. The vaccine candidate is a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the original SARS-CoV-2 virus, formulated within Lipid Nanoparticles, or LNPs. On June 30, 2021, we published preclinical data in Nature Communications demonstrating full protection by CV2CoV and our first-generation vaccine candidate CVnCoV, from lethal infection caused by SARS-CoV-2 ancestral strain BavPat1 or the Beta variant (B.1.351) in a transgenic mouse model. On August 4, 2022, we further published in the journal Vaccines data from a preclinical study in rats, showing that CV2CoV is able to induce high levels of antigen production in an in vitro setup as well as strong and dose-dependent immune responses in vivo. In a subsequent Nature publication issued on November 18, 2021, we further presented preclinical data investigating immune responses as well as the protective efficacy of CV2CoV in comparison to CVnCoV, against SARS-CoV-2 challenge in non-human primates. A direct comparison of CV2CoV with a licensed mRNA vaccine in non-human primates was able to show that neutralizing antibody levels measured following full vaccination of animals with either 12&#181;g of CV2CoV or a 30&#181;g standard dose of the licensed mRNA vaccine were highly comparable. On March 30, 2022, we announced the start of a Phase 1 clinical trial with CV2CoV. The Phase 1 dose-escalation study is being conducted at clinical sites in the United States and evaluates the safety, reactogenicity and immunogenicity of a single booster dose of CV2CoV in the dose range of 2&#181;g to 20&#181;g. On April 21, 2022, the preclinical data for CV2CoV and the second-generation mRNA backbone was extended by a study conducted in collaboration with the Friedrich-Loeffler-Institute, comparing immune responses and protective efficacy of monovalent and bivalent mRNA vaccines encoding Beta and/or Delta variants, primarily in a transgenic mouse model and a Wistar rat model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Within the joint vaccine program with GSK, we also extended our technology platform to chemically modified mRNA constructs to allow for data-driven selection of the best candidate. We announced the start of a Phase 1 clinical trial with a chemically modified COVID-19 mRNA vaccine candidate based on our second-generation backbone, CV0501, on August 18, 2022. CV0501 specifically targets the Omicron BA.1 variant. The study is being conducted at clinical sites in the United States, Australia, and the Philippines and evaluates the safety, reactogenicity and immunogenicity of a single booster dose of CV0501 in the dose range of 3&#181;g to 200&#181;g.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">On January 6, 2023, we announced that the second-generation mRNA backbone using modified mRNA was selected as the preferred technology for further clinical development in the COVID-19 program. In January and April 2023, we also announced positive preliminary data from the CV0501 Phase 1 trial. The data are based on cohort sizes of up to 20 participants in the younger adults age group (age 18-64) and 10 participants in the older adults age group (age &#8805;65). Reported safety data cover the fully recruited dose groups of 3, 6, 12, 25, 50, 100 and 200&#181;g in the younger adult age group and 12, 25, 50, 100 and 200&#181;g in the older adult age group. CV0501 was shown to be generally well tolerated. Immunogenicity data in both age groups showed relevant titers of neutralizing antibodies beginning at the lowest tested dose. On day 29 at the 12&#181;g dose level, CV0501 generated a ratio of post-boost to pre-boost serum neutralizing titers against the Omicron BA.1 variant of 8.1. in younger adults and 13.3 in older adults. The data read-out for both age groups are currently being finalized. A Phase 2 clinical study, initiated on August 1, 2023, will assess monovalent and/or bivalent vaccine candidates designed to target clinically relevant variants. A pivotal Phase 3 trial may be initiated in 2024, contingent on discussion with regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Seasonal Flu Program (second-generation mRNA backbone)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Influenza was disclosed as the first indication from the initial collaboration we started with GSK in July 2020, which focuses on the development of new products for different targets in the field of infectious diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The first non-COVID-19 vaccine candidate within the broader infectious disease program applying our second-generation backbone we tested in collaboration with GSK is the influenza candidate, CVSQIV, a differentiated multivalent vaccine candidate featuring multiple non-chemically modified mRNA constructs to induce immune responses against relevant targets of four different influenza strains. On February 10, 2022, we announced the start of a Phase 1 dose-escalation study in Panama evaluating the safety, reactogenicity and immunogenicity of CVSQIV in the dose range of 3&#181;g to 28&#181;g. Preliminary safety data reported on April 28, 2022, showed a benign reactogenicity profile across the tested dose groups.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In line with the mRNA development strategy to also test chemically modified mRNA and similar to the setup of the COVID-19 vaccine program, CureVac and GSK announced the start of a Phase 1 dose-escalation study with a chemically modified influenza vaccine candidate, Flu-SV-mRNA, on August 18, 2022. The candidate is a monovalent candidate. The Phase 1 dose-escalation study is being conducted in Canada, Spain and Belgium to evaluate the safety, reactogenicity and immunogenicity of Flu-SV-mRNA.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">On January 6, 2023, the second-generation mRNA backbone using modified mRNA was selected as the preferred technology for further clinical development in the seasonal flu vaccine program. In the Phase 1 study of the monovalent Flu-SV-mRNA, expressing an H1N1 hemagglutinin antigen (subtype of influenza A), five doses ranging from 2 to 54&#956;g with up to 25 subjects per dose cohort were evaluated in younger adults (age 18-45). In this age group, preliminary safety and reactogenicity data showed that the monovalent Flu-SV-mRNA candidate was generally well tolerated with no safety concerns observed to date across all tested dose levels. A single dose of Flu-SV-mRNA (dose level undisclosed) was assessed for safety and reactogenicity in older adults (age 60-80) and was also observed to be safe and well tolerated with no grade 3 adverse events in the 32 subjects who were administered the mRNA construct. Immunogenicity of the monovalent Flu-SV-mRNA was assessed in parallel with a licensed seasonal flu vaccine comparator in both age groups. In younger adults, adjusted geometric mean hemagglutinin inhibition antibody titers elicited by Flu-SV-mRNA increased up to approximately 3.3 times those elicited by the licensed flu vaccine comparator in younger adults. In older adults, adjusted geometric mean hemagglutinin inhibition antibody titers elicited by Flu-SV-mRNA were approximately 2.3 times those elicited by the licensed flu vaccine comparator. In the same age group, the percentage of subjects achieving seroconversion was 89.7% for Flu-SV-mRNA and 56.2% for the licensed flu vaccine comparator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">The vaccine candidate for future clinical development is expected to target all four strains recommended by the World Health Organization (WHO) for influenza vaccines. Dosing of the first participant in a Phase 1/2 study for multivalent vaccine candidates was announced on May 8, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">COVID-19 candidate CVnCoV (first-generation mRNA backbone)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 12, 2021, we announced the strategic decision to withdraw our first-generation COVID-19 vaccine candidate, CVnCoV, from the approval process with the European Medicines Agency, or EMA, and to focus our COVID-19 vaccine program on the development of second-generation mRNA vaccine candidates in collaboration with GSK. The decision was aligned with the evolving dynamics of the pandemic response toward greater need for more differentiated vaccines. The rolling submission with the EMA was originally initiated in February 2021 to assess CVnCoV&#8217;s compliance with standards for vaccine efficacy, safety and pharmaceutical quality as a prerequisite for a formal market authorization application. Later in 2021, the EMA informed us that it would not start reviewing the provided CVnCoV data packages before 2022. As a result, we estimated that the earliest possible approval of CVnCoV would come in the second quarter of 2022. By this time, we expected candidates from the second-generation vaccine program to be progressing through clinical development. Consequently, CVnCoV was also withdrawn from a rolling submission with Swissmedic, Switzerland&#8217;s authority responsible for the authorization and supervision of therapeutic products, initiated in April 2021, to review the safety, efficacy and pharmaceutical quality of CVnCoV as a prerequisite for market authorization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All clinical studies with first-generation candidate, CVnCoV, have completed the scheduled safety follow-up times for all trial participants as per the respective trial protocols. These include a Phase 1 study in Germany (initiated in June 2020), a Phase 2a study in Peru and Panama (initiated in September 2020), the Phase 2b/3 (HERALD) study in Europe and Latin America (initiated in December 2020), a Phase 3 study in healthcare workers in Germany (initiated in December 2020), and a Phase 3 study in participants with comorbidities in Belgium (initiated in April 2021).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Data analyses of the Phase 2b/3 (HERALD) study and Phase 3 study in healthcare workers in Germany have been finalized. Primary data of the Phase 2b/3 (HERALD) trial was published in The Lancet Infectious Diseases (&#8220;The Lancet&#8221;) on November 23, 2021. Data of an interim analysis of the Phase 1 trial in Germany was published in Wiener klinische Wochenschrift on August 10, 2021. Safety and immunogenicity data of the Phase 2a clinical trial in Peru and Panama was published in Vaccine: X on July 1, 2022. Neutralizing antibody data against the ancestral strain and the beta variant after a third dose of CVnCoV in the same trial were published in Vaccines on March 25, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Previously announced studies to be initiated with CVnCoV, including a Phase 2 clinical trial, focusing on immunogenicity in older adults above the age of 65 years old compared to younger adults and a flu-co-administration study, planned to be initiated together with Bayer AG to assess compatibility with established seasonal vaccines in an older population, were cancelled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To assess the benefit of booster vaccinations, CVnCoV was also included in the Cov-Boost trial sponsored by the University of Southampton, UK. The Cov-Boost trial started in June 2021 across 18 sites in the United Kingdom and dosed overall 2,878 participants with a third dose vaccine. Initial results from the Cov-Boost trial were published in The Lancet on December 2, 2021.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our pivotal Phase 2b/3 trial for CVnCoV, which included approximately 40,000 participants, reported interim analysis outcomes on May 28, 2021, and on June 16, 2021. In the highly dynamic variant environment, the HERALD trial met the prespecified success criteria for efficacy against symptomatic COVID-19 of any severity and for efficacy against moderate-to-severe COVID-19, as defined in the protocol. Vaccine efficacy against COVID-19 of any severity was 48.2% in the overall primary efficacy analysis set of SARS-CoV-2 naive participants, and 52.5% in those aged 18&#8211;60 years. Vaccine efficacy against moderate-to-severe COVID-19 was 70.7% overall and 77.2% in participants aged 18&#8211;60 years. There were too few participants aged 61 years or older who developed COVID-19 to allow a meaningful estimate of efficacy in this age group. HERALD was conducted in an unprecedented evolving landscape with an increasing number of SARS-CoV-2 variants adding additional challenges to the assessment of COVID-19 vaccine candidates. About 50% of cases of COVID-19 in our trial were caused by variants of concern, 35% were caused by variants of interest, as classified by WHO in September 2021, and about 3% were caused by wild-type, with the remaining 11% caused by other variants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beyond the GSK COVID-19 and general infectious disease collaboration, our next advanced prophylactic vaccine program, CV7202, is being developed for prophylactic vaccination against rabies. CV7202 is an mRNA based on our first-generation backbone that encodes the rabies virus glycoprotein, RABV-G, formulated with Lipid Nanoparticles. Safety, reactogenicity, and immunogenicity of CV7202 was investigated in a Phase 1 clinical trial that has completed the scheduled follow-up time for all trial participants as per trial protocol. In January 2021, we published data from our Phase 1 trial of CV7202. CV7202 induced adaptive immune response as shown by rabies-specific virus-neutralizing antibodies above the World Health Organization thresholds considered to be protective, after the second dose in all subjects, at the lowest 1&#956;g and 2&#956;g dose levels. We also showed that the lowest dose levels (1&#956;g and 2&#956;g mRNA) were generally well tolerated. We are currently assessing the path forward for advancing CV7202.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Oncology</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In oncology, we plan to build a meaningful portfolio and create long-term value to accelerate growth beyond the recent progress in prophylactic vaccines. Developing new oncology candidates is characterized by similar medical challenges as in infectious diseases, including selection and accessibility of disease-relevant antigens, enhancing antigen-induced immune activation, and triggering immune responses led by a strong induction of tumor-killing T cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.85pt;margin:0pt 0pt 12pt 0pt;">Taking advantage of recent technology platform advances, particularly our second-generation mRNA backbone in COVID-19 and flu, we are evaluating targeted expansions of our unique mRNA approaches for the development of cancer vaccines. This targeted expansion is based on three strategic pillars:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Validation and optimization of our broad mRNA technology approach for T cell mediated tumor control</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Build-up of a pipeline of cancer vaccine candidates targeting antigens predicted to be immuno&#173;genic and presented on tumors in cancer patients</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Addition of complementary platform technologies for improved antigen discovery, validation and optimization of vaccine design focusing on T cell activation</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To deliver on this strategy, we are exploring a range of potential approaches, including intratumoral therapy and novel cancer vaccines targeting neoantigens and tumor associated antigens.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A key component to deliver on this strategy is the build-up of a powerful antigen discovery engine. To gain access to state-of-the-art antigen discovery technologies we announced a partnership with Belgium-based company myNEO NV (&#8220;myNEO&#8221;) on May 25, 2022, and the acquisition of Netherlands-based Frame Cancer Therapeutics (&#8220;Frame&#8221;) on June 8, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Together with immunotherapy company myNEO, we aim to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies.&#160;myNEO utilizes a broad range of underlying genomic alterations to identify constantly emerging, novel classes of antigens of defined tumor types. Incorporating new ranking methodologies based on tumor cell antigen processing and presentation is expected to allow for selection of antigens with the highest confidence of success for potential clinical testing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">With the acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics, to identify both shared and unique neoantigens across different cancer types, we complement existing in-house expertise to identify and validate promising antigens for mRNA cancer vaccine candidates. The former Frame Cancer Therapeutics site was inaugurated as CureVac Netherlands and will further develop the proprietary technology platform, which has the potential to identify a broad panel of neoantigens and tumor-associated antigens that go beyond conventional approaches and could strongly increase the likelihood of developing highly effective cancer vaccines that activate the human immune system against cancer.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The field of immuno-therapy has advanced with the progression of available technologies to extract data from patient samples, such as next-generation sequencing. Conventional approaches have so far focused on the exome, the protein-coding part of the genome, which represents only about 1.5% of the total genetic information. More recently, breakthrough developments in sequencing capacity have enabled the extraction of vastly larger amounts of data that allows us to utilize the remaining 98.5% of genetic information. The technologies brought in house with the acquisition of Frame Cancer Therapeutics are based on whole-genome-sequencing for every patient sample combined with short as well as long-range RNA sequencing to map the full inventory of genomic changes. More specifically, downstream of the sequencing, a software package integrates all the data to retrieve the exact changes in the DNA of the tumor cells compared to healthy cells. Correlation of this data with changes in the RNA transcription of the tumor results in entirely new and potentially antigenic tumor antigens that we plan to test as targets for a portfolio of new cancer vaccine candidates. These new antigens are not only entirely foreign to the body but are also uniquely expressed in the tumor and not in healthy tissue. In their foreignness, these constructs are expected to raise stronger immune responses than antigens derived from exome-based conventional approaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The highly synergistic antigen discovery technologies of Frame Cancer Therapeutics and myNEO are expected to significantly accelerate CureVac&#8217;s oncology strategy to build a meaningful portfolio of new cancer vaccine candidates. Within this strategy, we follow two approaches. The first approach assesses tumor antigens shared by different cancer patients for the development of off-the-shelf cancer vaccines. The second approach is tailored to the individual tumor setup of a patient for personalized therapy. We plan to advance new antigens for both approaches based on our second-generation mRNA backbone. To assess the safety and immunogenicity of our second-generation backbone in an oncology setting, we initiated a proof-of-principle study in the second quarter of 2023, assessing an mRNA construct encoding eight epitopes from tumor associated antigens in patients with surgically resected Glioblastoma Multiforme.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In our oncology strategy, we are committed to drive innovation by also leveraging The RNA Printer&#174;, CureVac&#8217;s automated end-to-end manufacturing solution for GMP-grade mRNA vaccines and therapeutics. The highly standardized system is expected to allow for rapid and highly flexible availability of mRNA to screen new targets and transition promising mRNA product candidates more efficiently into the clinic. Designed for small-scale quantities, the automated GMP-grade output of The RNA Printer&#174; is designed to open avenues for personalized mRNA-based cancer therapies. The system is currently undergoing regulatory approval processes to obtain its first manufacturing licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our clinical oncology candidate, CV8102, is a complex of single-stranded non-coding RNA, which has been optimized to maximize activation of cellular receptors that normally detect viral pathogens entering the cells (such as toll-like receptor 7, or TLR7, toll-like receptor 8, or TLR8, and retinoic acid inducible gene I, or RIG-I pathways), mimicking a viral infection of the tumor. Clinical data support the hypothesis that CV8102 is able to recruit and activate antigen-presenting cells at the site of injection to present tumor antigens released from tumor cells to T cells in the draining lymph node. This potentially leads to activation of tumor-specific T cells, which can kill tumor cells at the injected site, but also at distant non-injected tumor lesions or metastases. CV8102 is currently being evaluated in a Phase 1 clinical trial as a single agent and in combination with anti-PD 1 antibodies. The trial consists of two parts. The first dose-escalating part assesses CV8102 in 58 patients with solid tumors, namely&#8201;cutaneous melanoma, adenoid cystic carcinoma, squamous cell carcinoma of skin, and squamous cell carcinoma of head and neck, or HNSCC. As of June 21, 2021, in the single-agent cohort, we observed one patient with a complete response and two patients with a partial response according to Response Evaluation Criteria In Solid Tumors, RECIST, 1.1. In addition, twelve patients experienced a best response of stable disease. In the PD 1 combination cohort, one PD 1 refractory melanoma patient experienced a partial response according to RECIST 1.1. In addition, three patients experienced a best response of stable disease. On November 10, 2021, we added an extensive analysis of immune cell activation. The data showed efficient stimulation of the immune system characterized by the induction of interferon alpha and interferon gamma. Serial tumor biopsies from individual patients demonstrated increased infiltration of T cells in the micro-environment of injected as well as non-injected tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2021, we initiated an expansion of our Phase 1 study to confirm the safety, tolerability and efficacy of CV8102 at a 600&#956;g dose in 40 patients with advanced melanoma. On November 11, 2022, we presented preliminary data from the expansion study. As of August 30, 2022, preliminary efficacy was observed in the cohort of 30 patients treated in combination with anti-PD-1 antibodies, 40% of whom were pretreated with anti-CTLA-4 antibodies. In this anti-PD-1 combination cohort, five out of 30 patients (17%) experienced a partial response according to RECIST 1.1. Responses appeared durable for up to one year from the start of treatment. No objective responses were observed in the 10 patients of the single-agent cohort, 50% of whom were pretreated with anti-CTLA-4 antibodies. Analysis of immune cell activation confirmed that CV8102 single agent or combination treatment, after the first dose, activated systemic pathways of immune response. Preliminary analysis of the tumor microenvironment in a subgroup of patients showed the positive outcome of increased infiltration of T cells, following intra-tumoral injection in 4 out of 8 (single agent cohort) and 10 out of 18 (anti- PD1 combination cohort) analyzed paired biopsy samples.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Final study results are expected to be submitted for publication in a peer reviewed journal in the first half of 2023. A scientific paper assessing the mode of action and efficacy of CV8102 for local immunotherapy in preclinical models was published on November 2, 2022, in Cancer Immunology, Immunotherapy.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the context of our strategic focus on antigen discovery and hence the development of mRNA-based cancer vaccine candidates that target tumor-specific antigens, the clinically validated immuno-modulatory characteristics of CV8102 represent a potentially complementary technology. We would therefore only consider a potential further clinical development of CV8102 based on an integration into our cancer vaccine developments, for example, as a potential immuno-modulatory adjunct to a defined mRNA cancer vaccine candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Molecular Therapies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In molecular therapies, we published preclinical mouse data in liver fibrosis in the Journal of Hepatology in August&#160;2021. Progression of liver fibrosis is associated with the gradual decrease of hepatocyte nuclear factor 4 alpha, or HNF4 alpha, an important regulator and key factor in liver metabolism. In the published study, four independent mouse models of the disease were treated with mRNA encoding HNF4A. The treatment was able to restore HNF4A levels and thereby significantly reduced liver injury. The study was conducted in collaboration with the REBIRTH-Research Center for Translational Regenerative Medicine and Department of Gastroenterology, Hepatology and Endocrinology at the Hannover Medical School, Hannover (Germany). It provides the first preclinical data demonstrating the therapeutic applicability of mRNA encoded HNF4A in the treatment of liver fibrosis and cirrhosis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We further expect to publish data from our collaboration with the Schepens Eye Research Institute.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Key Factors Affecting Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that the most significant factors affecting our results of operations include:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to successfully pioneer a robust mRNA technology platform and develop innovative product candidates will be the primary factor affecting our future growth and development. Our approach to the discovery and development of product candidates based on mRNA technology is still being demonstrated. As such, we do not know whether we will be able to successfully develop any products. Developing novel product candidates requires a significant investment of resources over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. We have chosen to leverage our platform to initially focus on advancing our product candidates in the areas of prophylactic vaccines, oncology and molecular therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All of the product candidates are still in development, and we have incurred and will continue to incur significant research and development costs for preclinical studies and clinical trials. We expect that our research and development expenses will constitute the most substantial part of our expenses in future periods in line with the advance and expansion of the development of our product candidates. Due to our accelerated efforts to develop our first-generation backbone COVID-19 vaccine candidate, CVnCoV, we incurred research and development expenses that significantly exceeded our historical levels of research and developments expenses. Additionally, our October 2021 notification to the European Commission, or EC, of the withdrawal of our regulatory approval application for CVnCoV resulted in our recognition of several expenses, which have contributed to our increased expense levels, but which we do not expect to recur in future periods. In April 2021, we entered into a collaboration agreement with GSK for the development of a broad COVID-19 vaccine program based on our second-generation backbone. CV2CoV, a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within LNPs, is the first representative of our COVID-19 vaccine program based on the second-generation backbone and presently in the Phase 1 clinical trial, as announced on March 30, 2022. Within this COVID-19 vaccine program, we plan to extend our technology platform also to chemically modified mRNA constructs to allow for data-driven selection of the best candidate. We expect to incur significant expenses related to such second-generation backbone vaccine candidates. But, as we and GSK agreed to equally share the development costs for GSK COVID Products, our current level of research and development expenses will not continue to increase in the level as it did from 2020 to 2021. Once we conclude our research and development efforts related to a selected second-generation backbone vaccine candidate, we expect that our research and development expenses shall be consistent with our past trends before the COVID-19 pandemic, but we may find it necessary to continue such current trend with respect to our research and developments expenses or we may continue to increase further our research and development expenses. For example, we may continue to increase our research and development expenses for future research and development related to the next generation backbone for our COVID-19 vaccine candidates, such as for our second-generation backbone COVID-19 vaccine candidates or may pursue new indications with our technology platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have historically funded the research and development expenses primarily through public offerings of our common stock, private placements of equity securities, convertible loans, grants from government agencies and similar bodies and payments for collaborative research and development services with strategic partners. In addition, we signed an advance purchase agreement, or APA, with the EC that provided substantial support for our efforts to advance our first-generation backbone vaccine candidate, CVnCoV. In October 2021, we notified the European Commission of the withdrawal of our regulatory approval application for CVnCoV, which automatically terminated the APA.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Our and Our Collaborators&#8217; Ability to Commercialize Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ability to generate revenue from our product candidates depends on our and our collaborators&#8217; ability to successfully advance clinical trials for our product candidates and receive regulatory approval, particularly in the United States, Europe, and other major markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that our broad portfolio of product candidates with both novel and validated targets enhances the likelihood that our research and development efforts will yield successful product candidates. Nonetheless, we cannot be certain if any of our product candidates will receive regulatory approvals. Even if such approvals are granted, we will thereafter need to maintain manufacturing and supply arrangements and engage in extensive marketing prior to generating any revenue from such products, and the ultimate commercial success of our products will depend on their acceptance by patients, the medical community and third-party payors and their ability to compete effectively with other therapies on the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The competitive environment is also an important factor with the commercial success of our product candidates, and our ability to successfully commercialize a product candidate will depend on whether there are competing product candidates being developed or already marketed by other companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently do not have any product candidates that have received regulatory approval. As such, we have not incurred any material commercialization expenses in connection with an approved product candidate. In February&#160;2021, we initiated a rolling submission for our first generation COVID-19 vaccine candidate, CVnCoV, with the EMA, which was designed to allow the EMA to assess CVnCoV&#8217;s compliance with standards for vaccine efficacy, safety and pharmaceutical quality as a prerequisite for a formal market authorization application. Later in 2021, EMA informed us that the EMA would not start reviewing our submission for CVnCoV before the beginning of 2022. As a result, we estimated that the earliest possible approval of CVnCoV would come in the second quarter of 2022. Data on the efficacy of CVnCoV was generated and published in June&#160;2021. This efficacy data did not live up to our pre-trial expectations and fell behind the efficacy of competing COVID-19 vaccine products. The application for the marketing authorization for CVnCoV was withdrawn in early October&#160;2021, as a necessary reaction to the efficacy data as well as the concerns and uncertainties resulting from such data on the granting of a marketing authorization and the expected concerns of prescribers and patients about using a COVID-19 vaccine with a lower efficacy compared to the vaccines already available on the market. After the withdrawal of the application for a marketing authorization for CVnCoV, we have focused our efforts on second-generation mRNA vaccines. The decision is aligned with the evolving dynamics of the pandemic response toward greater need for differentiated vaccines with the gradual transition from an acute pandemic to an endemic SARS-CoV-2 environment. In connection with the regulatory approval process, and in preparation for the commercialization of a second-generation COVID-19 vaccine, we expect our expenses related to commercialization to significantly decrease in the short-term due to our past commercialization efforts for CVnCoV. However, we expect that our expenses related to commercialization will significantly increase in the long term if a second-generation COVID-19 vaccine candidate reaches late clinical stages, but we expect that this increase in expenses will be mitigated by the GSK COVID Agreement, as described below. As part of the commercialization process of CVnCoV, we also entered into strategic partnerships with Bayer for the development, production and distribution of CVnCoV. In addition, pursuant to a preliminary agreement regarding the secondary manufacturing of CVnCoV we entered into with GSK, GSK would have supported the secondary manufacturing of up to 100 million doses of CVnCoV in 2021. Additionally, we also partnered with Fareva, Rentschler Biopharma SE, and Novartis AG, among others, to develop an integrated European manufacturing network. Due to our decision to withdraw CVnCoV from the regulatory approval process and focus our efforts on second-generation mRNA vaccine, separate agreements with Celonic and Wacker were terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Our Collaborations, Related License Agreements and Advance Purchase Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our results of operations have been, and we expect them to continue to be, affected by our contractual collaborations with third parties for the development and commercialization of certain of our product candidates. In addition, our future results of operation may be affected by future advance purchase agreements for our COVID-19 vaccine candidates. To date, our revenues have been recognized pursuant to license and collaboration agreements, which include up-front payments for licenses or options to obtain licenses, milestone payments, payments for product sales and payments for research and development services. Grants from government agencies or similar bodies are recognized as other operating income or as a reduction to depreciation and amortization expense recognized from assets purchased under the associated arrangements.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have entered into strategic collaborations and license agreements with third parties. In addition, on November&#160;30, 2020, we entered into an advance purchase agreement, or APA, with the European Commission, which provided for the advance purchase by the commission of our first-generation vaccine candidate, CVnCoV. In October&#160;2021, we notified the EC of the withdrawal of our regulatory approval application for CVnCoV, which automatically terminated the APA. As part of our business development strategy, we aim to increase the number of our strategic collaborations in order to derive further value from our platform and more fully exploit the potential of our collaboration and license agreements. Relatedly, on April 8, 2022, we received a letter from the Federal Republic of Germany&#39;s counsel confirming that the CureVac-GSK Consortium (as defined below), was awarded with the Pandemic Preparedness Agreement (as defined below).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain key terms of our current material collaboration and license agreements, our advance purchase agreement with the EC, the CureVac-GSK Consortium and the Pandemic Preparedness Agreement (&quot;PPA&quot;) are summarized below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">GlaxoSmithKline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2020, we entered into a Collaboration and License Agreement with GSK, which we refer to as the 2020 GSK Agreement, pursuant to which we are collaborating with GSK to research, develop and commercialize prophylactic and therapeutic non-replicating mRNA-based vaccines and antibodies targeting infectious disease pathogens. The 2020 GSK Agreement was amended and restated in April&#160;2021, September&#160;2021, February&#160;2022 and March&#160;2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">GSK paid us an upfront payment of &#8364;120 million and is required to pay us a manufacturing capacity reservation fee of &#8364;30 million following a certain regulatory milestone event, which is creditable against future milestone payments. We are eligible to receive up to between &#8364;28 million to &#8364;45 million in development milestone payments, &#8364;32 million to &#8364;35 million in regulatory milestone payments and &#8364;70 million to &#8364;100 million in commercial milestone payments, depending on the product. Under the 2020 GSK Agreement, we granted GSK an exclusive option to add additional products in the field of infectious diseases to the license granted under the 2020 GSK Agreement and, upon each exercise of such option, GSK is required to compensate us for certain development costs and pay any accrued milestone payments. Additionally, GSK has the right to replace products licensed under the 2020 GSK Agreement and, if the replacement product was already under development by us, GSK must compensate us for certain development costs and pay any accrued milestone payments. We are additionally eligible to receive tiered royalty payments ranging from single-digit&#160;to low-teens&#160;percentages on net sales, subject to certain customary reductions. GSK is required to compensate us for certain development and regulatory costs we may incur in connection with performing our obligations under the 2020 GSK Agreement, and we are eligible to receive up to &#8364;20,000 in reimbursements for expenses incurred by recording or registering the licenses granted under the 2020 GSK Agreement. We retain the right to commercialize products developed under the 2020 GSK Agreement in Germany, Austria and Switzerland, as GSK&#8217;s exclusive distributor in these markets. Under any such distribution agreement to be entered into between us and GSK, we will be required to purchase supply from GSK and pay GSK a low thirties&#160;percentage royalty on net sales. Pursuant to the amendment in September&#160;2021, we and GSK are required to complete certain development activities set forth in updated development plans. We and GSK agree to decide whether the products required for clinical studies will be manufactured by us, GSK or jointly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, in April 2021, we entered into a new collaboration agreement with GSK, which we refer to as the GSK COVID Agreement, pursuant to which we are collaborating with GSK to research, develop and manufacture next-generation mRNA vaccines targeting the original SARS-CoV 2 strain as well as emerging variants, including multivalent and monovalent approaches, such as our second-generation COVID 19 vaccine candidate, CV2CoV. These vaccine candidates may either be used to protect unvaccinated individuals or to serve as boosters in the event that SARS-CoV-2 immunity gained from an initial vaccination reduces over time. The GSK COVID Agreement was amended and restated in September 2021, February 2022 and March 2022, and further amended to update the research and development plan in August 2022. Pursuant to the amendment in September 2021, we and GSK are required to complete certain development activities with respect to the GSK COVID Products set forth in updated development plans. We and GSK agree to decide whether the GSK COVID Products required for clinical studies will be manufactured by us, GSK or jointly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Under the GSK COVID Agreement, GSK paid us an upfront payment of &#8364;75 million. We and GSK agreed to equally share all development costs for GSK COVID Products, subject to certain exceptions. We and GSK will share all net profits generated from sales of GSK COVID Products, other than Combination Products (as defined therein), under profit sharing arrangements that in certain cases vary depending upon the GSK COVID Product in question, the time of sale, the number of doses sold and the party to whom the sale is made. We are eligible to receive tiered royalty payments ranging from sub-teen to mid-teen percentages on net sales of Combination Products, subject to certain customary reductions. Under the GSK COVID Agreement we have the right to commercialize GSK COVID Products in Austria, Germany and Switzerland and if we exercise such right, our sales of GSK COVID Products, other than Combination Products will be subject to the profit share and we will be required to pay GSK a high-teen percentage royalty on net sales of all Combination Products in such countries.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Genmab</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2019, we entered into a Collaboration and License Agreement, which we refer to as the Genmab Agreement, with Genmab to research and develop up to four potential differentiated mRNA-based antibody products, to be selected by Genmab, based on the combination of our proprietary RNAntibody technology with Genmab&#8217;s proprietary antibody technology for the treatment of human diseases. We will collaborate on research to identify an initial product candidate designed to express a certain Genmab proprietary antibody, and we will contribute a portion of the overall costs for the development of such product candidate, until submission of an IND. Genmab will thereafter be responsible for the development and commercialization of the product candidate. Under the Genmab Agreement, we further grant Genmab a license for the preclinical development of up to four additional mRNA antibody product concepts and options to obtain commercial licenses under our mRNA technology to develop, manufacture and commercialize product candidates for up to three of such product concepts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Genmab Agreement, Genmab paid us a $10 million up-front fee and made a &#8364;20 million equity investment in March 2020. Genmab will be obligated to pay us a $0.5 million reservation fee upon the selection of each additional product concept for development under the Genmab Agreement and $5 million upon selection of a product targeting Genmab&#8217;s proprietary antibody for further development and commercialization. Genmab is additionally required to pay us up to $30 million in option exercise fees. If Genmab exercises any of its options to obtain commercial licenses for the additional mRNA antibody concepts, Genmab would fund all research and would develop and commercialize any resulting product candidates. We are additionally eligible to receive up to between $25 million and $43 million in development milestone payments, $100 million and $125 million in regulatory milestone payments and $150 million and $200 million in commercial milestone payments for each product, depending on the specific product concept. In addition, we are eligible to receive a mid single-digit to low teens percentage tiered royalty on aggregate net sales of licensed products, on a per-product basis and subject to certain customary reductions. If Genmab grants a sublicense to the initial product candidate developed under the Genmab Agreement before a certain milestone event, Genmab must pay us a one-time $10 million payment. We are responsible for any payments to third parties related to the LNP technology we license to Genmab for use in relation to the initial product candidate developed under the Genmab Agreement and a portion of such payments with respect to LNP technology used in the additional product concepts. We retain an option to participate in development and commercialization of one of the potential additional mRNA antibody product concepts under predefined terms and conditions. In the event we exercise such right, we must pay Genmab a one-time payment of $3 million and refund any option fee paid by Genmab with respect to such product. As of June 30, 2023, we have received $1 million in development cost reimbursements and we have not received any reservation, product selection, option exercise or sublicense fees or milestone or royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Arcturus</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2018, we entered into a Development and Option Agreement, which we refer to as the Arcturus Agreement, with Arcturus, which provides us with access to Arcturus LNP formulation technology which we use in combination with our mRNA technology. We paid Arcturus an up-front fee of $5 million and must pay an extension fee of $1 million if we exercise our option to extend the initial term of the Arcturus Agreement beyond July 2023. We did not exercise such option to extend the Arcturus Agreement beyond July 2023. We are required to reimburse Arcturus for certain costs incurred in connection with development activities and provide certain FTE funding. We are additionally required to pay up to an aggregate of $5 million in connection with our acceptance of the irrevocable offer to obtain licenses for further development and commercialization of selected targets. As of June 30, 2023, we have not exercised our option to extend and have not accepted any such irrevocable offer. Under each license agreement to be entered into in connection with our acceptance of the irrevocable offer, to the extent applicable, we will additionally be required to make certain royalty payments, which are not in excess of 10% on net sales of licensed products, and pay Arcturus up to $6 million in development milestone payments, $9 million in regulatory milestone payments and $8 million in commercial milestone payments. As of June 30, 2023, we have made payments totaling $5.5 million to Arcturus reimbursing Arcturus for development costs and in connection with our FTE funding obligations, and we have not accepted the irrevocable offer with respect to any target and therefore have not paid any acceptance fees or made any milestone or royalty payments to Arcturus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Acuitas</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In April 2016, we entered into a Development and Option Agreement, which as amended we refer to as the Acuitas Agreement, with Acuitas, which provides us with access to Acuitas LNP formulation technology that we use in combination with our mRNA technology. We are required to pay Acuitas annual target reservation and maintenance fees of up to $1.4 million if we reserve the maximum number of targets permitted under the Acuitas Agreement and to reimburse Acuitas for certain costs incurred in connection with development activities and certain FTE costs. We are additionally required to pay an option exercise fee ranging from $50,000 to $2 million upon each exercise of our option to obtain a license for further development and commercialization with respect to a selected target, subject to certain additional fees ranging from $10,000 to $200,000 for the exercise of our option for certain other vaccine targets. We paid Acuitas a $5 million upfront fee in connection with an amendment to the Acuitas Agreement dated July 2020 and, upon each exercise of our option to exchange a vaccine target licensed under any non-exclusive license, we are required to pay an exchange fee of $3 million. We additionally paid Acuitas a $3 million upfront fee in connection with an amendment to the Acuitas Agreement dated December 2020 and are required to pay an additional $250,000 per option for certain options not yet exercised. Under each license agreement in connection with our exercise of our option, we will additionally be required to make low single-digit </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">percentage tiered royalty payments and must pay up to between $1.1 million and $9 million in development milestone payments, $1.3 million and $7 million in regulatory milestone payments and $1.3 million and $7 million in commercial milestone payments, depending on whether the license is exclusive or non-exclusive and the number of options exercised to date. As of June 30, 2023, we have exercised our option to obtain a non-exclusive license to 18 targets, subject to customary closing conditions. As of June 30, 2023, we have paid Acuitas $8.0 million in reservation and option exercise fees and $1.25 million for certain options not yet exercised and have made payments totaling $8.9 million reimbursing Acuitas for development costs and LNP batches and in connection with our FTE funding obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For each option that we have exercised under the Acuitas Agreement, we have entered into a non-exclusive license agreement with Acuitas with respect to such optioned target, all based on the same form agreement, which we refer to as the Acuitas License Agreements. We are required to pay Acuitas up to between $1.1 million and $1.6 million in development milestone payments, $1.3 million and $1.8 million in regulatory milestone payments and between $1.3 million and $1.8 million in commercial milestone payments under each Acuitas License Agreement. We must pay Acuitas annual fees ranging from $5,000 to $10,000 for any additional protein targeted by a vaccine product licensed under each Acuitas License Agreement after a certain milestone event. Additionally, we are obligated to pay Acuitas a low single-digit percentage royalty on net sales of licensed products. As of June 30, 2023, we have made $100,000 in development milestone payments to Acuitas with respect to the license agreement relating to Rabies RAV-G, $1.4 million in development milestone payments (Phase I, Phase II and Phase III milestone payments) to Acuitas with respect to the license agreement relating to the SARS-CoV-2 Spike protein S, $100,000 in development milestone payments to Acuitas with respect to the license agreement relating to the Influenza hemagglutinin (HA) antigen, and have not made any royalty payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">CRISPR Therapeutics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2017, we entered into a Development and License Agreement with CRISPR Therapeutics, which, as amended by an amendment entered into in June 2020, we refer to as the CRISPR Therapeutics Agreement, pursuant to which we will develop novel Cas9 mRNA constructs for use in gene editing therapeutics. Under the CRISPR Therapeutics Agreement, we granted CRISPR Therapeutics an exclusive worldwide license to use our improved Cas9 constructs for the development and commercialization of three of its in vivo gene-editing programs for certain diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CRISPR Therapeutics has paid us an up-front one-time technology access fee of $3 million, and we are eligible to receive up to $13 million in development milestone payments, $33 million in regulatory milestone payments and $133 million in commercial milestone payments, as well as mid-single-digit percentage royalties from CRISPR Therapeutics on the net sales of licensed products on a product-by-product and country-by-country basis, subject to certain potential customary reductions. Additionally, CRISPR Therapeutics will make payments to us for services provided by us in conjunction with research programs under the CRISPR Therapeutics Agreement. In the event CRISPR Therapeutics exercises its right to sublicense under the CRISPR Therapeutics Agreement, CRISPR Therapeutics must pay us a low-teens to mid-twenties percentage of any non-royalty sublicense income, depending on the timing of the sublicense and whether the sublicense is granted through an affiliate of CRISPR Therapeutics. As of June 30, 2023, we have received &#8364;5.5 million in payments and we have invoiced &#8364;2.7 million for the supply of materials and FTE cost, development reimbursements and up-front one-time technology access fee and no milestone, royalty or sublicense fee payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Bill&#160;&amp; Melinda Gates Foundation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May 2014, we were awarded a grant from the Bill &amp; Melinda Gates Foundation for the development of a vaccine for rotaviruses, as amended in November 2020, for up to $2.8 million in funding. As of June 30, 2023, we have received $3.0 million in funding under the agreement. In March 2015, the Bill &amp; Melinda Gates Foundation made an equity investment of $40 million to support continued development of our RNA technology platform and the construction of an industrial-scale cGMP production facility. We entered into a Global Access Commitments Agreement with the Bill &amp; Melinda Gates Foundation in February 2015 pursuant to which we are required to take certain actions to support the Bill &amp; Melinda Gates Foundation mission. In connection with the investment by the Bill &amp; Melinda Gates Foundation, we are required to conduct development activities for up to three concurrent projects to be proposed by the Bill &amp; Melinda Gates Foundation. The costs of such projects will be allocated on a project-by-project basis in proportion to the allocation of the expected benefits. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2016, in connection with the Global Access Commitments Agreement, we were awarded a grant for up to $0.9 million in funding from the Bill &amp; Melinda Gates Foundation for the development of a vaccine for picornaviruses. As of June 30, 2023, we have received $0.7 million in funding under the picornaviruses grant agreement. The term of the picornavirus grant expired in June 2022; however, our global access commitments survive. In November 2017, we were awarded two additional grants each for up to $1.9 million and $1.5 million in funding from the Bill &amp; Melinda Gates Foundation for the development of a universal influenza and a malaria vaccine, respectively. By an amendment entered into November 2020, our grant for the development of a malaria vaccine was increased by an additional $0.8 million. As of June 30, 2023, we have received $1.9 million and $2.2 million, respectively, in funding under each grant agreement. The malaria grant agreement expired in December 2022 and the universal influenza grant agreement expired in March 2022. We and the Bill &amp; Melinda Gates Foundation are currently assessing options to continue the influenza grant agreement.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Coalition for Epidemic Preparedness Innovations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2019, we entered into a framework partnership agreement, which as amended we refer to as the CEPI Agreement, with the Coalition for Epidemic Preparedness, or CEPI, to develop our RNA Printer using certain intellectual property controlled by us covering the development and manufacture of mRNA products, as well as certain additional intellectual property licensed to us. In connection with the CEPI Agreement we have entered into work orders for the preclinical development of a Lassa virus vaccine, a yellow fever vaccine and our rabies virus vaccine. In addition, we entered into a work package for the preclinical development and a Phase 1 clinical trial for our first-generation COVID-19 vaccine candidate, CVnCoV. The CEPI Agreement terminated in February 2022, except with respect to certain ongoing projects, which are contemplated to be completed in December 2023. CEPI agreed to contribute up to $34 million in funding for projects undertaken under the CEPI Agreement and an additional $15.3 million in connection with development of CVnCoV. As of June 30, 2023, we have received &#8364;27.1 million in funding for projects undertaken under the CEPI Agreement. Following the completion of the CEPI Agreement, CEPI requested a partial reimbursement of $1.0 million for unspent funds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Tesla Automation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In November 2015, we entered into a development and intellectual property agreement with Tesla Automation, formerly trading under the name of Tesla Grohmann Automation, which we refer to as the Tesla Automation Agreement, pursuant to which Tesla Automation agreed to design, develop and manufacture certain automated manufacturing machines on our behalf. We are obligated to pay Tesla Automation a fee for each machine delivered by Tesla Automation and up to $50 million to $60 million in commercial milestone payments as well as certain development costs under each associated work order. As of June 30, 2023, we have paid Tesla Automation &#8364;21 million to &#8364;22 million in development costs under various work orders, and we have not paid any fees for machines provided under the Tesla Automation Agreement or made any milestone payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Option Agreement with myNEO</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On May 12, 2022, we entered into a Research and Option Agreement (&#8220;R&amp;O&#8221;) with myNEO, pursuant to which we will both collaborate to identify specific antigens found on the surface of tumors for the development of novel mRNA immunotherapies. To achieve this goal, myNEO will leverage its biological datasets, its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit a strong immune response. Under the R&amp;O, we aim to develop and commercialize at least two new medicinal products for the treatment of non-small cell lung cancer and melanoma (the &#8220;Main Indications&#8221;) and potentially other indications. We are required to use commercially reasonable efforts to develop at least one product for each of the Main Indications, to file marketing approval applications for such products and commercialize such products in at least one of certain countries. Under the R&amp;O, myNEO will own all intellectual property rights generated solely by myNEO or jointly with us during the first three phases of the R&amp;D plan (the &#8220;R&amp;D Project IP&#8221;). We receive a non-exclusive, royalty-free, non-assignable, sublicensable, worldwide license under certain patents and know-how owned by myNEO and R&amp;D Project IP to the extent required to perform our research and development obligations under the agreement until the completion of a certain phase of the R&amp;D plan. We were also granted an exclusive option to acquire all of myNEO&#8217;s rights under certain R&amp;D Project IP relating to certain target lists, which we exercised on April 12, 2023. myNEO receives a non-exclusive, royalty-free, perpetual license back to such IP to make, use or sell certain targets in the field of patient-specific vaccines. Under the R&amp;O, myNEO agrees to work exclusively with us to develop and validate shared antigens for the Main Indications until the earlier of the date of the first phase I clinical trial for either Main Indication or 24 months after we exercised our option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the R&amp;O, we paid myNEO an upfront one-time technology access fee of &#8364;138,000 and myNEO is eligible to receive up to &#8364;17.5 million in research and development milestone payments with respect to the Main Indications, up to &#8364;175,000 in research and development milestone payments with respect to indications other than the Main Indications, up to &#8364;30 million in commercial milestone payments with respect to the Main Indications and up to &#8364;7.5 million in commercial milestone payments with respect to indications other than the Main Indications, as well as low single-digit percentage royalties on the net sales of licensed products in the Main Indications and sub single-digit percentage royalties on the net sales of licensed products for indications other than the Main Indications. Our royalty obligations continue on a product-by-product and country-by-country basis until the earlier of the date when there are no valid patent claims covering such licensed product in such country and 10 years following the date of first commercial sale of such licensed product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Advance Purchase Agreement for our First-Generation COVID-19 Vaccine Candidate</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On November 30, 2020, we entered into an APA with the EC, acting on behalf and in the name of all Member States of the European Union, which provided for the advance purchase by the Member States of 225 million doses of the vaccine to be allocated among the Member States and the option to purchase up to an additional 180 million doses. Pursuant to the APA, we received an up-front payment of &#8364;450 million. Such up-front payment had to be used solely for the development and commercial supply of CVnCoV. We are required to return any unspent amounts of the up-front payment if, among others, we fail to successfully develop CVnCoV or if we successfully develop CVnCoV, but we do not receive EU marketing authorization or fail to supply any doses of CVnCoV to any of the Member States by late 2021, unless we and the EC mutually agree to a later date. In October 2021, we notified the EC of the </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">withdrawal of our regulatory approval application for CVnCoV, which notification automatically terminated the APA. According to the APA, in such case of termination, CureVac would only return the unspent amount of the up-front payment. In the context of the APA, &#8220;spent&#8221; means either costs incurred or commitments made in connection with the purposes set forth in the APA. On March 8, 2022, we received a letter signed by the EC acknowledging and outlining that we will not be required to return any portion of the up-front payment. Due to the termination of the APA, we will not receive any further payments related to the APA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In other respects, upon the EC&#8217;s request, we will transfer any raw materials and/or primary components paid for with the upfront payment that were not used as of the termination date. Additionally, should the EC request, or should we successfully sell, any raw materials and/or primary components, then an applicable portion of such raw materials, primary components or proceeds, as the case may be, will be remitted to the EC. This repayment agreement expired at the end of 2022 and an amount of &#8364;4.1 million is accrued as of June 30, 2023, for the related amount due to be remitted to the EC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Acquisition of Frame Pharmaceuticals</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 8, 2022, we entered into a Share Purchase Agreement (&#8220;SPA&#8221;), to acquire all of the issued and outstanding shares of Frame Pharmaceuticals B.V., domiciled in Amsterdam, the Netherlands, a private company with limited liability (<i style="font-style:italic;">besloten vennootschap met beperkte aansprakelijkheid</i>), organized and existing under the laws of the Netherlands, focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types. Under the SPA, the total consideration for the purchase was &#8364;34 million, conditioned on certain development milestone payments, as described therein. This acquisition serves to complement and strengthen our discovery capabilities to identify and validate promising neoantigens for our mRNA cancer vaccine programs and could strongly increase the likelihood of developing highly effective cancer vaccines for patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Financial Operations Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, our revenues have consisted of up-front licensing payments, milestone payments, product sales and compensation for research and development services, all of which relate to our license and collaboration agreements. Certain of these payments are initially recorded on our statement of financial position and are subsequently recognized as revenue in accordance with our accounting policy as described further in note 3 to our audited consolidated financial statements included in the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Cost of Sales</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cost of sales consists primarily of personnel costs, costs for materials and third-party services, including any relating to written-off inventory, as well as maintenance and lease costs, and depreciation and amortization. Costs of sales includes costs of product sales, idle production costs and costs from set-up and quality assurance activities for our production processes, including those relating to pharmaceutical products which are under development in our collaboration agreements and for which we have not yet generated revenues. See &#8220;Research and Development Expenses&#8221; below for additional information on recognition of costs relating to pre-launch products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Selling and Distribution Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Selling and distribution expenses primarily consist of personnel expenses which include salary and salary-related expenses and expenses from share-based compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred for our research and preclinical and clinical development activities, including our product discovery efforts and certain activities relating to the design of GMP-manufacturing facilities. Research and development expenses contain wages and salaries, share-based compensation, fringe benefits and other personnel costs, the costs of clinical testing and the associated clinical production costs, research material production costs, fees for contractual partners, consultants and other third parties, fees to register legal rights, amortization of licensed software and intellectual property as well as costs for plant and facilities. Research and development expenses contain costs for independent research and development work as well as work carried out in the context of collaboration and licensing agreements; such expenses include all costs related to research and development services delivered under our collaboration arrangements. Additionally, prior to initial regulatory approval, if any, costs relating to production of products are expensed as research and development expenses in the period incurred. If pre-launch products are sold, the respective product gross margin may be higher compared to the expected recurring margin, as the underlying costs will not be included in cost of sales as they will have been recognized in research and development expense in the period incurred.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expense research and development expenses as incurred. We recognize costs for certain development activities, such as preclinical studies and clinical trials, based on an evaluation of the progress to completion of specific tasks. We use information provided to us by our vendors such as patient enrollment or clinical site activations for services received and efforts expended. We expect to incur significant expenses related to such second-generation vaccine candidates. But, as we and GSK agreed to equally share the development costs for GSK COVID products, our current level of research and development expenses will not continue to increase in the level as it did from 2020 to 2021. Once we conclude our research and development efforts related to a selected second-generation vaccine candidate, we expect that our research and development expenses shall be consistent with our past trends before the COVID-19 pandemic, but we may find it necessary to continue such current trend with respect to our research and developments expenses or we may continue to increase further our research and development expenses. For example, we may continue to increase our research and development expenses for future research and development related to the next generations of our COVID-19 vaccine candidates, such as for our second-generation COVID-19 vaccine candidates or may pursue new indications with our technology platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses generally include wages and salaries, share-based compensation, fringe benefits and other personnel costs of our senior management and administrative personnel, costs for professional services, including legal, audit and consulting services and costs of facilities and office expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Comparison of the Six Months Ended June 30, 2022 to the Six Months Ended June 30, 2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have based the following discussion of our financial condition and results of operations on our unaudited interim condensed consolidated financial statements for the six months ended June 30, 2022 and 2023 and the notes thereto, included elsewhere in this Report of Foreign Private Issuer on Form 6-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our historical results for the six months ended June 30, 2022 and 2023 are not necessarily indicative of results to be expected for a full year or any other interim period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our consolidated results of operations for the six months ended June 30, 2022 and 2023:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Six Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands of euros, except per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Statement of Operations and Comprehensive Income (Loss) Data:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 44,519</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 14,708</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (79,913)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (46,489)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (819)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,232)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (22,422)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (55,118)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (51,678)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (45,532)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other operating income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 35,207</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 3,448</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (461)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (942)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Operating loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (75,567)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (132,157)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 5,343</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 10,085</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,535)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,734)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss before income tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (72,759)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (124,806)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax benefit (expense)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 82</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (27)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (72,677)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (124,833)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other comprehensive income/loss:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><i style="font-style:italic;">Items that may be subsequently reclassified to profit or loss</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  <font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Foreign currency adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (212)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 16</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (72,889)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (124,816)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss per share (basic and diluted)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (0.39)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (0.57)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Revenue was &#8364;14.7 million for the six months ended June 30, 2023, representing a decrease of &#8364;29.8 million, or 67%, from &#8364;44.5 million for the six months June 30, 2022. The decrease was primarily driven by lower sales to GSK due to changes in the timeline of certain projects. In total, for both the 2020 GSK agreement and the GSK COVID Agreement, revenue of &#8364;12.8 million was recognized for the six months ended June 30, 2023.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Cost of Sales</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cost of sales was &#8364;46.5 million for the six months ended June 30, 2023, representing a decrease of &#8364;33.4 million, or 42%, from &#8364;79.9 million for the six months ended June 30, 2022. The decrease was primarily attributable to a decrease in write-offs of raw materials, which were in prior periods procured for manufacturing products to sell to GSK. Personnel expenses increased mainly due to increased workforce.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Six Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (13,869)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (17,559)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (36,883)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (12,630)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Third party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (19,516)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (11,839)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,150)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,115)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization, depreciation and derecognition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (8,326)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,219)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (169)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,127)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (79,913)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (46,489)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Selling and Distribution Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Selling and distribution expenses were &#8364;2.2 million for the six months ended June 30, 2023, representing an increase of &#8364;1.4 million, or 175%, from &#8364;0.8 million for the six months ended June 30, 2022. The increase was primarily attributable to higher personnel expenses due to an increased business development workforce.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Six Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (560)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,030)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (32)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (6)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (227)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (196)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (819)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (2,232)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development costs were &#8364;55.1 million for the six months ended June 30, 2023, representing an increase of &#8364;32.7 million, or 146%, from &#8364;22.4 million for the six months ended June 30, 2022. The increase was primarily attributable to prior year impacts caused by (i) the reversal of provision for onerous contracts in the amount of &#8364;21.3 million as a result of more participants leaving the clinical trials, prior to completion, than originally estimated; and (ii) renegotiations of contracts with CROs. Additionally, a net gain for a change of estimate in the contract termination provisions resulted primarily from GSK taking over, from the Group, committed capacity at CMO. Personnel expenses increased mainly due to increased workforce and the acquisition of Frame Pharmaceuticals. Additionally, share-based payment expense was higher compared to prior year period.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Six Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (23,419)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (9,217)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (14,849)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (23,570)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,119)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,508)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,354)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,048)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="white-space:pre-wrap;"> 21,053</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (11,773)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (464)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,593)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,270)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,410)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (22,422)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (55,118)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table reflects our research and development costs for each of our programs for the six months ended June 30, 2022 and 2023:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Six Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Key Programs (CV8102, CV7202, CV2CoV and CVnCoV)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CV8102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,414)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (1,120)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CVGBM</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (815)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,354)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CV7202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (120)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (17)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Second Generation Covid (CV2CoV and CV0501)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (10,990)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (10,180)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">CVnCoV</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 18,300</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 3,600</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other Research and Development Programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (2,399)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (9,467)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unallocated costs(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (24,983)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (35,581)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (22,422)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (55,118)</b></p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unallocated costs primarily consist of costs associated with personnel expenses, patents and fees to register a legal right, amortization and depreciation, maintenance and lease expenses, certain third-party service expenses and certain material expenses.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that our research and development expenses will constitute the most substantial part of our expenses in future periods in line with the advance and expansion of the development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 18pt;">Considering that, our research and development expenses primarily relate to the following key programs:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For SARS-CoV-2, our modified mRNA vaccine candidate, CV0501 is a monovalent construct developed in collaboration with GSK. A Phase 1 study was initiated in August 2022. We reported positive preliminary data in early 2023. A Phase 2 clinical study, initiated on August 1, 2023, assesses a monovalent (CV0601) and bivalent (CV0701) vaccine candidate designed to target the Omicron BA.4-5 variant or a combination of the Omicron BA.4-5 variant and the original SARS-CoV-2 strain. In our oncology therapeutic area, we work on novel cancer vaccine candidates based on differentiated antigen discovery technologies and bioinformatics to target antigens that are overexpressed in tumor tissues with no or little expression on healthy tissues. Within this strategy, we follow two approaches. The first approach assesses tumor antigens shared across different cancer indications for the development of off-the-shelf cancer vaccines. The second approach is tailored to the individual tumor setup of a patient for personalized therapy. We plan to advance new antigens for both approaches based on our second-generation mRNA backbone. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our oncology program, CVGBM, a single mRNA construct encoding eight epitopes from known tumor associated antigens with demonstrated relevance in glioblastoma, is currently in a Phase 1 study to assess the safety and immunogenicity of our second-generation backbone in an oncology setting. The study evaluates the safety and tolerability of CVGBM as a monotherapy in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma or astrocytoma with a molecular signature of glioblastoma. The study consists of two parts, a dose-escalation part (Part A) and a dose-expansion part (Part B). In currently ongoing Part A, patients receive a total of seven intramuscular administrations of CVGBM at escalating doses in the range of 12&#181;g to 100&#181;g. </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our oncology program, CV8102, has completed a Phase 1 dose escalating clinical trial for four types of solid tumors as a monotherapy and in combination with anti-PD-1 and an expansion of the Phase 1 study to confirm the safety, tolerability and efficacy of CV8102 at a 600&#956;g dose, the selected dose to be advanced in a Phase 2 clinical trial.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our vaccine program, CV7202, which has completed a Phase 1 clinical trial as a vaccine candidate for rabies.</font></td></tr></table><div style="margin-top:12pt;"></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses were &#8364;45.5 million for the six months ended June 30, 2023, representing a decrease of &#8364;6.2 million, or 12%, from &#8364;51.7 million for the six months ended June 30, 2022. The decrease was primarily attributable to less personnel expenses due to lower workforce in the corporate service functions and to less other expenses due to the allocation of costs to research and development expenses.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the Six Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (18,971)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (15,742)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,704)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,915)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (12,796)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (12,873)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5,320)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (6,074)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (6,091)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (6,071)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5,796)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,857)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (51,678)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (45,532)</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Other Operating Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other operating income was &#8364;3.4 million for the six months ended June 30, 2023, representing a decrease of &#8364;31.8 million, or 90%, from &#8364;35.2 million for the six months ended June 30, 2022. The decrease was primarily attributable to the impacts of the amendments to the 2020 GSK Agreement and the GSK Covid Agreement, under which CureVac was entitled to further compensation by GSK for set-up activities undertaken by CureVac (&#8364;20.5 million) and for reimbursement of prepayments (&#8364;12.0 million) in prior year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Other Operating Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other operating expense was &#8364;0.9 million for the six months ended June 30, 2023, representing an increase of &#8364;0.4 million, or 80%, from &#8364;0.5 million for the six months ended June 30, 2022. Other operating expense related primarily to compensation expense of our Supervisory Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Finance Income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finance income was &#8364;10.1 million for the six months ended June 30, 2023, representing an increase of &#8364;4.8 million, or 91%, from &#8364;5.3 million for the six months ended June 30, 2022. The increase was primarily attributable to positive interest on cash investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Finance Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Finance expenses were &#8364;2.7 million for the six months ended June 30, 2023, representing an increase of &#8364;0.2 million, or 8%, from &#8364;2.5 million for the six months ended June 30, 2022 and were relatively unchanged compared to prior year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Income Tax (Expense)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An income tax expense of &#8364;27.0 thousand was generated for the six months ended June 30, 2023, representing an increase of &#8364;108.9 thousand, from an income tax benefit of &#8364;81.9 thousand generated for the six months ended June 30, 2022. The increase to an expense was primarily attributable to the income tax expense of CureVac Swiss AG and CureVac Belgium S.A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our financial condition and liquidity are and will continue to be influenced by a variety of factors, including:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to generate cash flows from our operations;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future indebtedness and the interest we are obligated to pay on this indebtedness;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of public and private debt and equity financing;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in exchange rates which will impact our generation of cash flows from operations when measured in euros; and</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our capital expenditure requirements.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, we have incurred significant operating losses. For the six months ended June 30, 2022 and 2023, we incurred net losses of &#8364;72.7 million and &#8364;124.8 million, respectively. To date, we have financed our operations primarily through the IPO in August 2020, the public offering in February 2021, private placements of equity securities, issuance of convertible debt, grants from government agencies and similar bodies and payments for collaborative research and development services. Our cash and cash equivalents as of June 30, 2023 were &#8364;537.9 million. Our primary cash needs are to fund our non-clinical and clinical development programs, for working capital requirements and for capital expenditures. We believe our existing cash, cash equivalents, borrowings available to us, receipts from grants and short-term investments will enable us to fund our operating expenses and capital expenditure requirements at least through the middle of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2023, we sold an additional 27,027,028 common shares in an underwritten public offering at an offering price of $9.25 per share raising $234.2 million in net proceeds, after deducting underwriting discounts and commissions and offering expenses payable by us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2021, we entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Securities LLC, as sales agents, to establish an at-the-market offering program (&#8220;ATM Program&#8221;), pursuant to which we may sell, from time to time, ordinary shares for aggregate gross proceeds of up to $600.0 million. For the six months ended June 30, 2023, we issued 1,748,218 common shares through the ATM program and the remaining value authorized for sale under the at-the-market program is $497.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 9.35pt;">Comparative Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><i style="font-style:italic;">Comparison of the six months ended June 30, 2022 and 2023</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our cash flows from operating, investing and financing activities for the periods indicated:</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Six Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands&#160;of&#160;euros)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash flow from (used in):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (201,175)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (163,702)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (44,715)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (27,369)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 3,409</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 233,513</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Effect of currency translation gains on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,583</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (314)</font></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Overall cash inflow</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (237,898)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 42,128</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 18pt;">Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities for the six months ended June 30, 2023 was &#8364;163.7 million as compared to net cash used in operating activities of &#8364;201.2 million for the six months ended June 30, 2022. The decrease in net cash in operating activities was primarily attributable to less payments for service agreements with Contract Research Organizations and Contract Manufacturing Organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities for the six months ended June 30, 2023 was &#8364;27.4 million as compared to net cash used in investing activities of &#8364;44.7 million for the six months ended June 30, 2022. The change in cash flows from investing activities was primarily attributable to decreased purchases of property, plant and equipment for manufacturing facilities and intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash provided by financing activities was &#8364;233.5 million for the six months ended June 30, 2023 as compared to cash provided by financing activities of &#8364;3.4 million for the six months ended June 30, 2022. The increase in cash flow provided by financing activities was mainly attributable to the raising of cash in the follow-on underwritten public offering conducted in February 2023.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources, except for those noncancellable contractual obligations from certain of our arrangements with contract manufacturing organizations disclosed in &#8220;Liquidity and Capital Resources&#8221; and &#8220;Contractual Obligations and Commitments.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Safe Harbor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Forward-Looking Statements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements are prepared in accordance with International Financial Reporting Standards, or the IFRS, as issued by the International Accounting Standards Board, or IASB. Some of the accounting methods and policies used in preparing the financial statements under IFRS are based on complex and subjective assessments by our management or on estimates based on past experience and assumptions deemed realistic and reasonable based on the circumstances concerned. The actual value of our assets, liabilities and shareholders&#8217; equity and of our earnings could differ from the value derived from these estimates if conditions changed and these changes had an impact on the assumptions adopted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our significant accounting policies that we believe to be critical to the judgments and estimates used in the preparation of our financial statements are included in &#8220;note 2&#8201;&#8212;&#8201;Significant accounting policies&#8221; and &#8220;note 10&#8201;&#8212;&#8201;Share-based payments&#8221; to our consolidated financial statements included in the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have applied, in our audited consolidated financial statements for the&#160;year ended December&#160;31, 2022, new standards and amendments as issued by IASB and that are mandatory as of January 1, 2022. See note 2 to our audited consolidated financial statements included in the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">We have applied, in our unaudited interim condensed consolidated financial statements for the six months ended June 30, 2023, new standards and amendments as issued by IASB and as issued by IASB and that are mandatory as of January 1, 2022. See note 2 to our unaudited interim condensed consolidated financial statements included elsewhere in this Report of Foreign Private Issuer on Form 6-K for further information on these new standards and amendments.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>cvac-20230630xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 cvac-20230630xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !E 2(# 2(  A$! Q$!_\0
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M2?VMT..?[0M>/^V451FN+J8.-)T_M347Z,UR3 T<?.LJVT(2DM;:JUCZ]!R
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MA0O&-91NGJU=V.9U#]KCPK;7;Q6NGZI>Q*<":.) K?0,X/YBJ_\ PV#X=_Z
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M:%IZ1K:Q8'V9#_ .22,D^YK;_P"$*T ?\P33\_\ 7JG^%=+J8&+:]D_O_P"
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M7;R:+XKNM.B?JKP[FQV&Y67^5,_X96UO'_(^W/\ X#O_ /':XL-AJU"E&E/
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' %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>cvac-20230630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/17/2023 6:46:42 PM-->
<!--Modified on: 8/17/2023 6:46:42 PM-->
<xsd:schema targetNamespace="http://www.curevac.com/20230630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:cvac="http://www.curevac.com/20230630" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:fact-explanatoryFact="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:us-types="http://fasb.org/us-types/2022">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" id="StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss">
        <link:definition>00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" id="StatementInterimCondensedConsolidatedStatementsOfFinancialPosition">
        <link:definition>00200 - Statement - Interim Condensed Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" id="StatementInterimCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails" id="DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails">
        <link:definition>40305 - Disclosure - Notes to the Consolidated Statements of Operations - Cost of sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails" id="DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails">
        <link:definition>40309 - Disclosure - Notes to the Consolidated Statements of Operations - Other operating income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" id="DisclosureShareBasedPaymentsExpensesDetails">
        <link:definition>40501 - Disclosure - Share-based payments - Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" id="DisclosureTradeAndOtherPayablesDetails">
        <link:definition>41101 - Disclosure - Trade and other payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" id="StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity">
        <link:definition>00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" id="DisclosureShareBasedPaymentsTables">
        <link:definition>30503 - Disclosure - Share-based payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureCorporateInformationDetails" id="DisclosureCorporateInformationDetails">
        <link:definition>40101 - Disclosure - Corporate Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails" id="DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails">
        <link:definition>40301 - Disclosure - Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails" id="DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails">
        <link:definition>40302 - Disclosure - Notes to the Consolidated Statements of Operations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" id="DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails">
        <link:definition>40303 - Disclosure - Notes to the Consolidated Statements of Operations - Summary of upfront payments and related revenues recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails" id="DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails">
        <link:definition>40304 - Disclosure - Notes to the Consolidated Statements of Operations - Contract balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails" id="DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails">
        <link:definition>40306 - Disclosure - Notes to the Consolidated Statements of Operations - Selling and distribution expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails" id="DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails">
        <link:definition>40307 - Disclosure - Notes to the Consolidated Statements of Operations - Research and development expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails" id="DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails">
        <link:definition>40308 - Disclosure - Notes to the Consolidated Statements of Operations - General and administrative expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" id="DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails">
        <link:definition>40310 - Disclosure - Notes to the Consolidated Statements of Operations - Grants with government agencies and similar bodies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" id="DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails">
        <link:definition>40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails" id="DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails">
        <link:definition>40402 - Disclosure - Issued Capital and Reserves - At-the-market offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" id="DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails">
        <link:definition>40403 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails" id="DisclosureShareBasedPaymentsEquitySettledProgramsDetails">
        <link:definition>40502 - Disclosure - Share-based payments - Equity-settled programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" id="DisclosureShareBasedPaymentsDetails">
        <link:definition>40503 - Disclosure - Share-based payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" id="DisclosureFixedAssetsIntangibleAssetsDetails">
        <link:definition>40601 - Disclosure - Fixed Assets - Intangible assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" id="DisclosureFixedAssetsPropertyPlantAndEquipmentDetails">
        <link:definition>40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureInventoriesDetails" id="DisclosureInventoriesDetails">
        <link:definition>40801 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" id="DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails">
        <link:definition>40901 - Disclosure - Prepaid expenses and other assets (current) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" id="DisclosureOtherLiabilitiesAndProvisionsDetails">
        <link:definition>41201 - Disclosure - Other liabilities and provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails" id="DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails">
        <link:definition>41401 - Disclosure - Disclosure of financial instruments and risk management - Foreign currency risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" id="DisclosureRelatedPartyDisclosuresDetails">
        <link:definition>41601 - Disclosure - Related party disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41701 - Disclosure - Subsequent events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureCorporateInformation" id="DisclosureCorporateInformation">
        <link:definition>10101 - Disclosure - Corporate Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureBasisOfPreparation" id="DisclosureBasisOfPreparation">
        <link:definition>10201 - Disclosure - Basis of preparation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperations" id="DisclosureNotesToConsolidatedStatementsOfOperations">
        <link:definition>10301 - Disclosure - Notes to the Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves" id="DisclosureIssuedCapitalAndReserves">
        <link:definition>10401 - Disclosure - Issued Capital and Reserves</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureShareBasedPayments" id="DisclosureShareBasedPayments">
        <link:definition>10501 - Disclosure - Share-based payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFixedAssets" id="DisclosureFixedAssets">
        <link:definition>10601 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSale" id="DisclosureAssetsHeldForSale">
        <link:definition>10701 - Disclosure - Assets held for sale</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>10801 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent" id="DisclosurePrepaidExpensesAndOtherAssetsCurrent">
        <link:definition>10901 - Disclosure - Prepaid expenses and other assets (current)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities" id="DisclosureFinancialAssetsAndFinancialLiabilities">
        <link:definition>11001 - Disclosure - Financial assets and financial liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayables" id="DisclosureTradeAndOtherPayables">
        <link:definition>11101 - Disclosure - Trade and other payables</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions" id="DisclosureOtherLiabilitiesAndProvisions">
        <link:definition>11201 - Disclosure - Other liabilities and provisions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIncomeTax" id="DisclosureIncomeTax">
        <link:definition>11301 - Disclosure - Income tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement" id="DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement">
        <link:definition>11401 - Disclosure - Disclosure of financial instruments and risk management</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEarningsPerShare" id="DisclosureEarningsPerShare">
        <link:definition>11501 - Disclosure - Earnings per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosures" id="DisclosureRelatedPartyDisclosures">
        <link:definition>11601 - Disclosure - Related party disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11701 - Disclosure - Subsequent events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies" id="DisclosureBasisOfPreparationPolicies">
        <link:definition>20202 - Disclosure - Basis of preparation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsTables" id="DisclosureNotesToConsolidatedStatementsOfOperationsTables">
        <link:definition>30303 - Disclosure - Notes to the Consolidated Statements of Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables" id="DisclosureIssuedCapitalAndReservesTables">
        <link:definition>30403 - Disclosure - Issued Capital and Reserves (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" id="DisclosureAssetsHeldForSaleDetails">
        <link:definition>40701 - Disclosure - Assets held for sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" id="DisclosureFinancialAssetsAndFinancialLiabilitiesDetails">
        <link:definition>41001 - Disclosure - Financial assets and financial liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureEarningsPerShareDetails" id="DisclosureEarningsPerShareDetails">
        <link:definition>41501 - Disclosure - Earnings per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20230630_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="cvac-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.curevac.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:import namespace="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd" />
  <xsd:element name="CorporateInformationAbstract" id="cvac_CorporateInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CorporateInformationTextBlock" id="cvac_CorporateInformationTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CorporateReorganizationStockSplitRatio" id="cvac_CorporateReorganizationStockSplitRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChangesInWorkingCapitalAbstract" id="cvac_ChangesInWorkingCapitalAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" id="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IfrsProductMember" id="cvac_IfrsProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" id="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" id="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EliLillyAndCompanyMember" id="cvac_EliLillyAndCompanyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BoehringerIngelheimMember" id="cvac_BoehringerIngelheimMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherCustomersMember" id="cvac_OtherCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CrisprMember" id="cvac_CrisprMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchServicesCombinedWithIpLicenseMember" id="cvac_ResearchServicesCombinedWithIpLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ResearchAndDevelopmentServicesMember" id="cvac_ResearchAndDevelopmentServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GenmabMember" id="cvac_GenmabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="UpfrontPaymentsReceivedOrReceivable" id="cvac_UpfrontPaymentsReceivedOrReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="UpfrontPaymentsIncludedInContractLiabilities" id="cvac_UpfrontPaymentsIncludedInContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="IfrsIncomeStatementLocationAxis" id="cvac_IfrsIncomeStatementLocationAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsIncomeStatementLocationDomain" id="cvac_IfrsIncomeStatementLocationDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsCostOfSalesMember" id="cvac_IfrsCostOfSalesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PersonnelExpenses" id="cvac_PersonnelExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ThirdPartyServiceExpenses" id="cvac_ThirdPartyServiceExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MaintenanceAndLeaseExpenses" id="cvac_MaintenanceAndLeaseExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="SellingAndDistributionExpensesMember" id="cvac_SellingAndDistributionExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsResearchAndDevelopmentExpenseMember" id="cvac_IfrsResearchAndDevelopmentExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PatentsAndFeesToRegisterLegalRight" id="cvac_PatentsAndFeesToRegisterLegalRight" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ReversalOfProvisionsForPersonnelExpenses" id="cvac_ReversalOfProvisionsForPersonnelExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="IfrsGeneralAndAdministrativeExpenseMember" id="cvac_IfrsGeneralAndAdministrativeExpenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MiscellaneousOtherOperatingIncomeOther" id="cvac_MiscellaneousOtherOperatingIncomeOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfGovernmentGrantsTable" id="cvac_DisclosureOfGovernmentGrantsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GovernmentGrantsAxis" id="cvac_GovernmentGrantsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GovernmentGrantsDomain" id="cvac_GovernmentGrantsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CoalitionForEpidemicPreparednessInnovationsMember" id="cvac_CoalitionForEpidemicPreparednessInnovationsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BillAndMelindaGatesFoundationBmgfMember" id="cvac_BillAndMelindaGatesFoundationBmgfMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" id="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" id="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfGovernmentGrantsLineItems" id="cvac_DisclosureOfGovernmentGrantsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PartnershipAgreementMaximumAmount" id="cvac_PartnershipAgreementMaximumAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PartnershipAgreementTerm" id="cvac_PartnershipAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PartnershipAgreementPeriodOfCostsToBeCovered" id="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmountDeductedFromCarryingAmountOfQualifyingAssets" id="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfAdditionalGrantsReceived" id="cvac_NumberOfAdditionalGrantsReceived" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfFixedAssetsAbstract" id="cvac_DisclosureOfFixedAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfFixedAssetsExplanatory" id="cvac_DisclosureOfFixedAssetsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" id="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" id="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesSharesMember" id="cvac_SeriesSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesCSharesMember" id="cvac_SeriesCSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VirtualSharesProgramIMember" id="cvac_VirtualSharesProgramIMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VirtualSharesProgramIiMember" id="cvac_VirtualSharesProgramIiMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OptionsGrantedToThenChiefExecutiveOfficerMember" id="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" id="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" id="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IfrsVestingAxis" id="cvac_IfrsVestingAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsVestingDomain" id="cvac_IfrsVestingDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsShareBasedPaymentArrangementTrancheOneMember" id="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BenefitExpenseRecognizedForShareBasedPayment" id="cvac_BenefitExpenseRecognizedForShareBasedPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ExpenseRecognizedForEmployeeServices" id="cvac_ExpenseRecognizedForEmployeeServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" id="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RittershausRechtsanwaelteMember" id="cvac_RittershausRechtsanwaelteMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DietmarHoppMember" id="cvac_DietmarHoppMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" id="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionConsultingFees" id="cvac_RelatedPartyTransactionConsultingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RelatedPartyTransactionNumberOfLoansReceived" id="cvac_RelatedPartyTransactionNumberOfLoansReceived" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ManagementBoardMember" id="cvac_ManagementBoardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherOperatingIncomeGovernmentGrants" id="cvac_OtherOperatingIncomeGovernmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="FinancialInstrumentsAndRiskManagementAbstract" id="cvac_FinancialInstrumentsAndRiskManagementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsCashAndCashEquivalentsMember" id="cvac_IfrsCashAndCashEquivalentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TradeAndOtherPayablesMember" id="cvac_TradeAndOtherPayablesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="OtherExpense" id="cvac_OtherExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IfrsOtherLiabilitiesAbstract" id="cvac_IfrsOtherLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" id="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" id="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GlaxosmithklineMember" id="cvac_GlaxosmithklineMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GermanFederalMinistryOfEducationAndResearchMember" id="cvac_GermanFederalMinistryOfEducationAndResearchMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" id="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RealEstateTransferTaxes" id="cvac_RealEstateTransferTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MaximumGrantToBeReceived" id="cvac_MaximumGrantToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="IfrsStockholdersEquityNoteStockSplitConversionRatio" id="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSaleOfStockAxis" id="cvac_IfrsSaleOfStockAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsSaleOfStockDomain" id="cvac_IfrsSaleOfStockDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CapitalIncreaseByGenmabMember" id="cvac_CapitalIncreaseByGenmabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PrivatePlacementIsa2020Member" id="cvac_PrivatePlacementIsa2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExerciseOfGreenshoeMember" id="cvac_ExerciseOfGreenshoeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ExerciseOfOptionsMember" id="cvac_ExerciseOfOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IncreaseInNumberOfSharesOutstanding" id="cvac_IncreaseInNumberOfSharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsOverAllotmentOptionMember" id="cvac_IfrsOverAllotmentOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BepharbelManufacturingS.aMember" id="cvac_BepharbelManufacturingS.aMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BaronJeanStephenneMember" id="cvac_BaronJeanStephenneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="VincentStphenneMember" id="cvac_VincentStphenneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PublicOfferingOfCommonSharesMember" id="cvac_PublicOfferingOfCommonSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="RightToExercisePercentageOfVestedVirtualShares" id="cvac_RightToExercisePercentageOfVestedVirtualShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ProvisionForEmployerTaxes" id="cvac_ProvisionForEmployerTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="LockUpPeriodAfterInitialListing" id="cvac_LockUpPeriodAfterInitialListing" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LongTermIncentivePlanMember" id="cvac_LongTermIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChiefScientificOfficerMember" id="cvac_ChiefScientificOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChiefBusinessOfficerAndChiefCommercialOfficerMember" id="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ThenChiefExecutiveOfficerMember" id="cvac_ThenChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfShareOptionsVestedInShareBasedPaymentArrangement" id="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SoftwareMember" id="cvac_SoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="InitialPublicOfferingAndPrivatePlacementMember" id="cvac_InitialPublicOfferingAndPrivatePlacementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="CommonSharesIssuedAndOutstanding" id="cvac_CommonSharesIssuedAndOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element name="ShareOptionExercises" id="cvac_ShareOptionExercises" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfBasisOfPreparationAbstract" id="cvac_DisclosureOfBasisOfPreparationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfBasisOfPreparationExplanatoryTextBlock" id="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" id="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="FollowOnPublicOfferingMember" id="cvac_FollowOnPublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedPaymentExpenseIncl.DeferredTaxes" id="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfExpenseRecognizedForProgramsTableTextBlock" id="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ChangeInTradeAndOtherPayables" id="cvac_ChangeInTradeAndOtherPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="TechnicalEquipmentAndMachinesAndOtherEquipmentMember" id="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LicensesSoftwareAndPrepaymentsMember" id="cvac_LicensesSoftwareAndPrepaymentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="AmountOfLiabilityCashClaimAwards" id="cvac_AmountOfLiabilityCashClaimAwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="UpfrontPaymentReceived" id="cvac_UpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AdditionalDevelopmentMilestonePaymentsReceived" id="cvac_AdditionalDevelopmentMilestonePaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AmountOfRestrictedStockUnitsReceived" id="cvac_AmountOfRestrictedStockUnitsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NetLoss" id="cvac_NetLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ClarentisSrlMember" id="cvac_ClarentisSrlMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="TerminationOfExclusiveCollaborationAndLicenseAgreementMember" id="cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ImpairmentsOfInventoryAndPrepayments" id="cvac_ImpairmentsOfInventoryAndPrepayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PlanNameAxis" id="cvac_PlanNameAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PlanNameDomain" id="cvac_PlanNameDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" id="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ChiefDevelopmentOfficerMember" id="cvac_ChiefDevelopmentOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsContractualObligation" id="cvac_IfrsContractualObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisclosureOfOtherLiabilitiesTable" id="cvac_DisclosureOfOtherLiabilitiesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfOtherLiabilitiesLineItems" id="cvac_DisclosureOfOtherLiabilitiesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RestrictedStockUnitsMember" id="cvac_RestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MembersOfExecutiveBoardAndVariousKeyEmployeesMember" id="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TypeOfArrangementAxis" id="cvac_TypeOfArrangementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ArrangementsAndNonArrangementTransactionsMember" id="cvac_ArrangementsAndNonArrangementTransactionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CrisprTherapeuticsMember" id="cvac_CrisprTherapeuticsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EliLillyMember" id="cvac_EliLillyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" id="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" id="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AdvancedPurchaseAgreementWithEuropeanCommissionMember" id="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsMilestonePaymentReceived" id="cvac_IfrsMilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsRemainingGrantIncome" id="cvac_IfrsRemainingGrantIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" id="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" id="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" id="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GskAgreement2020Member" id="cvac_GskAgreement2020Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DecreaseInNumberOfSharesDueToTreasuryOfShares" id="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CompanyOwnedGmpIvFacilityMember" id="cvac_CompanyOwnedGmpIvFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EquipmentPhysicallyLocatedAtCmoFacilitiesMember" id="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PrepaidCompensationForContractManufacturingOrganizationsTransfer" id="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ChangeInOtherLiabilities" id="cvac_ChangeInOtherLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfKeyEmployees" id="cvac_NumberOfKeyEmployees" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MilestoneRevenuesMember" id="cvac_MilestoneRevenuesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CompensationForContractManufacturingOrganizationsTransfer" id="cvac_CompensationForContractManufacturingOrganizationsTransfer" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" id="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" id="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SettlementOfShareBasedPaymentAwardsAmount" id="cvac_SettlementOfShareBasedPaymentAwardsAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdjustmentsForNonCashIncomeFromReleaseOfProvisions" id="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" id="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" id="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CostOfReimbursementClaim" id="cvac_CostOfReimbursementClaim" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SaleOfEquipment" id="cvac_SaleOfEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AntonyBlancMember" id="cvac_AntonyBlancMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InventoriesTable" id="cvac_InventoriesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="InventoriesLineItem" id="cvac_InventoriesLineItem" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseDecreaseInInventory" id="cvac_IncreaseDecreaseInInventory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NetValueOfInventoryTransferred" id="cvac_NetValueOfInventoryTransferred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AtMarketOfferingProgramMember" id="cvac_AtMarketOfferingProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AggregateGrossProceedsReceivableFromIssuingShares" id="cvac_AggregateGrossProceedsReceivableFromIssuingShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsStockIssuedDuringPeriodSharesNewIssues" id="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodForExercises" id="cvac_StockIssuedDuringPeriodForExercises" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="KeyEmployeesMember" id="cvac_KeyEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExecutiveBoardMembersMember" id="cvac_ExecutiveBoardMembersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SupervisoryBoardMembersMember" id="cvac_SupervisoryBoardMembersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" id="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" id="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" id="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PurchasePriceAllocationSharePriceAsOfClosingDate" id="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" id="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" id="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" id="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ContingentLiabilityArisingFromPatentInfringementLawsuitMember" id="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" id="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LossContingencyPatentsAllegedlyInfringedNumber" id="cvac_LossContingencyPatentsAllegedlyInfringedNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LossContingencyPatentsFoundNotInfringedNumber" id="cvac_LossContingencyPatentsFoundNotInfringedNumber" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AssetsHeldForSaleAxis" id="cvac_AssetsHeldForSaleAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetsHeldForSaleDomain" id="cvac_AssetsHeldForSaleDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MilestonesMember" id="cvac_MilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" id="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ChiefBusinessOfficerMember" id="cvac_ChiefBusinessOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FormerFrameEmployeesMember" id="cvac_FormerFrameEmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfNotesToConsolidatedFinancialStatementsTable" id="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" id="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="RemainingAuthorizedForSaleValue" id="cvac_RemainingAuthorizedForSaleValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuanceDuringPeriodForExistingShareholders" id="cvac_StockIssuanceDuringPeriodForExistingShareholders" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" id="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GlaxosmithklineCovidAgreementMember" id="cvac_GlaxosmithklineCovidAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BundesministeriumFurBildungUndForschungMember" id="cvac_BundesministeriumFurBildungUndForschungMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CumulativeAmortizationAndImpairmentMember" id="cvac_CumulativeAmortizationAndImpairmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GrossCarryingAmountOfAcquisitionCostMember" id="cvac_GrossCarryingAmountOfAcquisitionCostMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AdvancePaymentsIntangibleAssetMember" id="cvac_AdvancePaymentsIntangibleAssetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsInventoryFinishedGoodsWriteDown" id="cvac_IfrsInventoryFinishedGoodsWriteDown" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PersonnelAccruedLiabilities" id="cvac_PersonnelAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OutstandingInvoicesCurrent" id="cvac_OutstandingInvoicesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ProfessionalFessCurrent" id="cvac_ProfessionalFessCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CurrentValueAddedTaxAndOtherTaxesPayables" id="cvac_CurrentValueAddedTaxAndOtherTaxesPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OtherLiabilityCurrent" id="cvac_OtherLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes" id="cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LicenseFeePayable" id="cvac_LicenseFeePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CurrentGrantReceivable" id="cvac_CurrentGrantReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsCurrentGrantReceivables" id="cvac_IfrsCurrentGrantReceivables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DiluteEffectOfOrdinarySharesIssued" id="cvac_DiluteEffectOfOrdinarySharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TradeAndOtherReceivablesMember" id="cvac_TradeAndOtherReceivablesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MonetaryLiabilitiesInForeignCurrencyMember" id="cvac_MonetaryLiabilitiesInForeignCurrencyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MonetaryAssetsInForeignCurrencyMember" id="cvac_MonetaryAssetsInForeignCurrencyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TradeAndOtherPayablesTwoMember" id="cvac_TradeAndOtherPayablesTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfMrnaVaccinesDoses" id="cvac_NumberOfMrnaVaccinesDoses" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" id="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="TechnologyMember" id="cvac_TechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ImpairmentOfAssetsHeldForSale" id="cvac_ImpairmentOfAssetsHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccruedOtherLiabilityForUpFrontPayment" id="cvac_AccruedOtherLiabilityForUpFrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LaboratoriesMember" id="cvac_LaboratoriesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaximumUnspentFundsReimbursable" id="cvac_MaximumUnspentFundsReimbursable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" id="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfSharesIssuedForRsuDeliveries" id="cvac_NumberOfSharesIssuedForRsuDeliveries" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OtherMiscellaneousNonCurrentLiabilities" id="cvac_OtherMiscellaneousNonCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AmortizationOfGovernmentGrants" id="cvac_AmortizationOfGovernmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ReimbursementOfApprovedExpenses" id="cvac_ReimbursementOfApprovedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OtherLiabilitiesAndProvisionsAbstract" id="cvac_OtherLiabilitiesAndProvisionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DieviniHoppBiotechHoldingGmbhCo.KgMember" id="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MariolaFotinMleczekMember" id="cvac_MariolaFotinMleczekMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FlorianVonDerMlbeMember" id="cvac_FlorianVonDerMlbeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Dr.IngmarHrrMember" id="cvac_Dr.IngmarHrrMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncomeTaxAndSocialSecurityLiabilityReceivable" id="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CollaborationAndLicenseAgreementMember" id="cvac_CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsTypeOfArrangementAxis" id="cvac_IfrsTypeOfArrangementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ArrangementsAndNonArrangementTransactionsDomain" id="cvac_ArrangementsAndNonArrangementTransactionsDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsPlanNameAxis" id="cvac_IfrsPlanNameAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsPlanNameDomain" id="cvac_IfrsPlanNameDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="TradeAndOtherPayablesOneMember" id="cvac_TradeAndOtherPayablesOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OtherLiabilitiesAndProvisionsTextBlock" id="cvac_OtherLiabilitiesAndProvisionsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsProvisionForLossOnContracts" id="cvac_IfrsProvisionForLossOnContracts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" id="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve" id="cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IfrsSharesIssuedPricePerShare" id="cvac_IfrsSharesIssuedPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PublicOfferingMember" id="cvac_PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses" id="cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PriorVirtualStockOptionsPlanMember" id="cvac_PriorVirtualStockOptionsPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NewVirtualStockOptionsPlanMember" id="cvac_NewVirtualStockOptionsPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsRestrictedStockUnitMember" id="cvac_IfrsRestrictedStockUnitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="LongTermIncentivePlanAndRestrictedStockUnitMember" id="cvac_LongTermIncentivePlanAndRestrictedStockUnitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetsHeldForSaleNetBookValueSold" id="cvac_AssetsHeldForSaleNetBookValueSold" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="GrossBookValueOfCmoEquipmentHeldForSale" id="cvac_GrossBookValueOfCmoEquipmentHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu" id="cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExpensesToHandleFutureServiceAgreement" id="cvac_ExpensesToHandleFutureServiceAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses" id="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" id="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="BarkerBiomedicalGmbhMember" id="cvac_BarkerBiomedicalGmbhMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExpenseRecognizedFromRelatedPartyTransaction" id="cvac_ExpenseRecognizedFromRelatedPartyTransaction" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CraigToomanMember" id="cvac_CraigToomanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfVotingInterestsHeld" id="cvac_PercentageOfVotingInterestsHeld" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LargestShareholderMember" id="cvac_LargestShareholderMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract" id="cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PatentInfringementLawsuitFilledMember" id="cvac_PatentInfringementLawsuitFilledMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfIntellectualPropertyRightsInfringementCaseFilled" id="cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TotalNumberOfIntellectualPropertyRightsInfringementCase" id="cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfPatentOnWhichNullityActionIsFilled" id="cvac_NumberOfPatentOnWhichNullityActionIsFilled" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProvisionsForDecreaseInContractTerminations" id="cvac_ProvisionsForDecreaseInContractTerminations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities" id="cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>cvac-20230630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/17/2023 6:46:42 PM-->
<!--Modified on: 8/17/2023 6:46:42 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#StatementInterimCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureShareBasedPaymentsExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureTradeAndOtherPayablesDetails" roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <calculationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ComprehensiveIncome" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638278947973869941" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638278947973869941" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638278947973869941" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss_638278947973869941" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_638278947973869941" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638278947973869941" xlink:to="ifrs-full_ProfitLossBeforeTax_638278947973869941" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638278947973869941" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_638278947973869941" xlink:to="ifrs-full_FinanceIncome_638278947973869941" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638278947973869941" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_638278947973869941" xlink:to="ifrs-full_FinanceCosts_638278947973869941" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_638278947973869941" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax_638278947973869941" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_638278947973869941" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638278947973879940" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638278947973869941" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638278947973879940" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales_638278947973879940" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638278947973869941" xlink:to="ifrs-full_CostOfSales_638278947973879940" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_638278947973879940" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638278947973869941" xlink:to="ifrs-full_SalesAndMarketingExpense_638278947973879940" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638278947973879940" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638278947973869941" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638278947973879940" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638278947973879940" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638278947973869941" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638278947973879940" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_638278947973879940" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638278947973869941" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_638278947973879940" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_638278947973879940" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638278947973869941" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_638278947973879940" order="7" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638278947973889946" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss_638278947973869941" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638278947973889946" order="2" use="optional" weight="-1" priority="3" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00200 - Statement - Interim Condensed Consolidated Statements of Financial Position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_638278947973889946" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="ifrs-full_NoncurrentAssets_638278947973889946" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_638278947973889946" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638278947973889946" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_638278947973889946" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638278947973889946" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638278947973889946" xlink:to="ifrs-full_PropertyPlantAndEquipment_638278947973889946" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets_638278947973889946" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638278947973889946" xlink:to="ifrs-full_OtherNoncurrentAssets_638278947973889946" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets_638278947973889946" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638278947973889946" xlink:to="ifrs-full_NetDeferredTaxAssets_638278947973889946" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_638278947973889946" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638278947973889946" xlink:to="ifrs-full_RightofuseAssets_638278947973889946" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638278947973899938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="ifrs-full_CurrentAssets_638278947973899938" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_638278947973899938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638278947973899938" xlink:to="ifrs-full_Inventories_638278947973899938" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables_638278947973899938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638278947973899938" xlink:to="ifrs-full_CurrentTradeReceivables_638278947973899938" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets_638278947973899938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638278947973899938" xlink:to="ifrs-full_CurrentContractAssets_638278947973899938" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638278947973899938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638278947973899938" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638278947973899938" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="ifrs-full_OtherCurrentFinancialAssets_638278947973899938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638278947973899938" xlink:to="ifrs-full_OtherCurrentFinancialAssets_638278947973899938" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638278947973899938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638278947973899938" xlink:to="ifrs-full_CashAndCashEquivalents_638278947973899938" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638278947973899938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638278947973899938" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638278947973899938" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="EquityAndLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638278947973909938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_Equity_638278947973909938" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_638278947973909938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638278947973909938" xlink:to="ifrs-full_IssuedCapital_638278947973909938" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares_638278947973909938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638278947973909938" xlink:to="ifrs-full_TreasuryShares_638278947973909938" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve_638278947973909938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638278947973909938" xlink:to="ifrs-full_CapitalReserve_638278947973909938" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_638278947973909938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638278947973909938" xlink:to="ifrs-full_RetainedEarnings_638278947973909938" order="4" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_638278947973909938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638278947973909938" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_638278947973909938" order="5" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638278947973909938" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_Liabilities_638278947973909938" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_638278947973919939" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638278947973909938" xlink:to="ifrs-full_NoncurrentLiabilities_638278947973919939" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_638278947973919939" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638278947973919939" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_638278947973919939" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities_638278947973919939" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638278947973919939" xlink:to="ifrs-full_NoncurrentContractLiabilities_638278947973919939" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_638278947973919939" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638278947973919939" xlink:to="ifrs-full_OtherNoncurrentLiabilities_638278947973919939" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions_638278947973919939" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638278947973919939" xlink:to="ifrs-full_NoncurrentProvisions_638278947973919939" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_638278947973919939" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638278947973909938" xlink:to="ifrs-full_CurrentLiabilities_638278947973919939" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_638278947973929937" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638278947973919939" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_638278947973929937" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_638278947973929937" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638278947973919939" xlink:to="ifrs-full_CurrentLeaseLiabilities_638278947973929937" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638278947973929937" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638278947973919939" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638278947973929937" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638278947973929937" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638278947973919939" xlink:to="ifrs-full_OtherCurrentLiabilities_638278947973929937" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities_638278947973929937" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638278947973919939" xlink:to="ifrs-full_CurrentTaxLiabilities_638278947973929937" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities_638278947973929937" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638278947973919939" xlink:to="ifrs-full_CurrentContractLiabilities_638278947973929937" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions_638278947973939975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638278947973919939" xlink:to="ifrs-full_CurrentProvisions_638278947973939975" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_638278947973939975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="ifrs-full_ProfitLossBeforeTax_638278947973939975" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_638278947973939975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_638278947973939975" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_638278947973939975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_638278947973939975" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_638278947973939975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_638278947973939975" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_638278947973939975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_638278947973939975" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_638278947973949955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_638278947973949955" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ImpairmentsOfInventoryAndPrepayments" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_638278947973949955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="cvac_ImpairmentsOfInventoryAndPrepayments_638278947973949955" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_638278947973949955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_638278947973949955" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_638278947973949955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_638278947973949955" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638278947973949955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638278947973949955" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities_638278947973949955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities_638278947973949955" order="11" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638278947973949955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638278947973949955" order="12" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638278947973949955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638278947973949955" order="13" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638278947973959952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638278947973959952" order="14" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638278947973959952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638278947973959952" order="15" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638278947973959952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638278947973959952" order="16" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_638278947973959952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense_638278947973959952" order="17" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638278947973959952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947973939975" xlink:to="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638278947973959952" order="18" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_638278947973959952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_638278947973959952" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638278947973959952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638278947973959952" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638278947973959952" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_638278947973969952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638278947973959952" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_638278947973969952" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638278947973969952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638278947973969952" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638278947973969952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638278947973969952" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638278947973969952" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_638278947973969952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638278947973969952" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_638278947973969952" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_638278947973969952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638278947973969952" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_638278947973969952" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_638278947973969952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638278947973969952" xlink:to="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_638278947973969952" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_638278947973979955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638278947973969952" xlink:to="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_638278947973979955" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638278947973979955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638278947973969952" xlink:to="ifrs-full_ProceedsFromIssuingShares_638278947973979955" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures_638278947973979955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638278947973969952" xlink:to="ifrs-full_RepaymentsOfBondsNotesAndDebentures_638278947973979955" order="7" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_638278947973979955" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638278947973969952" xlink:to="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_638278947973979955" order="8" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Notes to the Consolidated Statements of Operations - Cost of sales (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ExpenseByNature" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638278947973989953" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="cvac_PersonnelExpenses_638278947973989953" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_638278947973989953" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_638278947973989953" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_638278947973989953" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="cvac_ThirdPartyServiceExpenses_638278947973989953" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638278947973989953" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="cvac_MaintenanceAndLeaseExpenses_638278947973989953" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638278947973989953" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638278947973989953" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638278947973989953" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ExpenseByNature" xlink:to="cvac_OtherExpense_638278947973989953" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails" xlink:type="extended" xlink:title="40309 - Disclosure - Notes to the Consolidated Statements of Operations - Other operating income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="MiscellaneousOtherOperatingIncome" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SaleOfEquipment" xlink:label="cvac_SaleOfEquipment_638278947973989953" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_SaleOfEquipment_638278947973989953" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CostOfReimbursementClaim" xlink:label="cvac_CostOfReimbursementClaim_638278947973989953" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_CostOfReimbursementClaim_638278947973989953" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_638278947973999932" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransfer_638278947973999932" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ReversalOfProvisionsForPersonnelExpenses" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_638278947973999932" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_ReversalOfProvisionsForPersonnelExpenses_638278947973999932" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherOperatingIncomeGovernmentGrants" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_638278947973999932" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_OtherOperatingIncomeGovernmentGrants_638278947973999932" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MiscellaneousOtherOperatingIncomeOther" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_638278947973999932" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="MiscellaneousOtherOperatingIncome" xlink:to="cvac_MiscellaneousOtherOperatingIncomeOther_638278947973999932" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Share-based payments - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:label="BenefitExpenseRecognizedForShareBasedPayment" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638278947973999932" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BenefitExpenseRecognizedForShareBasedPayment" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638278947973999932" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses" xlink:label="cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses_638278947973999932" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BenefitExpenseRecognizedForShareBasedPayment" xlink:to="cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses_638278947973999932" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638278947973999932" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BenefitExpenseRecognizedForShareBasedPayment" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638278947973999932" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses_638278947973999932" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="BenefitExpenseRecognizedForShareBasedPayment" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses_638278947973999932" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Trade and other payables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638278947974009952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638278947974009952" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LicenseFeePayable" xlink:label="cvac_LicenseFeePayable_638278947974009952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="cvac_LicenseFeePayable_638278947974009952" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables_638278947974009952" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_OtherCurrentPayables_638278947974009952" order="3" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>cvac-20230630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/17/2023 6:46:42 PM-->
<!--Modified on: 8/17/2023 6:46:42 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureShareBasedPaymentsTables" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureCorporateInformationDetails" roleURI="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureShareBasedPaymentsExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureShareBasedPaymentsEquitySettledProgramsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureShareBasedPaymentsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureFixedAssetsIntangibleAssetsDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureInventoriesDetails" roleURI="http://www.curevac.com/role/DisclosureInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureOtherLiabilitiesAndProvisionsDetails" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureRelatedPartyDisclosuresDetails" roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.curevac.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureStandardAndCustomAxisDomainDefaults" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.curevac.com/role/DisclosureStandardAndCustomAxisDomainDefaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="EntityAddressesAddressTypeAxis" xlink:title="EntityAddressesAddressTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="AddressTypeDomain" xlink:title="AddressTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="EntityAddressesAddressTypeAxis" xlink:to="AddressTypeDomain" xlink:title="definition: EntityAddressesAddressTypeAxis to AddressTypeDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:title="RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="RestatedMember" xlink:title="RestatedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="RestatedMember" xlink:title="definition: RetrospectiveApplicationAndRetrospectiveRestatementAxis to RestatedMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ComponentsOfEquityAxis" xlink:title="ComponentsOfEquityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="EquityMember" xlink:title="EquityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ComponentsOfEquityAxis" xlink:to="EquityMember" xlink:title="definition: ComponentsOfEquityAxis to EquityMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="TypesOfSharebasedPaymentArrangementsAxis" xlink:title="TypesOfSharebasedPaymentArrangementsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="SharebasedPaymentArrangementsMember" xlink:title="SharebasedPaymentArrangementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfSharebasedPaymentArrangementsAxis" xlink:to="SharebasedPaymentArrangementsMember" xlink:title="definition: TypesOfSharebasedPaymentArrangementsAxis to SharebasedPaymentArrangementsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="IfrsSaleOfStockAxis" xlink:title="IfrsSaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="IfrsSaleOfStockDomain" xlink:title="IfrsSaleOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsSaleOfStockAxis" xlink:to="IfrsSaleOfStockDomain" xlink:title="definition: IfrsSaleOfStockAxis to IfrsSaleOfStockDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="RangesMember" xlink:title="RangesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangesMember" xlink:title="definition: RangeAxis to RangesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="StatementScenarioAxis" xlink:title="StatementScenarioAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="ScenarioUnspecifiedDomain" xlink:title="ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementScenarioAxis" xlink:to="ScenarioUnspecifiedDomain" xlink:title="definition: StatementScenarioAxis to ScenarioUnspecifiedDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="MaturityAxis" xlink:title="MaturityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="AggregatedTimeBandsMember" xlink:title="AggregatedTimeBandsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MaturityAxis" xlink:to="AggregatedTimeBandsMember" xlink:title="definition: MaturityAxis to AggregatedTimeBandsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsVestingAxis" xlink:label="IfrsVestingAxis" xlink:title="IfrsVestingAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsVestingDomain" xlink:label="IfrsVestingDomain" xlink:title="IfrsVestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsVestingAxis" xlink:to="IfrsVestingDomain" xlink:title="definition: IfrsVestingAxis to IfrsVestingDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="NonadjustingEventsAfterReportingPeriodAxis" xlink:title="NonadjustingEventsAfterReportingPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="NonadjustingEventsMember" xlink:title="NonadjustingEventsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="NonadjustingEventsAfterReportingPeriodAxis" xlink:to="NonadjustingEventsMember" xlink:title="definition: NonadjustingEventsAfterReportingPeriodAxis to NonadjustingEventsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="BusinessCombinationsAxis" xlink:title="BusinessCombinationsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="EntitysTotalForBusinessCombinationsMember" xlink:title="EntitysTotalForBusinessCombinationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BusinessCombinationsAxis" xlink:to="EntitysTotalForBusinessCombinationsMember" xlink:title="definition: BusinessCombinationsAxis to EntitysTotalForBusinessCombinationsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="ConsolidatedEntitiesAxis" xlink:title="ConsolidatedEntitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="ConsolidatedEntitiesDomain" xlink:title="ConsolidatedEntitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidatedEntitiesAxis" xlink:to="ConsolidatedEntitiesDomain" xlink:title="definition: ConsolidatedEntitiesAxis to ConsolidatedEntitiesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ProductsAndServicesAxis" xlink:title="ProductsAndServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ProductsAndServicesMember" xlink:title="ProductsAndServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductsAndServicesAxis" xlink:to="ProductsAndServicesMember" xlink:title="definition: ProductsAndServicesAxis to ProductsAndServicesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="TimingOfTransferOfGoodsOrServicesAxis" xlink:title="TimingOfTransferOfGoodsOrServicesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesMember" xlink:label="TimingOfTransferOfGoodsOrServicesMember" xlink:title="TimingOfTransferOfGoodsOrServicesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TimingOfTransferOfGoodsOrServicesAxis" xlink:to="TimingOfTransferOfGoodsOrServicesMember" xlink:title="definition: TimingOfTransferOfGoodsOrServicesAxis to TimingOfTransferOfGoodsOrServicesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ClassesOfAssetsAxis" xlink:title="ClassesOfAssetsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ClassesOfAssetsMember" xlink:title="ClassesOfAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfAssetsAxis" xlink:to="ClassesOfAssetsMember" xlink:title="definition: ClassesOfAssetsAxis to ClassesOfAssetsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="InitiallyAppliedIFRSsAxis" xlink:title="InitiallyAppliedIFRSsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="InitiallyAppliedIFRSsMember" xlink:title="InitiallyAppliedIFRSsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="InitiallyAppliedIFRSsAxis" xlink:to="InitiallyAppliedIFRSsMember" xlink:title="definition: InitiallyAppliedIFRSsAxis to InitiallyAppliedIFRSsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConcentrationsOfRiskAxis" xlink:label="ConcentrationsOfRiskAxis" xlink:title="ConcentrationsOfRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConcentrationsOfRiskMember" xlink:label="ConcentrationsOfRiskMember" xlink:title="ConcentrationsOfRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationsOfRiskAxis" xlink:to="ConcentrationsOfRiskMember" xlink:title="definition: ConcentrationsOfRiskAxis to ConcentrationsOfRiskMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:title="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="IntangibleAssetsOtherThanGoodwillMember" xlink:title="IntangibleAssetsOtherThanGoodwillMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:to="IntangibleAssetsOtherThanGoodwillMember" xlink:title="definition: ClassesOfIntangibleAssetsOtherThanGoodwillAxis to IntangibleAssetsOtherThanGoodwillMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:title="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CarryingAmountMember" xlink:label="CarryingAmountMember" xlink:title="CarryingAmountMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:to="CarryingAmountMember" xlink:title="definition: CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis to CarryingAmountMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ClassesOfPropertyPlantAndEquipmentAxis" xlink:title="ClassesOfPropertyPlantAndEquipmentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="PropertyPlantAndEquipmentMember" xlink:title="PropertyPlantAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="PropertyPlantAndEquipmentMember" xlink:title="definition: ClassesOfPropertyPlantAndEquipmentAxis to PropertyPlantAndEquipmentMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="GeographicalAreasAxis" xlink:title="GeographicalAreasAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="GeographicalAreasMember" xlink:title="GeographicalAreasMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GeographicalAreasAxis" xlink:to="GeographicalAreasMember" xlink:title="definition: GeographicalAreasAxis to GeographicalAreasMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="MajorCustomersMember" xlink:title="MajorCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="MajorCustomersMember" xlink:title="definition: MajorCustomersAxis to MajorCustomersMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GovernmentGrantsAxis" xlink:label="GovernmentGrantsAxis" xlink:title="GovernmentGrantsAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GovernmentGrantsDomain" xlink:label="GovernmentGrantsDomain" xlink:title="GovernmentGrantsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="GovernmentGrantsAxis" xlink:to="GovernmentGrantsDomain" xlink:title="definition: GovernmentGrantsAxis to GovernmentGrantsDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="IfrsIncomeStatementLocationAxis" xlink:title="IfrsIncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="IfrsIncomeStatementLocationDomain" xlink:title="IfrsIncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IfrsIncomeStatementLocationAxis" xlink:to="IfrsIncomeStatementLocationDomain" xlink:title="definition: IfrsIncomeStatementLocationAxis to IfrsIncomeStatementLocationDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ClassesOfShareCapitalAxis" xlink:title="ClassesOfShareCapitalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ClassesOfShareCapitalMember" xlink:title="ClassesOfShareCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfShareCapitalAxis" xlink:to="ClassesOfShareCapitalMember" xlink:title="definition: ClassesOfShareCapitalAxis to ClassesOfShareCapitalMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="CategoriesOfRelatedPartiesAxis" xlink:title="CategoriesOfRelatedPartiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="EntitysTotalForRelatedPartiesMember" xlink:title="EntitysTotalForRelatedPartiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CategoriesOfRelatedPartiesAxis" xlink:to="EntitysTotalForRelatedPartiesMember" xlink:title="definition: CategoriesOfRelatedPartiesAxis to EntitysTotalForRelatedPartiesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="BorrowingsByNameAxis" xlink:title="BorrowingsByNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="BorrowingsByNameMember" xlink:title="BorrowingsByNameMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="BorrowingsByNameAxis" xlink:to="BorrowingsByNameMember" xlink:title="definition: BorrowingsByNameAxis to BorrowingsByNameMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:title="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:to="TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:title="definition: TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis to TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="CurrencyAxis" xlink:title="CurrencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="AllCurrenciesDomain" xlink:title="AllCurrenciesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CurrencyAxis" xlink:to="AllCurrenciesDomain" xlink:title="definition: CurrencyAxis to AllCurrenciesDomain" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="TypesOfRisksAxis" xlink:title="TypesOfRisksAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="TypesOfRisksMember" xlink:title="TypesOfRisksMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypesOfRisksAxis" xlink:to="TypesOfRisksMember" xlink:title="definition: TypesOfRisksAxis to TypesOfRisksMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ClassesOfFinancialInstrumentsAxis" xlink:title="ClassesOfFinancialInstrumentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ClassesOfFinancialInstrumentsMember" xlink:title="ClassesOfFinancialInstrumentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassesOfFinancialInstrumentsAxis" xlink:to="ClassesOfFinancialInstrumentsMember" xlink:title="definition: ClassesOfFinancialInstrumentsAxis to ClassesOfFinancialInstrumentsMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="LevelsOfFairValueHierarchyAxis" xlink:title="LevelsOfFairValueHierarchyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="AllLevelsOfFairValueHierarchyMember" xlink:title="AllLevelsOfFairValueHierarchyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LevelsOfFairValueHierarchyAxis" xlink:to="AllLevelsOfFairValueHierarchyMember" xlink:title="definition: LevelsOfFairValueHierarchyAxis to AllLevelsOfFairValueHierarchyMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="LiabilitiesArisingFromFinancingActivitiesAxis" xlink:title="LiabilitiesArisingFromFinancingActivitiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:label="LiabilitiesArisingFromFinancingActivitiesMember" xlink:title="LiabilitiesArisingFromFinancingActivitiesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LiabilitiesArisingFromFinancingActivitiesAxis" xlink:to="LiabilitiesArisingFromFinancingActivitiesMember" xlink:title="definition: LiabilitiesArisingFromFinancingActivitiesAxis to LiabilitiesArisingFromFinancingActivitiesMember" use="optional" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PlanNameAxis" xlink:label="cvac_PlanNameAxis_1" xlink:title="cvac_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PlanNameDomain" xlink:label="cvac_PlanNameDomain_1" xlink:title="cvac_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_PlanNameAxis_1" xlink:to="cvac_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_PlanNameAxis_1 To cvac_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis_1" xlink:title="ifrs-full_TypesOfContractsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember_1" xlink:title="ifrs-full_TypesOfContractsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TypesOfContractsAxis_1" xlink:to="ifrs-full_TypesOfContractsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TypesOfContractsAxis_1 To ifrs-full_TypesOfContractsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis_1" xlink:title="cvac_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember_1" xlink:title="cvac_ArrangementsAndNonArrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_TypeOfArrangementAxis_1" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_TypeOfArrangementAxis_1 To cvac_ArrangementsAndNonArrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1" xlink:title="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" xlink:title="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_1 To cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_1" xlink:title="ifrs-full_CounterpartiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember_1" xlink:title="ifrs-full_CounterpartiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CounterpartiesAxis_1" xlink:to="ifrs-full_CounterpartiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CounterpartiesAxis_1 To ifrs-full_CounterpartiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis" xlink:label="ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1" xlink:title="ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember" xlink:label="ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" xlink:title="ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1" xlink:to="ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_AssetsAndLiabilitiesClassifiedAsHeldForSaleAxis_1 To ifrs-full_AssetsAndLiabilitiesNotClassifiedAsHeldForSaleMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" xlink:title="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_1" xlink:title="ifrs-full_EntitysTotalForSubsidiariesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1 To ifrs-full_EntitysTotalForSubsidiariesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis_1" xlink:title="ifrs-full_ClassesOfContingentLiabilitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember_1" xlink:title="ifrs-full_ContingentLiabilitiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis_1" xlink:to="ifrs-full_ContingentLiabilitiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfContingentLiabilitiesAxis_1 To ifrs-full_ContingentLiabilitiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AssetsHeldForSaleAxis" xlink:label="cvac_AssetsHeldForSaleAxis_1" xlink:title="cvac_AssetsHeldForSaleAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AssetsHeldForSaleDomain" xlink:label="cvac_AssetsHeldForSaleDomain_1" xlink:title="cvac_AssetsHeldForSaleDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_AssetsHeldForSaleAxis_1" xlink:to="cvac_AssetsHeldForSaleDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_AssetsHeldForSaleAxis_1 To cvac_AssetsHeldForSaleDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_1" xlink:title="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember_1" xlink:title="ifrs-full_IntangibleAssetsAndGoodwillMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_1" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_1 To ifrs-full_IntangibleAssetsAndGoodwillMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassifiedItemsAxis" xlink:label="ifrs-full_ReclassifiedItemsAxis_1" xlink:title="ifrs-full_ReclassifiedItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReclassifiedItemsMember" xlink:label="ifrs-full_ReclassifiedItemsMember_1" xlink:title="ifrs-full_ReclassifiedItemsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ReclassifiedItemsAxis_1" xlink:to="ifrs-full_ReclassifiedItemsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ReclassifiedItemsAxis_1 To ifrs-full_ReclassifiedItemsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsTypeOfArrangementAxis" xlink:label="cvac_IfrsTypeOfArrangementAxis_1" xlink:title="cvac_IfrsTypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ArrangementsAndNonArrangementTransactionsDomain" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsDomain_1" xlink:title="cvac_ArrangementsAndNonArrangementTransactionsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_IfrsTypeOfArrangementAxis_1" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_IfrsTypeOfArrangementAxis_1 To cvac_ArrangementsAndNonArrangementTransactionsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsPlanNameAxis" xlink:label="cvac_IfrsPlanNameAxis_1" xlink:title="cvac_IfrsPlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsPlanNameDomain" xlink:label="cvac_IfrsPlanNameDomain_1" xlink:title="cvac_IfrsPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="cvac_IfrsPlanNameAxis_1" xlink:to="cvac_IfrsPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:cvac_IfrsPlanNameAxis_1 To cvac_IfrsPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis_1" xlink:title="ifrs-full_ClassesOfProvisionsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherProvisionsMember" xlink:label="ifrs-full_OtherProvisionsMember_1" xlink:title="ifrs-full_OtherProvisionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfProvisionsAxis_1" xlink:to="ifrs-full_OtherProvisionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfProvisionsAxis_1 To ifrs-full_OtherProvisionsMember_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CountryRegion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="40" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="41" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="42" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="43" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="44" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="45" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RestatedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InAccordanceWithIFRS9Member" xlink:label="ifrs-full_InAccordanceWithIFRS9Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_InAccordanceWithIFRS9Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_PreviouslyStatedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_CapitalReserveMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_TreasurySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NetLoss" xlink:label="cvac_NetLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="cvac_NetLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="cvac_SettlementOfShareBasedPaymentAwardsAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Share-based payments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_RestrictedStockUnitsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Corporate Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LargestShareholderMember" xlink:label="cvac_LargestShareholderMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_LargestShareholderMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PercentageOfVotingInterestsHeld" xlink:label="cvac_PercentageOfVotingInterestsHeld" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PercentageOfVotingInterestsHeld" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CorporateReorganizationStockSplitRatio" xlink:label="cvac_CorporateReorganizationStockSplitRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_CorporateReorganizationStockSplitRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_GeographicalAreasAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BE" xlink:label="country_BE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_BE" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="country_DE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_DE" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="country_CH" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_CH" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NL" xlink:label="country_NL" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_NL" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GlaxosmithklineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_BoehringerIngelheimMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_CrisprMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GenmabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_EliLillyAndCompanyMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherCustomersMember" xlink:label="cvac_OtherCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_OtherCustomersMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_ProductsAndServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsProductMember" xlink:label="cvac_IfrsProductMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_IfrsProductMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ResearchAndDevelopmentServicesMember" xlink:label="cvac_ResearchAndDevelopmentServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_ResearchAndDevelopmentServicesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Notes to the Consolidated Statements of Operations - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_BoehringerIngelheimMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_CrisprTherapeuticsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GenmabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_EliLillyMember" xlink:label="cvac_EliLillyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_EliLillyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="cvac_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_TypeOfArrangementAxis" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:to="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GlaxosmithklineCovidAgreementMember" xlink:label="cvac_GlaxosmithklineCovidAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:to="cvac_GlaxosmithklineCovidAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember" xlink:label="cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:to="cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CollaborationAndLicenseAgreementMember" xlink:label="cvac_CollaborationAndLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:to="cvac_CollaborationAndLicenseAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_ProductsAndServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MilestoneRevenuesMember" xlink:label="cvac_MilestoneRevenuesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_MilestoneRevenuesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_GeographicalAreasAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BE" xlink:label="country_BE" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="country_BE" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_AdditionalDevelopmentMilestonePaymentsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Notes to the Consolidated Statements of Operations - Summary of upfront payments and related revenues recognized (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_ProductsAndServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_MajorCustomersAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_CrisprMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GenmabMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_UpfrontPaymentsIncludedInContractLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Notes to the Consolidated Statements of Operations - Contract balances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_CurrentTradeReceivables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_CurrentContractAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ContractLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Notes to the Consolidated Statements of Operations - Cost of sales (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsCostOfSalesMember" xlink:label="cvac_IfrsCostOfSalesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsCostOfSalesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_ThirdPartyServiceExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails" xlink:type="extended" xlink:title="40306 - Disclosure - Notes to the Consolidated Statements of Operations - Selling and distribution expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SellingAndDistributionExpensesMember" xlink:label="cvac_SellingAndDistributionExpensesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_SellingAndDistributionExpensesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails" xlink:type="extended" xlink:title="40307 - Disclosure - Notes to the Consolidated Statements of Operations - Research and development expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsResearchAndDevelopmentExpenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_ThirdPartyServiceExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract" xlink:label="cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsProvisionForLossOnContracts" xlink:label="cvac_IfrsProvisionForLossOnContracts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_IfrsProvisionForLossOnContracts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails" xlink:type="extended" xlink:title="40308 - Disclosure - Notes to the Consolidated Statements of Operations - General and administrative expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_IfrsIncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsGeneralAndAdministrativeExpenseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="ifrs-full_ClassesOfAssetsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LaboratoriesMember" xlink:label="cvac_LaboratoriesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="cvac_LaboratoriesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="ifrs-full_RightofuseAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_RightofuseAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_PersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_MaintenanceAndLeaseExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_ThirdPartyServiceExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ProfessionalFeesExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_DepreciationAndAmortisationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_OtherExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseByNature" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AccruedOtherLiabilityForUpFrontPayment" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_AccruedOtherLiabilityForUpFrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TravelExpense" xlink:label="ifrs-full_TravelExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_TravelExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InsuranceExpense" xlink:label="ifrs-full_InsuranceExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_InsuranceExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RealEstateTransferTaxes" xlink:label="cvac_RealEstateTransferTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_RealEstateTransferTaxes" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails" xlink:type="extended" xlink:title="40309 - Disclosure - Notes to the Consolidated Statements of Operations - Other operating income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransfer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CostOfReimbursementClaim" xlink:label="cvac_CostOfReimbursementClaim" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_CostOfReimbursementClaim" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SaleOfEquipment" xlink:label="cvac_SaleOfEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_SaleOfEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherOperatingIncomeGovernmentGrants" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_OtherOperatingIncomeGovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ReversalOfProvisionsForPersonnelExpenses" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_ReversalOfProvisionsForPersonnelExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MiscellaneousOtherOperatingIncomeOther" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_MiscellaneousOtherOperatingIncomeOther" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xlink:type="extended" xlink:title="40310 - Disclosure - Notes to the Consolidated Statements of Operations - Grants with government agencies and similar bodies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfGovernmentGrantsTable" xlink:label="cvac_DisclosureOfGovernmentGrantsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="cvac_GovernmentGrantsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_GovernmentGrantsAxis" xlink:to="cvac_GovernmentGrantsDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_CoalitionForEpidemicPreparednessInnovationsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_BillAndMelindaGatesFoundationBmgfMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BundesministeriumFurBildungUndForschungMember" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BundesministeriumFurBildungUndForschungMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GlaxosmithklineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GskAgreement2020Member" xlink:label="cvac_GskAgreement2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GskAgreement2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_BoehringerIngelheimMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_CrisprTherapeuticsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_GenmabMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_EliLillyMember" xlink:label="cvac_EliLillyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="cvac_EliLillyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="cvac_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_TypeOfArrangementAxis" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:to="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfGovernmentGrantsLineItems" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_DisclosureOfGovernmentGrantsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="ifrs-full_RevenueFromGovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ReimbursementOfApprovedExpenses" xlink:label="cvac_ReimbursementOfApprovedExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_ReimbursementOfApprovedExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AmortizationOfGovernmentGrants" xlink:label="cvac_AmortizationOfGovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_AmortizationOfGovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaximumGrantToBeReceived" xlink:label="cvac_MaximumGrantToBeReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_MaximumGrantToBeReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AccruedOtherLiabilityForUpFrontPayment" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_AccruedOtherLiabilityForUpFrontPayment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_UpfrontPaymentReceived" xlink:label="cvac_UpfrontPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_UpfrontPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsMilestonePaymentReceived" xlink:label="cvac_IfrsMilestonePaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_IfrsMilestonePaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsRemainingGrantIncome" xlink:label="cvac_IfrsRemainingGrantIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_IfrsRemainingGrantIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GovernmentGrants" xlink:label="ifrs-full_GovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="ifrs-full_GovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaximumUnspentFundsReimbursable" xlink:label="cvac_MaximumUnspentFundsReimbursable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_MaximumUnspentFundsReimbursable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PartnershipAgreementMaximumAmount" xlink:label="cvac_PartnershipAgreementMaximumAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_PartnershipAgreementMaximumAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PartnershipAgreementTerm" xlink:label="cvac_PartnershipAgreementTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_PartnershipAgreementTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfAdditionalGrantsReceived" xlink:label="cvac_NumberOfAdditionalGrantsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_NumberOfAdditionalGrantsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_PreferenceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="cvac_IfrsSaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsOverAllotmentOptionMember" xlink:label="cvac_IfrsOverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_IfrsOverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_TreasurySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Issued Capital and Reserves - At-the-market offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="cvac_IfrsSaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AtMarketOfferingProgramMember" xlink:label="cvac_AtMarketOfferingProgramMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_AtMarketOfferingProgramMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_FollowOnPublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSharesIssuedPricePerShare" xlink:label="cvac_IfrsSharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_IfrsSharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_AggregateGrossProceedsReceivableFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve" xlink:label="cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RemainingAuthorizedForSaleValue" xlink:label="cvac_RemainingAuthorizedForSaleValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_RemainingAuthorizedForSaleValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ShareIssueRelatedCost" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="cvac_IfrsSaleOfStockAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CapitalIncreaseByGenmabMember" xlink:label="cvac_CapitalIncreaseByGenmabMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_CapitalIncreaseByGenmabMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PrivatePlacementIsa2020Member" xlink:label="cvac_PrivatePlacementIsa2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_PrivatePlacementIsa2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_InitialPublicOfferingAndPrivatePlacementMember" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_InitialPublicOfferingAndPrivatePlacementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExerciseOfGreenshoeMember" xlink:label="cvac_ExerciseOfGreenshoeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_ExerciseOfGreenshoeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PublicOfferingMember" xlink:label="cvac_PublicOfferingMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_PublicOfferingMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SeriesSharesMember" xlink:label="cvac_SeriesSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="cvac_SeriesSharesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SeriesCSharesMember" xlink:label="cvac_SeriesCSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="cvac_SeriesCSharesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_CommonSharesIssuedAndOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ShareOptionExercises" xlink:label="cvac_ShareOptionExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_ShareOptionExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_StockIssuedDuringPeriodForExercises" xlink:label="cvac_StockIssuedDuringPeriodForExercises" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_StockIssuedDuringPeriodForExercises" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_StockIssuanceDuringPeriodForExistingShareholders" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_StockIssuanceDuringPeriodForExistingShareholders" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" xlink:label="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfSharesIssuedForRsuDeliveries" xlink:label="cvac_NumberOfSharesIssuedForRsuDeliveries" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="cvac_NumberOfSharesIssuedForRsuDeliveries" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Share-based payments - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PlanNameAxis" xlink:label="cvac_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="cvac_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PlanNameDomain" xlink:label="cvac_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_PlanNameAxis" xlink:to="cvac_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses" xlink:label="cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_BenefitExpenseRecognizedForShareBasedPayment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Share-based payments - Equity-settled programs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" priority="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_LongTermIncentivePlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsRestrictedStockUnitMember" xlink:label="cvac_IfrsRestrictedStockUnitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_IfrsRestrictedStockUnitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NewVirtualStockOptionsPlanMember" xlink:label="cvac_NewVirtualStockOptionsPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_NewVirtualStockOptionsPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PriorVirtualStockOptionsPlanMember" xlink:label="cvac_PriorVirtualStockOptionsPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_PriorVirtualStockOptionsPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LongTermIncentivePlanAndRestrictedStockUnitMember" xlink:label="cvac_LongTermIncentivePlanAndRestrictedStockUnitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_LongTermIncentivePlanAndRestrictedStockUnitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseRecognizedForEmployeeServices" xlink:label="cvac_ExpenseRecognizedForEmployeeServices" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpenseRecognizedForEmployeeServices" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Share-based payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="cvac_IfrsSaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExerciseOfOptionsMember" xlink:label="cvac_ExerciseOfOptionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_ExerciseOfOptionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefScientificOfficerMember" xlink:label="cvac_ChiefScientificOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefScientificOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefOperatingOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefDevelopmentOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefDevelopmentOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ThenChiefExecutiveOfficerMember" xlink:label="cvac_ThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ThenChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ManagementBoardMember" xlink:label="cvac_ManagementBoardMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ManagementBoardMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_KeyEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExecutiveBoardMembersMember" xlink:label="cvac_ExecutiveBoardMembersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ExecutiveBoardMembersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SupervisoryBoardMembersMember" xlink:label="cvac_SupervisoryBoardMembersMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_SupervisoryBoardMembersMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefBusinessOfficerMember" xlink:label="cvac_ChiefBusinessOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_ChiefBusinessOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_FormerFrameEmployeesMember" xlink:label="cvac_FormerFrameEmployeesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_FormerFrameEmployeesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_MaturityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_AggregatedTimeBandsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_NotLaterThanOneYearMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsVestingAxis" xlink:label="cvac_IfrsVestingAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="cvac_IfrsVestingAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsVestingAxis" xlink:to="cvac_IfrsVestingDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsVestingDomain" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_LongTermIncentivePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIiMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfKeyEmployees" xlink:label="cvac_NumberOfKeyEmployees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_NumberOfKeyEmployees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu" xlink:label="cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_RightToExercisePercentageOfVestedVirtualShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LockUpPeriodAfterInitialListing" xlink:label="cvac_LockUpPeriodAfterInitialListing" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_LockUpPeriodAfterInitialListing" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_ProvisionForEmployerTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AmountOfLiabilityCashClaimAwards" xlink:label="cvac_AmountOfLiabilityCashClaimAwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_AmountOfLiabilityCashClaimAwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AmountOfRestrictedStockUnitsReceived" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_AmountOfRestrictedStockUnitsReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fixed Assets - Intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="ifrs-full_GrossCarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SoftwareMember" xlink:label="cvac_SoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="cvac_SoftwareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrs-full_LicencesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TechnologyMember" xlink:label="cvac_TechnologyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="cvac_TechnologyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdvancePaymentsIntangibleAssetMember" xlink:label="cvac_AdvancePaymentsIntangibleAssetMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="cvac_AdvancePaymentsIntangibleAssetMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LicensesSoftwareAndPrepaymentsMember" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="cvac_LicensesSoftwareAndPrepaymentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="ifrs-full_GoodwillMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrs-full_GoodwillMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="ifrs-full_GrossCarryingAmountMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="ifrs-full_BuildingsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_BuildingsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CompanyOwnedGmpIvFacilityMember" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_CompanyOwnedGmpIvFacilityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_PropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_InventoriesTable" xlink:label="cvac_InventoriesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_InventoriesTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_InventoriesLineItem" xlink:label="cvac_InventoriesLineItem" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_InventoriesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RawMaterials" xlink:label="ifrs-full_RawMaterials" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_InventoriesLineItem" xlink:to="ifrs-full_RawMaterials" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncreaseDecreaseInInventory" xlink:label="cvac_IncreaseDecreaseInInventory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_IncreaseDecreaseInInventory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NetValueOfInventoryTransferred" xlink:label="cvac_NetValueOfInventoryTransferred" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_NetValueOfInventoryTransferred" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsInventoryFinishedGoodsWriteDown" xlink:label="cvac_IfrsInventoryFinishedGoodsWriteDown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_IfrsInventoryFinishedGoodsWriteDown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinishedGoods" xlink:label="ifrs-full_FinishedGoods" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_InventoriesLineItem" xlink:to="ifrs-full_FinishedGoods" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_InventoriesLineItem" xlink:to="ifrs-full_InventoryWritedown2011" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Prepaid expenses and other assets (current) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_InventoriesTable" xlink:label="cvac_InventoriesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_InventoriesTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_InventoriesLineItem" xlink:label="cvac_InventoriesLineItem" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_InventoriesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_InventoriesLineItem" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="ifrs-full_CurrentAdvancesToSuppliers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_InventoriesLineItem" xlink:to="ifrs-full_CurrentAdvancesToSuppliers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_InventoriesLineItem" xlink:to="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_InventoriesLineItem" xlink:to="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CurrentGrantReceivable" xlink:label="cvac_CurrentGrantReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_CurrentGrantReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsCurrentGrantReceivables" xlink:label="cvac_IfrsCurrentGrantReceivables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_IfrsCurrentGrantReceivables" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Other liabilities and provisions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfOtherLiabilitiesTable" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable" xlink:to="ifrs-full_TypesOfContractsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_DisclosureOfOtherLiabilitiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChangeInOtherLiabilities" xlink:label="cvac_ChangeInOtherLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_ChangeInOtherLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProvisionsForDecreaseInContractTerminations" xlink:label="cvac_ProvisionsForDecreaseInContractTerminations" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_ProvisionsForDecreaseInContractTerminations" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInOtherProvisions" xlink:label="ifrs-full_ChangesInOtherProvisions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="ifrs-full_ChangesInOtherProvisions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherMiscellaneousNonCurrentLiabilities" xlink:label="cvac_OtherMiscellaneousNonCurrentLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_OtherMiscellaneousNonCurrentLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PersonnelAccruedLiabilities" xlink:label="cvac_PersonnelAccruedLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_PersonnelAccruedLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentGovernmentGrants" xlink:label="ifrs-full_CurrentGovernmentGrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="ifrs-full_CurrentGovernmentGrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OutstandingInvoicesCurrent" xlink:label="cvac_OutstandingInvoicesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_OutstandingInvoicesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProfessionalFessCurrent" xlink:label="cvac_ProfessionalFessCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_ProfessionalFessCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CurrentValueAddedTaxAndOtherTaxesPayables" xlink:label="cvac_CurrentValueAddedTaxAndOtherTaxesPayables" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_CurrentValueAddedTaxAndOtherTaxesPayables" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherLiabilityCurrent" xlink:label="cvac_OtherLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_OtherLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherLiabilities" xlink:label="ifrs-full_OtherLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="ifrs-full_OtherLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes" xlink:label="cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Disclosure of financial instruments and risk management - Foreign currency risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="srt_CurrencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="currency_USD" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF" xlink:label="currency_CHF" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_CHF" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="currency_EUR" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_EUR" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP" xlink:label="currency_GBP" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_GBP" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_CurrencyRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsCashAndCashEquivalentsMember" xlink:label="cvac_IfrsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_IfrsCashAndCashEquivalentsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TradeAndOtherPayablesMember" xlink:label="cvac_TradeAndOtherPayablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_TradeAndOtherPayablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TradeAndOtherReceivablesMember" xlink:label="cvac_TradeAndOtherReceivablesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_TradeAndOtherReceivablesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MonetaryLiabilitiesInForeignCurrencyMember" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_MonetaryLiabilitiesInForeignCurrencyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MonetaryAssetsInForeignCurrencyMember" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_MonetaryAssetsInForeignCurrencyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TradeAndOtherPayablesOneMember" xlink:label="cvac_TradeAndOtherPayablesOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_TradeAndOtherPayablesOneMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TradeAndOtherPayablesTwoMember" xlink:label="cvac_TradeAndOtherPayablesTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="cvac_TradeAndOtherPayablesTwoMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Related party disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BaronJeanStephenneMember" xlink:label="cvac_BaronJeanStephenneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_BaronJeanStephenneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VincentStphenneMember" xlink:label="cvac_VincentStphenneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_VincentStphenneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AntonyBlancMember" xlink:label="cvac_AntonyBlancMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="cvac_AntonyBlancMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RittershausRechtsanwaelteMember" xlink:label="cvac_RittershausRechtsanwaelteMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_RittershausRechtsanwaelteMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" xlink:label="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DietmarHoppMember" xlink:label="cvac_DietmarHoppMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_DietmarHoppMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BepharbelManufacturingS.aMember" xlink:label="cvac_BepharbelManufacturingS.aMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_BepharbelManufacturingS.aMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BarkerBiomedicalGmbhMember" xlink:label="cvac_BarkerBiomedicalGmbhMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_BarkerBiomedicalGmbhMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CraigToomanMember" xlink:label="cvac_CraigToomanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_CraigToomanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ClarentisSrlMember" xlink:label="cvac_ClarentisSrlMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_ClarentisSrlMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MariolaFotinMleczekMember" xlink:label="cvac_MariolaFotinMleczekMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_MariolaFotinMleczekMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_FlorianVonDerMlbeMember" xlink:label="cvac_FlorianVonDerMlbeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_FlorianVonDerMlbeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_Dr.IngmarHrrMember" xlink:label="cvac_Dr.IngmarHrrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="cvac_Dr.IngmarHrrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="cvac_VirtualSharesProgramIMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RelatedPartyTransactionConsultingFees" xlink:label="cvac_RelatedPartyTransactionConsultingFees" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_RelatedPartyTransactionConsultingFees" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_RelatedPartyTransactionNumberOfLoansReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsContractualObligation" xlink:label="cvac_IfrsContractualObligation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_IfrsContractualObligation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_WeightedAverageSharePrice2019" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" xlink:label="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpensesToHandleFutureServiceAgreement" xlink:label="cvac_ExpensesToHandleFutureServiceAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_ExpensesToHandleFutureServiceAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseRecognizedFromRelatedPartyTransaction" xlink:label="cvac_ExpenseRecognizedFromRelatedPartyTransaction" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="cvac_ExpenseRecognizedFromRelatedPartyTransaction" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_BusinessCombinationsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="ifrs-full_BusinessCombinationsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrs-full_BusinessCombinationsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_ClassesOfContingentLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ContingentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherContingentLiabilitiesMember" xlink:label="ifrs-full_OtherContingentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ContingentLiabilitiesMember" xlink:to="ifrs-full_OtherContingentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" xlink:label="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ContingentLiabilitiesMember" xlink:to="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_ProductsAndServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MilestonesMember" xlink:label="cvac_MilestonesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="cvac_MilestonesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_CounterpartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GskAgreement2020Member" xlink:label="cvac_GskAgreement2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="cvac_GskAgreement2020Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PatentInfringementLawsuitFilledMember" xlink:label="cvac_PatentInfringementLawsuitFilledMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="cvac_PatentInfringementLawsuitFilledMember" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="cvac_IfrsSaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PublicOfferingOfCommonSharesMember" xlink:label="cvac_PublicOfferingOfCommonSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_PublicOfferingOfCommonSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled" xlink:label="cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase" xlink:label="cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfPatentOnWhichNullityActionIsFilled" xlink:label="cvac_NumberOfPatentOnWhichNullityActionIsFilled" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfPatentOnWhichNullityActionIsFilled" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" xlink:label="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" xlink:label="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" xlink:label="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" xlink:label="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" xlink:label="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" xlink:label="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_LossContingencyPatentsAllegedlyInfringedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LossContingencyPatentsFoundNotInfringedNumber" xlink:label="cvac_LossContingencyPatentsFoundNotInfringedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_LossContingencyPatentsFoundNotInfringedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfMrnaVaccinesDoses" xlink:label="cvac_NumberOfMrnaVaccinesDoses" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="cvac_NumberOfMrnaVaccinesDoses" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>cvac-20230630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/17/2023 6:46:42 PM-->
<!--Modified on: 8/17/2023 6:46:42 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses, Address Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Address Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Contact</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Registration Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Shell Company Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contact Personnel Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Country Region</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contact Personnel Email Address</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Accounting Standard</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Description</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and marketing expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and distribution expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeneralAndAdministrativeExpense" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous other operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingExpense" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous other operating expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) before tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax benefit/ (expense)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income, net of tax, exchange differences on translation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency adjustments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss for the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted earnings (loss) per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Condensed Consolidated Statements of Financial Position</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets and goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets and goodwill</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NetDeferredTaxAssets" xlink:to="ifrs-full_NetDeferredTaxAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NetDeferredTaxAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Assets Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets or disposal groups classified as held for sale or as held for distribution to owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current trade receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentContractAssets" xlink:to="ifrs-full_CurrentContractAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentContractAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="ifrs-full_OtherCurrentFinancialAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialAssets" xlink:to="ifrs-full_OtherCurrentFinancialAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current financial assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentFinancialAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current prepayments and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity And Liabilities Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserve" xlink:to="ifrs-full_CapitalReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasuryShares" xlink:to="ifrs-full_TreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_TreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current Liabilities Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentContractLiabilities" xlink:to="ifrs-full_NoncurrentContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentProvisions" xlink:to="ifrs-full_NoncurrentProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentLiabilities" xlink:to="ifrs-full_OtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisions" xlink:to="ifrs-full_CurrentProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current tax liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total equity and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Condensed Consolidated Statements of Changes in Shareholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retrospective application and retrospective restatement [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestatedMember" xlink:to="ifrs-full_RestatedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currently stated [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InAccordanceWithIFRS9Member" xlink:label="ifrs-full_InAccordanceWithIFRS9Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InAccordanceWithIFRS9Member" xlink:to="ifrs-full_InAccordanceWithIFRS9Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InAccordanceWithIFRS9Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effects from the first-time adoption of IFRS 9</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effects from the first-time adoption of IFRS 15</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreviouslyStatedMember" xlink:to="ifrs-full_PreviouslyStatedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreviouslyStatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Previously stated</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of equity [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CapitalReserveMember" xlink:to="ifrs-full_CapitalReserveMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CapitalReserveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CapitalReserveMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasurySharesMember" xlink:to="ifrs-full_TreasurySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TreasurySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TreasurySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NetLoss" xlink:label="cvac_NetLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NetLoss" xlink:to="cvac_NetLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NetLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NetLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NetLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherComprehensiveIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:to="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Share-based payment expense (incl. deferred taxes)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment expense (incl. deferred taxes)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments (net of taxes)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of share capital (net of transaction costs)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued on exercise of option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:to="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of share based payment awards settled in cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement Of Share Based Payment Awards , Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement of share-based payment awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through treasury share transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchase of common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interim Condensed Consolidated Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile profit (loss) [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile loss before tax to net cash flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:label="ifrs-full_AdjustmentsForFinanceIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceIncome" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="ifrs-full_AdjustmentsForFinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForFinanceCosts" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and impairment of property, plant and equipment and right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for losses (gains) on disposal of non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of fixed assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ImpairmentsOfInventoryAndPrepayments" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ImpairmentsOfInventoryAndPrepayments" xlink:to="cvac_ImpairmentsOfInventoryAndPrepayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairments of inventory and prepayments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairments of inventory and prepayments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of inventory and prepayments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment expense</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xlink:to="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for non cash income from release of provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Non Cash Income From Release Of Provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash income from release of provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChangesInWorkingCapitalAbstract" xlink:label="cvac_ChangesInWorkingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChangesInWorkingCapitalAbstract" xlink:to="cvac_ChangesInWorkingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChangesInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChangesInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in Working Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChangesInWorkingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Working capital changes</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:to="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in non-current assets or disposal groups classified as held for sale or as held for distribution to owners to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Decrease (Increase) In Non-current Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in trade and other receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in trade receivables and contract assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in other assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for increase (decrease) in trade and other payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">(Decrease) / increase in trade and other payables, other liabilities and contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for deferred tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease / (increase) in deferred taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes paid, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes paid</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities" xlink:to="cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash inflow (outflow) of income taxes paid classified as operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment Of Income Taxes Paid Classified As Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid, classified as operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash flow (used in) operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, plant and equipment, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of intangible assets, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash flow (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of lease liabilities, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments on lease obligations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash received from issuance of shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of Shares (net of transaction costs)</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" xlink:to="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of proceed from issuing other equity instrument or exercise of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceed From Issuing Other Equity Instrument Or Exercise of Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment on / proceeds from treasury shares/exercise of options</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from borrowings obtained. [Refer: Borrowings]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (Repayments of) borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (repayment of) the EIB loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issue of bonds, notes and debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the convertible loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:to="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to acquire or redeem entity's shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment on treasury shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuing other equity instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment on treasury shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:to="ifrs-full_RepaymentsOfBondsNotesAndDebentures_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of bonds, notes and debentures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of convertible loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash flow provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation gains (losses) on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CorporateInformationAbstract" xlink:label="cvac_CorporateInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CorporateInformationAbstract" xlink:to="cvac_CorporateInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CorporateInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CorporateInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CorporateInformationTextBlock" xlink:label="cvac_CorporateInformationTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CorporateInformationTextBlock" xlink:to="cvac_CorporateInformationTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CorporateInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on corporate information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CorporateInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CorporateInformationTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfBasisOfPreparationAbstract" xlink:label="cvac_DisclosureOfBasisOfPreparationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DisclosureOfBasisOfPreparationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfBasisOfPreparationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of the basis used for the preparation of the financial statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfBasisOfPreparationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" xlink:to="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The disclosure of the basis used for the preparation of the financial statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Basis of Preparation Explanatory [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:to="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of notes and other explanatory information [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued Capital and Reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of share capital, reserves and other equity interest [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued Capital and Reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of share-based payment arrangements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="cvac_DisclosureOfFixedAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfFixedAssetsAbstract" xlink:to="cvac_DisclosureOfFixedAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfFixedAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfFixedAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfFixedAssetsExplanatory" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfFixedAssetsExplanatory" xlink:to="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for fixed assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Fixed Assets, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:to="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of non-current assets held for sale and discontinued operations [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="ifrs-full_ClassesOfInventoriesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfInventoriesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfInventoriesExplanatory" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of inventories [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets (current)</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xlink:to="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for prepaid expenses and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Prepaid Expenses And Other Current Assets, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets (current)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets and financial liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets and financial liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of trade and other payables [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:label="cvac_OtherLiabilitiesAndProvisionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:to="cvac_OtherLiabilitiesAndProvisionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherLiabilitiesAndProvisionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherLiabilitiesAndProvisionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities and provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherLiabilitiesAndProvisionsTextBlock" xlink:label="cvac_OtherLiabilitiesAndProvisionsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherLiabilitiesAndProvisionsTextBlock" xlink:to="cvac_OtherLiabilitiesAndProvisionsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherLiabilitiesAndProvisionsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of other liabilities and provisions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherLiabilitiesAndProvisionsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities and Provisions [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OtherLiabilitiesAndProvisionsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities and provisions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of income tax [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="cvac_FinancialInstrumentsAndRiskManagementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:to="cvac_FinancialInstrumentsAndRiskManagementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FinancialInstrumentsAndRiskManagementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FinancialInstrumentsAndRiskManagementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments and risk management</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial risk management [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments and risk management</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="ifrs-full_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareExplanatory" xlink:to="ifrs-full_EarningsPerShareExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party disclosures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of related party [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party disclosures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of events after reporting period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent events</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of basis of preparation of financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" xlink:to="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The description of the entity's accounting policy for New standards, interpretations and amendments adopted by the Group.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Accounting Policy of New Standards, Interpretations and Amendments Adopted [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New standards, interpretations and amendments adopted by the Group</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" xlink:to="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for Covid-19 impact.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Accounting Policy for Covid-19 Impact, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impact of COVID-19 and the Russia-Ukraine Conflict</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for research and development expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" xlink:to="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of accounting policy for Pre-launch products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Description of Accounting Policy for Pre-Launch Products, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-launch products</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of revenue from contract with customers recognized</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xlink:to="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about upfront payments and related revenues recognized.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Upfront Payments And Related Revenues Recognized, Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of upfront payments and related revenues recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:to="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Explanation of significant changes in contract assets and contract liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of contract balances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:to="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transaction price allocated to remaining performance obligations [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of expenses by nature [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other operating income [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other operating income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:to="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other operating expense [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of other operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of total shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of share-based payment arrangements [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangements [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_VirtualSharesProgramIMember" xlink:to="cvac_VirtualSharesProgramIMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_VirtualSharesProgramIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Virtual shares program I.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_VirtualSharesProgramIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior VSOP [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_VirtualSharesProgramIMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior VSOP</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for options granted to Dan Menichella, the then Chief Executive Officer (CEO).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Chief Executive Officer Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Chief Executive Officer Grant</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RestrictedStockUnitsMember" xlink:to="cvac_RestrictedStockUnitsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Restricted stock Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RestrictedStockUnitsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Stock Units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of number and weighted average exercise prices of share options [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation of outstanding awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of inputs used in the measurement of the fair value at grant date</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:to="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of expense recognized for employee services explanatory.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Expense Recognized For Employee Services Explanatory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of share-based payments expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:to="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of expense recognized for the programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Expense Recognized for the Programs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule for expense recognized for the equity-settled programs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about business combination [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ranges [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ranges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of Individual [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LargestShareholderMember" xlink:label="cvac_LargestShareholderMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LargestShareholderMember" xlink:to="cvac_LargestShareholderMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LargestShareholderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LargestShareholderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Largest Shareholder [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LargestShareholderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dievini</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about business combination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Information</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PercentageOfVotingInterestsHeld" xlink:label="cvac_PercentageOfVotingInterestsHeld" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PercentageOfVotingInterestsHeld" xlink:to="cvac_PercentageOfVotingInterestsHeld_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PercentageOfVotingInterestsHeld_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of voting equity interests held in the Entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PercentageOfVotingInterestsHeld_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Voting Interests Held</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PercentageOfVotingInterestsHeld_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Voting interests held</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CorporateReorganizationStockSplitRatio" xlink:label="cvac_CorporateReorganizationStockSplitRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CorporateReorganizationStockSplitRatio" xlink:to="cvac_CorporateReorganizationStockSplitRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CorporateReorganizationStockSplitRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock split ratio upon corporate reorganization for determining the basis for issuance of shares to the holders of the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CorporateReorganizationStockSplitRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate Reorganization, Stock Split Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CorporateReorganizationStockSplitRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share split ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proportion of ownership interest in subsidiary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership percentage</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to disclosure of notes to the consolidated financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Notes To The Consolidated Financial Statements [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasMember" xlink:to="ifrs-full_GeographicalAreasMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GeographicalAreasMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical areas</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BE" xlink:label="country_BE" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BE" xlink:to="country_BE_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Belgium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_BE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Belgium</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="country_CH" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CH" xlink:to="country_CH_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CH_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Switzerland</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_CH_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Switzerland</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NL" xlink:label="country_NL" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NL" xlink:to="country_NL_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_NL_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Netherlands</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_NL_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Netherlands</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="country_DE" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DE" xlink:to="country_DE_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_DE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Germany</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_DE_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Germany</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorCustomersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major customers [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersMember" xlink:to="ifrs-full_MajorCustomersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customers [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MajorCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Customers</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GlaxosmithklineMember" xlink:to="cvac_GlaxosmithklineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GlaxosmithklineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for GlaxoSmithKline.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GlaxosmithklineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GSK [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_GlaxosmithklineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GSK</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CrisprMember" xlink:to="cvac_CrisprMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CrisprMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for CRISPR.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CrisprMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CRISPR</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CrisprMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CRISPR</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GenmabMember" xlink:to="cvac_GenmabMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Genmab.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genmab [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_GenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genmab</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BoehringerIngelheimMember" xlink:to="cvac_BoehringerIngelheimMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BoehringerIngelheimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Boehringer Ingelheim.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BoehringerIngelheimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Boehringer Ingelheim</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_BoehringerIngelheimMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Boehringer Ingelheim</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherCustomersMember" xlink:label="cvac_OtherCustomersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherCustomersMember" xlink:to="cvac_OtherCustomersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Other customers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OtherCustomersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EliLillyAndCompanyMember" xlink:to="cvac_EliLillyAndCompanyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EliLillyAndCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Eli Lilly and Company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EliLillyAndCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eli Lilly.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_EliLillyAndCompanyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eli Lilly.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="ifrs-full_ProductsAndServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProductsAndServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for research services combined with an IP license.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research services combined with an IP license [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research services combined with an IP license</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsProductMember" xlink:label="cvac_IfrsProductMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsProductMember" xlink:to="cvac_IfrsProductMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Article or substance produced by nature, labor or machinery.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsProductMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ResearchAndDevelopmentServicesMember" xlink:label="cvac_ResearchAndDevelopmentServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ResearchAndDevelopmentServicesMember" xlink:to="cvac_ResearchAndDevelopmentServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for research and development services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development services [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development services</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents of disclosure of notes to the consolidated financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Notes To The Consolidated Financial Statements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CrisprTherapeuticsMember" xlink:to="cvac_CrisprTherapeuticsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CrisprTherapeuticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for CRISPR Therapeutics</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CrisprTherapeuticsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CRISPR Therapeutics</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_EliLillyMember" xlink:label="cvac_EliLillyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EliLillyMember" xlink:to="cvac_EliLillyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EliLillyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Eli Lilly</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EliLillyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Eli Lilly</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TypeOfArrangementAxis" xlink:to="cvac_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Type Of Arrangement [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Arrangements And Non-arrangement Transactions [Member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xlink:to="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GlaxosmithklineCovidAgreementMember" xlink:label="cvac_GlaxosmithklineCovidAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GlaxosmithklineCovidAgreementMember" xlink:to="cvac_GlaxosmithklineCovidAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GlaxosmithklineCovidAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Collaboration Agreement With GlaxoSmithKline COVID Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GlaxosmithklineCovidAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GlaxoSmithKline COVID Agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember" xlink:label="cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember" xlink:to="cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for termination of exclusive collobaration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Termination of Exclusive Collaboration And License Agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CollaborationAndLicenseAgreementMember" xlink:label="cvac_CollaborationAndLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CollaborationAndLicenseAgreementMember" xlink:to="cvac_CollaborationAndLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for termination of exclusive collobaration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration And License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and License Agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MilestoneRevenuesMember" xlink:label="cvac_MilestoneRevenuesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MilestoneRevenuesMember" xlink:to="cvac_MilestoneRevenuesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MilestoneRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for milestone revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MilestoneRevenuesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the Consolidated Statements of Operations</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:to="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of additional development milestone payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Development Milestone Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional development milestone payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:to="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of development milestone payment included in contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Development Milestone Payment Included In Contract Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestone payment included in contract liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UpfrontPaymentsReceivedOrReceivable" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront payments received or receivable by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payments Received Or Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and milestone payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:to="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of upfront payments of the company included in contract liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payments Included In Contract Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront and milestones payments included in contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue that was included in contract liability balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognized from upfront and milestones payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContractLiabilities" xlink:to="ifrs-full_ContractLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ContractLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsIncomeStatementLocationAxis" xlink:to="cvac_IfrsIncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsIncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by location in the income statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsIncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsIncomeStatementLocationDomain" xlink:to="cvac_IfrsIncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsIncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Location in the income statement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsIncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsCostOfSalesMember" xlink:label="cvac_IfrsCostOfSalesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsCostOfSalesMember" xlink:to="cvac_IfrsCostOfSalesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsCostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing cost of sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsCostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsCostOfSalesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of property, plant and equipment [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment [Member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PersonnelExpenses" xlink:to="cvac_PersonnelExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of personnel expenses incurred by the company during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_PersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RawMaterialsAndConsumablesUsed" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials and consumables used</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Materials</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Materials</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ThirdPartyServiceExpenses" xlink:to="cvac_ThirdPartyServiceExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ThirdPartyServiceExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses incurred by the company for third party services during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ThirdPartyServiceExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third Party Service Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_ThirdPartyServiceExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third-party services</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MaintenanceAndLeaseExpenses" xlink:to="cvac_MaintenanceAndLeaseExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MaintenanceAndLeaseExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of maintenance and lease expenses incurred by the company during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MaintenanceAndLeaseExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maintenance And Lease Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_MaintenanceAndLeaseExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maintenance and lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationAndAmortisationExpense" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization and depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization and depreciation</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherExpense" xlink:to="cvac_OtherExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_OtherExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseByNature" xlink:to="ifrs-full_ExpenseByNature_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseByNature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses, by nature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_ExpenseByNature_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term employee benefits expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Salary and salary-related expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Salary and salary-related expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses from share-based payments</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SellingAndDistributionExpensesMember" xlink:label="cvac_SellingAndDistributionExpensesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SellingAndDistributionExpensesMember" xlink:to="cvac_SellingAndDistributionExpensesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SellingAndDistributionExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for selling and distribution expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SellingAndDistributionExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and distribution expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SellingAndDistributionExpensesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and distribution expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:to="cvac_IfrsResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption in which the reported facts about research and development expense have been included.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PatentsAndFeesToRegisterLegalRight" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expenses incurred by the company for registering a legal right.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents And Fees To Register Legal Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patents and fees to register a legal right</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract" xlink:label="cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract" xlink:to="cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of increase in R&amp;D expenses due to reversal of provision for onerous contracts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in Research and Development Expenses due to Reversal of Provision for Onerous Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in research and development expenses due to reversal of provision for onerous contracts</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsProvisionForLossOnContracts" xlink:label="cvac_IfrsProvisionForLossOnContracts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsProvisionForLossOnContracts" xlink:to="cvac_IfrsProvisionForLossOnContracts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsProvisionForLossOnContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of provision for loss on contracts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsProvisionForLossOnContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Provision For Loss on Contracts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsProvisionForLossOnContracts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated contract termination provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xlink:to="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase in expense related to in-effective set-up activities and settlement costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Increase In Expense Related To Ineffective Set-up activities And Settlement Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognition of expenses related to ineffective set-up activities and settlement costs</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:to="cvac_IfrsGeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing general and administrative expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsAxis" xlink:to="ifrs-full_ClassesOfAssetsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of assets [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfAssetsMember" xlink:to="ifrs-full_ClassesOfAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LaboratoriesMember" xlink:label="cvac_LaboratoriesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LaboratoriesMember" xlink:to="cvac_LaboratoriesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LaboratoriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for laboratories.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LaboratoriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratories [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LaboratoriesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="ifrs-full_RightofuseAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssetsMember" xlink:to="ifrs-full_RightofuseAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use-assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfessionalFeesExpense" xlink:to="ifrs-full_ProfessionalFeesExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProfessionalFeesExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal and other professional services</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AccruedOtherLiabilityForUpFrontPayment" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AccruedOtherLiabilityForUpFrontPayment" xlink:to="cvac_AccruedOtherLiabilityForUpFrontPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of accrued other liability for up-front payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Other Liability for Up-front Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued other liability for up-front payment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TravelExpense" xlink:label="ifrs-full_TravelExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TravelExpense" xlink:to="ifrs-full_TravelExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TravelExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Travel expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TravelExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Travel expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InsuranceExpense" xlink:label="ifrs-full_InsuranceExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InsuranceExpense" xlink:to="ifrs-full_InsuranceExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InsuranceExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InsuranceExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Insurance expense</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RealEstateTransferTaxes" xlink:label="cvac_RealEstateTransferTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RealEstateTransferTaxes" xlink:to="cvac_RealEstateTransferTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RealEstateTransferTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of real estate transfer taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RealEstateTransferTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Real Estate Transfer Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RealEstateTransferTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Real estate transfer taxes</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of income recognised on compensation for contract manufacturing organizations transfer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for Contract Manufacturing organizations Transfer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for CMO/Materials transfer</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CostOfReimbursementClaim" xlink:label="cvac_CostOfReimbursementClaim" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CostOfReimbursementClaim" xlink:to="cvac_CostOfReimbursementClaim_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CostOfReimbursementClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cost of reimbursement claim.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CostOfReimbursementClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of reimbursement claim</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CostOfReimbursementClaim_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement claim</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SaleOfEquipment" xlink:label="cvac_SaleOfEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SaleOfEquipment" xlink:to="cvac_SaleOfEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of sale of equipment in operating income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SaleOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of equipment</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherOperatingIncomeGovernmentGrants" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherOperatingIncomeGovernmentGrants" xlink:to="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other operating income recognized in relation to government agencies and similar bodies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Operating Income, Government Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants and other reimbursements from government agencies and similar bodies</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ReversalOfProvisionsForPersonnelExpenses" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReversalOfProvisionsForPersonnelExpenses" xlink:to="cvac_ReversalOfProvisionsForPersonnelExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of personnel expenses reversed during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal Of Provisions For Personnel Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from reversal of provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MiscellaneousOtherOperatingIncomeOther" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MiscellaneousOtherOperatingIncomeOther" xlink:to="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of miscellaneous other operating income, classified as other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous Other Operating Income, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfGovernmentGrantsTable" xlink:label="cvac_DisclosureOfGovernmentGrantsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfGovernmentGrantsTable" xlink:to="cvac_DisclosureOfGovernmentGrantsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfGovernmentGrantsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to disclosure of government grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfGovernmentGrantsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Government Grants [Table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GovernmentGrantsAxis" xlink:to="cvac_GovernmentGrantsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GovernmentGrantsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to government grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GovernmentGrantsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Grants [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GovernmentGrantsDomain" xlink:to="cvac_GovernmentGrantsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GovernmentGrantsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information pertaining to government grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GovernmentGrantsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Grants [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for German Federal Ministry of Education and Research.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">German Federal Ministry of Education and Research</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:to="cvac_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants related to Coalition for Epidemic Preparedness Innovations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Coalition for Epidemic Preparedness Innovations</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:to="cvac_BillAndMelindaGatesFoundationBmgfMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bill &amp; Melinda Gates Foundation (BMGF)</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for development of a universal influenza vaccine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bill &amp; Melinda Gates Foundation (BMGF), Grant for development of a universal influenza vaccine</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for malaria vaccine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bill &amp; Melinda Gates Foundation (BMGF), Grant for malaria vaccine</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BundesministeriumFurBildungUndForschungMember" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BundesministeriumFurBildungUndForschungMember" xlink:to="cvac_BundesministeriumFurBildungUndForschungMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Bundesministerium fr Bildung und Forschung.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bundesministerium fr Bildung und Forschung</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GskAgreement2020Member" xlink:label="cvac_GskAgreement2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GskAgreement2020Member" xlink:to="cvac_GskAgreement2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GskAgreement2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for GSK Agreement 2020.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GskAgreement2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 GSK AGREEMENT</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:to="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Advance Purchase Agreement with European Commission</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advance Purchase Agreement with European Commission</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfGovernmentGrantsLineItems" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems" xlink:to="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Government Grants [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notes to the consolidated financial statements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromGovernmentGrants" xlink:to="ifrs-full_RevenueFromGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from government grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RevenueFromGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income from release of governmental contract liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ReimbursementOfApprovedExpenses" xlink:label="cvac_ReimbursementOfApprovedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReimbursementOfApprovedExpenses" xlink:to="cvac_ReimbursementOfApprovedExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReimbursementOfApprovedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of reimbursement of approved expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReimbursementOfApprovedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement of Approved Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ReimbursementOfApprovedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement of approved expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AmortizationOfGovernmentGrants" xlink:label="cvac_AmortizationOfGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmortizationOfGovernmentGrants" xlink:to="cvac_AmortizationOfGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmortizationOfGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of amortization of the grants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmortizationOfGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of the Government Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmortizationOfGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of the grants</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:to="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Doses of SARS-CoV-2 Can be Purchased By Member States under Advance purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaximumGrantToBeReceived" xlink:label="cvac_MaximumGrantToBeReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MaximumGrantToBeReceived" xlink:to="cvac_MaximumGrantToBeReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MaximumGrantToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of maximum grant receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MaximumGrantToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Grant To Be Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MaximumGrantToBeReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum grant</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_UpfrontPaymentReceived" xlink:label="cvac_UpfrontPaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_UpfrontPaymentReceived" xlink:to="cvac_UpfrontPaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_UpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of upfront payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_UpfrontPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront Payment Received</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsMilestonePaymentReceived" xlink:label="cvac_IfrsMilestonePaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsMilestonePaymentReceived" xlink:to="cvac_IfrsMilestonePaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of milestone payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Milestone Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment received</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsRemainingGrantIncome" xlink:label="cvac_IfrsRemainingGrantIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsRemainingGrantIncome" xlink:to="cvac_IfrsRemainingGrantIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsRemainingGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of remaining grant income classified as other operating income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsRemainingGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Remaining Grant Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsRemainingGrantIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining grant income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GovernmentGrants" xlink:label="ifrs-full_GovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GovernmentGrants" xlink:to="ifrs-full_GovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants received and deferred</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaximumUnspentFundsReimbursable" xlink:label="cvac_MaximumUnspentFundsReimbursable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MaximumUnspentFundsReimbursable" xlink:to="cvac_MaximumUnspentFundsReimbursable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MaximumUnspentFundsReimbursable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of maximum unspent funds reimbursable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MaximumUnspentFundsReimbursable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Unspent Funds Reimbursable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MaximumUnspentFundsReimbursable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum unspent funds reimbursable</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PartnershipAgreementMaximumAmount" xlink:label="cvac_PartnershipAgreementMaximumAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PartnershipAgreementMaximumAmount" xlink:to="cvac_PartnershipAgreementMaximumAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PartnershipAgreementMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount agreed under the partnership agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PartnershipAgreementMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partnership Agreement, Maximum Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PartnershipAgreementMaximumAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount under the partnership agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PartnershipAgreementTerm" xlink:label="cvac_PartnershipAgreementTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PartnershipAgreementTerm" xlink:to="cvac_PartnershipAgreementTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PartnershipAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the partnership agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PartnershipAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partnership Agreement, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PartnershipAgreementTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the partnership agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:to="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which the costs are to be covered by the funds received under the partnership agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partnership Agreement, Period Of Costs To Be Covered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which the costs are to be covered</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from government grants, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government grants</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xlink:to="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount pertaining to grants deducted from the carrying amount of qualifying assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount Deducted From Carrying Amount Of Qualifying Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount deducted from the carrying amount of qualifying assets</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfAdditionalGrantsReceived" xlink:label="cvac_NumberOfAdditionalGrantsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfAdditionalGrantsReceived" xlink:to="cvac_NumberOfAdditionalGrantsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfAdditionalGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional grants received by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfAdditionalGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Additional Grants Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfAdditionalGrantsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of additional grants received</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from government grants and similar bodies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipts from Government Grants Classified as Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant amount received/eligible to receive</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for consideration for set-up activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for Contract Manufacturing organizations Transfer, Consideration for Set-up Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation consist for set-up activities</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for Manufacturing Interim Period Reimbursable Expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation for Contract Manufacturing organizations Transfer, Manufacturing Interim Period Reimbursable Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reimbursement of prepayments</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xlink:to="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of provisions reversed due to certain reserved capacity taken over from the group.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal Of Provision Recognized Due to Certain Reserved Capacity Taken Over</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversal of provision recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of share capital [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreferenceSharesMember" xlink:to="ifrs-full_PreferenceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreferenceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PreferenceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsSaleOfStockAxis" xlink:to="cvac_IfrsSaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsSaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by type of sale of the entity's stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsSaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsSaleOfStockDomain" xlink:to="cvac_IfrsSaleOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsSaleOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsSaleOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsSaleOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Sale of Stock</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsOverAllotmentOptionMember" xlink:label="cvac_IfrsOverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsOverAllotmentOptionMember" xlink:to="cvac_IfrsOverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsOverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right given to the underwriter to sell additional shares over the initial allotment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsOverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsOverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Over-Allotment Option</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued Capital and Reserves</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notional value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xlink:to="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share split ratio</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AtMarketOfferingProgramMember" xlink:label="cvac_AtMarketOfferingProgramMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AtMarketOfferingProgramMember" xlink:to="cvac_AtMarketOfferingProgramMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AtMarketOfferingProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to at the market offering program.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AtMarketOfferingProgramMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ATM Offering Program</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FollowOnPublicOfferingMember" xlink:to="cvac_FollowOnPublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to follow on public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FollowOnPublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Follow-on public offering, incl. Greenshoe</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:to="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSharesIssuedPricePerShare" xlink:label="cvac_IfrsSharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsSharesIssuedPricePerShare" xlink:to="cvac_IfrsSharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsSharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per share or per unit amount of equity securities issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsSharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsSharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per shares issued in follow-on public offering</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:to="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of aggregate gross proceeds receivable from issuance of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate Gross Proceeds Receivable From Issuing Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate gross proceeds</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve" xlink:label="cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve" xlink:to="cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of additional offering costs recognized as reduction to capital reserve.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Offering Costs Recognized As Reduction To Capital Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional offering costs recognized as reduction to capital reserve</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RemainingAuthorizedForSaleValue" xlink:label="cvac_RemainingAuthorizedForSaleValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RemainingAuthorizedForSaleValue" xlink:to="cvac_RemainingAuthorizedForSaleValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RemainingAuthorizedForSaleValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of remaining authorized for sale value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RemainingAuthorizedForSaleValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining Authorized For Sale Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RemainingAuthorizedForSaleValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining authorized for sale value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareIssueRelatedCost" xlink:to="ifrs-full_ShareIssueRelatedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issue related cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ShareIssueRelatedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering costs for legal, accounting, printing and registration fees</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CapitalIncreaseByGenmabMember" xlink:label="cvac_CapitalIncreaseByGenmabMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CapitalIncreaseByGenmabMember" xlink:to="cvac_CapitalIncreaseByGenmabMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CapitalIncreaseByGenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Genmab, capital increase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CapitalIncreaseByGenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genmab Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CapitalIncreaseByGenmabMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Genmab Investment</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PrivatePlacementIsa2020Member" xlink:label="cvac_PrivatePlacementIsa2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PrivatePlacementIsa2020Member" xlink:to="cvac_PrivatePlacementIsa2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PrivatePlacementIsa2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for private Placement "ISA 2020".</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PrivatePlacementIsa2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Private Investment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PrivatePlacementIsa2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2020 Private Investment</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_InitialPublicOfferingAndPrivatePlacementMember" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_InitialPublicOfferingAndPrivatePlacementMember" xlink:to="cvac_InitialPublicOfferingAndPrivatePlacementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for initial public offering and private placement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering and Private Placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial Public Offering and Private Placement</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExerciseOfGreenshoeMember" xlink:label="cvac_ExerciseOfGreenshoeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExerciseOfGreenshoeMember" xlink:to="cvac_ExerciseOfGreenshoeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExerciseOfGreenshoeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for exercise of Greenshoe.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExerciseOfGreenshoeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise "Greenshoe"</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ExerciseOfGreenshoeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise "Greenshoe"</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PublicOfferingMember" xlink:label="cvac_PublicOfferingMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PublicOfferingMember" xlink:to="cvac_PublicOfferingMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to follow on public offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Offering [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PublicOfferingMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public Offering</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SeriesSharesMember" xlink:label="cvac_SeriesSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SeriesSharesMember" xlink:to="cvac_SeriesSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SeriesSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Series A shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SeriesSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SeriesSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SeriesCSharesMember" xlink:label="cvac_SeriesCSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SeriesCSharesMember" xlink:to="cvac_SeriesCSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SeriesCSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Series C shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SeriesCSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SeriesCSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share transaction</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CommonSharesIssuedAndOutstanding" xlink:to="cvac_CommonSharesIssuedAndOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares issued and outstanding for during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Shares Issued And Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares issued and outstanding ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="cvac_CommonSharesIssuedAndOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common shares issued and outstanding beginning</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseInNumberOfSharesOutstanding" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase in the number of shares outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase In Number Of Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Investment</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ShareOptionExercises" xlink:label="cvac_ShareOptionExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ShareOptionExercises" xlink:to="cvac_ShareOptionExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ShareOptionExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of share option exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ShareOptionExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Option Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ShareOptionExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share option exercises</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xlink:to="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This element represents for decrease in number of shares due to treasury of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease In Number Of Shares Due To Treasury Of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_StockIssuedDuringPeriodForExercises" xlink:label="cvac_StockIssuedDuringPeriodForExercises" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_StockIssuedDuringPeriodForExercises" xlink:to="cvac_StockIssuedDuringPeriodForExercises_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_StockIssuedDuringPeriodForExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock issued during the period, upon exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_StockIssuedDuringPeriodForExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, For Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_StockIssuedDuringPeriodForExercises_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share issuances for exercises</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_StockIssuanceDuringPeriodForExistingShareholders" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_StockIssuanceDuringPeriodForExistingShareholders" xlink:to="cvac_StockIssuanceDuringPeriodForExistingShareholders_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new stock issued during the period for existing shareholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issuance During Period For Existing Shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued to former shareholders of Frame Pharmaceuticals</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" xlink:label="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" xlink:to="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares issued for RSU deliveries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Issued on Exercise of Options and RSU Deliveries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued for LTIP option exercises and RSU deliveries</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfSharesIssuedForRsuDeliveries" xlink:label="cvac_NumberOfSharesIssuedForRsuDeliveries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfSharesIssuedForRsuDeliveries" xlink:to="cvac_NumberOfSharesIssuedForRsuDeliveries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfSharesIssuedForRsuDeliveries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of shares issued for RSU deliveries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfSharesIssuedForRsuDeliveries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Issued for RSU Deliveries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfSharesIssuedForRsuDeliveries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued for RSU deliveries</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PlanNameAxis" xlink:label="cvac_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PlanNameAxis" xlink:to="cvac_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by plan name for share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PlanNameDomain" xlink:label="cvac_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PlanNameDomain" xlink:to="cvac_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan name for share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in cost of sales.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets, In Cost of Sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses" xlink:label="cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses" xlink:to="cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSalesAndMarketingExpenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling and distribution expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Research And Development Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In General And Administrative Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in other operating expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Other Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating expenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:to="cvac_BenefitExpenseRecognizedForShareBasedPayment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of benefit expense benefit recognized for share-based payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Benefit Expense Recognized For Share Based Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LongTermIncentivePlanMember" xlink:to="cvac_LongTermIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LongTermIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Long-Term Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LongTermIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LTIP Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LongTermIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LTIP Stock Options</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsRestrictedStockUnitMember" xlink:label="cvac_IfrsRestrictedStockUnitMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsRestrictedStockUnitMember" xlink:to="cvac_IfrsRestrictedStockUnitMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsRestrictedStockUnitMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Restricted stock unit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsRestrictedStockUnitMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU Supervisory Board</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsRestrictedStockUnitMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSU Supervisory Board</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NewVirtualStockOptionsPlanMember" xlink:label="cvac_NewVirtualStockOptionsPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NewVirtualStockOptionsPlanMember" xlink:to="cvac_NewVirtualStockOptionsPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NewVirtualStockOptionsPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Virtual stock option plan II.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NewVirtualStockOptionsPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New VSOP.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_NewVirtualStockOptionsPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New VSOP</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PriorVirtualStockOptionsPlanMember" xlink:label="cvac_PriorVirtualStockOptionsPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PriorVirtualStockOptionsPlanMember" xlink:to="cvac_PriorVirtualStockOptionsPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PriorVirtualStockOptionsPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Virtual stock option plan I.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PriorVirtualStockOptionsPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior VSOP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PriorVirtualStockOptionsPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior VSOP</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LongTermIncentivePlanAndRestrictedStockUnitMember" xlink:label="cvac_LongTermIncentivePlanAndRestrictedStockUnitMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LongTermIncentivePlanAndRestrictedStockUnitMember" xlink:to="cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Long-Term Incentive Plan and Restricted stock units.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LTIP RSU</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseRecognizedForEmployeeServices" xlink:label="cvac_ExpenseRecognizedForEmployeeServices" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseRecognizedForEmployeeServices" xlink:to="cvac_ExpenseRecognizedForEmployeeServices_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense recognized for employee services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense Recognized For Employee Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExerciseOfOptionsMember" xlink:label="cvac_ExerciseOfOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExerciseOfOptionsMember" xlink:to="cvac_ExerciseOfOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExerciseOfOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for exercise of options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExerciseOfOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ExerciseOfOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of options</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefScientificOfficerMember" xlink:label="cvac_ChiefScientificOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefScientificOfficerMember" xlink:to="cvac_ChiefScientificOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefScientificOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Chief Scientific Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefScientificOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Scientific Officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChiefScientificOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Chief Scientific Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xlink:to="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Person with designation of Chief operating officer and Chief development officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Operating Officer and Chief Development Officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Operating Officer and Chief Development Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Chief Business Officer and Chief Commercial Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Business Officer and Chief Commercial Officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Business Officer and Chief Commercial Officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefOperatingOfficerMember" xlink:to="srt_ChiefOperatingOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Operating Officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefOperatingOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Operating Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefDevelopmentOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefDevelopmentOfficerMember" xlink:to="cvac_ChiefDevelopmentOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefDevelopmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Chief Development Officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefDevelopmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Development Officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChiefDevelopmentOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Development Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ThenChiefExecutiveOfficerMember" xlink:label="cvac_ThenChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ThenChiefExecutiveOfficerMember" xlink:to="cvac_ThenChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Dan Menichella, then Chief Executive Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">the Chief Executive Officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ThenChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">the Chief Executive Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ManagementBoardMember" xlink:label="cvac_ManagementBoardMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ManagementBoardMember" xlink:to="cvac_ManagementBoardMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ManagementBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for management board of the entity's key management personnel.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ManagementBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Management Board</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ManagementBoardMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Management Board</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:to="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for person or persons designated as part of Executive board and various key employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members of executive board and various key employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Members of executive board and various key employees</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_KeyEmployeesMember" xlink:to="cvac_KeyEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_KeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for key employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_KeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_KeyEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Key employees</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExecutiveBoardMembersMember" xlink:label="cvac_ExecutiveBoardMembersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExecutiveBoardMembersMember" xlink:to="cvac_ExecutiveBoardMembersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExecutiveBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for executive board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExecutiveBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive board members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ExecutiveBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Executive Board members</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SupervisoryBoardMembersMember" xlink:label="cvac_SupervisoryBoardMembersMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SupervisoryBoardMembersMember" xlink:to="cvac_SupervisoryBoardMembersMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SupervisoryBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for supervisory board members.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SupervisoryBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supervisory board members</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SupervisoryBoardMembersMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supervisory Board members</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefBusinessOfficerMember" xlink:label="cvac_ChiefBusinessOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChiefBusinessOfficerMember" xlink:to="cvac_ChiefBusinessOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChiefBusinessOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Chief Business Officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChiefBusinessOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Business Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChiefBusinessOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Chief Business Officer</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_FormerFrameEmployeesMember" xlink:label="cvac_FormerFrameEmployeesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FormerFrameEmployeesMember" xlink:to="cvac_FormerFrameEmployeesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FormerFrameEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Frame employee's</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FormerFrameEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Frame Employees [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_FormerFrameEmployeesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Former Frame employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MaturityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maturity [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedTimeBandsMember" xlink:to="ifrs-full_AggregatedTimeBandsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedTimeBandsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregated time bands [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Within one year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Within one year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsVestingAxis" xlink:label="cvac_IfrsVestingAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsVestingAxis" xlink:to="cvac_IfrsVestingAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsVestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information by vesting schedule of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsVestingAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Vesting [Axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsVestingDomain" xlink:to="cvac_IfrsVestingDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsVestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting schedule of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsVestingDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Vesting [Domain]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First tranche</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">First tranche</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_VirtualSharesProgramIiMember" xlink:to="cvac_VirtualSharesProgramIiMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_VirtualSharesProgramIiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Virtual shares program II (New VSOP).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_VirtualSharesProgramIiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New VSOP</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_VirtualSharesProgramIiMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New VSOP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from share-based payment transactions with employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based based payments expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options exercised in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options exercised</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfKeyEmployees" xlink:label="cvac_NumberOfKeyEmployees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfKeyEmployees" xlink:to="cvac_NumberOfKeyEmployees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfKeyEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of key employees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfKeyEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Key Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfKeyEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of key employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSU's awarded</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:to="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of other equity instruments settled in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Other Equity Instruments Settled In Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSUs settled</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price of share options exercised in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Average share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from equity-settled share-based payment transactions in which goods or services received did not qualify for recognition as assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Benefit expenses recognized</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu" xlink:label="cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu" xlink:to="cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets Rsu. [Refer: Expense from share-based payment transactions]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhicGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsin Rsu</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses recognized with RSU</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSU awards granted</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:to="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the right to exercise percentage of vested virtual shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right To Exercise Percentage Of Vested Virtual Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right to exercise percentage of vested virtual shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Options exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereof exercisable</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LockUpPeriodAfterInitialListing" xlink:label="cvac_LockUpPeriodAfterInitialListing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LockUpPeriodAfterInitialListing" xlink:to="cvac_LockUpPeriodAfterInitialListing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LockUpPeriodAfterInitialListing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the lock-up period, which is days after the initial listing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LockUpPeriodAfterInitialListing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">lock Up Period, After Initial Listing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LockUpPeriodAfterInitialListing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lock-up period</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProvisionForEmployerTaxes" xlink:to="cvac_ProvisionForEmployerTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProvisionForEmployerTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of provision for employer taxes arising according to US regulations for future exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProvisionForEmployerTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for Employer Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ProvisionForEmployerTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for employer taxes</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AmountOfLiabilityCashClaimAwards" xlink:label="cvac_AmountOfLiabilityCashClaimAwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountOfLiabilityCashClaimAwards" xlink:to="cvac_AmountOfLiabilityCashClaimAwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountOfLiabilityCashClaimAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of liability recognized in financial statements towards cash claim of Awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountOfLiabilityCashClaimAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Liability, Cash Claim Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmountOfLiabilityCashClaimAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of liability, cash claim awards</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AmountOfRestrictedStockUnitsReceived" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AmountOfRestrictedStockUnitsReceived" xlink:to="cvac_AmountOfRestrictedStockUnitsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Restricted Stock Units Received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Restricted Stock Units Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of restricted stock units received</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:to="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of share options vested in a share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Share Options Vested In Share-Based Payment Arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about intangible assets [table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [axis]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossCarryingAmountMember" xlink:to="ifrs-full_GrossCarryingAmountMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GrossCarryingAmountMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition costs</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CumulativeAmortizationAndImpairmentMember" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for accumulated depreciation, amortization and impairment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Amortization And Impairment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative Amortization And Impairment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cumulative amortization and impairment charges</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Carrying Amount of Acquisition Cost [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of intangible assets and goodwill [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets and goodwill [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SoftwareMember" xlink:label="cvac_SoftwareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_SoftwareMember" xlink:to="cvac_SoftwareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_SoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The member stands for software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_SoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Software [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_SoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LicencesMember" xlink:to="ifrs-full_LicencesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LicencesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licence [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LicencesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licenses</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TechnologyMember" xlink:label="cvac_TechnologyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TechnologyMember" xlink:to="cvac_TechnologyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TechnologyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TechnologyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technology [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_TechnologyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technology</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="ifrs-full_GoodwillMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodwillMember" xlink:to="ifrs-full_GoodwillMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GoodwillMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GoodwillMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwil</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdvancePaymentsIntangibleAssetMember" xlink:label="cvac_AdvancePaymentsIntangibleAssetMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AdvancePaymentsIntangibleAssetMember" xlink:to="cvac_AdvancePaymentsIntangibleAssetMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AdvancePaymentsIntangibleAssetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for advance payments, intangible asset.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AdvancePaymentsIntangibleAssetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Advance Payments [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AdvancePaymentsIntangibleAssetMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwil</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LicensesSoftwareAndPrepaymentsMember" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LicensesSoftwareAndPrepaymentsMember" xlink:to="cvac_LicensesSoftwareAndPrepaymentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">licenses, software and prepayments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">licenses, software and prepayments [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about intangible assets [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions other than through business combinations, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through transfers, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortisation, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through net exchange differences, intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="ifrs-full_BuildingsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BuildingsMember" xlink:to="ifrs-full_BuildingsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BuildingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Buildings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_BuildingsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Buildings</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:to="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for technical equipment and machines and other equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technical equipment and machines [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Technical equipment and machines</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other property, plant and equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other equipment, furniture and fixtures:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ConstructionInProgressMember" xlink:to="ifrs-full_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets under construction</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CompanyOwnedGmpIvFacilityMember" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CompanyOwnedGmpIvFacilityMember" xlink:to="cvac_CompanyOwnedGmpIvFacilityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for company-owned GMP IV facility.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company-owned GMP IV facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Company-owned GMP IV facility</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xlink:to="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for equipment physically located at the CMO facilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment physically located at the CMO facilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment physically located at the CMO facilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about property, plant and equipment [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions other than through business combinations, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:to="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease through classified as held for sale, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disposals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through transfers from construction in progress, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassifications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment loss recognised in profit or loss, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through net exchange differences, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through transfers, property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Attributions</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xlink:to="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of increase in PPE off set by impairment in equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase In Property and Equipment Off Set By Impairment of Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Partial offset of increase in property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GrossBookValueOfCmoEquipmentHeldForSale" xlink:label="cvac_GrossBookValueOfCmoEquipmentHeldForSale" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_GrossBookValueOfCmoEquipmentHeldForSale" xlink:to="cvac_GrossBookValueOfCmoEquipmentHeldForSale_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_GrossBookValueOfCmoEquipmentHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of gross book value of CMO-Equipment held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_GrossBookValueOfCmoEquipmentHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross book value of CMO-Equipment held for sale</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ImpairmentOfAssetsHeldForSale" xlink:label="cvac_ImpairmentOfAssetsHeldForSale" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ImpairmentOfAssetsHeldForSale" xlink:to="cvac_ImpairmentOfAssetsHeldForSale_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ImpairmentOfAssetsHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of impairment loss on assets held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ImpairmentOfAssetsHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Assets Held for Sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ImpairmentOfAssetsHeldForSale_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of assets held for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoriesAtFairValueLessCostsToSell" xlink:label="ifrs-full_InventoriesAtFairValueLessCostsToSell" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoriesAtFairValueLessCostsToSell" xlink:to="ifrs-full_InventoriesAtFairValueLessCostsToSell_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InventoriesAtFairValueLessCostsToSell_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories, at fair value less costs to sell</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_InventoriesAtFairValueLessCostsToSell_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories fair value costs to sell</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AssetsHeldForSaleNetBookValueSold" xlink:label="cvac_AssetsHeldForSaleNetBookValueSold" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AssetsHeldForSaleNetBookValueSold" xlink:to="cvac_AssetsHeldForSaleNetBookValueSold_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AssetsHeldForSaleNetBookValueSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The net book value sold of assets held for sale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AssetsHeldForSaleNetBookValueSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets Held for Sale, Net Book Value Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AssetsHeldForSaleNetBookValueSold_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets held for sale with a net book value sold</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_InventoriesTable" xlink:label="cvac_InventoriesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_InventoriesTable" xlink:to="cvac_InventoriesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_InventoriesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_InventoriesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories [Table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_InventoriesLineItem" xlink:label="cvac_InventoriesLineItem" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_InventoriesLineItem" xlink:to="cvac_InventoriesLineItem_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_InventoriesLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_InventoriesLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories [Line item</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_InventoriesLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_InventoriesLineItem_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RawMaterials" xlink:label="ifrs-full_RawMaterials" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RawMaterials" xlink:to="ifrs-full_RawMaterials_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current raw materials</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RawMaterials_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncreaseDecreaseInInventory" xlink:label="cvac_IncreaseDecreaseInInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncreaseDecreaseInInventory" xlink:to="cvac_IncreaseDecreaseInInventory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncreaseDecreaseInInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in inventory during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncreaseDecreaseInInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncreaseDecreaseInInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in inventory</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NetValueOfInventoryTransferred" xlink:label="cvac_NetValueOfInventoryTransferred" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NetValueOfInventoryTransferred" xlink:to="cvac_NetValueOfInventoryTransferred_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NetValueOfInventoryTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of net value of inventory transferred during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NetValueOfInventoryTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Value Of Inventory Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NetValueOfInventoryTransferred_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net inventory transferred</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsInventoryFinishedGoodsWriteDown" xlink:label="cvac_IfrsInventoryFinishedGoodsWriteDown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsInventoryFinishedGoodsWriteDown" xlink:to="cvac_IfrsInventoryFinishedGoodsWriteDown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsInventoryFinishedGoodsWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expense recognised related to the write-down of inventories, finished goods.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsInventoryFinishedGoodsWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Inventory, Finished Goods, Write down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsInventoryFinishedGoodsWriteDown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods written down</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinishedGoods" xlink:label="ifrs-full_FinishedGoods" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinishedGoods" xlink:to="ifrs-full_FinishedGoods_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current finished goods</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinishedGoods_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finished goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InventoryWritedown2011" xlink:to="ifrs-full_InventoryWritedown2011_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InventoryWritedown2011_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory write-down</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_InventoryWritedown2011_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Raw materials write-offs and scrap</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xlink:to="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of prepaid compensation for contract manufacturing organizations transfer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Compensation for Contract Manufacturing organizations Transfer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments for compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="ifrs-full_CurrentAdvancesToSuppliers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAdvancesToSuppliers" xlink:to="ifrs-full_CurrentAdvancesToSuppliers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current advances to suppliers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments for future service agreements and goods</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:to="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receivables from taxes other than income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax claims</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:to="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current receivables from taxes other than income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding VAT refund claims</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CurrentGrantReceivable" xlink:label="cvac_CurrentGrantReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurrentGrantReceivable" xlink:to="cvac_CurrentGrantReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurrentGrantReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of grant receivable, classified as current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurrentGrantReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Grant Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CurrentGrantReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current grant receivable</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsCurrentGrantReceivables" xlink:label="cvac_IfrsCurrentGrantReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsCurrentGrantReceivables" xlink:to="cvac_IfrsCurrentGrantReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsCurrentGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of current grant receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsCurrentGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Current Grant Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsCurrentGrantReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grant receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" xlink:to="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 1 into Level 2 of fair value hierarchy, assets held at end of reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from Level 1 to Level 2, Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" xlink:to="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 2 into Level 1 of fair value hierarchy, assets held at end of reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from Level 2 to Level 1, Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" xlink:to="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 1 into Level 2 of fair value hierarchy, liabilities held at end of reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from Level 1 to Level 2, Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" xlink:to="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 2 into Level 1 of fair value hierarchy, liabilities held at end of reporting period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfer from Level 2 to Level 1, Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers into Level 3 of fair value hierarchy, assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers into Level 3, Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 3 of fair value hierarchy, assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 3, Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers into Level 3 of fair value hierarchy, liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers into Level 3, Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 3 of fair value hierarchy, liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Transfers out of Level 3, Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current trade payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade payables</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LicenseFeePayable" xlink:label="cvac_LicenseFeePayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LicenseFeePayable" xlink:to="cvac_LicenseFeePayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LicenseFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of license fee payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LicenseFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License Fee Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LicenseFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">License fees payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentPayables" xlink:to="ifrs-full_OtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_OtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChangeInTradeAndOtherPayables" xlink:label="cvac_ChangeInTradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChangeInTradeAndOtherPayables" xlink:to="cvac_ChangeInTradeAndOtherPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChangeInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of change in trade and other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChangeInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Trade and Other Payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ChangeInTradeAndOtherPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of decrease in trade and other payables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:to="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payables on social security and taxes other than income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll-related taxes and social-security liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsOtherLiabilitiesAbstract" xlink:label="cvac_IfrsOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsOtherLiabilitiesAbstract" xlink:to="cvac_IfrsOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities and provisions.</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfOtherLiabilitiesTable" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable" xlink:to="cvac_DisclosureOfOtherLiabilitiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule disclosing information related to other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Other liabilities [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfContractsAxis" xlink:to="ifrs-full_TypesOfContractsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfContractsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of contracts [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfContractsMember" xlink:to="ifrs-full_TypesOfContractsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfContractsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of contracts [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:to="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NA</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Other liabilities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities and provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChangeInOtherLiabilities" xlink:label="cvac_ChangeInOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ChangeInOtherLiabilities" xlink:to="cvac_ChangeInOtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ChangeInOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in other liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ChangeInOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in Other Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_ChangeInOtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in other liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProvisionsForDecreaseInContractTerminations" xlink:label="cvac_ProvisionsForDecreaseInContractTerminations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProvisionsForDecreaseInContractTerminations" xlink:to="cvac_ProvisionsForDecreaseInContractTerminations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProvisionsForDecreaseInContractTerminations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) in contract terminations provisions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProvisionsForDecreaseInContractTerminations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provisions For Decrease In Contract Terminations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProvisionsForDecreaseInContractTerminations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in contract terminations provisions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInOtherProvisions" xlink:label="ifrs-full_ChangesInOtherProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ChangesInOtherProvisions" xlink:to="ifrs-full_ChangesInOtherProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ChangesInOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in other provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ChangesInOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in provisions</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherMiscellaneousNonCurrentLiabilities" xlink:label="cvac_OtherMiscellaneousNonCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherMiscellaneousNonCurrentLiabilities" xlink:to="cvac_OtherMiscellaneousNonCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherMiscellaneousNonCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of other miscellaneous non-current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherMiscellaneousNonCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Miscellaneous Non-current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OtherMiscellaneousNonCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other (e.g. license liabilities, Deferred Tax Liability)</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PersonnelAccruedLiabilities" xlink:label="cvac_PersonnelAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PersonnelAccruedLiabilities" xlink:to="cvac_PersonnelAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PersonnelAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of personnel accrued liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PersonnelAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PersonnelAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Personnel accrued liabilities (e.g. bonus, vacation)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentGovernmentGrants" xlink:label="ifrs-full_CurrentGovernmentGrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentGovernmentGrants" xlink:to="ifrs-full_CurrentGovernmentGrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current government grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentGovernmentGrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grants from government agencies and similar bodies</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OutstandingInvoicesCurrent" xlink:label="cvac_OutstandingInvoicesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OutstandingInvoicesCurrent" xlink:to="cvac_OutstandingInvoicesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OutstandingInvoicesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of current outstanding invoices.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OutstandingInvoicesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding Invoices, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OutstandingInvoicesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding invoices</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProfessionalFessCurrent" xlink:label="cvac_ProfessionalFessCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ProfessionalFessCurrent" xlink:to="cvac_ProfessionalFessCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ProfessionalFessCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of current professional fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ProfessionalFessCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional Fess, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ProfessionalFessCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CurrentValueAddedTaxAndOtherTaxesPayables" xlink:label="cvac_CurrentValueAddedTaxAndOtherTaxesPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CurrentValueAddedTaxAndOtherTaxesPayables" xlink:to="cvac_CurrentValueAddedTaxAndOtherTaxesPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CurrentValueAddedTaxAndOtherTaxesPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of current value added tax and other taxes payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CurrentValueAddedTaxAndOtherTaxesPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Value Added Tax And Other Taxes Payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CurrentValueAddedTaxAndOtherTaxesPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">VAT and other taxes (real estate transfer taxes)</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherLiabilityCurrent" xlink:label="cvac_OtherLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_OtherLiabilityCurrent" xlink:to="cvac_OtherLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_OtherLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_OtherLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_OtherLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherLiabilities" xlink:label="ifrs-full_OtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherLiabilities" xlink:to="ifrs-full_OtherLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_OtherLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total other liabilities (current &amp; non-current)</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes" xlink:label="cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes" xlink:to="cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of accrued liability for other taxes consists of real estate transfer taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liability For Other Taxes Consists Of Real Estate Transfer Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liability for other taxes consists of real estate transfer taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of nature and extent of risks arising from financial instruments [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CurrencyAxis" xlink:to="srt_CurrencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CurrencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Currency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_AllCurrenciesDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_AllCurrenciesDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All Currencies [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="currency_USD" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_USD" xlink:to="currency_USD_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_USD_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">USD</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF" xlink:label="currency_CHF" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_CHF" xlink:to="currency_CHF_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_CHF_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CHF</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="currency_EUR" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_EUR" xlink:to="currency_EUR_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_EUR_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EUR</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP" xlink:label="currency_GBP" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="currency_GBP" xlink:to="currency_GBP_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="currency_GBP_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GBP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of risks [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksMember" xlink:to="ifrs-full_TypesOfRisksMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfRisksMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrencyRiskMember" xlink:to="ifrs-full_CurrencyRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrencyRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of financial instruments [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial instruments, class [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsCashAndCashEquivalentsMember" xlink:label="cvac_IfrsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsCashAndCashEquivalentsMember" xlink:to="cvac_IfrsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TradeAndOtherPayablesMember" xlink:label="cvac_TradeAndOtherPayablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TradeAndOtherPayablesMember" xlink:to="cvac_TradeAndOtherPayablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TradeAndOtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for trade and other payables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TradeAndOtherPayablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other payables and provision</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TradeAndOtherReceivablesMember" xlink:label="cvac_TradeAndOtherReceivablesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TradeAndOtherReceivablesMember" xlink:to="cvac_TradeAndOtherReceivablesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TradeAndOtherReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TradeAndOtherReceivablesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade And Other Receivables</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MonetaryAssetsInForeignCurrencyMember" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MonetaryAssetsInForeignCurrencyMember" xlink:to="cvac_MonetaryAssetsInForeignCurrencyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monetary Assets In Foreign Currency</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MonetaryLiabilitiesInForeignCurrencyMember" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MonetaryLiabilitiesInForeignCurrencyMember" xlink:to="cvac_MonetaryLiabilitiesInForeignCurrencyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">"This member stands for a type
 of market risk representing the
 risk that the fair value or future
 cash flows of a financial
 instrument will fluctuate
 because of changes in foreign
 exchange rates."</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monetary Liabilities In Foreign Currency</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TradeAndOtherPayablesOneMember" xlink:label="cvac_TradeAndOtherPayablesOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TradeAndOtherPayablesOneMember" xlink:to="cvac_TradeAndOtherPayablesOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TradeAndOtherPayablesOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TradeAndOtherPayablesOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade And Other Payables One</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TradeAndOtherPayablesTwoMember" xlink:label="cvac_TradeAndOtherPayablesTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TradeAndOtherPayablesTwoMember" xlink:to="cvac_TradeAndOtherPayablesTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TradeAndOtherPayablesTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TradeAndOtherPayablesTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade And Other Payables Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of nature and extent of risks arising from financial instruments [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments and risk management</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:to="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk exposure associated with instruments sharing characteristic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exposure in (foreign) currency</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DiluteEffectOfOrdinarySharesIssued" xlink:label="cvac_DiluteEffectOfOrdinarySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DiluteEffectOfOrdinarySharesIssued" xlink:to="cvac_DiluteEffectOfOrdinarySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DiluteEffectOfOrdinarySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of dilutive potential ordinary shares that relate to the assumed issuance of new shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DiluteEffectOfOrdinarySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dilute Effect Of Ordinary Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DiluteEffectOfOrdinarySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New issue of shares for the purpose of calculating earning per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of ordinary shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted number of shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transactions between related parties [table]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BaronJeanStephenneMember" xlink:label="cvac_BaronJeanStephenneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BaronJeanStephenneMember" xlink:to="cvac_BaronJeanStephenneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BaronJeanStephenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Baron Jean Stephenne.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BaronJeanStephenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Baron Jean Stephenne [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_BaronJeanStephenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Baron Jean Stephenne</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VincentStphenneMember" xlink:label="cvac_VincentStphenneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_VincentStphenneMember" xlink:to="cvac_VincentStphenneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_VincentStphenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Vincent Stphenne.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_VincentStphenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vincent Stephenne [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_VincentStphenneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vincent Stephenne</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AntonyBlancMember" xlink:label="cvac_AntonyBlancMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_AntonyBlancMember" xlink:to="cvac_AntonyBlancMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_AntonyBlancMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Antony Blanc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_AntonyBlancMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antony Blanc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_AntonyBlancMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antony Blanc</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of related parties [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for related parties [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DietmarHoppMember" xlink:label="cvac_DietmarHoppMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DietmarHoppMember" xlink:to="cvac_DietmarHoppMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DietmarHoppMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for Mr. Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG , a majority shareholder of the entity, a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DietmarHoppMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dietmar Hopp [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DietmarHoppMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dietmar Hopp</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" xlink:label="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" xlink:to="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Dievini Hopp BioTech holding GmbH &amp; Co. KG.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dievini Hopp BioTech holding GmbH &amp; Co. KG [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dievini Hopp BioTech holding GmbH &amp; Co. KG</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ClarentisSrlMember" xlink:label="cvac_ClarentisSrlMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ClarentisSrlMember" xlink:to="cvac_ClarentisSrlMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ClarentisSrlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for Clarentis SRL, wholly owned consulting company of Antony Blanc, Chief business officer, a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ClarentisSrlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clarentis SRL [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ClarentisSrlMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clarentis SRL</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BepharbelManufacturingS.aMember" xlink:label="cvac_BepharbelManufacturingS.aMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BepharbelManufacturingS.aMember" xlink:to="cvac_BepharbelManufacturingS.aMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BepharbelManufacturingS.aMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for BePharBel Manufacturing S.A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BepharbelManufacturingS.aMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BePharBel Manufacturing S.A [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_BepharbelManufacturingS.aMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BePharBel Manufacturing S.A</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BarkerBiomedicalGmbhMember" xlink:label="cvac_BarkerBiomedicalGmbhMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_BarkerBiomedicalGmbhMember" xlink:to="cvac_BarkerBiomedicalGmbhMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_BarkerBiomedicalGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for barker biomedical GmbH member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_BarkerBiomedicalGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Barker BioMedical GmbH [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_BarkerBiomedicalGmbhMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Barker BioMedical GmbH</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CraigToomanMember" xlink:label="cvac_CraigToomanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_CraigToomanMember" xlink:to="cvac_CraigToomanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_CraigToomanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for craig tooman.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_CraigToomanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Craig Tooman [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_CraigToomanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Craig Tooman</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RittershausRechtsanwaelteMember" xlink:label="cvac_RittershausRechtsanwaelteMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RittershausRechtsanwaelteMember" xlink:to="cvac_RittershausRechtsanwaelteMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RittershausRechtsanwaelteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Member stands for Rittershaus Rechtsanwaelte , a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RittershausRechtsanwaelteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rittershaus Rechtsanwaelte [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RittershausRechtsanwaelteMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rittershaus Rechtsanwaelte</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MariolaFotinMleczekMember" xlink:label="cvac_MariolaFotinMleczekMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MariolaFotinMleczekMember" xlink:to="cvac_MariolaFotinMleczekMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MariolaFotinMleczekMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Mariola Fotin-Mleczek.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MariolaFotinMleczekMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mariola Fotin-Mleczek [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_MariolaFotinMleczekMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mariola Fotin-Mleczek</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_FlorianVonDerMlbeMember" xlink:label="cvac_FlorianVonDerMlbeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_FlorianVonDerMlbeMember" xlink:to="cvac_FlorianVonDerMlbeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_FlorianVonDerMlbeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Florian von der Mlbe.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_FlorianVonDerMlbeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Florian von der Mlbe [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_FlorianVonDerMlbeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Florian von der Mlbe</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_Dr.IngmarHrrMember" xlink:label="cvac_Dr.IngmarHrrMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_Dr.IngmarHrrMember" xlink:to="cvac_Dr.IngmarHrrMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_Dr.IngmarHrrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Dr. Ingmar Hrr.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_Dr.IngmarHrrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dr. Ingmar Hrr [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_Dr.IngmarHrrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dr. Ingmar Hrr</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of transactions between related parties [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party disclosures</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares received from the participants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Number Of Shares Outstanding Through Transfer From Shareholders To Entity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares received</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:to="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period of notice for termination of the agreement at the option of the party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Notice Period for Termination of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Notice period for termination at the option</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RelatedPartyTransactionConsultingFees" xlink:label="cvac_RelatedPartyTransactionConsultingFees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RelatedPartyTransactionConsultingFees" xlink:to="cvac_RelatedPartyTransactionConsultingFees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RelatedPartyTransactionConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of consulting fees incurred as a part of related party transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RelatedPartyTransactionConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Consulting Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RelatedPartyTransactionConsultingFees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting fees</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:to="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of loans received from a related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Number of Loans Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of convertible loans</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsContractualObligation" xlink:label="cvac_IfrsContractualObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IfrsContractualObligation" xlink:to="cvac_IfrsContractualObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IfrsContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IfrsContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IfrsContractualObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual obligation amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments made by entity, related party transactions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Settlement amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proportion of ownership interest in associate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity interest held</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageSharePrice2019" xlink:to="ifrs-full_WeightedAverageSharePrice2019_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageSharePrice2019_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of borrowings, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount paid</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" xlink:label="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" xlink:to="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of income tax and social security liability receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax and Social Security Liability Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax and social security liability receivable</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpensesToHandleFutureServiceAgreement" xlink:label="cvac_ExpensesToHandleFutureServiceAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpensesToHandleFutureServiceAgreement" xlink:to="cvac_ExpensesToHandleFutureServiceAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpensesToHandleFutureServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of expenses to handle future service agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpensesToHandleFutureServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses To Handle Future Service Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ExpensesToHandleFutureServiceAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses to handle future service agreement</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseRecognizedFromRelatedPartyTransaction" xlink:label="cvac_ExpenseRecognizedFromRelatedPartyTransaction" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ExpenseRecognizedFromRelatedPartyTransaction" xlink:to="cvac_ExpenseRecognizedFromRelatedPartyTransaction_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ExpenseRecognizedFromRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of expense recognized during the period from related party transaction.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ExpenseRecognizedFromRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense Recognized From Related Party Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_ExpenseRecognizedFromRelatedPartyTransaction_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense recognized from related party transaction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsAxis" xlink:to="ifrs-full_BusinessCombinationsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combinations [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for business combinations [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="ifrs-full_BusinessCombinationsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BusinessCombinationsMember" xlink:to="ifrs-full_BusinessCombinationsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BusinessCombinationsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business combinations [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfContingentLiabilitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of contingent liabilities [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ContingentLiabilitiesMember" xlink:to="ifrs-full_ContingentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ContingentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contingent liabilities [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherContingentLiabilitiesMember" xlink:label="ifrs-full_OtherContingentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherContingentLiabilitiesMember" xlink:to="ifrs-full_OtherContingentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherContingentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other contingent liabilities</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" xlink:label="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" xlink:to="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative arrangement and arrangement other than contingent liability arising from patent Infringement lawsuit .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Infringement Lawsuit</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MilestonesMember" xlink:label="cvac_MilestonesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_MilestonesMember" xlink:to="cvac_MilestonesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_MilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">These member stand for milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_MilestonesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestones</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparties [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="ifrs-full_CounterpartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparties [member]</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PatentInfringementLawsuitFilledMember" xlink:label="cvac_PatentInfringementLawsuitFilledMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PatentInfringementLawsuitFilledMember" xlink:to="cvac_PatentInfringementLawsuitFilledMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PatentInfringementLawsuitFilledMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for patent infringement lawsuit filled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PatentInfringementLawsuitFilledMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Infringement Lawsuit Filled [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PatentInfringementLawsuitFilledMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent infringement lawsuit</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PublicOfferingOfCommonSharesMember" xlink:label="cvac_PublicOfferingOfCommonSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PublicOfferingOfCommonSharesMember" xlink:to="cvac_PublicOfferingOfCommonSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PublicOfferingOfCommonSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for public offering of common shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PublicOfferingOfCommonSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Public offering of common shares</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled" xlink:label="cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled" xlink:to="cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of intellectual property rights infringement case filled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Intellectual Property Rights Infringement Case Filled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of intellectual property rights infringement case filled</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase" xlink:label="cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase" xlink:to="cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the total number of intellectual property rights infringement case.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Number Of Intellectual Property Rights Infringement Case</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total number of intellectual property rights infringement case</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfPatentOnWhichNullityActionIsFilled" xlink:label="cvac_NumberOfPatentOnWhichNullityActionIsFilled" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfPatentOnWhichNullityActionIsFilled" xlink:to="cvac_NumberOfPatentOnWhichNullityActionIsFilled_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfPatentOnWhichNullityActionIsFilled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of patent on which nullity action is filled.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfPatentOnWhichNullityActionIsFilled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Patent On Which Nullity Action Is Filled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_NumberOfPatentOnWhichNullityActionIsFilled_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patent on which nullity action is filled</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" xlink:label="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" xlink:to="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of trading days used for calculation of preliminary total purchase price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preliminary Purchase Price Allocation, Number of Trading Days Used</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of trading days</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" xlink:label="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" xlink:to="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the signing date share price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preliminary Purchase Price Allocation, Calculation of Volume Weighted Average Share Price over Sixty Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Signing date share price</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" xlink:label="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" xlink:to="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the closing date share price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Price Allocation, Share Price as of Closing Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Closing date share price</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" xlink:label="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" xlink:to="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the total number of milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Price Allocation, Number of Milestones Used for Payment of Fifty Percent of Purchase Price to be Paid in Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of milestones</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" xlink:label="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" xlink:to="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of first milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Price Allocation, Percent of First Milestone Payment Due Upon Achievement of Successful Investigational New Drug Application Filing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of first milestone payment</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" xlink:label="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" xlink:to="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of second milestone payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Price Allocation, Percent of Second Milestone Payment Due Upon Successful Proof of Mechanism in Humans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of second milestone payment</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" xlink:to="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of another entity's patents that the entity has allegedly infringed in the utility model.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Patents Allegedly Infringed, Number Of Utility Models</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of utility models infringed</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LossContingencyPatentsAllegedlyInfringedNumber" xlink:to="cvac_LossContingencyPatentsAllegedlyInfringedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of another entity's patents that the entity has allegedly infringed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Patents Allegedly Infringed, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patents infringed</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LossContingencyPatentsFoundNotInfringedNumber" xlink:label="cvac_LossContingencyPatentsFoundNotInfringedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_LossContingencyPatentsFoundNotInfringedNumber" xlink:to="cvac_LossContingencyPatentsFoundNotInfringedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_LossContingencyPatentsFoundNotInfringedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of another entity's patents that the entity was found not to have infringed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_LossContingencyPatentsFoundNotInfringedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss Contingency, Patents Found Not Infringed, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="cvac_LossContingencyPatentsFoundNotInfringedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patents that does not infringe</label>
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfMrnaVaccinesDoses" xlink:label="cvac_NumberOfMrnaVaccinesDoses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="cvac_NumberOfMrnaVaccinesDoses" xlink:to="cvac_NumberOfMrnaVaccinesDoses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="cvac_NumberOfMrnaVaccinesDoses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents number of vaccines during the  pandemic.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="cvac_NumberOfMrnaVaccinesDoses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of MRNA Vaccines Doses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current financial liabilities</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>cvac-20230630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.3.0.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/17/2023 6:46:42 PM-->
<!--Modified on: 8/17/2023 6:46:42 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#StatementInterimCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureCorporateInformation" roleURI="http://www.curevac.com/role/DisclosureCorporateInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureBasisOfPreparation" roleURI="http://www.curevac.com/role/DisclosureBasisOfPreparation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperations" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureIssuedCapitalAndReserves" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureShareBasedPayments" roleURI="http://www.curevac.com/role/DisclosureShareBasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureFixedAssets" roleURI="http://www.curevac.com/role/DisclosureFixedAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureAssetsHeldForSale" roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSale" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureInventories" roleURI="http://www.curevac.com/role/DisclosureInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosurePrepaidExpensesAndOtherAssetsCurrent" roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureFinancialAssetsAndFinancialLiabilities" roleURI="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureTradeAndOtherPayables" roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureOtherLiabilitiesAndProvisions" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureIncomeTax" roleURI="http://www.curevac.com/role/DisclosureIncomeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureEarningsPerShare" roleURI="http://www.curevac.com/role/DisclosureEarningsPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureRelatedPartyDisclosures" roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosures" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureSubsequentEvents" roleURI="http://www.curevac.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureBasisOfPreparationPolicies" roleURI="http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsTables" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureIssuedCapitalAndReservesTables" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureShareBasedPaymentsTables" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureCorporateInformationDetails" roleURI="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" roleURI="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" roleURI="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureShareBasedPaymentsExpensesDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureShareBasedPaymentsEquitySettledProgramsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureShareBasedPaymentsDetails" roleURI="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureFixedAssetsIntangibleAssetsDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" roleURI="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureAssetsHeldForSaleDetails" roleURI="http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureInventoriesDetails" roleURI="http://www.curevac.com/role/DisclosureInventoriesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" roleURI="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" roleURI="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureTradeAndOtherPayablesDetails" roleURI="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureOtherLiabilitiesAndProvisionsDetails" roleURI="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails" roleURI="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureEarningsPerShareDetails" roleURI="http://www.curevac.com/role/DisclosureEarningsPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureRelatedPartyDisclosuresDetails" roleURI="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="cvac-20230630.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://www.curevac.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_638278947975389934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentInformationTable_638278947975389934" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_638278947975389934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638278947975389934" xlink:to="dei_EntityAddressesAddressTypeAxis_638278947975389934" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_638278947975389934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis_638278947975389934" xlink:to="dei_AddressTypeDomain_638278947975389934" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember_638278947975399960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain_638278947975389934" xlink:to="dei_BusinessContactMember_638278947975399960" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_638278947975399960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_638278947975389934" xlink:to="dei_DocumentInformationLineItems_638278947975399960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638278947975399960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_DocumentType_638278947975399960" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement_638278947975399960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_DocumentRegistrationStatement_638278947975399960" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638278947975399960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_DocumentAnnualReport_638278947975399960" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638278947975399960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_DocumentTransitionReport_638278947975399960" order="4" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport_638278947975399960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_DocumentShellCompanyReport_638278947975399960" order="5" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638278947975399960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityRegistrantName_638278947975399960" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638278947975399960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_DocumentPeriodEndDate_638278947975399960" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638278947975399960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityIncorporationStateCountryCode_638278947975399960" order="8" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638278947975399960" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityAddressAddressLine1_638278947975399960" order="9" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638278947975409939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityAddressAddressLine2_638278947975409939" order="10" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638278947975409939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityAddressCityOrTown_638278947975409939" order="11" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638278947975409939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityAddressStateOrProvince_638278947975409939" order="12" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_638278947975409939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityAddressCountry_638278947975409939" order="13" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638278947975409939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityAddressPostalZipCode_638278947975409939" order="14" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638278947975409939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_CityAreaCode_638278947975409939" order="15" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638278947975409939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_LocalPhoneNumber_638278947975409939" order="16" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName_638278947975409939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_ContactPersonnelName_638278947975409939" order="17" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion_638278947975409939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_CountryRegion_638278947975409939" order="18" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress_638278947975409939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_ContactPersonnelEmailAddress_638278947975409939" order="19" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638278947975419932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_Security12bTitle_638278947975419932" order="20" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638278947975419932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_TradingSymbol_638278947975419932" order="21" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638278947975419932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_SecurityExchangeName_638278947975419932" order="22" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638278947975419932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityFileNumber_638278947975419932" order="23" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638278947975419932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityWellKnownSeasonedIssuer_638278947975419932" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638278947975419932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityCurrentReportingStatus_638278947975419932" order="25" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638278947975419932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityFilerCategory_638278947975419932" order="26" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638278947975419932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityInteractiveDataCurrent_638278947975419932" order="27" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638278947975429931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityEmergingGrowthCompany_638278947975429931" order="28" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638278947975429931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityExTransitionPeriod_638278947975429931" order="29" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard_638278947975429931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_DocumentAccountingStandard_638278947975429931" order="30" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638278947975429931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityShellCompany_638278947975429931" order="31" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638278947975429931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityCommonStockSharesOutstanding_638278947975429931" order="32" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638278947975429931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_CurrentFiscalYearEndDate_638278947975429931" order="33" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638278947975429931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_DocumentFiscalYearFocus_638278947975429931" order="34" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638278947975439930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_DocumentFiscalPeriodFocus_638278947975439930" order="35" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638278947975439930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityCentralIndexKey_638278947975439930" order="36" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638278947975439930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_AmendmentFlag_638278947975439930" order="37" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638278947975439930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_IcfrAuditorAttestationFlag_638278947975439930" order="38" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription_638278947975439930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_AmendmentDescription_638278947975439930" order="39" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638278947975439930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityVoluntaryFilers_638278947975439930" order="40" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638278947975449931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_EntityPublicFloat_638278947975449931" order="41" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638278947975449931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_AuditorName_638278947975449931" order="42" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638278947975449931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_AuditorFirmId_638278947975449931" order="43" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638278947975449931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_638278947975399960" xlink:to="dei_AuditorLocation_638278947975449931" order="44" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="StatementOfComprehensiveIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638278947975459936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638278947975459936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales_638278947975459936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_CostOfSales_638278947975459936" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_638278947975459936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense_638278947975459936" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638278947975459936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638278947975459936" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeneralAndAdministrativeExpense" xlink:label="ifrs-full_GeneralAndAdministrativeExpense_638278947975459936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_GeneralAndAdministrativeExpense_638278947975459936" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_638278947975459936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_638278947975459936" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingExpense" xlink:label="ifrs-full_MiscellaneousOtherOperatingExpense_638278947975459936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingExpense_638278947975459936" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_638278947975459936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_638278947975459936" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638278947975459936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_FinanceIncome_638278947975459936" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638278947975459936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_FinanceCosts_638278947975459936" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_638278947975459936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax_638278947975459936" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_638278947975459936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_638278947975459936" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638278947975459936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLoss_638278947975459936" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeAbstract" xlink:label="ifrs-full_OtherComprehensiveIncomeAbstract_638278947975469936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeAbstract_638278947975469936" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638278947975469936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherComprehensiveIncomeAbstract_638278947975469936" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_638278947975469936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_638278947975469936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComprehensiveIncome_638278947975469936" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_638278947975469936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare_638278947975469936" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare_638278947975469936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare_638278947975469936" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00200 - Statement - Interim Condensed Consolidated Statements of Financial Position" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract_638278947975469936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract_638278947975469936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract_638278947975469936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638278947975469936" xlink:to="ifrs-full_NoncurrentAssetsAbstract_638278947975469936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_638278947975469936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638278947975469936" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_638278947975469936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638278947975479935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638278947975469936" xlink:to="ifrs-full_PropertyPlantAndEquipment_638278947975479935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_638278947975479935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638278947975469936" xlink:to="ifrs-full_RightofuseAssets_638278947975479935" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentAssets" xlink:label="ifrs-full_OtherNoncurrentAssets_638278947975479935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638278947975469936" xlink:to="ifrs-full_OtherNoncurrentAssets_638278947975479935" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NetDeferredTaxAssets" xlink:label="ifrs-full_NetDeferredTaxAssets_638278947975479935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638278947975469936" xlink:to="ifrs-full_NetDeferredTaxAssets_638278947975479935" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_638278947975479935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638278947975469936" xlink:to="ifrs-full_NoncurrentAssets_638278947975479935" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract_638278947975479935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638278947975469936" xlink:to="ifrs-full_CurrentAssetsAbstract_638278947975479935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638278947975479935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638278947975479935" xlink:to="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638278947975479935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_638278947975479935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638278947975479935" xlink:to="ifrs-full_Inventories_638278947975479935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables_638278947975479935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638278947975479935" xlink:to="ifrs-full_CurrentTradeReceivables_638278947975479935" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets_638278947975479935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638278947975479935" xlink:to="ifrs-full_CurrentContractAssets_638278947975479935" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentFinancialAssets" xlink:label="ifrs-full_OtherCurrentFinancialAssets_638278947975479935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638278947975479935" xlink:to="ifrs-full_OtherCurrentFinancialAssets_638278947975479935" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638278947975479935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638278947975479935" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638278947975479935" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638278947975489933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638278947975479935" xlink:to="ifrs-full_CashAndCashEquivalents_638278947975489933" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638278947975489933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638278947975479935" xlink:to="ifrs-full_CurrentAssets_638278947975489933" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_638278947975489933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract_638278947975469936" xlink:to="ifrs-full_Assets_638278947975489933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_638278947975489933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_638278947975489933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract_638278947975489933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638278947975489933" xlink:to="ifrs-full_EquityAbstract_638278947975489933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_638278947975489933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638278947975489933" xlink:to="ifrs-full_IssuedCapital_638278947975489933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalReserve" xlink:label="ifrs-full_CapitalReserve_638278947975489933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638278947975489933" xlink:to="ifrs-full_CapitalReserve_638278947975489933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasuryShares" xlink:label="ifrs-full_TreasuryShares_638278947975489933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638278947975489933" xlink:to="ifrs-full_TreasuryShares_638278947975489933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_638278947975489933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638278947975489933" xlink:to="ifrs-full_RetainedEarnings_638278947975489933" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AccumulatedOtherComprehensiveIncome" xlink:label="ifrs-full_AccumulatedOtherComprehensiveIncome_638278947975489933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638278947975489933" xlink:to="ifrs-full_AccumulatedOtherComprehensiveIncome_638278947975489933" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638278947975499932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638278947975489933" xlink:to="ifrs-full_Equity_638278947975499932" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_638278947975499932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638278947975489933" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_638278947975499932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_638278947975499932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638278947975499932" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_638278947975499932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities_638278947975499932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638278947975499932" xlink:to="ifrs-full_NoncurrentContractLiabilities_638278947975499932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentProvisions" xlink:label="ifrs-full_NoncurrentProvisions_638278947975499932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638278947975499932" xlink:to="ifrs-full_NoncurrentProvisions_638278947975499932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherNoncurrentLiabilities" xlink:label="ifrs-full_OtherNoncurrentLiabilities_638278947975499932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638278947975499932" xlink:to="ifrs-full_OtherNoncurrentLiabilities_638278947975499932" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_638278947975499932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638278947975499932" xlink:to="ifrs-full_NoncurrentLiabilities_638278947975499932" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_638278947975499932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638278947975489933" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_638278947975499932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_638278947975509932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638278947975499932" xlink:to="ifrs-full_CurrentLeaseLiabilities_638278947975509932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638278947975509932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638278947975499932" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638278947975509932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions_638278947975509932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638278947975499932" xlink:to="ifrs-full_CurrentProvisions_638278947975509932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities_638278947975509932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638278947975499932" xlink:to="ifrs-full_OtherCurrentLiabilities_638278947975509932" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities_638278947975509932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638278947975499932" xlink:to="ifrs-full_CurrentTaxLiabilities_638278947975509932" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities_638278947975509932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638278947975499932" xlink:to="ifrs-full_CurrentContractLiabilities_638278947975509932" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_638278947975509932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638278947975499932" xlink:to="ifrs-full_CurrentLiabilities_638278947975509932" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638278947975519932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638278947975489933" xlink:to="ifrs-full_Liabilities_638278947975519932" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities_638278947975519932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract_638278947975489933" xlink:to="ifrs-full_EquityAndLiabilities_638278947975519932" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="StatementOfChangesInEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable_638278947975519932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable_638278947975519932" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis" xlink:label="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_638278947975519932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638278947975519932" xlink:to="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_638278947975519932" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InAccordanceWithIFRS9Member" xlink:label="ifrs-full_InAccordanceWithIFRS9Member_638278947975519932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_638278947975519932" xlink:to="ifrs-full_InAccordanceWithIFRS9Member_638278947975519932" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member" xlink:label="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_638278947975519932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_638278947975519932" xlink:to="ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member_638278947975519932" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreviouslyStatedMember" xlink:label="ifrs-full_PreviouslyStatedMember_638278947975519932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_638278947975519932" xlink:to="ifrs-full_PreviouslyStatedMember_638278947975519932" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RestatedMember" xlink:label="ifrs-full_RestatedMember_638278947975529937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis_638278947975519932" xlink:to="ifrs-full_RestatedMember_638278947975529937" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_638278947975529937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638278947975519932" xlink:to="ifrs-full_ComponentsOfEquityAxis_638278947975529937" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_638278947975529937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638278947975529937" xlink:to="ifrs-full_IssuedCapitalMember_638278947975529937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CapitalReserveMember" xlink:label="ifrs-full_CapitalReserveMember_638278947975529937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638278947975529937" xlink:to="ifrs-full_CapitalReserveMember_638278947975529937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember_638278947975529937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638278947975529937" xlink:to="ifrs-full_TreasurySharesMember_638278947975529937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember_638278947975529937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638278947975529937" xlink:to="ifrs-full_RetainedEarningsMember_638278947975529937" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_638278947975529937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638278947975529937" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_638278947975529937" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_638278947975529937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638278947975529937" xlink:to="ifrs-full_EquityMember_638278947975529937" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_638278947975529937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638278947975519932" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_638278947975529937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638278947975529937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638278947975529937" xlink:to="ifrs-full_Equity_638278947975529937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NetLoss" xlink:label="cvac_NetLoss_638278947975529937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638278947975529937" xlink:to="cvac_NetLoss_638278947975529937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638278947975529937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638278947975529937" xlink:to="ifrs-full_ProfitLoss_638278947975529937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherComprehensiveIncome" xlink:label="ifrs-full_OtherComprehensiveIncome_638278947975539932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638278947975529937" xlink:to="ifrs-full_OtherComprehensiveIncome_638278947975539932" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome_638278947975539932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638278947975529937" xlink:to="ifrs-full_ComprehensiveIncome_638278947975539932" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes" xlink:label="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_638278947975539932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638278947975529937" xlink:to="cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes_638278947975539932" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity_638278947975539932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638278947975529937" xlink:to="ifrs-full_IssueOfEquity_638278947975539932" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughExerciseOfOptions" xlink:label="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_638278947975539932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638278947975529937" xlink:to="ifrs-full_IncreaseDecreaseThroughExerciseOfOptions_638278947975539932" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SettlementOfShareBasedPaymentAwardsAmount" xlink:label="cvac_SettlementOfShareBasedPaymentAwardsAmount_638278947975539932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638278947975529937" xlink:to="cvac_SettlementOfShareBasedPaymentAwardsAmount_638278947975539932" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_638278947975539932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638278947975529937" xlink:to="ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions_638278947975539932" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638278947975539932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638278947975529937" xlink:to="ifrs-full_Equity_638278947975539932" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638278947975549932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638278947975549932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax_638278947975549932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638278947975549932" xlink:to="ifrs-full_ProfitLossBeforeTax_638278947975549932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638278947975549932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638278947975549932" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638278947975549932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceIncome" xlink:label="ifrs-full_AdjustmentsForFinanceIncome_638278947975549932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638278947975549932" xlink:to="ifrs-full_AdjustmentsForFinanceIncome_638278947975549932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForFinanceCosts" xlink:label="ifrs-full_AdjustmentsForFinanceCosts_638278947975549932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638278947975549932" xlink:to="ifrs-full_AdjustmentsForFinanceCosts_638278947975549932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_638278947975549932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638278947975549932" xlink:to="ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense_638278947975549932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets" xlink:label="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_638278947975549932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638278947975549932" xlink:to="ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets_638278947975549932" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ImpairmentsOfInventoryAndPrepayments" xlink:label="cvac_ImpairmentsOfInventoryAndPrepayments_638278947975549932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638278947975549932" xlink:to="cvac_ImpairmentsOfInventoryAndPrepayments_638278947975549932" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638278947975549932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638278947975549932" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638278947975549932" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions" xlink:label="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_638278947975549932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638278947975549932" xlink:to="cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions_638278947975549932" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChangesInWorkingCapitalAbstract" xlink:label="cvac_ChangesInWorkingCapitalAbstract_638278947975549932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638278947975549932" xlink:to="cvac_ChangesInWorkingCapitalAbstract_638278947975549932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners" xlink:label="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638278947975559937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638278947975549932" xlink:to="cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners_638278947975559937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638278947975559937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638278947975549932" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_638278947975559937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638278947975559937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638278947975549932" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638278947975559937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_638278947975559937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638278947975549932" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets_638278947975559937" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638278947975559937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638278947975549932" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_638278947975559937" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdjustmentsForDeferredTaxExpense" xlink:label="ifrs-full_AdjustmentsForDeferredTaxExpense_638278947975559937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638278947975549932" xlink:to="ifrs-full_AdjustmentsForDeferredTaxExpense_638278947975559937" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_638278947975559937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638278947975549932" xlink:to="ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities_638278947975559937" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities" xlink:label="cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities_638278947975559937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638278947975549932" xlink:to="cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities_638278947975559937" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638278947975559937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638278947975549932" xlink:to="ifrs-full_InterestReceivedClassifiedAsOperatingActivities_638278947975559937" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InterestPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638278947975559937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638278947975549932" xlink:to="ifrs-full_InterestPaidClassifiedAsOperatingActivities_638278947975559937" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947975569931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ChangesInWorkingCapitalAbstract_638278947975549932" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638278947975569931" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638278947975569931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638278947975569931" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638278947975569931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638278947975569931" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638278947975569931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_638278947975569931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638278947975569931" xlink:to="ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities_638278947975569931" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_638278947975569931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638278947975569931" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_638278947975569931" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638278947975569931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638278947975569931" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638278947975569931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638278947975569931" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638278947975569931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638278947975569931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638278947975569931" xlink:to="ifrs-full_ProceedsFromIssuingShares_638278947975569931" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions" xlink:label="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_638278947975569931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638278947975569931" xlink:to="cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions_638278947975569931" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_638278947975579932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638278947975569931" xlink:to="cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities_638278947975579932" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_638278947975579932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638278947975569931" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_638278947975579932" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_638278947975579932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638278947975569931" xlink:to="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_638278947975579932" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingOtherEquityInstruments" xlink:label="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_638278947975579932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638278947975569931" xlink:to="ifrs-full_ProceedsFromIssuingOtherEquityInstruments_638278947975579932" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfBondsNotesAndDebentures" xlink:label="ifrs-full_RepaymentsOfBondsNotesAndDebentures_638278947975579932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638278947975569931" xlink:to="ifrs-full_RepaymentsOfBondsNotesAndDebentures_638278947975579932" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638278947975579932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638278947975569931" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638278947975579932" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_638278947975579932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_638278947975579932" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_638278947975589931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_638278947975589931" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638278947975589931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_638278947975589931" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_6382789479755899311" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_6382789479755899311" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureCorporateInformation" xlink:type="extended" xlink:title="10101 - Disclosure - Corporate Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CorporateInformationAbstract" xlink:label="CorporateInformationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CorporateInformationTextBlock" xlink:label="cvac_CorporateInformationTextBlock_638278947975589931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CorporateInformationAbstract" xlink:to="cvac_CorporateInformationTextBlock_638278947975589931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureBasisOfPreparation" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of preparation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfBasisOfPreparationAbstract" xlink:label="DisclosureOfBasisOfPreparationAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock" xlink:label="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_638278947975599944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock_638278947975599944" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="10301 - Disclosure - Notes to the Consolidated Statements of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory" xlink:label="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_638278947975599944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory_638278947975599944" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves" xlink:type="extended" xlink:title="10401 - Disclosure - Issued Capital and Reserves" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_638278947975599944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_638278947975599944" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPayments" xlink:type="extended" xlink:title="10501 - Disclosure - Share-based payments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_638278947975599944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_638278947975599944" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssets" xlink:type="extended" xlink:title="10601 - Disclosure - Fixed Assets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfFixedAssetsExplanatory" xlink:label="cvac_DisclosureOfFixedAssetsExplanatory_638278947975599944" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="cvac_DisclosureOfFixedAssetsExplanatory_638278947975599944" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAssetsHeldForSale" xlink:type="extended" xlink:title="10701 - Disclosure - Assets held for sale" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory" xlink:label="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_638278947975609937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:to="ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory_638278947975609937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureInventories" xlink:type="extended" xlink:title="10801 - Disclosure - Inventories" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="ClassesOfInventoriesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfInventoriesExplanatory" xlink:label="ifrs-full_DisclosureOfInventoriesExplanatory_638278947975609937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassesOfInventoriesAbstract" xlink:to="ifrs-full_DisclosureOfInventoriesExplanatory_638278947975609937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent" xlink:type="extended" xlink:title="10901 - Disclosure - Prepaid expenses and other assets (current)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory" xlink:label="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_638278947975609937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory_638278947975609937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities" xlink:type="extended" xlink:title="11001 - Disclosure - Financial assets and financial liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="DisclosureOfFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_638278947975609937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_638278947975609937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureTradeAndOtherPayables" xlink:type="extended" xlink:title="11101 - Disclosure - Trade and other payables" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="TradeAndOtherCurrentPayablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory" xlink:label="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_638278947975619939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory_638278947975619939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions" xlink:type="extended" xlink:title="11201 - Disclosure - Other liabilities and provisions" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherLiabilitiesAndProvisionsAbstract" xlink:label="cvac_OtherLiabilitiesAndProvisionsAbstract_2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherLiabilitiesAndProvisionsTextBlock" xlink:label="cvac_OtherLiabilitiesAndProvisionsTextBlock_638278947975619939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_OtherLiabilitiesAndProvisionsAbstract_2" xlink:to="cvac_OtherLiabilitiesAndProvisionsTextBlock_638278947975619939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIncomeTax" xlink:type="extended" xlink:title="11301 - Disclosure - Income tax" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract" xlink:label="MajorComponentsOfTaxExpenseIncomeAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIncomeTaxExplanatory" xlink:label="ifrs-full_DisclosureOfIncomeTaxExplanatory_638278947975619939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorComponentsOfTaxExpenseIncomeAbstract" xlink:to="ifrs-full_DisclosureOfIncomeTaxExplanatory_638278947975619939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement" xlink:type="extended" xlink:title="11401 - Disclosure - Disclosure of financial instruments and risk management" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="FinancialInstrumentsAndRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialRiskManagementExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_638278947975619939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ifrs-full_DisclosureOfFinancialRiskManagementExplanatory_638278947975619939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEarningsPerShare" xlink:type="extended" xlink:title="11501 - Disclosure - Earnings per share" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareExplanatory" xlink:label="ifrs-full_EarningsPerShareExplanatory_638278947975629938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareExplanatory_638278947975629938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureRelatedPartyDisclosures" xlink:type="extended" xlink:title="11601 - Disclosure - Related party disclosures" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfRelatedPartyExplanatory" xlink:label="ifrs-full_DisclosureOfRelatedPartyExplanatory_638278947975629938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfRelatedPartyExplanatory_638278947975629938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11701 - Disclosure - Subsequent events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_638278947975629938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_638278947975629938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Basis of preparation (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfBasisOfPreparationAbstract" xlink:label="DisclosureOfBasisOfPreparationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_638278947975639937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_638278947975639937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock" xlink:label="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_638278947975639937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock_638278947975639937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory" xlink:label="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_638278947975639937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory_638278947975639937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory" xlink:label="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_638278947975639937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory_638278947975639937" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory" xlink:label="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_638278947975639937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfBasisOfPreparationAbstract" xlink:to="cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory_638278947975639937" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Notes to the Consolidated Statements of Operations (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_638278947975639937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_638278947975639937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory" xlink:label="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_638278947975639937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory_638278947975639937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory" xlink:label="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_638278947975639937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory_638278947975639937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory" xlink:label="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_638278947975639937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory_638278947975639937" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfExpensesByNatureExplanatory" xlink:label="ifrs-full_DisclosureOfExpensesByNatureExplanatory_638278947975639937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfExpensesByNatureExplanatory_638278947975639937" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_638278947975639937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory_638278947975639937" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory" xlink:label="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_638278947975639937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory_638278947975639937" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Issued Capital and Reserves (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_638278947975649935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory_638278947975649935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Share-based payments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975649935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975649935" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947975649935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975649935" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947975649935" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638278947975649935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947975649935" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638278947975649935" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638278947975649935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638278947975649935" xlink:to="cvac_VirtualSharesProgramIMember_638278947975649935" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638278947975649935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638278947975649935" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638278947975649935" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RestrictedStockUnitsMember" xlink:label="cvac_RestrictedStockUnitsMember_638278947975649935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638278947975649935" xlink:to="cvac_RestrictedStockUnitsMember_638278947975649935" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975649935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975649935" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975649935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_638278947975659935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975649935" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory_638278947975659935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_638278947975659935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975649935" xlink:to="ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory_638278947975659935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory" xlink:label="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_638278947975659935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975649935" xlink:to="cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory_638278947975659935" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock" xlink:label="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_638278947975659935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975649935" xlink:to="cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock_638278947975659935" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureCorporateInformationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Corporate Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CorporateInformationAbstract" xlink:label="CorporateInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947975659935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CorporateInformationAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947975659935" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638278947975659935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947975659935" xlink:to="ifrs-full_RangeAxis_638278947975659935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638278947975659935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638278947975659935" xlink:to="ifrs-full_RangesMember_638278947975659935" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638278947975659935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638278947975659935" xlink:to="ifrs-full_BottomOfRangeMember_638278947975659935" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638278947975659935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638278947975659935" xlink:to="ifrs-full_TopOfRangeMember_638278947975659935" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638278947975659935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947975659935" xlink:to="srt_TitleOfIndividualAxis_638278947975659935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975659935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638278947975659935" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975659935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LargestShareholderMember" xlink:label="cvac_LargestShareholderMember_638278947975669941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975659935" xlink:to="cvac_LargestShareholderMember_638278947975669941" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947975669941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947975659935" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947975669941" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PercentageOfVotingInterestsHeld" xlink:label="cvac_PercentageOfVotingInterestsHeld_638278947975669941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947975669941" xlink:to="cvac_PercentageOfVotingInterestsHeld_638278947975669941" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CorporateReorganizationStockSplitRatio" xlink:label="cvac_CorporateReorganizationStockSplitRatio_638278947975669941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947975669941" xlink:to="cvac_CorporateReorganizationStockSplitRatio_638278947975669941" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInSubsidiary" xlink:label="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_638278947975669941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947975669941" xlink:to="ifrs-full_ProportionOfOwnershipInterestInSubsidiary_638278947975669941" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975669941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975669941" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis_638278947975669941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975669941" xlink:to="ifrs-full_GeographicalAreasAxis_638278947975669941" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_638278947975669941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis_638278947975669941" xlink:to="ifrs-full_GeographicalAreasMember_638278947975669941" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BE" xlink:label="country_BE_638278947975669941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638278947975669941" xlink:to="country_BE_638278947975669941" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CH" xlink:label="country_CH_638278947975669941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638278947975669941" xlink:to="country_CH_638278947975669941" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NL" xlink:label="country_NL_638278947975669941" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638278947975669941" xlink:to="country_NL_638278947975669941" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_DE" xlink:label="country_DE_638278947975679937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638278947975669941" xlink:to="country_DE_638278947975679937" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="country_US_638278947975679937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638278947975669941" xlink:to="country_US_638278947975679937" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis_638278947975679937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975669941" xlink:to="ifrs-full_MajorCustomersAxis_638278947975679937" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_638278947975679937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis_638278947975679937" xlink:to="ifrs-full_MajorCustomersMember_638278947975679937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_638278947975719955" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638278947975679937" xlink:to="cvac_GlaxosmithklineMember_638278947975719955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember_638278947975729969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638278947975679937" xlink:to="cvac_CrisprMember_638278947975729969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_638278947975729969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638278947975679937" xlink:to="cvac_GenmabMember_638278947975729969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember_638278947975729969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638278947975679937" xlink:to="cvac_BoehringerIngelheimMember_638278947975729969" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherCustomersMember" xlink:label="cvac_OtherCustomersMember_638278947975729969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638278947975679937" xlink:to="cvac_OtherCustomersMember_638278947975729969" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_EliLillyAndCompanyMember" xlink:label="cvac_EliLillyAndCompanyMember_638278947975729969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638278947975679937" xlink:to="cvac_EliLillyAndCompanyMember_638278947975729969" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_638278947975729969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975669941" xlink:to="ifrs-full_ProductsAndServicesAxis_638278947975729969" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_638278947975729969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis_638278947975729969" xlink:to="ifrs-full_ProductsAndServicesMember_638278947975729969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember_638278947975729969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638278947975729969" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember_638278947975729969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsProductMember" xlink:label="cvac_IfrsProductMember_638278947975729969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638278947975729969" xlink:to="cvac_IfrsProductMember_638278947975729969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ResearchAndDevelopmentServicesMember" xlink:label="cvac_ResearchAndDevelopmentServicesMember_638278947975729969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638278947975729969" xlink:to="cvac_ResearchAndDevelopmentServicesMember_638278947975729969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975729969" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975669941" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975729969" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638278947975739935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975729969" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638278947975739935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Notes to the Consolidated Statements of Operations - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638278947975739935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638278947975739935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis_638278947975739935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638278947975739935" xlink:to="ifrs-full_MajorCustomersAxis_638278947975739935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_638278947975739935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis_638278947975739935" xlink:to="ifrs-full_MajorCustomersMember_638278947975739935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_638278947975739935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638278947975739935" xlink:to="cvac_GlaxosmithklineMember_638278947975739935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis_638278947975739935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638278947975739935" xlink:to="ifrs-full_GeographicalAreasAxis_638278947975739935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_638278947975739935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis_638278947975739935" xlink:to="ifrs-full_GeographicalAreasMember_638278947975739935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_BE" xlink:label="country_BE_638278947975739935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasMember_638278947975739935" xlink:to="country_BE_638278947975739935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638278947975739935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638278947975739935" xlink:to="srt_CounterpartyNameAxis_638278947975739935" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975749939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638278947975739935" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975749939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember_638278947975749939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975749939" xlink:to="cvac_BoehringerIngelheimMember_638278947975749939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember_638278947975749939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975749939" xlink:to="cvac_CrisprTherapeuticsMember_638278947975749939" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_638278947975749939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975749939" xlink:to="cvac_GenmabMember_638278947975749939" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_EliLillyMember" xlink:label="cvac_EliLillyMember_638278947975749939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975749939" xlink:to="cvac_EliLillyMember_638278947975749939" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis_638278947975749939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638278947975739935" xlink:to="cvac_TypeOfArrangementAxis_638278947975749939" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember_638278947975749939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_TypeOfArrangementAxis_638278947975749939" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember_638278947975749939" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember" xlink:label="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_638278947975749939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember_638278947975749939" xlink:to="cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember_638278947975749939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GlaxosmithklineCovidAgreementMember" xlink:label="cvac_GlaxosmithklineCovidAgreementMember_638278947975749939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember_638278947975749939" xlink:to="cvac_GlaxosmithklineCovidAgreementMember_638278947975749939" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember" xlink:label="cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember_638278947975749939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember_638278947975749939" xlink:to="cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember_638278947975749939" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CollaborationAndLicenseAgreementMember" xlink:label="cvac_CollaborationAndLicenseAgreementMember_638278947975749939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember_638278947975749939" xlink:to="cvac_CollaborationAndLicenseAgreementMember_638278947975749939" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_638278947975749939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638278947975739935" xlink:to="ifrs-full_ProductsAndServicesAxis_638278947975749939" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_638278947975759933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis_638278947975749939" xlink:to="ifrs-full_ProductsAndServicesMember_638278947975759933" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MilestoneRevenuesMember" xlink:label="cvac_MilestoneRevenuesMember_638278947975759933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638278947975759933" xlink:to="cvac_MilestoneRevenuesMember_638278947975759933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638278947975759933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638278947975739935" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638278947975759933" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_638278947975759933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638278947975759933" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_638278947975759933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdditionalDevelopmentMilestonePaymentsReceived" xlink:label="cvac_AdditionalDevelopmentMilestonePaymentsReceived_638278947975759933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638278947975759933" xlink:to="cvac_AdditionalDevelopmentMilestonePaymentsReceived_638278947975759933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities" xlink:label="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_638278947975759933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638278947975759933" xlink:to="cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities_638278947975759933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails" xlink:type="extended" xlink:title="40303 - Disclosure - Notes to the Consolidated Statements of Operations - Summary of upfront payments and related revenues recognized (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975759933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975759933" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_638278947975769937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975759933" xlink:to="ifrs-full_ProductsAndServicesAxis_638278947975769937" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_638278947975769937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis_638278947975769937" xlink:to="ifrs-full_ProductsAndServicesMember_638278947975769937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ResearchServicesCombinedWithIpLicenseMember" xlink:label="cvac_ResearchServicesCombinedWithIpLicenseMember_638278947975769937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638278947975769937" xlink:to="cvac_ResearchServicesCombinedWithIpLicenseMember_638278947975769937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638278947975769937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975759933" xlink:to="ifrs-full_RangeAxis_638278947975769937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638278947975769937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638278947975769937" xlink:to="ifrs-full_RangesMember_638278947975769937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638278947975769937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638278947975769937" xlink:to="ifrs-full_BottomOfRangeMember_638278947975769937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis_638278947975769937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975759933" xlink:to="ifrs-full_MajorCustomersAxis_638278947975769937" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_638278947975769937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis_638278947975769937" xlink:to="ifrs-full_MajorCustomersMember_638278947975769937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_638278947975769937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638278947975769937" xlink:to="cvac_GlaxosmithklineMember_638278947975769937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CrisprMember" xlink:label="cvac_CrisprMember_638278947975769937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638278947975769937" xlink:to="cvac_CrisprMember_638278947975769937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_638278947975769937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersMember_638278947975769937" xlink:to="cvac_GenmabMember_638278947975769937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975769937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975759933" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975769937" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_UpfrontPaymentsReceivedOrReceivable" xlink:label="cvac_UpfrontPaymentsReceivedOrReceivable_638278947975769937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975769937" xlink:to="cvac_UpfrontPaymentsReceivedOrReceivable_638278947975769937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_UpfrontPaymentsIncludedInContractLiabilities" xlink:label="cvac_UpfrontPaymentsIncludedInContractLiabilities_638278947975779933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975769937" xlink:to="cvac_UpfrontPaymentsIncludedInContractLiabilities_638278947975779933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod" xlink:label="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_638278947975779933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975769937" xlink:to="ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod_638278947975779933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails" xlink:type="extended" xlink:title="40304 - Disclosure - Notes to the Consolidated Statements of Operations - Contract balances (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975779933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975779933" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638278947975779933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975779933" xlink:to="srt_StatementScenarioAxis_638278947975779933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638278947975779933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638278947975779933" xlink:to="srt_ScenarioUnspecifiedDomain_638278947975779933" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975779933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975779933" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975779933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables_638278947975779933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975779933" xlink:to="ifrs-full_CurrentTradeReceivables_638278947975779933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentContractAssets" xlink:label="ifrs-full_CurrentContractAssets_638278947975779933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975779933" xlink:to="ifrs-full_CurrentContractAssets_638278947975779933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContractLiabilities" xlink:label="ifrs-full_ContractLiabilities_638278947975779933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975779933" xlink:to="ifrs-full_ContractLiabilities_638278947975779933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails" xlink:type="extended" xlink:title="40305 - Disclosure - Notes to the Consolidated Statements of Operations - Cost of sales (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975789937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975789937" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_638278947975789937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975789937" xlink:to="cvac_IfrsIncomeStatementLocationAxis_638278947975789937" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638278947975789937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_638278947975789937" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638278947975789937" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsCostOfSalesMember" xlink:label="cvac_IfrsCostOfSalesMember_638278947975789937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_638278947975789937" xlink:to="cvac_IfrsCostOfSalesMember_638278947975789937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638278947975789937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975789937" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638278947975789937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_638278947975789937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638278947975789937" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_638278947975789937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975789937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975789937" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975789937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638278947975789937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975789937" xlink:to="cvac_PersonnelExpenses_638278947975789937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_638278947975789937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975789937" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_638278947975789937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_638278947975789937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975789937" xlink:to="cvac_ThirdPartyServiceExpenses_638278947975789937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638278947975789937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975789937" xlink:to="cvac_MaintenanceAndLeaseExpenses_638278947975789937" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638278947975789937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975789937" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638278947975789937" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638278947975789937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975789937" xlink:to="cvac_OtherExpense_638278947975789937" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_638278947975799935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975789937" xlink:to="ifrs-full_ExpenseByNature_638278947975799935" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_638278947975799935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975789937" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_638278947975799935" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638278947975799935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975789937" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638278947975799935" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails" xlink:type="extended" xlink:title="40306 - Disclosure - Notes to the Consolidated Statements of Operations - Selling and distribution expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975799935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975799935" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_638278947975799935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975799935" xlink:to="cvac_IfrsIncomeStatementLocationAxis_638278947975799935" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638278947975799935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_638278947975799935" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638278947975799935" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SellingAndDistributionExpensesMember" xlink:label="cvac_SellingAndDistributionExpensesMember_638278947975799935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_638278947975799935" xlink:to="cvac_SellingAndDistributionExpensesMember_638278947975799935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975799935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975799935" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975799935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638278947975799935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975799935" xlink:to="cvac_PersonnelExpenses_638278947975799935" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638278947975799935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975799935" xlink:to="cvac_MaintenanceAndLeaseExpenses_638278947975799935" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638278947975799935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975799935" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638278947975799935" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638278947975809936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975799935" xlink:to="cvac_OtherExpense_638278947975809936" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_638278947975809936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975799935" xlink:to="ifrs-full_ExpenseByNature_638278947975809936" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_638278947975809936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975799935" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_638278947975809936" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638278947975809936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975799935" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638278947975809936" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails" xlink:type="extended" xlink:title="40307 - Disclosure - Notes to the Consolidated Statements of Operations - Research and development expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975809936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975809936" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_638278947975809936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975809936" xlink:to="cvac_IfrsIncomeStatementLocationAxis_638278947975809936" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638278947975809936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_638278947975809936" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638278947975809936" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsResearchAndDevelopmentExpenseMember" xlink:label="cvac_IfrsResearchAndDevelopmentExpenseMember_638278947975809936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_638278947975809936" xlink:to="cvac_IfrsResearchAndDevelopmentExpenseMember_638278947975809936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975809936" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RawMaterialsAndConsumablesUsed" xlink:label="ifrs-full_RawMaterialsAndConsumablesUsed_638278947975809936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" xlink:to="ifrs-full_RawMaterialsAndConsumablesUsed_638278947975809936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638278947975809936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" xlink:to="cvac_PersonnelExpenses_638278947975809936" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638278947975819936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638278947975819936" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PatentsAndFeesToRegisterLegalRight" xlink:label="cvac_PatentsAndFeesToRegisterLegalRight_638278947975819936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" xlink:to="cvac_PatentsAndFeesToRegisterLegalRight_638278947975819936" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_638278947975819936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" xlink:to="cvac_ThirdPartyServiceExpenses_638278947975819936" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638278947975819936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" xlink:to="cvac_MaintenanceAndLeaseExpenses_638278947975819936" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638278947975819936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" xlink:to="cvac_OtherExpense_638278947975819936" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_638278947975819936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" xlink:to="ifrs-full_ExpenseByNature_638278947975819936" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract" xlink:label="cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract_638278947975819936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" xlink:to="cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract_638278947975819936" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsProvisionForLossOnContracts" xlink:label="cvac_IfrsProvisionForLossOnContracts_638278947975819936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" xlink:to="cvac_IfrsProvisionForLossOnContracts_638278947975819936" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638278947975819936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638278947975819936" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_638278947975819936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_638278947975819936" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts" xlink:label="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_638278947975819936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975809936" xlink:to="cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts_638278947975819936" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails" xlink:type="extended" xlink:title="40308 - Disclosure - Notes to the Consolidated Statements of Operations - General and administrative expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975829934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975829934" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationAxis" xlink:label="cvac_IfrsIncomeStatementLocationAxis_638278947975829934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975829934" xlink:to="cvac_IfrsIncomeStatementLocationAxis_638278947975829934" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsIncomeStatementLocationDomain" xlink:label="cvac_IfrsIncomeStatementLocationDomain_638278947975829934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationAxis_638278947975829934" xlink:to="cvac_IfrsIncomeStatementLocationDomain_638278947975829934" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsGeneralAndAdministrativeExpenseMember" xlink:label="cvac_IfrsGeneralAndAdministrativeExpenseMember_638278947975829934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsIncomeStatementLocationDomain_638278947975829934" xlink:to="cvac_IfrsGeneralAndAdministrativeExpenseMember_638278947975829934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis_638278947975829934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975829934" xlink:to="ifrs-full_ClassesOfAssetsAxis_638278947975829934" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_638278947975829934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsAxis_638278947975829934" xlink:to="ifrs-full_ClassesOfAssetsMember_638278947975829934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LaboratoriesMember" xlink:label="cvac_LaboratoriesMember_638278947975829934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember_638278947975829934" xlink:to="cvac_LaboratoriesMember_638278947975829934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RightofuseAssetsMember" xlink:label="ifrs-full_RightofuseAssetsMember_638278947975829934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfAssetsMember_638278947975829934" xlink:to="ifrs-full_RightofuseAssetsMember_638278947975829934" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975829934" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PersonnelExpenses" xlink:label="cvac_PersonnelExpenses_638278947975829934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" xlink:to="cvac_PersonnelExpenses_638278947975829934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaintenanceAndLeaseExpenses" xlink:label="cvac_MaintenanceAndLeaseExpenses_638278947975829934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" xlink:to="cvac_MaintenanceAndLeaseExpenses_638278947975829934" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ThirdPartyServiceExpenses" xlink:label="cvac_ThirdPartyServiceExpenses_638278947975829934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" xlink:to="cvac_ThirdPartyServiceExpenses_638278947975829934" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProfessionalFeesExpense" xlink:label="ifrs-full_ProfessionalFeesExpense_638278947975839936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" xlink:to="ifrs-full_ProfessionalFeesExpense_638278947975839936" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationAndAmortisationExpense" xlink:label="ifrs-full_DepreciationAndAmortisationExpense_638278947975839936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" xlink:to="ifrs-full_DepreciationAndAmortisationExpense_638278947975839936" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherExpense" xlink:label="cvac_OtherExpense_638278947975839936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" xlink:to="cvac_OtherExpense_638278947975839936" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseByNature" xlink:label="ifrs-full_ExpenseByNature_638278947975839936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" xlink:to="ifrs-full_ExpenseByNature_638278947975839936" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShorttermEmployeeBenefitsExpense" xlink:label="ifrs-full_ShorttermEmployeeBenefitsExpense_638278947975839936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" xlink:to="ifrs-full_ShorttermEmployeeBenefitsExpense_638278947975839936" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638278947975839936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638278947975839936" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AccruedOtherLiabilityForUpFrontPayment" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment_638278947975839936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" xlink:to="cvac_AccruedOtherLiabilityForUpFrontPayment_638278947975839936" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TravelExpense" xlink:label="ifrs-full_TravelExpense_638278947975839936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" xlink:to="ifrs-full_TravelExpense_638278947975839936" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InsuranceExpense" xlink:label="ifrs-full_InsuranceExpense_638278947975839936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" xlink:to="ifrs-full_InsuranceExpense_638278947975839936" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RealEstateTransferTaxes" xlink:label="cvac_RealEstateTransferTaxes_638278947975839936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975829934" xlink:to="cvac_RealEstateTransferTaxes_638278947975839936" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails" xlink:type="extended" xlink:title="40309 - Disclosure - Notes to the Consolidated Statements of Operations - Other operating income (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975849937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975849937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638278947975849937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975849937" xlink:to="srt_CounterpartyNameAxis_638278947975849937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975849937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638278947975849937" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975849937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_638278947975849937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975849937" xlink:to="cvac_GlaxosmithklineMember_638278947975849937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems" xlink:label="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975849937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable_638278947975849937" xlink:to="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975849937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransfer_638278947975849937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975849937" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransfer_638278947975849937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CostOfReimbursementClaim" xlink:label="cvac_CostOfReimbursementClaim_638278947975849937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975849937" xlink:to="cvac_CostOfReimbursementClaim_638278947975849937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SaleOfEquipment" xlink:label="cvac_SaleOfEquipment_638278947975849937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975849937" xlink:to="cvac_SaleOfEquipment_638278947975849937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherOperatingIncomeGovernmentGrants" xlink:label="cvac_OtherOperatingIncomeGovernmentGrants_638278947975849937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975849937" xlink:to="cvac_OtherOperatingIncomeGovernmentGrants_638278947975849937" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ReversalOfProvisionsForPersonnelExpenses" xlink:label="cvac_ReversalOfProvisionsForPersonnelExpenses_638278947975849937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975849937" xlink:to="cvac_ReversalOfProvisionsForPersonnelExpenses_638278947975849937" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MiscellaneousOtherOperatingIncomeOther" xlink:label="cvac_MiscellaneousOtherOperatingIncomeOther_638278947975859942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975849937" xlink:to="cvac_MiscellaneousOtherOperatingIncomeOther_638278947975859942" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_638278947975859942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems_638278947975849937" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_638278947975859942" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails" xlink:type="extended" xlink:title="40310 - Disclosure - Notes to the Consolidated Statements of Operations - Grants with government agencies and similar bodies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:label="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfGovernmentGrantsTable" xlink:label="cvac_DisclosureOfGovernmentGrantsTable_638278947975859942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesToConsolidatedFinancialStatementsAbstract" xlink:to="cvac_DisclosureOfGovernmentGrantsTable_638278947975859942" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638278947975859942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638278947975859942" xlink:to="srt_StatementScenarioAxis_638278947975859942" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638278947975859942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638278947975859942" xlink:to="srt_ScenarioUnspecifiedDomain_638278947975859942" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GovernmentGrantsAxis" xlink:label="cvac_GovernmentGrantsAxis_638278947975859942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638278947975859942" xlink:to="cvac_GovernmentGrantsAxis_638278947975859942" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GovernmentGrantsDomain" xlink:label="cvac_GovernmentGrantsDomain_638278947975859942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsAxis_638278947975859942" xlink:to="cvac_GovernmentGrantsDomain_638278947975859942" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GermanFederalMinistryOfEducationAndResearchMember" xlink:label="cvac_GermanFederalMinistryOfEducationAndResearchMember_638278947975859942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_638278947975859942" xlink:to="cvac_GermanFederalMinistryOfEducationAndResearchMember_638278947975859942" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CoalitionForEpidemicPreparednessInnovationsMember" xlink:label="cvac_CoalitionForEpidemicPreparednessInnovationsMember_638278947975859942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_638278947975859942" xlink:to="cvac_CoalitionForEpidemicPreparednessInnovationsMember_638278947975859942" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BillAndMelindaGatesFoundationBmgfMember" xlink:label="cvac_BillAndMelindaGatesFoundationBmgfMember_638278947975859942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_GovernmentGrantsDomain_638278947975859942" xlink:to="cvac_BillAndMelindaGatesFoundationBmgfMember_638278947975859942" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_638278947975859942" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember_638278947975859942" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember_638278947975859942" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember" xlink:label="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_638278947975869946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember_638278947975859942" xlink:to="cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember_638278947975869946" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BundesministeriumFurBildungUndForschungMember" xlink:label="cvac_BundesministeriumFurBildungUndForschungMember_638278947975869946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_BillAndMelindaGatesFoundationBmgfMember_638278947975859942" xlink:to="cvac_BundesministeriumFurBildungUndForschungMember_638278947975869946" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638278947975869946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638278947975859942" xlink:to="srt_CounterpartyNameAxis_638278947975869946" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975869946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638278947975869946" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975869946" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GlaxosmithklineMember" xlink:label="cvac_GlaxosmithklineMember_638278947975869946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975869946" xlink:to="cvac_GlaxosmithklineMember_638278947975869946" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GskAgreement2020Member" xlink:label="cvac_GskAgreement2020Member_638278947975869946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975869946" xlink:to="cvac_GskAgreement2020Member_638278947975869946" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BoehringerIngelheimMember" xlink:label="cvac_BoehringerIngelheimMember_638278947975869946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975869946" xlink:to="cvac_BoehringerIngelheimMember_638278947975869946" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CrisprTherapeuticsMember" xlink:label="cvac_CrisprTherapeuticsMember_638278947975869946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975869946" xlink:to="cvac_CrisprTherapeuticsMember_638278947975869946" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GenmabMember" xlink:label="cvac_GenmabMember_638278947975869946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975869946" xlink:to="cvac_GenmabMember_638278947975869946" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_EliLillyMember" xlink:label="cvac_EliLillyMember_638278947975869946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638278947975869946" xlink:to="cvac_EliLillyMember_638278947975869946" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TypeOfArrangementAxis" xlink:label="cvac_TypeOfArrangementAxis_638278947975869946" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638278947975859942" xlink:to="cvac_TypeOfArrangementAxis_638278947975869946" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ArrangementsAndNonArrangementTransactionsMember" xlink:label="cvac_ArrangementsAndNonArrangementTransactionsMember_638278947975879943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_TypeOfArrangementAxis_638278947975869946" xlink:to="cvac_ArrangementsAndNonArrangementTransactionsMember_638278947975879943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember" xlink:label="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_638278947975879943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_ArrangementsAndNonArrangementTransactionsMember_638278947975879943" xlink:to="cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember_638278947975879943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfGovernmentGrantsLineItems" xlink:label="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsTable_638278947975859942" xlink:to="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RevenueFromGovernmentGrants" xlink:label="ifrs-full_RevenueFromGovernmentGrants_638278947975879943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="ifrs-full_RevenueFromGovernmentGrants_638278947975879943" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ReimbursementOfApprovedExpenses" xlink:label="cvac_ReimbursementOfApprovedExpenses_638278947975879943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_ReimbursementOfApprovedExpenses_638278947975879943" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AmortizationOfGovernmentGrants" xlink:label="cvac_AmortizationOfGovernmentGrants_638278947975879943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_AmortizationOfGovernmentGrants_638278947975879943" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement" xlink:label="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_638278947975879943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement_638278947975879943" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaximumGrantToBeReceived" xlink:label="cvac_MaximumGrantToBeReceived_638278947975879943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_MaximumGrantToBeReceived_638278947975879943" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AccruedOtherLiabilityForUpFrontPayment" xlink:label="cvac_AccruedOtherLiabilityForUpFrontPayment_638278947975879943" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_AccruedOtherLiabilityForUpFrontPayment_638278947975879943" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_UpfrontPaymentReceived" xlink:label="cvac_UpfrontPaymentReceived_638278947975889935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_UpfrontPaymentReceived_638278947975889935" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsMilestonePaymentReceived" xlink:label="cvac_IfrsMilestonePaymentReceived_638278947975889935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_IfrsMilestonePaymentReceived_638278947975889935" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsRemainingGrantIncome" xlink:label="cvac_IfrsRemainingGrantIncome_638278947975889935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_IfrsRemainingGrantIncome_638278947975889935" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GovernmentGrants" xlink:label="ifrs-full_GovernmentGrants_638278947975889935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="ifrs-full_GovernmentGrants_638278947975889935" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MaximumUnspentFundsReimbursable" xlink:label="cvac_MaximumUnspentFundsReimbursable_638278947975889935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_MaximumUnspentFundsReimbursable_638278947975889935" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PartnershipAgreementMaximumAmount" xlink:label="cvac_PartnershipAgreementMaximumAmount_638278947975889935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_PartnershipAgreementMaximumAmount_638278947975889935" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PartnershipAgreementTerm" xlink:label="cvac_PartnershipAgreementTerm_638278947975889935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_PartnershipAgreementTerm_638278947975889935" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PartnershipAgreementPeriodOfCostsToBeCovered" xlink:label="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_638278947975889935" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_PartnershipAgreementPeriodOfCostsToBeCovered_638278947975889935" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_638278947975899932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities_638278947975899932" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets" xlink:label="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_638278947975899932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets_638278947975899932" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfAdditionalGrantsReceived" xlink:label="cvac_NumberOfAdditionalGrantsReceived_638278947975899932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_NumberOfAdditionalGrantsReceived_638278947975899932" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities" xlink:label="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_638278947975899932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities_638278947975899932" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_638278947975899932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities_638278947975899932" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses" xlink:label="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_638278947975899932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses_638278947975899932" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver" xlink:label="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_638278947975899932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfGovernmentGrantsLineItems_638278947975879943" xlink:to="cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver_638278947975899932" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975909932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975909932" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947975909932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975909932" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947975909932" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638278947975909932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947975909932" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638278947975909932" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638278947975909932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638278947975909932" xlink:to="cvac_VirtualSharesProgramIMember_638278947975909932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_638278947975909932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975909932" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_638278947975909932" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_638278947975909932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_638278947975909932" xlink:to="ifrs-full_ClassesOfShareCapitalMember_638278947975909932" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_638278947975909932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638278947975909932" xlink:to="ifrs-full_OrdinarySharesMember_638278947975909932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember_638278947975909932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638278947975909932" xlink:to="ifrs-full_PreferenceSharesMember_638278947975909932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_638278947975919937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975909932" xlink:to="cvac_IfrsSaleOfStockAxis_638278947975919937" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638278947975919937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_638278947975919937" xlink:to="cvac_IfrsSaleOfStockDomain_638278947975919937" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsOverAllotmentOptionMember" xlink:label="cvac_IfrsOverAllotmentOptionMember_638278947975919937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638278947975919937" xlink:to="cvac_IfrsOverAllotmentOptionMember_638278947975919937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_638278947975919937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975909932" xlink:to="ifrs-full_ComponentsOfEquityAxis_638278947975919937" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_638278947975919937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638278947975919937" xlink:to="ifrs-full_EquityMember_638278947975919937" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember_638278947975919937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember_638278947975919937" xlink:to="ifrs-full_TreasurySharesMember_638278947975919937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975919937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975909932" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975919937" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised_638278947975919937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975919937" xlink:to="ifrs-full_NumberOfSharesAuthorised_638278947975919937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare_638278947975919937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975919937" xlink:to="ifrs-full_ParValuePerShare_638278947975919937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued_638278947975919937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975919937" xlink:to="ifrs-full_NumberOfSharesIssued_638278947975919937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio" xlink:label="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_638278947975919937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975919937" xlink:to="cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio_638278947975919937" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Issued Capital and Reserves - At-the-market offering (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975929932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_2" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975929932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_638278947975929932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975929932" xlink:to="cvac_IfrsSaleOfStockAxis_638278947975929932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638278947975929932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_638278947975929932" xlink:to="cvac_IfrsSaleOfStockDomain_638278947975929932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AtMarketOfferingProgramMember" xlink:label="cvac_AtMarketOfferingProgramMember_638278947975929932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638278947975929932" xlink:to="cvac_AtMarketOfferingProgramMember_638278947975929932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_FollowOnPublicOfferingMember" xlink:label="cvac_FollowOnPublicOfferingMember_638278947975929932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638278947975929932" xlink:to="cvac_FollowOnPublicOfferingMember_638278947975929932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975929932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975929932" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975929932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638278947975929932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975929932" xlink:to="ifrs-full_ProceedsFromIssuingShares_638278947975929932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_638278947975929932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975929932" xlink:to="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_638278947975929932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSharesIssuedPricePerShare" xlink:label="cvac_IfrsSharesIssuedPricePerShare_638278947975929932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975929932" xlink:to="cvac_IfrsSharesIssuedPricePerShare_638278947975929932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AggregateGrossProceedsReceivableFromIssuingShares" xlink:label="cvac_AggregateGrossProceedsReceivableFromIssuingShares_638278947975929932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975929932" xlink:to="cvac_AggregateGrossProceedsReceivableFromIssuingShares_638278947975929932" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve" xlink:label="cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve_638278947975929932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975929932" xlink:to="cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve_638278947975929932" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RemainingAuthorizedForSaleValue" xlink:label="cvac_RemainingAuthorizedForSaleValue_638278947975939937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975929932" xlink:to="cvac_RemainingAuthorizedForSaleValue_638278947975939937" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ShareIssueRelatedCost" xlink:label="ifrs-full_ShareIssueRelatedCost_638278947975939937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975929932" xlink:to="ifrs-full_ShareIssueRelatedCost_638278947975939937" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="DisclosureOfClassesOfShareCapitalAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975939937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975939937" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_638278947975939937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975939937" xlink:to="cvac_IfrsSaleOfStockAxis_638278947975939937" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638278947975939937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_638278947975939937" xlink:to="cvac_IfrsSaleOfStockDomain_638278947975939937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CapitalIncreaseByGenmabMember" xlink:label="cvac_CapitalIncreaseByGenmabMember_638278947975939937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638278947975939937" xlink:to="cvac_CapitalIncreaseByGenmabMember_638278947975939937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PrivatePlacementIsa2020Member" xlink:label="cvac_PrivatePlacementIsa2020Member_638278947975939937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638278947975939937" xlink:to="cvac_PrivatePlacementIsa2020Member_638278947975939937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_InitialPublicOfferingAndPrivatePlacementMember" xlink:label="cvac_InitialPublicOfferingAndPrivatePlacementMember_638278947975939937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638278947975939937" xlink:to="cvac_InitialPublicOfferingAndPrivatePlacementMember_638278947975939937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExerciseOfGreenshoeMember" xlink:label="cvac_ExerciseOfGreenshoeMember_638278947975939937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638278947975939937" xlink:to="cvac_ExerciseOfGreenshoeMember_638278947975939937" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PublicOfferingMember" xlink:label="cvac_PublicOfferingMember_638278947975939937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638278947975939937" xlink:to="cvac_PublicOfferingMember_638278947975939937" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_638278947975939937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975939937" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_638278947975939937" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_638278947975949939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_638278947975939937" xlink:to="ifrs-full_ClassesOfShareCapitalMember_638278947975949939" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SeriesSharesMember" xlink:label="cvac_SeriesSharesMember_638278947975949939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638278947975949939" xlink:to="cvac_SeriesSharesMember_638278947975949939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SeriesCSharesMember" xlink:label="cvac_SeriesCSharesMember_638278947975949939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638278947975949939" xlink:to="cvac_SeriesCSharesMember_638278947975949939" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638278947975949939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975939937" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638278947975949939" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_638278947975949939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638278947975949939" xlink:to="ifrs-full_NonadjustingEventsMember_638278947975949939" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember_638278947975949939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638278947975949939" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember_638278947975949939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975949939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638278947975939937" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975949939" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding_638278947975949939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975949939" xlink:to="cvac_CommonSharesIssuedAndOutstanding_638278947975949939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncreaseInNumberOfSharesOutstanding" xlink:label="cvac_IncreaseInNumberOfSharesOutstanding_638278947975949939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975949939" xlink:to="cvac_IncreaseInNumberOfSharesOutstanding_638278947975949939" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ShareOptionExercises" xlink:label="cvac_ShareOptionExercises_638278947975949939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975949939" xlink:to="cvac_ShareOptionExercises_638278947975949939" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares" xlink:label="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_638278947975949939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975949939" xlink:to="cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares_638278947975949939" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_StockIssuedDuringPeriodForExercises" xlink:label="cvac_StockIssuedDuringPeriodForExercises_638278947975959933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975949939" xlink:to="cvac_StockIssuedDuringPeriodForExercises_638278947975959933" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsStockIssuedDuringPeriodSharesNewIssues" xlink:label="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_638278947975959933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975949939" xlink:to="cvac_IfrsStockIssuedDuringPeriodSharesNewIssues_638278947975959933" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_StockIssuanceDuringPeriodForExistingShareholders" xlink:label="cvac_StockIssuanceDuringPeriodForExistingShareholders_638278947975959933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975949939" xlink:to="cvac_StockIssuanceDuringPeriodForExistingShareholders_638278947975959933" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries" xlink:label="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries_638278947975959933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975949939" xlink:to="cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries_638278947975959933" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CommonSharesIssuedAndOutstanding" xlink:label="cvac_CommonSharesIssuedAndOutstanding_638278947975959933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975949939" xlink:to="cvac_CommonSharesIssuedAndOutstanding_638278947975959933" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfSharesIssuedForRsuDeliveries" xlink:label="cvac_NumberOfSharesIssuedForRsuDeliveries_638278947975959933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638278947975949939" xlink:to="cvac_NumberOfSharesIssuedForRsuDeliveries_638278947975959933" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Share-based payments - Expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975969932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975969932" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947975969932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975969932" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947975969932" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638278947975969932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947975969932" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638278947975969932" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PlanNameAxis" xlink:label="cvac_PlanNameAxis_638278947975969932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975969932" xlink:to="cvac_PlanNameAxis_638278947975969932" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PlanNameDomain" xlink:label="cvac_PlanNameDomain_638278947975969932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_PlanNameAxis_638278947975969932" xlink:to="cvac_PlanNameDomain_638278947975969932" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975969932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975969932" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975969932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_638278947975969932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975969932" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales_638278947975969932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses" xlink:label="cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses_638278947975969932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975969932" xlink:to="cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses_638278947975969932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638278947975969932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975969932" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses_638278947975969932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638278947975969932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975969932" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses_638278947975969932" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses" xlink:label="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses_638278947975969932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975969932" xlink:to="cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses_638278947975969932" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BenefitExpenseRecognizedForShareBasedPayment" xlink:label="cvac_BenefitExpenseRecognizedForShareBasedPayment_638278947975969932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975969932" xlink:to="cvac_BenefitExpenseRecognizedForShareBasedPayment_638278947975969932" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Share-based payments - Equity-settled programs (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975979931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_1" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975979931" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947975979931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975979931" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947975979931" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638278947975979931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947975979931" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638278947975979931" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember_638278947975979931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638278947975979931" xlink:to="cvac_LongTermIncentivePlanMember_638278947975979931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsRestrictedStockUnitMember" xlink:label="cvac_IfrsRestrictedStockUnitMember_638278947975979931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638278947975979931" xlink:to="cvac_IfrsRestrictedStockUnitMember_638278947975979931" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NewVirtualStockOptionsPlanMember" xlink:label="cvac_NewVirtualStockOptionsPlanMember_638278947975979931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638278947975979931" xlink:to="cvac_NewVirtualStockOptionsPlanMember_638278947975979931" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PriorVirtualStockOptionsPlanMember" xlink:label="cvac_PriorVirtualStockOptionsPlanMember_638278947975979931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638278947975979931" xlink:to="cvac_PriorVirtualStockOptionsPlanMember_638278947975979931" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LongTermIncentivePlanAndRestrictedStockUnitMember" xlink:label="cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_638278947975979931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638278947975979931" xlink:to="cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_638278947975979931" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975979931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975979931" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975979931" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseRecognizedForEmployeeServices" xlink:label="cvac_ExpenseRecognizedForEmployeeServices_638278947975979931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947975979931" xlink:to="cvac_ExpenseRecognizedForEmployeeServices_638278947975979931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails" xlink:type="extended" xlink:title="40503 - Disclosure - Share-based payments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975989934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975989934" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_638278947975989934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975989934" xlink:to="cvac_IfrsSaleOfStockAxis_638278947975989934" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638278947975989934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_638278947975989934" xlink:to="cvac_IfrsSaleOfStockDomain_638278947975989934" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExerciseOfOptionsMember" xlink:label="cvac_ExerciseOfOptionsMember_638278947975989934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638278947975989934" xlink:to="cvac_ExerciseOfOptionsMember_638278947975989934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638278947975989934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975989934" xlink:to="srt_TitleOfIndividualAxis_638278947975989934" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638278947975989934" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefScientificOfficerMember" xlink:label="cvac_ChiefScientificOfficerMember_638278947975989934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" xlink:to="cvac_ChiefScientificOfficerMember_638278947975989934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_638278947975989934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" xlink:to="cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember_638278947975989934" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember" xlink:label="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_638278947975989934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" xlink:to="cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_638278947975989934" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ChiefOperatingOfficerMember" xlink:label="srt_ChiefOperatingOfficerMember_638278947975989934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" xlink:to="srt_ChiefOperatingOfficerMember_638278947975989934" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefDevelopmentOfficerMember" xlink:label="cvac_ChiefDevelopmentOfficerMember_638278947975989934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" xlink:to="cvac_ChiefDevelopmentOfficerMember_638278947975989934" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ThenChiefExecutiveOfficerMember" xlink:label="cvac_ThenChiefExecutiveOfficerMember_638278947975989934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" xlink:to="cvac_ThenChiefExecutiveOfficerMember_638278947975989934" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ManagementBoardMember" xlink:label="cvac_ManagementBoardMember_638278947975999934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" xlink:to="cvac_ManagementBoardMember_638278947975999934" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember" xlink:label="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_638278947975999934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" xlink:to="cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_638278947975999934" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_KeyEmployeesMember" xlink:label="cvac_KeyEmployeesMember_638278947975999934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" xlink:to="cvac_KeyEmployeesMember_638278947975999934" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExecutiveBoardMembersMember" xlink:label="cvac_ExecutiveBoardMembersMember_638278947975999934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" xlink:to="cvac_ExecutiveBoardMembersMember_638278947975999934" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SupervisoryBoardMembersMember" xlink:label="cvac_SupervisoryBoardMembersMember_638278947975999934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" xlink:to="cvac_SupervisoryBoardMembersMember_638278947975999934" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChiefBusinessOfficerMember" xlink:label="cvac_ChiefBusinessOfficerMember_638278947975999934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" xlink:to="cvac_ChiefBusinessOfficerMember_638278947975999934" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_FormerFrameEmployeesMember" xlink:label="cvac_FormerFrameEmployeesMember_638278947975999934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947975989934" xlink:to="cvac_FormerFrameEmployeesMember_638278947975999934" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638278947975999934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975989934" xlink:to="ifrs-full_RangeAxis_638278947975999934" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638278947975999934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638278947975999934" xlink:to="ifrs-full_RangesMember_638278947975999934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638278947975999934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975989934" xlink:to="srt_StatementScenarioAxis_638278947975999934" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638278947976009933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638278947975999934" xlink:to="srt_ScenarioUnspecifiedDomain_638278947976009933" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis_638278947976009933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975989934" xlink:to="ifrs-full_MaturityAxis_638278947976009933" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_638278947976009933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis_638278947976009933" xlink:to="ifrs-full_AggregatedTimeBandsMember_638278947976009933" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember_638278947976009933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638278947976009933" xlink:to="ifrs-full_NotLaterThanOneYearMember_638278947976009933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_638278947976009933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedTimeBandsMember_638278947976009933" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember_638278947976009933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsVestingAxis" xlink:label="cvac_IfrsVestingAxis_638278947976009933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975989934" xlink:to="cvac_IfrsVestingAxis_638278947976009933" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsVestingDomain" xlink:label="cvac_IfrsVestingDomain_638278947976009933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsVestingAxis_638278947976009933" xlink:to="cvac_IfrsVestingDomain_638278947976009933" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsShareBasedPaymentArrangementTrancheOneMember" xlink:label="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_638278947976009933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsVestingDomain_638278947976009933" xlink:to="cvac_IfrsShareBasedPaymentArrangementTrancheOneMember_638278947976009933" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947976009933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975989934" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947976009933" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638278947976019930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947976009933" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638278947976019930" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LongTermIncentivePlanMember" xlink:label="cvac_LongTermIncentivePlanMember_638278947976019930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638278947976019930" xlink:to="cvac_LongTermIncentivePlanMember_638278947976019930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OptionsGrantedToThenChiefExecutiveOfficerMember" xlink:label="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638278947976019930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638278947976019930" xlink:to="cvac_OptionsGrantedToThenChiefExecutiveOfficerMember_638278947976019930" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638278947976019930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638278947976019930" xlink:to="cvac_VirtualSharesProgramIMember_638278947976019930" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VirtualSharesProgramIiMember" xlink:label="cvac_VirtualSharesProgramIiMember_638278947976019930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638278947976019930" xlink:to="cvac_VirtualSharesProgramIiMember_638278947976019930" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638278947975989934" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638278947976019930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638278947976019930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638278947976029933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement_638278947976029933" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_638278947976029933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement_638278947976029933" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfKeyEmployees" xlink:label="cvac_NumberOfKeyEmployees_638278947976029933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="cvac_NumberOfKeyEmployees_638278947976029933" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638278947976029933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638278947976029933" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_638278947976029933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_638278947976029933" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_638278947976029933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_638278947976029933" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638278947976029933" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638278947976029933" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu" xlink:label="cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu_638278947976039932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu_638278947976039932" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_638278947976039932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement_638278947976039932" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RightToExercisePercentageOfVestedVirtualShares" xlink:label="cvac_RightToExercisePercentageOfVestedVirtualShares_638278947976039932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="cvac_RightToExercisePercentageOfVestedVirtualShares_638278947976039932" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_638278947976039932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement_638278947976039932" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LockUpPeriodAfterInitialListing" xlink:label="cvac_LockUpPeriodAfterInitialListing_638278947976039932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="cvac_LockUpPeriodAfterInitialListing_638278947976039932" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProvisionForEmployerTaxes" xlink:label="cvac_ProvisionForEmployerTaxes_638278947976039932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="cvac_ProvisionForEmployerTaxes_638278947976039932" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AmountOfLiabilityCashClaimAwards" xlink:label="cvac_AmountOfLiabilityCashClaimAwards_638278947976049931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="cvac_AmountOfLiabilityCashClaimAwards_638278947976049931" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AmountOfRestrictedStockUnitsReceived" xlink:label="cvac_AmountOfRestrictedStockUnitsReceived_638278947976049931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="cvac_AmountOfRestrictedStockUnitsReceived_638278947976049931" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement" xlink:label="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_638278947976049931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638278947976019930" xlink:to="cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement_638278947976049931" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Fixed Assets - Intangible assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsTable" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsTable_638278947976059937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsTable_638278947976059937" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638278947976059937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_638278947976059937" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638278947976059937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638278947976059937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638278947976059937" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638278947976059937" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember_638278947976059937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638278947976059937" xlink:to="ifrs-full_GrossCarryingAmountMember_638278947976059937" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_638278947976059937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638278947976059937" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember_638278947976059937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember_638278947976059937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638278947976059937" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember_638278947976059937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_638278947976059937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_638278947976059937" xlink:to="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_638278947976059937" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsAndGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsAndGoodwillMember_638278947976059937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_638278947976059937" xlink:to="ifrs-full_IntangibleAssetsAndGoodwillMember_638278947976059937" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_SoftwareMember" xlink:label="cvac_SoftwareMember_638278947976059937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember_638278947976059937" xlink:to="cvac_SoftwareMember_638278947976059937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_LicencesMember" xlink:label="ifrs-full_LicencesMember_638278947976059937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember_638278947976059937" xlink:to="ifrs-full_LicencesMember_638278947976059937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TechnologyMember" xlink:label="cvac_TechnologyMember_638278947976059937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember_638278947976059937" xlink:to="cvac_TechnologyMember_638278947976059937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GoodwillMember" xlink:label="ifrs-full_GoodwillMember_638278947976059937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember_638278947976059937" xlink:to="ifrs-full_GoodwillMember_638278947976059937" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AdvancePaymentsIntangibleAssetMember" xlink:label="cvac_AdvancePaymentsIntangibleAssetMember_638278947976059937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember_638278947976059937" xlink:to="cvac_AdvancePaymentsIntangibleAssetMember_638278947976059937" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LicensesSoftwareAndPrepaymentsMember" xlink:label="cvac_LicensesSoftwareAndPrepaymentsMember_638278947976069932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IntangibleAssetsAndGoodwillMember_638278947976059937" xlink:to="cvac_LicensesSoftwareAndPrepaymentsMember_638278947976069932" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfIntangibleAssetsLineItems" xlink:label="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638278947976069932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsTable_638278947976059937" xlink:to="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638278947976069932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_638278947976069932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638278947976069932" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_638278947976069932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_638278947976069932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638278947976069932" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill_638278947976069932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_638278947976069932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638278947976069932" xlink:to="ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill_638278947976069932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_638278947976069932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638278947976069932" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill_638278947976069932" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_638278947976069932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638278947976069932" xlink:to="ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill_638278947976069932" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_638278947976069932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638278947976069932" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill_638278947976069932" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_6382789479760699321" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfIntangibleAssetsLineItems_638278947976069932" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_6382789479760699321" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfFixedAssetsAbstract" xlink:label="DisclosureOfFixedAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638278947976079932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFixedAssetsAbstract" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638278947976079932" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638278947976079932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638278947976079932" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638278947976079932" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain" xlink:label="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638278947976079932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_638278947976079932" xlink:to="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638278947976079932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_GrossCarryingAmountMember" xlink:label="ifrs-full_GrossCarryingAmountMember_638278947976079932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638278947976079932" xlink:to="ifrs-full_GrossCarryingAmountMember_638278947976079932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CumulativeAmortizationAndImpairmentMember" xlink:label="cvac_CumulativeAmortizationAndImpairmentMember_638278947976079932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638278947976079932" xlink:to="cvac_CumulativeAmortizationAndImpairmentMember_638278947976079932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GrossCarryingAmountOfAcquisitionCostMember" xlink:label="cvac_GrossCarryingAmountOfAcquisitionCostMember_638278947976079932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain_638278947976079932" xlink:to="cvac_GrossCarryingAmountOfAcquisitionCostMember_638278947976079932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638278947976079932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638278947976079932" xlink:to="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638278947976079932" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_638278947976079932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_638278947976079932" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_638278947976079932" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BuildingsMember" xlink:label="ifrs-full_BuildingsMember_638278947976079932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638278947976079932" xlink:to="ifrs-full_BuildingsMember_638278947976079932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember" xlink:label="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_638278947976079932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638278947976079932" xlink:to="cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_638278947976079932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherPropertyPlantAndEquipmentMember" xlink:label="ifrs-full_OtherPropertyPlantAndEquipmentMember_638278947976079932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638278947976079932" xlink:to="ifrs-full_OtherPropertyPlantAndEquipmentMember_638278947976079932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ConstructionInProgressMember" xlink:label="ifrs-full_ConstructionInProgressMember_638278947976089936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638278947976079932" xlink:to="ifrs-full_ConstructionInProgressMember_638278947976089936" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CompanyOwnedGmpIvFacilityMember" xlink:label="cvac_CompanyOwnedGmpIvFacilityMember_638278947976089936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638278947976079932" xlink:to="cvac_CompanyOwnedGmpIvFacilityMember_638278947976089936" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember" xlink:label="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_638278947976089936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PropertyPlantAndEquipmentMember_638278947976079932" xlink:to="cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember_638278947976089936" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems" xlink:label="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638278947976089936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable_638278947976079932" xlink:to="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638278947976089936" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638278947976089936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638278947976089936" xlink:to="ifrs-full_PropertyPlantAndEquipment_638278947976089936" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment" xlink:label="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_638278947976089936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638278947976089936" xlink:to="ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment_638278947976089936" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment" xlink:label="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_638278947976089936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638278947976089936" xlink:to="ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment_638278947976089936" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisposalsPropertyPlantAndEquipment" xlink:label="ifrs-full_DisposalsPropertyPlantAndEquipment_638278947976089936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638278947976089936" xlink:to="ifrs-full_DisposalsPropertyPlantAndEquipment_638278947976089936" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_638278947976089936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638278947976089936" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment_638278947976089936" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DepreciationPropertyPlantAndEquipment" xlink:label="ifrs-full_DepreciationPropertyPlantAndEquipment_638278947976089936" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638278947976089936" xlink:to="ifrs-full_DepreciationPropertyPlantAndEquipment_638278947976089936" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_638278947976099932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638278947976089936" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_638278947976099932" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_638278947976099932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638278947976089936" xlink:to="ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment_638278947976099932" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment" xlink:label="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_638278947976099932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638278947976089936" xlink:to="ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment_638278947976099932" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638278947976099932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638278947976089936" xlink:to="ifrs-full_PropertyPlantAndEquipment_638278947976099932" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment" xlink:label="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_638278947976099932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems_638278947976089936" xlink:to="cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment_638278947976099932" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Assets held for sale (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract" xlink:label="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GrossBookValueOfCmoEquipmentHeldForSale" xlink:label="cvac_GrossBookValueOfCmoEquipmentHeldForSale_638278947976109940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_1" xlink:to="cvac_GrossBookValueOfCmoEquipmentHeldForSale_638278947976109940" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ImpairmentOfAssetsHeldForSale" xlink:label="cvac_ImpairmentOfAssetsHeldForSale_638278947976109940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_1" xlink:to="cvac_ImpairmentOfAssetsHeldForSale_638278947976109940" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoriesAtFairValueLessCostsToSell" xlink:label="ifrs-full_InventoriesAtFairValueLessCostsToSell_638278947976109940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_1" xlink:to="ifrs-full_InventoriesAtFairValueLessCostsToSell_638278947976109940" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AssetsHeldForSaleNetBookValueSold" xlink:label="cvac_AssetsHeldForSaleNetBookValueSold_638278947976109940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract_1" xlink:to="cvac_AssetsHeldForSaleNetBookValueSold_638278947976109940" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureInventoriesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Inventories (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfInventoriesAbstract" xlink:label="ifrs-full_ClassesOfInventoriesAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_InventoriesTable" xlink:label="cvac_InventoriesTable_638278947976109940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfInventoriesAbstract" xlink:to="cvac_InventoriesTable_638278947976109940" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638278947976109940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesTable_638278947976109940" xlink:to="srt_CounterpartyNameAxis_638278947976109940" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638278947976109940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638278947976109940" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638278947976109940" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_InventoriesLineItem" xlink:label="cvac_InventoriesLineItem_638278947976109940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesTable_638278947976109940" xlink:to="cvac_InventoriesLineItem_638278947976109940" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RawMaterials" xlink:label="ifrs-full_RawMaterials_638278947976109940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638278947976109940" xlink:to="ifrs-full_RawMaterials_638278947976109940" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncreaseDecreaseInInventory" xlink:label="cvac_IncreaseDecreaseInInventory_638278947976109940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638278947976109940" xlink:to="cvac_IncreaseDecreaseInInventory_638278947976109940" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NetValueOfInventoryTransferred" xlink:label="cvac_NetValueOfInventoryTransferred_638278947976119939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638278947976109940" xlink:to="cvac_NetValueOfInventoryTransferred_638278947976119939" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsInventoryFinishedGoodsWriteDown" xlink:label="cvac_IfrsInventoryFinishedGoodsWriteDown_638278947976119939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638278947976109940" xlink:to="cvac_IfrsInventoryFinishedGoodsWriteDown_638278947976119939" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_FinishedGoods" xlink:label="ifrs-full_FinishedGoods_638278947976119939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638278947976109940" xlink:to="ifrs-full_FinishedGoods_638278947976119939" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_InventoryWritedown2011" xlink:label="ifrs-full_InventoryWritedown2011_638278947976119939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638278947976109940" xlink:to="ifrs-full_InventoryWritedown2011_638278947976119939" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Prepaid expenses and other assets (current) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_InventoriesTable" xlink:label="cvac_InventoriesTable_638278947976119939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="cvac_InventoriesTable_638278947976119939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638278947976119939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesTable_638278947976119939" xlink:to="srt_CounterpartyNameAxis_638278947976119939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638278947976119939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638278947976119939" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638278947976119939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_InventoriesLineItem" xlink:label="cvac_InventoriesLineItem_638278947976119939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesTable_638278947976119939" xlink:to="cvac_InventoriesLineItem_638278947976119939" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets" xlink:label="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638278947976119939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638278947976119939" xlink:to="ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets_638278947976119939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer" xlink:label="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_638278947976119939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638278947976119939" xlink:to="cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer_638278947976119939" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentAdvancesToSuppliers" xlink:label="ifrs-full_CurrentAdvancesToSuppliers_638278947976129939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638278947976119939" xlink:to="ifrs-full_CurrentAdvancesToSuppliers_638278947976129939" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_638278947976129939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638278947976119939" xlink:to="ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax_638278947976129939" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax" xlink:label="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_638278947976129939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638278947976119939" xlink:to="ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax_638278947976129939" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CurrentGrantReceivable" xlink:label="cvac_CurrentGrantReceivable_638278947976129939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638278947976119939" xlink:to="cvac_CurrentGrantReceivable_638278947976129939" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsCurrentGrantReceivables" xlink:label="cvac_IfrsCurrentGrantReceivables_638278947976129939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_InventoriesLineItem_638278947976119939" xlink:to="cvac_IfrsCurrentGrantReceivables_638278947976129939" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Financial assets and financial liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="DisclosureOfFinancialInstrumentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_638278947976129939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets_638278947976129939" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_638278947976129939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets_638278947976129939" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_638278947976129939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities_638278947976129939" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_638278947976129939" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities_638278947976129939" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_638278947976139940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets_638278947976139940" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_638278947976139940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets_638278947976139940" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_638278947976139940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities_638278947976139940" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities" xlink:label="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_638278947976139940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities_638278947976139940" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Trade and other payables (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesAbstract" xlink:label="TradeAndOtherCurrentPayablesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638278947976139940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_638278947976139940" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LicenseFeePayable" xlink:label="cvac_LicenseFeePayable_638278947976139940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="cvac_LicenseFeePayable_638278947976139940" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherCurrentPayables" xlink:label="ifrs-full_OtherCurrentPayables_638278947976139940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_OtherCurrentPayables_638278947976139940" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638278947976139940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638278947976139940" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChangeInTradeAndOtherPayables" xlink:label="cvac_ChangeInTradeAndOtherPayables_638278947976139940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="cvac_ChangeInTradeAndOtherPayables_638278947976139940" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax" xlink:label="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_638278947976229940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradeAndOtherCurrentPayablesAbstract" xlink:to="ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax_638278947976229940" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Other liabilities and provisions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsOtherLiabilitiesAbstract" xlink:label="IfrsOtherLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfOtherLiabilitiesTable" xlink:label="cvac_DisclosureOfOtherLiabilitiesTable_638278947976229940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IfrsOtherLiabilitiesAbstract" xlink:to="cvac_DisclosureOfOtherLiabilitiesTable_638278947976229940" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsAxis" xlink:label="ifrs-full_TypesOfContractsAxis_638278947976229940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable_638278947976229940" xlink:to="ifrs-full_TypesOfContractsAxis_638278947976229940" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfContractsMember" xlink:label="ifrs-full_TypesOfContractsMember_638278947976229940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfContractsAxis_638278947976229940" xlink:to="ifrs-full_TypesOfContractsMember_638278947976229940" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DisclosureOfOtherLiabilitiesLineItems" xlink:label="cvac_DisclosureOfOtherLiabilitiesLineItems_638278947976229940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesTable_638278947976229940" xlink:to="cvac_DisclosureOfOtherLiabilitiesLineItems_638278947976229940" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ChangeInOtherLiabilities" xlink:label="cvac_ChangeInOtherLiabilities_638278947976229940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638278947976229940" xlink:to="cvac_ChangeInOtherLiabilities_638278947976229940" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProvisionsForDecreaseInContractTerminations" xlink:label="cvac_ProvisionsForDecreaseInContractTerminations_638278947976229940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638278947976229940" xlink:to="cvac_ProvisionsForDecreaseInContractTerminations_638278947976229940" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ChangesInOtherProvisions" xlink:label="ifrs-full_ChangesInOtherProvisions_638278947976229940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638278947976229940" xlink:to="ifrs-full_ChangesInOtherProvisions_638278947976229940" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherMiscellaneousNonCurrentLiabilities" xlink:label="cvac_OtherMiscellaneousNonCurrentLiabilities_638278947976229940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638278947976229940" xlink:to="cvac_OtherMiscellaneousNonCurrentLiabilities_638278947976229940" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PersonnelAccruedLiabilities" xlink:label="cvac_PersonnelAccruedLiabilities_638278947976239940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638278947976229940" xlink:to="cvac_PersonnelAccruedLiabilities_638278947976239940" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrentGovernmentGrants" xlink:label="ifrs-full_CurrentGovernmentGrants_638278947976239940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638278947976229940" xlink:to="ifrs-full_CurrentGovernmentGrants_638278947976239940" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OutstandingInvoicesCurrent" xlink:label="cvac_OutstandingInvoicesCurrent_638278947976239940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638278947976229940" xlink:to="cvac_OutstandingInvoicesCurrent_638278947976239940" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ProfessionalFessCurrent" xlink:label="cvac_ProfessionalFessCurrent_638278947976239940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638278947976229940" xlink:to="cvac_ProfessionalFessCurrent_638278947976239940" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CurrentValueAddedTaxAndOtherTaxesPayables" xlink:label="cvac_CurrentValueAddedTaxAndOtherTaxesPayables_638278947976239940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638278947976229940" xlink:to="cvac_CurrentValueAddedTaxAndOtherTaxesPayables_638278947976239940" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_OtherLiabilityCurrent" xlink:label="cvac_OtherLiabilityCurrent_638278947976239940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638278947976229940" xlink:to="cvac_OtherLiabilityCurrent_638278947976239940" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherLiabilities" xlink:label="ifrs-full_OtherLiabilities_638278947976239940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638278947976229940" xlink:to="ifrs-full_OtherLiabilities_638278947976239940" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes" xlink:label="cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes_638278947976239940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_DisclosureOfOtherLiabilitiesLineItems_638278947976229940" xlink:to="cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes_638278947976239940" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Disclosure of financial instruments and risk management - Foreign currency risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_FinancialInstrumentsAndRiskManagementAbstract" xlink:label="FinancialInstrumentsAndRiskManagementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638278947976239940" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinancialInstrumentsAndRiskManagementAbstract" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638278947976239940" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis_638278947976249938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638278947976239940" xlink:to="srt_CurrencyAxis_638278947976249938" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_638278947976249938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis_638278947976249938" xlink:to="currency_AllCurrenciesDomain_638278947976249938" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_USD" xlink:label="currency_USD_638278947976249938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_638278947976249938" xlink:to="currency_USD_638278947976249938" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_CHF" xlink:label="currency_CHF_638278947976249938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_638278947976249938" xlink:to="currency_CHF_638278947976249938" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_EUR" xlink:label="currency_EUR_638278947976249938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_638278947976249938" xlink:to="currency_EUR_638278947976249938" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2022/currency-2022.xsd#currency_GBP" xlink:label="currency_GBP_638278947976249938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain_638278947976249938" xlink:to="currency_GBP_638278947976249938" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis_638278947976249938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638278947976239940" xlink:to="ifrs-full_TypesOfRisksAxis_638278947976249938" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_638278947976249938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis_638278947976249938" xlink:to="ifrs-full_TypesOfRisksMember_638278947976249938" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CurrencyRiskMember" xlink:label="ifrs-full_CurrencyRiskMember_638278947976249938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksMember_638278947976249938" xlink:to="ifrs-full_CurrencyRiskMember_638278947976249938" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_638278947976249938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638278947976239940" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_638278947976249938" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_638278947976249938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis_638278947976249938" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_638278947976249938" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsCashAndCashEquivalentsMember" xlink:label="cvac_IfrsCashAndCashEquivalentsMember_638278947976249938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638278947976249938" xlink:to="cvac_IfrsCashAndCashEquivalentsMember_638278947976249938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TradeAndOtherPayablesMember" xlink:label="cvac_TradeAndOtherPayablesMember_638278947976249938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638278947976249938" xlink:to="cvac_TradeAndOtherPayablesMember_638278947976249938" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TradeAndOtherReceivablesMember" xlink:label="cvac_TradeAndOtherReceivablesMember_638278947976259947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638278947976249938" xlink:to="cvac_TradeAndOtherReceivablesMember_638278947976259947" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MonetaryAssetsInForeignCurrencyMember" xlink:label="cvac_MonetaryAssetsInForeignCurrencyMember_638278947976259947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638278947976249938" xlink:to="cvac_MonetaryAssetsInForeignCurrencyMember_638278947976259947" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MonetaryLiabilitiesInForeignCurrencyMember" xlink:label="cvac_MonetaryLiabilitiesInForeignCurrencyMember_638278947976259947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638278947976249938" xlink:to="cvac_MonetaryLiabilitiesInForeignCurrencyMember_638278947976259947" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TradeAndOtherPayablesOneMember" xlink:label="cvac_TradeAndOtherPayablesOneMember_638278947976259947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638278947976249938" xlink:to="cvac_TradeAndOtherPayablesOneMember_638278947976259947" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TradeAndOtherPayablesTwoMember" xlink:label="cvac_TradeAndOtherPayablesTwoMember_638278947976259947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsMember_638278947976249938" xlink:to="cvac_TradeAndOtherPayablesTwoMember_638278947976259947" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_638278947976259947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable_638278947976239940" xlink:to="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_638278947976259947" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic" xlink:label="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_638278947976259947" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems_638278947976259947" xlink:to="ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic_638278947976259947" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureEarningsPerShareDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Earnings per share (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DiluteEffectOfOrdinarySharesIssued" xlink:label="cvac_DiluteEffectOfOrdinarySharesIssued_638278947976269932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="cvac_DiluteEffectOfOrdinarySharesIssued_638278947976269932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares_638278947976269932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_WeightedAverageShares_638278947976269932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_638278947976269932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare_638278947976269932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Related party disclosures (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:label="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638278947976269932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTransactionsBetweenRelatedPartiesAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638278947976269932" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638278947976269932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638278947976269932" xlink:to="ifrs-full_RangeAxis_638278947976269932" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638278947976269932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638278947976269932" xlink:to="ifrs-full_RangesMember_638278947976269932" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638278947976269932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638278947976269932" xlink:to="srt_TitleOfIndividualAxis_638278947976269932" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947976269932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638278947976269932" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947976269932" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BaronJeanStephenneMember" xlink:label="cvac_BaronJeanStephenneMember_638278947976269932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947976269932" xlink:to="cvac_BaronJeanStephenneMember_638278947976269932" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VincentStphenneMember" xlink:label="cvac_VincentStphenneMember_638278947976269932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947976269932" xlink:to="cvac_VincentStphenneMember_638278947976269932" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_AntonyBlancMember" xlink:label="cvac_AntonyBlancMember_638278947976269932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638278947976269932" xlink:to="cvac_AntonyBlancMember_638278947976269932" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638278947976279938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638278947976269932" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638278947976279938" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638278947976279938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638278947976279938" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638278947976279938" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DietmarHoppMember" xlink:label="cvac_DietmarHoppMember_638278947976279938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638278947976279938" xlink:to="cvac_DietmarHoppMember_638278947976279938" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember" xlink:label="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_638278947976279938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638278947976279938" xlink:to="cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember_638278947976279938" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ClarentisSrlMember" xlink:label="cvac_ClarentisSrlMember_638278947976279938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638278947976279938" xlink:to="cvac_ClarentisSrlMember_638278947976279938" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BepharbelManufacturingS.aMember" xlink:label="cvac_BepharbelManufacturingS.aMember_638278947976279938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638278947976279938" xlink:to="cvac_BepharbelManufacturingS.aMember_638278947976279938" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_BarkerBiomedicalGmbhMember" xlink:label="cvac_BarkerBiomedicalGmbhMember_638278947976279938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638278947976279938" xlink:to="cvac_BarkerBiomedicalGmbhMember_638278947976279938" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_CraigToomanMember" xlink:label="cvac_CraigToomanMember_638278947976279938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638278947976279938" xlink:to="cvac_CraigToomanMember_638278947976279938" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RittershausRechtsanwaelteMember" xlink:label="cvac_RittershausRechtsanwaelteMember_638278947976279938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638278947976279938" xlink:to="cvac_RittershausRechtsanwaelteMember_638278947976279938" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MariolaFotinMleczekMember" xlink:label="cvac_MariolaFotinMleczekMember_638278947976279938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638278947976279938" xlink:to="cvac_MariolaFotinMleczekMember_638278947976279938" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_FlorianVonDerMlbeMember" xlink:label="cvac_FlorianVonDerMlbeMember_638278947976279938" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638278947976279938" xlink:to="cvac_FlorianVonDerMlbeMember_638278947976279938" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_Dr.IngmarHrrMember" xlink:label="cvac_Dr.IngmarHrrMember_638278947976289930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638278947976279938" xlink:to="cvac_Dr.IngmarHrrMember_638278947976289930" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947976289930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638278947976269932" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947976289930" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638278947976289930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638278947976289930" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638278947976289930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_VirtualSharesProgramIMember" xlink:label="cvac_VirtualSharesProgramIMember_638278947976289930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638278947976289930" xlink:to="cvac_VirtualSharesProgramIMember_638278947976289930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_638278947976289930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638278947976269932" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_638278947976289930" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_638278947976289930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_638278947976289930" xlink:to="ifrs-full_ClassesOfShareCapitalMember_638278947976289930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_638278947976289930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638278947976289930" xlink:to="ifrs-full_OrdinarySharesMember_638278947976289930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_638278947976269932" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity" xlink:label="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638278947976289930" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" xlink:to="cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity_638278947976289930" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement" xlink:label="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_638278947976299929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" xlink:to="cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement_638278947976299929" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RelatedPartyTransactionConsultingFees" xlink:label="cvac_RelatedPartyTransactionConsultingFees_638278947976299929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" xlink:to="cvac_RelatedPartyTransactionConsultingFees_638278947976299929" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_RelatedPartyTransactionNumberOfLoansReceived" xlink:label="cvac_RelatedPartyTransactionNumberOfLoansReceived_638278947976299929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" xlink:to="cvac_RelatedPartyTransactionNumberOfLoansReceived_638278947976299929" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsContractualObligation" xlink:label="cvac_IfrsContractualObligation_638278947976299929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" xlink:to="cvac_IfrsContractualObligation_638278947976299929" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions" xlink:label="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_638278947976299929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" xlink:to="ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions_638278947976299929" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_638278947976299929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_638278947976299929" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued_638278947976299929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" xlink:to="ifrs-full_NumberOfSharesIssued_638278947976299929" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_WeightedAverageSharePrice2019" xlink:label="ifrs-full_WeightedAverageSharePrice2019_638278947976299929" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" xlink:to="ifrs-full_WeightedAverageSharePrice2019_638278947976299929" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638278947976309928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_638278947976309928" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IncomeTaxAndSocialSecurityLiabilityReceivable" xlink:label="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable_638278947976309928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" xlink:to="cvac_IncomeTaxAndSocialSecurityLiabilityReceivable_638278947976309928" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpensesToHandleFutureServiceAgreement" xlink:label="cvac_ExpensesToHandleFutureServiceAgreement_638278947976309928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" xlink:to="cvac_ExpensesToHandleFutureServiceAgreement_638278947976309928" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ExpenseRecognizedFromRelatedPartyTransaction" xlink:label="cvac_ExpenseRecognizedFromRelatedPartyTransaction_638278947976309928" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems_638278947976289930" xlink:to="cvac_ExpenseRecognizedFromRelatedPartyTransaction_638278947976309928" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.curevac.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Subsequent events (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsTable" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947976319937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947976319937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsAxis" xlink:label="ifrs-full_BusinessCombinationsAxis_638278947976319937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947976319937" xlink:to="ifrs-full_BusinessCombinationsAxis_638278947976319937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_EntitysTotalForBusinessCombinationsMember" xlink:label="ifrs-full_EntitysTotalForBusinessCombinationsMember_638278947976319937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BusinessCombinationsAxis_638278947976319937" xlink:to="ifrs-full_EntitysTotalForBusinessCombinationsMember_638278947976319937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_BusinessCombinationsMember" xlink:label="ifrs-full_BusinessCombinationsMember_638278947976319937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForBusinessCombinationsMember_638278947976319937" xlink:to="ifrs-full_BusinessCombinationsMember_638278947976319937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638278947976319937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947976319937" xlink:to="ifrs-full_RangeAxis_638278947976319937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638278947976319937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638278947976319937" xlink:to="ifrs-full_RangesMember_638278947976319937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ClassesOfContingentLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfContingentLiabilitiesAxis_638278947976319937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947976319937" xlink:to="ifrs-full_ClassesOfContingentLiabilitiesAxis_638278947976319937" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ContingentLiabilitiesMember" xlink:label="ifrs-full_ContingentLiabilitiesMember_638278947976319937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfContingentLiabilitiesAxis_638278947976319937" xlink:to="ifrs-full_ContingentLiabilitiesMember_638278947976319937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_OtherContingentLiabilitiesMember" xlink:label="ifrs-full_OtherContingentLiabilitiesMember_638278947976319937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContingentLiabilitiesMember_638278947976319937" xlink:to="ifrs-full_OtherContingentLiabilitiesMember_638278947976319937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember" xlink:label="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember_638278947976319937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ContingentLiabilitiesMember_638278947976319937" xlink:to="cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember_638278947976319937" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_638278947976319937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947976319937" xlink:to="ifrs-full_ProductsAndServicesAxis_638278947976319937" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_638278947976319937" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis_638278947976319937" xlink:to="ifrs-full_ProductsAndServicesMember_638278947976319937" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_MilestonesMember" xlink:label="cvac_MilestonesMember_638278947976329934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638278947976319937" xlink:to="cvac_MilestonesMember_638278947976329934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_638278947976329934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947976319937" xlink:to="ifrs-full_CounterpartiesAxis_638278947976329934" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember_638278947976329934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis_638278947976329934" xlink:to="ifrs-full_CounterpartiesMember_638278947976329934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_GskAgreement2020Member" xlink:label="cvac_GskAgreement2020Member_638278947976329934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesMember_638278947976329934" xlink:to="cvac_GskAgreement2020Member_638278947976329934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638278947976329934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947976319937" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638278947976329934" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_638278947976329934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638278947976329934" xlink:to="ifrs-full_NonadjustingEventsMember_638278947976329934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PatentInfringementLawsuitFilledMember" xlink:label="cvac_PatentInfringementLawsuitFilledMember_638278947976329934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638278947976329934" xlink:to="cvac_PatentInfringementLawsuitFilledMember_638278947976329934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockAxis" xlink:label="cvac_IfrsSaleOfStockAxis_638278947976329934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947976319937" xlink:to="cvac_IfrsSaleOfStockAxis_638278947976329934" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_IfrsSaleOfStockDomain" xlink:label="cvac_IfrsSaleOfStockDomain_638278947976329934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockAxis_638278947976329934" xlink:to="cvac_IfrsSaleOfStockDomain_638278947976329934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PublicOfferingOfCommonSharesMember" xlink:label="cvac_PublicOfferingOfCommonSharesMember_638278947976329934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="cvac_IfrsSaleOfStockDomain_638278947976329934" xlink:to="cvac_PublicOfferingOfCommonSharesMember_638278947976329934" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd#ifrs-full_DisclosureOfBusinessCombinationsLineItems" xlink:label="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsTable_638278947976319937" xlink:to="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled" xlink:label="cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled_638278947976339931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" xlink:to="cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled_638278947976339931" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase" xlink:label="cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase_638278947976339931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" xlink:to="cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase_638278947976339931" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfPatentOnWhichNullityActionIsFilled" xlink:label="cvac_NumberOfPatentOnWhichNullityActionIsFilled_638278947976339931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" xlink:to="cvac_NumberOfPatentOnWhichNullityActionIsFilled_638278947976339931" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed" xlink:label="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed_638278947976339931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" xlink:to="cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed_638278947976339931" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays" xlink:label="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays_638278947976339931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" xlink:to="cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays_638278947976339931" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PurchasePriceAllocationSharePriceAsOfClosingDate" xlink:label="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate_638278947976339931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" xlink:to="cvac_PurchasePriceAllocationSharePriceAsOfClosingDate_638278947976339931" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares" xlink:label="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares_638278947976339931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" xlink:to="cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares_638278947976339931" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling" xlink:label="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling_638278947976339931" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" xlink:to="cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling_638278947976339931" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans" xlink:label="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans_638278947976349932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" xlink:to="cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans_638278947976349932" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels_638278947976349932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" xlink:to="cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels_638278947976349932" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="cvac_LossContingencyPatentsAllegedlyInfringedNumber_638278947976349932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" xlink:to="cvac_LossContingencyPatentsAllegedlyInfringedNumber_638278947976349932" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_LossContingencyPatentsFoundNotInfringedNumber" xlink:label="cvac_LossContingencyPatentsFoundNotInfringedNumber_638278947976349932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" xlink:to="cvac_LossContingencyPatentsFoundNotInfringedNumber_638278947976349932" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="cvac-20230630.xsd#cvac_NumberOfMrnaVaccinesDoses" xlink:label="cvac_NumberOfMrnaVaccinesDoses_638278947976349932" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfBusinessCombinationsLineItems_638278947976329934" xlink:to="cvac_NumberOfMrnaVaccinesDoses_638278947976349932" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345811496320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CureVac N.V.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001809122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345812963984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue</a></td>
<td class="nump">&#8364; 7,579<span></span>
</td>
<td class="nump">&#8364; 20,146<span></span>
</td>
<td class="nump">&#8364; 14,708<span></span>
</td>
<td class="nump">&#8364; 44,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="num">(25,854)<span></span>
</td>
<td class="num">(42,681)<span></span>
</td>
<td class="num">(46,489)<span></span>
</td>
<td class="num">(79,913)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">Selling and distribution expenses</a></td>
<td class="num">(1,408)<span></span>
</td>
<td class="num">(548)<span></span>
</td>
<td class="num">(2,232)<span></span>
</td>
<td class="num">(819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(30,868)<span></span>
</td>
<td class="num">(11,635)<span></span>
</td>
<td class="num">(55,118)<span></span>
</td>
<td class="num">(22,422)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(22,245)<span></span>
</td>
<td class="num">(27,112)<span></span>
</td>
<td class="num">(45,532)<span></span>
</td>
<td class="num">(51,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other operating income</a></td>
<td class="nump">1,442<span></span>
</td>
<td class="nump">1,771<span></span>
</td>
<td class="nump">3,448<span></span>
</td>
<td class="nump">35,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingExpense', window );">Other operating expenses</a></td>
<td class="num">(447)<span></span>
</td>
<td class="num">(238)<span></span>
</td>
<td class="num">(942)<span></span>
</td>
<td class="num">(461)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating loss</a></td>
<td class="num">(71,801)<span></span>
</td>
<td class="num">(60,298)<span></span>
</td>
<td class="num">(132,157)<span></span>
</td>
<td class="num">(75,567)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="nump">6,197<span></span>
</td>
<td class="nump">3,322<span></span>
</td>
<td class="nump">10,085<span></span>
</td>
<td class="nump">5,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="num">(1,783)<span></span>
</td>
<td class="num">(594)<span></span>
</td>
<td class="num">(2,734)<span></span>
</td>
<td class="num">(2,535)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income tax</a></td>
<td class="num">(67,387)<span></span>
</td>
<td class="num">(57,570)<span></span>
</td>
<td class="num">(124,806)<span></span>
</td>
<td class="num">(72,759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income tax benefit/ (expense)</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss for the period</a></td>
<td class="num">(67,414)<span></span>
</td>
<td class="num">(57,584)<span></span>
</td>
<td class="num">(124,833)<span></span>
</td>
<td class="num">(72,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Foreign currency adjustments</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive loss for the period</a></td>
<td class="num">&#8364; (67,416)<span></span>
</td>
<td class="num">&#8364; (57,742)<span></span>
</td>
<td class="num">&#8364; (124,816)<span></span>
</td>
<td class="num">&#8364; (72,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Net loss per share basic</a></td>
<td class="num">&#8364; (0.30)<span></span>
</td>
<td class="num">&#8364; (0.31)<span></span>
</td>
<td class="num">&#8364; (0.57)<span></span>
</td>
<td class="num">&#8364; (0.39)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Net loss per share diluted</a></td>
<td class="num">&#8364; (0.30)<span></span>
</td>
<td class="num">&#8364; (0.31)<span></span>
</td>
<td class="num">&#8364; (0.57)<span></span>
</td>
<td class="num">&#8364; (0.39)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2022-03-24<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345810236096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Financial Position - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets and goodwill</a></td>
<td class="nump">&#8364; 31,700<span></span>
</td>
<td class="nump">&#8364; 31,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">219,539<span></span>
</td>
<td class="nump">197,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">42,031<span></span>
</td>
<td class="nump">43,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">1,704<span></span>
</td>
<td class="nump">1,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NetDeferredTaxAssets', window );">Deferred tax assets</a></td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">1,297<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">296,270<span></span>
</td>
<td class="nump">276,443<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners', window );">Assets held for sale</a></td>
<td class="nump">9,954<span></span>
</td>
<td class="nump">10,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">22,194<span></span>
</td>
<td class="nump">23,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">6,443<span></span>
</td>
<td class="nump">6,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractAssets', window );">Contract assets</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialAssets', window );">Other financial assets</a></td>
<td class="nump">5,354<span></span>
</td>
<td class="nump">4,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">21,221<span></span>
</td>
<td class="nump">40,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">537,925<span></span>
</td>
<td class="nump">495,797<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">603,210<span></span>
</td>
<td class="nump">584,029<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">899,480<span></span>
</td>
<td class="nump">860,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Issued capital</a></td>
<td class="nump">26,866<span></span>
</td>
<td class="nump">23,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CapitalReserve', window );">Capital reserve</a></td>
<td class="nump">2,052,951<span></span>
</td>
<td class="nump">1,817,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TreasuryShares', window );">Treasury Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(1,430,647)<span></span>
</td>
<td class="num">(1,305,814)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AccumulatedOtherComprehensiveIncome', window );">Other comprehensive income</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="nump">649,047<span></span>
</td>
<td class="nump">533,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">35,276<span></span>
</td>
<td class="nump">37,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">58,862<span></span>
</td>
<td class="nump">72,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentProvisions', window );">Provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">94,157<span></span>
</td>
<td class="nump">170,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">5,205<span></span>
</td>
<td class="nump">4,980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">13,419<span></span>
</td>
<td class="nump">73,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="nump">61,608<span></span>
</td>
<td class="nump">1,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">35,514<span></span>
</td>
<td class="nump">40,491<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilities', window );">Income taxes payable</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">39,901<span></span>
</td>
<td class="nump">34,759<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">156,276<span></span>
</td>
<td class="nump">156,225<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">250,433<span></span>
</td>
<td class="nump">327,219<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 899,480<span></span>
</td>
<td class="nump">&#8364; 860,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AccumulatedOtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AccumulatedOtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CapitalReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the capital reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CapitalReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.
Effective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An entity&#8217;s own equity instruments, held by the entity or other members of the consolidated group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2022-03-24<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345813117808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Changes in Shareholders' Equity - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Issued capital</div></th>
<th class="th"><div>Capital reserve</div></th>
<th class="th"><div>Treasury share</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Currency translation reserve</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the beginning at Dec. 31, 2021</a></td>
<td class="nump">&#8364; 22,454<span></span>
</td>
<td class="nump">&#8364; 1,728,658<span></span>
</td>
<td class="num">&#8364; (5,817)<span></span>
</td>
<td class="num">&#8364; (1,056,785)<span></span>
</td>
<td class="num">&#8364; (34)<span></span>
</td>
<td class="nump">&#8364; 688,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,677)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,677)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(72,677)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="num">(72,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes', window );">Share-based payments (net of taxes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital (net of transaction costs)</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">4,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions', window );">Exercise of options</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SettlementOfShareBasedPaymentAwardsAmount', window );">Settlement of share-based payment awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,452)<span></span>
</td>
<td class="nump">4,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the end at Jun. 30, 2022</a></td>
<td class="nump">22,496<span></span>
</td>
<td class="nump">1,732,148<span></span>
</td>
<td class="num">(1,734)<span></span>
</td>
<td class="num">(1,129,462)<span></span>
</td>
<td class="num">(246)<span></span>
</td>
<td class="nump">623,202<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the beginning at Dec. 31, 2022</a></td>
<td class="nump">23,400<span></span>
</td>
<td class="nump">1,817,287<span></span>
</td>
<td class="num">(1,481)<span></span>
</td>
<td class="num">(1,305,814)<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="nump">533,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(124,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(124,833)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncome', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(124,833)<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(124,816)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes', window );">Share-based payments (net of taxes)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of share capital (net of transaction costs)</a></td>
<td class="nump">3,453<span></span>
</td>
<td class="nump">232,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SettlementOfShareBasedPaymentAwardsAmount', window );">Settlement of share-based payment awards</a></td>
<td class="nump">13<span></span>
</td>
<td class="num">(1,295)<span></span>
</td>
<td class="nump">&#8364; 1,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at the end at Jun. 30, 2023</a></td>
<td class="nump">&#8364; 26,866<span></span>
</td>
<td class="nump">&#8364; 2,052,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (1,430,647)<span></span>
</td>
<td class="num">&#8364; (123)<span></span>
</td>
<td class="nump">&#8364; 649,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SettlementOfShareBasedPaymentAwardsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of share based payment awards settled in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SettlementOfShareBasedPaymentAwardsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Share-based payment expense (incl. deferred taxes)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from the exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B12<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B12_b_viii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective on first application of IFRS 9<br> -Name IFRS<br> -Number 4<br> -IssueDate 2022-03-24<br> -Paragraph 39L<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=4&amp;code=ifrs-tx-2022-en-b&amp;anchor=para_39L_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Note Effective 2023-01-01<br> -Name IFRS<br> -Number 17<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809704416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Interim Condensed Consolidated Statements of Cash Flows - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Loss before income tax</a></td>
<td class="num">&#8364; (124,806)<span></span>
</td>
<td class="num">&#8364; (72,759)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments to reconcile loss before tax to net cash flows</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceIncome', window );">Finance income</a></td>
<td class="num">(10,085)<span></span>
</td>
<td class="num">(5,343)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForFinanceCosts', window );">Finance expense</a></td>
<td class="nump">2,734<span></span>
</td>
<td class="nump">2,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense', window );">Depreciation and impairment of property, plant and equipment and right-of-use assets</a></td>
<td class="nump">11,489<span></span>
</td>
<td class="nump">16,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ImpairmentsOfInventoryAndPrepayments', window );">Impairment of inventory and prepayments</a></td>
<td class="nump">6,879<span></span>
</td>
<td class="nump">25,687<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment expense</a></td>
<td class="nump">4,572<span></span>
</td>
<td class="nump">3,597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions', window );">Non-cash income from release of provisions</a></td>
<td class="num">(1,634)<span></span>
</td>
<td class="num">(47,242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ChangesInWorkingCapitalAbstract', window );"><strong>Working capital changes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners', window );">Decrease / (increase) in assets held for sale</a></td>
<td class="nump">513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Decrease / (increase) in trade receivables and contract assets</a></td>
<td class="nump">2,440<span></span>
</td>
<td class="nump">5,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease / (increase) in inventory</a></td>
<td class="num">(5,084)<span></span>
</td>
<td class="nump">16,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets', window );">Decrease / (increase) in other assets</a></td>
<td class="nump">18,751<span></span>
</td>
<td class="num">(14,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">(Decrease) / increase in trade and other payables, other liabilities and contract liabilities</a></td>
<td class="num">(76,002)<span></span>
</td>
<td class="num">(129,038)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDeferredTaxExpense', window );">Decrease / (increase) in deferred taxes</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities', window );">Income taxes paid</a></td>
<td class="nump">18<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities', window );">Interest received</a></td>
<td class="nump">6,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities', window );">Interest paid</a></td>
<td class="num">(994)<span></span>
</td>
<td class="num">(2,608)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash flow (used in) operating activities</a></td>
<td class="num">(163,702)<span></span>
</td>
<td class="num">(201,175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(27,222)<span></span>
</td>
<td class="num">(43,507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities', window );">Purchase of intangible assets</a></td>
<td class="num">(147)<span></span>
</td>
<td class="num">(1,208)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash flow (used in) investing activities</a></td>
<td class="num">(27,369)<span></span>
</td>
<td class="num">(44,715)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payments on lease obligations</a></td>
<td class="num">(2,526)<span></span>
</td>
<td class="num">(1,943)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from the issuance of Shares (net of transaction costs)</a></td>
<td class="nump">235,840<span></span>
</td>
<td class="nump">4,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions', window );">Payment on / proceeds from treasury shares/exercise of options</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash flow provided by financing activities</a></td>
<td class="nump">233,513<span></span>
</td>
<td class="nump">3,409<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">42,442<span></span>
</td>
<td class="num">(242,481)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Currency translation gains (losses) on cash and cash equivalents</a></td>
<td class="num">(314)<span></span>
</td>
<td class="nump">4,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">495,797<span></span>
</td>
<td class="nump">811,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">&#8364; 537,925<span></span>
</td>
<td class="nump">&#8364; 573,566<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of income taxes paid classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in non-current assets or disposal groups classified as held for sale or as held for distribution to owners to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non cash income from release of provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ChangesInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ChangesInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ImpairmentsOfInventoryAndPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairments of inventory and prepayments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ImpairmentsOfInventoryAndPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of proceed from issuing other equity instrument or exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDeferredTaxExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDeferredTaxExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForFinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForFinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 14<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_14&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for interest paid, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InterestReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from interest received, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InterestReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345812604288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Corporate Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CorporateInformationAbstract', window );"><strong>Corporate Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CorporateInformationTextBlock', window );">Corporate Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">1. Corporate Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">CureVac N.V. (&#8220;CureVac&#8221; or &#8220;CV&#8221; or the &#8220;Company&#8221;) is the parent company of CureVac Group (&#8220;Group&#8221;) and, along with its subsidiaries, is a global biopharmaceutical company developing a new class of transformative medicines based on the messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company is incorporated in the Netherlands and is registered in the commercial register at the Netherlands Chamber of Commerce under 77798031. The Company&#8217;s registered headquarters is Friedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany. During 2021 until now, Dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac. Together with its related parties, dievini has held shares and voting rights in CureVac between appr. 37 &#8211; 46 % during that period. dievini is thus considered to be the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CorporateInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CorporateInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CorporateInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on corporate information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CorporateInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345825048416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfBasisOfPreparationAbstract', window );"><strong>Basis of preparation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock', window );">Basis of preparation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Basis of preparation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements for the three and six months ended June 30, 2023, have been prepared in accordance with IAS 34 Interim Financial Reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#8217;s annual consolidated financial statements as of December 31, 2022. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on August 16, 2023. The Group&#8217;s interim condensed consolidated financial statements are presented in Euros (&#8220;EUR&#8221;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts. Due to rounding, differences may arise when individual amounts or percentages are added together.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New standards, interpretations and amendments adopted by the Group</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#8217;s annual consolidated financial statements for the year ended December 31, 2022. The new and amended standards and interpretations applied for the first time as of January 1, 2023, as disclosed in the notes to the consolidated financial statements as of December 31, 2022, had no impact on the interim condensed consolidated financial statements of the Group as of and for the three and six months ended June 30, 2023. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Impact of COVID-19 and the Russia-Ukraine Conflict</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#8217;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#8217;s operations, including research and manufacturing, could also be disrupted due to the potential impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to the Group&#8217;s laboratory and production operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#8217;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfBasisOfPreparationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfBasisOfPreparationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345825035968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Operations<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory', window );">Notes to the Consolidated Statements of Operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3. Notes to the Consolidated Statements of Operations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.1 Revenue from contract with customers</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Group recognized the following revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Belgium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,756</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 406</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,053</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netherlands</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 892</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 899</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 20,146</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,579</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 44,519</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 14,708</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of these revenues, all of which were recognized over time as part of collaboration agreements, during the six months ended June 30, 2023 EUR 8,545k (June 30, 2022: EUR 31,818k) related to (i) delivery of research services combined with an IP license (recognized from the upfront payments and achievement of certain milestones as further illustrated in the table below), (ii) EUR 903k (June 30, 2022: EUR 431k) related to delivery of products and (iii) EUR 5,260k (June 30, 2022: EUR 12,270k) were recognized from research and development services that are considered distinct from other performance obligations in the agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Of the total revenues recognized, in the six months ended June 30, 2023, EUR 12,756k in revenue was recognized under the collaboration agreements with GSK, entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens (&#8220;GSK I&#8221;) and in April 2021 for research, development and manufacturing of next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as the CureVac&#8217;s second-generation COVID-19 vaccine candidate, CV2CoV (&#8220;GSK II&#8221;). In the first quarter of 2022, the Company reached a development milestone of EUR 10,000k under the GSK I collaboration. Therefore, revenue for the six months ending June 30, 2023, also includes recognition of EUR 755k of the milestone amount (June 30, 2022: EUR 5,321k). The remaining EUR 2,989k of the milestone amount is deferred as contract liability and will be recognized into revenue through the latest expected submission to authorities, which represents the period of time during which CureVac is responsible for development as, subsequent to this period, GSK will be responsible for further development and commercialization. In the six months ended June 30, 2022, revenue consisted of EUR 43,041k primarily recognized from the upfront payments under both collaboration agreements with GSK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Group has received upfront payments which were initially deferred and are subsequently recognized as revenue as the Group renders services over the performance period. Below is a summary of such payments and the related revenues recognized:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and milestone&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;liabilities&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;liabilities&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">GSK  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:25.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR 205,000k (EUR 10,000k milestone payment included)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95,307</p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">CRISPR  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD 3,000k (EUR 2,524k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 775</p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Genmab  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:25.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD 10,000k (EUR 8,937k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,681</p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 107,308</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 98,763</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* Translated at the currency exchange rate prevailing on the transaction date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;width:37.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue&#160;recognized&#160;from</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;width:37.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">upfront&#160;and&#160;milestones&#160;payments</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;three&#160;months&#160;ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:16.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;six&#160;months&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,769</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,496</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 155</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 13,575</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,397</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 31,818</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,545</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Contract balances:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,443</p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 119</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,763</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.2 Cost of sales</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The cost of sales consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,933)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,371)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,869)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,559)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,055)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,096)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36,883)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,630)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,552)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,386)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,516)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,839)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (919)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (534)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,150)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,115)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,158)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,049)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,326)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,219)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (64)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (418)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (169)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,127)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (42,681)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (25,854)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (79,913)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (46,489)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the six months ended June 30, 2023, cost of sales decreased in comparison to corresponding period in 2022. This decline was primarily attributable to higher material costs in the prior year, which were driven by write-offs of raw materials originally procured for the manufacturing of products intended to be sold to GSK. However, these raw materials were no longer expected to be sold to them. Personnel expenses increased mainly due to increased workforce in the manufacturing organization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.3 Selling and distribution expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.75pt;margin:0pt;">Selling and distribution expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (363)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,314)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (560)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,030)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (169)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (227)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (196)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (548)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,408)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (819)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (2,232)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.4 Research and development expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">R&amp;D expenses consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,131)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,728)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,419)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,217)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,795)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,533)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,849)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,570)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,106)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,783)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,508)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,354)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,048)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,081)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,773)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (428)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,827)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (464)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,593)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (929)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (727)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,410)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (11,635)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (30,868)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (22,422)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (55,118)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2023, research and development expenses increased in comparison to the same period of 2022, as the prior year period was largely impacted by the reversal of provision for onerous contracts in the amount of EUR 21,303k as a result of more participants leaving the clinical trials, prior to completion, than originally estimated and of renegotiations of contracts with CROs. Additionally in 2022, GSK took over the Group&#8217;s committed capacity at Novartis (see Note 3.6 for additional information) which resulted in a reduction in the estimated contract termination provisions in the amount of EUR 25,059k. The net effect of these two events resulted in an overall gain within the Third-party services category.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses increased mainly due to increased workforce and the acquisition of Frame Pharmaceuticals. Additionally, share-based payment expense was higher compared to prior year period (refer to Note 5 for further details).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.5 General and administrative expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">General and administrative expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,190)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,644)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,971)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,742)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,404)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,614)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,704)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,915)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,514)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,871)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,796)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,873)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,995)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,446)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,320)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,074)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,152)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,965)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,091)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,071)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,857)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (705)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,796)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,857)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (27,112)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (22,245)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (51,678)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (45,532)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Personnel expenses decreased due to lower workforce in the corporate service functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Others include mainly expenses for D&amp;O insurance and allocations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">3.6 Other operating income</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Compensation for CMO/Material transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 949</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,961</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,803</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Reimbursement Claim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sale of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 484</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Grants and other cost reimbursements from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 239</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 922</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,771</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,442</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 35,207</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,448</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">In March 2022, CureVac AG and GlaxoSmithKline Biologicals SA amended and restated the 2020 GSK agreement and the GSK COVID Agreement in connection with GSK entering into a direct agreement with Novartis for use of Novartis as a CMO at the same time as CureVac exits its CMO agreement with Novartis. Additionally, under the restated agreement, CureVac is entitled to further compensation by GSK. The compensations mainly consist of a consideration for set-up activities undertaken by CureVac (EUR 20,500k) and for reimbursement of prepayments (EUR 12,000k), which were recognized in other operating income in the six months ended June&#160;30, 2022. As an additional result of this agreement, certain reserved capacity at Novartis was also taken over from the Group by GSK, which resulted in the reversal of provisions of EUR 25,059k which had been recognized as of December 31, 2021, and the recognition of a corresponding gain in research and development expenses in the six months ended June 30, 2022 (see Note 3.4).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of notes and other explanatory information as part of a complete set of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345811538320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Issued Capital and Reserves</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">4. Issued Capital and Reserves</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Company&#8217;s articles of association, the Company&#8217;s authorized shares are divided into 386,250,000 common shares and 386,250,000 preferred shares, each having a <span style="-sec-ix-hidden:Hidden_MiCnzCrlpkmaZN49iUzGgg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">nominal</span></span> value of EUR 0.12. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of June 30, 2023, no preferred shares had been issued and all issued common shares issued and outstanding were fully paid.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All payments received from shareholders in excess of the nominal value of the shares issued and net of transaction costs are recognized in capital reserves. Capital reserves also consists of recognition of share-based payments and the equity components of convertible loans. The Company may only make distributions, whether a distribution of profits or of freely distributable reserves, to shareholders to the extent shareholders&#8217; equity exceeds the sum of the paid-in and called-up share capital plus any reserves required by Dutch law or by the Company&#8217;s articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In September 2021, the Company entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market (ATM) offering program, pursuant to which it may sell, from time to time, ordinary shares for aggregate gross proceeds of up to USD 600.0 million. In the first quarter of 2023, 1,748,218 shares were issued under the ATM program, raising USD 17.5 million in net proceeds; related offering expenses were recorded against the proceeds in equity. Following these issuances, the remaining value authorized for sale under the at-the-market program amounts to $497.5 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2023, the Group completed a follow-on public offering whereby it sold 27,027,028 common shares at a price of USD 9.25 per share. The aggregate proceeds, net of underwriting discounts, received by the Group from these transactions were EUR&#160;219,832k. Additional offering costs for legal, accounting, printing and registration fees of EUR 14,580k were recognized as reduction to capital reserve against the proceeds from the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The number of shares issued and outstanding developed as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2022</b></p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 194,997,091</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At-the-market offering program issuances</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,748,218</p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances as part of the public offering</p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,027,028</p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between Jan to Mar 2023</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112,089</p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,913)</p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at March 31, 2023</b></p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 223,851,513</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between Apr to Jun 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,524</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,953)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 223,883,084</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345868452128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based payments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">5. Share-based payments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2023 and 2022, the Group recognized share-based payment expenses of EUR 4,572k and EUR 3,597k, respectively, as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 609</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 761</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,221</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 291</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,324</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,994</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,597</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,572</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Expense recognized for the equity-settled programs was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LTIP Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,337</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU Supervisory Board</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 291</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">New VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (185)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prior VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LTIP RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,920</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,324</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,994</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3,597</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4,572</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 16, 2020, CureVac granted 266,155 options to the former Chief Scientific Officer (CSO). Furthermore, on December 1, 2020, CureVac granted 266,156 options (in 3 tranches) to the Group&#8217;s Chief Business Officer (CBO) and Chief Commercial Officer (CCO). All grants were made under the terms of a new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, none of the options granted to the CBO/CCO under the LTIP were exercised. The CSO exercised 6,303 options during the six months ended June 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 1, 2021, CureVac granted 20,000 options to the Chief Operations Officer (COO). This grant was made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, none of the options granted to the COO were exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 1, 2021, CureVac granted 2,000 options to a key employee and on January 1, 2022, CureVac granted 9,500 options to a key employee. All grants were made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, none of the options were exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 1, 2022, CureVac granted 130,000 options to the Executive Board. All grants were made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June&#160;30, 2023, none of the options were exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2022, CureVac granted 700 options to a key employee. All grants were made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, none of the options were exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On April 1, 2023, CureVac granted 144,379 options to the newly appointed CEO. All grants were made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, none of the options were exercised.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expenses recognized for employee services received under the LTIP Stock Options during the three and six months ended June 30, 2023, is in the amount of EUR 1,362k and EUR 2,337k, respectively (2022: EUR 1,254k and EUR 3,078k, respectively) and is included in general and administrative expenses and selling and distribution expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2021, as part of the LTIP program, the Group awarded RSUs (restricted stock units) to senior executives as well as Supervisory Board members. On June 24, 2021, the Group awarded 10,956 RSUs to Supervisory Board members and on December 23, 2021, the Group awarded 63,095 RSUs to the Executive Board and various key employees. Up to June 30, 2023, 47,424 RSUs were settled. The related RSU expense is recorded in the functional cost category to which the award recipient&#8217;s costs are classified.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 1, 2022, CureVac awarded 36,000 RSUs to the Chief Executive Officer (CEO). The related RSU expense is included in general and administrative expenses. For the three and six months ended June 30, 2023, all RSUs were settled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 31, 2022, CureVac awarded 5,000 RSUs to the Chief Operations Officer (COO) and 30,000 RSUs to the Chief Business Officer (CBO). The related RSU expense is included in general and administrative expenses. Up to June 30, 2023, none of these RSUs were settled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 22, 2022, the Group awarded 36,902 RSUs to Supervisory Board members and 188,986 RSUs to the Executive Board and various key employees. On November 30, 2022, the Group awarded further 7,633 RSU awards to key employees who joined the Group during fiscal 2022. The related RSU expense is recorded in the functional cost category to which the award recipient&#8217;s costs are classified. Up to June 30, 2023, 73,056 RSUs were settled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Effective July 1, 2022, CureVac N.V. acquired all shares of Frame Pharmaceuticals B.V., Amsterdam, Netherlands (formerly Frame Pharmaceuticals), now CureVac Netherlands B.V. On July 1, 2022, CureVac awarded 89,655 RSUs to the former Frame employees. The related RSU expense is recorded in the functional cost category to which the award recipients&#8217; costs are classified. Up to June 30, 2023, 29,881 RSUs were settled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 31, 2023, the Group awarded 92,701 RSUs to the Supervisory Board members and 646,914 RSUs to the Executive Board and various key employees. The related RSU expense is recorded in the functional cost category to which the award recipient's costs are classified. Up to June 30, 2023, no RSUs were settled.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The expenses recognized for employee services received under the LTIP RSUs during the three and six months ended June 30, 2023, is in an amount of EUR 1,379k and EUR 1,920k, respectively (2022: EUR 281k and EUR 497k, respectively) and is included in research and development expenses, general and administrative expenses and selling and distribution expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the former CEO has left the Group as of March 31, 2023, all remaining unvested awards are subject to accelerated vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a Supervisory Board member has left the Group as of June 19, 2023, all remaining unvested awards are subject to accelerated vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the CSO has left the Group as of July 14, 2023, all remaining unvested awards are subject to accelerated vesting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exercise of options</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the New VSOP plan, 11,643 and 48,159 options were exercised within the three and six months ended June 30, 2023, respectively, at a weighted average share price of USD 7.90 and USD 9.81, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345825418928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfFixedAssetsAbstract', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfFixedAssetsExplanatory', window );">Fixed Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6. Fixed Assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6.1 Intangible assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2023, the Group acquired intangible assets of EUR 2,567k (six months ended June 30, 2022: EUR 1,207k). Acquired intangibles mainly related to licenses, software and prepayments made to acquire those.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">6.2 Property, plant and equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2023, the increase in property, plant and equipment was attributable to the purchase of technical equipment and machines and other equipment of EUR 5,940k (June 30, 2022: EUR 3,034k) as well as additional amounts recognized as construction in progress of EUR 22,421k (June 30, 2022: EUR 39,386k) primarily related to the Company-owned GMP IV facility EUR 20,666k.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfFixedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfFixedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfFixedAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for fixed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfFixedAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809858944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets held for sale<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract', window );"><strong>Assets held for sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory', window );">Assets held for sale</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">7. Assets held for sale</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2022, Management decided to dispose of certain equipment which had been procured for CMO activities (CMO Equipment) but that was no longer planned to be used by the Company. An external service-provider was appointed on June 14, 2022 to organize the sale of the CMO Equipment. As of December 31, 2022, the CMO-Equipment identified for sale had a gross book value of EUR 29,531k and was written down by EUR 19,064k (with the corresponding expense recognized in cost of sales) to EUR 10,467k, the fair value less anticipated costs to sell. Criteria for the determination of the fair value were defined based on certain sales scenarios considering different sales campaigns. All sales activities are scheduled for 2023 and as of June 30, 2023 Assets held for sale with a net book value of EUR 513k were sold through an external service provider.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for non-current assets held for sale and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2022-03-24<br> -Section Presentation and disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS05_g30-42__IFRS05_g30-42_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345825034016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfInventoriesAbstract', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfInventoriesExplanatory', window );">Inventories</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">8. Inventories</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The inventories include only raw materials and supplies amounting to EUR 22,194k (December 31, 2022: EUR 23,989k), which are recoverable under the Company&#8217;s agreements with its collaboration partners. During the six months ended June 30, 2023, the decrease in inventory of EUR 1,795k is due primarily to further write-offs and the usage of raw material for R&amp;D purposes, partially compensated by purchases of raw material.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfInventoriesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfInventoriesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfInventoriesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS02_g36-39__IAS02_g36-39_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfInventoriesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809765536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid expenses and other assets (current)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid expenses and other assets (current)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory', window );">Prepaid expenses and other assets (current)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">9. Prepaid expenses and other assets (current)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Prepaid expenses and other current assets as of June 30, 2023 amounted to EUR 21,221k (December 31, 2022: 40,287k) and include receivables for the GSK compensation of EUR 1,491k (December 31, 2022; EUR 5,595k). In addition, other assets include tax claims against the tax authorities of EUR 7,852k (December 31, 2022: EUR 24,840k). These net amounts of VAT refund claims and VAT payables do not bear interest and are reported to the tax authorities on a monthly basis.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345824962880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and financial liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial assets and financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial assets and financial liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">10. Financial assets and financial liabilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fair values of cash and cash equivalents, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. Cash and cash equivalents compromise cash at banks and term deposits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Cash and cash equivalents compromise cash at banks and term deposits. There were no transfers between Level 1 and Level 2 fair value measurements and no transfers into or out of Level 3 fair value measurements during the six months ended June 30, 2023 and 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345825375728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other payables.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory', window );">Trade and other payables</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">11. Trade and other payables</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">Trade and other payables are all due within one year amounting to EUR 13,419k (December 31, 2022: EUR 73,463k). During the six months ended June 30, 2023, the decrease of EUR 60,043k in trade and other payables was primarily due payments to raw material suppliers for invoices received before December 31, 2022.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of trade and other payables. [Refer: Trade and other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345811410384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other liabilities and provisions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherLiabilitiesAndProvisionsAbstract', window );"><strong>Other liabilities and provisions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherLiabilitiesAndProvisionsTextBlock', window );">Other liabilities and provisions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">12. Other liabilities and provisions</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During the six months ended June 30, 2023, the decrease of EUR 4,977k in other liabilities was primarily due to lower accruals for outstanding invoices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of June 30, 2023 the contract terminations provisions of EUR 61,320k which are reflecting amounts which the Company expects to pay out to settle its obligations under certain CMO contracts which it has terminated, were reclassed from Provisions (non-current) into Provisions (current) due to an expected maturity within one year. In addition, during the six months ended June 30, 2023, the decrease of EUR 1,932k in Provisions (current) was primarily due to a consumption of the CRO provision for onerous losses.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherLiabilitiesAndProvisionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherLiabilitiesAndProvisionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherLiabilitiesAndProvisionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of other liabilities and provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherLiabilitiesAndProvisionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345811308416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income tax<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract', window );"><strong>Income tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIncomeTaxExplanatory', window );">Income tax</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">13. Income tax</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The increase in expense was primarily attributable to the income tax expense of CureVac Swiss AG and CureVac Belgium S.A.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIncomeTaxExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS12_g79-88__IAS12_g79-88_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIncomeTaxExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345813126912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Disclosure of financial instruments and risk management<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_FinancialInstrumentsAndRiskManagementAbstract', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory', window );">Disclosure of financial instruments and risk management</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">14. Disclosure of financial instruments and risk management</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group requires significant liquid funds available for the financing of its COVID-19 and influenza research and development activities, during the six months ended June 30, 2023, it has maintained funds as cash and cash equivalents and not in less liquid financial instruments. The Group has distributed the cash amongst several banks and amongst the legal entities in the Group in order to reduce negative interest penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Refer to note 16 to the consolidated financial statements as of December&#160;31, 2022 for additional information on the Group&#8217;s risk management activities. As of June 30, 2023, the Group held cash and cash equivalents of USD 73,600k and CHF 132k, which are exposed to foreign currency exchange risk. The Group intends to settle expenses arising in US dollars using these US dollar funds. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_FinancialInstrumentsAndRiskManagementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_FinancialInstrumentsAndRiskManagementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialRiskManagementExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the entity's financial risk management practices and policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialRiskManagementExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345811318592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareExplanatory', window );">Earnings per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">15. Earnings per share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;">Earnings per share is calculated pursuant to <i style="font-style:italic;">IAS 33 Earnings per Share</i> by dividing the consolidated net loss in CureVac N.V. by the average weighted number of shares outstanding in the fiscal period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt;">The weighted number of shares outstanding for the three and six months ended June 30, 2023 was 223,883,084 and 217,698,351, respectively (2022: 187,089,253 and 187,041,805, respectively). This has led to a basic loss per share for the three and six months ended June 30, 2023 of EUR 0.30 and EUR 0.57, respectively (2022: EUR 0.31 and EUR 0.39, respectively). Since the conversion of options to ordinary shares would decrease loss per share, they are considered antidilutive. Therefore, the diluted earnings per share equals basic earnings per share for the three and six months ended June 30, 2023 and 2022. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345825047952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRelatedPartyExplanatory', window );">Related party disclosures</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">16. Related party disclosures</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dietmar Hopp</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">During fiscal 2019, Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), the largest shareholder of the Group, granted two convertible loans to the Group, which were repaid in 2020. Additionally, in August 2020, DH-LT Investments GmbH, a company beneficially owned by Dietmar Hopp, managing director of dievini, the Group<span style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</span>s largest shareholder, purchased EUR 100,000k of the Group<span style="font-family:'Arial','Helvetica','sans-serif';">&#8217;</span>s common shares at a price of USD 16.00 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Antony Blanc</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.2pt;margin:0pt 0pt 8pt 0pt;">In 2020, a consulting agreement between CureVac AG and Clarentis SRL was made. Clarentis SRL is a wholly owned consulting company of Antony Blanc, PhD, the CBO of CureVac. After the transition of Antony Blanc to the Management Board in February 2021, the contract was no longer active, and no new orders were placed. In Q3 2021, a milestone payment, which related to the submission of the EMA dossier for CVnCoV and which amounted to EUR 100k was made to fulfill a contractual obligation from the consulting agreement in place before Antony Blanc joined the Management Board. In addition to his Management Board position at CureVac N.V., Antony also took over the role as Management Director at CureVac Belgium SA. He executes this function by using Clarentis SRL. As it relates to these services, CureVac paid in 2023 until June 2023 an amount of EUR 42k. The amounts invoiced for this function/services will be offset/deducted from his base compensation for his function on the Board of Management of CureVac N.V.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">BePharBel Manufacturing S.A.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In December 2020, CureVac Real Estate GmbH and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group&#8217;s first concentrated COVID-19 vaccine candidate, CVnCoV, to the amount specified by each dose level. Pursuant to the terms of the agreement, it was intended that BePharBel Manufacturing would manufacture and deliver to CureVac Real Estate GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021 due to COVID-19 virus drift, WHO COVID vaccine efficiency recommendation and market expectations, CureVac Real Estate GmbH terminated the commercial and supply agreement with BePahrBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of EUR 3,900k, which had been already recognized in provisions, based on an estimate, as of December 31, 2021. In total an amount of EUR 4,016k was paid. Baron Jean St&#233;phenne, Chairman of our Supervisory Board, holds directly and indirectly 15.61% of BePharBel Manufacturing&#8217;s equity and is a director of BePharBel Manufacturing, and Baron Jean St&#233;phenne&#8217;s son, Vincent St&#233;phenne, holds 1.43% of BePharBel Manufacturing&#8217;s equity and is a managing director of BePharBel Manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Franz-Werner Haas</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In Q1 2023, a consulting agreement between CureVac SE and Franz-Werner Haas was entered into. For the six-month period ended June 30, 2023 no costs have been paid under this agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alexander Zehnder</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In Q1 2023, a first addendum to the future service agreement was entered into to ensure a smooth transition from CEO Franz-Werner Haas to the new CEO Alexander Zehnder. Total compensation amounted to EUR 51k during the month of March.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Barker BioMedical GmbH</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In Q1 2023, a consulting agreement between CureVac SE and Barker BioMedical GmbH was entered into. Barker BioMedical GmBH is a wholly-owned consulting company of Debra Barker, Supervisory Board member of CureVac N.V.. For the six-month period ended June 30, 2023 total costs incurred under this agreement amount to EUR 14k.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Craig Tooman</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">In Q1 2023, a consulting agreement was entered into between CureVac SE and Craig Tooman. For the six-month period ended June&#160;30, 2023, no costs have been incurred under this agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRelatedPartyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Section Disclosures<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS24_g13-24__IAS24_g13-24_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRelatedPartyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345825362416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Subsequent events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">17. Subsequent events</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of July 14, 2023, Dr. Igor Splawski, CureVac&#8217;s Chief Scientific Officer (CSO), stepped down from his role as CSO. During the search for a successor, CureVac&#8217;s Chief Development Officer, Dr. Myriam Mendila, will head the advancement of CureVac&#8217;s mRNA technology platform and its integration with the clinical development of novel mRNA vaccines and therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">CureVac filed a patent infringement lawsuit in Germany against BioNTech regarding four of its intellectual property rights in June 2022. The patent litigation was strengthened by the addition of a fifth intellectual property right as announced in May 2023. In July 2023, CureVac announced that it has extended these five intellectual property rights by three more recent intellectual property rights. In total, the patent litigation in Germany now covers eight intellectual property rights. A first public hearing on this lawsuit took place on August 15, 2023, before the Regional Court D&#252;sseldorf. A nullity action covering one of the patents at issue was filed by Pfizer/BioNTech in September 2022. A preliminary opinion issued in April 2023 by the German Federal Patent Court supports the validity of the CureVac patent. In the U.S., Pfizer/BioNTech filed a case in late July 2022, asking for confirmation that Comirnaty&#174; does not infringe three CureVac patents. In May 2023, CureVac filed a counterclaim in the U.S. that alleges infringement of nine U.S. patents, expanding the scope of the case beyond the three patents originally named by Pfizer/BioNTech. These nine patents have been extended by a tenth patent as announced in July 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2022-03-24<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2022-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_IAS10_g17-22_TI<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345811246704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of preparation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfBasisOfPreparationAbstract', window );"><strong>Basis of preparation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements for the three and six months ended June 30, 2023, have been prepared in accordance with IAS 34 Interim Financial Reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#8217;s annual consolidated financial statements as of December 31, 2022. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on August 16, 2023. The Group&#8217;s interim condensed consolidated financial statements are presented in Euros (&#8220;EUR&#8221;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts. Due to rounding, differences may arise when individual amounts or percentages are added together.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock', window );">New standards, interpretations and amendments adopted by the Group</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">New standards, interpretations and amendments adopted by the Group</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#8217;s annual consolidated financial statements for the year ended December 31, 2022. The new and amended standards and interpretations applied for the first time as of January 1, 2023, as disclosed in the notes to the consolidated financial statements as of December 31, 2022, had no impact on the interim condensed consolidated financial statements of the Group as of and for the three and six months ended June 30, 2023. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory', window );">Impact of COVID-19 and the Russia-Ukraine Conflict</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Impact of COVID-19 and the Russia-Ukraine Conflict</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#8217;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#8217;s operations, including research and manufacturing, could also be disrupted due to the potential impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to the Group&#8217;s laboratory and production operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#8217;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of accounting policy for Covid-19 impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the entity's accounting policy for New standards, interpretations and amendments adopted by the Group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfBasisOfPreparationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfBasisOfPreparationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809204768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Schedule of revenue from contract with customers recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Belgium</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,283</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 43,041</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,756</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 406</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,053</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Netherlands</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 445</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 892</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 899</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 20,146</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 7,579</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 44,519</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 14,708</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory', window );">Summary of upfront payments and related revenues recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones payments included</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in contract</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Upfront and milestone&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;liabilities&#160;at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;liabilities&#160;at</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">payments</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">GSK  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:25.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">EUR 205,000k (EUR 10,000k milestone payment included)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 102,804</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 95,307</p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">CRISPR  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD 3,000k (EUR 2,524k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 929</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 775</p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">Genmab  </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:25.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">USD 10,000k (EUR 8,937k)*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,681</p></td></tr><tr><td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 107,308</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 98,763</b></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">* Translated at the currency exchange rate prevailing on the transaction date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="7" style="vertical-align:bottom;width:37.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Revenue&#160;recognized&#160;from</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;width:37.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">upfront&#160;and&#160;milestones&#160;payments</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;three&#160;months&#160;ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:16.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">for&#160;six&#160;months&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Customer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(EUR k)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">GSK</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,051</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 30,769</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,496</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">CRISPR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 155</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Genmab</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 447</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 894</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 13,575</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,397</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 31,818</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 8,545</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory', window );">Schedule of contract balances</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,443</p></td></tr><tr><td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,707</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 119</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 107,308</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 98,763</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory', window );">Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">The cost of sales consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,933)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,371)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (13,869)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (17,559)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,055)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,096)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (36,883)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,630)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,552)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,386)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (19,516)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,839)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (919)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (534)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,150)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,115)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,158)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,049)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,326)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,219)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (64)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (418)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (169)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,127)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (42,681)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (25,854)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (79,913)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (46,489)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.75pt;margin:0pt;">Selling and distribution expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (363)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,314)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (560)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,030)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (169)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (88)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (227)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (196)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (548)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (1,408)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (819)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (2,232)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">R&amp;D expenses consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,131)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,728)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,419)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,217)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,795)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,533)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (14,849)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (23,570)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,106)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,783)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,119)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,508)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patents and fees to register a legal right</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,191)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,354)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,048)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,252</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,081)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,053</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,773)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (428)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,827)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (464)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,593)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (929)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (727)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,270)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,410)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (11,635)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (30,868)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (22,422)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (55,118)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">General and administrative expenses consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,190)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,644)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (18,971)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (15,742)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maintenance and lease </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,404)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,614)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,704)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,915)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Third-party services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,514)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,871)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,796)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,873)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Legal and other professional services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,995)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4,446)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,320)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,074)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization and depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,152)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,965)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,091)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,071)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,857)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (705)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,796)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,857)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (27,112)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (22,245)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (51,678)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (45,532)</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory', window );">Schedule of other operating income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Compensation for CMO/Material transfer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 949</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 259</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 33,961</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,803</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Reimbursement Claim</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Sale of equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 310</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 484</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Grants and other cost reimbursements from government agencies and similar bodies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 35</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 237</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 239</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 222</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 922</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,771</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,442</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 35,207</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,448</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of detailed information about upfront payments and related revenues recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfExpensesByNatureExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of expenses by nature. [Refer: Expenses, by nature]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfExpensesByNatureExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345825283280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory', window );">Schedule of total shares</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at December 31, 2022</b></p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 194,997,091</b></p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">At-the-market offering program issuances</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,748,218</p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances as part of the public offering</p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 27,027,028</p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between Jan to Mar 2023</p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112,089</p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32,913)</p></td></tr><tr><td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at March 31, 2023</b></p></td><td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 223,851,513</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share issuances for exercises between Apr to Jun 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 41,524</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasury shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,953)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Common shares issued and outstanding at June 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 223,883,084</b></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of classes of share capital. [Refer: Share capital [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809030048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory', window );">Schedule of share-based payments expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cost of sales</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling and distribution expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 153</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 609</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 90</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 761</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,359</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,221</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other operating expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 291</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 1,324</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 2,994</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 3,597</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;"> 4,572</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock', window );">Schedule for expense recognized for the equity-settled programs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Program</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EUR&#160;k</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LTIP Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,337</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">RSU Supervisory Board</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 291</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">New VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (185)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (12)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (82)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 45</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prior VSOP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (75)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (21)</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">LTIP RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,920</p></td></tr><tr><td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 1,324</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 2,994</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 3,597</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 4,572</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of expense recognized for employee services explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of expense recognized for the programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345812926832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Corporate Information (Details) - Dievini<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Corporate Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PercentageOfVotingInterestsHeld', window );">Voting interests held</a></td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Corporate Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PercentageOfVotingInterestsHeld', window );">Voting interests held</a></td>
<td class="nump">46.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PercentageOfVotingInterestsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of voting equity interests held in the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PercentageOfVotingInterestsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_LargestShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_LargestShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345810180864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">&#8364; 7,579<span></span>
</td>
<td class="nump">&#8364; 20,146<span></span>
</td>
<td class="nump">&#8364; 14,708<span></span>
</td>
<td class="nump">&#8364; 44,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">Research services combined with an IP license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,545<span></span>
</td>
<td class="nump">31,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember', window );">Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">903<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesMember', window );">Research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,260<span></span>
</td>
<td class="nump">12,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_BE', window );">Belgium | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">6,283<span></span>
</td>
<td class="nump">19,295<span></span>
</td>
<td class="nump">12,756<span></span>
</td>
<td class="nump">43,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_CH', window );">Switzerland | CRISPR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">844<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_NL', window );">Netherlands | Genmab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Total revenues</a></td>
<td class="nump">&#8364; 452<span></span>
</td>
<td class="nump">&#8364; 445<span></span>
</td>
<td class="nump">&#8364; 899<span></span>
</td>
<td class="nump">&#8364; 892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_IfrsProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_CrisprMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_CrisprMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_NL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_NL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GenmabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GenmabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345812872432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Operations - Additional Information (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="nump">&#8364; 7,579<span></span>
</td>
<td class="nump">&#8364; 20,146<span></span>
</td>
<td class="nump">&#8364; 14,708<span></span>
</td>
<td class="nump">&#8364; 44,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_MilestoneRevenuesMember', window );">Milestone revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">5,321<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdditionalDevelopmentMilestonePaymentsReceived', window );">Additional development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities', window );">Development milestone payment included in contract liabilities</a></td>
<td class="nump">2,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember', window );">GSK | Belgium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Revenue recognized</a></td>
<td class="nump">&#8364; 6,283<span></span>
</td>
<td class="nump">&#8364; 19,295<span></span>
</td>
<td class="nump">&#8364; 12,756<span></span>
</td>
<td class="nump">&#8364; 43,041<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdditionalDevelopmentMilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additional development milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdditionalDevelopmentMilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of development milestone payment included in contract liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_MilestoneRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_MilestoneRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_BE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_BE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345810046432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Operations - Summary of upfront payments and related revenues recognized (Details)<br> &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">&#8364; 98,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 98,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 107,308<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront and milestone payments</a></td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">95,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,804<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=cvac_CrisprMember', window );">CRISPR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront and milestone payments</a></td>
<td class="nump">2,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">929<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=cvac_GenmabMember', window );">Genmab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront and milestone payments</a></td>
<td class="nump">8,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,937<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsIncludedInContractLiabilities', window );">Upfront and milestones payments included in contract liabilities</a></td>
<td class="nump">2,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember', window );">Minimum | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_UpfrontPaymentsReceivedOrReceivable', window );">Upfront and milestone payments</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">Research services combined with an IP license</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">4,397<span></span>
</td>
<td class="nump">&#8364; 13,575<span></span>
</td>
<td class="nump">8,545<span></span>
</td>
<td class="nump">&#8364; 31,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">Research services combined with an IP license | GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">3,873<span></span>
</td>
<td class="nump">13,051<span></span>
</td>
<td class="nump">7,496<span></span>
</td>
<td class="nump">30,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">Research services combined with an IP license | CRISPR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember', window );">Research services combined with an IP license | Genmab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod', window );">Revenue recognized from upfront and milestones payments</a></td>
<td class="nump">&#8364; 447<span></span>
</td>
<td class="nump">&#8364; 447<span></span>
</td>
<td class="nump">&#8364; 894<span></span>
</td>
<td class="nump">&#8364; 894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UpfrontPaymentsIncludedInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payments of the company included in contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UpfrontPaymentsIncludedInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_UpfrontPaymentsReceivedOrReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of upfront payments received or receivable by the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_UpfrontPaymentsReceivedOrReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 116<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_116_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_CrisprMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_CrisprMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=cvac_GenmabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=cvac_GenmabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=cvac_ResearchServicesCombinedWithIpLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809160816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Operations - Contract balances (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">&#8364; 6,443<span></span>
</td>
<td class="nump">&#8364; 6,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractAssets', window );">Contract assets</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">2,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">&#8364; 98,763<span></span>
</td>
<td class="nump">&#8364; 107,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an entity&#8217;s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 116<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_116_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract assets. [Refer: Contract assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2022-03-24<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809976544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Operations - Cost of sales (Details) - Cost of sales - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">&#8364; (9,371)<span></span>
</td>
<td class="num">&#8364; (5,933)<span></span>
</td>
<td class="num">&#8364; (17,559)<span></span>
</td>
<td class="num">&#8364; (13,869)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Materials</a></td>
<td class="num">(8,096)<span></span>
</td>
<td class="num">(14,055)<span></span>
</td>
<td class="num">(12,630)<span></span>
</td>
<td class="num">(36,883)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="num">(6,386)<span></span>
</td>
<td class="num">(18,552)<span></span>
</td>
<td class="num">(11,839)<span></span>
</td>
<td class="num">(19,516)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(534)<span></span>
</td>
<td class="num">(919)<span></span>
</td>
<td class="num">(1,115)<span></span>
</td>
<td class="num">(1,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(1,049)<span></span>
</td>
<td class="num">(3,158)<span></span>
</td>
<td class="num">(2,219)<span></span>
</td>
<td class="num">(8,326)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(418)<span></span>
</td>
<td class="num">(64)<span></span>
</td>
<td class="num">(1,127)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">&#8364; (25,854)<span></span>
</td>
<td class="num">&#8364; (42,681)<span></span>
</td>
<td class="num">&#8364; (46,489)<span></span>
</td>
<td class="num">&#8364; (79,913)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaintenanceAndLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maintenance and lease expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaintenanceAndLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ThirdPartyServiceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for third party services during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ThirdPartyServiceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterialsAndConsumablesUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterialsAndConsumablesUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsCostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsCostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809975296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Operations - Selling and distribution expenses (Details) - Selling and distribution expenses - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">&#8364; (1,314)<span></span>
</td>
<td class="num">&#8364; (363)<span></span>
</td>
<td class="num">&#8364; (2,030)<span></span>
</td>
<td class="num">&#8364; (560)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(88)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="num">(196)<span></span>
</td>
<td class="num">(227)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">&#8364; (1,408)<span></span>
</td>
<td class="num">&#8364; (548)<span></span>
</td>
<td class="num">&#8364; (2,232)<span></span>
</td>
<td class="num">&#8364; (819)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_SellingAndDistributionExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_SellingAndDistributionExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809932192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Operations - Research and development expenses (Details) - Research and development expenses - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterialsAndConsumablesUsed', window );">Materials</a></td>
<td class="nump">&#8364; 5,728<span></span>
</td>
<td class="nump">&#8364; 6,131<span></span>
</td>
<td class="nump">&#8364; 9,217<span></span>
</td>
<td class="nump">&#8364; 23,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">(12,533)<span></span>
</td>
<td class="num">(7,795)<span></span>
</td>
<td class="num">(23,570)<span></span>
</td>
<td class="num">(14,849)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(1,783)<span></span>
</td>
<td class="num">(1,106)<span></span>
</td>
<td class="num">(3,508)<span></span>
</td>
<td class="num">(2,119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PatentsAndFeesToRegisterLegalRight', window );">Patents and fees to register a legal right</a></td>
<td class="num">(1,191)<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="num">(2,048)<span></span>
</td>
<td class="num">(1,354)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="num">(7,081)<span></span>
</td>
<td class="nump">4,252<span></span>
</td>
<td class="num">(11,773)<span></span>
</td>
<td class="nump">21,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(1,827)<span></span>
</td>
<td class="num">(428)<span></span>
</td>
<td class="num">(3,593)<span></span>
</td>
<td class="num">(464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(727)<span></span>
</td>
<td class="num">(929)<span></span>
</td>
<td class="num">(1,410)<span></span>
</td>
<td class="num">(1,270)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">&#8364; (30,868)<span></span>
</td>
<td class="num">&#8364; (11,635)<span></span>
</td>
<td class="num">(55,118)<span></span>
</td>
<td class="num">&#8364; (22,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract', window );">Increase in research and development expenses due to reversal of provision for onerous contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 21,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsProvisionForLossOnContracts', window );">Estimated contract termination provisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,059<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsProvisionForLossOnContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of provision for loss on contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsProvisionForLossOnContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of increase in R&amp;D expenses due to reversal of provision for onerous contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaintenanceAndLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maintenance and lease expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaintenanceAndLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PatentsAndFeesToRegisterLegalRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for registering a legal right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PatentsAndFeesToRegisterLegalRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ThirdPartyServiceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for third party services during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ThirdPartyServiceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterialsAndConsumablesUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterialsAndConsumablesUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809924944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Operations - General and administrative expenses (Details) - General and administrative expenses - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PersonnelExpenses', window );">Personnel</a></td>
<td class="num">&#8364; (6,644)<span></span>
</td>
<td class="num">&#8364; (9,190)<span></span>
</td>
<td class="num">&#8364; (15,742)<span></span>
</td>
<td class="num">&#8364; (18,971)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MaintenanceAndLeaseExpenses', window );">Maintenance and lease</a></td>
<td class="num">(1,614)<span></span>
</td>
<td class="num">(1,404)<span></span>
</td>
<td class="num">(2,915)<span></span>
</td>
<td class="num">(2,704)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ThirdPartyServiceExpenses', window );">Third-party services</a></td>
<td class="num">(5,871)<span></span>
</td>
<td class="num">(7,514)<span></span>
</td>
<td class="num">(12,873)<span></span>
</td>
<td class="num">(12,796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfessionalFeesExpense', window );">Legal and other professional services</a></td>
<td class="num">(4,446)<span></span>
</td>
<td class="num">(2,995)<span></span>
</td>
<td class="num">(6,074)<span></span>
</td>
<td class="num">(5,320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationAndAmortisationExpense', window );">Amortization and depreciation</a></td>
<td class="num">(2,965)<span></span>
</td>
<td class="num">(3,152)<span></span>
</td>
<td class="num">(6,071)<span></span>
</td>
<td class="num">(6,091)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherExpense', window );">Other</a></td>
<td class="num">(705)<span></span>
</td>
<td class="num">(2,857)<span></span>
</td>
<td class="num">(1,857)<span></span>
</td>
<td class="num">(5,796)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseByNature', window );">Total</a></td>
<td class="num">&#8364; (22,245)<span></span>
</td>
<td class="num">&#8364; (27,112)<span></span>
</td>
<td class="num">&#8364; (45,532)<span></span>
</td>
<td class="num">&#8364; (51,678)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MaintenanceAndLeaseExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maintenance and lease expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MaintenanceAndLeaseExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PersonnelExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of personnel expenses incurred by the company during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PersonnelExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ThirdPartyServiceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred by the company for third party services during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ThirdPartyServiceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationAndAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 28<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_28_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph B13<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B13_d&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2022-03-24<br> -Paragraph 23<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_23_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 104<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_104&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationAndAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseByNature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseByNature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfessionalFeesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fees paid or payable for professional services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfessionalFeesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsGeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsIncomeStatementLocationAxis=cvac_IfrsGeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345811224928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Operations - Other operating income (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems', window );"><strong>Notes to the Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CompensationForContractManufacturingOrganizationsTransfer', window );">Compensation for CMO/Materials transfer</a></td>
<td class="nump">&#8364; 259<span></span>
</td>
<td class="nump">&#8364; 949<span></span>
</td>
<td class="nump">&#8364; 1,803<span></span>
</td>
<td class="nump">&#8364; 33,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CostOfReimbursementClaim', window );">Reimbursement claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_SaleOfEquipment', window );">Sale of equipment</a></td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_OtherOperatingIncomeGovernmentGrants', window );">Grants and other reimbursements from government agencies and similar bodies</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">239<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_MiscellaneousOtherOperatingIncomeOther', window );">Other</a></td>
<td class="nump">770<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">922<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Total</a></td>
<td class="nump">&#8364; 1,442<span></span>
</td>
<td class="nump">&#8364; 1,771<span></span>
</td>
<td class="nump">&#8364; 3,448<span></span>
</td>
<td class="nump">&#8364; 35,207<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CompensationForContractManufacturingOrganizationsTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of income recognised on compensation for contract manufacturing organizations transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CompensationForContractManufacturingOrganizationsTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CostOfReimbursementClaim">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cost of reimbursement claim.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CostOfReimbursementClaim</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents of disclosure of notes to the consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_MiscellaneousOtherOperatingIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_MiscellaneousOtherOperatingIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_OtherOperatingIncomeGovernmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other operating income recognized in relation to government agencies and similar bodies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_OtherOperatingIncomeGovernmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_SaleOfEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of sale of equipment in operating income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_SaleOfEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809177920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes to the Consolidated Statements of Operations - Grants with government agencies and similar bodies (Details) - GSK [Member] - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfGovernmentGrantsLineItems', window );"><strong>Notes to the consolidated financial statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities', window );">Compensation consist for set-up activities</a></td>
<td class="nump">&#8364; 20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses', window );">Reimbursement of prepayments</a></td>
<td class="nump">&#8364; 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver', window );">Reversal of provision recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25,059<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for consideration for set-up activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for Manufacturing Interim Period Reimbursable Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfGovernmentGrantsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfGovernmentGrantsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of provisions reversed due to certain reserved capacity taken over from the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=cvac_GlaxosmithklineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345811251536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Issued Capital and Reserves - Overview and General Remarks (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>&#8364; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Common shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorized</a></td>
<td class="nump">386,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Notional value per share | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember', window );">Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorized</a></td>
<td class="nump">386,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Notional value per share | &#8364; / shares</a></td>
<td class="nump">&#8364; 0.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809612640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves - At-the-market offering (Details)<br> $ / shares in Units, &#8364; in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Cash received from issuance of shares | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 235,840<span></span>
</td>
<td class="nump">&#8364; 4,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember', window );">ATM Offering Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Cash received from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,748,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AggregateGrossProceedsReceivableFromIssuingShares', window );">Aggregate gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RemainingAuthorizedForSaleValue', window );">Remaining authorized for sale value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 497,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsSaleOfStockAxis=cvac_FollowOnPublicOfferingMember', window );">Follow-on public offering, incl. Greenshoe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Cash received from issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsStockIssuedDuringPeriodSharesNewIssues', window );">Shares issued | shares</a></td>
<td class="nump">27,027,028<span></span>
</td>
<td class="nump">27,027,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,027,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsSharesIssuedPricePerShare', window );">Price per shares issued in follow-on public offering | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve', window );">Additional offering costs recognized as reduction to capital reserve | &#8364;</a></td>
<td class="nump">&#8364; 14,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional offering costs recognized as reduction to capital reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AggregateGrossProceedsReceivableFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of aggregate gross proceeds receivable from issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AggregateGrossProceedsReceivableFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RemainingAuthorizedForSaleValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of remaining authorized for sale value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RemainingAuthorizedForSaleValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSaleOfStockAxis=cvac_AtMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsSaleOfStockAxis=cvac_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsSaleOfStockAxis=cvac_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345812779840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Issued Capital and Reserves - Impact of share split (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Issued Capital and Reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CommonSharesIssuedAndOutstanding', window );">Common shares issued and outstanding beginning</a></td>
<td class="nump">223,851,513<span></span>
</td>
<td class="nump">194,997,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares', window );">Treasury shares</a></td>
<td class="num">(9,953)<span></span>
</td>
<td class="num">(32,913)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_StockIssuedDuringPeriodForExercises', window );">Share issuances for exercises</a></td>
<td class="nump">41,524<span></span>
</td>
<td class="nump">112,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CommonSharesIssuedAndOutstanding', window );">Common shares issued and outstanding ending</a></td>
<td class="nump">223,883,084<span></span>
</td>
<td class="nump">223,851,513<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CommonSharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued and outstanding for during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CommonSharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents for decrease in number of shares due to treasury of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_StockIssuedDuringPeriodForExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period, upon exercises.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_StockIssuedDuringPeriodForExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809007248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Expenses (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales', window );">Cost of sales</a></td>
<td class="nump">&#8364; 147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses', window );">Selling and distribution expenses</a></td>
<td class="nump">112<span></span>
</td>
<td class="num">&#8364; (6)<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">&#8364; 61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses', window );">Research and development expenses</a></td>
<td class="nump">609<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">761<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">1,380<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
<td class="nump">3,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses', window );">Other operating expenses</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_BenefitExpenseRecognizedForShareBasedPayment', window );">Total</a></td>
<td class="nump">&#8364; 2,994<span></span>
</td>
<td class="nump">&#8364; 1,324<span></span>
</td>
<td class="nump">&#8364; 4,572<span></span>
</td>
<td class="nump">&#8364; 3,597<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_BenefitExpenseRecognizedForShareBasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit expense benefit recognized for share-based payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_BenefitExpenseRecognizedForShareBasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in cost of sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in other operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809941824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments - Equity-settled programs (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Total</a></td>
<td class="nump">&#8364; 2,994<span></span>
</td>
<td class="nump">&#8364; 1,324<span></span>
</td>
<td class="nump">&#8364; 4,572<span></span>
</td>
<td class="nump">&#8364; 3,597<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Total</a></td>
<td class="nump">1,362<span></span>
</td>
<td class="nump">1,254<span></span>
</td>
<td class="nump">2,337<span></span>
</td>
<td class="nump">3,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_IfrsRestrictedStockUnitMember', window );">RSU Supervisory Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Total</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_NewVirtualStockOptionsPlanMember', window );">New VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Total</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_PriorVirtualStockOptionsPlanMember', window );">Prior VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Total</a></td>
<td class="nump">30<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanAndRestrictedStockUnitMember', window );">LTIP RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedForEmployeeServices', window );">Total</a></td>
<td class="nump">&#8364; 1,379<span></span>
</td>
<td class="nump">&#8364; 281<span></span>
</td>
<td class="nump">&#8364; 1,920<span></span>
</td>
<td class="nump">&#8364; 497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseRecognizedForEmployeeServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized for employee services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseRecognizedForEmployeeServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_IfrsRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_IfrsRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_NewVirtualStockOptionsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_NewVirtualStockOptionsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_PriorVirtualStockOptionsPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_PriorVirtualStockOptionsPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanAndRestrictedStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanAndRestrictedStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345803972880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based payments (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 01, 2023 </div>
<div>Option</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>Option</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jul. 01, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jun. 22, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Apr. 01, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Mar. 01, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 23, 2021 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jun. 24, 2021 </div>
<div>Option</div>
</th>
<th class="th">
<div>Mar. 01, 2021 </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 01, 2020 </div>
<div>Option</div>
</th>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>Option</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;) </div>
<div>Option</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;) </div>
<div>Option </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Option</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based based payments expenses | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement', window );">Number of RSUs settled | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember', window );">LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement', window );">Number of RSUs settled | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Benefit expenses recognized | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,254<span></span>
</td>
<td class="nump">&#8364; 2,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu', window );">Expenses recognized with RSU | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 281<span></span>
</td>
<td class="nump">&#8364; 1,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember', window );">New VSOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019', window );">Average share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ChiefScientificOfficerMember', window );">Former Chief Scientific Officer | LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember', window );">Chief Business Officer and Chief Commercial Officer | LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operating Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of RSU awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember', window );">Chief Operating Officer | LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ThenChiefExecutiveOfficerMember', window );">the Chief Executive Officer | LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember', window );">Members of executive board and various key employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember', window );">Members of executive board and various key employees | LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement', window );">Number of RSU awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember', window );">Key employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement', window );">Number of RSUs settled | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember', window );">Key employees | LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ExecutiveBoardMembersMember', window );">Executive Board members | LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement', window );">Number of share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement', window );">Number of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_SupervisoryBoardMembersMember', window );">Supervisory Board members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_SupervisoryBoardMembersMember', window );">Supervisory Board members | LTIP Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerMember', window );">Chief Business Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_FormerFrameEmployeesMember', window );">Former Frame employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Share-based payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSU's awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement', window );">Number of RSUs settled | shares</a></td>
<td class="nump">29,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets Rsu. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments settled in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 51<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_51_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of instruments granted in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph IG23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_IG23&amp;doctype=Implementation%20Guidance<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options exercised in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_ii&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_b_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=cvac_VirtualSharesProgramIiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefScientificOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefScientificOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefOperatingOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ThenChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ThenChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_KeyEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ExecutiveBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ExecutiveBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_SupervisoryBoardMembersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_SupervisoryBoardMembersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_ChiefBusinessOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_FormerFrameEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_FormerFrameEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345812939056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets - Intangible assets (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember', window );">Acquisition costs | licenses, software and prepayments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill', window );">Additions</a></td>
<td class="nump">&#8364; 2,567<span></span>
</td>
<td class="nump">&#8364; 1,207<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2022-03-24<br> -Paragraph 118<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_118_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis=ifrs-full_GrossCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=cvac_LicensesSoftwareAndPrepaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis=cvac_LicensesSoftwareAndPrepaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345811284432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets - Property, plant and equipment (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Beginning balance</a></td>
<td class="nump">&#8364; 197,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Ending balance</a></td>
<td class="nump">219,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember', window );">Technical equipment and machines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">5,940<span></span>
</td>
<td class="nump">&#8364; 3,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember', window );">Assets under construction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">22,421<span></span>
</td>
<td class="nump">&#8364; 39,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_CompanyOwnedGmpIvFacilityMember', window );">Company-owned GMP IV facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems', window );"><strong>Fixed Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment', window );">Additions</a></td>
<td class="nump">&#8364; 20,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2022-03-24<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=ifrs-full_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_CompanyOwnedGmpIvFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis=cvac_CompanyOwnedGmpIvFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345824944864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets held for sale (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract', window );"><strong>Assets held for sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_GrossBookValueOfCmoEquipmentHeldForSale', window );">Gross book value of CMO-Equipment held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 29,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ImpairmentOfAssetsHeldForSale', window );">Impairment of assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InventoriesAtFairValueLessCostsToSell', window );">Inventories fair value costs to sell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_AssetsHeldForSaleNetBookValueSold', window );">Assets held for sale with a net book value sold</a></td>
<td class="nump">&#8364; 513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_AssetsHeldForSaleNetBookValueSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value sold of assets held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_AssetsHeldForSaleNetBookValueSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_GrossBookValueOfCmoEquipmentHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of gross book value of CMO-Equipment held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_GrossBookValueOfCmoEquipmentHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ImpairmentOfAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss on assets held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ImpairmentOfAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InventoriesAtFairValueLessCostsToSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of inventories carried at fair value less costs to sell. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 36<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_36_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InventoriesAtFairValueLessCostsToSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809148848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_InventoriesLineItem', window );"><strong>Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RawMaterials', window );">Raw materials</a></td>
<td class="nump">&#8364; 22,194<span></span>
</td>
<td class="nump">&#8364; 23,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IncreaseDecreaseInInventory', window );">Increase in inventory</a></td>
<td class="nump">&#8364; 1,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IncreaseDecreaseInInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in inventory during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IncreaseDecreaseInInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_InventoriesLineItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_InventoriesLineItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 37<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_37&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345825432800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid expenses and other assets (current) (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_InventoriesLineItem', window );"><strong>Prepaid expenses and other current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">&#8364; 21,221<span></span>
</td>
<td class="nump">&#8364; 40,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer', window );">Prepayments for compensation</a></td>
<td class="nump">1,491<span></span>
</td>
<td class="nump">5,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax', window );">Tax claims</a></td>
<td class="nump">&#8364; 7,852<span></span>
</td>
<td class="nump">&#8364; 24,840<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_InventoriesLineItem">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_InventoriesLineItem</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of prepaid compensation for contract manufacturing organizations transfer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345825362416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial assets and financial liabilities (Details) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>Financial assets and financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets', window );">Transfer from Level 1 to Level 2, Assets</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets', window );">Transfers into Level 3, Assets</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers of assets into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_e_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2022-03-24<br> -Paragraph 93<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_93_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345824972080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Trade and other payables (Details) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract', window );"><strong>Trade and other payables.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Trade and other payables</a></td>
<td class="nump">&#8364; 13,419<span></span>
</td>
<td class="nump">&#8364; 73,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ChangeInTradeAndOtherPayables', window );">Amount of decrease in trade and other payables</a></td>
<td class="nump">&#8364; 60,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ChangeInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in trade and other payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ChangeInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345825489024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other liabilities and provisions (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_DisclosureOfOtherLiabilitiesLineItems', window );"><strong>Other liabilities and provisions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ChangeInOtherLiabilities', window );">Decrease in other liabilities</a></td>
<td class="nump">&#8364; 4,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ProvisionsForDecreaseInContractTerminations', window );">Decrease in contract terminations provisions</a></td>
<td class="nump">61,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInOtherProvisions', window );">Decrease in provisions</a></td>
<td class="nump">&#8364; 1,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ChangeInOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ChangeInOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_DisclosureOfOtherLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>NA</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_DisclosureOfOtherLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ProvisionsForDecreaseInContractTerminations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in contract terminations provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ProvisionsForDecreaseInContractTerminations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2022-03-24<br> -Paragraph 84<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_84&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345825421536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Disclosure of financial instruments and risk management - Foreign currency risk (Details) - Jun. 30, 2023 - Foreign currency risk - Cash and cash equivalents<br> SFr in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th"><div>CHF (SFr)</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_USD', window );">USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency | $</a></td>
<td class="nump">$ 73,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">CHF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems', window );"><strong>Disclosure of financial instruments and risk management</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic', window );">Exposure in (foreign) currency | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Financial instruments, class [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph B8<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_B8_c&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfRisksAxis=ifrs-full_CurrencyRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_IfrsCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=cvac_IfrsCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809603296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per share (Details) - &#8364; / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>Earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Weighted number of shares outstanding</a></td>
<td class="nump">223,883,084<span></span>
</td>
<td class="nump">187,089,253<span></span>
</td>
<td class="nump">217,698,351<span></span>
</td>
<td class="nump">187,041,805<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Net loss per share basic</a></td>
<td class="num">&#8364; (0.30)<span></span>
</td>
<td class="num">&#8364; (0.31)<span></span>
</td>
<td class="num">&#8364; (0.57)<span></span>
</td>
<td class="num">&#8364; (0.39)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2022-03-24<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345810244416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related party disclosures (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>loan</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpensesToHandleFutureServiceAgreement', window );">Expenses to handle future service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DietmarHoppMember', window );">Dietmar Hopp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RelatedPartyTransactionNumberOfLoansReceived', window );">Number of convertible loans | loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageSharePrice2019', window );">Price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ClarentisSrlMember', window );">Clarentis SRL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_IfrsContractualObligation', window );">Contractual obligation amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BepharbelManufacturingS.aMember', window );">BePharBel Manufacturing S.A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions', window );">Settlement amount</a></td>
<td class="nump">&#8364; 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 4,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BarkerBiomedicalGmbhMember', window );">Barker BioMedical GmbH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedFromRelatedPartyTransaction', window );">Expense recognized from related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_CraigToomanMember', window );">Craig Tooman</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_ExpenseRecognizedFromRelatedPartyTransaction', window );">Expense recognized from related party transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_BaronJeanStephenneMember', window );">Baron Jean Stephenne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Equity interest held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.61%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_VincentStphenneMember', window );">Vincent Stephenne</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Equity interest held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.43%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=cvac_AntonyBlancMember', window );">Antony Blanc | Clarentis SRL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems', window );"><strong>Related party disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_RelatedPartyTransactionConsultingFees', window );">Consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpenseRecognizedFromRelatedPartyTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense recognized during the period from related party transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpenseRecognizedFromRelatedPartyTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_ExpensesToHandleFutureServiceAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenses to handle future service agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_ExpensesToHandleFutureServiceAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_IfrsContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_IfrsContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RelatedPartyTransactionConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consulting fees incurred as a part of related party transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RelatedPartyTransactionConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_RelatedPartyTransactionNumberOfLoansReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of loans received from a related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_RelatedPartyTransactionNumberOfLoansReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 24<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=24&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_i&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2022-03-24<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2022-03-24<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2022-03-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2022-03-24<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2022-03-24<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageSharePrice2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average share price. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2022-03-24<br> -Paragraph 45<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2022-en-r&amp;anchor=para_45_c&amp;doctype=Standard<br> -URIDate 2022-03-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageSharePrice2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DietmarHoppMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_DietmarHoppMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ClarentisSrlMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_ClarentisSrlMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BepharbelManufacturingS.aMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BepharbelManufacturingS.aMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BarkerBiomedicalGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_BarkerBiomedicalGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_CraigToomanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=cvac_CraigToomanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_BaronJeanStephenneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_BaronJeanStephenneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_VincentStphenneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_VincentStphenneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=cvac_AntonyBlancMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=cvac_AntonyBlancMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140345809135440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent events (Details) - item<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled', window );">Number of intellectual property rights infringement case filled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfPatentOnWhichNullityActionIsFilled', window );">Number of patent on which nullity action is filled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=cvac_PatentInfringementLawsuitFilledMember', window );">Patent infringement lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems', window );"><strong>Disclosure of detailed information about business combination</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled', window );">Number of intellectual property rights infringement case filled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase', window );">Total number of intellectual property rights infringement case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cvac_NumberOfPatentOnWhichNullityActionIsFilled', window );">Number of patent on which nullity action is filled</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of intellectual property rights infringement case filled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_NumberOfPatentOnWhichNullityActionIsFilled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of patent on which nullity action is filled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_NumberOfPatentOnWhichNullityActionIsFilled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total number of intellectual property rights infringement case.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cvac_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBusinessCombinationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBusinessCombinationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=cvac_PatentInfringementLawsuitFilledMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=cvac_PatentInfringementLawsuitFilledMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>cvac-20230630x6k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:currency="http://xbrl.sec.gov/currency/2022"
  xmlns:cvac="http://www.curevac.com/20230630"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cvac-20230630.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_jJMos62EfkW5YNIpjhOWeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_c616ZXiH_EKOpj5dNuZ83w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_tuyUV0cxakyr_-Yg3O_syQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">cvac:IfrsCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfRisksAxis">ifrs-full:CurrencyRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_P3-yf9evlk-uil2HqOhCJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_BqGmW8UGOUGYcz2zq4SB2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_daj6pxuUI0CyzoQOjX4GZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_iZr_fiR4-kqzHWO6nRRciw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_T1yTr60wpEmNL4M4Ko8K2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_KiOskkojkkONBK40fmVQSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_2VGMUPX1L0m2mtmN3QdB5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_wLsvd5ls7kqTDYk-S9CpjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_YqWM6UyJ9EOQ0t7oMP82XQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_5Y1Bpfn7ukWQA4eeXs_knA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_3anFBkhjW0Csz9tHCp7JTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_lgsJNQOs-kebpPDEL6dBqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_p5-6N-xf00qjDgzfyTQFUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_4_d4F69gaEGw4TgM7DDcuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_mqqCc3YqhUaOpO3VV41sVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_0FmV3jCD_EecBMzp1kB-ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_c9WMa6qFu0SqkKP148olXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_FGpCXR_Dc0CnL6--y0XVzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_gLKqZqvImUCP4bVr6G8mmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_W2T3qdsYzUe0esN9Oty_VA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_mI2esD2990ujSWl2t4bAJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_CTQr6H0pakGthZr8dk5c2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_vUXz2-MgLkyPVrGTn6EwAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_NmehV27LsECWx1f7ZlhZVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_1JdarqUTqUixoudVPfLIxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_pfPO-Kfo-02aNkaKFsNshw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_Susx1Gdb5kyVZMPzZFwQjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_JrMg0504CkiFtakq5tBxSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:NL</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_DrPAKCYehUOOTvRPc2PSVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_lYvFatpdQkefXIkc7q5t-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:BE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_uu0hAMQGFE6RW7mIBHTXqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchServicesCombinedWithIpLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_VPTtXuLSnUmuuBX4S-iEMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_9dT7Tb1Duk2jWvysh9Lqaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_t_V-9jzIX06zZ0Zkpmf8dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:IfrsProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_vDdXBJ99MUy29plp5BCfpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BepharbelManufacturingS.aMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_fO5tW3MsVE60EMuNs7InYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:VincentStphenneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_YRShJABpk0-UxZwCv3pqAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:BaronJeanStephenneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_bb_-yK9N50-YjTv-FAr2SA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_k77XHGsGdUayZMsUw-y9ZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_1dYKs1W9uU6tOrLCufufjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_bao9oCjt3kWO6XoHSsX7IQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ThenChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-01</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_VWrFMaoDW0iaJ10vlf3I3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_K24THxuJwkSYpgfVd96a9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_NDbK_W7H-0umensvBwuEXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_xb55tI_uTEK9tu0gMHp17g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-01</endDate>
        </period>
    </context>
    <context id="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_SYdnaM4Hv0amPp2G2fTAcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-01</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_JiZFgfyfoUWlbX4a-OgfAw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_KwYMhWFPZU6Rg7XLlTdlAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_xUdA4vFkmkehfhynMJzhzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_46FI4ABSf02M9Rryg4sClw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_OUkDYWpJJkyy_omK2KmOjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ThenChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_yrSvY_lt6UyqrvMk85XVag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_eekSXKejL0WDf-eAeVRHbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ExecutiveBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_xmJZx23S6Ee9MA0czFqYMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerAndChiefCommercialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_4WXyX6UBnEeF_hShCcUFxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:VirtualSharesProgramIiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_eOb3THsiDEK9JLgQVfEwTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefScientificOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_UlK7_VcP00Ke20ec2b3Low">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:SupervisoryBoardMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_TvnlUpmmVUa_HJFdi00FrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-31</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_11_30_2022_To_11_30_2022_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_z47nsJniAkW9xj3JyFsA3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-30</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_7_1_2022_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_Nww_GsAWTEubPvNVau2dgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:FormerFrameEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-01</endDate>
        </period>
    </context>
    <context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_q81lEiXrw0OgCYslUicbLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:SupervisoryBoardMembersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_zK3-o7Q200KTZ8l2pvMR8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-22</startDate>
            <endDate>2022-06-22</endDate>
        </period>
    </context>
    <context id="Duration_1_31_2022_To_1_31_2022_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerMember_g2GxNhtCAEyWmUGgwRuryA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:ChiefBusinessOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_g-FjX7APF0qbbMyAZKIHGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="Duration_6_24_2021_To_6_24_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_41E5ssbhMEW4sOS5GBDjpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:SupervisoryBoardMembersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-24</endDate>
        </period>
    </context>
    <context id="Duration_1_31_2022_To_1_31_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_aDZJW6AtK0-IUzIePmSJgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefOperatingOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="Duration_12_23_2021_To_12_23_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_YkGL88cFUUiH_hFBBekkPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:MembersOfExecutiveBoardAndVariousKeyEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-23</startDate>
            <endDate>2021-12-23</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_OAM4KSbtK0GhMJvgcN7Cyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_OQguCGk5x0movmkxQwGifA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_wa5QFol_rkS8gG7WwJPCXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_slG_08aRiU2zjF60wKoFFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_GHafoSH-TkqVmnjZDhADVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_wLccfvwhOU-7QN08Mnbskw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3RD6LGn_q0aJE9VANwQwiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_earTaqxquUCS_GN9m5R30w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_iDouUQemZEC34ma64ZGubg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_BYtQ55ZkAkixCPBAi-kTXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_uyKdAo0yT0en_uX9rr_yVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_89R1ELqZg0iF1defo-Zzrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ajhe72dYmU6ikfxrecPTtw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_q2iBsZHaNEGTSntINrtOmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Q6eV7yFRmkKgW83cIj_dXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_nLufrI8XVUO1H8-sgxRRdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_DUk2M43_BkOYQjRrfn4Oaw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_LeOPOA5JLUa_Tp1X3mtBNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3SmXevtwJUGcfplEE1poRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_oMKzJtdhmE-IN4Rb0YyEGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_f-R_nyf_ukOQR2DltOYQdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_X5PE41bPzEOwyIJ4t92A6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_EL-e9XEpg060VUWMc35I0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_6j-rWZQ0mEyD1-UORlTFiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_kPAAhLB8vEeSoaGBtF4VwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BepharbelManufacturingS.aMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2022_cSA1WqHadE-LZYGzr1BGfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_CeiTmQbyAU6m7Qb98_JtDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_C0dEV8ymUEuwP4xIHoAt0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember__JCd2jsBx0aS7CNRVo1ClA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_CompanyOwnedGmpIvFacilityMember_epTIr0WyBkir6RkvPsvAWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:CompanyOwnedGmpIvFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_TQ5I85ZFr0KjUsctPczaJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">ifrs-full:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_tDwKd8WW10KShixVy7Uj8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfPropertyPlantAndEquipmentAxis">cvac:TechnicalEquipmentAndMachinesAndOtherEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_F3innQ88Ak6o2rkcUJY0ZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:LicensesSoftwareAndPrepaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_xDhMyn6Lpkahl29jhpRNOg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis">ifrs-full:GrossCarryingAmountMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfIntangibleAssetsAndGoodwillAxis">cvac:LicensesSoftwareAndPrepaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_kEyr9vg-3UGfXM6bAe71zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ZuAhdHNvcUy-pqQHWJ5p2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_61WhBItdi0aToAp0G6sGBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_xXPjPpafwkWy53dbFgOTyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_JK3MBg80MEGeA_HLbxHAbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_3c8WG3Tl-EmEVVoAZn9cRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:GenmabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember__rwT7Mu1jUex_FmfwPvK4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">cvac:CrisprMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_IcUfvwha0UqENVJCntKS0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_qyAt21N52UKd6WnZPLKiQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_v1QdYh7Q4UaITnRX6S5L5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_oTatH5MWGk2wkKXabym88g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_6ysCqrsi0EqepTGp5T4G7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:CapitalReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3ZJGf8rl2EqLWLcsDr1j5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_1A2s3zl5FUeobT5soQuz-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_kXJFYB4hY0uYWJFAb4CEQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:DietmarHoppMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_GIDUORdEfE2sHWHYyWOsSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:AntonyBlancMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_HRw1loMHOkC_Vjug3m60AQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:LargestShareholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_gU3vE82A102SoPkxvd1bwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:LargestShareholderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_K4r7ZDLT-E2fEsXEmmY8ZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_av40YHBBh0K9mS0uze6WHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_XOHc_alf0UOQ75cQ9xGNTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_H6yYmBXYOEe8_bIhxb-C8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:SellingAndDistributionExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2023_To_8_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_PatentInfringementLawsuitFilledMember_OxwKIZvNZUe6ydx3xJju_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">cvac:PatentInfringementLawsuitFilledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_4_30_2023_MpR9Fyh8qkmIM9QPSU-9Eg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="Duration_6_30_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_AZJ95UjEWEaSLSw3FoAPFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:FormerFrameEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-30</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_Zhw8mSG_RkaWjTgdo48LVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">cvac:KeyEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_7_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_PatentInfringementLawsuitFilledMember_Qz-L5Ejndka-M5jETiVyOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">cvac:PatentInfringementLawsuitFilledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_PatentInfringementLawsuitFilledMember_oqeBQyU8LUS4jK_f0UnMNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">cvac:PatentInfringementLawsuitFilledMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2023_To_5_31_2023_opUMBeSJAU6Y3pCknLUBYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2022_To_6_30_2022_IMdJRoUvhk2KhVqXkyy6DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsGeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_LfUbJgvVEEOMs9Xu0dY_aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_0W76eZNJTky2YBlodKXOPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_1OMKhPZxMEiydfIE4wQ-aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_TeB4gwzvG0OqfuENGvfJvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_6Escb8lmq0qNNDpw732R3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsIncomeStatementLocationAxis">cvac:IfrsResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_hOXsDH0Qk0OcmChZ7BhnqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_xghJZOz2zkyZscGxuWn0yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:ClarentisSrlMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_CraigToomanMember_PoIqBBw0NUOkeFya4T-Bsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:CraigToomanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BarkerBiomedicalGmbhMember_mv3p0pRW2UerXnYaXscbzg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">cvac:BarkerBiomedicalGmbhMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_MgjlzqfYXUmUABPH0VTY7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:PriorVirtualStockOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember_GWqoCAnOUEuJVuboxaAwqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:NewVirtualStockOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_0ynCSSVH80efoVzNnwRQmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanAndRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_y9w5TmE7JUaqCnNvnmrbsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_Qk-XTh-xFkGe4eGf7kiL-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:PriorVirtualStockOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember__LjcvGfb1UeNNJhvKnzSfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:NewVirtualStockOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_FNWBdKYT4kyF3rOWErcVcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanAndRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_eyoLMAfpYEmjeoloCR63rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_RTmSmZOXXk-2ImmT99fn8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:PriorVirtualStockOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember_B5CF27FqDkiLjSzyYwknTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:NewVirtualStockOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_Ef21cT4Rt0mtb7YnbaYYow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanAndRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_fVrZQK9ylkijyiOuCYXjRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_OP3JSfO8UkukL75fSOwjDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:PriorVirtualStockOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember_Fdqd0vf59kCIZsGxx1aGZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:NewVirtualStockOptionsPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_QbDJ8ZCETEeFxx_3bkTRQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanAndRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_DRNBrHJkukm3DAjZM2_dVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:IfrsRestrictedStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_jV-ZSqS8kU2_OpwJggs-Ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_H7lU27CSYkW4Hf-ukTllUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_lxpzPHOK-kuFcVc1SH9Lbw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_2zrm9PnhCkaFBrsWd2DlfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">cvac:LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_3_31_2023_f3TFOs23C0GFOdZGdiwIzA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_T6BMdSYhU0uLBiXs_xHhqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">cvac:GlaxosmithklineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2023_nZ9aTIkD-kKH94WcSt1n3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2021_To_9_30_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_ayQw-BmgEkylsqF_f4Z52Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:AtMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_3EZn4_xdeES1B53nwQWIjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="cvac:IfrsSaleOfStockAxis">cvac:FollowOnPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_DI_gvTm7Okm-0sSSRRNn3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001809122</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">cvac:MilestoneRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_CHF_jBH-rjz8PUGNxxRiXvE2kQ">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_WivF9OzOw0qggSizEvs2xg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ">
        <measure>cvac:item</measure>
    </unit>
    <unit id="Unit_Standard_pure_OIXcQb-ZL02u7t-A0Qaj8g">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_loan_5iHDzlzZyki6zzA0B9i78A">
        <measure>cvac:loan</measure>
    </unit>
    <unit id="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">
        <measure>cvac:Option</measure>
    </unit>
    <dei:DocumentType
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Narr_U_uVL5GAuE6G2YBU0RwKow">6-K</dei:DocumentType>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Narr_ro_e58693EqJh3UloQVcOQ">CureVac N.V.</dei:EntityRegistrantName>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tc_NGnz0PbQ-E2JXAd0yiYv-Q_7_1">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tc_yad1LJJvlkmgYJqJr4VJug_15_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tc_u3nQaPVOO0iWMoZZoq6CcA_16_1">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tc_H1m5I97MA0uENqiL59C1lQ_17_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tc_HRMEMyIBP0mYU1xsblbMTg_18_1">0001809122</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tc_YiIvo9dvAkas9Eh6xcvvJA_19_1">false</dei:AmendmentFlag>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_1dYKs1W9uU6tOrLCufufjQ"
      decimals="INF"
      id="Hidden_MiCnzCrlpkmaZN49iUzGgg"
      unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">0.12</ifrs-full:ParValuePerShare>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_eko0ETKRnEOj9atVrfCNUQ_4_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">20146000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_l07HI9wB-ECNXueEHBfwlQ_4_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">7579000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_Zjovh9ADJUCbh3VVsw1jZA_4_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">44519000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_BKXj7BjEyUqkhLnPjzJKlQ_4_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">14708000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:CostOfSales
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_Yc-Tw07_A0uEy4l84a02qg_5_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">42681000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_xlTCw70y1UyNPttW8WI36A_5_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">25854000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_n9EZCV_IeUuyPlnou9rkhw_5_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">79913000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_Wru5XMfckk6HvLUl8o9POw_5_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">46489000</ifrs-full:CostOfSales>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_bhBIGlKN7UCj0eURNr5FaQ_6_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">548000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_FD2xHZCUfkSAB5B5qoAxxQ_6_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1408000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_aXvnQkGkqUC1XfBF0szTJg_6_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">819000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_IB5mOdn1a0GglL-U7lZOxg_6_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2232000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_Kv6Lu0jj10G_DLtUB6goqg_7_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">11635000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_M_bdBPRuUE6wEi9YpRlRKg_7_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">30868000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_g-BcMi3EgUWE9vF-qr9dbQ_7_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">22422000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_xM8qoVbOfkOTggTdHsIixQ_7_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">55118000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_kBMfdOA75kG6ULVT8MprPg_8_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">27112000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_Jayudat5Ek2QeYDmMYyVGA_8_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">22245000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_LFXA_R-4N0Ssh5JXvdTZ2w_8_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">51678000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_So9rM41AH0-p4RVeAQeJaQ_8_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">45532000</ifrs-full:GeneralAndAdministrativeExpense>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_TP6pg2Q_7USkdPa7gOlZcw_9_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1771000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_koIwpO28o0ShGXszs3dq5w_9_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1442000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_Du1vpBj9uU6gz9XqGIqzHw_9_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">35207000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_zdbL4y5n2EmWl5dHG50SaQ_9_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3448000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_MZpYgT0u10qw0npfQpxUIA_10_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">238000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_ey6S4Svbt02zf7j95rKmcg_10_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">447000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_i0zVno-hSUOLKxyw2JPi8Q_10_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">461000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:MiscellaneousOtherOperatingExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_TwkW1Yy7DEmkCC5mkG3lwA_10_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">942000</ifrs-full:MiscellaneousOtherOperatingExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_EVSytpN0o0qy39wqYuqmVg_11_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-60298000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_o6kHTPDNskm7ohUTKrLp9A_11_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-71801000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_NDqQPbbFVUGQCwBTVk9iwA_11_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-75567000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_SZR4ss-SqEeCRDpI4IGsmA_11_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-132157000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_CZeozgiL_E-oHkjL2P0ACA_12_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3322000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_Ql1-aAUcK0ik6ma0krObCQ_12_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6197000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_OgcJQiU02keHgyqyy24O2A_12_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">5343000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_5xs3qZDzF0ioxvJKgPq8VQ_12_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">10085000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_EmaUk-oZoE-VLb_vq6Tflw_13_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">594000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_pcjJIYPlOEOMIFdSed8D2A_13_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1783000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_l_4vgyp3SkuhEFn1BYjsbg_13_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2535000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_10EQCEVFBU27j-63fSqw-w_13_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2734000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_kYzS9qjdrEqcM-VKk3nD1A_14_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-57570000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_C82yC6ABkUCh-AuyUFHZiA_14_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-67387000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_xOVm6BXj5k-KIB6k644FBA_14_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-72759000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_39uFCaqSpE2RHp1TcL0voA_14_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-124806000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_Nl2V2pP6eUu4R9dTHsU11A_15_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">14000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_c_rxiJ8mX0uCAF3xDl9_1Q_15_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">26000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_TB60QvrKn0iuSXsKj95DDQ_15_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-82000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_8NDlfEUEeUyCx6fSx0lnDw_15_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">27000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_g8s15-QQD0iP9GYHDYIibA_16_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-57584000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_AbTlT6PLG0CEcppMZofwoA_16_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-67414000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_M0m8AVWY0E2b_LxNyUkqTw_16_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-72677000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_VhXA4mzlcUGrH23U_RbuPA_16_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-124833000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_KVhRcMdOUkK96pLPJ9apgw_18_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-158000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_2n7t-B5P3k6tkUYj7QVABQ_18_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-3000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_5ERhUZbizEizLAXCKTSBew_18_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-212000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_vKT9Kr1mh02jj9liDfG8vg_18_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">16000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_hPcIoEIM3kW6An9Ay50gNw_19_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-57742000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_nppLadYcA0S6ondstNnZVw_19_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-67416000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_BNPMlHaPp0muKOg6SaZfOg_19_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-72889000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_BGFiqrVL8U6yNGbizYR8LA_19_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-124816000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="2"
      id="Tc_AMNs1elE50-2RUo5KbD5yw_20_4"
      unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">-0.31</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="2"
      id="Tc_AMNs1elE50-2RUo5KbD5yw_20_4_2"
      unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">-0.31</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="2"
      id="Tc_FujabZ_KI0esQLT8qVI0UA_20_6"
      unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">-0.30</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="2"
      id="Tc_FujabZ_KI0esQLT8qVI0UA_20_6_2"
      unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">-0.30</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="2"
      id="Tc_U5sCrOmJKEaDglFnQV6gnA_20_8"
      unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">-0.39</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="2"
      id="Tc_U5sCrOmJKEaDglFnQV6gnA_20_8_2"
      unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">-0.39</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="2"
      id="Tc_L2_sq3N8c0eP22v65xAE3w_20_10"
      unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">-0.57</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="2"
      id="Tc_L2_sq3N8c0eP22v65xAE3w_20_10_2"
      unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">-0.57</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_QeEwpSKzoUek3FAs0zAL_w_6_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">31778000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_ko5crp8xb0Of-7GaXZhz9A_6_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">31700000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_YeJIMUX93kOjiEHwC7ctAA_7_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">197941000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_9mhdGrkw7Uyc3gJMyaQSGg_7_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">219539000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_hccnLPE6P0aKtNlNzWR4tQ_8_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">43761000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_k_rX7ReYrkyF-fDTw-zDyg_8_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">42031000</ifrs-full:RightofuseAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_PbkTaZjslE-qxtFDclw0vA_9_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1666000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:OtherNoncurrentAssets
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_rJJaa2R8iEGmihR5c5aMOw_9_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1704000</ifrs-full:OtherNoncurrentAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_pPhPss6YP0iJ0gxfe16jpg_10_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1297000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NetDeferredTaxAssets
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_klmKI1mUskWLt-S7bRMCYw_10_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1296000</ifrs-full:NetDeferredTaxAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_vCZAkLfRP0OtfrCIw6vbSw_11_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">276443000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_AfwFGdxdFka7nJUcCs3-Eg_11_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">296270000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_tfsNDD673kKeXJUgQRTKmg_13_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">10467000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_9fsLxFUExkaxBM541gTwRw_13_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">9954000</ifrs-full:NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:Inventories
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_aobjQXFid0ioruGmEBEEYQ_14_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">23989000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_TLT-GlU5x0CukfCyAkL9Iw_14_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">22194000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_IsdadCeQRUCuWCVCEnSogg_15_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6295000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_XNmggKCat0-Mbb5hpDntNQ_15_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6443000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentContractAssets
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_afGggTohvE-ZzpyKVOV03w_16_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2707000</ifrs-full:CurrentContractAssets>
    <ifrs-full:CurrentContractAssets
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_OYlelHZZg02o-CKGZwrTVA_16_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">119000</ifrs-full:CurrentContractAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_pD3djsliwkad81X182V2-g_17_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4487000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:OtherCurrentFinancialAssets
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_hyKIRsQ100yVKUmi5MBKFw_17_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">5354000</ifrs-full:OtherCurrentFinancialAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_gwHKaXv2X0KR32O4kHOWCw_18_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">40287000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_87CZYVWD3E2HGayBUiZWxQ_18_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">21221000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_4UhfhTo0Dku-o-DBpLsJZA_19_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">495797000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_bKa-AkwD2kalAWkwnGwZaA_19_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">537925000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_H-HghU-exkWYXiO6hYKmDQ_20_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">584029000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_vVgu_nXxg0OKW1s0UfNokQ_20_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">603210000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_mFxx91197ku4kTRfeZip6Q_21_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">860472000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_nJdjB4BgSUGXxgSLCFEePQ_21_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">899480000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_8yX-c9p2KUe7MK1k8smC9A_24_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">23400000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_E8coekaJekycRiQdM_nkTg_24_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">26866000</ifrs-full:IssuedCapital>
    <ifrs-full:CapitalReserve
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_o40sFcLDVEGCTskjBnqAPQ_25_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1817287000</ifrs-full:CapitalReserve>
    <ifrs-full:CapitalReserve
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_-g2NlV9hHki2j8R-Fw3kDw_25_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2052951000</ifrs-full:CapitalReserve>
    <ifrs-full:TreasuryShares
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_vi-nOc0VtEu4JDHkizHmMw_26_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1481000</ifrs-full:TreasuryShares>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_05yLuvw6JEOeFyIE-d_FyQ_27_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-1305814000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_QoD5CiOH4kW7auZHJYxq1w_27_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-1430647000</ifrs-full:RetainedEarnings>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_ilpYOkgwtUW_Jc5P4vqdeA_28_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-139000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:AccumulatedOtherComprehensiveIncome
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_3KlUri77gECiCUjeXQyAmw_28_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-123000</ifrs-full:AccumulatedOtherComprehensiveIncome>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_lfJ6zoLv7UyBFt0EHz1jfg_29_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">533253000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_SdBnG4grEUm6EwRTkvzXQw_29_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">649047000</ifrs-full:Equity>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_cD7llIDoSU6mEpgIZ03GrA_31_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">37106000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_2E64VLQtjkS1HTG1KJ4CyA_31_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">35276000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_jeiR7DdH6UG_-2WLeGNKZg_32_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">72549000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_bWyzmX8puE-UEsgN-an5DA_32_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">58862000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentProvisions
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_UaLitzZhYUKNdrLEGjBiUQ_33_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">61320000</ifrs-full:NoncurrentProvisions>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_2ATXj5fgYk6-1tO04lx4FQ_34_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">19000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:OtherNoncurrentLiabilities
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_LgupaQ8AFUqu61n6zM8q8w_34_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">19000</ifrs-full:OtherNoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_db3IqlRXcE2g1BpZvFGoBw_35_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">170994000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_icP50DSzYU-VIWvIs8x0aA_35_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">94157000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_RcKTNmyttUaSCuqMgGIRCg_37_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4980000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_jYjaSE5MVkiIhRsZH1Riiw_37_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">5205000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_TG5eo893H0WeQlty0X23IA_38_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">73463000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_bBlMCtVwZkaW4VP0Sz5gKg_38_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">13419000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentProvisions
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_d65S9-oNRUOtsEhZJFFpvw_39_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1922000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_jbZt7alYDUOtVJWcYSL6pQ_39_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">61608000</ifrs-full:CurrentProvisions>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_LmcT1AdKFkWmGO0tF7Q-hw_40_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">40491000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_MxIKjgIFc0-JgKiXLyqzsg_40_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">35514000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_qBP34i6B6U-Y6v8rGryQAA_41_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">610000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_QBZ2mjUhh0uKmFlHIHkLDA_41_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">629000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_SkNrMf8uhkmBJPdV9qomzg_42_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">34759000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_kMQgW4QwF0yjkpVCgVqbvg_42_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">39901000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_vsQoaahdH0-kXWcfeggWYg_43_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">156225000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_YFId4uVt20ecumWWsE0rIQ_43_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">156276000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_TtvjbOTXm06Shv9Vu2rK_w_44_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">327219000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_OoC1_StTTEeREkv4LD7Sww_44_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">250433000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_n5l9IXdmRkOfcbSzffK9gA_45_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">860472000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_UW2uireSKEaI5kG_wXi1GQ_45_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">899480000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3SmXevtwJUGcfplEE1poRw"
      decimals="-3"
      id="Tc_8XIFPA-I2E-Pya_5drTl9Q_4_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">22454000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_oMKzJtdhmE-IN4Rb0YyEGQ"
      decimals="-3"
      id="Tc_Sj93zgWH20iMaN97x_QMeQ_4_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1728658000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_nLufrI8XVUO1H8-sgxRRdA"
      decimals="-3"
      id="Tc_DD-xRz-FW0Gr8nr4MroDng_4_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-5817000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_DUk2M43_BkOYQjRrfn4Oaw"
      decimals="-3"
      id="Tc_2ZxEaJf25UWXovCedMgB8g_4_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-1056785000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_LeOPOA5JLUa_Tp1X3mtBNw"
      decimals="-3"
      id="Tc_gb-3fWVSyk6WuKrB2H9HYQ_4_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-34000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2021_CeiTmQbyAU6m7Qb98_JtDw"
      decimals="-3"
      id="Tc_Rf-NGduwGEaYYa3pi_XohQ_4_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">688476000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_EL-e9XEpg060VUWMc35I0A"
      decimals="-3"
      id="Tc_N5kOuH025EaAl01HcUuLDA_5_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-72677000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_xAlZ-z13LkSyFgcDGgH_5g_5_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-72677000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_6j-rWZQ0mEyD1-UORlTFiQ"
      decimals="-3"
      id="Tc_BOU_RwCAcEqCY_DpzNwnQg_6_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-212000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_KRl_7c1rgk2FsM9JxX4rkg_6_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-212000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_EL-e9XEpg060VUWMc35I0A"
      decimals="-3"
      id="Tc_oifdczIGaEqNXz_1uZag5Q_7_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-72677000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_6j-rWZQ0mEyD1-UORlTFiQ"
      decimals="-3"
      id="Tc_ehcKjBC0IUqgCgXqLSuS6g_7_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-212000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_Opoor8bx-0u7DVOZzV9Bjw_7_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-72889000</ifrs-full:ComprehensiveIncome>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_6ysCqrsi0EqepTGp5T4G7g"
      decimals="-3"
      id="Tc_F5krPDHm7U2_tPREUhuNyg_8_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2262000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_S1kWaWtdYke2BA2tE43Lzw_8_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2262000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_OAM4KSbtK0GhMJvgcN7Cyw"
      decimals="-3"
      id="Tc_g9A4gYpHJkmgYvHnt-40iA_9_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">41000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_6ysCqrsi0EqepTGp5T4G7g"
      decimals="-3"
      id="Tc_5At97KLcmEq8yZhuvmHJSA_9_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4680000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_j8tuQQ7g9EqB3Wipq7Qt4g_9_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4721000</ifrs-full:IssueOfEquity>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_OAM4KSbtK0GhMJvgcN7Cyw"
      decimals="-3"
      id="Tc_3otER7AGBEO7T7L5vEMZHg_10_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <ifrs-full:IncreaseDecreaseThroughExerciseOfOptions
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_DhqbtC4gIEaQfbgdye339A_10_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1000</ifrs-full:IncreaseDecreaseThroughExerciseOfOptions>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_6ysCqrsi0EqepTGp5T4G7g"
      decimals="-3"
      id="Tc_lxeXTS_yC0OKHK9GJCpSDA_11_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-3452000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_oTatH5MWGk2wkKXabym88g"
      decimals="-3"
      id="Tc_nvj2yTIyCUKvAaKO2C9_Hg_11_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4083000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_qWMaglAvZUuDQS77YuXpCw_11_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">631000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_q2iBsZHaNEGTSntINrtOmg"
      decimals="-3"
      id="Tc_WnE-FD6OtUeMFjL5sC9yBg_12_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">22496000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_Q6eV7yFRmkKgW83cIj_dXw"
      decimals="-3"
      id="Tc__8oRiSOw7EKQsAZONv-wxQ_12_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1732148000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_uyKdAo0yT0en_uX9rr_yVw"
      decimals="-3"
      id="Tc_hA7Eo4C2OkOMLIRLAx5eZA_12_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-1734000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_89R1ELqZg0iF1defo-Zzrw"
      decimals="-3"
      id="Tc_b-nhHovJpUy5Iquk8FYE7A_12_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-1129462000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_ajhe72dYmU6ikfxrecPTtw"
      decimals="-3"
      id="Tc_HnA74gErfEShG-MKpIa-xg_12_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-246000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2022_cSA1WqHadE-LZYGzr1BGfQ"
      decimals="-3"
      id="Tc_-vLaxeUSnUG70Dk_Rte4ww_12_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">623202000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_iDouUQemZEC34ma64ZGubg"
      decimals="-3"
      id="Tc_CqDwlyCk4E-Q7rW_Q4X4TQ_4_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">23400000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_BYtQ55ZkAkixCPBAi-kTXg"
      decimals="-3"
      id="Tc_kqoUtUpLKE6RX-olLTXiYg_4_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1817287000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_wLccfvwhOU-7QN08Mnbskw"
      decimals="-3"
      id="Tc_tA1A3lXjDkePC2s8Y2hZbA_4_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-1481000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_3RD6LGn_q0aJE9VANwQwiA"
      decimals="-3"
      id="Tc_vOD-q5wJG0uTH6C7PrpAag_4_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-1305814000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_earTaqxquUCS_GN9m5R30w"
      decimals="-3"
      id="Tc_7tCFGKXTCkah8ZzFkU3b-g_4_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-139000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_F0ZdkCq5JEuAnLO8GkYzAA_4_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">533253000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_f-R_nyf_ukOQR2DltOYQdw"
      decimals="-3"
      id="Tc_LZ59zywcG0O9w8TSrVGy2Q_5_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-124833000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_V0JXUOL6uEut4HYOhmI91Q_5_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-124833000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_X5PE41bPzEOwyIJ4t92A6w"
      decimals="-3"
      id="Tc_tu8q7noOyk60LlHkdiZSoQ_6_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">16000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:OtherComprehensiveIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_mHhEmLJwIUKJIgYnNVIiaA_6_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">16000</ifrs-full:OtherComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_f-R_nyf_ukOQR2DltOYQdw"
      decimals="-3"
      id="Tc_EqWXzZod7UG9rIokaTt_fQ_7_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-124833000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_X5PE41bPzEOwyIJ4t92A6w"
      decimals="-3"
      id="Tc_8xMo7dGU70ulLLW2voFtGw_7_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">16000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_99Gt6uRC40qYV66BOpqNmw_7_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-124816000</ifrs-full:ComprehensiveIncome>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_v1QdYh7Q4UaITnRX6S5L5w"
      decimals="-3"
      id="Tc_clL36HZh1Uihw5IWTU9kXQ_8_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4572000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_8M_ULEoCQEmrkvr7r8k8TA_8_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4572000</cvac:ShareBasedPaymentExpenseIncl.DeferredTaxes>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_qyAt21N52UKd6WnZPLKiQQ"
      decimals="-3"
      id="Tc_oUU1BNmr-k2XBE4_of4Mgw_9_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3453000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_v1QdYh7Q4UaITnRX6S5L5w"
      decimals="-3"
      id="Tc_lPWw8NkJy0OpnQtGt2jSYw_9_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">232387000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_eUVULYXjD0KSHoN0dq0bKQ_9_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">235840000</ifrs-full:IssueOfEquity>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_qyAt21N52UKd6WnZPLKiQQ"
      decimals="-3"
      id="Tc_JnsaIzrDKk6MD8YJK9joBQ_10_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">13000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_v1QdYh7Q4UaITnRX6S5L5w"
      decimals="-3"
      id="Tc_sdpLprrWjECNldZGLB2Zcw_10_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-1295000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_TreasurySharesMember_IcUfvwha0UqENVJCntKS0Q"
      decimals="-3"
      id="Tc_rvNJFkpeG0W9vfnTiCRYLQ_10_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1481000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <cvac:SettlementOfShareBasedPaymentAwardsAmount
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_-E6U7UQbBkW5HaaTgtYK2w_10_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">199000</cvac:SettlementOfShareBasedPaymentAwardsAmount>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_slG_08aRiU2zjF60wKoFFw"
      decimals="-3"
      id="Tc_boe3eqq9AEGLHVXi3BV4LQ_11_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">26866000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_CapitalReserveMember_GHafoSH-TkqVmnjZDhADVA"
      decimals="-3"
      id="Tc_hk3uRzdJDEmv8p2ppyJHgQ_11_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2052951000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_OQguCGk5x0movmkxQwGifA"
      decimals="-3"
      id="Tc_CX6fpq6Eq0qUU1juMtdW1g_11_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-1430647000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_wa5QFol_rkS8gG7WwJPCXQ"
      decimals="-3"
      id="Tc_9HhQs0VEgUy3Y_7e-DSUoA_11_10"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-123000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_oVLh6STzF0u9vGV1axPsqg_11_12"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">649047000</ifrs-full:Equity>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_eTSPa1xbx0qroY4O-xndkw_5_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-72759000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_m-kADuHy4UmBGPW7xbmX-Q_5_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-124806000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_ISVNYktCskOr-QhhkwGf_g_7_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">5343000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_e9fzJMlFQ0KydEfbblXj6g_7_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">10085000</ifrs-full:AdjustmentsForFinanceIncome>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_-5EhBpaUq0yEm_oO8TzurA_8_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2536000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForFinanceCosts
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_6P5tvHsNnEiPmhCrTiB07Q_8_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2734000</ifrs-full:AdjustmentsForFinanceCosts>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_A66Ywyr1MU6yKV0AjopMbQ_9_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">16651000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_MnbQVa5T4UmyCodz8_uV2g_9_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">11489000</ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense>
    <ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_-kReIjew-kiVfXInNY5LtQ_10_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">694000</ifrs-full:AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets>
    <cvac:ImpairmentsOfInventoryAndPrepayments
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc__PP6e2k0WUaCzSLOvmKGpg_11_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">25687000</cvac:ImpairmentsOfInventoryAndPrepayments>
    <cvac:ImpairmentsOfInventoryAndPrepayments
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_S_bJZq9wI0W3q2DJV4P1PQ_11_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6879000</cvac:ImpairmentsOfInventoryAndPrepayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_GsE9vwa6VUiJWfaF_0jwJw_12_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3597000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_KgH6lUtbfUa84w4SzilqcQ_12_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4572000</ifrs-full:AdjustmentsForSharebasedPayments>
    <cvac:AdjustmentsForNonCashIncomeFromReleaseOfProvisions
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_6dyUi58M4kWiF7PWnTq9OQ_13_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">47242000</cvac:AdjustmentsForNonCashIncomeFromReleaseOfProvisions>
    <cvac:AdjustmentsForNonCashIncomeFromReleaseOfProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_uOS8a_Hs2E-6-s-PQonr-Q_13_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1634000</cvac:AdjustmentsForNonCashIncomeFromReleaseOfProvisions>
    <cvac:AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_Y-o1umhVpEKKBIvz8Cv1wA_16_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">513000</cvac:AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_ddvV0MdELUy-cNh82MBqxg_17_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">5164000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_At5y-O_xXEqK9HMze30arA_17_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2440000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_mn7Rv7rFVUSNPl3gQf-iYw_18_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">16367000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_6ZDAEbuS10GNNoveoRnDRA_18_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-5084000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_eh32LUH-7USRWu4YSF3ATA_19_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-14051000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_0aU8krbGokiQcq3kxuFImw_19_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">18751000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherAssets>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_V3r-uxJDMECrEGak0YZ_rg_20_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-129038000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_RQ3y_yvYhEeLUDV4S9Vp5w_20_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-76002000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForDeferredTaxExpense
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_c6UobIfXBk-a1U0I7FSx-g_21_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-10000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <ifrs-full:AdjustmentsForDeferredTaxExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_n3XUp9Y0i0evJ36zPZQPoQ_21_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-25000</ifrs-full:AdjustmentsForDeferredTaxExpense>
    <cvac:AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_yiwIx1lUAE2RvtQF3FA9Bw_22_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">126000</cvac:AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities>
    <cvac:AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_kwnAQLMOpkG_GX8C-yXHMA_22_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-18000</cvac:AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestReceivedClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_p37h0RMTIUaGnmhboTZfiA_23_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6838000</ifrs-full:InterestReceivedClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_96yJcXSDe0asdi9OT8wASA_24_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2608000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:InterestPaidClassifiedAsOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_j6dNJAsq2U6LtStOUmydfA_24_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">994000</ifrs-full:InterestPaidClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_g2QOwAPGqkmj0GOn2gjudg_25_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-201175000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_VLnvUBuxAU-g4se3hQWg6w_25_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-163702000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_tyDhKXn8GUaZVImTqMs3pg_28_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">43507000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_kLR9k2f8h0a6vfCsuYMJ0Q_28_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">27222000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_i14tOvthkU2xcEI2tI-s1g_29_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1208000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_3z4lkCMeP0GtIysFCdZoiA_29_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">147000</ifrs-full:PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_MhUQ6pTwA0qU-_93pnfQnw_30_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-44715000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_9CulnPJCv0Gq4ghc0VbBxg_30_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-27369000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_eZwOF-p8SkuaYt_qhY8nrw_33_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1943000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_z9vO1mfFTUWyWRGcbQbATg_33_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2526000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_IU5Zsg3efEWkNex0SLa2WA_34_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4721000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_g5dXqJ_7IE2-9ZQ4lxhWjQ_34_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">235840000</ifrs-full:ProceedsFromIssuingShares>
    <cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_t0POOmq4kUaSaJkRvTOMnA_35_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">631000</cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions>
    <cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_D4zSR05SDkGPyM3sFNXX4w_35_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">199000</cvac:ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_0FC6H2sCtUuuHR_AQFIjiw_36_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3409000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_qFwuJ-ca2k6fJqrzXXwo5g_36_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">233513000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_nNrLHanxvEqJ8QQUxZVBRg_37_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-242481000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_LutRKJfB402tdpcAfONxiw_37_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">42442000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_VfDMKEqaTEmg_z2Ncd9syA_38_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4583000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_I8j2d-tenky48okImx8DXQ_38_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-314000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2021_CeiTmQbyAU6m7Qb98_JtDw"
      decimals="-3"
      id="Tc_wBn0FW3HFkapgZvvKXldFA_39_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">811464000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_1aqkuqdTpk-uVHvz57K1mg_39_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">495797000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2022_cSA1WqHadE-LZYGzr1BGfQ"
      decimals="-3"
      id="Tc_I_1tXOhUfUG2ixW53ekz4Q_40_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">573566000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_CW2jIkqHqke5jcb4GgZNCQ_40_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">537925000</ifrs-full:CashAndCashEquivalents>
    <cvac:CorporateInformationTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_PJop5EfKeESzFZ5tMsUIaw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;1. Corporate Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;CureVac N.V. (&#x201c;CureVac&#x201d; or &#x201c;CV&#x201d; or the &#x201c;Company&#x201d;) is the parent company of CureVac Group (&#x201c;Group&#x201d;) and, along with its subsidiaries, is a global biopharmaceutical company developing a new class of transformative medicines based on the messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company is incorporated in the Netherlands and is registered in the commercial register at the Netherlands Chamber of Commerce under 77798031. The Company&#x2019;s registered headquarters is Friedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany. During 2021 until now, Dievini Hopp BioTech holding GmbH &amp;amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac. Together with its related parties, dievini has held shares and voting rights in CureVac between appr. 37 &#x2013; 46 % during that period. dievini is thus considered to be the de facto parent of the Group. Dietmar Hopp, Daniel Hopp and Oliver Hopp are the ultimate controlling persons (of the main shareholders) of dievini, and, therefore, control the voting and investment decisions of dievini.&lt;/p&gt;</cvac:CorporateInformationTextBlock>
    <cvac:PercentageOfVotingInterestsHeld
      contextRef="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_gU3vE82A102SoPkxvd1bwQ"
      decimals="2"
      id="Narr_L1vb7FBmwEagYRwP4PI1OQ"
      unitRef="Unit_Standard_pure_OIXcQb-ZL02u7t-A0Qaj8g">0.37</cvac:PercentageOfVotingInterestsHeld>
    <cvac:PercentageOfVotingInterestsHeld
      contextRef="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_HRw1loMHOkC_Vjug3m60AQ"
      decimals="2"
      id="Narr_YrWYYsKjMEOdb91kWDcCQg"
      unitRef="Unit_Standard_pure_OIXcQb-ZL02u7t-A0Qaj8g">0.46</cvac:PercentageOfVotingInterestsHeld>
    <cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_JLGEw9F140eT278v8y1Q5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Basis of preparation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The interim condensed consolidated financial statements for the three and six months ended June 30, 2023, have been prepared in accordance with IAS 34 Interim Financial Reporting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#x2019;s annual consolidated financial statements as of December 31, 2022. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on August 16, 2023. The Group&#x2019;s interim condensed consolidated financial statements are presented in Euros (&#x201c;EUR&#x201d;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts. Due to rounding, differences may arise when individual amounts or percentages are added together.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;New standards, interpretations and amendments adopted by the Group&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#x2019;s annual consolidated financial statements for the year ended December 31, 2022. The new and amended standards and interpretations applied for the first time as of January 1, 2023, as disclosed in the notes to the consolidated financial statements as of December 31, 2022, had no impact on the interim condensed consolidated financial statements of the Group as of and for the three and six months ended June 30, 2023. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Impact of COVID-19 and the Russia-Ukraine Conflict&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#x2019;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#x2019;s operations, including research and manufacturing, could also be disrupted due to the potential impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to the Group&#x2019;s laboratory and production operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#x2019;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.&lt;/p&gt;</cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_Y5sMOzQi7E2ZTN8PK4OhNw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The interim condensed consolidated financial statements for the three and six months ended June 30, 2023, have been prepared in accordance with IAS 34 Interim Financial Reporting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual consolidated financial statements and should be read in conjunction with the Group&#x2019;s annual consolidated financial statements as of December 31, 2022. The interim condensed consolidated financial statements were authorized by the Management Board for presentation to the Supervisory Board on August 16, 2023. The Group&#x2019;s interim condensed consolidated financial statements are presented in Euros (&#x201c;EUR&#x201d;). Unless otherwise stated, amounts are rounded to thousands of Euros, except per share amounts. Due to rounding, differences may arise when individual amounts or percentages are added together.&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <cvac:DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_4b-gA7jIDkWkmjS0vUZxzQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;New standards, interpretations and amendments adopted by the Group&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group&#x2019;s annual consolidated financial statements for the year ended December 31, 2022. The new and amended standards and interpretations applied for the first time as of January 1, 2023, as disclosed in the notes to the consolidated financial statements as of December 31, 2022, had no impact on the interim condensed consolidated financial statements of the Group as of and for the three and six months ended June 30, 2023. The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective.&lt;/p&gt;</cvac:DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock>
    <cvac:DescriptionOfAccountingPolicyForCovid19ImpactExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_tu4Wz8x0vU-TZbZ8kTimmQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;"&gt;Impact of COVID-19 and the Russia-Ukraine Conflict&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Group is currently devoting significant resources to the development of COVID vaccines, such development may impair the ability to timely progress other product candidates in clinical trials or into clinical trials from their current preclinical stage. In addition, enrollment in other programs may be delayed as a result of the COVID-19 pandemic and our focus on developing a COVID vaccine could have a negative impact on our progress on and associated revenue recognition from our non-COVID-19 collaborations. The partial disruption, even temporary, may negatively impact the Company&#x2019;s operations and overall business by delaying the progress of its clinical trials and preclinical studies. The Group&#x2019;s operations, including research and manufacturing, could also be disrupted due to the potential impact of staff absences as a result of self-isolation procedures or extended illness. However, the Group has taken a series of actions aimed at safeguarding its employees and business associates, including implementing a work-from-home policy for employees except for those related to the Group&#x2019;s laboratory and production operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The ongoing military conflict between Russia and Ukraine has not and is not expected to have a material direct or indirect effect on the Group&#x2019;s operations or financial condition: however, the Group is currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine. As a result of this instability and responding actions taken by the United States, Russia, EU, and other Foreign Governments, this may limit or prevent filing, prosecuting, and maintaining of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our patents or patent applications in Russia, resulting in partial or complete loss of patent rights in Russia. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit, without consent or compensation, inventions owned by patentees that have citizenship or nationality in, are registered in, or have predominately primary place of business or profit-making activities in countries that Russia has deemed unfriendly. Consequently, we would not be able to prevent third parties from using our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be materially adversely affected.&lt;/p&gt;</cvac:DescriptionOfAccountingPolicyForCovid19ImpactExplanatory>
    <ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_3J43JMZkR0GVaM5gZzkDTw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;3. Notes to the Consolidated Statements of Operations &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.1 Revenue from contract with customers&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group recognized the following revenues:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Belgium&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;GSK&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43,041&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,756&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Switzerland&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;CRISPR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 406&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 844&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,053&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Netherlands&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Genmab&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 445&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 892&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 20,146&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,579&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 44,519&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 14,708&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Of these revenues, all of which were recognized over time as part of collaboration agreements, during the six months ended June 30, 2023 EUR 8,545k (June 30, 2022: EUR 31,818k) related to (i) delivery of research services combined with an IP license (recognized from the upfront payments and achievement of certain milestones as further illustrated in the table below), (ii) EUR 903k (June 30, 2022: EUR 431k) related to delivery of products and (iii) EUR 5,260k (June 30, 2022: EUR 12,270k) were recognized from research and development services that are considered distinct from other performance obligations in the agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Of the total revenues recognized, in the six months ended June 30, 2023, EUR 12,756k in revenue was recognized under the collaboration agreements with GSK, entered into in July 2020, for the research, development, manufacturing and commercialization of mRNA-based vaccines and monoclonal antibodies targeting infectious disease pathogens (&#x201c;GSK I&#x201d;) and in April 2021 for research, development and manufacturing of next-generation mRNA vaccines targeting the original SARS-CoV-2 strain as well as emerging variants, including multivalent and monovalent approaches, such as the CureVac&#x2019;s second-generation COVID-19 vaccine candidate, CV2CoV (&#x201c;GSK II&#x201d;). In the first quarter of 2022, the Company reached a development milestone of EUR 10,000k under the GSK I collaboration. Therefore, revenue for the six months ending June 30, 2023, also includes recognition of EUR 755k of the milestone amount (June 30, 2022: EUR 5,321k). The remaining EUR 2,989k of the milestone amount is deferred as contract liability and will be recognized into revenue through the latest expected submission to authorities, which represents the period of time during which CureVac is responsible for development as, subsequent to this period, GSK will be responsible for further development and commercialization. In the six months ended June 30, 2022, revenue consisted of EUR 43,041k primarily recognized from the upfront payments under both collaboration agreements with GSK.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Group has received upfront payments which were initially deferred and are subsequently recognized as revenue as the Group renders services over the performance period. Below is a summary of such payments and the related revenues recognized:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;milestones payments included&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;milestones payments included&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in contract&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in contract&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and milestone&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;liabilities&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;liabilities&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Customer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;GSK  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:25.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR 205,000k (EUR 10,000k milestone payment included)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95,307&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;CRISPR  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD 3,000k (EUR 2,524k)*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 929&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 775&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Genmab  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:25.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD 10,000k (EUR 8,937k)*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,681&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 107,308&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 98,763&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;* Translated at the currency exchange rate prevailing on the transaction date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;width:37.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&#160;recognized&#160;from&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;width:37.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;upfront&#160;and&#160;milestones&#160;payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;three&#160;months&#160;ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:16.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;six&#160;months&#160;ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Customer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;GSK&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,051&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,873&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,769&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,496&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;CRISPR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Genmab&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 447&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 447&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 894&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 894&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 13,575&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,397&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 31,818&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 8,545&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Contract balances:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,443&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,707&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 119&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 98,763&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.2 Cost of sales&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The cost of sales consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,933)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,371)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,869)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,559)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,055)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,096)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36,883)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,630)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,552)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,386)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,516)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,839)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (919)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (534)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,150)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,115)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,158)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,049)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,326)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,219)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (64)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (418)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (169)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,127)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (42,681)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (25,854)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (79,913)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (46,489)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;For the six months ended June 30, 2023, cost of sales decreased in comparison to corresponding period in 2022. This decline was primarily attributable to higher material costs in the prior year, which were driven by write-offs of raw materials originally procured for the manufacturing of products intended to be sold to GSK. However, these raw materials were no longer expected to be sold to them. Personnel expenses increased mainly due to increased workforce in the manufacturing organization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.3 Selling and distribution expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.75pt;margin:0pt;"&gt;Selling and distribution expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (363)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,314)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (560)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,030)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (169)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (227)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (196)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (548)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,408)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (819)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (2,232)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.4 Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;R&amp;amp;D expenses consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,131)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,728)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,419)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,217)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,795)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,533)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,849)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,570)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,106)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,783)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,119)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,508)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Patents and fees to register a legal right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 502&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,191)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,354)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,048)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,081)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,053&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,773)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (428)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,827)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (464)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,593)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (929)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (727)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,270)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,410)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (11,635)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (30,868)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (22,422)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (55,118)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the six months ended June 30, 2023, research and development expenses increased in comparison to the same period of 2022, as the prior year period was largely impacted by the reversal of provision for onerous contracts in the amount of EUR 21,303k as a result of more participants leaving the clinical trials, prior to completion, than originally estimated and of renegotiations of contracts with CROs. Additionally in 2022, GSK took over the Group&#x2019;s committed capacity at Novartis (see Note 3.6 for additional information) which resulted in a reduction in the estimated contract termination provisions in the amount of EUR 25,059k. The net effect of these two events resulted in an overall gain within the Third-party services category.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Personnel expenses increased mainly due to increased workforce and the acquisition of Frame Pharmaceuticals. Additionally, share-based payment expense was higher compared to prior year period (refer to Note 5 for further details).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023, the Group had no development expenditures which met the requirements for capitalization and thus none have been capitalized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.5 General and administrative expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;General and administrative expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,190)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,644)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,971)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,742)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,404)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,614)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,704)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,915)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,514)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,871)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,796)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,873)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Legal and other professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,995)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,446)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,320)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,074)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,152)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,965)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,091)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,071)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,857)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (705)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,796)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,857)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (27,112)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (22,245)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (51,678)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (45,532)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Personnel expenses decreased due to lower workforce in the corporate service functions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Others include mainly expenses for D&amp;amp;O insurance and allocations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;3.6 Other operating income&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Compensation for CMO/Material transfer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 949&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 259&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,961&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Reimbursement Claim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Sale of equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 310&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 484&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Grants and other cost reimbursements from government agencies and similar bodies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 239&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 222&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 922&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,771&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,442&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 35,207&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,448&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;In March 2022, CureVac AG and GlaxoSmithKline Biologicals SA amended and restated the 2020 GSK agreement and the GSK COVID Agreement in connection with GSK entering into a direct agreement with Novartis for use of Novartis as a CMO at the same time as CureVac exits its CMO agreement with Novartis. Additionally, under the restated agreement, CureVac is entitled to further compensation by GSK. The compensations mainly consist of a consideration for set-up activities undertaken by CureVac (EUR 20,500k) and for reimbursement of prepayments (EUR 12,000k), which were recognized in other operating income in the six months ended June&#160;30, 2022. As an additional result of this agreement, certain reserved capacity at Novartis was also taken over from the Group by GSK, which resulted in the reversal of provisions of EUR 25,059k which had been recognized as of December 31, 2021, and the recognition of a corresponding gain in research and development expenses in the six months ended June 30, 2022 (see Note 3.4).&lt;/p&gt;</ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_Rbyoh_lCeEmmoeEKF5Z6HQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Belgium&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;GSK&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,283&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 43,041&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,756&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Switzerland&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;CRISPR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 406&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 844&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,053&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Netherlands&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Genmab&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 445&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 892&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 899&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 20,146&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,579&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 44,519&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 14,708&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_Susx1Gdb5kyVZMPzZFwQjQ"
      decimals="-3"
      id="Tc_cGFzjFArOk-qXpi2al5qeQ_5_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">19295000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_c9WMa6qFu0SqkKP148olXQ"
      decimals="-3"
      id="Tc_qc6JklcU2U6Aa4oaN0XzwA_5_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6283000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_lYvFatpdQkefXIkc7q5t-A"
      decimals="-3"
      id="Tc_4LPjKO-ILEa8Yb6FvvJ1tg_5_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">43041000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_W2T3qdsYzUe0esN9Oty_VA"
      decimals="-3"
      id="Tc_t4HTz_xWtUWO-vnHiy-8AA_5_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">12756000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_pfPO-Kfo-02aNkaKFsNshw"
      decimals="-3"
      id="Tc_HRzks8xJukeCPmY2X4dS7A_7_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">406000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_0FmV3jCD_EecBMzp1kB-ig"
      decimals="-3"
      id="Tc_ln4oKxnAZEGHWmEjIj15mQ_7_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">844000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_DrPAKCYehUOOTvRPc2PSVA"
      decimals="-3"
      id="Tc_-jLL3v-YJUihPnA70wTx5w_7_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">586000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_CH_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_gLKqZqvImUCP4bVr6G8mmA"
      decimals="-3"
      id="Tc_z_tx5c0XIECHvgNuR-G1Lw_7_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1053000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_1JdarqUTqUixoudVPfLIxA"
      decimals="-3"
      id="Tc_DVVqK5T05ka5f_1naukuog_9_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">445000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_mqqCc3YqhUaOpO3VV41sVA"
      decimals="-3"
      id="Tc_T9ohJmiJykWc50RDozjMKQ_9_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">452000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_JrMg0504CkiFtakq5tBxSg"
      decimals="-3"
      id="Tc_gLvJlYnCCE61I7qWIOAAVw_9_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">892000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_NL_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_FGpCXR_Dc0CnL6--y0XVzA"
      decimals="-3"
      id="Tc_tbV4GGyW1kCdWNW2JUIfuw_9_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">899000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_DNgvEXfok0Cfj7ONyAD7HA_10_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">20146000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_V3_-DOvhbUSISq57PQDrRg_10_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">7579000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_u2ZySs2bFUG5cSNjER0NXw_10_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">44519000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_bGJz8hFm6kehx845xSkv5w_10_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">14708000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_mI2esD2990ujSWl2t4bAJA"
      decimals="-3"
      id="Narr_dZ8bB60qO0WFhPb-KPJ8OQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">8545000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_uu0hAMQGFE6RW7mIBHTXqw"
      decimals="-3"
      id="Narr_G8R9xr2VVke_e9qYIdW_7w"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">31818000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_NmehV27LsECWx1f7ZlhZVA"
      decimals="-3"
      id="Narr_VxMIzeO9fkq_-ZnemqKluA"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">903000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_IfrsProductMember_t_V-9jzIX06zZ0Zkpmf8dw"
      decimals="-3"
      id="Narr_YoUzku5u0U-gEERfJJMnUw"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">431000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_CTQr6H0pakGthZr8dk5c2w"
      decimals="-3"
      id="Narr_78daE2LRZE-dVZ7ROpXIMw"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">5260000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchAndDevelopmentServicesMember_VPTtXuLSnUmuuBX4S-iEMw"
      decimals="-3"
      id="Narr_K3CYL4U9w0m3doEPyFl_tw"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">12270000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_W2T3qdsYzUe0esN9Oty_VA"
      decimals="-3"
      id="Narr_tzGNisKdj0mtZ2crkxbjKQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">12756000</ifrs-full:RevenueFromContractsWithCustomers>
    <cvac:AdditionalDevelopmentMilestonePaymentsReceived
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_DI_gvTm7Okm-0sSSRRNn3g"
      decimals="-3"
      id="Narr_JUTEwpaQJkur4rbNeX7Kqg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">10000000</cvac:AdditionalDevelopmentMilestonePaymentsReceived>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_vUXz2-MgLkyPVrGTn6EwAw"
      decimals="-3"
      id="Narr_NmTzwEHpukiG_XsYKFA08g"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">755000</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_9dT7Tb1Duk2jWvysh9Lqaw"
      decimals="-3"
      id="Narr_qCjMncy8bU27anFVWHw1kg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">5321000</ifrs-full:RevenueFromContractsWithCustomers>
    <cvac:IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities
      contextRef="As_Of_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_hOXsDH0Qk0OcmChZ7BhnqA"
      decimals="-3"
      id="Narr_MxO34eCT0UaCZ92y5OuuiQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2989000</cvac:IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_GeographicalAreasAxis_country_BE_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_lYvFatpdQkefXIkc7q5t-A"
      decimals="-3"
      id="Narr_dGmAcdHOh0uQRjJG0QSAbQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">43041000</ifrs-full:RevenueFromContractsWithCustomers>
    <cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_oAyiSj00g0GppvnCqAFZ1A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;milestones payments included&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;milestones payments included&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in contract&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in contract&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Upfront and milestone&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;liabilities&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;liabilities&#160;at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Customer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;GSK  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:25.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;EUR 205,000k (EUR 10,000k milestone payment included)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 102,804&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 95,307&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;CRISPR  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD 3,000k (EUR 2,524k)*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 929&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 775&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;Genmab  &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:25.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;USD 10,000k (EUR 8,937k)*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,681&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:18.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:25.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 107,308&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 98,763&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:5.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;* Translated at the currency exchange rate prevailing on the transaction date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;width:37.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Revenue&#160;recognized&#160;from&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;width:37.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;upfront&#160;and&#160;milestones&#160;payments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;three&#160;months&#160;ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:16.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;for&#160;six&#160;months&#160;ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:16.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Customer&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(EUR k)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;GSK&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,051&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,873&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 30,769&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,496&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;CRISPR&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Genmab&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 447&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 447&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 894&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 894&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 13,575&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,397&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 31,818&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 8,545&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ZuAhdHNvcUy-pqQHWJ5p2A"
      decimals="-3"
      id="Narr_Itjl036pnUiR8lpKKwFtzQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">205000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_kEyr9vg-3UGfXM6bAe71zQ"
      decimals="-3"
      id="Narr_-Zi1l-N5kE2I2VtHEsMivg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">10000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_JK3MBg80MEGeA_HLbxHAbg"
      decimals="-3"
      id="Tc_6wDXBmLfnE-SGrZfboK-Jg_7_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">102804000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ZuAhdHNvcUy-pqQHWJ5p2A"
      decimals="-3"
      id="Tc_EFF-EbKvHEuwk2Ix4GunyQ_7_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">95307000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_xXPjPpafwkWy53dbFgOTyw"
      decimals="-3"
      id="Narr_aOgxYu6JL0iiYd_7QhddWw"
      unitRef="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw">3000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_xXPjPpafwkWy53dbFgOTyw"
      decimals="-3"
      id="Narr_CY1rLYEViUazQ7Ox6pOy2w"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2524000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember__rwT7Mu1jUex_FmfwPvK4w"
      decimals="-3"
      id="Tc_MEBe6XjC9Uu_c0Hol-fP9w_8_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">929000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_xXPjPpafwkWy53dbFgOTyw"
      decimals="-3"
      id="Tc_HG_GhHCaCkmZCZ-YE-crzA_8_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">775000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_61WhBItdi0aToAp0G6sGBw"
      decimals="-3"
      id="Narr_HuZfzFmlKUCd_SjY39TUCw"
      unitRef="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw">10000000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsReceivedOrReceivable
      contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_61WhBItdi0aToAp0G6sGBw"
      decimals="-3"
      id="Narr_euq-_AV_eU2emt7qKscELw"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">8937000</cvac:UpfrontPaymentsReceivedOrReceivable>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_3c8WG3Tl-EmEVVoAZn9cRw"
      decimals="-3"
      id="Tc_LEkdvNNJuEGeKrDemuOZ6Q_9_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3575000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_61WhBItdi0aToAp0G6sGBw"
      decimals="-3"
      id="Tc_HC--IRRmAEWvrYveUM9rDQ_9_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2681000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_aqQDEC4-fk-oap6JzOo0Ag_10_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">107308000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <cvac:UpfrontPaymentsIncludedInContractLiabilities
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_k0gRpiDfEkypDB3rIVRIVg_10_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">98763000</cvac:UpfrontPaymentsIncludedInContractLiabilities>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_wLsvd5ls7kqTDYk-S9CpjA"
      decimals="-3"
      id="Tc_4CLfy75qJkONfpGN8JflQw_7_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">13051000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_P3-yf9evlk-uil2HqOhCJA"
      decimals="-3"
      id="Tc_DL3t9_mLLU-jfSZvmQpyPA_7_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3873000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_lgsJNQOs-kebpPDEL6dBqg"
      decimals="-3"
      id="Tc_tfBdHRRxpUOs6NEe-0BmCw_7_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">30769000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GlaxosmithklineMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_T1yTr60wpEmNL4M4Ko8K2Q"
      decimals="-3"
      id="Tc_ikqCkA1NlEiwcxAPrxm50g_7_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">7496000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_5Y1Bpfn7ukWQA4eeXs_knA"
      decimals="-3"
      id="Tc_IOZrwMBPz0ufQBPcSKD7zQ_8_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">77000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_daj6pxuUI0CyzoQOjX4GZA"
      decimals="-3"
      id="Tc_VuD65cF4DEiKUgsMinTCKA_8_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">77000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_4_d4F69gaEGw4TgM7DDcuQ"
      decimals="-3"
      id="Tc_A4qlDPvb5EWlGwOrLN7W2g_8_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">155000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_CrisprMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_2VGMUPX1L0m2mtmN3QdB5w"
      decimals="-3"
      id="Tc_RJe0qiHA2EqGsQBUtHpgRg_8_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">155000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_YqWM6UyJ9EOQ0t7oMP82XQ"
      decimals="-3"
      id="Tc_W1oG7OKc20OqYeKRdbxQOQ_9_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">447000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_BqGmW8UGOUGYcz2zq4SB2w"
      decimals="-3"
      id="Tc_aLvM3qU9eka9DBXAV7RjSw_9_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">447000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_p5-6N-xf00qjDgzfyTQFUA"
      decimals="-3"
      id="Tc_xUe1bDsgGUS0t0LBAHJCyw_9_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">894000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_MajorCustomersAxis_cvac_GenmabMember_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_KiOskkojkkONBK40fmVQSQ"
      decimals="-3"
      id="Tc_6arc6felj0e29P7pdfuqCg_9_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">894000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_3anFBkhjW0Csz9tHCp7JTw"
      decimals="-3"
      id="Tc_Uf6asT8PvEiy_3f3uMkJXQ_10_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">13575000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_iZr_fiR4-kqzHWO6nRRciw"
      decimals="-3"
      id="Tc_T4q_A5e-NUCu_movkDuW2Q_10_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4397000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_uu0hAMQGFE6RW7mIBHTXqw"
      decimals="-3"
      id="Tc_-an1svXubUKX2M16It_WMw_10_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">31818000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_mI2esD2990ujSWl2t4bAJA"
      decimals="-3"
      id="Tc_Zmxp8qjmuEuboIrgxZpFoQ_10_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">8545000</ifrs-full:RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod>
    <ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_GMYPcGmTckehECDC1nW_gA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Trade receivables&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,443&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:74.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,707&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 119&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:74.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Contract liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 107,308&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 98,763&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_qZkcIku-S0-PhLkp128Mfg_4_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6295000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_PbGnERzIlEiAtin5xwVv9w_4_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6443000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentContractAssets
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_BcKEQwM6HkC3KfJbyc2wKQ_5_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2707000</ifrs-full:CurrentContractAssets>
    <ifrs-full:CurrentContractAssets
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_H3ZXT7sw7Uqkud12maObbA_5_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">119000</ifrs-full:CurrentContractAssets>
    <ifrs-full:ContractLiabilities
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Tc_gwr5KmD8vkiVWbE9OdUOGw_6_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">107308000</ifrs-full:ContractLiabilities>
    <ifrs-full:ContractLiabilities
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Tc_F68GKU-w7kKMQgoCGYlhfw_6_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">98763000</ifrs-full:ContractLiabilities>
    <ifrs-full:DisclosureOfExpensesByNatureExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Group_PmMgPIYmWkaSsVCtatsaRw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The cost of sales consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,933)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,371)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (13,869)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (17,559)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,055)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,096)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (36,883)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,630)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,552)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,386)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (19,516)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,839)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (919)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (534)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,150)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,115)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,158)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,049)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,326)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,219)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (64)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (418)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (169)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,127)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (42,681)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (25,854)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (79,913)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (46,489)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:16.75pt;margin:0pt;"&gt;Selling and distribution expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (363)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,314)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (560)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,030)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (169)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (88)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (227)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (196)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (548)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (1,408)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (819)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (2,232)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;R&amp;amp;D expenses consists of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,131)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,728)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,419)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,217)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,795)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,533)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (14,849)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (23,570)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,106)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,783)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,119)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,508)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Patents and fees to register a legal right&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 502&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,191)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,354)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,048)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,252&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,081)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,053&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (11,773)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (428)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,827)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (464)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,593)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (929)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (727)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,270)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,410)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (11,635)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (30,868)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (22,422)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (55,118)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;General and administrative expenses consist of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,190)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,644)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (18,971)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (15,742)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maintenance and lease &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,404)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,614)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,704)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,915)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Third-party services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,514)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,871)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,796)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,873)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Legal and other professional services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,995)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (4,446)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,320)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,074)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Amortization and depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,152)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,965)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,091)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6,071)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,857)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (705)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (5,796)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,857)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (27,112)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (22,245)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (51,678)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt; (45,532)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfExpensesByNatureExplanatory>
    <cvac:PersonnelExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A"
      decimals="-3"
      id="Tc_1hxDnjQjzUS3T1Bu6aQCDw_4_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">5933000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA"
      decimals="-3"
      id="Tc_ysZ4CeSVLkGwpa12c3C3Vg_4_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">9371000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ"
      decimals="-3"
      id="Tc_-5qsCIOJpUugXYpweAL_UQ_4_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">13869000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g"
      decimals="-3"
      id="Tc_QpJaj8oBbUWWm6RMysI_QA_4_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">17559000</cvac:PersonnelExpenses>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A"
      decimals="-3"
      id="Tc_rFHrrFafkU6r8C1XqjlCXQ_5_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">14055000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA"
      decimals="-3"
      id="Tc_HHGGe0_cykmxRNMRMQXeMA_5_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">8096000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ"
      decimals="-3"
      id="Tc_x9a42piRyUegLap_nw0iKg_5_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">36883000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g"
      decimals="-3"
      id="Tc_hoDmz7LhA0ufkFOJsmIsag_5_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">12630000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A"
      decimals="-3"
      id="Tc_sJrAoOE010C2wP3MNDlvqA_6_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">18552000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA"
      decimals="-3"
      id="Tc_MwuWoUtyr0mFXD1jvV2C3w_6_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6386000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ"
      decimals="-3"
      id="Tc_f_pvm_uztUaddSCR1MMPIg_6_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">19516000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g"
      decimals="-3"
      id="Tc_8S9BGqF4LkmoLHhwhlp4vw_6_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">11839000</cvac:ThirdPartyServiceExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A"
      decimals="-3"
      id="Tc_9dHHuCod10yJV_5EHyBNBw_7_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">919000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA"
      decimals="-3"
      id="Tc_AKSaL00l70Cb0ulrqlCwFA_7_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">534000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ"
      decimals="-3"
      id="Tc_SiqOeRDll0COUQcmxC4OJQ_7_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1150000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g"
      decimals="-3"
      id="Tc_T6kvFFxbskiRqOvq6h3uUw_7_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1115000</cvac:MaintenanceAndLeaseExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A"
      decimals="-3"
      id="Tc_mwYXXwMIckCsT2j2tvk98g_8_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3158000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA"
      decimals="-3"
      id="Tc_Xwwoum1Sb0yTLKpX6QgBdQ_8_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1049000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ"
      decimals="-3"
      id="Tc_j9wDb7bxQUubAmY7RQePrA_8_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">8326000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g"
      decimals="-3"
      id="Tc_02X1H3IOQE6TWvfCwGhhkw_8_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2219000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:OtherExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A"
      decimals="-3"
      id="Tc_SyKjMzrXFEa6i7hg-zQI4g_9_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">64000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA"
      decimals="-3"
      id="Tc_5FQLNvqjIUyTtCbMYFDrWw_9_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">418000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ"
      decimals="-3"
      id="Tc_Ky9Sjrfi6EGmT3B9zVi1ag_9_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">169000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g"
      decimals="-3"
      id="Tc_QsMT25HEDkaBM4K-1yWfow_9_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1127000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_uQFY18G9fU6C1Lr8kh0r8A"
      decimals="-3"
      id="Tc_gukhQocnHkyyNmbqJGGOTA_10_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">42681000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA"
      decimals="-3"
      id="Tc_yo-H7XiiDU2A2HBuFBBg9w_10_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">25854000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_69_nVLa8ok2k06HLvyN-HQ"
      decimals="-3"
      id="Tc_zsd3J91SEUSmf8EtgYwNNw_10_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">79913000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_bjmaUzMDTk2md3E5tC8g2g"
      decimals="-3"
      id="Tc_YriZBFsVWEqsW9zBdH1Iug_10_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">46489000</ifrs-full:ExpenseByNature>
    <cvac:PersonnelExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_XOHc_alf0UOQ75cQ9xGNTQ"
      decimals="-3"
      id="Tc_dnHMFSrNGkaLOXjHTwcdrg_4_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">363000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_K4r7ZDLT-E2fEsXEmmY8ZA"
      decimals="-3"
      id="Tc_etdlSqOUN0mX7PmY1SnYXw_4_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1314000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_H6yYmBXYOEe8_bIhxb-C8g"
      decimals="-3"
      id="Tc_UBpjQrAfE02aH1DVCAidMQ_4_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">560000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_av40YHBBh0K9mS0uze6WHQ"
      decimals="-3"
      id="Tc_jixU-7RBvUGFrsz9Oy6iYQ_4_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2030000</cvac:PersonnelExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_XOHc_alf0UOQ75cQ9xGNTQ"
      decimals="-3"
      id="Tc_9c6qufNd6U-R6ehbPg_srQ_5_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">16000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_K4r7ZDLT-E2fEsXEmmY8ZA"
      decimals="-3"
      id="Tc_SSdT8uXNlU-xNjAMLiweiw_5_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_H6yYmBXYOEe8_bIhxb-C8g"
      decimals="-3"
      id="Tc_BrjMH-2Zt0OJos-wxA8hHw_5_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">32000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_av40YHBBh0K9mS0uze6WHQ"
      decimals="-3"
      id="Tc_NQjV7ZkOnk6wqyFL7hOw2g_5_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:OtherExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_XOHc_alf0UOQ75cQ9xGNTQ"
      decimals="-3"
      id="Tc_GCwYNBTEbUG1hzXIiYjxDQ_6_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">169000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_K4r7ZDLT-E2fEsXEmmY8ZA"
      decimals="-3"
      id="Tc_l-C-oyHTS0-dycoh2QJ2Tg_6_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">88000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_H6yYmBXYOEe8_bIhxb-C8g"
      decimals="-3"
      id="Tc_DukY7dLRPEmrwieZwCKHVw_6_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">227000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_av40YHBBh0K9mS0uze6WHQ"
      decimals="-3"
      id="Tc_A51m-8E7rUSf8EsOU3H3rw_6_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">196000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_XOHc_alf0UOQ75cQ9xGNTQ"
      decimals="-3"
      id="Tc_uolUPQ-iI0a-Gsib421Png_7_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">548000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_K4r7ZDLT-E2fEsXEmmY8ZA"
      decimals="-3"
      id="Tc_cZ2vACc7Q0y55EZcaIQLrg_7_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1408000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_H6yYmBXYOEe8_bIhxb-C8g"
      decimals="-3"
      id="Tc_IvXhpz0ppEOhOXT9XHDm5Q_7_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">819000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_av40YHBBh0K9mS0uze6WHQ"
      decimals="-3"
      id="Tc_hRWigeRPtECSTbKvSd7SMg_7_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2232000</ifrs-full:ExpenseByNature>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA"
      decimals="-3"
      id="Tc_c_wprvfXoEiAEMA6CY6EhQ_4_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6131000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg"
      decimals="-3"
      id="Tc_CU0ExqQJgUCHIBQRkZkwog_4_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">5728000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA"
      decimals="-3"
      id="Tc_9S0O_p5uaEG8swRFsHXQjw_4_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">23419000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <ifrs-full:RawMaterialsAndConsumablesUsed
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA"
      decimals="-3"
      id="Tc_Er04GKlQr0GeF5pcwMVWJg_4_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">9217000</ifrs-full:RawMaterialsAndConsumablesUsed>
    <cvac:PersonnelExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA"
      decimals="-3"
      id="Tc_O2I-sZU2S0y2jBnGFwYV7g_5_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">7795000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg"
      decimals="-3"
      id="Tc_fn6z2CSXAUqLlIN4CbZfxg_5_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">12533000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA"
      decimals="-3"
      id="Tc_vcDrTMbecUuDZcNucboNcQ_5_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">14849000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA"
      decimals="-3"
      id="Tc_HG2D6qUoa0-eXZh4boFiDA_5_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">23570000</cvac:PersonnelExpenses>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA"
      decimals="-3"
      id="Tc_k4ww3oBjZ0CBTIMqawEAOQ_6_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1106000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg"
      decimals="-3"
      id="Tc_C0vdNhVgRk6MFyb0pM_k5A_6_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1783000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA"
      decimals="-3"
      id="Tc_V0ulmSBbB0Kj8UctZH8xFA_6_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2119000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA"
      decimals="-3"
      id="Tc_wXCMCg35WkqfLdcVw67b0g_6_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3508000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:PatentsAndFeesToRegisterLegalRight
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA"
      decimals="-3"
      id="Tc_DpHbR2F7qUG1cB6TNC-BIg_7_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-502000</cvac:PatentsAndFeesToRegisterLegalRight>
    <cvac:PatentsAndFeesToRegisterLegalRight
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg"
      decimals="-3"
      id="Tc_N4QEjp2_EkWfFYLoNAlGjA_7_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1191000</cvac:PatentsAndFeesToRegisterLegalRight>
    <cvac:PatentsAndFeesToRegisterLegalRight
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA"
      decimals="-3"
      id="Tc_bfap9Oi1FECFkgm6bZt93w_7_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1354000</cvac:PatentsAndFeesToRegisterLegalRight>
    <cvac:PatentsAndFeesToRegisterLegalRight
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA"
      decimals="-3"
      id="Tc_h8zCxT6BFUamXlCU2dEViw_7_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2048000</cvac:PatentsAndFeesToRegisterLegalRight>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA"
      decimals="-3"
      id="Tc_M8Cd65HmSkuUOxcGMm7HGQ_8_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-4252000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg"
      decimals="-3"
      id="Tc_SfWJ8guy2EmNAzNpYVkt2Q_8_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">7081000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA"
      decimals="-3"
      id="Tc_faEU_VYbWE65yrKTGH7U3A_8_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-21053000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA"
      decimals="-3"
      id="Tc_j878Ot8sXUaQkrD7CsfMTg_8_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">11773000</cvac:ThirdPartyServiceExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA"
      decimals="-3"
      id="Tc_EoD5azAHFUSk3ePVE1D8XA_9_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">428000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg"
      decimals="-3"
      id="Tc_kiBQkAGaukaSXIPObG0IIQ_9_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1827000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA"
      decimals="-3"
      id="Tc_90fbLjScPEaViKYOwzu2Wg_9_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">464000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA"
      decimals="-3"
      id="Tc_hzBjHSqiZ0uJWF6q0iCNrw_9_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3593000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:OtherExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA"
      decimals="-3"
      id="Tc_D2cwkdl7gEmDVs7FnjnKNQ_10_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">929000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg"
      decimals="-3"
      id="Tc_dENTb0XpiEuraaRe6A0DOA_10_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">727000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA"
      decimals="-3"
      id="Tc_Sj8SkwdwgUesKtXhF5duig_10_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1270000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA"
      decimals="-3"
      id="Tc_UFwhCIvTbE6lLCuNeai0fw_10_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1410000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_RNPBO4qRtEmIEF3knCFBwA"
      decimals="-3"
      id="Tc_fycjJ0V6DU6vEKgpRoR1Ng_11_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">11635000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg"
      decimals="-3"
      id="Tc_Cjz67lvoXUewt8FIiDinBg_11_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">30868000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_S9R9A5ysq0mEzMgu5qhEXA"
      decimals="-3"
      id="Tc_X8n0MN5FO0iDQ3JOnwgoiw_11_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">22422000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA"
      decimals="-3"
      id="Tc_RVxVscPj_Ui9Az9CBq2rAg_11_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">55118000</ifrs-full:ExpenseByNature>
    <cvac:IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_rhoJgejcgU2Kpyj0WLWUDA"
      decimals="-3"
      id="Narr_2quaIxGuqkOFKgunMH89Kw"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">21303000</cvac:IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract>
    <cvac:IfrsProvisionForLossOnContracts
      contextRef="As_Of_12_31_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_6Escb8lmq0qNNDpw732R3A"
      decimals="-3"
      id="Narr_Ivu_wIKvP0SB70iWmYwopQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">25059000</cvac:IfrsProvisionForLossOnContracts>
    <cvac:PersonnelExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw"
      decimals="-3"
      id="Tc_lZ0tUFI0yUKQwCXy3B8UTg_4_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">9190000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw"
      decimals="-3"
      id="Tc_PFoiRunHjkiJn9WGQSGaZg_4_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6644000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w"
      decimals="-3"
      id="Tc_BaUWfQrgMESJK-CNbpC_Kg_4_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">18971000</cvac:PersonnelExpenses>
    <cvac:PersonnelExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A"
      decimals="-3"
      id="Tc_e0J0EB8G1UeLxJd-oVpiBQ_4_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">15742000</cvac:PersonnelExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw"
      decimals="-3"
      id="Tc_045kDvveHEuH1k_iCa-2Ww_5_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1404000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw"
      decimals="-3"
      id="Tc_EDz-C7Zs6kuHYeXiT1zaMw_5_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1614000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w"
      decimals="-3"
      id="Tc_h3vL0X7wXkiv3xc3pgbPxQ_5_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2704000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:MaintenanceAndLeaseExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A"
      decimals="-3"
      id="Tc_GikxI58PGE2hM3cEuXWTdg_5_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2915000</cvac:MaintenanceAndLeaseExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw"
      decimals="-3"
      id="Tc_zkJBu493DU-WqBQnVrurFw_6_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">7514000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw"
      decimals="-3"
      id="Tc_W3XvKB6A9kOIOfcmnl_7kQ_6_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">5871000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w"
      decimals="-3"
      id="Tc_huT-R_uYrUOZ0RVomTk_lg_6_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">12796000</cvac:ThirdPartyServiceExpenses>
    <cvac:ThirdPartyServiceExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A"
      decimals="-3"
      id="Tc_BfvxGl0iG0yInWmL5qZ6MA_6_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">12873000</cvac:ThirdPartyServiceExpenses>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw"
      decimals="-3"
      id="Tc_LF4_w2RHi066jAPuef1DoA_7_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2995000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw"
      decimals="-3"
      id="Tc_C2GQLtK64U-wbBgVBdMxNQ_7_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4446000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w"
      decimals="-3"
      id="Tc_BYOPNXaUM02In88ZiDXeNA_7_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">5320000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:ProfessionalFeesExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A"
      decimals="-3"
      id="Tc_PO0fjZjCpkyQKrp8ShVmoA_7_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6074000</ifrs-full:ProfessionalFeesExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw"
      decimals="-3"
      id="Tc_zlxuAr2_bEuSan-NgM1wcQ_8_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3152000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw"
      decimals="-3"
      id="Tc_zjHHDkEaKEmPW33WXn9REA_8_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2965000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w"
      decimals="-3"
      id="Tc_y3zk2uStA0aHpfGgDLDMUw_8_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6091000</ifrs-full:DepreciationAndAmortisationExpense>
    <ifrs-full:DepreciationAndAmortisationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A"
      decimals="-3"
      id="Tc_YzCPBNGM7EWA7irKryjeug_8_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">6071000</ifrs-full:DepreciationAndAmortisationExpense>
    <cvac:OtherExpense
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw"
      decimals="-3"
      id="Tc_uIVSInRwkEO42aeX6EWBMg_9_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2857000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw"
      decimals="-3"
      id="Tc_ZPAInXuLEEO_33VL0ipzsg_9_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">705000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w"
      decimals="-3"
      id="Tc_HsxSZ_aWDEOrngDovP0yUw_9_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">5796000</cvac:OtherExpense>
    <cvac:OtherExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A"
      decimals="-3"
      id="Tc_8lB262NM9kOtPSK_YB4cgg_9_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1857000</cvac:OtherExpense>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_4_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_W-zSJSqC-0ugt3RYch6iTw"
      decimals="-3"
      id="Tc_rZwJJme7TU6Y1zScpSJDaQ_10_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">27112000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw"
      decimals="-3"
      id="Tc_06thqdMUa0uH9x3OSsQMPQ_10_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">22245000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_GnMnyu_G20O6UrUO2b1W3w"
      decimals="-3"
      id="Tc_csxuXS_S7EC3-BYcypZCKw_10_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">51678000</ifrs-full:ExpenseByNature>
    <ifrs-full:ExpenseByNature
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_4ekI2rvnQU2LizY_xHbY_A"
      decimals="-3"
      id="Tc_nzEFCObuIEyd2Y1PoFVU5w_10_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">45532000</ifrs-full:ExpenseByNature>
    <ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_grwepVLzF0C6WVVKqe43hg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Compensation for CMO/Material transfer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 949&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 259&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 33,961&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,803&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Reimbursement Claim&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Sale of equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 176&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 310&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 484&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Grants and other cost reimbursements from government agencies and similar bodies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 35&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 237&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 239&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 770&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 222&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 922&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,771&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,442&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 35,207&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,448&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory>
    <cvac:CompensationForContractManufacturingOrganizationsTransfer
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_BIhH128ClEaDIklaGaqqFA_4_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">949000</cvac:CompensationForContractManufacturingOrganizationsTransfer>
    <cvac:CompensationForContractManufacturingOrganizationsTransfer
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_7rCSmLt4V0uwaStEWFxx-g_4_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">259000</cvac:CompensationForContractManufacturingOrganizationsTransfer>
    <cvac:CompensationForContractManufacturingOrganizationsTransfer
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_emdc5Cu3aUqas7EAZkeTjg_4_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">33961000</cvac:CompensationForContractManufacturingOrganizationsTransfer>
    <cvac:CompensationForContractManufacturingOrganizationsTransfer
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_w3CDQkqeZ06NmNb62lSqqQ_4_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1803000</cvac:CompensationForContractManufacturingOrganizationsTransfer>
    <cvac:CostOfReimbursementClaim
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_oBUgzsBHTk20gfBKtluIFQ_5_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">610000</cvac:CostOfReimbursementClaim>
    <cvac:CostOfReimbursementClaim
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_l5Bag6ya-UO1FBnSEjRO2Q_5_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">610000</cvac:CostOfReimbursementClaim>
    <cvac:SaleOfEquipment
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_nPWmR0jeJkSwj8bAXkvVGA_6_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">176000</cvac:SaleOfEquipment>
    <cvac:SaleOfEquipment
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_xzqr4Y7c-UeBrkuS4cqF8A_6_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">310000</cvac:SaleOfEquipment>
    <cvac:SaleOfEquipment
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_19AXtOzJVUa4SNx5jzJ7ow_6_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">484000</cvac:SaleOfEquipment>
    <cvac:OtherOperatingIncomeGovernmentGrants
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_u6muM6K9EkK81ybYDKkuig_7_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">35000</cvac:OtherOperatingIncomeGovernmentGrants>
    <cvac:OtherOperatingIncomeGovernmentGrants
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_A7IWrSqZE0ilEbs-RFAPfQ_7_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">237000</cvac:OtherOperatingIncomeGovernmentGrants>
    <cvac:OtherOperatingIncomeGovernmentGrants
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_dO5Kp8mF80GoCN8xGGcnFg_7_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">104000</cvac:OtherOperatingIncomeGovernmentGrants>
    <cvac:OtherOperatingIncomeGovernmentGrants
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_ccoIPkHjXUerjjC1-Rrv7g_7_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">239000</cvac:OtherOperatingIncomeGovernmentGrants>
    <cvac:MiscellaneousOtherOperatingIncomeOther
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_ffDETpQzNUubn8RDwXmgJQ_8_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">177000</cvac:MiscellaneousOtherOperatingIncomeOther>
    <cvac:MiscellaneousOtherOperatingIncomeOther
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_gsZrfZnUtEmAev5ehM-IGg_8_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">770000</cvac:MiscellaneousOtherOperatingIncomeOther>
    <cvac:MiscellaneousOtherOperatingIncomeOther
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_smfM8npIsUuUtZmfdle_aA_8_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">222000</cvac:MiscellaneousOtherOperatingIncomeOther>
    <cvac:MiscellaneousOtherOperatingIncomeOther
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_Y77RoDnZjEuFmuG5eKaZ6Q_8_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">922000</cvac:MiscellaneousOtherOperatingIncomeOther>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_t_py8xIDvEKd9hgZKxosIg_9_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1771000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_tth9UVovvkCBkJTkq1_w8Q_9_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1442000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_-zH5Cf_8h0CJp_NliU6Ipg_9_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">35207000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_RaGXeTv4YUy80dSEiau94A_9_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3448000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <cvac:CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_T6BMdSYhU0uLBiXs_xHhqQ"
      decimals="-3"
      id="Narr_FytWbQVO40e3hLWgbf_K3g"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">20500000</cvac:CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities>
    <cvac:CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_T6BMdSYhU0uLBiXs_xHhqQ"
      decimals="-3"
      id="Narr_gObbRoQ_JkG8eRpf0Z215w"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">12000000</cvac:CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses>
    <cvac:ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver
      contextRef="As_Of_12_31_2021_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_3ZJGf8rl2EqLWLcsDr1j5A"
      decimals="-3"
      id="Narr_ta_WLqn9q0OrhmgsObwwiA"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">25059000</cvac:ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_T_qyOs_9eUesd3noTJAMZQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;4. Issued Capital and Reserves&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;According to the Company&#x2019;s articles of association, the Company&#x2019;s authorized shares are divided into 386,250,000 common shares and 386,250,000 preferred shares, each having a &lt;span style="-sec-ix-hidden:Hidden_MiCnzCrlpkmaZN49iUzGgg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;nominal&lt;/span&gt;&lt;/span&gt; value of EUR 0.12. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2023, no preferred shares had been issued and all issued common shares issued and outstanding were fully paid.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;All payments received from shareholders in excess of the nominal value of the shares issued and net of transaction costs are recognized in capital reserves. Capital reserves also consists of recognition of share-based payments and the equity components of convertible loans. The Company may only make distributions, whether a distribution of profits or of freely distributable reserves, to shareholders to the extent shareholders&#x2019; equity exceeds the sum of the paid-in and called-up share capital plus any reserves required by Dutch law or by the Company&#x2019;s articles of association.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2021, the Company entered into a sales agreement, the Open Sale Agreement, with Jefferies LLC and SVB Leerink LLC, as sales agents, to establish an at-the-market (ATM) offering program, pursuant to which it may sell, from time to time, ordinary shares for aggregate gross proceeds of up to USD 600.0 million. In the first quarter of 2023, 1,748,218 shares were issued under the ATM program, raising USD 17.5 million in net proceeds; related offering expenses were recorded against the proceeds in equity. Following these issuances, the remaining value authorized for sale under the at-the-market program amounts to $497.5 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2023, the Group completed a follow-on public offering whereby it sold 27,027,028 common shares at a price of USD 9.25 per share. The aggregate proceeds, net of underwriting discounts, received by the Group from these transactions were EUR&#160;219,832k. Additional offering costs for legal, accounting, printing and registration fees of EUR 14,580k were recognized as reduction to capital reserve against the proceeds from the offering.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The number of shares issued and outstanding developed as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 194,997,091&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;At-the-market offering program issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,748,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issuances as part of the public offering&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,027,028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issuances for exercises between Jan to Mar 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 112,089&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Treasury shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32,913)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at March 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 223,851,513&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issuances for exercises between Apr to Jun 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,524&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Treasury shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,953)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 223,883,084&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_1dYKs1W9uU6tOrLCufufjQ"
      decimals="INF"
      id="Narr_oNIyUm2hD0Kmwlf3-ZoqiQ"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">386250000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_k77XHGsGdUayZMsUw-y9ZA"
      decimals="INF"
      id="Narr_bF3y6vICaUO329jHkL2KLg"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">386250000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_k77XHGsGdUayZMsUw-y9ZA"
      decimals="INF"
      id="Narr_ow06z8JZvk-k-xkPDTzD7w"
      unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">0.12</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_k77XHGsGdUayZMsUw-y9ZA"
      decimals="INF"
      id="Narr_uLL7XMpzOkiZnyzaIxckiA"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">0</ifrs-full:NumberOfSharesIssued>
    <cvac:AggregateGrossProceedsReceivableFromIssuingShares
      contextRef="Duration_9_1_2021_To_9_30_2021_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_ayQw-BmgEkylsqF_f4Z52Q"
      decimals="-5"
      id="Narr_eNPhoIu6QU6D3USDcpfnAA"
      unitRef="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw">600000000.0</cvac:AggregateGrossProceedsReceivableFromIssuingShares>
    <cvac:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_1OMKhPZxMEiydfIE4wQ-aQ"
      decimals="INF"
      id="Narr_VvIQoHMn-0GPFddKkfuSzw"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">1748218</cvac:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_1OMKhPZxMEiydfIE4wQ-aQ"
      decimals="-5"
      id="Narr_xV2rBEIbQUaXSEMa88FVUA"
      unitRef="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw">17500000</ifrs-full:ProceedsFromIssuingShares>
    <cvac:RemainingAuthorizedForSaleValue
      contextRef="As_Of_6_30_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_1A2s3zl5FUeobT5soQuz-w"
      decimals="-5"
      id="Narr_f2iPbFv76E-6R528wBOP6A"
      unitRef="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw">497500000</cvac:RemainingAuthorizedForSaleValue>
    <cvac:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_3EZn4_xdeES1B53nwQWIjg"
      decimals="INF"
      id="Narr_zEfH4RLDqUmb_OW9I_2qIw"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">27027028</cvac:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <cvac:IfrsSharesIssuedPricePerShare
      contextRef="As_Of_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_TeB4gwzvG0OqfuENGvfJvA"
      decimals="2"
      id="Narr_PqTPh1ffh0G2kRCf1-4pGA"
      unitRef="Unit_Divide_USD_shares_WivF9OzOw0qggSizEvs2xg">9.25</cvac:IfrsSharesIssuedPricePerShare>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_3EZn4_xdeES1B53nwQWIjg"
      decimals="-3"
      id="Narr_I0K9BFqdtkGHD66GkS9TXQ"
      unitRef="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw">219832000</ifrs-full:ProceedsFromIssuingShares>
    <cvac:AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve
      contextRef="Duration_2_1_2023_To_2_28_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_3EZn4_xdeES1B53nwQWIjg"
      decimals="-3"
      id="Narr_qjlc7BNzo0ycR7DMZdx5_A"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">14580000</cvac:AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve>
    <ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_TexrmAA1ZEiwHmcm3dFeHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at December 31, 2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 194,997,091&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;At-the-market offering program issuances&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,748,218&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issuances as part of the public offering&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 27,027,028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issuances for exercises between Jan to Mar 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 112,089&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Treasury shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32,913)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:80.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at March 31, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 223,851,513&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Share issuances for exercises between Apr to Jun 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 41,524&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Treasury shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (9,953)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:80.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Common shares issued and outstanding at June 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 223,883,084&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory>
    <cvac:CommonSharesIssuedAndOutstanding
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="INF"
      id="Tc_tCos-eR-3E2vjXdm5B9opg_1_2"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">194997091</cvac:CommonSharesIssuedAndOutstanding>
    <cvac:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_1OMKhPZxMEiydfIE4wQ-aQ"
      decimals="INF"
      id="Tc_dc1QVCNchUO3ox3yN7wnbg_2_2"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">1748218</cvac:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <cvac:IfrsStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_FollowOnPublicOfferingMember_0W76eZNJTky2YBlodKXOPw"
      decimals="INF"
      id="Tc_bIxVPyc1b0WlD_yq9nfaRA_3_2"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">27027028</cvac:IfrsStockIssuedDuringPeriodSharesNewIssues>
    <cvac:StockIssuedDuringPeriodForExercises
      contextRef="Duration_1_1_2023_To_3_31_2023_f3TFOs23C0GFOdZGdiwIzA"
      decimals="INF"
      id="Tc_WbP0o1tSnkyfdSqco5MA1A_4_2"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">112089</cvac:StockIssuedDuringPeriodForExercises>
    <cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares
      contextRef="Duration_1_1_2023_To_3_31_2023_f3TFOs23C0GFOdZGdiwIzA"
      decimals="INF"
      id="Tc_VFoJq71VqEG66X0pKMAaWA_5_2"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">-32913</cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares>
    <cvac:CommonSharesIssuedAndOutstanding
      contextRef="As_Of_3_31_2023_nZ9aTIkD-kKH94WcSt1n3g"
      decimals="INF"
      id="Tc_3v004IoZzkiyKq0gDuBZpg_6_2"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">223851513</cvac:CommonSharesIssuedAndOutstanding>
    <cvac:StockIssuedDuringPeriodForExercises
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="INF"
      id="Tc_zkycjLlP-k-T-Za-NHCpOw_7_2"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">41524</cvac:StockIssuedDuringPeriodForExercises>
    <cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="INF"
      id="Tc_RGnN2D6IK0injVdiZ0GQow_8_2"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">-9953</cvac:DecreaseInNumberOfSharesDueToTreasuryOfShares>
    <cvac:CommonSharesIssuedAndOutstanding
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="INF"
      id="Tc_eyRrJv9Lik6QKjpX7g4dng_9_2"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">223883084</cvac:CommonSharesIssuedAndOutstanding>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_0cH4bsk0q0uQ58Y9ul3UWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;5. Share-based payments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the six months ended June 30, 2023 and 2022, the Group recognized share-based payment expenses of EUR 4,572k and EUR 3,597k, respectively, as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cost of sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 147&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling and distribution expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 153&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 609&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 761&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,891&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,221&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other operating expenses &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 235&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 291&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,324&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,994&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,597&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,572&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Expense recognized for the equity-settled programs was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Program&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;LTIP Stock Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;RSU Supervisory Board&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 235&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 291&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;New VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (185)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prior VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;LTIP RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,379&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 497&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,920&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,324&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,994&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,597&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,572&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 16, 2020, CureVac granted 266,155 options to the former Chief Scientific Officer (CSO). Furthermore, on December 1, 2020, CureVac granted 266,156 options (in 3 tranches) to the Group&#x2019;s Chief Business Officer (CBO) and Chief Commercial Officer (CCO). All grants were made under the terms of a new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, none of the options granted to the CBO/CCO under the LTIP were exercised. The CSO exercised 6,303 options during the six months ended June 30, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On July 1, 2021, CureVac granted 20,000 options to the Chief Operations Officer (COO). This grant was made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, none of the options granted to the COO were exercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 1, 2021, CureVac granted 2,000 options to a key employee and on January 1, 2022, CureVac granted 9,500 options to a key employee. All grants were made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, none of the options were exercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 1, 2022, CureVac granted 130,000 options to the Executive Board. All grants were made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June&#160;30, 2023, none of the options were exercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 1, 2022, CureVac granted 700 options to a key employee. All grants were made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, none of the options were exercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On April 1, 2023, CureVac granted 144,379 options to the newly appointed CEO. All grants were made under the terms of the new long-term incentive plan (LTIP) put in place by CureVac N.V. Options will be settled in shares of CureVac N.V. As of June 30, 2023, none of the options were exercised.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The expenses recognized for employee services received under the LTIP Stock Options during the three and six months ended June 30, 2023, is in the amount of EUR 1,362k and EUR 2,337k, respectively (2022: EUR 1,254k and EUR 3,078k, respectively) and is included in general and administrative expenses and selling and distribution expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2021, as part of the LTIP program, the Group awarded RSUs (restricted stock units) to senior executives as well as Supervisory Board members. On June 24, 2021, the Group awarded 10,956 RSUs to Supervisory Board members and on December 23, 2021, the Group awarded 63,095 RSUs to the Executive Board and various key employees. Up to June 30, 2023, 47,424 RSUs were settled. The related RSU expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 1, 2022, CureVac awarded 36,000 RSUs to the Chief Executive Officer (CEO). The related RSU expense is included in general and administrative expenses. For the three and six months ended June 30, 2023, all RSUs were settled.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 31, 2022, CureVac awarded 5,000 RSUs to the Chief Operations Officer (COO) and 30,000 RSUs to the Chief Business Officer (CBO). The related RSU expense is included in general and administrative expenses. Up to June 30, 2023, none of these RSUs were settled.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On June 22, 2022, the Group awarded 36,902 RSUs to Supervisory Board members and 188,986 RSUs to the Executive Board and various key employees. On November 30, 2022, the Group awarded further 7,633 RSU awards to key employees who joined the Group during fiscal 2022. The related RSU expense is recorded in the functional cost category to which the award recipient&#x2019;s costs are classified. Up to June 30, 2023, 73,056 RSUs were settled.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective July 1, 2022, CureVac N.V. acquired all shares of Frame Pharmaceuticals B.V., Amsterdam, Netherlands (formerly Frame Pharmaceuticals), now CureVac Netherlands B.V. On July 1, 2022, CureVac awarded 89,655 RSUs to the former Frame employees. The related RSU expense is recorded in the functional cost category to which the award recipients&#x2019; costs are classified. Up to June 30, 2023, 29,881 RSUs were settled.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 31, 2023, the Group awarded 92,701 RSUs to the Supervisory Board members and 646,914 RSUs to the Executive Board and various key employees. The related RSU expense is recorded in the functional cost category to which the award recipient's costs are classified. Up to June 30, 2023, no RSUs were settled.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The expenses recognized for employee services received under the LTIP RSUs during the three and six months ended June 30, 2023, is in an amount of EUR 1,379k and EUR 1,920k, respectively (2022: EUR 281k and EUR 497k, respectively) and is included in research and development expenses, general and administrative expenses and selling and distribution expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the former CEO has left the Group as of March 31, 2023, all remaining unvested awards are subject to accelerated vesting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As a Supervisory Board member has left the Group as of June 19, 2023, all remaining unvested awards are subject to accelerated vesting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the CSO has left the Group as of July 14, 2023, all remaining unvested awards are subject to accelerated vesting.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise of options&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the New VSOP plan, 11,643 and 48,159 options were exercised within the three and six months ended June 30, 2023, respectively, at a weighted average share price of USD 7.90 and USD 9.81, respectively.&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Narr_Vmtq59SX6k-m1uHOeew4lg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4572000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Narr__EsyWNbQg0OUwrj5a2jUbw"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3597000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_OgTCqx_WiUSXNC4JmxEH-A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cost of sales&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 147&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 147&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Selling and distribution expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (6)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 61&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 153&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 609&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 90&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 761&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,891&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,359&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,221&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other operating expenses &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 235&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 291&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,324&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,994&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,597&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,572&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_CuQvHw1-AkSVgFUqNl9tjw_4_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">147000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_b1bJkchgXEug492pvdwMhA_4_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">147000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales>
    <cvac:Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_AoZLGRuPzEWevSGReANcGA_5_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-6000</cvac:Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses>
    <cvac:Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_z5diGzCkIEO-hFLsQfd_Dw_5_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">112000</cvac:Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses>
    <cvac:Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_UOOkfIaAGU2qMmw_7p3iOg_5_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">61000</cvac:Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses>
    <cvac:Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_7OXTQSvHH0WzTIbjus1utA_5_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">153000</cvac:Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_7TCTq6g9NUepxKaSRmSkEw_6_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-100000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_SsQvhHCMi0mNiYOm0QcKeg_6_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">609000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_Dw5bfIvMC0ynoT0z6cbhFQ_6_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">90000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_1TsgC9gUvUyFGI4htGHvrQ_6_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">761000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_afyjBQi-U0K2mKx4ly2QUg_7_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1380000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_0LmJZjgqWU-qhDOyxikyJw_7_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1891000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_UyEB-R8xEUWMRGZdUzzXPg_7_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3359000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc__ZDiesp9z0yCxZ5ja2KO4g_7_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3221000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc__oVgsaQNuEeYciaA9wJobA_8_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">50000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_tIXmlL1ZDk6md0mXhdhLTQ_8_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">235000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_TinGoYsYuUKbP-WMN8BfAg_8_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">87000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses>
    <cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_gp_wbi7Z0U2IMfu7CeQX0g_8_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">291000</cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses>
    <cvac:BenefitExpenseRecognizedForShareBasedPayment
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_AfyHMsH3S0yfWDL0qCq7rg_9_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1324000</cvac:BenefitExpenseRecognizedForShareBasedPayment>
    <cvac:BenefitExpenseRecognizedForShareBasedPayment
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_iCsUyj0IMUG6bQMUZkiLXg_9_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2994000</cvac:BenefitExpenseRecognizedForShareBasedPayment>
    <cvac:BenefitExpenseRecognizedForShareBasedPayment
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_WudmAYsIHkudRGzmr36llA_9_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3597000</cvac:BenefitExpenseRecognizedForShareBasedPayment>
    <cvac:BenefitExpenseRecognizedForShareBasedPayment
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_0nmIDYIDVU-lmRNQi0a0nA_9_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4572000</cvac:BenefitExpenseRecognizedForShareBasedPayment>
    <cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_2pw78Y87BEK8gesQ5lNIeA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:23.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six months ended June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Program&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;EUR&#160;k&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;LTIP Stock Options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,337&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;RSU Supervisory Board&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 235&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 291&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;New VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (185)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (12)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (82)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 45&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prior VSOP&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (75)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (21)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;LTIP RSUs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,379&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 497&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,920&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 1,324&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 2,994&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 3,597&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 4,572&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_lxpzPHOK-kuFcVc1SH9Lbw"
      decimals="-3"
      id="Tc_iqn3uEGRxEa33JVLjVPIaA_4_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1254000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_jV-ZSqS8kU2_OpwJggs-Ig"
      decimals="-3"
      id="Tc_k-PXCvJkCEi8w1-IjGXg3A_4_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1362000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_2zrm9PnhCkaFBrsWd2DlfQ"
      decimals="-3"
      id="Tc_LAVvgOr97kS5LpmUMCYUbw_4_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3078000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_H7lU27CSYkW4Hf-ukTllUA"
      decimals="-3"
      id="Tc_4_1d3qWMf0yNLDan-trMBw_4_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2337000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_fVrZQK9ylkijyiOuCYXjRw"
      decimals="-3"
      id="Tc_nYpO-Wkc5EyPyQZW3iYvCg_5_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">50000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_y9w5TmE7JUaqCnNvnmrbsw"
      decimals="-3"
      id="Tc_4iMI24StE0qEtZWThxfOdw_5_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">235000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_DRNBrHJkukm3DAjZM2_dVQ"
      decimals="-3"
      id="Tc_9Vc7lnwsf0mCp4wUNu5gtA_5_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">87000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_IfrsRestrictedStockUnitMember_eyoLMAfpYEmjeoloCR63rw"
      decimals="-3"
      id="Tc_mweSpSiR0UmsOGyDr9WzAA_5_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">291000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember_B5CF27FqDkiLjSzyYwknTA"
      decimals="-3"
      id="Tc_HNtKai0E2ECq-W_ZbqLbQg_6_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-185000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember_GWqoCAnOUEuJVuboxaAwqA"
      decimals="-3"
      id="Tc_3ggOXMt1Ak-spK-NIMGm9w_6_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-12000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember_Fdqd0vf59kCIZsGxx1aGZg"
      decimals="-3"
      id="Tc_TlfGs0BSIkWWFYQei13OYA_6_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-82000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_NewVirtualStockOptionsPlanMember__LjcvGfb1UeNNJhvKnzSfg"
      decimals="-3"
      id="Tc_OV7IHuex7UqDB2AbrMpRGQ_6_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">45000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_RTmSmZOXXk-2ImmT99fn8A"
      decimals="-3"
      id="Tc_8Pwu7gYp1kmhd-qKSErjdA_7_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-75000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_MgjlzqfYXUmUABPH0VTY7Q"
      decimals="-3"
      id="Tc_Yn_V4FcCbkqDdkzMLWwF1w_7_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">30000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_OP3JSfO8UkukL75fSOwjDA"
      decimals="-3"
      id="Tc_AIom0MmjpkKU-viwXdJI8Q_7_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">17000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_PriorVirtualStockOptionsPlanMember_Qk-XTh-xFkGe4eGf7kiL-g"
      decimals="-3"
      id="Tc_GSCpinU0Y0mcXT3L-_AfAg_7_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">-21000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_Ef21cT4Rt0mtb7YnbaYYow"
      decimals="-3"
      id="Tc_jlllR_8V8kWOYzSlDo-JQQ_8_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">281000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_0ynCSSVH80efoVzNnwRQmg"
      decimals="-3"
      id="Tc_QF8Jy0OO9EaaA65vvaaCig_8_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1379000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_QbDJ8ZCETEeFxx_3bkTRQA"
      decimals="-3"
      id="Tc_usHoWHvBIky0IDcgPFJEQA_8_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">497000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanAndRestrictedStockUnitMember_FNWBdKYT4kyF3rOWErcVcA"
      decimals="-3"
      id="Tc_YCFdeuXlrUmcuAEFqHAHfQ_8_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1920000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="-3"
      id="Tc_e8b1R3nYLUayF36B9rVIdw_9_2"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1324000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="-3"
      id="Tc_8uxCS-THjEWaoPp5NnHSJA_9_4"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2994000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="-3"
      id="Tc_z2PH9rXAGkeJtos25rjOdw_9_6"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3597000</cvac:ExpenseRecognizedForEmployeeServices>
    <cvac:ExpenseRecognizedForEmployeeServices
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Tc_UW6-hkGygUGGibSXdzncMA_9_8"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4572000</cvac:ExpenseRecognizedForEmployeeServices>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_11_16_2020_To_11_16_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_KwYMhWFPZU6Rg7XLlTdlAA"
      decimals="INF"
      id="Narr_HuUy0i-y0kiX7mLSk7Rzbg"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">266155</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_12_1_2020_To_12_1_2020_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_JiZFgfyfoUWlbX4a-OgfAw"
      decimals="INF"
      id="Narr_Si9JqVE2d0qXDOaBnI4ZHA"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">266156</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember_xmJZx23S6Ee9MA0czFqYMg"
      decimals="INF"
      id="Narr_SSzzpAoq3UCVl3JEJtZToQ"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_12_31_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ChiefScientificOfficerMember_eOb3THsiDEK9JLgQVfEwTA"
      decimals="INF"
      id="Narr_Iyug2e7at0-jutmOGxne3A"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">6303</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_7_1_2021_To_7_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_xb55tI_uTEK9tu0gMHp17g"
      decimals="INF"
      id="Narr_JYc28nabekG8joHpKXt8Hw"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">20000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_46FI4ABSf02M9Rryg4sClw"
      decimals="INF"
      id="Narr_IpxltZjfvE6MIFZiKeWvsQ"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_3_1_2021_To_3_1_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_SYdnaM4Hv0amPp2G2fTAcA"
      decimals="INF"
      id="Narr_wYT_PvlQaUeOftRn5yhDOA"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">2000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2022_To_1_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_NDbK_W7H-0umensvBwuEXw"
      decimals="INF"
      id="Narr_dV1HbwVe-EOjjFzUb4Yynw"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">9500</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_yrSvY_lt6UyqrvMk85XVag"
      decimals="INF"
      id="Narr_uop4p1lwikqSHqZU3rJPdQ"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_3_1_2022_To_3_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_K24THxuJwkSYpgfVd96a9w"
      decimals="INF"
      id="Narr_DxMfAeBAhEWE8FxH7LVPfw"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">130000</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ExecutiveBoardMembersMember_eekSXKejL0WDf-eAeVRHbQ"
      decimals="INF"
      id="Narr_hrMXSm6KakGqC8rzpC7qgw"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_4_1_2022_To_4_1_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_VWrFMaoDW0iaJ10vlf3I3A"
      decimals="INF"
      id="Narr_TIh3dqjSVUiWeyOv6R0d1Q"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">700</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_yrSvY_lt6UyqrvMk85XVag"
      decimals="INF"
      id="Narr_OEbKtEYiW0utjwbAqU2Nfg"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_4_1_2023_To_4_1_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_bao9oCjt3kWO6XoHSsX7IQ"
      decimals="INF"
      id="Narr_B4rgN2WITkekZoUhaWbt8Q"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">144379</ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_ThenChiefExecutiveOfficerMember_OUkDYWpJJkyy_omK2KmOjA"
      decimals="INF"
      id="Narr_Romphp_xzUWqH1wzPylP9g"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">0</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_jV-ZSqS8kU2_OpwJggs-Ig"
      decimals="-3"
      id="Narr_PpzkybfrZEavT9Y8IYpJIg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1362000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_H7lU27CSYkW4Hf-ukTllUA"
      decimals="-3"
      id="Narr_nR1UtdXIvEmSQ5mY2y3UfQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2337000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_lxpzPHOK-kuFcVc1SH9Lbw"
      decimals="-3"
      id="Narr_7SvGfO05WUelq_gUZF6SHQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1254000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_2zrm9PnhCkaFBrsWd2DlfQ"
      decimals="-3"
      id="Narr_XtaGSay9sUuJlFO1jeUAOQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3078000</ifrs-full:ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_24_2021_To_6_24_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_41E5ssbhMEW4sOS5GBDjpg"
      decimals="INF"
      id="Narr_QhuWAVaGc0CxzijNmqk4Pg"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">10956</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_12_23_2021_To_12_23_2021_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_YkGL88cFUUiH_hFBBekkPw"
      decimals="INF"
      id="Narr_9fSMtNV2xkCfdbjBDZdM4w"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">63095</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_H7lU27CSYkW4Hf-ukTllUA"
      decimals="INF"
      id="Narr_GrMY2khe_UadRL66zDmDhQ"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">47424</cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_1_2022_To_1_1_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_g-FjX7APF0qbbMyAZKIHGA"
      decimals="INF"
      id="Narr_AynjbcZRXEqJdTC2r-nyNA"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">36000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement
      contextRef="Duration_1_31_2022_To_1_31_2022_srt_TitleOfIndividualAxis_srt_ChiefOperatingOfficerMember_aDZJW6AtK0-IUzIePmSJgg"
      decimals="INF"
      id="Narr__SgXujy150O1yX_BFwXZSg"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">5000</ifrs-full:NumberOfInstrumentsGrantedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_1_31_2022_To_1_31_2022_srt_TitleOfIndividualAxis_cvac_ChiefBusinessOfficerMember_g2GxNhtCAEyWmUGgwRuryA"
      decimals="INF"
      id="Narr_h2Ak7uuHn0-8LpNMf08_cQ"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">30000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_q81lEiXrw0OgCYslUicbLw"
      decimals="INF"
      id="Narr_ZbIrjpvemEa3cF3R2BrUbw"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">36902</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_22_2022_To_6_22_2022_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_zK3-o7Q200KTZ8l2pvMR8w"
      decimals="INF"
      id="Narr_RVmtd5_zfE2gU6E49OeJQQ"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">188986</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_11_30_2022_To_11_30_2022_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_z47nsJniAkW9xj3JyFsA3w"
      decimals="INF"
      id="Narr_PKra9VeA3UaEFS7P7u-RGg"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">7633</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="INF"
      id="Narr_20f4qvGR2U686o1qgQTPxw"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">73056</cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_7_1_2022_To_7_1_2022_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_Nww_GsAWTEubPvNVau2dgw"
      decimals="INF"
      id="Narr_ugZnicXcGECJ5jtS8rhLaA"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">89655</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement
      contextRef="Duration_6_30_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_FormerFrameEmployeesMember_AZJ95UjEWEaSLSw3FoAPFg"
      decimals="INF"
      id="Narr_Ee1yYQDkPkas5RecDzFQeg"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">29881</cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_cvac_SupervisoryBoardMembersMember_UlK7_VcP00Ke20ec2b3Low"
      decimals="INF"
      id="Narr_Sy8rGl7X7EG0XTCVJgFoOQ"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">92701</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_3_31_2023_To_3_31_2023_srt_TitleOfIndividualAxis_cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember_TvnlUpmmVUa_HJFdi00FrQ"
      decimals="INF"
      id="Narr_KHTHQYR5TUe6VJga73_4xA"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">646914</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_KeyEmployeesMember_Zhw8mSG_RkaWjTgdo48LVQ"
      decimals="INF"
      id="Narr_yaOX-l5KLkmowkCIN6Mv-A"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">0</cvac:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement>
    <cvac:ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_jV-ZSqS8kU2_OpwJggs-Ig"
      decimals="-3"
      id="Narr_xwwmLcXNGEGI_GEcQgPI9Q"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1379000</cvac:ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu>
    <cvac:ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_H7lU27CSYkW4Hf-ukTllUA"
      decimals="-3"
      id="Narr_cF4z7mfPsEC4muP1QUNa4A"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1920000</cvac:ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu>
    <cvac:ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu
      contextRef="Duration_4_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_lxpzPHOK-kuFcVc1SH9Lbw"
      decimals="-3"
      id="Narr_asnewevp_EK_uTP4fRbPDA"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">281000</cvac:ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu>
    <cvac:ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_LongTermIncentivePlanMember_2zrm9PnhCkaFBrsWd2DlfQ"
      decimals="-3"
      id="Narr_KMwYPhw4HE2vxM9_brDkGA"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">497000</cvac:ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_xUdA4vFkmkehfhynMJzhzA"
      decimals="INF"
      id="Narr_eOq_I7_8TkCNtiZLxwr0IA"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">11643</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_4WXyX6UBnEeF_hShCcUFxg"
      decimals="INF"
      id="Narr_oVhosA2EBEKIljxPLBXi7Q"
      unitRef="Unit_Standard_Option_CKnpgyx2okOQUf81KqoBag">48159</ifrs-full:NumberOfShareOptionsExercisedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="Duration_4_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_xUdA4vFkmkehfhynMJzhzA"
      decimals="2"
      id="Narr_KM5MFHMexE-GSGKhGpUS9g"
      unitRef="Unit_Divide_USD_shares_WivF9OzOw0qggSizEvs2xg">7.90</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_cvac_VirtualSharesProgramIiMember_4WXyX6UBnEeF_hShCcUFxg"
      decimals="2"
      id="Narr_7v0HVwNJLUSlG4BHBwt4Ow"
      unitRef="Unit_Divide_USD_shares_WivF9OzOw0qggSizEvs2xg">9.81</ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019>
    <cvac:DisclosureOfFixedAssetsExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_xt9he-TzwkuhkUvIBkWNMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;6. Fixed Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;6.1 Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the six months ended June 30, 2023, the Group acquired intangible assets of EUR 2,567k (six months ended June 30, 2022: EUR 1,207k). Acquired intangibles mainly related to licenses, software and prepayments made to acquire those.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;6.2 Property, plant and equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the six months ended June 30, 2023, the increase in property, plant and equipment was attributable to the purchase of technical equipment and machines and other equipment of EUR 5,940k (June 30, 2022: EUR 3,034k) as well as additional amounts recognized as construction in progress of EUR 22,421k (June 30, 2022: EUR 39,386k) primarily related to the Company-owned GMP IV facility EUR 20,666k.&lt;/p&gt;</cvac:DisclosureOfFixedAssetsExplanatory>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_6_30_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_F3innQ88Ak6o2rkcUJY0ZQ"
      decimals="-3"
      id="Narr_HXIrIP8hz0Sxaian-Kk4Lg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">2567000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2022_To_6_30_2022_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_xDhMyn6Lpkahl29jhpRNOg"
      decimals="-3"
      id="Narr_7_jd-z8UWU2BH1Ayb5e4mA"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1207000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember__JCd2jsBx0aS7CNRVo1ClA"
      decimals="-3"
      id="Narr_T6NL6xRkjkKrQ4mMw6JUgw"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">5940000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember_tDwKd8WW10KShixVy7Uj8g"
      decimals="-3"
      id="Narr_uvtxITfJj0WKBdYJ3jIlig"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3034000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_C0dEV8ymUEuwP4xIHoAt0Q"
      decimals="-3"
      id="Narr___Jp9PhUO0GG80syXgS3sg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">22421000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_6_30_2022_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_ifrs-full_ConstructionInProgressMember_TQ5I85ZFr0KjUsctPczaJA"
      decimals="-3"
      id="Narr_1eTHyy7dAEeC5b9TD252jg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">39386000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_CompanyOwnedGmpIvFacilityMember_epTIr0WyBkir6RkvPsvAWQ"
      decimals="-3"
      id="Narr_RaTe4ulNQEWKaMtrea5Uyw"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">20666000</ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment>
    <ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_g503DTzXq0uL7dkJ3qGjWw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;7. Assets held for sale&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;In 2022, Management decided to dispose of certain equipment which had been procured for CMO activities (CMO Equipment) but that was no longer planned to be used by the Company. An external service-provider was appointed on June 14, 2022 to organize the sale of the CMO Equipment. As of December 31, 2022, the CMO-Equipment identified for sale had a gross book value of EUR 29,531k and was written down by EUR 19,064k (with the corresponding expense recognized in cost of sales) to EUR 10,467k, the fair value less anticipated costs to sell. Criteria for the determination of the fair value were defined based on certain sales scenarios considering different sales campaigns. All sales activities are scheduled for 2023 and as of June 30, 2023 Assets held for sale with a net book value of EUR 513k were sold through an external service provider.&lt;/p&gt;</ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory>
    <cvac:GrossBookValueOfCmoEquipmentHeldForSale
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Narr_pvTZKfbUVE2NR6jjG0f2uA"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">29531000</cvac:GrossBookValueOfCmoEquipmentHeldForSale>
    <cvac:ImpairmentOfAssetsHeldForSale
      contextRef="Duration_1_1_2022_To_12_31_2022_LfUbJgvVEEOMs9Xu0dY_aQ"
      decimals="-3"
      id="Narr_sOT0RZLiRkCksIgaGpF70w"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">19064000</cvac:ImpairmentOfAssetsHeldForSale>
    <ifrs-full:InventoriesAtFairValueLessCostsToSell
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Narr_LCE0-X0y-UKs1c5ay7wgBw"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">10467000</ifrs-full:InventoriesAtFairValueLessCostsToSell>
    <cvac:AssetsHeldForSaleNetBookValueSold
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Narr_EUrVSe-3pkmWx5ca6A37iQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">513000</cvac:AssetsHeldForSaleNetBookValueSold>
    <ifrs-full:DisclosureOfInventoriesExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_tyiwvFyIVUGufokOQjWyBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;8. Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The inventories include only raw materials and supplies amounting to EUR 22,194k (December 31, 2022: EUR 23,989k), which are recoverable under the Company&#x2019;s agreements with its collaboration partners. During the six months ended June 30, 2023, the decrease in inventory of EUR 1,795k is due primarily to further write-offs and the usage of raw material for R&amp;amp;D purposes, partially compensated by purchases of raw material.&lt;/p&gt;</ifrs-full:DisclosureOfInventoriesExplanatory>
    <ifrs-full:RawMaterials
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Narr_fSDvkcoy-0mDghxhEem9fg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">22194000</ifrs-full:RawMaterials>
    <ifrs-full:RawMaterials
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Narr_9IhOBTOmzEyUHsaGyscmPw"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">23989000</ifrs-full:RawMaterials>
    <cvac:IncreaseDecreaseInInventory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Narr_nXCG0Qs83E-QW2KS_m7yCA"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1795000</cvac:IncreaseDecreaseInInventory>
    <cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_-djELHnenE2CaM2sBW7k2w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;9. Prepaid expenses and other assets (current)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Prepaid expenses and other current assets as of June 30, 2023 amounted to EUR 21,221k (December 31, 2022: 40,287k) and include receivables for the GSK compensation of EUR 1,491k (December 31, 2022; EUR 5,595k). In addition, other assets include tax claims against the tax authorities of EUR 7,852k (December 31, 2022: EUR 24,840k). These net amounts of VAT refund claims and VAT payables do not bear interest and are reported to the tax authorities on a monthly basis.&lt;/p&gt;</cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Narr_iURLnW2AgkCF5k7EODyOdg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">21221000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Narr_2Izf3qi_k0uqMq33zQi-vQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">40287000</ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets>
    <cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Narr_s-gVgC9NkEm65CN_LBIfrg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1491000</cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer>
    <cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Narr_Jnjl26xkr0WworXt_VMjmA"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">5595000</cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer>
    <ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Narr_w5zzTAg4i0ix95btN3CxrA"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">7852000</ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Narr_Ea1-xo4500ivfs-JxCf4Ow"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">24840000</ifrs-full:ReceivablesFromTaxesOtherThanIncomeTax>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_-s4R9y95Okaaxm6KsKPprQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;10. Financial assets and financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Fair values of cash and cash equivalents, trade receivables, trade payables, and other current liabilities approximate their carrying amounts largely due to the short-term maturities of these instruments. Cash and cash equivalents compromise cash at banks and term deposits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Cash and cash equivalents compromise cash at banks and term deposits. There were no transfers between Level 1 and Level 2 fair value measurements and no transfers into or out of Level 3 fair value measurements during the six months ended June 30, 2023 and 2022.&lt;/p&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="0"
      id="Narr_qOQ_jsTN-kKYL7Gnj9lE3g"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">0</ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets>
    <ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="0"
      id="Narr_EgaNkQUYakmkKTr9nv5upg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">0</ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets>
    <ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="0"
      id="Narr_TxNE8jYJZEWIdzbn7hbNfw"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">0</ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets>
    <ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="0"
      id="Narr_V_0mNo1Rlk6Qipus6t2OAg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">0</ifrs-full:TransfersIntoLevel3OfFairValueHierarchyAssets>
    <ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb__yHZ3-VWM0qBoqfKmwbGFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;11. Trade and other payables&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;Trade and other payables are all due within one year amounting to EUR 13,419k (December 31, 2022: EUR 73,463k). During the six months ended June 30, 2023, the decrease of EUR 60,043k in trade and other payables was primarily due payments to raw material suppliers for invoices received before December 31, 2022.&lt;/p&gt;</ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Narr_KwyMmJJSZE6aeZPa6iR01Q"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">13419000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew"
      decimals="-3"
      id="Narr_8pkaedMSC0SEGGWPHW-1Qg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">73463000</ifrs-full:TradeAndOtherCurrentPayables>
    <cvac:ChangeInTradeAndOtherPayables
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Narr_a67YJqD2MEqORSigJ6w2eQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">60043000</cvac:ChangeInTradeAndOtherPayables>
    <cvac:OtherLiabilitiesAndProvisionsTextBlock
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_8SVY98r-DU6WsjDWKr47tA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;12. Other liabilities and provisions&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;During the six months ended June 30, 2023, the decrease of EUR 4,977k in other liabilities was primarily due to lower accruals for outstanding invoices.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of June 30, 2023 the contract terminations provisions of EUR 61,320k which are reflecting amounts which the Company expects to pay out to settle its obligations under certain CMO contracts which it has terminated, were reclassed from Provisions (non-current) into Provisions (current) due to an expected maturity within one year. In addition, during the six months ended June 30, 2023, the decrease of EUR 1,932k in Provisions (current) was primarily due to a consumption of the CRO provision for onerous losses.&lt;/p&gt;</cvac:OtherLiabilitiesAndProvisionsTextBlock>
    <cvac:ChangeInOtherLiabilities
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Narr_PLPLenAEikiKjZ9GeNsPxg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4977000</cvac:ChangeInOtherLiabilities>
    <cvac:ProvisionsForDecreaseInContractTerminations
      contextRef="As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ"
      decimals="-3"
      id="Narr_mBbuCUSWCUCsGKFnjlcrhg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">61320000</cvac:ProvisionsForDecreaseInContractTerminations>
    <ifrs-full:ChangesInOtherProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Narr_DJAq7kOzQUGW2UYnv_FpoQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">1932000</ifrs-full:ChangesInOtherProvisions>
    <ifrs-full:DisclosureOfIncomeTaxExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_2tk4o2I6uEira7KKY29dBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;13. Income tax&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;The increase in expense was primarily attributable to the income tax expense of CureVac Swiss AG and CureVac Belgium S.A.&lt;/p&gt;</ifrs-full:DisclosureOfIncomeTaxExplanatory>
    <ifrs-full:DisclosureOfFinancialRiskManagementExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_2ePzb00zQ0C2WY-le9x_0w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;14. Disclosure of financial instruments and risk management&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As the Group requires significant liquid funds available for the financing of its COVID-19 and influenza research and development activities, during the six months ended June 30, 2023, it has maintained funds as cash and cash equivalents and not in less liquid financial instruments. The Group has distributed the cash amongst several banks and amongst the legal entities in the Group in order to reduce negative interest penalties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Refer to note 16 to the consolidated financial statements as of December&#160;31, 2022 for additional information on the Group&#x2019;s risk management activities. As of June 30, 2023, the Group held cash and cash equivalents of USD 73,600k and CHF 132k, which are exposed to foreign currency exchange risk. The Group intends to settle expenses arising in US dollars using these US dollar funds. &lt;/p&gt;</ifrs-full:DisclosureOfFinancialRiskManagementExplanatory>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_c616ZXiH_EKOpj5dNuZ83w"
      decimals="-3"
      id="Narr_lFvU2xnZu0maFNbXh-nhzw"
      unitRef="Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw">73600000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic
      contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_CHF_tuyUV0cxakyr_-Yg3O_syQ"
      decimals="-3"
      id="Narr_g1I8j5ijCUSluU_RF99TCA"
      unitRef="Unit_Standard_CHF_jBH-rjz8PUGNxxRiXvE2kQ">132000</ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic>
    <ifrs-full:EarningsPerShareExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_ovt343xpCE2Dk0PVuxXsUg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;15. Earnings per share&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.2pt;margin:0pt 0pt 12pt 0pt;"&gt;Earnings per share is calculated pursuant to &lt;i style="font-style:italic;"&gt;IAS 33 Earnings per Share&lt;/i&gt; by dividing the consolidated net loss in CureVac N.V. by the average weighted number of shares outstanding in the fiscal period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18.2pt;margin:0pt;"&gt;The weighted number of shares outstanding for the three and six months ended June 30, 2023 was 223,883,084 and 217,698,351, respectively (2022: 187,089,253 and 187,041,805, respectively). This has led to a basic loss per share for the three and six months ended June 30, 2023 of EUR 0.30 and EUR 0.57, respectively (2022: EUR 0.31 and EUR 0.39, respectively). Since the conversion of options to ordinary shares would decrease loss per share, they are considered antidilutive. Therefore, the diluted earnings per share equals basic earnings per share for the three and six months ended June 30, 2023 and 2022. &lt;/p&gt;</ifrs-full:EarningsPerShareExplanatory>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="0"
      id="Narr_qA-Bn9t85kGTv_SZNPnuYQ"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">223883084</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="0"
      id="Narr_iCOZYifSzkCYJOdD4gPZSw"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">217698351</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="0"
      id="Narr_K4cjYwsOSU6tosN43x7NRA"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">187089253</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="0"
      id="Narr_aOMmm-eCLUONy-Xd7RjSiA"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">187041805</ifrs-full:WeightedAverageShares>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg"
      decimals="2"
      id="Narr_nv2ObAlDoEOgf5StwQpa6w"
      unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">-0.30</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="2"
      id="Narr_QnxAv3YnEE-GXNjZ4AYHNg"
      unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">-0.57</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_4_1_2022_To_6_30_2022_F_WddVj4V0OEYOea00mkWA"
      decimals="2"
      id="Narr_WwBqHdBYMkCmDVHDojfW-w"
      unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">-0.31</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2022_To_6_30_2022__sj66D2PQ0a5rI469EDZMA"
      decimals="2"
      id="Narr_riVFeonjGUK7c_4UjWvgAg"
      unitRef="Unit_Divide_EUR_shares_NbEbJyxkZUOL6h-TDd_m0Q">-0.39</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DisclosureOfRelatedPartyExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_oiLIkikIjkS5xdAvoJLgow">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;16. Related party disclosures&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Dietmar Hopp&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;During fiscal 2019, Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp;amp; Co. KG (dievini), the largest shareholder of the Group, granted two convertible loans to the Group, which were repaid in 2020. Additionally, in August 2020, DH-LT Investments GmbH, a company beneficially owned by Dietmar Hopp, managing director of dievini, the Group&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2019;&lt;/span&gt;s largest shareholder, purchased EUR 100,000k of the Group&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2019;&lt;/span&gt;s common shares at a price of USD 16.00 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Antony Blanc&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18.2pt;margin:0pt 0pt 8pt 0pt;"&gt;In 2020, a consulting agreement between CureVac AG and Clarentis SRL was made. Clarentis SRL is a wholly owned consulting company of Antony Blanc, PhD, the CBO of CureVac. After the transition of Antony Blanc to the Management Board in February 2021, the contract was no longer active, and no new orders were placed. In Q3 2021, a milestone payment, which related to the submission of the EMA dossier for CVnCoV and which amounted to EUR 100k was made to fulfill a contractual obligation from the consulting agreement in place before Antony Blanc joined the Management Board. In addition to his Management Board position at CureVac N.V., Antony also took over the role as Management Director at CureVac Belgium SA. He executes this function by using Clarentis SRL. As it relates to these services, CureVac paid in 2023 until June 2023 an amount of EUR 42k. The amounts invoiced for this function/services will be offset/deducted from his base compensation for his function on the Board of Management of CureVac N.V.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;BePharBel Manufacturing S.A.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;In December 2020, CureVac Real Estate GmbH and BePharBel Manufacturing S.A., entered into a commercial supply agreement to develop and manufacture the diluent that was expected to be used to dilute the Group&#x2019;s first concentrated COVID-19 vaccine candidate, CVnCoV, to the amount specified by each dose level. Pursuant to the terms of the agreement, it was intended that BePharBel Manufacturing would manufacture and deliver to CureVac Real Estate GmbH a low seven figure amount of commercial batches of diluent per year, in 2021 and 2022. Following the withdrawal of the CVnCoV in October 2021 due to COVID-19 virus drift, WHO COVID vaccine efficiency recommendation and market expectations, CureVac Real Estate GmbH terminated the commercial and supply agreement with BePahrBel and entered into negotiations on a structured and rapid wind-down of the ordered production. The Parties agreed on a settlement in May 2022 of all claims resulting from the commercial and supply agreement for an amount of EUR 3,900k, which had been already recognized in provisions, based on an estimate, as of December 31, 2021. In total an amount of EUR 4,016k was paid. Baron Jean St&#xe9;phenne, Chairman of our Supervisory Board, holds directly and indirectly 15.61% of BePharBel Manufacturing&#x2019;s equity and is a director of BePharBel Manufacturing, and Baron Jean St&#xe9;phenne&#x2019;s son, Vincent St&#xe9;phenne, holds 1.43% of BePharBel Manufacturing&#x2019;s equity and is a managing director of BePharBel Manufacturing.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Franz-Werner Haas&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;In Q1 2023, a consulting agreement between CureVac SE and Franz-Werner Haas was entered into. For the six-month period ended June 30, 2023 no costs have been paid under this agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Alexander Zehnder&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;In Q1 2023, a first addendum to the future service agreement was entered into to ensure a smooth transition from CEO Franz-Werner Haas to the new CEO Alexander Zehnder. Total compensation amounted to EUR 51k during the month of March.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Barker BioMedical GmbH&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"&gt;In Q1 2023, a consulting agreement between CureVac SE and Barker BioMedical GmbH was entered into. Barker BioMedical GmBH is a wholly-owned consulting company of Debra Barker, Supervisory Board member of CureVac N.V.. For the six-month period ended June 30, 2023 total costs incurred under this agreement amount to EUR 14k.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Craig Tooman&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;In Q1 2023, a consulting agreement was entered into between CureVac SE and Craig Tooman. For the six-month period ended June&#160;30, 2023, no costs have been incurred under this agreement.&lt;/p&gt;</ifrs-full:DisclosureOfRelatedPartyExplanatory>
    <cvac:RelatedPartyTransactionNumberOfLoansReceived
      contextRef="Duration_1_1_2019_To_12_31_2019_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_kXJFYB4hY0uYWJFAb4CEQg"
      decimals="INF"
      id="Narr_8O1L33vVQ0awQwIMXBlHTQ"
      unitRef="Unit_Standard_loan_5iHDzlzZyki6zzA0B9i78A">2</cvac:RelatedPartyTransactionNumberOfLoansReceived>
    <ifrs-full:NumberOfSharesIssued
      contextRef="As_Of_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_bb_-yK9N50-YjTv-FAr2SA"
      decimals="INF"
      id="Narr_uJLZ-8AAsUKw62deg_-cJA"
      unitRef="Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q">100000</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:WeightedAverageSharePrice2019
      contextRef="Duration_8_1_2020_To_8_31_2020_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_DietmarHoppMember_jJMos62EfkW5YNIpjhOWeQ"
      decimals="2"
      id="Narr_2J4Pnk0XHEGhF8sC6wpJUQ"
      unitRef="Unit_Divide_USD_shares_WivF9OzOw0qggSizEvs2xg">16.00</ifrs-full:WeightedAverageSharePrice2019>
    <cvac:IfrsContractualObligation
      contextRef="As_Of_9_30_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_xghJZOz2zkyZscGxuWn0yg"
      decimals="-3"
      id="Narr_ax2K5X3HhkaxLqf3DeeXuw"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">100000</cvac:IfrsContractualObligation>
    <cvac:RelatedPartyTransactionConsultingFees
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_ClarentisSrlMember_srt_TitleOfIndividualAxis_cvac_AntonyBlancMember_GIDUORdEfE2sHWHYyWOsSA"
      decimals="-3"
      id="Narr_QcIrFzE8o0eRKVLprOr_Ew"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">42000</cvac:RelatedPartyTransactionConsultingFees>
    <ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions
      contextRef="Duration_5_1_2022_To_5_31_2022_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_kPAAhLB8vEeSoaGBtF4VwQ"
      decimals="-3"
      id="Narr_QSLJcbqo60-a8jG5IWMfCQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">3900000</ifrs-full:CommitmentsMadeByEntityRelatedPartyTransactions>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BepharbelManufacturingS.aMember_vDdXBJ99MUy29plp5BCfpQ"
      decimals="-3"
      id="Narr_EJlika1Q40Cm5T3C9OEepQ"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">4016000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_BaronJeanStephenneMember_YRShJABpk0-UxZwCv3pqAA"
      decimals="4"
      id="Narr_6E-mODaPNEyJ3yvS8K0i3A"
      unitRef="Unit_Standard_pure_OIXcQb-ZL02u7t-A0Qaj8g">0.1561</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="Duration_1_1_2023_To_6_30_2023_srt_TitleOfIndividualAxis_cvac_VincentStphenneMember_fO5tW3MsVE60EMuNs7InYQ"
      decimals="4"
      id="Narr_hhMd9XwgqUeFsYzaoJyYBg"
      unitRef="Unit_Standard_pure_OIXcQb-ZL02u7t-A0Qaj8g">0.0143</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <cvac:ExpensesToHandleFutureServiceAgreement
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      decimals="-3"
      id="Narr_vKff8sE4L020jqqa5z3fDA"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">51000</cvac:ExpensesToHandleFutureServiceAgreement>
    <cvac:ExpenseRecognizedFromRelatedPartyTransaction
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_BarkerBiomedicalGmbhMember_mv3p0pRW2UerXnYaXscbzg"
      decimals="-3"
      id="Narr_C4n0v7M_r0yx7DhPg3rVBg"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">14000</cvac:ExpenseRecognizedFromRelatedPartyTransaction>
    <cvac:ExpenseRecognizedFromRelatedPartyTransaction
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfRelatedPartiesAxis_cvac_CraigToomanMember_PoIqBBw0NUOkeFya4T-Bsw"
      decimals="-3"
      id="Narr_ezmebbNh302SJGzH0Tw9IA"
      unitRef="Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ">0</cvac:ExpenseRecognizedFromRelatedPartyTransaction>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw"
      id="Tb_kTTTlFsHnEGRTZS6sbFk3g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;17. Subsequent events&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;As of July 14, 2023, Dr. Igor Splawski, CureVac&#x2019;s Chief Scientific Officer (CSO), stepped down from his role as CSO. During the search for a successor, CureVac&#x2019;s Chief Development Officer, Dr. Myriam Mendila, will head the advancement of CureVac&#x2019;s mRNA technology platform and its integration with the clinical development of novel mRNA vaccines and therapeutics.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;CureVac filed a patent infringement lawsuit in Germany against BioNTech regarding four of its intellectual property rights in June 2022. The patent litigation was strengthened by the addition of a fifth intellectual property right as announced in May 2023. In July 2023, CureVac announced that it has extended these five intellectual property rights by three more recent intellectual property rights. In total, the patent litigation in Germany now covers eight intellectual property rights. A first public hearing on this lawsuit took place on August 15, 2023, before the Regional Court D&#xfc;sseldorf. A nullity action covering one of the patents at issue was filed by Pfizer/BioNTech in September 2022. A preliminary opinion issued in April 2023 by the German Federal Patent Court supports the validity of the CureVac patent. In the U.S., Pfizer/BioNTech filed a case in late July 2022, asking for confirmation that Comirnaty&#xae; does not infringe three CureVac patents. In May 2023, CureVac filed a counterclaim in the U.S. that alleges infringement of nine U.S. patents, expanding the scope of the case beyond the three patents originally named by Pfizer/BioNTech. These nine patents have been extended by a tenth patent as announced in July 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <cvac:NumberOfIntellectualPropertyRightsInfringementCaseFilled
      contextRef="Duration_6_1_2022_To_6_30_2022_IMdJRoUvhk2KhVqXkyy6DA"
      decimals="INF"
      id="Narr_i4CiEsvYqkCXjDDrgEwuOA"
      unitRef="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ">4</cvac:NumberOfIntellectualPropertyRightsInfringementCaseFilled>
    <cvac:NumberOfIntellectualPropertyRightsInfringementCaseFilled
      contextRef="Duration_5_1_2023_To_5_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_PatentInfringementLawsuitFilledMember_oqeBQyU8LUS4jK_f0UnMNg"
      decimals="INF"
      id="Narr_8xPqKVWHP0K1d9EpmmSSpg"
      unitRef="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ">5</cvac:NumberOfIntellectualPropertyRightsInfringementCaseFilled>
    <cvac:NumberOfIntellectualPropertyRightsInfringementCaseFilled
      contextRef="Duration_7_1_2023_To_7_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_PatentInfringementLawsuitFilledMember_Qz-L5Ejndka-M5jETiVyOw"
      decimals="INF"
      id="Narr_x0FkDTwS6Eel3W9og3brkw"
      unitRef="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ">3</cvac:NumberOfIntellectualPropertyRightsInfringementCaseFilled>
    <cvac:TotalNumberOfIntellectualPropertyRightsInfringementCase
      contextRef="Duration_7_1_2023_To_7_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_PatentInfringementLawsuitFilledMember_Qz-L5Ejndka-M5jETiVyOw"
      decimals="INF"
      id="Narr_Bs3ya8PWSUqG4GxMzy4Wqw"
      unitRef="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ">8</cvac:TotalNumberOfIntellectualPropertyRightsInfringementCase>
    <cvac:NumberOfPatentOnWhichNullityActionIsFilled
      contextRef="Duration_8_1_2023_To_8_31_2023_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_cvac_PatentInfringementLawsuitFilledMember_OxwKIZvNZUe6ydx3xJju_Q"
      decimals="INF"
      id="Narr_x-JmZ1zdPkqi3KHLROS7Sw"
      unitRef="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ">1</cvac:NumberOfPatentOnWhichNullityActionIsFilled>
    <cvac:NumberOfIntellectualPropertyRightsInfringementCaseFilled
      contextRef="Duration_5_1_2023_To_5_31_2023_opUMBeSJAU6Y3pCknLUBYw"
      decimals="INF"
      id="Narr_UFGO8arDWEKlGyoB6Xm--w"
      unitRef="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ">9</cvac:NumberOfIntellectualPropertyRightsInfringementCaseFilled>
    <cvac:NumberOfPatentOnWhichNullityActionIsFilled
      contextRef="Duration_4_1_2023_To_4_30_2023_MpR9Fyh8qkmIM9QPSU-9Eg"
      decimals="INF"
      id="Narr_oCqsCvY9gUuiGBDOlyyU1A"
      unitRef="Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ">3</cvac:NumberOfPatentOnWhichNullityActionIsFilled>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>66
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M>"G9<^'-I_H,F:Q$>JP?B V*3[(&TQ2F= &7+\QFCG"PL$XK*_'N@RCQIH+
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M^\H6_]PB7VB4K;I\>!3Y#^8[:YAS0QCW2['RW &_:QMQ%?+4XC%5!TMH,D9
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MV6SJS5X<NC$@2:!_9\3;K]W$\8[O)AQ(1X]2/R\@-VZ3SC:YNJ[/F+3[$80
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MHGA4U^1V_*'P0?I*?))>B*<#DR@.PL52?,%AR-:#8G7K+Z9QL(RF+W\Y4_
M@6S3-/B),7F+>13,H^DO,EY5AAGC:^@0:0:0>/8XX66PG/\&WX.OK4.ZBRE2
M,^N>_>QS>+)W9BG(;/W)S H_1\WQI7_:'_Y6S9EGV-Z<')&W+88"P[B!:3@^
MF8^$:4YCS8W3E3\!K;7#><I?9CC DN$-6-]H[;H;=M ?B<__ U!+ P04
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MJT46J[*5DBS#GI75J4U/(RM@"']W>^E4-V^R*O2@;-NMZ]0N<<LT0FCD- ]
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MN\9]FZ_#.'<9Q+(,WRTOR-S L+RP9R:"J4LMJ]A]OK-OW8XIL,I*7RJC1(_
M^(*5]0,F (@WY/AN^HZ,AZ&I\>,B' ;6)J;AOIO)4>?"&#QNH:_%,5] D)5W
MQ\UN<_-^45XXM\?+:WOPQT6<E>8Z&YC#L3<@HKP*+Q>*Y_KZ^9XKQ5/]N&0P
M^@H\ ._GG*MZ@02:_T<X_Q=02P,$%     @ V(,15[=9=4P@ P  -P<  !D
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M94/K'?A\8PP];'R \:U<_@102P,$%     @ V(,15WP<4WJ: P  [P<  !D
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M;46JC-H%D'^EE-T?W 6#SN=_ %!+ P04    " #8@Q%7C$!922(#  !O!P
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M)VS\0!5OO*G"1Z&9\=Z4X3)'?R'+&[ ^1SVU-RR@^TIX_']02P,$%     @
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MQL-4LI'MW'4EFLIC@\G]T>,\-/(A/'5H#SJRI08Z6L'USDOO3[CC&"?I30
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MJ/(;ER#;'1SV\P0S%MMDLG5:-HT"W,'^#?2.8"<;WOA1+"3E@040PP*(KUB
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MV(\9T#SJA\&#N,'@N) $X\4TG!PBV+.2&1JZF/!02\!RJS4:" 0><)\T@O#
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MH>2X0%1@1@%'VY5UXUZGKJ<5:HD_,3J*DS'0H3PR]DF_?,A7EJ,]0@1E4D-
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MM1=VUOJZ;GSUON&K#VX9E7L!4IJC?$0_F=:/)O1MQ5M'GO=$WMJ;!/REHE?
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MU([<M* /!F@;0.=+1>70+FQ/ZCY!Z7]02P,$%     @ V(,15Z%-*(C! P
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M;"]W;W)K<VAE971S+W-H965T,S0N>&ULK5C;;MLX%/P50@6*%MA$(G6S4]M
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M#\#*ITHJ6X\D*R@KAXB..OG1,JR=Q2=$8M_K*'+)@.OQ@&>ZQ:UN\:ANC[0
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MUG!K7+LUUKKU7#UJE_>VGQJ9M)QS98*$.9 PMX0-&S+UQ[8U/M )LE$?$A8
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M)>7:0+U?,29?;O0 U1G<Y']02P,$%     @ V(,15\5&)GM[%@  Z=@! !D
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M-175-%334<U -1/5+%2S4<U!-1?5/%3S42U M1#5(E2+42U!M135,E3+4:U
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MU4I*:T3NL*XM&O:0'<\A6E>$:BJJ::BFHYJ!:B:J6:AFHYJ#:BZJ>:CFHUJ
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M@V#H%Y0)+XE=[$XEL:P,9P+N%-%545#U,@$NZY'7\]:!>[;(C0WX25S2!3R
M>2SO%,[\CB5C!0C-I" *YB-OW#N;#FR^2_C)H-8;8V*=S*1\LI/K;.0%5A!P
M2(UEH/A:PA0XMT0HX[GE]+HM+7!SO&:_<M[1RXQJF$K^BV4F'WFG'LE@3BMN
M[F7]'5H_3F JN79/4C>Y0TQ.*VUDT8)10<%$\Z:KM@X; .39#@A;0/@>T/\
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M&0TZ?JKY,<3!.XB"*.X+:%A^A9F1ATX>#803=[L2.[]XAUWI2W/C,NIWL0?
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M(U0V ZO9:%&ZGG\6VDP0M\S-C =I \S]6@B]V]@$W;]&\@M02P,$%     @
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M.SV91N/X\AQU"T0YNBU%HPR)2GUM]-F[^'FGY:K5@E_1\K7A(Q0%[Q .<#0
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MFFH:G 90XH*VW-S)]3?L_7B!A>3:_\*ZRTW# (I6&UGW8*N@9J)[TN>^#EL
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M5JCJ!EZW,++Q,V,NC9U /JSL-P*52[#G"RG-9N$N&+XZ^1]02P,$%     @
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M.!GAUE+-2=]TC*S<87DG#1Z]KEG@Y0B4#<#ON93FI6//W^ZZE?X$4$L#!!0
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M6P>=L^J[G=6OB8A+8]U=8Z#^*I060&DAE!9!:11%LY72^;#^,;#&0*U8*"V
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MF55O-YPMN2HW,)^OI-1/"V6"=KJ0^?]02P,$%     @ V(,15XSR!1R> P
M\A,  !D   !X;"]W;W)K<VAE971S+W-H965T-34N>&ULO9AO;]LV$,:_"J$!
M0PMLD2S9CI/: I+(0C<@0]!LZVM:.EM$*5(E*;OY]B,I1;4<6XD'(F]L_>'S
MNQ,?ZFC??,?%-UD */2CI$PNO$*IZMKW959 B>4%KX#I.VLN2JSTJ=CXLA*
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M?W.EO6'_T[)C7@W&.]>KJQ=.S Z\<AENZ1*6.H+U;!T%/__-!N_P@ZD-LF_
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #8@Q%7(/&&G'H$  "^)
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MV1SR6?>5PN034$L! A0#%     @ V(,15P=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #8@Q%79:QC
MT^\    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " #8@Q%7F5R<(Q &  "<)P  $P              @ '- 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( -B#$5<7TA62KP(  +((
M   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " #8@Q%7)O%+]K\%  !=&0  &               @('S"@
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ V(,15U]=%0B"
M!@  .!\  !@              ("!Z!   'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( -B#$5<H1,"?S 4  (@B   8              "
M@: 7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " #8@Q%7
M:XJMD3T'  ##'@  &               @(&B'0  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ V(,15[<<.(]@!   >0D  !@
M     ("!%24  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M -B#$5?/+)NXO0@  &@6   8              " @:LI  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    " #8@Q%7 ^GOA: /  !T,0  &
M            @(&>,@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ V(,15QSWZ"Q!!@  '@\  !@              ("!=$(  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( -B#$5=]UP_C?P@  )L@
M   9              " @>M(  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ V(,15[=9=4P@ P  -P<  !D              ("!H5$
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " #8@Q%7?!Q3
M>IH#  #O!P  &0              @('X5   >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( -B#$5=NM5M'X@(  "X&   9
M  " @<E8  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
MV(,15[!4G<[9 @  T@8  !D              ("!XEL  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    " #8@Q%7%;;CQ]4"   3!P  &0
M            @('R7@  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( -B#$5>X>C]REP(  /,%   9              " @?YA  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ V(,15XQ 64DB P
M;P<  !D              ("!S&0  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    " #8@Q%7.IX)ORL"  #T!   &0              @($E
M:   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( -B#$5<.
M49$.F ,  'L(   9              " @8=J  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ V(,15R+0\FL" P  6 <  !D
M     ("!5FX  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M" #8@Q%7TII%/@$(   Q%   &0              @(&/<0  >&PO=V]R:W-H
M965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -B#$5>T"(7[W@0   ,+   9
M              " @<=Y  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L!
M A0#%     @ V(,15YH2,NCG"   MQ<  !D              ("!W'X  'AL
M+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " #8@Q%7391^OTP(
M  "/'@  &0              @('ZAP  >&PO=V]R:W-H965T<R]S:&5E=#(T
M+GAM;%!+ 0(4 Q0    ( -B#$5=N?Y7@X0(  .@&   9              "
M@7V0  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ V(,1
M5P"U"D:7 P  >PH  !D              ("!E9,  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    " #8@Q%7F6-#$"8"  !8!@  &0
M        @(%CEP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( -B#$5=="Z4>^@0   4B   9              " @<"9  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ V(,15_(R9_OA P  C!,
M !D              ("!\9X  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    " #8@Q%7EP3\;^X&  "(0@  &0              @($)HP
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( -B#$5=,$@<,
M?0(  (X&   9              " @2ZJ  !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ V(,15Z%-*(C! P  GPT  !D
M ("!XJP  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #8
M@Q%7GTH8>2H#  #D"@  &0              @(':L   >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( -B#$5=T);1&RP0  ,(5   9
M          " @3NT  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#
M%     @ V(,15W0^(@K9 P  Z T  !D              ("!/;D  'AL+W=O
M<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " #8@Q%7_SI"&K,#  !
M#0  &0              @(%-O0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM
M;%!+ 0(4 Q0    ( -B#$5?#W87>\P(  /$'   9              " @3?!
M  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ V(,15Y9#
MX<>7 @  8@@  !D              ("!8<0  'AL+W=O<FMS:&5E=',O<VAE
M970S."YX;6Q02P$"% ,4    " #8@Q%7'Y ^MWP%   7*0  &0
M    @($OQP  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M -B#$5< ;M0?S@(  .('   9              " @>+,  !X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ V(,15\AR<;1S P  N0P  !D
M             ("!Y\\  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    " #8@Q%7"MVEZ5($  "/&P  &0              @(&1TP  >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( -B#$5?%1B9[>Q8
M .G8 0 9              " @1K8  !X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ V(,15U*EU4*) @  NP8  !D              ("!
MS.X  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " #8@Q%7
M#/_7@F8#  !,#@  &0              @(&,\0  >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    ( -B#$5?S+-$_T (  *@(   9
M      " @2GU  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ V(,15W.A[*9F @  008  !D              ("!,/@  'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #8@Q%7._$71G("  "&!@
M&0              @('-^@  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    ( -B#$5>"V6\S90(  ' &   9              " @7;]  !X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ V(,15T@WKOMM
M @  @08  !D              ("!$@ ! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    " #8@Q%7=>C6Z5X"  #>!0  &0
M@(&V @$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( -B#
M$5= RL=,JP(  'H)   9              " @4L% 0!X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ V(,15^;)74#  @  PP@  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #8@Q%7EXJ[',     3 @  "P
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52P4&     #\ /P P$0  3B,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>187</ContextCount>
  <ElementCount>202</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>61</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss</Role>
      <ShortName>Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - Interim Condensed Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>Interim Condensed Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity</Role>
      <ShortName>Interim Condensed Consolidated Statements of Changes in Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Interim Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Corporate Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureCorporateInformation</Role>
      <ShortName>Corporate Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of preparation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureBasisOfPreparation</Role>
      <ShortName>Basis of preparation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Notes to the Consolidated Statements of Operations</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperations</Role>
      <ShortName>Notes to the Consolidated Statements of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Issued Capital and Reserves</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves</Role>
      <ShortName>Issued Capital and Reserves</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Share-based payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPayments</Role>
      <ShortName>Share-based payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Assets held for sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAssetsHeldForSale</Role>
      <ShortName>Assets held for sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureInventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Prepaid expenses and other assets (current)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent</Role>
      <ShortName>Prepaid expenses and other assets (current)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Financial assets and financial liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities</Role>
      <ShortName>Financial assets and financial liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Trade and other payables</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureTradeAndOtherPayables</Role>
      <ShortName>Trade and other payables</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Other liabilities and provisions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions</Role>
      <ShortName>Other liabilities and provisions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Income tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIncomeTax</Role>
      <ShortName>Income tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Disclosure of financial instruments and risk management</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement</Role>
      <ShortName>Disclosure of financial instruments and risk management</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Earnings per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEarningsPerShare</Role>
      <ShortName>Earnings per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Related party disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureRelatedPartyDisclosures</Role>
      <ShortName>Related party disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Subsequent events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Basis of preparation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies</Role>
      <ShortName>Basis of preparation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Notes to the Consolidated Statements of Operations (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsTables</Role>
      <ShortName>Notes to the Consolidated Statements of Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperations</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Issued Capital and Reserves (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables</Role>
      <ShortName>Issued Capital and Reserves (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Share-based payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsTables</Role>
      <ShortName>Share-based payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureShareBasedPayments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Corporate Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureCorporateInformationDetails</Role>
      <ShortName>Corporate Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureCorporateInformation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails</Role>
      <ShortName>Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Notes to the Consolidated Statements of Operations - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails</Role>
      <ShortName>Notes to the Consolidated Statements of Operations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Notes to the Consolidated Statements of Operations - Summary of upfront payments and related revenues recognized (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails</Role>
      <ShortName>Notes to the Consolidated Statements of Operations - Summary of upfront payments and related revenues recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Notes to the Consolidated Statements of Operations - Contract balances (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails</Role>
      <ShortName>Notes to the Consolidated Statements of Operations - Contract balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40305 - Disclosure - Notes to the Consolidated Statements of Operations - Cost of sales (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails</Role>
      <ShortName>Notes to the Consolidated Statements of Operations - Cost of sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40306 - Disclosure - Notes to the Consolidated Statements of Operations - Selling and distribution expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails</Role>
      <ShortName>Notes to the Consolidated Statements of Operations - Selling and distribution expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40307 - Disclosure - Notes to the Consolidated Statements of Operations - Research and development expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails</Role>
      <ShortName>Notes to the Consolidated Statements of Operations - Research and development expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40308 - Disclosure - Notes to the Consolidated Statements of Operations - General and administrative expenses (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails</Role>
      <ShortName>Notes to the Consolidated Statements of Operations - General and administrative expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40309 - Disclosure - Notes to the Consolidated Statements of Operations - Other operating income (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails</Role>
      <ShortName>Notes to the Consolidated Statements of Operations - Other operating income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40310 - Disclosure - Notes to the Consolidated Statements of Operations - Grants with government agencies and similar bodies (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails</Role>
      <ShortName>Notes to the Consolidated Statements of Operations - Grants with government agencies and similar bodies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails</Role>
      <ShortName>Issued Capital and Reserves - Overview and General Remarks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Issued Capital and Reserves - At-the-market offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails</Role>
      <ShortName>Issued Capital and Reserves - At-the-market offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails</Role>
      <ShortName>Issued Capital and Reserves - Impact of share split (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Share-based payments - Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails</Role>
      <ShortName>Share-based payments - Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Share-based payments - Equity-settled programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails</Role>
      <ShortName>Share-based payments - Equity-settled programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40503 - Disclosure - Share-based payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails</Role>
      <ShortName>Share-based payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureShareBasedPaymentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Fixed Assets - Intangible assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails</Role>
      <ShortName>Fixed Assets - Intangible assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Fixed Assets - Property, plant and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Assets held for sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails</Role>
      <ShortName>Assets held for sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureAssetsHeldForSale</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureInventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureInventories</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Prepaid expenses and other assets (current) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails</Role>
      <ShortName>Prepaid expenses and other assets (current) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Financial assets and financial liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails</Role>
      <ShortName>Financial assets and financial liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Trade and other payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails</Role>
      <ShortName>Trade and other payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureTradeAndOtherPayables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Other liabilities and provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails</Role>
      <ShortName>Other liabilities and provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Disclosure of financial instruments and risk management - Foreign currency risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails</Role>
      <ShortName>Disclosure of financial instruments and risk management - Foreign currency risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Earnings per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureEarningsPerShareDetails</Role>
      <ShortName>Earnings per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureEarningsPerShare</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Related party disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails</Role>
      <ShortName>Related party disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureRelatedPartyDisclosures</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="cvac-20230630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Subsequent events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.curevac.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>Subsequent events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.curevac.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" original="cvac-20230630x6k.htm">cvac-20230630x6k.htm</File>
    <File doctype="6-K" original="cvac-20230630xex99d1.htm">cvac-20230630xex99d1.htm</File>
    <File>cvac-20230630.xsd</File>
    <File>cvac-20230630_cal.xml</File>
    <File>cvac-20230630_def.xml</File>
    <File>cvac-20230630_lab.xml</File>
    <File>cvac-20230630_pre.xml</File>
    <File>cvac-20230630xex99d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>cvac-20230630xex99d1001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
    <BaseTaxonomy items="421">https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "cvac-20230630x6k.htm cvac-20230630xex99d1.htm": {
   "axisCustom": 3,
   "axisStandard": 16,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 8,
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 421
   },
   "contextCount": 187,
   "dts": {
    "calculationLink": {
     "local": [
      "cvac-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "cvac-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "cvac-20230630x6k.htm",
      "cvac-20230630xex99d1.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cvac-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cvac-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cvac-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 609,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 6,
    "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 1,
    "total": 7
   },
   "keyCustom": 70,
   "keyStandard": 132,
   "memberCustom": 42,
   "memberStandard": 18,
   "nsprefix": "cvac",
   "nsuri": "http://www.curevac.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630x6k.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.curevac.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630x6k.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Share-based payments",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPayments",
     "shortName": "Share-based payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfFixedAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Fixed Assets",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.curevac.com/role/DisclosureFixedAssets",
     "shortName": "Fixed Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfFixedAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Assets held for sale",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.curevac.com/role/DisclosureAssetsHeldForSale",
     "shortName": "Assets held for sale",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.curevac.com/role/DisclosureInventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfInventoriesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Prepaid expenses and other assets (current)",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent",
     "shortName": "Prepaid expenses and other assets (current)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Financial assets and financial liabilities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities",
     "shortName": "Financial assets and financial liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Trade and other payables",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.curevac.com/role/DisclosureTradeAndOtherPayables",
     "shortName": "Trade and other payables",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:OtherLiabilitiesAndProvisionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Other liabilities and provisions",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions",
     "shortName": "Other liabilities and provisions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:OtherLiabilitiesAndProvisionsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Income tax",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.curevac.com/role/DisclosureIncomeTax",
     "shortName": "Income tax",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Disclosure of financial instruments and risk management",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement",
     "shortName": "Disclosure of financial instruments and risk management",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss",
     "shortName": "Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:CostOfSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Earnings per share",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.curevac.com/role/DisclosureEarningsPerShare",
     "shortName": "Earnings per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:EarningsPerShareExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - Related party disclosures",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.curevac.com/role/DisclosureRelatedPartyDisclosures",
     "shortName": "Related party disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - Subsequent events",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.curevac.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Basis of preparation (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies",
     "shortName": "Basis of preparation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Notes to the Consolidated Statements of Operations (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsTables",
     "shortName": "Notes to the Consolidated Statements of Operations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Issued Capital and Reserves (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables",
     "shortName": "Issued Capital and Reserves (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Share-based payments (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables",
     "shortName": "Share-based payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "cvac:CorporateInformationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_gU3vE82A102SoPkxvd1bwQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "cvac:PercentageOfVotingInterestsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_OIXcQb-ZL02u7t-A0Qaj8g",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Corporate Information (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
     "shortName": "Corporate Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cvac:CorporateInformationTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_srt_TitleOfIndividualAxis_cvac_LargestShareholderMember_gU3vE82A102SoPkxvd1bwQ",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "cvac:PercentageOfVotingInterestsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_OIXcQb-ZL02u7t-A0Qaj8g",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails",
     "shortName": "Notes to the Consolidated Statements of Operations - Revenue from contract with customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_ResearchServicesCombinedWithIpLicenseMember_mI2esD2990ujSWl2t4bAJA",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40302 - Disclosure - Notes to the Consolidated Statements of Operations - Additional Information (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
     "shortName": "Notes to the Consolidated Statements of Operations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_cvac_MilestoneRevenuesMember_vUXz2-MgLkyPVrGTn6EwAw",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Interim Condensed Consolidated Statements of Financial Position",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition",
     "shortName": "Interim Condensed Consolidated Statements of Financial Position",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory",
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:UpfrontPaymentsIncludedInContractLiabilities",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40303 - Disclosure - Notes to the Consolidated Statements of Operations - Summary of upfront payments and related revenues recognized (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
     "shortName": "Notes to the Consolidated Statements of Operations - Summary of upfront payments and related revenues recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory",
       "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew",
      "decimals": "-3",
      "lang": null,
      "name": "cvac:UpfrontPaymentsIncludedInContractLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentTradeReceivables",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40304 - Disclosure - Notes to the Consolidated Statements of Operations - Contract balances (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails",
     "shortName": "Notes to the Consolidated Statements of Operations - Contract balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:ContractLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40305 - Disclosure - Notes to the Consolidated Statements of Operations - Cost of sales (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails",
     "shortName": "Notes to the Consolidated Statements of Operations - Cost of sales (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfExpensesByNatureExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsCostOfSalesMember_36cgHqaHIEmMwW9xGPevWA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_K4r7ZDLT-E2fEsXEmmY8ZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40306 - Disclosure - Notes to the Consolidated Statements of Operations - Selling and distribution expenses (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails",
     "shortName": "Notes to the Consolidated Statements of Operations - Selling and distribution expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_SellingAndDistributionExpensesMember_K4r7ZDLT-E2fEsXEmmY8ZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RawMaterialsAndConsumablesUsed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40307 - Disclosure - Notes to the Consolidated Statements of Operations - Research and development expenses (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails",
     "shortName": "Notes to the Consolidated Statements of Operations - Research and development expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsResearchAndDevelopmentExpenseMember_VcEjI5JdEEu3oTNBvAU9mg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RawMaterialsAndConsumablesUsed",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40308 - Disclosure - Notes to the Consolidated Statements of Operations - General and administrative expenses (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails",
     "shortName": "Notes to the Consolidated Statements of Operations - General and administrative expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_cvac_IfrsIncomeStatementLocationAxis_cvac_IfrsGeneralAndAdministrativeExpenseMember_uzwruwG8G0Wj4c1NFv1Oqw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:PersonnelExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:CompensationForContractManufacturingOrganizationsTransfer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40309 - Disclosure - Notes to the Consolidated Statements of Operations - Other operating income (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails",
     "shortName": "Notes to the Consolidated Statements of Operations - Other operating income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:CompensationForContractManufacturingOrganizationsTransfer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_T6BMdSYhU0uLBiXs_xHhqQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40310 - Disclosure - Notes to the Consolidated Statements of Operations - Grants with government agencies and similar bodies (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
     "shortName": "Notes to the Consolidated Statements of Operations - Grants with government agencies and similar bodies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2022_To_6_30_2022_srt_CounterpartyNameAxis_cvac_GlaxosmithklineMember_T6BMdSYhU0uLBiXs_xHhqQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_1dYKs1W9uU6tOrLCufufjQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Issued Capital and Reserves - Overview and General Remarks (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
     "shortName": "Issued Capital and Reserves - Overview and General Remarks (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_1dYKs1W9uU6tOrLCufufjQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ifrs-full:NumberOfSharesAuthorised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProceedsFromIssuingShares",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Issued Capital and Reserves - At-the-market offering (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails",
     "shortName": "Issued Capital and Reserves - At-the-market offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_3_31_2023_cvac_IfrsSaleOfStockAxis_cvac_AtMarketOfferingProgramMember_1OMKhPZxMEiydfIE4wQ-aQ",
      "decimals": "-5",
      "lang": null,
      "name": "ifrs-full:ProceedsFromIssuingShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3SmXevtwJUGcfplEE1poRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Interim Condensed Consolidated Statements of Changes in Shareholders' Equity",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity",
     "shortName": "Interim Condensed Consolidated Statements of Changes in Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_12_31_2021_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_3SmXevtwJUGcfplEE1poRw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:Equity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_3_31_2023_nZ9aTIkD-kKH94WcSt1n3g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvac:CommonSharesIssuedAndOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Issued Capital and Reserves - Impact of share split (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
     "shortName": "Issued Capital and Reserves - Impact of share split (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfClassesOfShareCapitalExplanatory",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew",
      "decimals": "INF",
      "lang": null,
      "name": "cvac:CommonSharesIssuedAndOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Share-based payments - Expenses (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
     "shortName": "Share-based payments - Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ExpenseRecognizedForEmployeeServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40502 - Disclosure - Share-based payments - Equity-settled programs (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails",
     "shortName": "Share-based payments - Equity-settled programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "cvac:ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ExpenseRecognizedForEmployeeServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40503 - Disclosure - Share-based payments (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
     "shortName": "Share-based payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "cvac:DisclosureOfFixedAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_F3innQ88Ak6o2rkcUJY0ZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Fixed Assets - Intangible assets (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
     "shortName": "Fixed Assets - Intangible assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cvac:DisclosureOfFixedAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis_ifrs-full_GrossCarryingAmountMember_ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis_cvac_LicensesSoftwareAndPrepaymentsMember_F3innQ88Ak6o2rkcUJY0ZQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:PropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40602 - Disclosure - Fixed Assets - Property, plant and equipment (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails",
     "shortName": "Fixed Assets - Property, plant and equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cvac:DisclosureOfFixedAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember__JCd2jsBx0aS7CNRVo1ClA",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:GrossBookValueOfCmoEquipmentHeldForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Assets held for sale (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails",
     "shortName": "Assets held for sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_12_31_2022_lQpnhiC0E0C48W9mhwjBew",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:GrossBookValueOfCmoEquipmentHeldForSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Inventories (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.curevac.com/role/DisclosureInventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfInventoriesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:CurrentPrepaymentsAndOtherCurrentAssets",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Prepaid expenses and other assets (current) (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails",
     "shortName": "Prepaid expenses and other assets (current) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cvac:DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ",
      "decimals": "-3",
      "lang": null,
      "name": "cvac:PrepaidCompensationForContractManufacturingOrganizationsTransfer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Financial assets and financial liabilities (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails",
     "shortName": "Financial assets and financial liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:ProfitLossBeforeTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Interim Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Interim Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": "-3",
      "lang": null,
      "name": "ifrs-full:AdjustmentsForFinanceIncome",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_b9l-NXkefE2LwsHP2a-ASQ",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:TradeAndOtherCurrentPayables",
      "reportCount": 1,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Trade and other payables (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails",
     "shortName": "Trade and other payables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": "-3",
      "lang": null,
      "name": "cvac:ChangeInTradeAndOtherPayables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "cvac:OtherLiabilitiesAndProvisionsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ChangeInOtherLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Other liabilities and provisions (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails",
     "shortName": "Other liabilities and provisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "cvac:OtherLiabilitiesAndProvisionsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ChangeInOtherLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_c616ZXiH_EKOpj5dNuZ83w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Disclosure of financial instruments and risk management - Foreign currency risk (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails",
     "shortName": "Disclosure of financial instruments and risk management - Foreign currency risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "As_Of_6_30_2023_ifrs-full_ClassesOfFinancialInstrumentsAxis_cvac_IfrsCashAndCashEquivalentsMember_ifrs-full_TypesOfRisksAxis_ifrs-full_CurrencyRiskMember_srt_CurrencyAxis_currency_USD_c616ZXiH_EKOpj5dNuZ83w",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ifrs-full:RiskExposureAssociatedWithInstrumentsSharingCharacteristic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_tSyv7oWCbUG_1fcCH4vzpw",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Earnings per share (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.curevac.com/role/DisclosureEarningsPerShareDetails",
     "shortName": "Earnings per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_4_1_2023_To_6_30_2023_HRobuTclS0O6R5EkvE8jIg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "ifrs-full:WeightedAverageShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_Ka6OIPAS_kaVP0mH-WhF5Q",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ExpensesToHandleFutureServiceAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - Related party disclosures (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
     "shortName": "Related party disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRelatedPartyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "cvac:ExpensesToHandleFutureServiceAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_EUR_8AdBuxgBd0OC8w0jbZbiYQ",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_5_1_2023_To_5_31_2023_opUMBeSJAU6Y3pCknLUBYw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvac:NumberOfIntellectualPropertyRightsInfringementCaseFilled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - Subsequent events (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.curevac.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "Subsequent events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_5_1_2023_To_5_31_2023_opUMBeSJAU6Y3pCknLUBYw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "cvac:NumberOfIntellectualPropertyRightsInfringementCaseFilled",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_MB3yZ2QyiEanAX1-PTQ9CQ",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:CorporateInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Corporate Information",
     "menuCat": "Notes",
     "order": "6",
     "role": "http://www.curevac.com/role/DisclosureCorporateInformation",
     "shortName": "Corporate Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:CorporateInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Basis of preparation",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.curevac.com/role/DisclosureBasisOfPreparation",
     "shortName": "Basis of preparation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "cvac:DisclosureOfBasisOfPreparationExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Notes to the Consolidated Statements of Operations",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperations",
     "shortName": "Notes to the Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Issued Capital and Reserves",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves",
     "shortName": "Issued Capital and Reserves",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "cvac-20230630xex99d1.htm",
      "contextRef": "Duration_1_1_2023_To_6_30_2023_qV2x8696gEy6l43MX0sprw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 61,
   "tag": {
    "country_BE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Belgium",
        "terseLabel": "Belgium"
       }
      }
     },
     "localname": "BE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland",
        "terseLabel": "Switzerland"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Germany",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_NL": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Netherlands",
        "terseLabel": "Netherlands"
       }
      }
     },
     "localname": "NL",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHF"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EUR"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GBP"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "USD"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued liability for other taxes consists of real estate transfer taxes.",
        "label": "Accrued Liability For Other Taxes Consists Of Real Estate Transfer Taxes",
        "terseLabel": "Accrued liability for other taxes consists of real estate transfer taxes"
       }
      }
     },
     "localname": "AccruedLiabilityForOtherTaxesConsistsOfRealEstateTransferTaxes",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AccruedOtherLiabilityForUpFrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of accrued other liability for up-front payment.",
        "label": "Accrued Other Liability for Up-front Payment",
        "terseLabel": "Additional depreciation expense",
        "verboseLabel": "Accrued other liability for up-front payment"
       }
      }
     },
     "localname": "AccruedOtherLiabilityForUpFrontPayment",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AdditionalDevelopmentMilestonePaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional development milestone payment received.",
        "label": "Additional Development Milestone Payments Received",
        "terseLabel": "Additional development milestone payments"
       }
      }
     },
     "localname": "AdditionalDevelopmentMilestonePaymentsReceived",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional offering costs recognized as reduction to capital reserve.",
        "label": "Additional Offering Costs Recognized As Reduction To Capital Reserve",
        "terseLabel": "Additional offering costs recognized as reduction to capital reserve"
       }
      }
     },
     "localname": "AdditionalOfferingCostsRecognizedAsReductionToCapitalReserve",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) of income taxes paid classified as operating activities.",
        "label": "Adjustment Of Income Taxes Paid Classified As Operating Activities",
        "negatedLabel": "Income taxes paid"
       }
      }
     },
     "localname": "AdjustmentOfIncomeTaxesPaidClassifiedAsOperatingActivities",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in non-current assets or disposal groups classified as held for sale or as held for distribution to owners to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Decrease (Increase) In Non-current Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners",
        "terseLabel": "Decrease / (increase) in assets held for sale"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInNonCurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AdjustmentsForNonCashIncomeFromReleaseOfProvisions": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for non cash income from release of provisions to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments For Non Cash Income From Release Of Provisions",
        "negatedLabel": "Non-cash income from release of provisions"
       }
      }
     },
     "localname": "AdjustmentsForNonCashIncomeFromReleaseOfProvisions",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AdvancePaymentsIntangibleAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for advance payments, intangible asset.",
        "label": "Advance Payments [Member]",
        "terseLabel": "Goodwil"
       }
      }
     },
     "localname": "AdvancePaymentsIntangibleAssetMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_AdvancedPurchaseAgreementWithEuropeanCommissionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Advance Purchase Agreement with European Commission",
        "label": "Advance Purchase Agreement with European Commission"
       }
      }
     },
     "localname": "AdvancedPurchaseAgreementWithEuropeanCommissionMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_AggregateGrossProceedsReceivableFromIssuingShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of aggregate gross proceeds receivable from issuance of shares.",
        "label": "Aggregate Gross Proceeds Receivable From Issuing Shares",
        "terseLabel": "Aggregate gross proceeds"
       }
      }
     },
     "localname": "AggregateGrossProceedsReceivableFromIssuingShares",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmortizationOfGovernmentGrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortization of the grants.",
        "label": "Amortization of the Government Grants",
        "terseLabel": "Amortization of the grants"
       }
      }
     },
     "localname": "AmortizationOfGovernmentGrants",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmountDeductedFromCarryingAmountOfQualifyingAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount pertaining to grants deducted from the carrying amount of qualifying assets.",
        "label": "Amount Deducted From Carrying Amount Of Qualifying Assets",
        "terseLabel": "Amount deducted from the carrying amount of qualifying assets"
       }
      }
     },
     "localname": "AmountDeductedFromCarryingAmountOfQualifyingAssets",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmountOfLiabilityCashClaimAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized in financial statements towards cash claim of Awards.",
        "label": "Amount of Liability, Cash Claim Awards",
        "terseLabel": "Amount of liability, cash claim awards"
       }
      }
     },
     "localname": "AmountOfLiabilityCashClaimAwards",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AmountOfRestrictedStockUnitsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Restricted Stock Units Received.",
        "label": "Amount of Restricted Stock Units Received",
        "terseLabel": "Amount of restricted stock units received"
       }
      }
     },
     "localname": "AmountOfRestrictedStockUnitsReceived",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AntonyBlancMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Antony Blanc.",
        "label": "Antony Blanc [Member]",
        "terseLabel": "Antony Blanc"
       }
      }
     },
     "localname": "AntonyBlancMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ArrangementsAndNonArrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Non-arrangement Transactions [Member]"
       }
      }
     },
     "localname": "ArrangementsAndNonArrangementTransactionsMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_AssetsHeldForSaleNetBookValueSold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value sold of assets held for sale.",
        "label": "Assets Held for Sale, Net Book Value Sold",
        "terseLabel": "Assets held for sale with a net book value sold"
       }
      }
     },
     "localname": "AssetsHeldForSaleNetBookValueSold",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_AtMarketOfferingProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to at the market offering program.",
        "label": "ATM Offering Program"
       }
      }
     },
     "localname": "AtMarketOfferingProgramMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BarkerBiomedicalGmbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for barker biomedical GmbH member.",
        "label": "Barker BioMedical GmbH [Member]",
        "terseLabel": "Barker BioMedical GmbH"
       }
      }
     },
     "localname": "BarkerBiomedicalGmbhMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BaronJeanStephenneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Baron Jean Stephenne.",
        "label": "Baron Jean Stephenne [Member]",
        "terseLabel": "Baron Jean Stephenne"
       }
      }
     },
     "localname": "BaronJeanStephenneMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BenefitExpenseRecognizedForShareBasedPayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit expense benefit recognized for share-based payment.",
        "label": "Benefit Expense Recognized For Share Based Payment",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "BenefitExpenseRecognizedForShareBasedPayment",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_BepharbelManufacturingS.aMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for BePharBel Manufacturing S.A.",
        "label": "BePharBel Manufacturing S.A [Member]",
        "terseLabel": "BePharBel Manufacturing S.A"
       }
      }
     },
     "localname": "BepharbelManufacturingS.aMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BillAndMelindaGatesFoundationBmgfMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF).",
        "label": "Bill &amp; Melinda Gates Foundation (BMGF)"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationBmgfMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for development of a universal influenza vaccine.",
        "label": "Bill &amp; Melinda Gates Foundation (BMGF), Grant for development of a universal influenza vaccine"
       }
      }
     },
     "localname": "BillMelindaGatesFoundationBmgfGrantForDevelopmentOfUniversalInfluenzaVaccineMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants from Bill &amp; Melinda Gates Foundation (BMGF) for malaria vaccine.",
        "label": "Bill &amp; Melinda Gates Foundation (BMGF), Grant for malaria vaccine"
       }
      }
     },
     "localname": "BillMelindaGatesFoundationBmgfGrantForMalariaVaccineMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BoehringerIngelheimMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Boehringer Ingelheim.",
        "label": "Boehringer Ingelheim",
        "terseLabel": "Boehringer Ingelheim"
       }
      }
     },
     "localname": "BoehringerIngelheimMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_BundesministeriumFurBildungUndForschungMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Bundesministerium fr Bildung und Forschung.",
        "label": "Bundesministerium fr Bildung und Forschung"
       }
      }
     },
     "localname": "BundesministeriumFurBildungUndForschungMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CapitalIncreaseByGenmabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Genmab, capital increase.",
        "label": "Genmab Investment",
        "terseLabel": "Genmab Investment"
       }
      }
     },
     "localname": "CapitalIncreaseByGenmabMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA.",
        "label": "Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [axis]"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountAxis",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount [Domain]",
        "terseLabel": "Carrying Amount Accumulated Depreciation Amortisation And Impairments And Gross Carrying Amount"
       }
      }
     },
     "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentsAndGrossCarryingAmountDomain",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ChangeInOtherLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in other liabilities.",
        "label": "Change in Other Liabilities",
        "verboseLabel": "Decrease in other liabilities"
       }
      }
     },
     "localname": "ChangeInOtherLiabilities",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ChangeInTradeAndOtherPayables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of change in trade and other payables.",
        "label": "Change in Trade and Other Payables",
        "terseLabel": "Amount of decrease in trade and other payables"
       }
      }
     },
     "localname": "ChangeInTradeAndOtherPayables",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ChangesInWorkingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Changes in Working Capital [Abstract]",
        "terseLabel": "Working capital changes"
       }
      }
     },
     "localname": "ChangesInWorkingCapitalAbstract",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_ChiefBusinessOfficerAndChiefCommercialOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Chief Business Officer and Chief Commercial Officer.",
        "label": "Chief Business Officer and Chief Commercial Officer",
        "terseLabel": "Chief Business Officer and Chief Commercial Officer"
       }
      }
     },
     "localname": "ChiefBusinessOfficerAndChiefCommercialOfficerMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ChiefBusinessOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Chief Business Officer.",
        "label": "Chief Business Officer [Member]",
        "terseLabel": "Chief Business Officer"
       }
      }
     },
     "localname": "ChiefBusinessOfficerMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ChiefDevelopmentOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Chief Development Officer",
        "label": "Chief Development Officer",
        "terseLabel": "Chief Development Officer"
       }
      }
     },
     "localname": "ChiefDevelopmentOfficerMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ChiefOperatingOfficerAndChiefDevelopmentOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of Chief operating officer and Chief development officer.",
        "label": "Chief Operating Officer and Chief Development Officer",
        "terseLabel": "Chief Operating Officer and Chief Development Officer"
       }
      }
     },
     "localname": "ChiefOperatingOfficerAndChiefDevelopmentOfficerMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ChiefScientificOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Chief Scientific Officer.",
        "label": "Chief Scientific Officer",
        "terseLabel": "Former Chief Scientific Officer"
       }
      }
     },
     "localname": "ChiefScientificOfficerMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ClarentisSrlMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for Clarentis SRL, wholly owned consulting company of Antony Blanc, Chief business officer, a related party.",
        "label": "Clarentis SRL [Member]",
        "terseLabel": "Clarentis SRL"
       }
      }
     },
     "localname": "ClarentisSrlMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CoalitionForEpidemicPreparednessInnovationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for grants related to Coalition for Epidemic Preparedness Innovations.",
        "label": "Coalition for Epidemic Preparedness Innovations"
       }
      }
     },
     "localname": "CoalitionForEpidemicPreparednessInnovationsMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines.",
        "label": "Collaboration Agreement For Research, Development, Manufacturing And Commercialization Of mRNA-based Vaccines"
       }
      }
     },
     "localname": "CollaborationAgreementForResearchDevelopmentManufacturingAndCommercializationOfMrnaBasedVaccinesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for termination of exclusive collobaration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CommonSharesIssuedAndOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued and outstanding for during the period.",
        "label": "Common Shares Issued And Outstanding",
        "periodEndLabel": "Common shares issued and outstanding ending",
        "periodStartLabel": "Common shares issued and outstanding beginning"
       }
      }
     },
     "localname": "CommonSharesIssuedAndOutstanding",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_CompanyOwnedGmpIvFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for company-owned GMP IV facility.",
        "label": "Company-owned GMP IV facility",
        "terseLabel": "Company-owned GMP IV facility"
       }
      }
     },
     "localname": "CompanyOwnedGmpIvFacilityMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CompensationForContractManufacturingOrganizationsTransfer": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of income recognised on compensation for contract manufacturing organizations transfer.",
        "label": "Compensation for Contract Manufacturing organizations Transfer",
        "terseLabel": "Compensation for CMO/Materials transfer"
       }
      }
     },
     "localname": "CompensationForContractManufacturingOrganizationsTransfer",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for consideration for set-up activities.",
        "label": "Compensation for Contract Manufacturing organizations Transfer, Consideration for Set-up Activities",
        "terseLabel": "Compensation consist for set-up activities"
       }
      }
     },
     "localname": "CompensationForContractManufacturingOrganizationsTransferConsiderationForSetUpActivities",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of income recognized on compensation for contract manufacturing organizations transfer which is mainly for Manufacturing Interim Period Reimbursable Expenses.",
        "label": "Compensation for Contract Manufacturing organizations Transfer, Manufacturing Interim Period Reimbursable Expenses",
        "terseLabel": "Reimbursement of prepayments"
       }
      }
     },
     "localname": "CompensationForContractManufacturingOrganizationsTransferManufacturingInterimPeriodReimbursableExpenses",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ContingentLiabilityArisingFromPatentInfringementLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than contingent liability arising from patent Infringement lawsuit .",
        "label": "Patent Infringement Lawsuit"
       }
      }
     },
     "localname": "ContingentLiabilityArisingFromPatentInfringementLawsuitMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CorporateInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Corporate Information"
       }
      }
     },
     "localname": "CorporateInformationAbstract",
     "nsuri": "http://www.curevac.com/20230630",
     "xbrltype": "stringItemType"
    },
    "cvac_CorporateInformationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on corporate information.",
        "label": "Corporate Information [Text Block]",
        "terseLabel": "Corporate Information"
       }
      }
     },
     "localname": "CorporateInformationTextBlock",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_CorporateReorganizationStockSplitRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock split ratio upon corporate reorganization for determining the basis for issuance of shares to the holders of the entity.",
        "label": "Corporate Reorganization, Stock Split Ratio",
        "terseLabel": "Share split ratio"
       }
      }
     },
     "localname": "CorporateReorganizationStockSplitRatio",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cvac_CostOfReimbursementClaim": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cost of reimbursement claim.",
        "label": "Cost of reimbursement claim",
        "terseLabel": "Reimbursement claim"
       }
      }
     },
     "localname": "CostOfReimbursementClaim",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_CraigToomanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for craig tooman.",
        "label": "Craig Tooman [Member]",
        "terseLabel": "Craig Tooman"
       }
      }
     },
     "localname": "CraigToomanMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CrisprMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CRISPR.",
        "label": "CRISPR",
        "terseLabel": "CRISPR"
       }
      }
     },
     "localname": "CrisprMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CrisprTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for CRISPR Therapeutics",
        "label": "CRISPR Therapeutics"
       }
      }
     },
     "localname": "CrisprTherapeuticsMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CumulativeAmortizationAndImpairmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for accumulated depreciation, amortization and impairment.",
        "label": "Cumulative Amortization And Impairment [Member]",
        "terseLabel": "Cumulative Amortization And Impairment",
        "verboseLabel": "Cumulative amortization and impairment charges"
       }
      }
     },
     "localname": "CumulativeAmortizationAndImpairmentMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_CurrentGrantReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of grant receivable, classified as current.",
        "label": "Current Grant Receivable",
        "terseLabel": "Current grant receivable"
       }
      }
     },
     "localname": "CurrentGrantReceivable",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_CurrentValueAddedTaxAndOtherTaxesPayables": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current value added tax and other taxes payables.",
        "label": "Current Value Added Tax And Other Taxes Payables",
        "terseLabel": "VAT and other taxes (real estate transfer taxes)"
       }
      }
     },
     "localname": "CurrentValueAddedTaxAndOtherTaxesPayables",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_DecreaseInNumberOfSharesDueToTreasuryOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents for decrease in number of shares due to treasury of shares.",
        "label": "Decrease In Number Of Shares Due To Treasury Of Shares",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "DecreaseInNumberOfSharesDueToTreasuryOfShares",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_DescriptionOfAccountingPolicyForCovid19ImpactExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for Covid-19 impact.",
        "label": "Description of Accounting Policy for Covid-19 Impact, Explanatory",
        "terseLabel": "Impact of COVID-19 and the Russia-Ukraine Conflict"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForCovid19ImpactExplanatory",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of accounting policy for Pre-launch products.",
        "label": "Description of Accounting Policy for Pre-Launch Products, Explanatory",
        "terseLabel": "Pre-launch products"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForPreLaunchProductsExplanatory",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the entity's accounting policy for New standards, interpretations and amendments adopted by the Group.",
        "label": "Description of Accounting Policy of New Standards, Interpretations and Amendments Adopted [Text Block]",
        "terseLabel": "New standards, interpretations and amendments adopted by the Group"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyOfNewStandardsInterpretationsAndAmendmentsAdoptedTextBlock",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DietmarHoppMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for Mr. Dietmar Hopp, principal of dievini Hopp BioTech holding GmbH &amp; Co. KG , a majority shareholder of the entity, a related party.",
        "label": "Dietmar Hopp [Member]",
        "terseLabel": "Dietmar Hopp"
       }
      }
     },
     "localname": "DietmarHoppMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_DieviniHoppBiotechHoldingGmbhCo.KgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Dievini Hopp BioTech holding GmbH &amp; Co. KG.",
        "label": "Dievini Hopp BioTech holding GmbH &amp; Co. KG [Member]",
        "terseLabel": "Dievini Hopp BioTech holding GmbH &amp; Co. KG"
       }
      }
     },
     "localname": "DieviniHoppBiotechHoldingGmbhCo.KgMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_DiluteEffectOfOrdinarySharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of dilutive potential ordinary shares that relate to the assumed issuance of new shares.",
        "label": "Dilute Effect Of Ordinary Shares Issued",
        "terseLabel": "New issue of shares for the purpose of calculating earning per share"
       }
      }
     },
     "localname": "DiluteEffectOfOrdinarySharesIssued",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_DisclosureOfBasisOfPreparationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statement.",
        "label": "Basis of preparation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationAbstract",
     "nsuri": "http://www.curevac.com/20230630",
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfBasisOfPreparationExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statement.",
        "label": "Disclosure of Basis of Preparation Explanatory [Text Block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationExplanatoryTextBlock",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of expense recognized for employee services explanatory.",
        "label": "Disclosure of Expense Recognized For Employee Services Explanatory",
        "terseLabel": "Schedule of share-based payments expenses"
       }
      }
     },
     "localname": "DisclosureOfExpenseRecognizedForEmployeeServicesExplanatory",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DisclosureOfFixedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Fixed Assets"
       }
      }
     },
     "localname": "DisclosureOfFixedAssetsAbstract",
     "nsuri": "http://www.curevac.com/20230630",
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfFixedAssetsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for fixed assets.",
        "label": "Disclosure Of Fixed Assets, Explanatory",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "DisclosureOfFixedAssetsExplanatory",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DisclosureOfGovernmentGrantsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table.",
        "label": "Disclosure Of Government Grants [Line Items]",
        "terseLabel": "Notes to the consolidated financial statements"
       }
      }
     },
     "localname": "DisclosureOfGovernmentGrantsLineItems",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfGovernmentGrantsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to disclosure of government grants.",
        "label": "Disclosure Of Government Grants [Table]"
       }
      }
     },
     "localname": "DisclosureOfGovernmentGrantsTable",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfNotesToConsolidatedFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Notes to the Consolidated Statements of Operations"
       }
      }
     },
     "localname": "DisclosureOfNotesToConsolidatedFinancialStatementsAbstract",
     "nsuri": "http://www.curevac.com/20230630",
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfNotesToConsolidatedFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents of disclosure of notes to the consolidated financial statements.",
        "label": "Disclosure Of Notes To The Consolidated Financial Statements [Line Items]",
        "terseLabel": "Notes to the Consolidated Statements of Operations"
       }
      }
     },
     "localname": "DisclosureOfNotesToConsolidatedFinancialStatementsLineItems",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfNotesToConsolidatedFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to disclosure of notes to the consolidated financial statements.",
        "label": "Disclosure Of Notes To The Consolidated Financial Statements [Table]"
       }
      }
     },
     "localname": "DisclosureOfNotesToConsolidatedFinancialStatementsTable",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfOtherLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NA",
        "label": "Disclosure of Other liabilities [Line Items]",
        "terseLabel": "Other liabilities and provisions"
       }
      }
     },
     "localname": "DisclosureOfOtherLiabilitiesLineItems",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfOtherLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule disclosing information related to other liabilities.",
        "label": "Disclosure of Other liabilities [table]"
       }
      }
     },
     "localname": "DisclosureOfOtherLiabilitiesTable",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Prepaid expenses and other assets (current)"
       }
      }
     },
     "localname": "DisclosureOfPrepaidExpensesAndOtherCurrentAssetsAbstract",
     "nsuri": "http://www.curevac.com/20230630",
     "xbrltype": "stringItemType"
    },
    "cvac_DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for prepaid expenses and other current assets.",
        "label": "Disclosure Of Prepaid Expenses And Other Current Assets, Explanatory",
        "terseLabel": "Prepaid expenses and other assets (current)"
       }
      }
     },
     "localname": "DisclosureOfPrepaidExpensesAndOtherCurrentAssetsExplanatory",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of detailed information about upfront payments and related revenues recognized.",
        "label": "Disclosure Of Upfront Payments And Related Revenues Recognized, Explanatory",
        "terseLabel": "Summary of upfront payments and related revenues recognized"
       }
      }
     },
     "localname": "DisclosureOfUpfrontPaymentsAndRelatedRevenuesRecognizedExplanatory",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_Dr.IngmarHrrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Dr. Ingmar Hrr.",
        "label": "Dr. Ingmar Hrr [Member]",
        "terseLabel": "Dr. Ingmar Hrr"
       }
      }
     },
     "localname": "Dr.IngmarHrrMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_EliLillyAndCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Eli Lilly and Company.",
        "label": "Eli Lilly.",
        "terseLabel": "Eli Lilly."
       }
      }
     },
     "localname": "EliLillyAndCompanyMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_EliLillyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Eli Lilly",
        "label": "Eli Lilly"
       }
      }
     },
     "localname": "EliLillyMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_EquipmentPhysicallyLocatedAtCmoFacilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for equipment physically located at the CMO facilities.",
        "label": "Equipment physically located at the CMO facilities",
        "terseLabel": "Equipment physically located at the CMO facilities"
       }
      }
     },
     "localname": "EquipmentPhysicallyLocatedAtCmoFacilitiesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ExecutiveBoardMembersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for executive board members.",
        "label": "Executive board members",
        "terseLabel": "Executive Board members"
       }
      }
     },
     "localname": "ExecutiveBoardMembersMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ExerciseOfGreenshoeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for exercise of Greenshoe.",
        "label": "Exercise \"Greenshoe\"",
        "terseLabel": "Exercise \"Greenshoe\""
       }
      }
     },
     "localname": "ExerciseOfGreenshoeMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ExerciseOfOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for exercise of options.",
        "label": "Exercise of options",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "ExerciseOfOptionsMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in cost of sales.",
        "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets, In Cost of Sales",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInCostOfSales",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": {
       "order": 1.0,
       "parentTag": "cvac_BenefitExpenseRecognizedForShareBasedPayment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in general and administrative expenses.",
        "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In General And Administrative Expenses",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInGeneralAndAdministrativeExpenses",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": {
       "order": 4.0,
       "parentTag": "cvac_BenefitExpenseRecognizedForShareBasedPayment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in other operating expenses.",
        "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Other Operating Expenses",
        "verboseLabel": "Other operating expenses"
       }
      }
     },
     "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInOtherOperatingExpenses",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": {
       "order": 3.0,
       "parentTag": "cvac_BenefitExpenseRecognizedForShareBasedPayment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.",
        "label": "Expense From Share-Based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets In Research And Development Expenses",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInResearchAndDevelopmentExpenses",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ExpenseRecognizedForEmployeeServices": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense recognized for employee services.",
        "label": "Expense Recognized For Employee Services",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "ExpenseRecognizedForEmployeeServices",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ExpenseRecognizedFromRelatedPartyTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense recognized during the period from related party transaction.",
        "label": "Expense Recognized From Related Party Transaction",
        "terseLabel": "Expense recognized from related party transaction"
       }
      }
     },
     "localname": "ExpenseRecognizedFromRelatedPartyTransaction",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets Rsu. [Refer: Expense from share-based payment transactions]",
        "label": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhicGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsin Rsu",
        "verboseLabel": "Expenses recognized with RSU"
       }
      }
     },
     "localname": "ExpensefromequitysettledsharebasedpaymenttransactionsinwhicgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinRsu",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails": {
       "order": 2.0,
       "parentTag": "cvac_BenefitExpenseRecognizedForShareBasedPayment",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets in research and development expenses.",
        "label": "ExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssetsInSalesAndMarketingExpenses",
        "terseLabel": "Selling and distribution expenses"
       }
      }
     },
     "localname": "Expensefromsharebasedpaymenttransactionsinwhichgoodsorservicesreceiveddidnotqualifyforrecognitionasassetsinsalesandmarketingexpenses",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ExpensesToHandleFutureServiceAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expenses to handle future service agreement.",
        "label": "Expenses To Handle Future Service Agreement",
        "terseLabel": "Expenses to handle future service agreement"
       }
      }
     },
     "localname": "ExpensesToHandleFutureServiceAgreement",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_FinancialInstrumentsAndRiskManagementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Disclosure of financial instruments and risk management"
       }
      }
     },
     "localname": "FinancialInstrumentsAndRiskManagementAbstract",
     "nsuri": "http://www.curevac.com/20230630",
     "xbrltype": "stringItemType"
    },
    "cvac_FlorianVonDerMlbeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Florian von der Mlbe.",
        "label": "Florian von der Mlbe [Member]",
        "terseLabel": "Florian von der Mlbe"
       }
      }
     },
     "localname": "FlorianVonDerMlbeMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_FollowOnPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to follow on public offering.",
        "label": "Follow-on public offering, incl. Greenshoe"
       }
      }
     },
     "localname": "FollowOnPublicOfferingMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_FormerFrameEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Frame employee's",
        "label": "Former Frame Employees [Member]",
        "terseLabel": "Former Frame employees"
       }
      }
     },
     "localname": "FormerFrameEmployeesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GenmabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Genmab.",
        "label": "Genmab [Member]",
        "terseLabel": "Genmab"
       }
      }
     },
     "localname": "GenmabMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GermanFederalMinistryOfEducationAndResearchMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for German Federal Ministry of Education and Research.",
        "label": "German Federal Ministry of Education and Research"
       }
      }
     },
     "localname": "GermanFederalMinistryOfEducationAndResearchMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GlaxosmithklineCovidAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Collaboration Agreement With GlaxoSmithKline COVID Agreement.",
        "label": "GlaxoSmithKline COVID Agreement"
       }
      }
     },
     "localname": "GlaxosmithklineCovidAgreementMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GlaxosmithklineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for GlaxoSmithKline.",
        "label": "GSK [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxosmithklineMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GovernmentGrantsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to government grants.",
        "label": "Government Grants [Axis]"
       }
      }
     },
     "localname": "GovernmentGrantsAxis",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_GovernmentGrantsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to government grants.",
        "label": "Government Grants [Domain]"
       }
      }
     },
     "localname": "GovernmentGrantsDomain",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GrossBookValueOfCmoEquipmentHeldForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gross book value of CMO-Equipment held for sale.",
        "label": "Gross book value of CMO-Equipment held for sale"
       }
      }
     },
     "localname": "GrossBookValueOfCmoEquipmentHeldForSale",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_GrossCarryingAmountOfAcquisitionCostMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon.",
        "label": "Gross Carrying Amount of Acquisition Cost [Member]",
        "terseLabel": "Acquisition costs"
       }
      }
     },
     "localname": "GrossCarryingAmountOfAcquisitionCostMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_GskAgreement2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for GSK Agreement 2020.",
        "label": "2020 GSK AGREEMENT"
       }
      }
     },
     "localname": "GskAgreement2020Member",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for cash and cash equivalents.",
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "IfrsCashAndCashEquivalentsMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "IFRS Contractual Obligation",
        "terseLabel": "Contractual obligation amount"
       }
      }
     },
     "localname": "IfrsContractualObligation",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsCostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of sales",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "IfrsCostOfSalesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsCurrentGrantReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current grant receivables.",
        "label": "IFRS Current Grant Receivables",
        "terseLabel": "Grant receivable"
       }
      }
     },
     "localname": "IfrsCurrentGrantReceivables",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of development milestone payment included in contract liabilities",
        "label": "IFRS Development Milestone Payment Included In Contract Liabilities",
        "terseLabel": "Development milestone payment included in contract liabilities"
       }
      }
     },
     "localname": "IfrsDevelopmentMilestonePaymentIncludedInContractLiabilities",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsGeneralAndAdministrativeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative expenses",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "IfrsGeneralAndAdministrativeExpenseMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsIncomeStatementLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Ifrs Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IfrsIncomeStatementLocationAxis",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_IfrsIncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Ifrs Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IfrsIncomeStatementLocationDomain",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in expense related to in-effective set-up activities and settlement costs",
        "label": "IFRS Increase In Expense Related To Ineffective Set-up activities And Settlement Costs",
        "terseLabel": "Recognition of expenses related to ineffective set-up activities and settlement costs"
       }
      }
     },
     "localname": "IfrsIncreaseInExpenseRelatedToIneffectiveSetUpActivitiesAndSettlementCosts",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsInventoryFinishedGoodsWriteDown": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognised related to the write-down of inventories, finished goods.",
        "label": "IFRS Inventory, Finished Goods, Write down",
        "terseLabel": "Finished goods written down"
       }
      }
     },
     "localname": "IfrsInventoryFinishedGoodsWriteDown",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of milestone payment received.",
        "label": "IFRS Milestone Payment Received",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "IfrsMilestonePaymentReceived",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares received from the participants.",
        "label": "IFRS Number Of Shares Outstanding Through Transfer From Shareholders To Entity",
        "terseLabel": "Number of shares received"
       }
      }
     },
     "localname": "IfrsNumberOfSharesOutstandingThroughTransferFromShareholdersToEntity",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_IfrsOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Other liabilities and provisions."
       }
      }
     },
     "localname": "IfrsOtherLiabilitiesAbstract",
     "nsuri": "http://www.curevac.com/20230630",
     "xbrltype": "stringItemType"
    },
    "cvac_IfrsOverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "IfrsOverAllotmentOptionMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product",
        "terseLabel": "Product"
       }
      }
     },
     "localname": "IfrsProductMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsProvisionForLossOnContracts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of provision for loss on contracts.",
        "label": "Ifrs Provision For Loss on Contracts",
        "terseLabel": "Estimated contract termination provisions"
       }
      }
     },
     "localname": "IfrsProvisionForLossOnContracts",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsRemainingGrantIncome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of remaining grant income classified as other operating income.",
        "label": "IFRS Remaining Grant Income",
        "terseLabel": "Remaining grant income"
       }
      }
     },
     "localname": "IfrsRemainingGrantIncome",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IfrsResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "IfrsResearchAndDevelopmentExpenseMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsRestrictedStockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Restricted stock unit.",
        "label": "RSU Supervisory Board",
        "terseLabel": "RSU Supervisory Board"
       }
      }
     },
     "localname": "IfrsRestrictedStockUnitMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsSaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "IFRS Sale of Stock [Axis]"
       }
      }
     },
     "localname": "IfrsSaleOfStockAxis",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_IfrsSaleOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "IFRS Sale of Stock [Domain]",
        "terseLabel": "IFRS Sale of Stock"
       }
      }
     },
     "localname": "IfrsSaleOfStockDomain",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsShareBasedPaymentArrangementTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "First tranche",
        "terseLabel": "First tranche"
       }
      }
     },
     "localname": "IfrsShareBasedPaymentArrangementTrancheOneMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_IfrsSharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Ifrs Shares Issued, Price Per Share",
        "terseLabel": "Price per shares issued in follow-on public offering"
       }
      }
     },
     "localname": "IfrsSharesIssuedPricePerShare",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvac_IfrsStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Ifrs Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Shares issued"
       }
      }
     },
     "localname": "IfrsStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_IfrsStockholdersEquityNoteStockSplitConversionRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "IFRS Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Share split ratio"
       }
      }
     },
     "localname": "IfrsStockholdersEquityNoteStockSplitConversionRatio",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "cvac_IfrsVestingAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Ifrs Vesting [Axis]"
       }
      }
     },
     "localname": "IfrsVestingAxis",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_IfrsVestingDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Ifrs Vesting [Domain]"
       }
      }
     },
     "localname": "IfrsVestingDomain",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ImpairmentOfAssetsHeldForSale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss on assets held for sale.",
        "label": "Impairment of Assets Held for Sale",
        "terseLabel": "Impairment of assets held for sale"
       }
      }
     },
     "localname": "ImpairmentOfAssetsHeldForSale",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ImpairmentsOfInventoryAndPrepayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairments of inventory and prepayments",
        "label": "Impairments of inventory and prepayments",
        "terseLabel": "Impairment of inventory and prepayments"
       }
      }
     },
     "localname": "ImpairmentsOfInventoryAndPrepayments",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IncomeTaxAndSocialSecurityLiabilityReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax and social security liability receivable.",
        "label": "Income Tax and Social Security Liability Receivable",
        "terseLabel": "Income tax and social security liability receivable"
       }
      }
     },
     "localname": "IncomeTaxAndSocialSecurityLiabilityReceivable",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IncreaseDecreaseInInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in inventory during the period.",
        "label": "Increase (Decrease) In Inventory",
        "terseLabel": "Increase in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventory",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IncreaseInNumberOfSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in the number of shares outstanding.",
        "label": "Increase In Number Of Shares Outstanding",
        "terseLabel": "Capital Investment"
       }
      }
     },
     "localname": "IncreaseInNumberOfSharesOutstanding",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in PPE off set by impairment in equipment.",
        "label": "Increase In Property and Equipment Off Set By Impairment of Equipment",
        "terseLabel": "Partial offset of increase in property, plant and equipment"
       }
      }
     },
     "localname": "IncreaseInPropertyAndEquipmentOffSetByImpairmentOfEquipment",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of increase in R&amp;D expenses due to reversal of provision for onerous contracts.",
        "label": "Increase in Research and Development Expenses due to Reversal of Provision for Onerous Contract",
        "terseLabel": "Increase in research and development expenses due to reversal of provision for onerous contracts"
       }
      }
     },
     "localname": "IncreaseInResearchAndDevelopmentExpensesDueToReversalOfProvisionForOnerousContract",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_InitialPublicOfferingAndPrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for initial public offering and private placement.",
        "label": "Initial Public Offering and Private Placement",
        "terseLabel": "Initial Public Offering and Private Placement"
       }
      }
     },
     "localname": "InitialPublicOfferingAndPrivatePlacementMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_InventoriesLineItem": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Inventories [Line item",
        "terseLabel": "Inventories",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "InventoriesLineItem",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails",
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_InventoriesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Inventories [Table]"
       }
      }
     },
     "localname": "InventoriesTable",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails",
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_KeyEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for key employees.",
        "label": "Key employees",
        "terseLabel": "Key employees"
       }
      }
     },
     "localname": "KeyEmployeesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_LaboratoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for laboratories.",
        "label": "Laboratories [Member]",
        "terseLabel": "Laboratories"
       }
      }
     },
     "localname": "LaboratoriesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_LargestShareholderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Dievini Hopp BioTech holding GmbH &amp; Co. KG (dievini), which is an investment company dedicated to the support of companies in health and life sciences, is the largest shareholder of CureVac.",
        "label": "Largest Shareholder [Member]",
        "terseLabel": "Dievini"
       }
      }
     },
     "localname": "LargestShareholderMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_LicenseFeePayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of license fee payables.",
        "label": "License Fee Payable",
        "terseLabel": "License fees payable"
       }
      }
     },
     "localname": "LicenseFeePayable",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_LicensesSoftwareAndPrepaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "licenses, software and prepayments",
        "label": "licenses, software and prepayments [Member]"
       }
      }
     },
     "localname": "LicensesSoftwareAndPrepaymentsMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_LockUpPeriodAfterInitialListing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the lock-up period, which is days after the initial listing.",
        "label": "lock Up Period, After Initial Listing",
        "terseLabel": "Lock-up period"
       }
      }
     },
     "localname": "LockUpPeriodAfterInitialListing",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvac_LongTermIncentivePlanAndRestrictedStockUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Long-Term Incentive Plan and Restricted stock units.",
        "label": "LTIP RSU"
       }
      }
     },
     "localname": "LongTermIncentivePlanAndRestrictedStockUnitMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_LongTermIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Long-Term Incentive Plan.",
        "label": "LTIP Stock Options",
        "terseLabel": "LTIP Stock Options"
       }
      }
     },
     "localname": "LongTermIncentivePlanMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Number of patents infringed"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed in the utility model.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number Of Utility Models",
        "terseLabel": "Number of utility models infringed"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumberOfUtilityModels",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_LossContingencyPatentsFoundNotInfringedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of another entity's patents that the entity was found not to have infringed.",
        "label": "Loss Contingency, Patents Found Not Infringed, Number",
        "terseLabel": "Number of patents that does not infringe"
       }
      }
     },
     "localname": "LossContingencyPatentsFoundNotInfringedNumber",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_MaintenanceAndLeaseExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maintenance and lease expenses incurred by the company during the period.",
        "label": "Maintenance And Lease Expenses",
        "negatedLabel": "Maintenance and lease"
       }
      }
     },
     "localname": "MaintenanceAndLeaseExpenses",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ManagementBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for management board of the entity's key management personnel.",
        "label": "Management Board",
        "terseLabel": "Management Board"
       }
      }
     },
     "localname": "ManagementBoardMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MariolaFotinMleczekMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Mariola Fotin-Mleczek.",
        "label": "Mariola Fotin-Mleczek [Member]",
        "terseLabel": "Mariola Fotin-Mleczek"
       }
      }
     },
     "localname": "MariolaFotinMleczekMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MaximumGrantToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of maximum grant receivable.",
        "label": "Maximum Grant To Be Received",
        "terseLabel": "Maximum grant"
       }
      }
     },
     "localname": "MaximumGrantToBeReceived",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_MaximumUnspentFundsReimbursable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of maximum unspent funds reimbursable.",
        "label": "Maximum Unspent Funds Reimbursable",
        "terseLabel": "Maximum unspent funds reimbursable"
       }
      }
     },
     "localname": "MaximumUnspentFundsReimbursable",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_MembersOfExecutiveBoardAndVariousKeyEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for person or persons designated as part of Executive board and various key employees.",
        "label": "Members of executive board and various key employees",
        "terseLabel": "Members of executive board and various key employees"
       }
      }
     },
     "localname": "MembersOfExecutiveBoardAndVariousKeyEmployeesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MilestoneRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for milestone revenues.",
        "label": "Milestone revenues"
       }
      }
     },
     "localname": "MilestoneRevenuesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "These member stand for milestones.",
        "label": "Milestones"
       }
      }
     },
     "localname": "MilestonesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MiscellaneousOtherOperatingIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income, classified as other.",
        "label": "Miscellaneous Other Operating Income, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "MiscellaneousOtherOperatingIncomeOther",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_MonetaryAssetsInForeignCurrencyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Monetary Assets In Foreign Currency"
       }
      }
     },
     "localname": "MonetaryAssetsInForeignCurrencyMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_MonetaryLiabilitiesInForeignCurrencyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"This member stands for a type\n of market risk representing the\n risk that the fair value or future\n cash flows of a financial\n instrument will fluctuate\n because of changes in foreign\n exchange rates.\"",
        "label": "Monetary Liabilities In Foreign Currency"
       }
      }
     },
     "localname": "MonetaryLiabilitiesInForeignCurrencyMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_NetLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income.",
        "label": "Net Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "NetLoss",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_NetValueOfInventoryTransferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net value of inventory transferred during the period.",
        "label": "Net Value Of Inventory Transferred",
        "terseLabel": "Net inventory transferred"
       }
      }
     },
     "localname": "NetValueOfInventoryTransferred",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_NewVirtualStockOptionsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Virtual stock option plan II.",
        "label": "New VSOP.",
        "verboseLabel": "New VSOP"
       }
      }
     },
     "localname": "NewVirtualStockOptionsPlanMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_NumberOfAdditionalGrantsReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional grants received by the company.",
        "label": "Number Of Additional Grants Received",
        "terseLabel": "Number of additional grants received"
       }
      }
     },
     "localname": "NumberOfAdditionalGrantsReceived",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement.",
        "label": "Number of Doses of SARS-CoV-2 Can be Purchased By Member States under Advance purchase Agreement",
        "terseLabel": "Number of doses of SARS-CoV-2 advance purchase by the Member States under agreement"
       }
      }
     },
     "localname": "NumberOfDosesOfSarsCov2CanBePurchasedByMemberStatesUnderAdvancePurchaseAgreement",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfIntellectualPropertyRightsInfringementCaseFilled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of intellectual property rights infringement case filled.",
        "label": "Number Of Intellectual Property Rights Infringement Case Filled",
        "terseLabel": "Number of intellectual property rights infringement case filled"
       }
      }
     },
     "localname": "NumberOfIntellectualPropertyRightsInfringementCaseFilled",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfKeyEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of key employees.",
        "label": "Number of Key Employees",
        "terseLabel": "Number of key employees"
       }
      }
     },
     "localname": "NumberOfKeyEmployees",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfMrnaVaccinesDoses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents number of vaccines during the  pandemic.",
        "label": "Number Of MRNA Vaccines Doses"
       }
      }
     },
     "localname": "NumberOfMrnaVaccinesDoses",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of other equity instruments settled in a share-based payment arrangement.",
        "label": "Number Of Other Equity Instruments Settled In Share-Based Payment Arrangement",
        "terseLabel": "Number of RSUs settled"
       }
      }
     },
     "localname": "NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_NumberOfPatentOnWhichNullityActionIsFilled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of patent on which nullity action is filled.",
        "label": "Number Of Patent On Which Nullity Action Is Filled",
        "terseLabel": "Number of patent on which nullity action is filled"
       }
      }
     },
     "localname": "NumberOfPatentOnWhichNullityActionIsFilled",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_NumberOfShareOptionsVestedInShareBasedPaymentArrangement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share options vested in a share-based payment arrangement.",
        "label": "Number Of Share Options Vested In Share-Based Payment Arrangement",
        "verboseLabel": "Number of options vested"
       }
      }
     },
     "localname": "NumberOfShareOptionsVestedInShareBasedPaymentArrangement",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "cvac_NumberOfSharesIssuedForRsuDeliveries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued for RSU deliveries.",
        "label": "Number of Shares Issued for RSU Deliveries",
        "terseLabel": "Number of shares issued for RSU deliveries"
       }
      }
     },
     "localname": "NumberOfSharesIssuedForRsuDeliveries",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued for RSU deliveries.",
        "label": "Number of Shares Issued on Exercise of Options and RSU Deliveries",
        "terseLabel": "Shares issued for LTIP option exercises and RSU deliveries"
       }
      }
     },
     "localname": "NumberOfSharesIssuedOnExerciseOfOptionsAndRsuDeliveries",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_OptionsGrantedToThenChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for options granted to Dan Menichella, the then Chief Executive Officer (CEO).",
        "label": "Former Chief Executive Officer Grant",
        "terseLabel": "Former Chief Executive Officer Grant"
       }
      }
     },
     "localname": "OptionsGrantedToThenChiefExecutiveOfficerMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_OtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Other customers.",
        "label": "Others",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherCustomersMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_OtherExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails": {
       "order": 6.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other expense.",
        "label": "Other Expense",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherExpense",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_OtherLiabilitiesAndProvisionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Other liabilities and provisions"
       }
      }
     },
     "localname": "OtherLiabilitiesAndProvisionsAbstract",
     "nsuri": "http://www.curevac.com/20230630",
     "xbrltype": "stringItemType"
    },
    "cvac_OtherLiabilitiesAndProvisionsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of other liabilities and provisions.",
        "label": "Other Liabilities and Provisions [Text Block]",
        "terseLabel": "Other liabilities and provisions"
       }
      }
     },
     "localname": "OtherLiabilitiesAndProvisionsTextBlock",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_OtherLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other current liabilities.",
        "label": "Other Liability, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilityCurrent",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_OtherMiscellaneousNonCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other miscellaneous non-current liabilities.",
        "label": "Other Miscellaneous Non-current Liabilities",
        "terseLabel": "Other (e.g. license liabilities, Deferred Tax Liability)"
       }
      }
     },
     "localname": "OtherMiscellaneousNonCurrentLiabilities",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_OtherOperatingIncomeGovernmentGrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of other operating income recognized in relation to government agencies and similar bodies.",
        "label": "Other Operating Income, Government Grants",
        "verboseLabel": "Grants and other reimbursements from government agencies and similar bodies"
       }
      }
     },
     "localname": "OtherOperatingIncomeGovernmentGrants",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_OutstandingInvoicesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current outstanding invoices.",
        "label": "Outstanding Invoices, Current",
        "terseLabel": "Outstanding invoices"
       }
      }
     },
     "localname": "OutstandingInvoicesCurrent",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PartnershipAgreementMaximumAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount agreed under the partnership agreement.",
        "label": "Partnership Agreement, Maximum Amount",
        "terseLabel": "Maximum amount under the partnership agreement"
       }
      }
     },
     "localname": "PartnershipAgreementMaximumAmount",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PartnershipAgreementPeriodOfCostsToBeCovered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for which the costs are to be covered by the funds received under the partnership agreement.",
        "label": "Partnership Agreement, Period Of Costs To Be Covered",
        "terseLabel": "Period for which the costs are to be covered"
       }
      }
     },
     "localname": "PartnershipAgreementPeriodOfCostsToBeCovered",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvac_PartnershipAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the partnership agreement.",
        "label": "Partnership Agreement, Term",
        "terseLabel": "Term of the partnership agreement"
       }
      }
     },
     "localname": "PartnershipAgreementTerm",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvac_PatentInfringementLawsuitFilledMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for patent infringement lawsuit filled.",
        "label": "Patent Infringement Lawsuit Filled [Member]",
        "terseLabel": "Patent infringement lawsuit"
       }
      }
     },
     "localname": "PatentInfringementLawsuitFilledMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_PatentsAndFeesToRegisterLegalRight": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred by the company for registering a legal right.",
        "label": "Patents And Fees To Register Legal Right",
        "negatedLabel": "Patents and fees to register a legal right"
       }
      }
     },
     "localname": "PatentsAndFeesToRegisterLegalRight",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PercentageOfVotingInterestsHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of voting equity interests held in the Entity.",
        "label": "Percentage of Voting Interests Held",
        "terseLabel": "Voting interests held"
       }
      }
     },
     "localname": "PercentageOfVotingInterestsHeld",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_PersonnelAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of personnel accrued liabilities.",
        "label": "Personnel Accrued Liabilities",
        "terseLabel": "Personnel accrued liabilities (e.g. bonus, vacation)"
       }
      }
     },
     "localname": "PersonnelAccruedLiabilities",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PersonnelExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of personnel expenses incurred by the company during the period.",
        "label": "Personnel Expenses",
        "negatedLabel": "Personnel"
       }
      }
     },
     "localname": "PersonnelExpenses",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PlanNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the signing date share price.",
        "label": "Preliminary Purchase Price Allocation, Calculation of Volume Weighted Average Share Price over Sixty Trading Days",
        "terseLabel": "Signing date share price"
       }
      }
     },
     "localname": "PreliminaryPurchasePriceAllocationCalculationOfVolumeWeightedAverageSharePriceOverSixtyTradingDays",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvac_PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of trading days used for calculation of preliminary total purchase price.",
        "label": "Preliminary Purchase Price Allocation, Number of Trading Days Used",
        "terseLabel": "Number of trading days"
       }
      }
     },
     "localname": "PreliminaryPurchasePriceAllocationNumberOfTradingDaysUsed",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_PrepaidCompensationForContractManufacturingOrganizationsTransfer": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of prepaid compensation for contract manufacturing organizations transfer.",
        "label": "Prepaid Compensation for Contract Manufacturing organizations Transfer",
        "terseLabel": "Prepayments for compensation"
       }
      }
     },
     "localname": "PrepaidCompensationForContractManufacturingOrganizationsTransfer",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PriorVirtualStockOptionsPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Virtual stock option plan I.",
        "label": "Prior VSOP",
        "terseLabel": "Prior VSOP"
       }
      }
     },
     "localname": "PriorVirtualStockOptionsPlanMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_PrivatePlacementIsa2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for private Placement \"ISA 2020\".",
        "label": "2020 Private Investment",
        "terseLabel": "2020 Private Investment"
       }
      }
     },
     "localname": "PrivatePlacementIsa2020Member",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of proceed from issuing other equity instrument or exercise of options.",
        "label": "Proceed From Issuing Other Equity Instrument Or Exercise of Options",
        "terseLabel": "Payment on / proceeds from treasury shares/exercise of options"
       }
      }
     },
     "localname": "ProceedFromIssuingOtherEquityInstrumentOrExerciseOfOptions",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]",
        "label": "Proceeds from (Repayments of) borrowings, classified as financing activities",
        "terseLabel": "Proceeds from (repayment of) the EIB loan"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ProfessionalFessCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current professional fees.",
        "label": "Professional Fess, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "ProfessionalFessCurrent",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ProvisionForEmployerTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of provision for employer taxes arising according to US regulations for future exercises.",
        "label": "Provision for Employer Taxes",
        "verboseLabel": "Provision for employer taxes"
       }
      }
     },
     "localname": "ProvisionForEmployerTaxes",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ProvisionsForDecreaseInContractTerminations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in contract terminations provisions.",
        "label": "Provisions For Decrease In Contract Terminations",
        "terseLabel": "Decrease in contract terminations provisions"
       }
      }
     },
     "localname": "ProvisionsForDecreaseInContractTerminations",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to follow on public offering.",
        "label": "Public Offering [Member]",
        "terseLabel": "Public Offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_PublicOfferingOfCommonSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for public offering of common shares.",
        "label": "Public offering of common shares"
       }
      }
     },
     "localname": "PublicOfferingOfCommonSharesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total number of milestones.",
        "label": "Purchase Price Allocation, Number of Milestones Used for Payment of Fifty Percent of Purchase Price to be Paid in Shares",
        "terseLabel": "Number of milestones"
       }
      }
     },
     "localname": "PurchasePriceAllocationNumberOfMilestonesUsedForPaymentOfFiftyPercentOfPurchasePriceToBePaidInShares",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of first milestone payment.",
        "label": "Purchase Price Allocation, Percent of First Milestone Payment Due Upon Achievement of Successful Investigational New Drug Application Filing",
        "terseLabel": "Percent of first milestone payment"
       }
      }
     },
     "localname": "PurchasePriceAllocationPercentOfFirstMilestonePaymentDueUponAchievementOfSuccessfulInvestigationalNewDrugApplicationFiling",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of second milestone payment.",
        "label": "Purchase Price Allocation, Percent of Second Milestone Payment Due Upon Successful Proof of Mechanism in Humans",
        "terseLabel": "Percent of second milestone payment"
       }
      }
     },
     "localname": "PurchasePriceAllocationPercentOfSecondMilestonePaymentDueUponSuccessfulProofOfMechanismInHumans",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_PurchasePriceAllocationSharePriceAsOfClosingDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the closing date share price.",
        "label": "Purchase Price Allocation, Share Price as of Closing Date",
        "terseLabel": "Closing date share price"
       }
      }
     },
     "localname": "PurchasePriceAllocationSharePriceAsOfClosingDate",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "cvac_RealEstateTransferTaxes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of real estate transfer taxes.",
        "label": "Real Estate Transfer Taxes",
        "terseLabel": "Real estate transfer taxes"
       }
      }
     },
     "localname": "RealEstateTransferTaxes",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from government grants and similar bodies.",
        "label": "Receipts from Government Grants Classified as Operating Activities",
        "verboseLabel": "Grant amount received/eligible to receive"
       }
      }
     },
     "localname": "ReceiptsFromGovernmentGrantsClassifiedAsOperatingActivities",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ReimbursementOfApprovedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of reimbursement of approved expenses",
        "label": "Reimbursement of Approved Expenses",
        "terseLabel": "Reimbursement of approved expenses"
       }
      }
     },
     "localname": "ReimbursementOfApprovedExpenses",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_RelatedPartyTransactionConsultingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consulting fees incurred as a part of related party transaction.",
        "label": "Related Party Transaction, Consulting Fees",
        "terseLabel": "Consulting fees"
       }
      }
     },
     "localname": "RelatedPartyTransactionConsultingFees",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_RelatedPartyTransactionNoticePeriodForTerminationOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of notice for termination of the agreement at the option of the party.",
        "label": "Related Party Transaction, Notice Period for Termination of Agreement",
        "terseLabel": "Notice period for termination at the option"
       }
      }
     },
     "localname": "RelatedPartyTransactionNoticePeriodForTerminationOfAgreement",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "cvac_RelatedPartyTransactionNumberOfLoansReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of loans received from a related party.",
        "label": "Related Party Transaction, Number of Loans Received",
        "terseLabel": "Number of convertible loans"
       }
      }
     },
     "localname": "RelatedPartyTransactionNumberOfLoansReceived",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_RemainingAuthorizedForSaleValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of remaining authorized for sale value.",
        "label": "Remaining Authorized For Sale Value",
        "terseLabel": "Remaining authorized for sale value"
       }
      }
     },
     "localname": "RemainingAuthorizedForSaleValue",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ResearchAndDevelopmentServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for research and development services.",
        "label": "Research and development services [Member]",
        "terseLabel": "Research and development services"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServicesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ResearchServicesCombinedWithIpLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for research services combined with an IP license.",
        "label": "Research services combined with an IP license [Member]",
        "terseLabel": "Research services combined with an IP license"
       }
      }
     },
     "localname": "ResearchServicesCombinedWithIpLicenseMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_RestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Restricted stock Units",
        "label": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of provisions reversed due to certain reserved capacity taken over from the group.",
        "label": "Reversal Of Provision Recognized Due to Certain Reserved Capacity Taken Over",
        "terseLabel": "Reversal of provision recognized"
       }
      }
     },
     "localname": "ReversalOfProvisionRecognizedDueToCertainReservedCapacityTakenOver",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ReversalOfProvisionsForPersonnelExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails": {
       "order": 4.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of personnel expenses reversed during the period.",
        "label": "Reversal Of Provisions For Personnel Expenses",
        "verboseLabel": "Income from reversal of provisions"
       }
      }
     },
     "localname": "ReversalOfProvisionsForPersonnelExpenses",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_RightToExercisePercentageOfVestedVirtualShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the right to exercise percentage of vested virtual shares.",
        "label": "Right To Exercise Percentage Of Vested Virtual Shares",
        "terseLabel": "Right to exercise percentage of vested virtual shares"
       }
      }
     },
     "localname": "RightToExercisePercentageOfVestedVirtualShares",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "cvac_RittershausRechtsanwaelteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for Rittershaus Rechtsanwaelte , a related party.",
        "label": "Rittershaus Rechtsanwaelte [Member]",
        "terseLabel": "Rittershaus Rechtsanwaelte"
       }
      }
     },
     "localname": "RittershausRechtsanwaelteMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_SaleOfEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_MiscellaneousOtherOperatingIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of sale of equipment in operating income.",
        "label": "Sale of equipment",
        "terseLabel": "Sale of equipment"
       }
      }
     },
     "localname": "SaleOfEquipment",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ScheduleOfExpenseRecognizedForProgramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of expense recognized for the programs.",
        "label": "Schedule of Expense Recognized for the Programs [Table Text Block]",
        "terseLabel": "Schedule for expense recognized for the equity-settled programs"
       }
      }
     },
     "localname": "ScheduleOfExpenseRecognizedForProgramsTableTextBlock",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "cvac_SellingAndDistributionExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for selling and distribution expenses.",
        "label": "Selling and distribution expenses",
        "terseLabel": "Selling and distribution expenses"
       }
      }
     },
     "localname": "SellingAndDistributionExpensesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_SeriesCSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series C shares.",
        "label": "Series C",
        "terseLabel": "Series C"
       }
      }
     },
     "localname": "SeriesCSharesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_SeriesSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series A shares.",
        "label": "Series A",
        "terseLabel": "Series A"
       }
      }
     },
     "localname": "SeriesSharesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_SettlementOfShareBasedPaymentAwardsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of share based payment awards settled in cash.",
        "label": "Settlement Of Share Based Payment Awards , Amount",
        "terseLabel": "Settlement of share-based payment awards"
       }
      }
     },
     "localname": "SettlementOfShareBasedPaymentAwardsAmount",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ShareBasedPaymentExpenseIncl.DeferredTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Share-based payment expense (incl. deferred taxes)",
        "label": "Share-based payment expense (incl. deferred taxes)",
        "terseLabel": "Share-based payments (net of taxes)"
       }
      }
     },
     "localname": "ShareBasedPaymentExpenseIncl.DeferredTaxes",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_ShareOptionExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of share option exercises.",
        "label": "Share Option Exercises",
        "terseLabel": "Share option exercises"
       }
      }
     },
     "localname": "ShareOptionExercises",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_SoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The member stands for software.",
        "label": "Software [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_StockIssuanceDuringPeriodForExistingShareholders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period for existing shareholders.",
        "label": "Stock Issuance During Period For Existing Shareholders",
        "terseLabel": "Shares issued to former shareholders of Frame Pharmaceuticals"
       }
      }
     },
     "localname": "StockIssuanceDuringPeriodForExistingShareholders",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_StockIssuedDuringPeriodForExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period, upon exercises.",
        "label": "Stock Issued During Period, For Exercises",
        "terseLabel": "Share issuances for exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodForExercises",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "cvac_SupervisoryBoardMembersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for supervisory board members.",
        "label": "Supervisory board members",
        "terseLabel": "Supervisory Board members"
       }
      }
     },
     "localname": "SupervisoryBoardMembersMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TechnicalEquipmentAndMachinesAndOtherEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for technical equipment and machines and other equipment.",
        "label": "Technical equipment and machines [Member]",
        "terseLabel": "Technical equipment and machines"
       }
      }
     },
     "localname": "TechnicalEquipmentAndMachinesAndOtherEquipmentMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity.",
        "label": "Technology [Member]",
        "terseLabel": "Technology"
       }
      }
     },
     "localname": "TechnologyMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TerminationOfExclusiveCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for termination of exclusive collobaration and license agreement.",
        "label": "Termination of Exclusive Collaboration And License Agreement"
       }
      }
     },
     "localname": "TerminationOfExclusiveCollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ThenChiefExecutiveOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Dan Menichella, then Chief Executive Officer.",
        "label": "the Chief Executive Officer",
        "terseLabel": "the Chief Executive Officer"
       }
      }
     },
     "localname": "ThenChiefExecutiveOfficerMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_ThirdPartyServiceExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred by the company for third party services during the period.",
        "label": "Third Party Service Expenses",
        "negatedLabel": "Third-party services"
       }
      }
     },
     "localname": "ThirdPartyServiceExpenses",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_TotalNumberOfIntellectualPropertyRightsInfringementCase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total number of intellectual property rights infringement case.",
        "label": "Total Number Of Intellectual Property Rights Infringement Case",
        "terseLabel": "Total number of intellectual property rights infringement case"
       }
      }
     },
     "localname": "TotalNumberOfIntellectualPropertyRightsInfringementCase",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "cvac_TradeAndOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for trade and other payables.",
        "label": "Trade and other payables and provision"
       }
      }
     },
     "localname": "TradeAndOtherPayablesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TradeAndOtherPayablesOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Trade And Other Payables One"
       }
      }
     },
     "localname": "TradeAndOtherPayablesOneMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TradeAndOtherPayablesTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Trade And Other Payables Two"
       }
      }
     },
     "localname": "TradeAndOtherPayablesTwoMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TradeAndOtherReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "Trade And Other Receivables"
       }
      }
     },
     "localname": "TradeAndOtherReceivablesMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_TypeOfArrangementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "cvac_UpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront payment received.",
        "label": "Upfront Payment Received"
       }
      }
     },
     "localname": "UpfrontPaymentReceived",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_UpfrontPaymentsIncludedInContractLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payments of the company included in contract liabilities.",
        "label": "Upfront Payments Included In Contract Liabilities",
        "terseLabel": "Upfront and milestones payments included in contract liabilities"
       }
      }
     },
     "localname": "UpfrontPaymentsIncludedInContractLiabilities",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_UpfrontPaymentsReceivedOrReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of upfront payments received or receivable by the company.",
        "label": "Upfront Payments Received Or Receivable",
        "terseLabel": "Upfront and milestone payments"
       }
      }
     },
     "localname": "UpfrontPaymentsReceivedOrReceivable",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "cvac_VincentStphenneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Vincent Stphenne.",
        "label": "Vincent Stephenne [Member]",
        "terseLabel": "Vincent Stephenne"
       }
      }
     },
     "localname": "VincentStphenneMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_VirtualSharesProgramIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Virtual shares program I.",
        "label": "Prior VSOP [Member]",
        "terseLabel": "Prior VSOP"
       }
      }
     },
     "localname": "VirtualSharesProgramIMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "cvac_VirtualSharesProgramIiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Virtual shares program II (New VSOP).",
        "label": "New VSOP",
        "terseLabel": "New VSOP"
       }
      }
     },
     "localname": "VirtualSharesProgramIiMember",
     "nsuri": "http://www.curevac.com/20230630",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r226",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r226",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r226",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r226",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document and Entity Information"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r226",
      "r227",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.curevac.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ifrs-full_AccumulatedOtherComprehensiveIncome": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 5.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, intangible assets other than goodwill",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Business combinations [member]; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Additions other than through business combinations, property, plant and equipment",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "auth_ref": [
      "r254"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in inventories",
        "terseLabel": "Decrease / (increase) in inventory"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": {
     "auth_ref": [
      "r257"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other assets",
        "terseLabel": "Decrease / (increase) in other assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "auth_ref": [
      "r257"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade and other receivables",
        "terseLabel": "Decrease / (increase) in trade receivables and contract assets"
       }
      }
     },
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDeferredTaxExpense": {
     "auth_ref": [
      "r257"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for deferred tax expense",
        "terseLabel": "Decrease / (increase) in deferred taxes"
       }
      }
     },
     "localname": "AdjustmentsForDeferredTaxExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation and amortisation expense",
        "terseLabel": "Depreciation and impairment of property, plant and equipment and right-of-use assets"
       }
      }
     },
     "localname": "AdjustmentsForDepreciationAndAmortisationExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceCosts": {
     "auth_ref": [
      "r256"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for finance costs to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance costs; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance costs",
        "terseLabel": "Finance expense"
       }
      }
     },
     "localname": "AdjustmentsForFinanceCosts",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForFinanceIncome": {
     "auth_ref": [
      "r257"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for finance income to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for finance income",
        "negatedLabel": "Finance income"
       }
      }
     },
     "localname": "AdjustmentsForFinanceIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "auth_ref": [
      "r257"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "(Decrease) / increase in trade and other payables, other liabilities and contract liabilities"
       }
      }
     },
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": {
     "auth_ref": [
      "r252"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for losses (gains) on disposal of non-current assets",
        "terseLabel": "Loss on disposal of fixed assets"
       }
      }
     },
     "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Adjustments to reconcile loss before tax to net cash flows"
       }
      }
     },
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "verboseLabel": "Share-based payment expense"
       }
      }
     },
     "localname": "AdjustmentsForSharebasedPayments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AggregatedTimeBandsMember": {
     "auth_ref": [
      "r22",
      "r122",
      "r128",
      "r129",
      "r148",
      "r171",
      "r172",
      "r174",
      "r180",
      "r193",
      "r213",
      "r214"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Aggregated time bands [member]"
       }
      }
     },
     "localname": "AggregatedTimeBandsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Amortisation, intangible assets other than goodwill",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AmortisationIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Assets": {
     "auth_ref": [
      "r20",
      "r109",
      "r110",
      "r113",
      "r163",
      "r165"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Abstract",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "auth_ref": [
      "r65",
      "r66"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      },
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "terseLabel": "Net loss per share basic"
       }
      }
     },
     "localname": "BasicEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShareDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_BottomOfRangeMember": {
     "auth_ref": [
      "r115",
      "r136",
      "r174",
      "r204",
      "r205",
      "r260"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Minimum",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "BottomOfRangeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BuildingsMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of plant, property and equipment representing depreciable buildings and similar structures for use in operations. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Buildings [Member]",
        "terseLabel": "Buildings"
       }
      }
     },
     "localname": "BuildingsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_BusinessCombinationsAxis": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Business combinations [axis]"
       }
      }
     },
     "localname": "BusinessCombinationsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_BusinessCombinationsMember": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for transactions or other events in which an acquirer obtains control of one or more businesses. Transactions sometimes referred to as 'true mergers' or 'mergers of equals' are also business combinations as that term is used in IFRS 3."
       }
      },
      "en-us": {
       "role": {
        "label": "Business combinations [member]"
       }
      }
     },
     "localname": "BusinessCombinationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CapitalReserve": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the capital reserves."
       }
      },
      "en-us": {
       "role": {
        "label": "Capital reserve.",
        "terseLabel": "Capital reserve"
       }
      }
     },
     "localname": "CapitalReserve",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CapitalReserveMember": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing capital reserves."
       }
      },
      "en-us": {
       "role": {
        "label": "Capital reserve",
        "terseLabel": "Capital reserve"
       }
      }
     },
     "localname": "CapitalReserveMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CashAndCashEquivalents": {
     "auth_ref": [
      "r14",
      "r88",
      "r105"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents.",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "auth_ref": [
      "r83",
      "r89"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash flow provided by financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "auth_ref": [
      "r83",
      "r89"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash flow (used in) investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "auth_ref": [
      "r83",
      "r89"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0
      }
     },
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      },
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash flow (used in) operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      }
     },
     "localname": "CategoriesOfRelatedPartiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ChangesInOtherProvisions": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in other provisions. [Refer: Other provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in other provisions",
        "terseLabel": "Decrease in provisions"
       }
      }
     },
     "localname": "ChangesInOtherProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ClassesOfAssetsAxis": {
     "auth_ref": [
      "r68",
      "r69",
      "r114",
      "r127"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of assets [axis]"
       }
      }
     },
     "localname": "ClassesOfAssetsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfAssetsMember": {
     "auth_ref": [
      "r68",
      "r114",
      "r127"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Assets [member]"
       }
      }
     },
     "localname": "ClassesOfAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfContingentLiabilitiesAxis": {
     "auth_ref": [
      "r71",
      "r142"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of contingent liabilities [axis]"
       }
      }
     },
     "localname": "ClassesOfContingentLiabilitiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "auth_ref": [
      "r151",
      "r153",
      "r154",
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfFinancialInstrumentsMember": {
     "auth_ref": [
      "r151",
      "r153",
      "r154",
      "r155"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Financial instruments, class [member]"
       }
      }
     },
     "localname": "ClassesOfFinancialInstrumentsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of intangible assets and goodwill [axis]"
       }
      }
     },
     "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfInventoriesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories"
       }
      }
     },
     "localname": "ClassesOfInventoriesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of property, plant and equipment [axis]"
       }
      }
     },
     "localname": "ClassesOfPropertyPlantAndEquipmentAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share capital [member]"
       }
      }
     },
     "localname": "ClassesOfShareCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CommitmentsMadeByEntityRelatedPartyTransactions": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of related-party commitments made by the entity to do something if a particular event occurs or does not occur in the future, including executory contracts (recognised and unrecognised). [Refer: Related parties [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Commitments made by entity, related party transactions",
        "terseLabel": "Settlement amount"
       }
      }
     },
     "localname": "CommitmentsMadeByEntityRelatedPartyTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      }
     },
     "localname": "ComponentsOfEquityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ComprehensiveIncome": {
     "auth_ref": [
      "r3",
      "r33",
      "r94",
      "r96",
      "r103",
      "r203"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      },
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "terseLabel": "Total comprehensive income (loss)",
        "totalLabel": "Total comprehensive loss for the period"
       }
      }
     },
     "localname": "ComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ConstructionInProgressMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Construction in progress [Member]",
        "terseLabel": "Assets under construction"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContingentLiabilitiesMember": {
     "auth_ref": [
      "r72",
      "r142"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for possible obligations that arise from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity; or, present obligations that arise from past events but are not recognised because (a) it is probable that an outflow of resources embodying economic benefits will be required to settle the obligations; or (b) the amount of the obligations cannot be measured with sufficient reliability. It also represents the standard value for the 'Classes of contingent liabilities' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Contingent liabilities [member]"
       }
      }
     },
     "localname": "ContingentLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ContractLiabilities": {
     "auth_ref": [
      "r116",
      "r119"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer."
       }
      },
      "en-us": {
       "role": {
        "label": "Contract liabilities",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CostOfSales": {
     "auth_ref": [
      "r1",
      "r38"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Cost of sales.",
        "negatedLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfSales",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CounterpartiesAxis": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Counterparties [axis]"
       }
      }
     },
     "localname": "CounterpartiesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CounterpartiesMember": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Counterparties [member]"
       }
      }
     },
     "localname": "CounterpartiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrencyRiskMember": {
     "auth_ref": [
      "r159",
      "r175",
      "r176",
      "r177",
      "r178"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Foreign currency risk"
       }
      }
     },
     "localname": "CurrencyRiskMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_CurrentAdvancesToSuppliers": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current advances made to suppliers before goods or services are received."
       }
      },
      "en-us": {
       "role": {
        "label": "Current advances to suppliers",
        "terseLabel": "Prepayments for future service agreements and goods"
       }
      }
     },
     "localname": "CurrentAdvancesToSuppliers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssets": {
     "auth_ref": [
      "r23",
      "r99",
      "r203"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "CurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets Abstract",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "CurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentContractAssets": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current contract assets. [Refer: Contract assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current contract assets",
        "terseLabel": "Contract assets",
        "verboseLabel": "Contract assets"
       }
      }
     },
     "localname": "CurrentContractAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentContractLiabilities": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 6.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current contract liabilities",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "CurrentContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentGovernmentGrants": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current government grants recognised in the statement of financial position as deferred income. [Refer: Government [member]; Government grants]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current government grants",
        "terseLabel": "Grants from government agencies and similar bodies"
       }
      }
     },
     "localname": "CurrentGovernmentGrants",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "CurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilities": {
     "auth_ref": [
      "r24",
      "r101",
      "r203"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "CurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_CurrentPrepaymentsAndOtherCurrentAssets": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current prepayments and other current assets. [Refer: Other current assets; Current prepayments]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current prepayments and other current assets",
        "terseLabel": "Prepaid expenses and other assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "CurrentPrepaymentsAndOtherCurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentProvisions": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 7.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current provisions",
        "terseLabel": "Provisions"
       }
      }
     },
     "localname": "CurrentProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentReceivablesFromTaxesOtherThanIncomeTax": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current receivables from taxes other than income tax. [Refer: Receivables from taxes other than income tax]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current receivables from taxes other than income tax",
        "terseLabel": "Outstanding VAT refund claims"
       }
      }
     },
     "localname": "CurrentReceivablesFromTaxesOtherThanIncomeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTaxLiabilities": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      },
      "en-us": {
       "role": {
        "label": "Current tax liabilities",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "CurrentTaxLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_CurrentTradeReceivables": {
     "auth_ref": [
      "r185",
      "r187"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade receivables",
        "terseLabel": "Trade receivables"
       }
      }
     },
     "localname": "CurrentTradeReceivables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment through classification as held for sale or inclusion in a disposal group classified as held for sale. [Refer: Disposal groups classified as held for sale [member]; Property, plant and equipment; Disposal groups classified as held for sale [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Decrease through classified as held for sale, property, plant and equipment",
        "negatedLabel": "Assets held for sale"
       }
      }
     },
     "localname": "DecreaseThroughClassifiedAsHeldForSalePropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationAndAmortisationExpense": {
     "auth_ref": [
      "r2",
      "r38",
      "r107",
      "r161",
      "r167",
      "r182"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails": {
       "order": 5.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives."
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation and amortisation expense",
        "negatedLabel": "Amortization and depreciation",
        "negatedTerseLabel": "Amortization and depreciation"
       }
      }
     },
     "localname": "DepreciationAndAmortisationExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DepreciationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r49",
      "r53"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Depreciation, property, plant and equipment",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": {
     "auth_ref": [
      "r261",
      "r262"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]\nEffective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]"
       }
      },
      "en-us": {
       "role": {
        "label": "Description of accounting policy for research and development expense [text block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "auth_ref": [
      "r65",
      "r66"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "terseLabel": "Net loss per share diluted"
       }
      }
     },
     "localname": "DilutedEarningsLossPerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "terseLabel": "Basis of preparation"
       }
      }
     },
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureBasisOfPreparationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination",
        "verboseLabel": "Corporate Information"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfBusinessCombinationsTable": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of business combinations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about business combination [table]"
       }
      }
     },
     "localname": "DisclosureOfBusinessCombinationsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued Capital and Reserves"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalExplanatory": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of classes of share capital. [Refer: Share capital [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [text block]",
        "verboseLabel": "Schedule of total shares"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]",
        "terseLabel": "Issued Capital and Reserves"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]"
       }
      }
     },
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]",
        "terseLabel": "Schedule of revenue from contract with customers recognized"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]",
        "terseLabel": "Notes to the Consolidated Statements of Operations"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      }
     },
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "terseLabel": "Subsequent events"
       }
      }
     },
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfExpensesByNatureExplanatory": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of expenses by nature [text block]",
        "terseLabel": "Schedule of cost of sales, selling and distribution expenses, research and development expenses and general and administrative expenses"
       }
      }
     },
     "localname": "DisclosureOfExpensesByNatureExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets and financial liabilities"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "terseLabel": "Financial assets and financial liabilities"
       }
      }
     },
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the entity's financial risk management practices and policies."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of financial risk management [text block]",
        "terseLabel": "Disclosure of financial instruments and risk management"
       }
      }
     },
     "localname": "DisclosureOfFinancialRiskManagementExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIncomeTaxExplanatory": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for income taxes."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of income tax [text block]",
        "terseLabel": "Income tax"
       }
      }
     },
     "localname": "DisclosureOfIncomeTaxExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIncomeTax"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]",
        "terseLabel": "Schedule of inputs used in the measurement of the fair value at grant date"
       }
      }
     },
     "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [line items]",
        "verboseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfIntangibleAssetsTable": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of intangible assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about intangible assets [table]"
       }
      }
     },
     "localname": "DisclosureOfIntangibleAssetsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfInventoriesExplanatory": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for inventories."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of inventories [text block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DisclosureOfInventoriesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [line items]",
        "verboseLabel": "Disclosure of financial instruments and risk management"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable": {
     "auth_ref": [
      "r149",
      "r150"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the nature and extent of risks arising from financial instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of nature and extent of risks arising from financial instruments [table]"
       }
      }
     },
     "localname": "DisclosureOfNatureAndExtentOfRisksArisingFromFinancialInstrumentsTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent events"
       }
      }
     },
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for non-current assets held for sale and discontinued operations."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of non-current assets held for sale and discontinued operations [text block]",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "DisclosureOfNoncurrentAssetsHeldForSaleAndDiscontinuedOperationsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSale"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of notes and other explanatory information [text block]",
        "terseLabel": "Notes to the Consolidated Statements of Operations"
       }
      }
     },
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of share options [text block]",
        "terseLabel": "Schedule of reconciliation of outstanding awards"
       }
      }
     },
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherOperatingExpenseExplanatory": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other operating expense. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other operating expense [text block]",
        "terseLabel": "Schedule of other operating expenses"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingExpenseExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of other operating income [text block]",
        "terseLabel": "Schedule of other operating income"
       }
      }
     },
     "localname": "DisclosureOfOtherOperatingIncomeExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [line items]",
        "verboseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of property, plant and equipment."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about property, plant and equipment [table]"
       }
      }
     },
     "localname": "DisclosureOfPropertyPlantAndEquipmentTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfRelatedPartyExplanatory": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of related party [text block]",
        "terseLabel": "Related party disclosures"
       }
      }
     },
     "localname": "DisclosureOfRelatedPartyExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share capital, reserves and other equity interest [text block]",
        "verboseLabel": "Issued Capital and Reserves"
       }
      }
     },
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReserves"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payments"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      }
     },
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of trade and other payables [text block]",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "DisclosureOfTradeAndOtherPayablesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of the transaction price allocated to the remaining performance obligations in contracts with customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transaction price allocated to remaining performance obligations [text block]",
        "terseLabel": "Schedule of contract liabilities allocated to the remaining performance obligations (unsatisfied or partially unsatisfied) as at year-end"
       }
      }
     },
     "localname": "DisclosureOfTransactionPriceAllocatedToRemainingPerformanceObligationsExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party disclosures"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [line items]",
        "terseLabel": "Related party disclosures"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      },
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      }
     },
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, intangible assets other than goodwill",
        "negatedLabel": "Disposals"
       }
      }
     },
     "localname": "DisposalsIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_DisposalsPropertyPlantAndEquipment": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Disposals, property, plant and equipment",
        "negatedLabel": "Disposals"
       }
      }
     },
     "localname": "DisposalsPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EarningsPerShareExplanatory": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The disclosure of earnings per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Earnings per share [text block]",
        "terseLabel": "Earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "auth_ref": [
      "r85",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "Currency translation gains (losses) on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EntitysTotalForBusinessCombinationsMember": {
     "auth_ref": [
      "r141",
      "r144"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for business combinations [member]"
       }
      }
     },
     "localname": "EntitysTotalForBusinessCombinationsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      }
     },
     "localname": "EntitysTotalForRelatedPartiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Equity": {
     "auth_ref": [
      "r20",
      "r26",
      "r93",
      "r95",
      "r109",
      "r110",
      "r113"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity.",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "Equity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityAndLiabilities": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "Total equity and liabilities"
       }
      }
     },
     "localname": "EquityAndLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity And Liabilities Abstract",
        "terseLabel": "Equity and liabilities"
       }
      }
     },
     "localname": "EquityAndLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_EquityMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      }
     },
     "localname": "EquityMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ExpenseByNature": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenses aggregated according to their nature (for example, depreciation, purchases of materials, transport costs, employee benefits and advertising costs), and not reallocated among functions within the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Expenses, by nature",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "ExpenseByNature",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from equity-settled share-based payment transactions in which the goods or services received did not qualify for recognition as assets. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from equity-settled share-based payment transactions in which goods or services received did not qualify for recognition as assets",
        "terseLabel": "Benefit expenses recognized"
       }
      }
     },
     "localname": "ExpenseFromEquitysettledSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from share-based payment transactions in which the goods or services received did not qualify for recognition as assets."
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets",
        "terseLabel": "Expenses from share-based payments"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "terseLabel": "Share-based based payments expenses"
       }
      }
     },
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The explanation of the significant changes in the contract assets and the contract liabilities. [Refer: Contract assets; Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Explanation of significant changes in contract assets and contract liabilities [text block]",
        "terseLabel": "Schedule of contract balances"
       }
      }
     },
     "localname": "ExplanationOfSignificantChangesInContractAssetsAndContractLiabilitiesExplanatory",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ifrs-full_FinanceCosts": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance costs",
        "negatedLabel": "Finance expenses"
       }
      }
     },
     "localname": "FinanceCosts",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinanceIncome": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "Finance income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_FinishedGoods": {
     "auth_ref": [
      "r188",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current finished goods",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "FinishedGoods",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 5.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to general and administrative activities of the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "negatedLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GeographicalAreasAxis": {
     "auth_ref": [
      "r169",
      "r192",
      "r207",
      "r220"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [axis]"
       }
      }
     },
     "localname": "GeographicalAreasAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_GeographicalAreasMember": {
     "auth_ref": [
      "r169",
      "r192",
      "r207",
      "r220"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Geographical areas [member]",
        "terseLabel": "Geographical areas"
       }
      }
     },
     "localname": "GeographicalAreasMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GoodwillMember": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Goodwill [Member]",
        "terseLabel": "Goodwil"
       }
      }
     },
     "localname": "GoodwillMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_GovernmentGrants": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Government grants",
        "terseLabel": "Grants received and deferred"
       }
      }
     },
     "localname": "GovernmentGrants",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_GrossCarryingAmountMember": {
     "auth_ref": [
      "r45",
      "r73",
      "r81",
      "r82",
      "r143",
      "r152",
      "r154",
      "r212",
      "r263",
      "r264"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]"
       }
      },
      "en-us": {
       "role": {
        "label": "Acquisition costs",
        "terseLabel": "Acquisition costs"
       }
      }
     },
     "localname": "GrossCarryingAmountMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails",
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "auth_ref": [
      "r37",
      "r48"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "verboseLabel": "Impairment"
       }
      }
     },
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InAccordanceWithIFRS9Member": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information reported in accordance with IFRS 9."
       }
      },
      "en-us": {
       "role": {
        "label": "Effects from the first-time adoption of IFRS 9"
       }
      }
     },
     "localname": "InAccordanceWithIFRS9Member",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "auth_ref": [
      "r35",
      "r41",
      "r42",
      "r43",
      "r61",
      "r108",
      "r162"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Tax expense (income)",
        "negatedLabel": "Income tax benefit/ (expense)"
       }
      }
     },
     "localname": "IncomeTaxExpenseContinuingOperations",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for income taxes paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Income taxes paid, classified as operating activities",
        "negatedLabel": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for IFRS 15 Revenue with Contracts with Customers."
       }
      },
      "en-us": {
       "role": {
        "label": "Effects from the first-time adoption of IFRS 15"
       }
      }
     },
     "localname": "IncreaseDecreaseDueToApplicationOfIFRS15Member",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughExerciseOfOptions": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from the exercise of options."
       }
      },
      "en-us": {
       "role": {
        "label": "Shares issued on exercise of option",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughExerciseOfOptions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill",
        "terseLabel": "Currency translation"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through net exchange differences, property, plant and equipment",
        "terseLabel": "Currency translation"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughNetExchangeDifferencesPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers from construction in progress. [Refer: Property, plant and equipment; Construction in progress]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers from construction in progress, property, plant and equipment",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersFromConstructionInProgressPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers, intangible assets other than goodwill",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transfers, property, plant and equipment",
        "terseLabel": "Attributions"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": {
     "auth_ref": [
      "r8"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]"
       }
      },
      "en-us": {
       "role": {
        "label": "Increase (decrease) through treasury share transactions, equity",
        "terseLabel": "Repurchase of common shares"
       }
      }
     },
     "localname": "IncreaseDecreaseThroughTreasuryShareTransactions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InsuranceExpense": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from purchased insurance."
       }
      },
      "en-us": {
       "role": {
        "label": "Insurance expense",
        "terseLabel": "Insurance expense"
       }
      }
     },
     "localname": "InsuranceExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill",
        "terseLabel": "Intangible assets and goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsAndGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IntangibleAssetsAndGoodwillMember": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets and goodwill [member]"
       }
      }
     },
     "localname": "IntangibleAssetsAndGoodwillMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r11",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestPaidClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for interest paid, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest paid, classified as operating activities",
        "negatedTerseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InterestReceivedClassifiedAsOperatingActivities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from interest received, classified as operating activities."
       }
      },
      "en-us": {
       "role": {
        "label": "Interest received, classified as operating activities",
        "verboseLabel": "Interest received"
       }
      }
     },
     "localname": "InterestReceivedClassifiedAsOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_Inventories": {
     "auth_ref": [
      "r13",
      "r54",
      "r185"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current inventories",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "Inventories",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InventoriesAtFairValueLessCostsToSell": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of inventories carried at fair value less costs to sell. [Refer: At fair value [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Inventories, at fair value less costs to sell",
        "terseLabel": "Inventories fair value costs to sell"
       }
      }
     },
     "localname": "InventoriesAtFairValueLessCostsToSell",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_InventoryWritedown2011": {
     "auth_ref": [
      "r37",
      "r56"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Inventory write-down",
        "verboseLabel": "Raw materials write-offs and scrap"
       }
      }
     },
     "localname": "InventoryWritedown2011",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssueOfEquity": {
     "auth_ref": [
      "r7"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      },
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "verboseLabel": "Issuance of share capital (net of transaction costs)"
       }
      }
     },
     "localname": "IssueOfEquity",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapital": {
     "auth_ref": [
      "r189"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital.",
        "terseLabel": "Issued capital"
       }
      }
     },
     "localname": "IssuedCapital",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_IssuedCapitalMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      },
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Issued capital"
       }
      }
     },
     "localname": "IssuedCapitalMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": {
     "auth_ref": [
      "r128",
      "r129",
      "r180",
      "r213",
      "r215",
      "r236"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than two years."
       }
      },
      "en-us": {
       "role": {
        "label": "2022",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_Liabilities": {
     "auth_ref": [
      "r20",
      "r109",
      "r110",
      "r113",
      "r163",
      "r166"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      },
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_LicencesMember": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of intangible assets representing the right to use certain intangible assets owned by another entity. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Licence [Member]",
        "terseLabel": "Licenses"
       }
      }
     },
     "localname": "LicencesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax"
       }
      }
     },
     "localname": "MajorComponentsOfTaxExpenseIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MajorCustomersAxis": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Major customers [axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MajorCustomersMember": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Customers [member]",
        "terseLabel": "Customers"
       }
      }
     },
     "localname": "MajorCustomersMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MajorOrdinaryShareTransactionsMember": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Share transaction",
        "terseLabel": "Share transaction"
       }
      }
     },
     "localname": "MajorOrdinaryShareTransactionsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_MaturityAxis": {
     "auth_ref": [
      "r22",
      "r122",
      "r128",
      "r129",
      "r148",
      "r156",
      "r171",
      "r172",
      "r174",
      "r180",
      "r193",
      "r213"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      }
     },
     "localname": "MaturityAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_MiscellaneousOtherOperatingExpense": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 7.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating expenses. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Miscellaneous other operating expense",
        "negatedLabel": "Other operating expenses"
       }
      }
     },
     "localname": "MiscellaneousOtherOperatingExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "auth_ref": [
      "r236"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 6.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Miscellaneous other operating income",
        "terseLabel": "Other operating income",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "MiscellaneousOtherOperatingIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NetDeferredTaxAssets": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Net deferred tax assets",
        "terseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "NetDeferredTaxAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      }
     },
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NonadjustingEventsMember": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]"
       }
      }
     },
     "localname": "NonadjustingEventsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesImpactOfShareSplitDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NoncurrentAssets": {
     "auth_ref": [
      "r23",
      "r100",
      "r203"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Total non-current assets",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Assets",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "localname": "NoncurrentAssetsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 7.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets or disposal groups classified as held for sale or as held for distribution to owners. [Refer: Non-current assets or disposal groups classified as held for distribution to owners; Non-current assets or disposal groups classified as held for sale]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current assets or disposal groups classified as held for sale or as held for distribution to owners",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwners",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets held for sale"
       }
      }
     },
     "localname": "NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current contract liabilities",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "NoncurrentContractLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "auth_ref": [
      "r125"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "NoncurrentLeaseLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilities": {
     "auth_ref": [
      "r24",
      "r102",
      "r203"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Liabilities Abstract",
        "terseLabel": "Non-current liabilities"
       }
      }
     },
     "localname": "NoncurrentLiabilitiesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_NoncurrentProvisions": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      },
      "en-us": {
       "role": {
        "label": "Non-current provisions",
        "terseLabel": "Provisions"
       }
      }
     },
     "localname": "NoncurrentProvisions",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "auth_ref": [
      "r21",
      "r128",
      "r129",
      "r180",
      "r213",
      "r215"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      },
      "en-us": {
       "role": {
        "label": "Within one year",
        "terseLabel": "Within one year"
       }
      }
     },
     "localname": "NotLaterThanOneYearMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_NumberOfInstrumentsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of instruments granted in share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of instruments granted in share-based payment arrangement",
        "terseLabel": "Number of RSU awards granted"
       }
      }
     },
     "localname": "NumberOfInstrumentsGrantedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "auth_ref": [
      "r139",
      "r259"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Number of RSU's awarded"
       }
      }
     },
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercisable in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Options exercisable",
        "terseLabel": "Thereof exercisable"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsExercisedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options exercised in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options exercised in share-based payment arrangement",
        "terseLabel": "Number of options exercised"
       }
      }
     },
     "localname": "NumberOfShareOptionsExercisedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of share options granted in a share-based payment arrangement."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of share options granted",
        "verboseLabel": "Number of share options granted"
       }
      }
     },
     "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares authorised",
        "terseLabel": "Number of shares authorized"
       }
      }
     },
     "localname": "NumberOfSharesAuthorised",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_NumberOfSharesIssued": {
     "auth_ref": [
      "r234"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Number of shares issued",
        "verboseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "NumberOfSharesIssued",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ifrs-full_OrdinarySharesMember": {
     "auth_ref": [
      "r65",
      "r241"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Common shares [Member]",
        "terseLabel": "Common shares"
       }
      }
     },
     "localname": "OrdinarySharesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherComprehensiveIncome": {
     "auth_ref": [
      "r6",
      "r32",
      "r36",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncome",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income [abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "auth_ref": [
      "r25",
      "r36"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other comprehensive income, net of tax, exchange differences on translation",
        "terseLabel": "Foreign currency adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherContingentLiabilitiesMember": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for contingent liabilities that the entity does not separately disclose in the same statement or note. [Refer: Contingent liabilities [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other contingent liabilities"
       }
      }
     },
     "localname": "OtherContingentLiabilitiesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_OtherCurrentFinancialAssets": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 5.0,
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial assets",
        "terseLabel": "Other financial assets"
       }
      }
     },
     "localname": "OtherCurrentFinancialAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "auth_ref": [
      "r18",
      "r106"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 1.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current financial liabilities"
       }
      }
     },
     "localname": "OtherCurrentFinancialLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherCurrentPayables": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails": {
       "order": 3.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other current payables",
        "terseLabel": "Miscellaneous liabilities"
       }
      }
     },
     "localname": "OtherCurrentPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherLiabilities": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of liabilities that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Other liabilities",
        "totalLabel": "Total other liabilities (current &amp; non-current)"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentAssets": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current assets that the entity does not separately disclose in the same statement or note. [Refer: Non-current assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other assets.",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherNoncurrentLiabilities": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other non-current liabilities.",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_OtherPropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a class of property, plant and equipment representing property, plant and equipment that the entity does not separately disclose in the same statement or note. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Other property, plant and equipment [Member]",
        "terseLabel": "Other equipment, furniture and fixtures:"
       }
      }
     },
     "localname": "OtherPropertyPlantAndEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ParValuePerShare": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      },
      "en-us": {
       "role": {
        "label": "Par value per share",
        "verboseLabel": "Notional value per share"
       }
      }
     },
     "localname": "ParValuePerShare",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Payables on social security and taxes other than income tax",
        "terseLabel": "Payroll-related taxes and social-security liabilities"
       }
      }
     },
     "localname": "PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      },
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedTerseLabel": "Payments on lease obligations"
       }
      }
     },
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire or redeem entity's shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Payments to acquire or redeem entity's shares",
        "negatedLabel": "Payment on treasury shares"
       }
      }
     },
     "localname": "PaymentsToAcquireOrRedeemEntitysShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PreferenceSharesMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Preferred shares",
        "terseLabel": "Preferred shares"
       }
      }
     },
     "localname": "PreferenceSharesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_PreviouslyStatedMember": {
     "auth_ref": [
      "r4",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information previously stated in the financial statements (ie before retrospective application or retrospective restatement)."
       }
      },
      "en-us": {
       "role": {
        "label": "Previously stated"
       }
      }
     },
     "localname": "PreviouslyStatedMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from government grants, classified as financing activities. [Refer: Government [member]; Government grants]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from government grants, classified as financing activities",
        "verboseLabel": "Government grants"
       }
      }
     },
     "localname": "ProceedsFromGovernmentGrantsClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of bonds, notes and debentures."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issue of bonds, notes and debentures",
        "verboseLabel": "Proceeds from the convertible loan"
       }
      }
     },
     "localname": "ProceedsFromIssueOfBondsNotesAndDebentures",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingOtherEquityInstruments": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing equity instruments that the entity does not separately disclose in the same statement or note."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing other equity instruments",
        "negatedLabel": "Payment on treasury shares"
       }
      }
     },
     "localname": "ProceedsFromIssuingOtherEquityInstruments",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Cash received from issuance of shares",
        "verboseLabel": "Proceeds from the issuance of Shares (net of transaction costs)"
       }
      }
     },
     "localname": "ProceedsFromIssuingShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "auth_ref": [
      "r168",
      "r206"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [axis]"
       }
      }
     },
     "localname": "ProductsAndServicesAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_ProductsAndServicesMember": {
     "auth_ref": [
      "r168",
      "r206"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Products and services [member]",
        "terseLabel": "Products and services"
       }
      }
     },
     "localname": "ProductsAndServicesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProfessionalFeesExpense": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of fees paid or payable for professional services."
       }
      },
      "en-us": {
       "role": {
        "label": "Professional fees expense",
        "negatedLabel": "Legal and other professional services"
       }
      }
     },
     "localname": "ProfessionalFeesExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r31",
      "r84",
      "r94",
      "r96",
      "r163",
      "r164",
      "r203",
      "r218",
      "r221"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss for the period"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "auth_ref": [
      "r145",
      "r182",
      "r183",
      "r216",
      "r217"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "terseLabel": "Loss before income tax",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "ProfitLossBeforeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "auth_ref": [
      "r195",
      "r242"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      },
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "ProfitLossFromOperatingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "auth_ref": [
      "r10",
      "r51"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period."
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipment",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PropertyPlantAndEquipmentMember": {
     "auth_ref": [
      "r52",
      "r196",
      "r209"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Property, plant and equipment [Member]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFixedAssetsPropertyPlantAndEquipmentDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "auth_ref": [
      "r62",
      "r63",
      "r98"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in associate",
        "terseLabel": "Equity interest held"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": {
     "auth_ref": [
      "r62",
      "r63",
      "r97"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in subsidiary",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "ProportionOfOwnershipInterestInSubsidiary",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ifrs-full_PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of intangible assets, classified as investing activities. [Refer: Intangible assets other than goodwill]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets, classified as investing activities",
        "negatedTerseLabel": "Purchase of intangible assets"
       }
      }
     },
     "localname": "PurchaseOfIntangibleAssetsClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "auth_ref": [
      "r198"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      },
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedTerseLabel": "Purchase of property, plant and equipment"
       }
      }
     },
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RangeAxis": {
     "auth_ref": [
      "r115",
      "r136",
      "r174",
      "r204",
      "r205",
      "r260"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RangesMember": {
     "auth_ref": [
      "r115",
      "r136",
      "r174",
      "r204",
      "r205",
      "r260"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Ranges [member]",
        "terseLabel": "Ranges"
       }
      }
     },
     "localname": "RangesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RawMaterials": {
     "auth_ref": [
      "r188",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A classification of current inventory representing the amount of assets to be consumed in the production process or in the rendering of services. [Refer: Inventories]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current raw materials",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "RawMaterials",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RawMaterialsAndConsumablesUsed": {
     "auth_ref": [
      "r38",
      "r182"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails": {
       "order": 2.0,
       "parentTag": "ifrs-full_ExpenseByNature",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of raw materials and consumables used in the production process or in the rendering of services. [Refer: Current raw materials]"
       }
      },
      "en-us": {
       "role": {
        "label": "Raw materials and consumables used",
        "negatedLabel": "Materials",
        "terseLabel": "Materials"
       }
      }
     },
     "localname": "RawMaterialsAndConsumablesUsed",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReceivablesFromTaxesOtherThanIncomeTax": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of receivables from taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity."
       }
      },
      "en-us": {
       "role": {
        "label": "Receivables from taxes other than income tax",
        "terseLabel": "Tax claims"
       }
      }
     },
     "localname": "ReceivablesFromTaxesOtherThanIncomeTax",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RepaymentsOfBondsNotesAndDebentures": {
     "auth_ref": [
      "r253"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow for repayments of bonds, notes and debentures."
       }
      },
      "en-us": {
       "role": {
        "label": "Repayments of bonds, notes and debentures",
        "negatedLabel": "Repayments of convertible loan"
       }
      }
     },
     "localname": "RepaymentsOfBondsNotesAndDebentures",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "auth_ref": [
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      },
      "en-us": {
       "role": {
        "label": "Repayments of borrowings, classified as financing activities",
        "verboseLabel": "Amount paid"
       }
      }
     },
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 4.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      },
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "negatedLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "auth_ref": [
      "r58",
      "r184"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      },
      "en-us": {
       "role": {
        "label": "Currency translation reserve",
        "terseLabel": "Currency translation reserve"
       }
      }
     },
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RestatedMember": {
     "auth_ref": [
      "r4",
      "r90",
      "r91",
      "r92",
      "r173",
      "r237"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the information currently stated in the financial statements. It also represents the standard value for the 'Retrospective application and retrospective restatement' and 'Departure from requirement of IFRS' axes if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Currently stated [member]"
       }
      }
     },
     "localname": "RestatedMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetainedEarnings": {
     "auth_ref": [
      "r189",
      "r190"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 4.0,
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarnings",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RetainedEarningsMember": {
     "auth_ref": [
      "r9",
      "r184"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      },
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis": {
     "auth_ref": [
      "r4",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Retrospective application and retrospective restatement [axis]"
       }
      }
     },
     "localname": "RetrospectiveApplicationAndRetrospectiveRestatementAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "auth_ref": [
      "r117",
      "r118"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      },
      "en-us": {
       "role": {
        "label": "Total revenues",
        "terseLabel": "Revenue",
        "totalLabel": "Total revenues",
        "verboseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "RevenueFromContractsWithCustomers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsRevenueFromContractWithCustomersDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueFromGovernmentGrants": {
     "auth_ref": [
      "r248"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of income recognised in relation to government grants. [Refer: Government grants]"
       }
      },
      "en-us": {
       "role": {
        "label": "Income from government grants",
        "verboseLabel": "Income from release of governmental contract liabilities"
       }
      }
     },
     "localname": "RevenueFromGovernmentGrants",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod": {
     "auth_ref": [
      "r120"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of revenue that was included in the contract liability balance at the beginning of the period. [Refer: Contract liabilities; Revenue from contracts with customers]"
       }
      },
      "en-us": {
       "role": {
        "label": "Revenue that was included in contract liability balance at beginning of period",
        "terseLabel": "Revenue recognized from upfront and milestones payments"
       }
      }
     },
     "localname": "RevenueThatWasIncludedInContractLiabilityBalanceAtBeginningOfPeriod",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSummaryOfUpfrontPaymentsAndRelatedRevenuesRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssets": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 5.0,
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      },
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightofuseAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_RightofuseAssetsMember": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]"
       }
      },
      "en-us": {
       "role": {
        "label": "Right of use-assets",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "RightofuseAssetsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_RiskExposureAssociatedWithInstrumentsSharingCharacteristic": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of risk exposure associated with financial instruments with a shared characteristic that identifies a concentration of risks. [Refer: Financial instruments, class [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Risk exposure associated with instruments sharing characteristic",
        "terseLabel": "Exposure in (foreign) currency"
       }
      }
     },
     "localname": "RiskExposureAssociatedWithInstrumentsSharingCharacteristic",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss": {
       "order": 3.0,
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      },
      "en-us": {
       "role": {
        "label": "Sales and marketing expense",
        "negatedLabel": "Selling and distribution expenses"
       }
      }
     },
     "localname": "SalesAndMarketingExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfOperationsAndOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_ShareIssueRelatedCost": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of cost related to the issuance of shares."
       }
      },
      "en-us": {
       "role": {
        "label": "Share issue related cost",
        "terseLabel": "Offering costs for legal, accounting, printing and registration fees"
       }
      }
     },
     "localname": "ShareIssueRelatedCost",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesAtMarketOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_ShorttermEmployeeBenefitsExpense": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services."
       }
      },
      "en-us": {
       "role": {
        "label": "Short-term employee benefits expense",
        "terseLabel": "Salary and salary-related expenses",
        "verboseLabel": "Salary and salary-related expenses"
       }
      }
     },
     "localname": "ShorttermEmployeeBenefitsExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsCostOfSalesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsResearchAndDevelopmentExpensesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsSellingAndDistributionExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Condensed Consolidated Statements of Changes in Shareholders' Equity"
       }
      }
     },
     "localname": "StatementOfChangesInEquityAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "Statement of changes in equity"
       }
      }
     },
     "localname": "StatementOfChangesInEquityLineItems",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      },
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      }
     },
     "localname": "StatementOfChangesInEquityTable",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interim Condensed Consolidated Statements of Financial Position"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TopOfRangeMember": {
     "auth_ref": [
      "r115",
      "r136",
      "r174",
      "r204",
      "r205",
      "r260"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      },
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "TopOfRangeMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 3.0,
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Trade and other payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayables",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other payables."
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesAbstract",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "auth_ref": [
      "r186",
      "r240"
     ],
     "calculation": {
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails": {
       "order": 1.0,
       "parentTag": "ifrs-full_TradeAndOtherCurrentPayables",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      },
      "en-us": {
       "role": {
        "label": "Current trade payables",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureTradeAndOtherPayablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of assets into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers into Level 3 of fair value hierarchy, assets",
        "terseLabel": "Transfers into Level 3, Assets"
       }
      }
     },
     "localname": "TransfersIntoLevel3OfFairValueHierarchyAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersIntoLevel3OfFairValueHierarchyLiabilities": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of liabilities into Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers into Level 3 of fair value hierarchy, liabilities",
        "terseLabel": "Transfers into Level 3, Liabilities"
       }
      }
     },
     "localname": "TransfersIntoLevel3OfFairValueHierarchyLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 1 into Level 2 of fair value hierarchy, assets held at end of reporting period",
        "terseLabel": "Transfer from Level 1 to Level 2, Assets"
       }
      }
     },
     "localname": "TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers out of Level 1 and into Level 2 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 1 into Level 2 of fair value hierarchy, liabilities held at end of reporting period",
        "terseLabel": "Transfer from Level 1 to Level 2, Liabilities"
       }
      }
     },
     "localname": "TransfersOutOfLevel1IntoLevel2OfFairValueHierarchyLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of assets held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 2 into Level 1 of fair value hierarchy, assets held at end of reporting period",
        "terseLabel": "Transfer from Level 2 to Level 1, Assets"
       }
      }
     },
     "localname": "TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers out of Level 2 and into Level 1 of the fair value hierarchy of liabilities held at the end of the reporting period. [Refer: Level 1 of fair value hierarchy [member]; Level 2 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 2 into Level 1 of fair value hierarchy, liabilities held at end of reporting period",
        "terseLabel": "Transfer from Level 2 to Level 1, Liabilities"
       }
      }
     },
     "localname": "TransfersOutOfLevel2IntoLevel1OfFairValueHierarchyLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyAssets": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of assets out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 3 of fair value hierarchy, assets",
        "terseLabel": "Transfers out of Level 3, Assets"
       }
      }
     },
     "localname": "TransfersOutOfLevel3OfFairValueHierarchyAssets",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TransfersOutOfLevel3OfFairValueHierarchyLiabilities": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of transfers of liabilities out of Level 3 of the fair value hierarchy. [Refer: Level 3 of fair value hierarchy [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Transfers out of Level 3 of fair value hierarchy, liabilities",
        "terseLabel": "Transfers out of Level 3, Liabilities"
       }
      }
     },
     "localname": "TransfersOutOfLevel3OfFairValueHierarchyLiabilities",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureFinancialAssetsAndFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TravelExpense": {
     "auth_ref": [
      "r236"
     ],
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "The amount of expense arising from travel."
       }
      },
      "en-us": {
       "role": {
        "label": "Travel expense",
        "terseLabel": "Travel expenses"
       }
      }
     },
     "localname": "TravelExpense",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGeneralAndAdministrativeExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasuryShares": {
     "auth_ref": [
      "r64",
      "r189"
     ],
     "calculation": {
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition": {
       "order": 2.0,
       "parentTag": "ifrs-full_Equity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en": {
       "role": {
        "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury shares.",
        "negatedLabel": "Treasury Shares"
       }
      }
     },
     "localname": "TreasuryShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfFinancialPosition"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ifrs-full_TreasurySharesMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      },
      "en-us": {
       "role": {
        "label": "Treasury share",
        "terseLabel": "Treasury share"
       }
      }
     },
     "localname": "TreasurySharesMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/StatementInterimCondensedConsolidatedStatementsOfChangesInShareholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfContractsAxis": {
     "auth_ref": [
      "r208",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of contracts [axis]"
       }
      }
     },
     "localname": "TypesOfContractsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfContractsMember": {
     "auth_ref": [
      "r208",
      "r219"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of contracts [member]"
       }
      }
     },
     "localname": "TypesOfContractsMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureOtherLiabilitiesAndProvisionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfRisksAxis": {
     "auth_ref": [
      "r147",
      "r149",
      "r150",
      "r175",
      "r176",
      "r177",
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of risks [axis]"
       }
      }
     },
     "localname": "TypesOfRisksAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_TypesOfRisksMember": {
     "auth_ref": [
      "r147",
      "r149",
      "r150",
      "r175",
      "r176",
      "r177",
      "r179"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      },
      "en-us": {
       "role": {
        "label": "Risks [member]"
       }
      }
     },
     "localname": "TypesOfRisksMember",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      },
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      }
     },
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureIssuedCapitalAndReservesOverviewAndGeneralRemarksDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsEquitySettledProgramsDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsExpensesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average exercise price of share options exercised in share-based payment arrangement",
        "terseLabel": "Average share price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageSharePrice2019": {
     "auth_ref": [
      "r135"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The weighted average share price. [Refer: Weighted average [member]]"
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average share price",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "WeightedAverageSharePrice2019",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ifrs-full_WeightedAverageShares": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      },
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding",
        "terseLabel": "Weighted number of shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageShares",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full",
     "presentation": [
      "http://www.curevac.com/role/DisclosureEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_ChiefOperatingOfficerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Chief Operating Officer",
        "terseLabel": "Chief Operating Officer"
       }
      }
     },
     "localname": "ChiefOperatingOfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails",
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureDisclosureOfFinancialInstrumentsAndRiskManagementForeignCurrencyRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureInventoriesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsAdditionalInformationDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsOtherOperatingIncomeDetails",
      "http://www.curevac.com/role/DisclosurePrepaidExpensesAndOtherAssetsCurrentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsContractBalancesDetails",
      "http://www.curevac.com/role/DisclosureNotesToConsolidatedStatementsOfOperationsGrantsWithGovernmentAgenciesAndSimilarBodiesDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.curevac.com/role/DisclosureCorporateInformationDetails",
      "http://www.curevac.com/role/DisclosureRelatedPartyDisclosuresDetails",
      "http://www.curevac.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r1": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r10": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r100": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Clause": "ix",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r110": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "14",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r120": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "116",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "120",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "C8",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_C8_a&doctype=Appendix&subtype=C",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r130": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r140": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "51",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_51_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B64",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "3",
   "Paragraph": "B67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "5",
   "Section": "Presentation and disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS05_g30-42__IFRS05_g30-42_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_j&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r150": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B8",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B8_c&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Defined terms",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA__IFRS07_APPA_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r160": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A__IFRS07_g3-5A_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r170": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_m&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r180": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r183": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r184": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r185": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r186": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r187": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r188": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r189": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r19": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r190": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r191": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "22",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r192": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r193": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "19",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r194": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "21",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_21_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r195": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r196": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r197": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "88",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_88&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r198": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r199": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r2": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "104",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r20": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r200": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r201": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r202": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r203": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r204": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r205": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "13",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r206": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r207": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r208": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "15",
   "Paragraph": "B89",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r209": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "16",
   "Paragraph": "53",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r21": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r210": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r211": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "IG23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_IG23&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r212": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r213": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r214": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r215": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r216": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r217": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r218": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r219": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r22": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r220": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective 2023-01-01",
   "Number": "17",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r221": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Effective on first application of IFRS 9",
   "Number": "4",
   "Paragraph": "39L",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r222": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r223": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r224": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r225": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r226": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r227": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r228": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r229": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r23": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r230": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r231": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r232": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r233": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r234": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r235": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r236": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r237": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "20",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_20_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r238": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r239": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r24": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r240": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r241": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r242": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r243": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r244": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r245": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r246": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "37",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r247": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "20",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r248": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "20",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=20&code=ifrs-tx-2022-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r249": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r25": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r250": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r251": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r252": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "14",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r253": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r254": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r255": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r256": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r257": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r258": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r259": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "2",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r26": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r260": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "7",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r261": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Effective 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r262": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Note": "Expiry date 2023-01-01",
   "Number": "1",
   "Paragraph": "117",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r263": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "37",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r264": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Note": "Expiry date 2023-01-01",
   "Number": "7",
   "Paragraph": "IG29",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r27": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r30": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r40": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "10",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS10_g17-22_IAS10_g17-22_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Paragraph": "81",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "12",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS12_g79-88__IAS12_g79-88_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Clause": "v",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_v&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r50": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_viii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "73",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "16",
   "Paragraph": "75",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Paragraph": "36",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "2",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS02_g36-39__IAS02_g36-39_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "21",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r60": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "24",
   "Section": "Disclosures",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS24_g13-24__IAS24_g13-24_TI",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Clause": "viii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "26",
   "Paragraph": "35",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "16",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "27",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "32",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "33",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "36",
   "Paragraph": "130",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_d_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Clause": "iii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r70": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "86",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_86&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "37",
   "Paragraph": "88",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_88&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Clause": "vi",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vi&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Clause": "vii",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "118",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r80": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "38",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "40",
   "Paragraph": "79",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "41",
   "Paragraph": "54",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r88": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r89": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "7",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r9": {
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "1",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r90": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "28",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_f_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r91": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "29",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_29_c_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r92": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IAS",
   "Number": "8",
   "Paragraph": "49",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_49_b_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r93": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r94": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r95": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r96": {
   "Clause": "ii",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "1",
   "Paragraph": "32",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r97": {
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "19B",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_c&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r98": {
   "Clause": "iv",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "21",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r99": {
   "Clause": "i",
   "IssueDate": "2022-03-24",
   "Name": "IFRS",
   "Number": "12",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2022-03-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0001410578-23-001985-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001410578-23-001985-xbrl.zip
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M_J2#?<.N2/=\&F 3[S:&=_"FYP/E/5/Z&$Q;#*(=;.BP9N^'OW'X]0#]0L,
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MM(I65LM[OL%U71P"HV^><4DE/A7"1T/W;\<D.J57*2"/)I'3[)6V>A\EOT1
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M'5K;Q6'H[T"[DPZS)>TWT_+U.C^)VGS"+#:]X4V4%B7JLR4<=U_VI0&?)0^
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M,_M%<:A^.L*1DOZ"+LG?_@]02P,$%     @ V(,15WO5Y>CY#@  6>,  !4
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M^T;L?]#V/.Q,Q/;=]CEV',^&ZM;63E6KMJJZ/;,O#A0)23A-$3H@6=7E7[\
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MZZ##-[<0W 4"!Z.%->+Z4-(4J:]#S3U:QI3O ,3I+'Z"2<J7'+/X/GM,4(@
MT4W=IA4H[-^F"K^DMW=GI,JP9@C1EE3(RZAL!X-# ]5B:SX=# 'FN.I]WPB/
MKQU]&^'$7/QT%\'NUU9.;96K<VU1U6K5J+!GLA*QJEW$2\LHU_+*4ETLZ6V4
MARUX<['2-\"RO_)78NC#%9FO$-1+=#FAY,!'1MHCVW+7FX34D/6N7%XZ\6$]
M \.ZFB0,[\Z>Y(QZ/ZGLIR!E/BMYIEW["DPF&(,J_)*>@F'-9*,MJ9"74=DN
M)QYSU6)K/EU.0EI<]:G("(^O'?T.!ML=[BR%:_6"44BM,$DIO>="T/12";V-
M(#KMD3JU8$-6''0Z">OU'J9@>?@@C6T6HUJ60W&DAI16&+2@I!X,'ESNLR"-
MT9#2BN&IJ%O%8)B(&1LP,6C@A8+I,OI"R6Q?J=^,0_BDQ.+]@I+<02B?8AMD
M5T7+4+ZNMDTFZK .YW.UI5* L0_IZ[_/Z*XD[-/(>TA_5Q.JM<MM_Y!*SVN7
M%JRYJB!N=GC;E%Q9$+/GZ]J_FM'\"3$)&+J+Z_0F6_C#$GZ)@K^LLF-2L_X7
M4BO$(*7O<C<N50HV8L7EAGN?]?KJ7\KR?K_ZV]L],5[3C_DO]>\*WFK0GI^?
MWP09@;0;OPGP^BV'=8$#?E.\_)<E\^=G1;-X@<F:QW2]JFD*?D]A',)P#_^[
M=^]^?C=Y/2DKJOX)XK#(43>I5[N.XJ3&WU;\']Z]^\C!/H($OMH:4>,$-2%$
M^9Z _K';#M /?Y1<5CA[ (\1W.L;:M*W?7*8BVX:A@3RG$3Y'VSQ(!C,3 IL
MN>WV=NB*EB1!]@A?;SM+U82KO=M$\*Q;FZ#9Z]>]JJ+2N'"%(:'I2>"5,:EH
M2"YM,R,J92[ ,*28S[($Q;1]=@9&E[C"R4I!UY>XN21>KXM6Y+*66DDI7@G?
M0XI8T/OHQ &Y\\ELZ*N0]R1P$$66 \@!A%+B\L%F?UE F0G37P*J&3K3749\
MK_7KJR1W5.Q^CW "PU]?I23K>_@O66?FI-!,_O.@IO^A&YWDG&\(PH0.45S5
M+GK"'5RBI'A#=.NZ4@A<0C^H!CYVHP$)%.<JF<9Q!J([N,%$I8DZV: *^*$;
M!=01.)<[]RUQR6EE?T@ZJ/Q_[&@(.D#A7 ?W*QA%YWB] ?&+5@LBXD'U\%,W
M>A#A<*:)?,E<CHUQRGQ>TMW6/MF@TO]+.^F+$3CO ;>0<A!>QN$%G9$4QK]'
M-ZCD_]J-W>]!<&SR[#$;PC(C;]<#_!H2>3G'H;P':$H-JI:?N^@0&D".E51L
M,HM_&)3W4M4(:8?=);_K0B-"'-[IX8.%'CX,K8>6^V@%#C_T<$[_G),'_"QR
MS4DIA]5!RWVS%(4?&N CY3P_SX@#^7PA(Q]6%RUWT&HH?BBDF+6T_:$D&U8!
M+7?08@A^"/X6)RF(_A_:*-=-8N)AE=!R&ZT"XDP5;&1D;S-+A%__>5AQM]PM
MUUEW)N!K6D=TN\(Q_)Q)#F@.2885=,N-\2'[[JPY/RJB&\4$QS&,),X(,=FP
M0F^Y)Q9#<"AX/J<P[P@6K2GW?A]6U"WWN7N\>V/<EQ1L5$PG!D9>)Q_V"*SE
MOE8-Q9E"[F&0L8;??WA\8/$] B4<D@PK^)8;V4/VG0G[@8 0Q<O[E_4CC@22
MWOM]6#&WW*ON\>[<H"^_!RL602V9/L5DPTJ\Y8Y4#,'QAN@*1?)%XB')L +O
M9 =:9=^QL'^'4?0?,7Z.[R&@LPH,9TF2*20OI1]6#9WL0:58'.LD?\HOS<\T
MV8"8@C23QV[*R(?52,MMJAJ*!R,2*9[6EKO&]JB&%7\GI[I[")R?+*:0)>E'
M3_ "I*"P#<61HIA\6#VTW,^JH3A6R.4:DB7ME9\(?DY71>2%5!\2ZF'5T<G9
MK@2):VU\WP4BY2$!<E4(2(<-/>SD1%<$PWG@R30(F&,DGZSB$!"1&E3$PRJB
MH]!H$1#'_:$:#B;M"76B847?R4EN'8#KA2I>KUFT"PZ^W:\ @<D\2Q-F#]0N
MY,M59:%A5=+)@:X:D#L_:;YJN$)) *+_@H#(@^/DI,.JH^7F6@[#^2RQX^F*
M?J.Z-'- .:P*.HJ1/D#AB0;R98.9#FJTPVJAHPAI 0[7,P9D#Z]%LSB$W_\#
MRN?I [IAY=_);OH @S/93RGC(3>("(@FYKW?AY5URQWS'N_.9#P+%F2:A8C6
M,TU32!< K%F)P%7$PTJ_Y099!<2]N5_ )""(-ZJR^AK9L#?"6NZ+Q1 <C_%?
M<42WAH#D[D2YW_J ;EC1=Q+<?(#!L>QOL\<(!5<1!G)':8UF6)EWL@6N\>]N
MD,E'/<G9<.W7867<<D];X]RU=*\06<]$#K6]WX>5<,MMZA[OKF7,XA9E,^0^
MQ;!R;KD7/>!>+^F_O>TP7=+V<CP_SD'K<TQW G$"0_I'@B,4LK?QMD0LW3^/
MP6 O=# WT@I'5 S)Y3\RRO*KFHRE:94^OF-IE;9UTK^+MB?;QB?5UG>DR00O
M)@4#$Q1/JBS\S\F6B?Z3,'7\[D^)KR+='(PH;Y-%N18]L^MLS2G!R0;RT\+I
M9D.GQO)QQ=I/=WQQ+DMAVD%][A-%6:M]/Q5T0^3=#=I=FP9G--3F[ZZ3.4Y
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MESFPV\U7-BA'T=6X9ZST9ZJ=?SLJEYFT.^A>>VC&H:>]D[6'%<'9<G7Y'9(
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M3':?(KIF2=8H77VCQ(I8- FAR[",1L:TG=0D@$[G_Z?S_][/_\_QFJUF^=J
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MU*QNDU4GU8,U/:Q9=1=X,IB 7*0C*Q[6^!.&%QE\P.>0I%2:[&XXH9/B.=B
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M[O_.?Z[R61RP("5X]J)[6TE38"2>80V*_E.8$;IE2.%M! +N%)LE0/T>GJ;
M2!S%&A3]CR9,-""J^ZGIC+[/ER( V[(&YR\L&$9D6\+J75.7W^G$AA*6!X%
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MQ+\3LD[,U:E,!XCSYL"8%).M9(H]6EH!AN)G!FS)@&&2%,!( 2Q$88S3?^3
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MUOG)X4J)20+C\!E%HJ=PFE3@ZQLYVC5B$["^ZEO!N&92-BCIS;5I6ZNN:]D
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M./:I,(UCK"LVY/@)DGA=;LVUGO)#>N?.GC8CG0Q4_P-=EB8IB%F.Q%G\A%$
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M7(\";(W2$_SM;2X^E-_I__?_#U!+ P04    " #8@Q%7*H3#8=*;  !.YPD
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M!$\#SS7+.Q"5O $7_M;B["YV(=_Q88-;[Q7FH2LY&W!1PN\N*5_3)#1X@)I
M3>#4JS=2]QRHAB*,,.^*/=(8(,G@';%=?)"AJQCT'#X-H.J4B&A51$+>,!@9
MMLS$T+(VU8GU3QM"S*@4)*IHCT?<ZB,E;R(J[*99 1B2<?*<..W$<=P**3!V
MB-60>I,W01VA-',Z*BFE3%=T5Q30OECBP74NF3A2S--N2O^#C4C/%QN1?IQF
M^'SQZ&+!PU,2'[9/5U]IXK.4JVHMDOWUFY$]".#WX)[*:+]NHNN-V^_["C%J
MVDH)D^EJW#VH&D)LC8A!G*7ES:6#JQ.1!VT\Z!8M-,M"M<%Z$H^L7KPD2&6
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M-%BE?Z9A -&R%])U4OR3M\\2]G@  WV(UR\1UV@WXL_("6:T=/OS:*+=N=C
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M&4R)A].J18LG;8I !2G'96&.XKQ;[[7/.LN<VL)@IJ>:V@#'D-2"H*>O1+9
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M*$XHME%:XEP_<_9$:W++0<@;J"S(_\G#NR@%U(?:X_".X[<6[Z<H3BHBB@O
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MU])83&S00Q3;SG7D3.@"!X>J61;N7'E)Q*)M>DL34:.I<X7=T@$]EG0)>_2
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M'U(R-'/97"?:LJ"6B=*A/_#%PTU&=XW9E*8=,2-'+^&-4J.+7MB1H9\0@XO
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M2&U+UQNX.4^#VGVNIHF@-P6D.#)"'46(WZ\[]K!\H#26,O02&)UD<64/OF
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M2P!=%$*T-O1W\3>5!+A#UH-ZM<$S8"\SG*_M-*J"9JE^"(:OTTHI0 G$OB&
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MW/0+@]O9>J?*Q@G!Z2);4=TYB]_S>_]IEK[$&]P:7ENO-E#"&VB&\]TIC:K
M=Z+Z(!B^ZBFD7+'WM0$5)&?R4+R5H;)0%M-UHLM@U)9-435#JP5&^"\7-/=(
MUVFYP[:)PVT33^I4 CJL^X$N?)G.&M#]&7T 8WP:=LA5\<)3VJYJKK/LS4R/
MO\F'N4*/;*.&680+0DR2 \?&&OK:3XP^2+9#7E.O,+I)7A!F4UQ[51G(_*2"
M5-FCKA> SCY*?8=VM\>?%[;WA TCJ,[SO[\,#G7?/2CN902"#E258C,9&N?
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M52UFH\&HQ:=J+B0$,KH8_6@1![ZAR,\R.TBR@5?!&EXHX<RBAY*$@]FUD F
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M]^["M+191>.,H&%K1@_UU:ENM10D-9474ML3D.G\>PF"M4]31A'I+SR,7ZF
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M4I'/2R^(QE<_5R B^E2+<?NX_P9[VO2[]'72T2IOG/RZ:-^9>+9'@)=T<KE
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MNS/X@661VHT>"^M:(^7ZHJ"!LK[BC;[R5R"2DKY@]$+T-:?J0J1SF;IPKJX
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MB_S.K'%8A6ER]0]U)KLVH0!^IA:#G[.&HAT0ZQ"L%FC9_EQR#'EJ\D)P:PR
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MFT3/I'2>S)=LW\#+)5[/QZM5"+/&R<*;6 0%OA^@-P,=!5UIUL!+Q8<?&P_
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M'+]U)^]: )Y[X TM4#A&D]ASN?"M@K,MUZH2D<?EQ>=;=TH&;\0?N^52DY>
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M\OYT^X$,AP/4*\8K$0SMC5M3-).PB&;H3']D.#CK?B ;R[6_VN+CK!L9-&&
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M=!G/.1$VQ2=.G7&>O:;_L0>">A[ ]XP%TI<GF$>#O/Q\B>*AFISS,A5' +1
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MVF!PP*2CR*CKZV3V7.RHGL3\[L;J^P#_%_+XIC3."5.CF\E266IE9S8;R/_
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M]UE^LNDAKM$=#;S=)B^R&Z<MDM$^5WAVU-BNY3J:(U=U+"=;>G[>%JEHRY'
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M=J1&@?Z$/\*Z*P(\+RF'YR7OUU",@%T815\A$3L+L;/P<YR%Q/X_,NB_&%P
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MV*T&?!!X"WPX*ACE-W9 ](UP1.%\H&S<F>8 ZP*8Q18\-E<LV(D1/,X'?*G
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MM04Q(CY/^EF-N7/>3?#@4;#>C@*<-O"HJ#BN8@ANV(<9Z!Y+LH-)&X*4,*?
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MZHS+P*(4*((E*82X3BVV& T/@89(Z^N/@H$I%E/,M+8J,YZO8I4U4?*,30>
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MB"A'X++,97F@Z@4RBTA3*8-E"!S.@=\_ 01,:^F*78.5ZBPID,*,,XWQ!NO
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MYDY",D1)3)R_&1-=[G@=KCJ[!E<$S078" V<X#MFHYZR_A,FBL5K9 $4]45
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M+7!S874S7>@\NVT4^BJFBSB3=O/4#)M=#S<=J\HO*#,W98=#G>PV-DZ%Z]
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M7:E9:L91T%G"@2H\+1H3;S_%VT^/XE1]$3PCWS<]'>U-D4V_7K-&9 <L2@>
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M[:?EPT@QX&N<7ZF7K1(Q]/\4$?SPWV=-(S!PN&"*N,U"E85$3'0!YIB89GK
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MS_VI7'[LL/OZD./3_?8VL]S7LZ8'IX,*F]&GG7N_H=.W8O&&8_L5KDR_<I0
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MD*M?19\ED OC^%#$6SY9D9-]KBGVPO>'.4GXDB1<@0HQ\7=^T/HWW#DIB!9
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M;ENOL^I4[G6?%4$]H(3DYQ).9LB9)(+Y+)V1<C.:!IE9EA"R.,^GTG3VA *
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MV]U4O50RK_:'<IE;M[6<LT0)U6G4>>CT]EF4Q>NGSQ'W.D*&&W47E;?D?>I
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MSCG ;.! 5A#1%VRTK?Y[7GPC[W]T;%V'H$$FK@J%FQ7RNP(2MGI]NB7(/L6
M7"N/"_OR>M*2WT)"T@8"0@-J3&L#XV-08+;HY?;7P-#?[U=Y<TURQ:%&UIFZ
M,QV8W;_^,<P3'$"20](C%CP"XB@*#T" '/X?R,+/>-7/=O*9&!SG^( -T- ^
M^_31#?B'.$A2,G6](JQ_HH4!.R<'55LI,8U<O2EWAQ+C#2ZNA?^$46H[5R9
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MB<;2MB7E02&_8$8,7=Y6L\UA1X*B,45^S,9X7'O0J2!"$C)(0?M98O(M3@5
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M',3N058K/&.B.M3@>'ZUT1L\N OHOR>]=S$]\))"(\$(3C]$^I@$</KR*UH
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M)$0- ]KNGGR._Q&QP#=.\CCP#$]JXY,3W(X(UUV56(/]0B< [\/Z 9(=U,D
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M+W6E)H*WW7V$!:- L*+42P=%]=PR(H"J16P.+"U3V6Q@&KQ7=>L&!"G,&Z+
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M#OJ^ZPNS&ZYXWZ%"H9C4^5VF-3-Y]Y IK;K+A#DFEEK(++^?>_2+IJ@LL6*
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M( +*/@D&0-E'MK&E6W(9I=T9BGPE2.O'8?\S-V07_[.R-]H__Q]02P,$%
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M$_7-T^6G '4HJ>R%+PQNB$I1HP#@]-,05/;3I95,R8Y 3X.(82UPQ3]&6CS
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MN&3K^;:= K0L.&3N:GV5LW(9.8)8<FO?'$#,XI#3L [+LO;?0<7MV^V'N(T
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MP"4(:&DDT.^\9_74)P]E6QW<&,D/'5KT!"OOPS&2%.!.+O1W4MORO4F5P<:
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ML5;PY:C/"^>.Y]*0G3_\-ED2.\*EDLC</V9T!Z+UGY(Z%67JOP!02P,$%
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M CAR%@#$)PLF/H!FA#@4C68++K/KG9? 89W;S=0HIMM 7E!F&0JBRTA=P7V
M:"HG4RML&!1SP%^_VE%9P-<>@%G+ -QN7@[^E@>R*/^2B\P+5888BAC4]=X"
M@_!&00BHFGMT)UX8E+FB+<+'R*$$)7P4<H3(L 2RNR <X\WRT>I;9/F+8,\
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MH\6%.<4D.F%#TP  G@*4@0U]\1T=S!L">X0WL'J#GSLLC7; ZUVA_3I0\%I
M],L "'X0*P.%:^'EUTZC?]C$%?QF@@2'?P PRI@W'DQ1D44-0)!HWI7K)7$A
MW#6\$7FXOEH0&(#N  ]X) 2-.QBD!)J<$1 (/2G5_ ,!D4>7+$_8?,2+2N=L
MR.(5\*L4T+9PM:<0*3>.#1X#)9?(6Q"'B*^6TREP@@"057!#1!TQ+KH?E0%
M*X2PY$VHKTA&P+B #^#?SP%0+)5_#B;3$^\MB*%D&'BOZ1BO4B!@\QH\P# +
MKI#7H:JBR5Y3A M4L2&;]^R;2_9AFR-%9@[P<>0RR,]@(90?,0H Y*JP?4!8
M6 '^4:C06!,">% Q58%<A"&N=P#&?2N>:+T_#V%5(B#DA79I!E*&"@3#$>^
M[RC[HA +0C4MF/-6&%"3!;HL2\U%W&@D"*Z&U17T3HWHQ35AM\@U1R5*"A=M
M\)?#K+Q 89;3_G(Y0 R@ /!<*J#S&#Y%V+F,"H283Q_6N!1?*Y"E!R+^ EAR
M#M\I?M*<C']=.<.%2H#'QQYPC"2=1"&P75#E"UP9+WR"R#B%O=#Z6L^RRI7!
M]3\3,NY(O14KHT14$/8.*COK<&4"YT66I&\(D4G>[2Y+%PWV HAX)%V0:K%E
MJF1"@OY#-V^M0_CY"-3S KZ_3.-+_-U'M%(#>N+/+QG:7 @D!+_5&6N(@)*7
MZ)B^N,C2JP*U'7S5Q:P-;:9*T ^WCPCC+J_APS*G\7.59$ $'FB8$7$.32H-
M&40<D_DY_QA@^5\@N&B$6@*07)XFB8H-+)QW9(IX-)..?M!W>;;#?X07DGW8
M?KF^W*P<N4Q@BRC2RB('[1'W)=\[1F+P%76FHE7U 'PG:44W. :E2M&KIVG.
MZ@\8>X"'49A[CS52G+W__.9%IW?\Q-<6@ ']J I]H@I242X#$*-E+G^);HCN
M D4?@ Z+:ES(VA<8ENXGMW8@^%;!"T!/%-QH,5)\+X[^6T9#S4I:[96N][ER
MB#GJK_LZK;P2U9#6TK(NJNG6Q>.1/,>#YN)'@$O0Z]S$I4 *,:@2Y+7"_[J:
M%&ZFXE3HFG<,4U@4;X",!T4Z=3J(M4T(BY539,>XCUPMLE168V+_F<2DQ^ =
M7:'LAI\!+1>,6H*MN)[S2*;@]C,2>7%L42^_/>HAG,0<%,!J6U VH;]D=TK=
MNKQJF+: N2T?Y6V?J?A2-;XH<V<#VA9%S2CG\^*&:[;6!=,F(1TB#$I+H)$
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MX04L83,]Q=+-9'0J7+S,/P?-#KT#%:6NTN=.NP^,@J</DGC[1W7Q#?JF@ $
MG( 6',]HWEGO)"P!7@J3XN## (Q1;'P.3"2%'X0S4JS#( ,11=_DP*JQ.S\[
MX<T7Q!N^1)+>MN A,&M8,B4J_$)D]-N[\[,SZG< 7W-E5T]7JFC%A[D. Y?;
M?Y%4-VVG4,G2*J/N3"@)Q$XR+@HT@JH+&0YZ2767/!B&:384R_VC_O2E))EA
M[Q%=T0(ZQSE!]I- ]N/+LS?GGWROU^6*&ETW #SG"B>(VI>3,SM2$GBCEOUV
M%N#(DXG2DG1H6[8A\KAXI:&!$* O,S7*:!#PS-RG 4WUG=><FT[2=A#*<;OM
M.=Z[TV7<B47P E) >5Y"CMJ96XHLAFLMBN[TGY8D9*-_>%A-4KI."57S+S<2
M2,4HL=F6I%Z :83QD'@Z#H2PS8<7P602=+USQ;GKQ&1P<FD>:0W;L7$,Q.R<
M)6(LNH$7R(HHUM6IJ.54.2TU[.XX95B6G7,80ONAFHQO55K&FUK/E[K!DSA9
ME&)$5;LPT"QR $LVJ73/X-QP9TA]=7H0,4%T07H'V#[>25P'4.[MU.E?.Y0U
MM=1PM.=TV:U,/IHS#< >B<Z@&9N4OMO).NX*9O_4/D<S-;EX:7>(O72=O=-T
M5+50S'1<,>/#R<G9>C6&C7*=*KH"E2WYH)^=??KCM+-7D4^F=:)9MHT!47/'
MM&QL]''O\*<GM^8\'VWCY.E4D<-B6-*X(M+IN>D=\CXL/'.:T^@VMG1 ;B_S
M#I7ROR4B91U@!(HZS'O. ;3'M4T&[=\6IJ?7LC:-^;JP0O"ZHF=0@J>]"G-8
MM^3#*@Z^41>U!8D9RJ*^.AO1L*EV::[WA6!N1US)94J1S!GCN0Z8 *3A:*I$
ME!VJ(36JS,JN882^,S>+LH8Z.FW(*K5(X!H)C\ <<('%=V8&9LA3/7B,+@FD
M9QMB/^&#HX28!C2XEQC\3,>,5L1:7]'P0.:2VF->=UQB(T[LC40N#[* W6%O
M>$]3A6.CJ3T1/*+'WIE&](@XXR >:4\3=1PEX4KZ^C3 ^JIJ,0[6H9('SQ92
MM#!GW$R<H@9=39:ADA [,HL&/>6UGAZ51B::F7);9S3CN0TH%[6\<1??QH\?
M1/SXC1::"?[(^&9-189T\;/MBFVP@/QEE.S3XO)N.HS:$J"I HY;8M:,6ULL
M9!UB9!OKU!7M5NX UFO7DM50\T(:^@D%F>@PA;*LI5W-<K7))>0OYU9P2 _<
M:(Z"5[IRT%UH<8MINPL[.3TQ(4=F+BB5T<=4!94;>O8YT/J5V*@O/<[,!IJP
MP#ZS24AYE('))EN8U[.6TU3>FGGGG[3#<:4E@/7YZY$D8K4/D.6Y?'I8$F>S
MCJ)!EJ)B('+C?T6, )K\ID#ZLV\QTMV?.!>16TY\J*9NU-?+W="$B?:C-[@D
ME)1<)/(JX(O"&9C[24DLRAN1$0SJ %ENXFEX9?ZD;"/TNJ&OR'ASB0=@WJ[\
MVAP2_44#L/1SVSW=0DA:"5$#7 2\GL;J3#$T:I.N,>=6"JZJ2+ALPC6XUU/M
M&Q*UKC)T%,OZD8CI05UFJT,(BLHAW;@E:"Y4D,C' 8VIS&;NP+Q&-X4Y(R4_
MOGS^YN.GWSH?952U=T9^6"Y!PF@!6]QP/Q^5#H6!HJ>[J](.7R@T #0O>1U@
M=)I6$;GMH T^_C(9IF$6Z:(G]@#^AFG+>)2W4NUY'H[3-/;M%X^E41DV?R]T
MYTUW!E!C.F=U #(IN4ZS1^D(6HN=<)G]4*Y!!_/-C36QFK+JHBP;XU_?B45A
M?JB=W\LZ(CF &85K5>]S;AX C)B=>R]GRC/7;^:)WN51*CNO5(U@'TZ^@6?C
M: AGA0?(C[E[8BHJ[FP;3?[M5ID .Q@NX*V_ Q=Y15PD]TXY$Q*0"@,O'T5?
M!]QX/]7IU2O*&L9>7[&D YG9!MB5QS(/X86 N>84B"69/45J3J%;%SU;_2T<
M=W?WZ8P&59GU6#WFY=<IQ>!6%X+3S 0#L)Q<SK,6IP!+12I9E@[0;52O_+0%
MU=C-05*+=3";AE4VHK.4C3Q0DH3('8M$RE4O5KJ_2P&_\P)VH]"^=5:'Q'>K
M.G1-5VS9B]$;Z^>B+!?>*#=.L9Y2<J1A?(_4DV%*>5)?DO3*NQI+]84RAS23
MN5VH:CAAIKONW%MM-D %#"W[I<:[F>(XCR4,[FJBSPG? _A"3#2Z9'4:Y5F"
MC9'0]\59TMQ;F?L2AFFF3 *H8Z5P/5 J$P2Q8IV+['/ A$"Z6>D7Y[9!$L@<
MTO*YG2ZVD:(@G^0S*'J#.W-8QMW%,\<F,ITSZ.$F($2^X;MRN=MF P??1I0I
MJZJF8<Y6V*18=T1OG@R=)XQZ<$8'@_FRK@2LP-[*3!<X$+*92R*(AGB+#H9D
M+N]QZ2),<TFO<K40W5R3=(1*D)&[K6C)C:Q:>'#[\DI8F]FC"&F'P9<#BI/J
MMCD:!\TO 0S""1A[<U:&W2%F.N^*O#RN)[\M9:P5H8#\&'3XM4VM(Z<1Z.8Y
M5\TQV2[N>;3,.( KYP*O!QU!N:I$JZ^A4GJ4-Q =,$^Z(M&^F0FT+IN;=8&/
MF5YBF-N+2^D1"=32$O@:O5%'Z1&89DK!&>8PD<'$\PG.? UOW1^=+2_&CF:.
MBM/6WFD\*,*<%7_^:9A>)":CFCK*P:_U&6R>QR6[6K)H4(K7D8T@[<N57PB$
M.%+/O[5,W.JC\%KZ=0WSR.1RFZIC;_J$1P&1JR&HZ:P!6)5<1&0&1,[)9-15
M-'-'.BPYS1RS"/J$9,'"*9&^M?"8$:E1*<$B4@;0SXS2JH.-:S!N/\4L%2D:
MT%?M]JG#)E*^[H_H=O""Q_]X]R'W=7$IVSS&;\1Z@F#*]:>WZ8>MU.=4WL4F
M7;$]78)=/=6Y*T@P.C)6S7F=/\?0R?"FB#$39:N.1.,4T_G#%*N3.VT:'9I%
M'4H43*H5@Y3<K?+*.$*'/;=) L-6R#LJF<68K;0 JFT)P<]+;N9WQ4"G"8Z(
M[;2@PMD!F"R(J;T-=+<RQS3#0P^,3# @RX_S7V1JV )V5A,P2,4U0<BN&<$$
M7@\KYS _1Q*+L+4\#S]'5]![FO=!W(0[\B^6;R(>'& &=H#>34#J#+JXB5S-
ML;<4:IJ2LF-X#<FY@!H"*RP$E)D>" 4[B5X&L@@[5#1%>A1A;D&!>3&@L9+W
MUE$!"57T]=#2>HYTKG%NT<:M^$&I(6]LO3'M)%@*#%WOE>O#7;3N<F!UID_-
M?=BY<X0J=69LNVI<JY6Y67*R!5_ZX06HLV =RBB#DT_++"\Y#]T.F,XM8K1P
MIU65"XM":Y48M -*RNGD*JWKKHIM2-BGIPO+.+R(Q0&4EVGZ;F'>-4FX%#.^
M=,TQ "!4$QUA1P.KP,QXP'') ^99:P5E7<9I@*$3X/R);K]]@586QYPQOAMJ
MO5EW@=-]%%$R!;.)*6=P-(7+!>?$?( HU&-,G(Y>TB&AEA2%4\(Y]3@PM=.(
M#B')0*./D-)V^N'4::#Z\HSYCAD-Y&KF.C-4HZ>C%NN7+%:+YVK#M']7[Z0S
ML.XI.-"B=-Z%LJF51\GQ%MS#1H(8>9=W XRV =O[&[#]MSX[<C(!1>)_SPS!
MIEDN11?>J?6<(7:J+(PHLY]^(4H-I@0(@UX+%Y_0)S(=*DNP'O<6?P1'D7)M
M>02BWX9MP)CG1M0LHN9*,-RDS0U"J>^A8M[8(.E:W\;JM(7S@F4J\PUI,T_*
MQ"3XVPRL6E7&3-W5;=OJ5>KQ6CVGV,@TI=&UI,<Z#2>&IER&>X!*@,EIC;"$
M4BE,G53I&=6^VVML=9J\ ]8.KXFI!/2*N#NJX*B.@L2DNA-N7C_7\<(O6W#3
M\):7:/=$(]&1].?D*2-!K(:^\;E2T)&3SA*ERSW -L>]5"M? AZI-D7\S*A<
MFF4S.9&2"ZY>=I* &6LHV3V+TLPA)%YM5B4GVJR=RZ8[#V%QVD1:G0BW,/U<
MJD 2T##]B>D;L7-J6A Y#4QEN&1SF(:S*68MZ*14&B3207K!YV<40>'=1!6V
M@"D;F*=NVF7$,DZ&:<>$Y;49S@!98>4M;Y@3^"JI?S(,IA):EQ"#47>NA7]%
M/==L;QZ'"RN\/VBN4;],'2L@?-55@5.-7\U 1:U_.W4;!T0?SN0:E-/LGKOH
M1"O+"?S+[9$MOC52\IV 1R-;B1X0/C!L8P35N L]SA7JQA..L"B4%+#8^V"]
MS_4G@T:?B!-%SV'@MU"626U_I*#J]'&;--(HFFT9 ZGE&[N\;C@SUAUGJE75
MJZ!:6\@N(GGH/D\R;9UBJL\U?Y0I6<I5>(LCV7%W#,!>2A(9W;RJF:8\X$ZZ
ML%024<T *ZV6<5"G,KP)JY'<?"4J;#/+<,Y(Q"#"+ ^=CD[,3'6XIHM]2^()
M(#^M(L_1.!+1Y&[+,J,VQZ=$+)$'UTTK*QA(*E80P+D>/*\=I(IREO0XL0-=
M*B-,L[XHFOC@!"2J0'"J3R3Y$J>3Y-(&3'02F@C)ET]M5HRT'CIW1(J%X$PP
M]T1:JML!M?J-I,$I;"TR4)FV_B4!G3OH<$O.H E@J0;#X07.H"&WZPF^TE9K
MBQRP_8:J\MD[-2GX56NY:+F^^4>MV,W"?TUW(<<C0$V*%LV9SFLSI*-O,T)Z
MSO3H9OJ>4UK. WVQC26&*,V["E(EE/SE!#T<I8.D1%VNL -K;H&VK^LS 5/@
M;JM$U)1@A(E-V-;QQW4D5P*ICK^RN7BCOXC):M2,#8L0>,S"T(9*R</<(FP%
M&2S2=+W? )\O5=;JYUYNCZ1"57?9</#CH +:9+0<M!P-#5D+-N>(23VWH7 <
MB6T\Y.[.*3#D[J :C!A@K9R>-2-5?3;@<6I=<2S4B54,T39,KTA"N2VYFL#0
M ^2-#.'B1=1[*R')IL=P'$US=YID2T32UUQ>,SDL9J;8JB"BX[NSOD?R.@>)
MI$:[=64V#@KD$&0F[,CW@T]4;3-',-8BK#J.ZA,H6?YRPS/V4(K;;L'"+!M[
M.SMP.Z"QP7FP)LD!I-9*Z@%R#5Z!H^97KX K7P:^]Q%Y>SB. :+/HY3U)N_\
M)1/Y.Z![[!CIG;[VL4\9;@5U=6Y=:1.";,.LH75[5H\ %C<.^:UD+!AF6MCY
MY/HTIA9M 2>2N"UEW]R$EX.JR)S+<2T+;IW!B71;];^"\ OE1:%&9ORK=VF=
MW(6?[\P-W6,)M?"B/[A%AJ58!M>I.+4^:.>Z_7YU7K[V9$@S =HD$1DVIB:5
M\!Y5:_F2B"<V92G3&Q #R;1RP:0%'<XJ)9?<G$$FW,.S1:1I1]&"U)P*DW$R
M ]L.2^$O3+QS3B"/SX^&Y,O$Z*@/$YMH[$63EBYVO+8DJU")GL,*I<6*@* U
M/<0DLN@Q\.6T W2+4XK<D)%NUD)S#:>F&[*T>-'?8O^/&)/RJ1?!3-:O+*2A
MG =Q6VCJVF!4UWM]300,^^K4 F#<"5)#"//V., [U3XT.#S58&:L]%.E@%9.
MAI@O@A486B(!$P5LJQKW[OJLRX$Y7.3FQH?<.8<U7Z?9E./^VP9[[F^PYQ9A
MYSFJ4HW'(;X9*J[)N0KKJ_,J6R+*)JWD%NVT9([=-%K;EHC'/,0$<#4?;BPL
MRFA8":>VQF^7"MO6G&+5V.W9=PW5NGHS!5;0RD8%I\+%*@W9I N^VU#:3F*M
MUFS6T *E5D;\))6&E29KA2?1V;B:FR9/[<G8;4R3*B(966QJ#DVZ0D56M.)@
M5VLIE,&IDQ./G%81QJ4:>+$JJ$)**X2OU)"R*3\JDS'A2:W2SS_L'I/CL(3W
MQ;H% *OMXB"3[G,=,FEHJGH1E1/OL3/LF&R9)SZ7BZ&9[MKX'[1Y_8&L7S6D
M>S)*5,M"*W)GGXF&@N5XB'(VGT32H!RO\_4WQMK#?%IW$S+\18#6OJ=KX?CS
M?\NT./GPX93_\813S,L)9LW\8RS.;ZJ,MP%7A@>]CH.OZ3D8RN/?442NK/[T
M?\O8>O?;&'35/B#P-RP#QSPUR<69&C&+$*<DI1OB73H> %==-#_DH)!Y)]">
M22+FLDO2T7S'>AS6XE"5JHA:5T?*#@:,86XKW12EL+S2"=*9!6N'WK0,*S8-
M\=B_USPFLX&)2H;BXL;*4=T[AAB7*TC,/&CWPT88ID\+4>*N_6Q%? (/.PTB
MBE_@"/!I18-'IO'S#T>[!WLGO;[U/9 'T!3VD.,+?D!+U.Q^TQ,=;SZ3WBPC
MI9R%=^VZMD5)8$PL1]Y:"P'-F,*8'SD.507UA?S(>NZ!V$]-J\*,Q%5Q=!'9
MMH#*QB &JKA"VTAVV#\R.X0OY<.]??-AM>:EU9#19^VWK+1;6:GUO,;00<C+
MSPYW6M9R/43<W$C'B]MVQ9%=&;+EE/9TO3^-R=%&^5<FAX%3J-&6 1.0,@[8
MQ.,<NZ$[^=UD")@.*7I.07.PK(X7:$FDWU8NV!;"QH<+1,L*J^O45SQYKH?/
MC&5G[(.K82]%CI(<74*E)#H*^C53P,7PI- ML)RLQ$3X%BRK^N'PI7HD"=DD
MC'64QVE!(^==YJ#12/QC)A74&,C$LB3 P@NYIQ@@H?*&)B4[PN_\[$)A@0."
M5G(#\X/*B=)9$'.B!Z,YFK8VS,6]HX;P<^E_@/Z)]*I3 (WF_ F8XSBN ;W>
MB,N)$C>!KR=TTRW+N<*2FBYG,VNMHW/@MFC!4L%0+4-*LKFYE*$E>@\;1MU:
MQX-34&4O1$-?=/?&%[:8@6G&M>.#0<]<)9H,0%X[GB,GMT"2$7#,NM*MQ,BC
M@JWA;9M8X\E9AAP)"3)%T*H@?4/:,^K;-)&%N ^KB;;O>Z<E^O>YK^ Y0/4?
MGA]$L0GXE<DDL,S)1 2X.T5!_?]U9ITP/<1MCJRZX0.KZG)OJ(J:I>5%F>NR
M$IO;-5!5.:EU9\GB(@QG)LJD1?_V.$,B(ON\CN&&7%Q$[Z)+UZAC9$"CTJ)A
MUJJ8N%4PF6I@/O7_;$5X3+2B/'-LQH[(A(/;4'G@I#[W6:PR$H;@%MRP]1F"
MQ>\F%5EL,'LAHJM7>)I(E=$U&'LU7X/?_)U&&&M;5;5LA?='U]7?T1B#:VKP
M%BCGK?&Y.]/.'2 W)OM46[!;31MWE0+%4Y\U'7OV^N25P-YI-N-!#\"#58"4
M22NQXRTGF.UP">@M7':28HT^_^G,P]1E*.TE* R9>6E+?7(+?2)&T%*:@CQ<
M182? Q0"0L1840@RI4SX)V(/Z&:EY$A&UQQV1<2-#=(4^:A1?4A]9:>$$YB/
M=/[C!=>IZ\"^E)I[^EUX*&Y((\7R6!;/]DL+)BPT8 Q;\*JFBE>U4IQ!E-I7
MI%?$^41$]HL+7ZC8T'0QDO2BY3B6=V?,JE[S5:4=7<QWUSRMY0WWD;L=&>9F
M;8-6QK.T17EH[)XF+%L*,H,X;M%(YQ5DMJA]6'\^%67/>1\G:)A7H$0%^A[A
M[ &;W,:** 6>T-_85@$J%\[>;=,'T]RYZQFD_-DH>>*+KL/OHTV0\>MF=A.7
M0 52*Z]D'UU2ZUQCOI'5TXIL^-/_EI@JR-VG%7$+LHF"6*:J6<\Q)Q7D:3PT
MGCI.P28AHMO#XLR)"'GC4"TTII?3[LL!*?*4]!X-^=_SU'G*=VB![@W4_(78
M:Y+$%FBL+?1,C(UT45]KIW6EE'TF(PYCBV%*<HO>PO[5?X5?FFLX@!"-2J.6
MTK9#JUYJ5$\<>E*_A5:5DW*[8*76[>!H/*JZQ>EVF4GKWL8H[V.,\F:^<95,
M@L'*7.(O@/F(VM [OJ5'?)&N3:>K/$H:-'_L*-&5YE)LE5.+0QLQJR5[.JYL
M\5[/G%(<Z4BLB_1!'>!7^M4N$VX+9IN<8N;EPBOTTDXUM7,"8S.[OPI:?J/#
MM)5F?3R'5COQN&LJM]#1(*<\7P.BHC*(V"BZS3H4MWQ AO\Y+F(!?MN6_0K/
ML\U69(:A4Y2;4I.6V%$KZME VH_8V!Z*\2**W:1^9(V)]^;=BZ[>7;W0:V!:
MA4>Z'_O2Z4>.J>R6?#BBK8FE-LQ+WAO]2&!\K'H'E<:.U>,[:.PX=LD(K*,L
M)Y5/Q6?8S/MQ/-/&K<3*$*Y>[VQFTPW]BCW:&CVJ5^K85O<\?*-QC[+3%?D*
M[*V9.&W[%6HTU[JU]V//.OM-[A4&5]AL'R*6&T^@>5*:!3CMUZ+$FGD[580=
M*.V:K(5Y?MSIVK!%/;ACU-%*WQ?RRC<# AK^G #O(%PY%YWI@#_N.X=/:SUF
M;#&;=4HLP^&XA49EZ/A\4C2@PFH U]7=$AAC!/QQMQ*>D5B)40@!=IB-,]+K
MZB]R78Z*1LERM&33:.;0J<9Z@U><EHQ=+$BKJ\@Q_FY^S)8+275Q2ELZY+(1
M@6H [L?^?B7H^./>[DVB;C^ZX3#Z?:]_PV#;C[W]VA+]&X38V-$>6&;3$G,S
M3<YK]-#LD3'/S@K0<*J$23R.D'@4(7'U^)I)1I[&"TQOQ][/KF)O(E%6!4EY
MZ$'6T1L%S4-:\BYM?5G<EFXD-.Y"BZ!"CS:=KP<T@P0-YB!5=%8_:,2-Y2<4
M_C(<#;[OD&WLLE6Y2(._=9%-Q:'ZLFG[;DYQK=G.'^\^5-0N&]^$!V1/)*RX
M,,,,A;X;L) 1ZFH]+ 3UYNO.L=IF2V?:\GP>GKM1GR!Q@L'<^2":XG9;XF>M
M:@[>F-9VC-:\O.*A?2O*N%U(OO+K$EXE-PW)V2<[SSS'<)[&%J,Y&8QQ?%L_
M[E:X!7:H2[C,5V QHO%?D:/"-T#O:B>5T6Z2B;EKB]E,HMR/O7F,$17:>OPO
M<+IR8OVES;=+*JD:IJ3&2E>_(;72S*5AE&'4T<D0'482:RZ@E25NG6:H.)8K
M*G; C"W07MG!WCMJLTY?U CC/0-[&=-4GZUAG.HO:KFV.?(]KMOD5@*PE%D#
MR5_W1"02=OB6WH#PJ<8$K18-GB=.(]J;-P0UI16)IRKM#<79N78V>\A%^*I;
MC>+IAO%(>T.7@5*IG3"6)M! ?LRP&AISZV1PSU_*5"I7N4/K:Y9=LA[&,#1J
M5W!3#M@P-<'ZEIR".6$/BBSSE9O%7GUZ2:H>Z SMNEE#A9U*1:G5%ZH7UK(?
MW996.G_H,8*P_<LTY*+?D:!PK1KD9GHX-UD5SXATE+F&;[I7.6S'&'R5>9:/
M(0R2KKYQ#&U_D[K72*%M2QNX/<A\4TG^M9!H*$U7D#Z"9+I5KK/F[9T$7RPN
MU)FSR5O/=+,*"IUPV68/9[8EU^J*.IO!8++8/P<W4M^/;ZBK'RVMF%^#'F0\
M.WH=RA70V'_<=XQ>EUMJTL6'*L3;GD(UY^(=HG03@OR&N#;8V$Y/=7T"<5;F
M*NE\6E:1S8+$F26I2^.>$>3D2$AFBR6Z"X[52?>PA(>^DW!G>:X3.WH'_T::
M.R'Z-L'.QVK*=?Y\&;$N*RR0ZA1GO(50KTLQHGIY79 DU*R <<_U$K&'"NN&
M$P?9M(?QQUYWKR;=^<?2@AU'H9<3)VZIVXA-L;BFJ*:F-:#'1%"1M_+(G8E;
M5\S20LL)V:#5)52-E_ZXSTE]"*9^U0/62'NMRC61L56/[_)"ML%5ZC*W-0CK
MF&MTQ]6S])RS[/"_M>-JSCG<*TJE:HFS=HS@-YJFQL*JJ]!JG'.:*IDL%)&Q
M303BE!"MS>TLRCRNJQ;A&$/[..*^LNUZYB_R6ZQUL*F+\H!Q!+7@CEE=J\C&
M%F7T<U&O#J'=;P$A)Q;'4)JW<P=+?NP+@D]5^Z6+^Q/%UDPY6MPU^M<<F=M^
M5S?0HM#-5G&];>/<]S;./=]RG^]"K6B@UJ-8=6/WNKVJ$_GX9F[L;M6K]./A
M39W8"Q>X296(F]FFB2QR4ZR!5*N,2R<2.?6I0L+6 "NX2<$U6OD\@\T(ME:.
M28U3CK1XJ HIXZ,.XY24=]<QN' O%?[YXU%WIWHC54VG+<ZC+\8)2"S%YJQ=
M.L](.>I:[*H8)HZ6TVZ7H'HX" IJ*'1S.V55PYQUB$4CA"BR-919H! Z&%;+
MRV[%IUINMEZNU8O+>W)4)!I\4)D+ M+4XS+K97Q\6I%OM'>Y5AF_CB7UNC<S
MSAL\I=<]NAE;<O:R>*G%,;;2BOVYX"'H&.Y<LT]:%--]HY?VK%I*!G(E]D%S
M9?AJ.2DGJ'<<K"MVB[<ID^?GAJ[:NCME+2%ZJ]@UU),EDOH:_IQEO"48:]75
M1HMQQS5(VU*RFW3&DA[K"E+O8S! *^OCZ>?.:[]F*5[[YL<\5>>-+^-UWKPA
M?--_O&GYS9-_MUU\PLGQ/Z],)#KWOQO8\(DWR2@N5?)/X(W5)+BXB$OX%M[[
M^+?3)YZ,V/:K?D_C_%F;",[9QS?G'S[*_&<J"E]=,$?W24'_S^$R_I\YM?<M
M9Q(9X+NNH<&L:GW5G<E$GJ810%UTM+SDVGHAZ?_,:1_<O_TLR(\;@Y^<J#7F
MS'M8C2UU0.9E;G[:-7MQZHO;GJS4&U^E63R\PMB&H^^5$@:*)M(@F79=V_ -
MTNTD;2SBQ.;+Z)+;J'?T.66N5JU&5.=!KJ@#2 ODL *Y4ILA\3<3R78<@N(]
M;/@2EBQ!_;%WLU2=W=V;VC357UQCQ#@E9UAEL%@D4C\XU /:8"AZVV*)*<DR
M_%=G,#,Y,XQDF!,_PX_EGYQ*T^I LYD/[1DU586@;<-$Q.2K<$6)!"C,I![3
M@(DJC43U_[M,PHKSCU/"#+J7RU%T+<FB[5F;ZH9$9DHOG,2")=_5#H-JJH\I
M'C=%)U>*.RP[J)".C!=."S]G-]SVK26=JX@FTK.3M'O["Z(:QWIV%[,EU7H<
M%#+ZT2B*(XFTMAQJV=0020%U8U=14B4F.Z'U,HU"^YM^][!BG?*^J7 91[A+
M"R%>0_NZ_0JMMR2>+,MU\-DDM=3L6X6UGG&R>K7D.4"):ZM_#B;3$^\M<,9D
M&'BO*07Y%?K\2)ZL3%=Y&U#2R1Z[-FE^@S2W"B0CW+38PK-XBX\Q?R*HMG^H
M)6-:!#1C4^4512:JJ$ZHK]@<[1_[5=O/9"DLF0>U6W7%:#^%TT.QPI5TXG-O
MWU_Z[*(4MV12HZ#<J_1ET3/(=+/2QH!O5%,6S2?GJ@Y17'1V,QYMR!5G<2</
ML2 O?/WV@]L >12$-/6#9VM6U=+7<3H @7+*M$;-^&0>=DTQ718B4>*6#O?V
MYU>?N]Z)PLU"X [YN0NSI>^#BR[F=C-W+DB:""ZQ:FN@!=V#*,7GA/[JE0:8
MBBCMUN!F4++GD@>"R>=IKH8WV!!7>+.SSBEAX%7-Z/8X3D/R!&@%!+\7!814
M"T[:C1+>0N8FF,J/C=;KC @8@+:+);%=;RV,K0._S3=)::_7H_8"#FBYT$[W
MN(V-W#V/G$9AFB6:32[-YG:ZAXO97'5=.:##^SY)P8G)L'6>EZ?A]B.)?6O3
MLG_BC75+?.1<%PQND=JA ^Z\!,7RD@?1-.WD"OB+J]3UJTEF.'G*G!OI.3<B
M3L+];W=%90*;ST#!Q_94XC7A#.I)$&.K"MM-7/PP-'NJZSU?9*37I!Y!T&!>
MZSYJ;Z-N#G9 ^* 1/=VQTG/YU.$Z9/O=OK7VW./Y35RC:VK%+KWUVI<N6KD!
MXKX1=VVP7["(;5%AZOJ7O7[JAV*F/O$<(M+>;8V-[3).DF3.?K;5S?<WZGLS
M]V.*LZ0TZW@YC5K:F+Y)L$T-8=#*I*6KCK6608_ @%<XD\$=L=&,02W.3#M[
M^>%-(RV-OK@>3-0?&A>H3)/0ZO"'#)/#,ADX9 8SPF<Q)AV5''\!<[W@D=DX
MR,PX+T(LYM5]B.HN/K=^%(U8?)N3N&K]1"TI3.WO-]X?<JO,54.KP&J/.=*%
M$-U9'^6"@MS ^P.8%D@'DMI&(@7>3-&0M1%*:B,[*!2-+:PYA%+Y4;/:K(8O
M@BKA%_2-7+<UEI0<5NG5)JA6!\PM-^;&-O#^U 2DTU&[:H=@SR)N^M((F)@P
M>W*1B@.7%&DW]QG12DVFIH1KH$RGH8;PVNWRKFSS&J?67-=^[K6J*SS9@-5X
M$JEH%B6NNZMZ7&XF4A'ZO?UNS1<Z/U/1F8-S(_=1_[#;NXO]X]1[W>55.A8@
M2!VCH\Y4Z&^TPL"((V6=:LF"N.I;XIJ0[D[%7U4F<..H7L%N5N<;^J3R./!.
MI0W\"GU KAZ^WT;D=1INYW>U!(CZ\<B;,U$X&J_(@II9D@3<?8A_]#I+QW#,
MI/+KN<D/]1<M#E\UGK:TR>TDYK>Y,YR??ZR&M:[&$]!YJ>-=RO.E!VH<Q".3
M@=$(QS>W0DY+4QPLZ\%^<!"BM/MJ_HA\I\1*]BL^IA\/;E"1W"+@FLE CFKO
MC!RQPFF9Y*C&_C4CZ;E[UQ_VYP6+W UACT!L$^Q(R69QA*EEH+2.$54PR'69
M&(?%Q_DX-:?VX5MXFF] Q;]$E3=66-"C7S^Z1?OU8@.FULGLW<OWOSR-?EW1
MO"?V1/?ZSK2'&A-:?(C'V,"AOW/RD4R[]_17[^2)<[A%L6P:1.ZVHW%;T)A*
M?,F%0.S!ZEV=J55FHT"*LLI)FLWM$L.!<E(LJ:=C6N@IU#2.";&1!ZECW"?%
MN?"T;]YAC"H;S?$&M!]$Z!%F]2HH@IP2&#D*;2:N:>:!IE.B9X3##WDR;4#A
M+^-1KG;<L9/8&V>W)1786CT49@;\*8P*3/T'A1L[ZN/Q3%5\I06-W(\[KF1!
M_X@"MY\7Y K";J@T%#RJM UO[3B$T;E\0GU[D*G%)?6<QW&FS-3!6$P A;W'
M^$O!G+?(\]XD0YG8DAL4HJ(U'6Z-]6#JR#[9FF.'N0;V-%35$>2@EV%47,^D
M<P^OCYHZ26)&$H@*5-\BF4@CX$'NI-.6Z3,2TW6GN+= N_H]RCEW3\YX,]N\
MK>UB':1-KQ+*;&S7%\@#X'93S-,8Y[2#D.,U;$=+)F/L!%\: XX'4;-'?3H.
M9.RAW<H+[B[J7K'^XH,XO=]\T)<L#0ITXXQ*AJ<),'9&\"Z?O@3Q!ZH"5U::
MF*,46C8R3UBLF,A]4)B8YY<DO>J,P2(#2+%XYY/C=\W-UJH[*QF=W#=<1A'-
MZ;;:WDW<JFW<KJJI?=N\0X)S&YBYJ1=Y;W&LI Y;SQL!$-+."3?0UL8SFP8\
M@A95H+4 PTUCTX^9JIG<VFQ7E0QQ79HGD@8,-(:XW'U^W>4#H*>*\%C?+OKQ
M3&(O7Q)F5?B<;82I%,2&W TVAQW(/.6.X;=VP/!<$J.+(R9"BH_9LD,N->YJ
MV?HXR*2AG BTK)7!."C!,\0S??E#24"PE,BX\:;-K)=6R;75$3C]/>S>7(QS
M27&]:D_G7WD/+E=LD2:IZ=3415V?*Z5G<>P>468G"2):!0LEKNO9WSOLUEH4
MS2'R%MV^+2VT*4IJK]NW,P)N_R9'2+J=2I?8P.X-;)=ESN>82;K/<'?_]J^X
MT<$<V^KZO.M(+9M+%K6_3W=>NK/WC-+L)N?M>C2\5>?D.#+'Q$QNDP5W#2NZ
M&JN$2]BE00$S.Y&VP)1 V70\P,2LZT>M=:=E5;BWX\W@A;DSA<CE?\S['.2A
M-L@Z$'_=&];26IP_#-CX:%^1C_9UBX_VL_AHS[2/]OO9E&Q&&F?6POF4IQ].
MJ\/I,%V#L_78:Z,+G5SG%*HK;WGQ\X)BAH*!9H#EGTETB]F5C37[3O67&>B-
M3YKJX+2:U<%3N)MKZ:"GTW!+O]MV;K$>X]Y1;9!XLQD_3^YT1S$Z^<+-9NY[
MUB75]<X1\QL/CP/M1J=F8F($7)^)[60<:L]U:_><HLP2<M9HKR\ JTP* ]/&
MAJ)1?:PY=DD-D/F0EH<RG4=>:MU*II,CGZ2N! L>\KU!24&>8>JVV/)>_NG:
M<&4Q3C.3:IXY;Z<CXVGJ@]ZEH8>V%"MH 'B&X0H9F5 F,6HE5S8F_O+,FY0%
M=]4W,PL"^DTF%9AOS(14.WAASG#4;<S[WL:\YXN,NYAXR_@B7R\Q_C;40Z=<
MWF,DJ+9$Y9?$>&6\J#0F31-RNQ #X 02EP',HW^3E4Z!OJ_F.7J[.!)H'?$=
M>!/@_+FV<6K]0;#NP\E^(L?QG!0UX,Q3GK/@#AHQT'BO,UH6#\25AM@B68 H
M@>*2]"I6PPOM!$S+ DTT/?]6^T"1&PWF,L]:6^PFT%Z4IE&G<R45X+EO,KX6
M],A+LQ$[":+:(!//O[+@&&N[HOKGOFUB_/+,NBPX"FE/6&2 $B-IV %44\V)
M?TJQT8@KS-,)+$BG)KL2J<:@1'U(BMR7-. B<1D8.>9"7:KF*S4@^9B(0M#"
M;!D]%/Q-77"AX\*_R0DH59H:?-K&8XW.HI6U_#8X<.0X5&K(MA/18I#SY+P!
M>MC,H KIZB-X\O(,$P%H6)^&6#,S3"8^8RLWU+1T@ADEYVFVH)47-[2=F\F&
M05N,2^LK&G5EL6&IE;66S:ZE\H^N.98O>,I7F Z$&1O9) BIO@1N;:5A(H+[
MT?PPT3F--&FQ772$Z/S#J?;Z^BW.2,KGR_-26BH L\R+@',:R&N6SP6+][S[
MN>N#8C:)PBCF9)#3"4[X&@83+B-X1W4^./@%41N1_Q+U,D1^I#,B_#@"1%$X
M;CL84*J^]WCQE0U4'F-XPKM429*F10XGGX)40G8.9O\7'&L [&B:!5]4'/W]
M!52H(5[A$R3^BR"AP=EX5O4URHMJ7#X.K@R#J6Q^E(:E.%3%K!FB)Q_/GK>%
MFMP($T7;RB0"#L3."O9&)BHU#LD@S%*<=*]G8>CH33&;5GVBYRA8B/UAHPLJ
MB8B&VBHU^4@:&S!-5CN8]FPNJVGOP0=J"X#/*1X<JCS,HH$RPYN$ P4.&5&'
M,DD:1;>ZL67R HYV03P3%:IAE)-_8D;CD>GN(U6%7,6)"TQR$E$>G LY;:)S
M+2Y#S6D^P 5ZXFB)AQ*QBV<F>YBO/4)4&:<I,4F! [X)IP!AB_;1B'-_:V_@
MUXLS^QMGUM G5VP.#-)XN(CE#5KH)T'<C)O+//KU583=Y]#$?#\55,J]]Y=8
M$JFN?GDZN$OF=\MS'7=W]^EH'[%VLES1J/E/W)_'%WN =I)SR@41(B5F4?L^
MT1;9'T:9=8:*VBC+M)<FKZ38_3QS5]/U7+>T+EWU-4=GXX,%,_4%@LVZU9=S
M1FP"FSG3Z8#$ ',W728S?8-C/1Z7F0=-[$*S6WM"1@:;M.%F6I[EY2!'/8Q"
MG+C(A3#C7$.3PK!D!Y'GR&T&B_H%03*%P\RJS$AKU/!KT!1!3]'G#LHA"1>\
MGI3YR-#9H=DXF3!Q*55YI(1S4Y2/"A6Z-:!L0P%GV,@<X'R.N+*BFGK9 J.K
MH'XNNFW$/BK@)#E:?3)*R'<F"E4+9FE60(?GZUE<MM-/N1>[C7U>9:A7)IUT
M-**2M@1-\FIEN]-1$]\0$Y^7;3#Y8,9N9//)0'L%K5V/,SDSQ65T/L&,W!:=
M5<@5]CJ,30X#KF@[2<F9:<"?*CHEAR5QGB/J.0&H71GOLEH\)_.J]'ID'>1Y
M%2S%&(SG"F"F%?7,QC-L*F]S"GK$!#R/)=!VR433H6637X;=N&PJ@V:&7>]<
MV?0#EV6Y/4!>RLQM[5$8*,K23K-JDKEH4\AD$LTNM*+.D*T</U.=."@3)ZEC
MG<CV')!3>R1>N".U-3!60\KNMBJ3OLU<=$O50NA5ZC;/,8H(L2!I!!)1XG]V
MM*5H?L JN/S!-(**L0Q_<P7@.MWCM4B]FGO\.$\],!#6MU?ATC7WG68^%67#
MK6X@IM9:ZF XF,ND'$;FJ/LZ'<QM$>QPP'J_)DY3QMV^?ONA4TU!EO)NRLU:
M"@3TLBN:J&IPDS8]#_? ],,W*5/[RV8R._#J,JYP2Y-M8HAB,U.''YQ<8O-,
M77SX]@ZTN&QYQN3V4IE%( EG4LA$=AX.HPJ2RJXKPWED#7)^7J ""[JBNL"J
M DI+\BNBL1(OS]-1<:7'J<[)D'>2K(WTQ_0IM@=O=WEV):0,;#O"R6%S?D^Y
M0LY&Z.\PR+*(,FX*K>\YWN^P,1K3ZO%6-IZP?\_L3W,^.SW1<>M>J[T[2>]V
M_E]M(\X\Y+JS$XB:AZWKX1XMT0H?HW6@3?FMPM.@EM5O6.V7 XJ6?MTM"33A
M_J-T:!@+3;QJ$=!L%0#/]<69J&ML#=>X(+\(\SUQB))13J&'"571V31!J=('
M?@5OY0H%_)WQJA)DXQEW.,UUOP )!+@&0%A1</G7,WZ:%* !]FMT#)A%:4,"
MFGF0V48/[VWT\ ;B^2]#1TO04) [A,-YNHQH#N]K\]FY,IAX4Y!7A'=>@%36
M_H5*UF+NS,_%'%;@%F5]S.I%)E,4JLFR)H.S"/(OG!K.+?"L]FX20[C?UF!&
MS T,AB%6#YB=LA?-4PD6L>K2$[OYJ! [R4WQUMS32<\8&OV" #H4(#)W8!89
MEAPXI.BL"WF'8].V<H6N4K<XLU&3"4=^7A9B?]+K:7ZX*;)2_^4\ QX]7D_Q
ML!=JAYT[HP91!DCG%"R((/?.]?ACN)HMVD^MOU/X$*^'J%;05"=2P*E!/3R,
M*0\8@D47#/=O(=&V,-M:0]V!H3,;80E(<G1#K@DC?XM?IT\+@.7PF';!Z1(?
M4CZIF@( .,SU0$2JK=3I6U-8%DNR39H*BIA1A!I-X24*S6XT8]P&"!R-EUNA
MI1O9DHLVGMN=IYE^8^M%::?64F# >E)LXQ\@;?H+UUT.K#P5@^H YSY<BULG
MJ#_9&\YUYL3\@F:'46G3HXDH"W[.Q6DSKG125#+C9FX:-&CI*K5.-B4G%K)U
M=3J< ,<#0YR$U8JM2G=C075C!E'XIF(.J1";^$;FE4:G7"41W7L27#BUX-7M
MF=^ZCD?@K"-%3;)0H+3X&LGT\=EK+ Z\1(_S-;+&.O;0VVUL&-[X"$2*!<Z=
M(]ER\9^/-(.8]F<C.FN$[V>DN4>YU2_.HZ_>6RZ,>$E=-MQT@[[I(+WHJ=W5
MD,A?XA-EU*;R$),XC2Z/DO!-XZX-/9@8+.%-9F\LM3$X":^4B0YC4#.0:$(_
M9J/L^L"&:5@)P)/:$]4"8MP%0M%X*3"0DG.8MTA]:QZI.%=7E'A.FD242XR$
M\@1 P**OYH,$^M]@8D&&YWB%U5H'G=]7E 2"*?JP5;"'29G4X+XQ;"0526L&
M$7$]%CB72K0S6IF38(Q)2KYM#_.,*+O>DS;ZNK22;Y5-PQ5!Z%,%<PO*9<K+
M";H*_T%!2^X(!]?:,?:& 'U&9R6S5]XHEB];D.3_F.;JF?Z'>[X#V+;8MVCR
MD?\FJ9JUF'-9M6KIDXK-R5:M:W'B)XX!^<@##G>1@(U)F3=@/1;&0I?W]SCJ
M7@SUYY<JHR!,AW[ZC,UN6?3PH-O;_<FY"?UZR>EWS5IG?72=CN!VGHVC(=RG
M^;MSE0739VR27P'8KC65Q0= +]:/!@.XV+)0E7-_HR3;G>[.OLU4P&>KR0KT
M._CR,LHC3@C21W[T*P:,=G9/?GF*C_[:<)T\+89+W,(86&DGGP8AYD0@].34
M_>Y>?WLOZW<OQ]W]WO9>UN]>MO2RGO=RW-T[WM[+-[N7IT6&*L"=B?N5 >&H
MS:A<%BK?E'/<:Y" K@I'!GUQ]]%MP=/K[NU]4_@<:=N -\2:[6* 55-*:PFD
MHO77[7.3.[HEG'M"."TVXO)HP(,?JI=^EP0A5J$(F-[TJT?FJ*>CG_>'8+0U
MO"60!T@@S?]MD,R_,90VATK0571'H'G@>($&P4;AQ6XKYZR9-3MSM/R*4-HW
M0JEVZO5DR?\*SQZ3QSXM<ZQI0\^M*K,T-]VA<=0\IRE@E\4G#XCTOIW.<G^H
MZK$),SVY"[7$)J\]^R$,E1J-5JNI+#KZN5N_Y-3 89@"8Y69&F/ZYR7.CL5Y
M=][C/](\?^*] #)Y=J=DLFY0<_6[[Z+ B0[ST,&PQ097<]D0,*R=,G'M4=UJ
MVS77 JX]BY;T=\2BOO51',E.86GW;+L+4=+=..;<T]8?_>KM[?G[O>-[9&M_
MSRM='#)9UROM[?F'.T=WQ&C6C,U6BHPW5:3>,5-:P>D6(?5BT3D/J1\?'OO'
MO=TG&ZY-W3'SVHRKWSOP]XZ.FU=__U2G:PNKMQ)XO92J6V+L4:\%7;<WN@XZ
MU2UOM._W=_MWQ8+63.A<6V:]E;8/2-'J]_V]?@NJ;Z]^XQ6M_7V_USO:!$5K
MB1JUK6#>"%5KO^<?'+;@[/92[[&VM;?O[V^LNO6>"[@YHHB# BE\N!6T]U''
MNIV'=G??[^\<;C6L>ZQAW?+B_;V]N_+,KQ,+V^I4:YEZ^>T<LKVMPK66297?
MZL:/]S95&UN8 _;><+@XS?.-3NJZ13[D'>MQ]XMLYL-K?@@3K)J#P[M-H7W
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M4I@._V)@)OF\2G%1Z N:$)@K?Z*3L\58U" #55[;',F#:-KB$--N4*TV33#
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M U!+ 0(4 Q0    ( -B#$5>XD+>35B(  #1W 0 1              "  0
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M+3(P,C,P-C,P7W!R92YX;6Q02P$"% ,4    " #8@Q%7;I@'I:$M  ")!@(
M%               @ '_>P$ 8W9A8RTR,#(S,#8S,'@V:RYH=&U02P$"% ,4
M    " #8@Q%76D!^!\T< 0"=C@P &               @ '2J0$ 8W9A8RTR
M,#(S,#8S,'AE>#DY9#$N:'1M4$L! A0#%     @ V8,15Q#;6F0X)0  628
M !L              ( !U<8" &-V86,M,C R,S V,S!X97@Y.60Q,# Q+FIP
M9U!+ 0(4 Q0    ( -F#$5>_:&QH0W\  ,^L P 8              "  4;L
M @!C=F%C+3(P,C,P-C,P>&5X.3ED,BYH=&U02P4&      D "0!B @  OVL#
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
